EP3110810B1 - Pyrazole amide derivative - Google Patents

Pyrazole amide derivative Download PDF

Info

Publication number
EP3110810B1
EP3110810B1 EP15713244.0A EP15713244A EP3110810B1 EP 3110810 B1 EP3110810 B1 EP 3110810B1 EP 15713244 A EP15713244 A EP 15713244A EP 3110810 B1 EP3110810 B1 EP 3110810B1
Authority
EP
European Patent Office
Prior art keywords
group
groups
group substituted
alkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15713244.0A
Other languages
German (de)
French (fr)
Other versions
EP3110810A1 (en
Inventor
Hilary Plake Beck
Shon Keith BOOKER
Howard Bregman
Victor J. Cee
Nagasree Chakka
Timothy D. Cushing
Oleg Epstein
Brian M. Fox
Stephanie Geuns-Meyer
Xiaolin Hao
Kenta HIBIYA
Jun Hirata
Zihao Hua
Jason Human
Shinji KAKUDA
Patricia Lopez
Ryota Nakajima
Kazuhisa Okada
Steven H. Olson
Hiroyuki Oono
Lewis D. Pennington
Kosuke Sasaki
Keiko Shimada
Youngsook Shin
Ryan D. WHITE
Ryan P. WURZ
Shuyan Yi
Xiao Mei Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Pharma Ltd
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Priority to SI201530248T priority Critical patent/SI3110810T1/en
Priority to PL15713244T priority patent/PL3110810T3/en
Priority to RS20180871A priority patent/RS57575B1/en
Publication of EP3110810A1 publication Critical patent/EP3110810A1/en
Application granted granted Critical
Publication of EP3110810B1 publication Critical patent/EP3110810B1/en
Priority to HRP20180750TT priority patent/HRP20180750T1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Definitions

  • the present invention relates to novel compounds that modulate ROR ⁇ activity, pharmaceutical composition, and use in treatment or prevention of autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.
  • Retinoid-related orphan receptor gamma is a nuclear receptor that binds to DNA and regulates transcription (NPL 1).
  • NPL DNA and regulates transcription
  • ROR ⁇ 1 and ROR ⁇ t are nuclear receptors that differ only in the N- terminus.
  • ROR ⁇ 1 and ROR ⁇ t are generated from the RORC gene; ROR ⁇ 1 and ROR ⁇ t (also referred to as ROR ⁇ 2) (NPL 2).
  • ROR ⁇ is used as a term to describe both isoforms of ROR ⁇ 1 and ROR ⁇ t.
  • ROR ⁇ 1 is expressed in a variety of tissues including muscle, kidney, liver, and lung and is known to regulate adipogenesis (NPL 3). Loss of the RORC gene in mice accelerates preadipocyte differentiation to small adipocytes and protects against high fat diet induced insulin resistance. Consequently, by inhibiting the function of ROR ⁇ 1, insulin resistance could be improved.
  • ROR ⁇ t is expressed exclusively in cells of the immune system (NPLs 4 and 5) and is a master regulator of a Th17 cell-related transcriptional network associated with autoimmune pathology.
  • Th17 cells are a subset of CD4+ helper T cells implicated as key drivers of the inflammatory process in autoimmunity and characterized by production of the pro-inflammatory cytokine IL-17A.
  • Th17 cells also express CCR6, which mediates migration to sites of inflammation, are maintained and expanded by IL-23, through the IL-23 receptor (IL23R), and express other pro-inflammatory cytokines and chemokines, including IL-17F, IL-21, IL-22, CCL20 and GM-CSF, which together promote recruitment of other inflammatory cell types, especially neutrophils, to mediate pathology at the target tissue.
  • IL-17F IL-17F
  • IL-21 IL-21
  • IL-22 CCL20
  • GM-CSF GM-CSF
  • ROR ⁇ -deficient mice have significantly reduced numbers of Th17 cells in vivo, lack the ability to produce IL-17A and other Th17-related cytokines ex vivo, and show resistance to induction of various disease models such as EAE, dermatitis, enteritis and nephritis (NPLs 6, and 12 to 14). Therefore, by inhibiting the function of ROR ⁇ , development of various autoimmune diseases and inflammatory diseases, in which the Th17 cell-related cytokines are involved, could be suppressed.
  • Th17 cell-related transcriptional network has been observed in other immune cell types that may also be important in disease pathogenesis, namely CD8+ T cells, so called Tc17s, ⁇ T cells, natural killer T cells, innate lymphoid cells, natural killer cells, and mast cells (NPLs 7 and 8).
  • Th17 cell-related cytokines and chemokines have been implicated in the pathogenesis of various human autoimmune and inflammatory diseases including multiple sclerosis, rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, cystic fibrosis, asthma, chronic obstructive pulmonary disease, emphysema, lung fibrosis, systemic erythematodes, vasculitis, Wegener granuloma, polymyalgia rheumatica, giant cell arteritis, arteriosclerosis, autoimmune myositis, uveitis, dry eye, inflammatory bowel disease, alcohol-induced hepatitis, non-alcoholic steatohepatitis, primary biliary cirrhosis, viral hepatitis and type 1 diabetes. (NPLs 9 to 11).
  • ROR ⁇ t is known to possess an inhibitory effect on the anti-tumorigenic activity of Th9 cells, a subtype of helper T cells (NPL 15).
  • Th9 cells a subtype of helper T cells (NPL 15).
  • NPL 15 helper T cells
  • a ROR ⁇ modulator can be expected to show therapeutic or preventive benefit in treatment of; metabolic diseases such as diabetes; for autoimmune diseases or inflammatory diseases and; for melanoma and other cancer diseases.
  • Heterocyclic ROR ⁇ modulators are disclosed in WO 2014/023367 .
  • the object of the present invention is to provide a compound having a function of inhibiting ROR ⁇ activity.
  • the present inventors conducted diligent research in order to achieve the above-described object and, as a result, found a novel compound represented by formula (I) or a pharmaceutically acceptable salt thereof, the compound or a pharmaceutically acceptable salt thereof having a function of inhibiting ROR ⁇ activity. That is, the present invention is as follows.
  • the present invention provides a novel compound having excellent activity of inhibiting ROR ⁇ and a method for producing the same.
  • the compound of the present invention or a pharmaceutically acceptable salt thereof is useful as a therapeutic agent or a preventive agent for autoimmune diseases, inflammatory diseases (for example, multiple sclerosis, chronic rheumatoid arthritis, ankylosing spondylitis, systemic erythematodes, psoriasis, psoriatic arthritis, inflammatory bowel disease, and asthma), metabolic diseases (especially diabetes), cancer diseases (especially malignant melanoma), or the like.
  • inflammatory diseases for example, multiple sclerosis, chronic rheumatoid arthritis, ankylosing spondylitis, systemic erythematodes, psoriasis, psoriatic arthritis, inflammatory bowel disease, and asthma
  • metabolic diseases especially diabetes
  • cancer diseases especially malignant melanoma
  • each group of the compounds represented by formula (I) of the present invention is defined as described below.
  • the writing order in each group indicates the order of the bonds in formula (I).
  • “a (C 3 to C 8 cycloalkyl)(C 1 to C 3 alkyl) group” in R 4 is represented by group wherein "a C 1 to C 3 alkyl group” is bonded to nitrogen in formula (I) and "a C 3 to C 8 cycloalkyl group” and "a C 1 to C 3 alkyl group” are bonded.
  • the number situated to the right of carbon indicates the number of the carbon.
  • C 1 to C 6 means a group having "1 to 6 carbons”.
  • different number of carbons means a group having that number of carbons.
  • a C 1 to C 4 alkyl group means alkyl groups having 1 to 4 carbon among those defined by “C 1 to C 4 alkyl group”. Treatment of the number of carbons in other groups is the same.
  • a C 1 to C 6 alkyl, group means a saturated linear or branched aliphatic hydrocarbon group having 1 to 6 carbons.
  • a methyl group an ethyl group, a n-propyl group, a n-butyl group, a n-pentyl group, a n-hexyl group, an isopropyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an isopentyl group, a 2-methylbutyl group, a 3-methylbutyl group, an 1-ethylpropyl group, an 1,1-dimethypropyl group, an 1,2-dimethylpropyl group, a neopentyl group, a 4-methylpentyl group, a 3-methylpentyl group, a 2-methylpentyl group, an 1-methylpentyl group, a 3,3
  • a C 1 to C 4 alkyl group means a saturated linear or branched aliphatic hydrocarbon group having 1 to 4 carbons.
  • a methyl group an ethyl group, a n-propyl group, an isopropyl group a n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group and the like.
  • a C 2 to C 4 alkyl group means a saturated linear or branched aliphatic hydrocarbon group having 2 to 4 carbons.
  • a C 2 to C 4 alkyl group means a saturated linear or branched aliphatic hydrocarbon group having 2 to 4 carbons.
  • an ethyl group a n-propyl group, an isopropyl group, a n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group and the like.
  • a C 1 to C 3 alkyl group means a saturated linear or branched aliphatic hydrocarbon group having 1 to 3 carbons.
  • a methyl group an ethyl group, a n-propyl group, an isopropyl group, and the like.
  • a C 2 to C 6 alkenyl group means a linear or branched aliphatic hydrocarbon group having 2 to 6 carbons with an unsaturated double bond.
  • a vinyl group an 1-propenyl group, a 2-propenyl group, a 2-methyl-1-propenyl group, a 2-methyl-2-propenyl group, a 2-buten-1-yl group, a 3-buten-1-yl group, a 2-penten-1-yl group, a 3-penten-1-yl group, a 4-penten-1-yl group, a 5-hexen-1-yl group, a 4-hexen-1-yl group, a 3-hexen-1-yl group, a 2-hexen-1-yl group, a 3-methyl-2-buten-1-yl group, a 3-methyl-3-penten-1-yl group, a 3-methyl-2-penten-1-yl group, a 4-methyl-3-penten-1-yl group, a 3-methyl-2-pen
  • a C 2 to C 6 alkynyl group means a linear or branched aliphatic hydrocarbon group having 2 to 6 carbons with an unsaturated triple bond.
  • an ethynyl group an 1-propyn-1-yl group, a 2-propyn-1-yl group, a 2-butyn-1-yl group, a 3-butyn-1-yl group, a 2-pentyn-1-yl group, a 3-pentyn-1-yl group, a 4-pentyn-1-yl group, a 5-hexyn-1-yl group, a 4-hexyn-1-yl group, a 3-hexyn-1-yl group, a 2-hexyn-1-yl group, and the like.
  • a C 1 to C 6 alkylene group means a bivalent group formed by removing hydrogen from "a C 1 to C 6 alkyl group".
  • a C 1 to C 6 alkyl group for example, there may be mentioned methylene, ethylene, propylene, butylene, pentylene, hexylene, and the like.
  • the C 1 to C 6 alkylene group can be bonded to one carbon atom or two different carbon atoms to form a ring.
  • a C 2 to C 6 alkenylene group means a bivalent group having a double bond at arbitrary position of "a C 2 to C 6 alkylene group”.
  • vinylene propenylene, 1-butenylene, 2-butenylene, 1-pentenyene, 2-pentenyene, 1-hexenyene, 2-hexenyene, 3-hexenyene, and the like.
  • a C 3 to C 8 cycloalkyl group means a cyclic alkyl group having 3 to 8 carbons.
  • a cyclopropyl group a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, and the like.
  • a C 4 to C 6 cycloalkyl group means a cyclic alkyl group having 4 to 6 carbons.
  • a cyclobutyl group a cyclopentyl group, a cyclohexyl group, and the like.
  • a C 6 to C 9 bicycloalkyl group means a bicyclic alkyl group having 6 to 9 carbons.
  • a bicyclo[3.1.0]hexanyl group a bicyclo[2.2.0]hexanyl group, a bicyclo[2.1.1]hexanyl group, bicyclo[3.2.0]heptanyl group, a bicyclo[2.2.1]heptanyl group, a bicyclo[3.1.1]heptanyl group, a bicyclo[4.1.0]heptanyl group, an octahydropentalenyl group, a bicyclo[2.2.2]octanyl group, a bicyclo[3.2.1]octanyl group, a bicyclo[4.2.0]octanyl group, a bicyclo[4.1.1]octanyl group, a bicyclo[5.1.0]octanyl group, an octahydro-1H-indeny
  • a C 5 to C 9 bicycloalkyl group means a bicyclic alkyl group having 5 to 9 carbons.
  • a bicyclo[1.1.1]pentanyl group bicyclo[3.1.0]hexanyl group, a bicyclo[2.2.0]hexanyl group, a bicyclo[2.1.1]hexanyl group, bicyclo[3.2.0]heptanyl group, a bicyclo[2.2.1]heptanyl group, a bicyclo[3.1.1]heptanyl group, a bicyclo[4.1.0]heptanyl group, an octahydropentalenyl group, a bicyclo[2.2.2]octanyl group, a bicyclo[3.2.1]octanyl group, a bicyclo[4.2.0]octanyl group, a bicyclo[4.1.1]octanyl group, a bicyclo[5.1.0]octanyl group, an
  • spiroalkyl group means a group consisting of two cycloalkyl moieties that have exactly one atom in common.
  • a C 6 to C 9 spiroalkyl group means a spiroalkyl group having 6 to 9 carbons.
  • a spiro[2.3]hexanyl group a spiro[2.4]heptanyl group, a spiro[3.3]heptanyl group, a spiro[2.5]octanyl group, a spiro[3.4]octanyl group, a spiro[2.6]nonanyl group, a spiro[3.5]nonanyl group, a spiro[4.4]nonanyl group, and the like.
  • a (C 6 to C 9 spiroalkyl)(C 1 to C 3 alkyl) group means a group obtained by substituting "a C 1 to C 3 alkyl group” with "a (C 6 to C 9 spiroalkyl) group” at arbitrary position.
  • a spiro[2.3]hexanyl methyl group a spiro[2.4]heptanyl methyl group, a spiro[3.3]heptanyl methyl group, a spiro[2.5]octanyl methyl group, a spiro[3.4]octanyl methyl group, a spiro[2.6]nonanyl methyl group, a spiro[3.5]nonanyl methyl group, a spiro[4.4]nonanyl methyl group, and the like.
  • a C 3 to C 8 cycloalkenyl group means a group having a double bond at arbitrary position of "a C 3 to C 8 cycloalkyl group” having 3 to 8 carbons.
  • a cyclopropenyl group a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a cyclooctenyl group, and the like.
  • a (C 3 to C 8 cycloalkyl)(C 1 to C 3 alkyl) group means a group obtained by substituting "a C 1 to C 3 alkyl group” with "a C 3 to C 8 cycloalkyl group” at arbitrary position.
  • a cyclopropylmethyl group for example, there may be mentioned a cyclopropylmethyl group, a cyclopropylethyl group, a cyclopropylpropyl group, a cyclobutylmethyl group, a cyclobutylethyl group, a cyclopentylmethyl group, a cyclopentylethyl group, a cyclohexylmethyl group, a cyclohexylethyl group, a cycloheptylmethyl group, a cycloheptylethyl group, a cyclooctylmethyl group, and the like.
  • a (C 3 to C 8 cycloalkenyl)(C 1 to C 3 alkyl) group means a group obtained by substituting "a C 1 to C 3 alkyl group” with "a C 3 to C 8 cycloalkenyl group” at arbitrary position.
  • a cyclopropenylmethyl group for example, there may be mentioned a cyclopropenylmethyl group, a cyclopropenylethyl group, a cyclopropenylpropyl group, a cyclobutenylmethyl group, a cyclobutenylethyl group, a cyclopentenylmethyl group, a cyclopentenylethyl group, a cyclohexenylmethyl group, a cyclohexenylethyl group, a cycloheptenylmethyl group, a cycloheptenylethyl group, a cyclooctenylmethyl group, and the like.
  • a (C 2 to C 6 alkenyl)(C1 to C 3 alkyl) group means a group obtained by substituting "a C 1 to C 3 alkyl group” with "a C 2 to C 6 alkenyl group” at arbitrary position.
  • a 2-propenyl group an 1-methyl-2-propenyl group, a 2-methyl-2-propenyl group, a 2-buten-1-yl group, a 3-buten-1-yl group, a 2-penten-1-yl group, a 3-penten-1-yl group, a 4-penyten-1-yl group, a 5-hexen-1-yl group, a 4-hexen-1-yl group, a 3-hexen-1-yl group, a 2-hexen-1-yl group, an 1-methyl-2-buten-1-yl group, an 1-ethyl-2-buten-1-yl group, a 2-methyl-2-buten-1-yl group, a 3-methyl-2-buten-1-yl group, a 3-methyl-3-penten-1-yl group, a 3-methyl-2-penten-1-yl group, a 3-ethyl-2-penten-1-yl group, a 4-methyl-3-penten-1-yl group, a 3-
  • a (C 2 to C 6 alkynyl)(C 1 to C 3 alkyl) group means a group obtained by substituting "a C 1 to C 3 alkyl group” with "a C 2 to C 6 alkynyl group” at arbitrary position.
  • a 2-propyn-1-yl group an 1-methyl-2-propyn-1-yl group, an 1-ethyl-2-propyn-1-yl group, a 2-butyn-1-yl group, an 1-methyl-2-butyn-1-yl group, an 1-ethyl-2-butyn-1-yl group, a 3-butyn-1-yl group, an 1-methyl-3-butyn-1-yl group, an 1-ethyl-3-butyn-1-yl group, a 2-pentyn-1-yl group, an 1-methyl-2-pentyn-1-yl group, a 3-pentyn-1-yl group, an 1-methyl-3-pentyn-1-yl group, a 4-pentyn-1-yl group, a 5-hexyn-1-yl group, a 4-hexyn-1-yl group, a 3-hexyn-1-yl group, a 2-hexyn-1-yl group
  • a C 1 to C 6 alkoxy group means a group obtained by substituting an oxy group with "a C 1 to C 6 alkyl group".
  • a (C 1 to C 6 alkoxy)(C 2 to C 4 alkyl) means a group obtained by substituting "a C 2 to C 4 alkyl group” with "a C 1 to C 6 alkoxy group” or, in other words, a group obtained by replacing one carbon of a C 4 to C 11 alkyl group with one oxygen at arbitrary chemically possible position.
  • a methoxyethyl group an ethoxyethyl group, a propyloxyethyl group, an isopropyloxyethyl group, a butyloxyethyl group, an isobutyloxyethyl group, a sec-butyloxyethyl group, a tert-butyloxyethyl group, an isopentyloxyethyl group, a 2-methylbutyloxyethyl group, a 3-methylbutyloxyethyl group, an 1-ethylpropyloxyethyl group, an 1,1-dimethylpropyloxyethyl group, an 1,2-dimethylpropyloxyethyl group, a neopentyloxyethyl group, a hexyloxyethyl group, a 4-methylpentyloxyethyl group, a 3-methylpentyloxyethyl group, a 3-
  • a C 1 to C 6 alkylthio group means a group obtained by substituting a thio group with "a C 1 to C 6 alkyl group”.
  • a methylthio group an ethylthio group, a propylthio group, an isopropylthio group, a butylthio group, an isobutylthio group, a sec-butylthio group, a tert-butylthio group, a pentylthio group, a neopentylthio group, a tert-pentylthio group, a 2-methylbutylthio group, a hexylthio group, an isohexylthio group, and the like.
  • a C 3 to C 8 cycloalkylthio group means a group obtained by substituting a thio group with "a C 3 to C 8 cycloalkyl group”.
  • a cyclopropylthio group a cyclobutylthio group, a cyclopentylthio group, a cyclohexylthio group, a cycloheptylthio group, a cyclooctylthio group, and the like.
  • a (C 1 to C 6 alkyl)carbonyl group means a group obtained by substituting a carbonyl group with "a C 1 to C 6 alkyl group”.
  • a (C 1 to C 6 alkoxy)carbonyl group means a group obtained by substituting a carbonyl group with "a C 1 to C 6 alkoxy group”.
  • a methoxycarbonyl group an ethoxycarbonyl group, a n-propoxycarbonyl group, an isopropoxycarbonyl group, a n-butoxycarbonyl group, an isobutoxycarbonyl group, a sec-butoxycarbonyl group, a tert-butoxycarbonyl group, a n-pentoxycarbonyl group, an isopentoxycarbonyl group, a 2-methylbutoxycarbonyl group, a 3-methylbutoxycarbonyl group, an 1-ethylpropoxycarbonyl group, an 1,1-dimethylpropoxycarbonyl group, an 1,2-dimethylpropoxycarbonyl group, a neopentoxycarbonyl group, a 4-methylpentoxycarbonyl group,
  • a C 3 to C 8 cycloalkyloxy group means a group obtained by substituting an oxy group with "a C 3 to C 8 cycloalkyl group”.
  • a cyclopropyloxy group a cyclobutyloxy group, a cyclopentyloxy group, a cyclohexyloxy group, a cycloheptyloxy group, a cyclooctyloxy group, and the like.
  • a mono(C 1 to C 6 alkyl)amino group means a group obtained by substituting an amino group with "a C 1 to C 6 alkyl group".
  • a methylamino group an ethylamino group, a propylamino group, an isopropylamino group, a butylamino group, an isobutylamino group, a sec-butylamino group, a tert-butylamino group, a pentylamino group, a hexylamino group, and the like.
  • a di(C 1 to C 6 alkyl)amino group means a group obtained by substituting an amino group with two of the same or different "a C 1 to C 6 alkyl group".
  • a dimethylamino group a diethylamino group, a dipropylamino group, a diisopropylamino group, a dibutylamino group, a diisobutylamino group, a di(sec-butyl)amino group, a di(tert-butyl)amino group, a dipentylamino group, a dihexylamino group, and the like.
  • a (C 1 to C 6 alkyl)aminocarbonyl group means a group obtained by substituting a carbonyl group with "a (C 1 to C 6 alkyl)amino group".
  • a methylaminocarbonyl group an ethylaminocarbonyl group, a propylaminocarbonyl group, an isopropylaminocarbonyl group, a butylaminocarbonyl group, an isobutylaminocarbonyl group, a sec-butylaminocarbonyl group, a tert-butylaminocarbonyl group, a pentylaminocarbonyl group, a hexylaminocarbonyl group, and the like.
  • a C 1 to C 6 alkylsulfonyl group means a group obtained by substituting a sulfonyl group with "a C 1 to C 6 alkyl group”.
  • a methylsulfonyl group an ethylsulfonyl group, a propylsulfonyl group, an isopropylsulfonyl group, a butylsulfonyl group, an isobutylsulfonyl group, a sec-butylsulfonyl group, a tert-butylsulfonyl group, a pentylsulfonyl group, a hexylsulfonyl group, and the like.
  • a C 1 to C 6 alkylaminosulfonyl group means a group obtained by substituting a sulfonyl group with "a mono(C 1 to C 6 alkyl)amino group".
  • a methylaminosulfonyl group an ethylaminosulfonyl group, a propylaminosulfonyl group, an isopropylaminosulfonyl group, a butylaminosulfonyl group, an isobutylaminosulfonyl group, a sec-butylaminosulfonyl group, a tert-butylaminosulfonyl group, a pentylaminosulfonyl group, a hexylaminosulfonyl group, and the like.
  • a (hydroxycarbonyl)(C 1 to C 3 alkyl) group means a group obtained by substituting "a C 1 to C 3 alkyl group” with "a (hydroxycarbonyl) group” at arbitrary position.
  • a hydroxycarbonylmethyl group a (1-hydroxycarbonyl)ethyl group, a (2-hydroxycarbonyl)ethyl group, a (3-hydroxycarbonyl)propyl group, an a (2-hydroxycarbonyl)propyl group, a (1-hydroxycarbonyl)propyl group, a (1-hydroxycarbonyl)(1-methyl)ethyl group, and the like.
  • a (C 1 to C 6 alkoxy)carbonyl(C 1 to C 3 alkyl) group means a group obtained by substituting "a C 1 to C 3 alkyl group” with "a (C 1 to C 6 alkoxy)carbonyl group” at arbitrary position.
  • a methoxycarbonylmethyl group a methoxycarbonylethyl group, a (3-methoxycarbonyl)propyl group, a (2-methoxycarbonyl)propyl group, a (1-methoxycarbonyl)propyl group, a (1-methoxycarbonyl)(1-methyl)ethyl group, an ethoxycarbonylmethyl group, an ethoxycarbonylethyl group, an (3-ethoxycarbonyl)propyl group, an (2-ethoxycarbonyl)propyl group, an (1-ethoxycarbonyl)propyl group, an (1-ethoxycarbonyl)(1-methyl)ethyl group, and the like.
  • a (C 1 to C 6 alkyl)sulfonyl(C 1 to C 3 alkyl) group means a group obtained by substituting "a C 1 to C 3 alkyl group” with "a (C 1 to C 6 alkyl)sulfonyl group” at arbitrary position.
  • a methlsulfonyl methyl group a methylsulfonylethyl group, a (3-methylsulfonyl)propyl group, a (2-methylsulfonyl)propyl group, a (1-methylsulfonyl)propyl group, a (1-methylsulfonyl)(1-methyl)ethyl group, an ethylsulfonylmethyl group, an ethylsulfonylethyl group, an (3-ethylsulfonyl)propyl group, an (2-ethylsulfonyl)propyl group, an (1-ethylsulfonyl)propyl group, an (1-ethylsulfonyl)(1-methyl)ethyl group , and the like.
  • a C 6 to C 10 aryl group means an aromatic hydrocarbon group having 6 to 10 carbons.
  • a phenyl group a naphthyl group, an indenyl group, a tetrahydronaphthyl group, an indanyl group, an azulenyl group, and the like.
  • a C 6 to C 10 aryloxy group means a group obtained by substituting an oxy group with "a C 6 to C 10 aryl group”.
  • a phenyloxy group for example, there may be mentioned a phenyloxy group, a naphthyloxy group, an indenyloxy group, a tetrahydronaphthyloxy group, an indanyloxy group, an azulenyloxy group, and the like.
  • a (C 6 to C 10 aryl)(C 1 to C 3 alkyl) group means a group obtained by substituting "a C 1 to C 3 alkyl group” with "a C 6 to C 10 aryl group”.
  • a benzyl group for example, there may be mentioned a benzyl group, a phenethyl group, a phenylpropyl group, a naphthylmethyl group, and the like.
  • a 5- to 10-membered heteroaryl group means a 5- to 10-membered monocyclic or bicyclic heterocyclic group having aromaticity, wherein the heterocyclic group contains 1 to 5 heteroatoms selected from oxygen, sulfur and nitrogen.
  • the other ring may be non-aromatic ring.
  • the number of respective heteroatoms and combinations thereof are not particularly limited as long as ring having prescribed number of members can be formed and can exist chemically stably.
  • a 5- to 10-membered heteroaryl group for example, there may be mentioned a pyridyl group, a pyrazyl group, a pyrimidyl group, a pyridazinyl group, a furyl group, a thienyl group, a pyrrole group, a pyrazolyl group, an 1,3-dioxaindanyl group, an isoxazolyl group, an isothiazolyl group, a benzofuranyl group, an isobenzofuryl group, a benzothienyl group, an indolyl group, an isoindolyl group, a chromanyl group, a benzothiazolyl group, a benzoimidazolyl group, a benzoxazolyl group, a pyranyl group, an imidazolyl group, an oxazolyl group, a thiazolyl group, a triazinyl
  • a (5- to 10-membered heteroaryl)(C 1 to C 3 alkyl) group means a group obtained by substituting "a C 1 to C 3 alkyl group” with "a 5- to 10-membered heteroaryl group”.
  • a pyridylmethyl group a thienylmethyl group, a thiazolylmethyl group, a benzothiazolylmethyl group, a benzothiophenylmethyl group, and the like.
  • a 3- to 8-membered heterocycloalkyl group means a 3- to 8-membered aliphatic heterocyclic group which may be saturated or partially unsaturated, wherein the ring contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen.
  • a piperidyl group a tetrahydrofuranyl group, a tetrahydropyranyl group, a tetrahydrothienyl group, a morpholyl group, and the like.
  • a (3- to 8-membered heterocycloalkyl)(C 1 to C 3 alkyl) group means a group obtained by substituting "a C 1 to C 3 alkyl group” with "a 3- to 8-membered heterocycloalkyl group".
  • a piperidylmethyl group a tetrahydrofuranylmethyl group, a tetrahydropyranylmethyl group, a tetrahydrothienylmethyl group, a morpholinoethyl group, a oxetan-3-ylmethyl group, and the like.
  • spiroheteroalkyl group means a spiroalkyl group in which 1 to 4 carbon atoms replaced with 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen.
  • a C 6 to C 9 spiroheteroalkyl group means a spiroalkyl group having 6 to 9 carbons. For example, there may be mentioned a 4-oxaspiro[2.4]heptanyl group, a 4-oxaspiro[2.5]octaneyl group, and the like.
  • a (C 5 to C 9 bicycloalkyl)(C 1 to C 3 alkyl) group means a group obtained by substituting "a C 1 to C 3 alkyl group” with "a C 5 to C 9 bicycloalkyl group” at arbitrary position.
  • a bicyclo[1.1.1]pentanyl methyl group a bicyclo[3.1.0]hexanyl methyl group, a bicyclo[3.1.0]hexanyl ethyl group, a bicyclo[2.2.0]hexanyl methyl group, a bicyclo[2.2.0]hexanyl ethyl group, a bicyclo[2.1.1]hexanyl methyl group, a bicyclo[2.1.1]hexanyl ethyl group, a bicyclo[3.2.0]heptanyl methyl group, a bicyclo[3.2.0]heptanyl ethyl group, a bicyclo[2.2.1]heptanyl methyl group, a bicyclo[2.2.1]heptanyl ethyl group, a bicyclo[3.1.1]heptanyl methyl group, a bicyclo[4.1.0]heptanyl methyl group, an octahydropentalenyl
  • heterocycloalkyl group means a bicycloalkyl group in which 1 to 4 carbon atoms replaced with 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen.
  • a C 6 to C 9 heterobicycloalkyl group means a heterobicycloalkyl group having 6 to 9 carbons. For example, there may be mentioned a 7-oxabicyclo[2.2.1]heptanyl group and the like.
  • a (C 6 to C 9 heterobicycloalkyl)(C 1 to C 3 alkyl) group means a group obtained by substituting "a C 1 to C 3 alkyl group” with "a C 6 to C 9 heterobicycloalkyl group” at arbitrary position.
  • a 7-oxabicyclo[2.2.1]heptanyl methyl group there may be mentioned a 7-oxabicyclo[2.2.1]heptanyl ethyl group, and the like.
  • each R a group can be selected independently and the C 1 to C 6 alkyl group can be substituted by the same R a groups or by different R a groups.
  • meaning of other expressions such as "a C 1 to C 6 alkyl group substituted by 0, 1, 2 or 3 R b groups" and the like mean similar situations.
  • the present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof:
  • R 1 is selected from F, Cl, Br, a C 1 to C 6 alkyl group substituted by 0, 1, 2 or 3 R a groups and a C 3 to C 8 cycloalkyl group substituted by 0, 1, 2 or 3 R a groups; wherein R a is, independently selected from F, C 1 to C 4 alkyl group, -OH, -CN, -NO 2 , -NH 2 , -CO 2 H, a C 1 to C 6 alkoxy group, a mono(C 1 to C 6 alkyl)amino group, a di(C 1 to C 6 alkyl)amino group, -CF 3 and an oxo group.
  • the "a C 1 to C 6 alkyl group substituted by 0, 1, 2 or 3 R a groups" in R 1 is preferably C 1 to C 3 alkyl group substituted by 0, 1, 2 or 3 R a groups, and more preferable is a trifluoromethyl group or a difluoromethyl group.
  • the "a C 3 to C 8 cycloalkyl group substituted by 0, 1, 2 or 3 R a groups" in R 1 is preferably C 3 to C 4 cycloalkyl group substituted by 0, 1, 2 or 3 R a groups, more preferable is a cyclopropyl group substituted by 0, 1, 2 or 3 R a groups.
  • R 1 is preferably Cl, a C 1 to C 4 alkyl group substituted by 0, 1, 2 or 3 R a groups or a cyclopropyl group substituted by 0, 1, 2 or 3 R a groups, and more preferable is a trifluoromethyl group, a difluoromethyl group or Cl.
  • Y is a C 4 to C 6 cycloalkyl group, a C 6 to C 9 bicycloalkyl group or a C 6 to C 9 spiroalkyl group, all of which are substituted by a R 2 group, 0 or 1 R 6 group and 0, 1, 2 or 3 R 7 groups; wherein R 2 is selected from -OH, -CO 2 H, -SO 3 H, -CONH 2 , -SO 2 NH 2 , a (C 1 to C 6 alkoxy)carbonyl group substituted by 0, 1, 2 or 3 R c groups, a (C 1 to C 6 alkyl)aminocarbonyl group substituted by 0, 1, 2 or 3 R c groups, a C 1 to C 6 alkylsulfonyl group substituted by 0, 1, 2 or 3 R c groups, a C 1 to C 6 alkylaminosulfonyl group substituted by 0, 1, 2 or 3 R c groups, a (hydroxycarbonyl)(
  • Y is preferably a group represented by formula (II-a), formula (II-c) or formula (II-d); and more preferably a group represented by formula (II-a) or formula (II-d).
  • variable, n is preferably 2 in a group represented by formula (II-d).
  • R 2 in Y is preferably -CO 2 H, -SO 3 H -CONH 2 , -SO 2 NH 2 a (C 1 to C 2 alkyl)aminocarbonyl group substituted by 0 or 1 R c groups, a C 1 to C 2 alkylsulfonyl group substituted by 0 or 1 R c groups, a C 1 to C 2 alkylaminosulfonyl group substituted by 0 or 1 R c groups or a (hydroxycarbonyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2 or 3 R c groups, and more preferable is -CO 2 H or a hydroxycarbonylmethyl group substituted by 0, 1 or 2 R c groups.
  • R 6 in Y is preferably H or a C 1 to C 4 alkyl group without R b group, and more preferable is H, a methyl group or an ethyl group.
  • R 7 in Y is preferably H or a C 1 to C 2 alkyl group without R b group, and more preferable is H or a methyl group.
  • R 3 is selected from H, F, Cl, -CH 3 and -CF 3 .
  • R 3 is preferably H.
  • R 4 is selected from a C 1 to C 6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 R e groups, a (C 2 to C 6 alkenyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R e groups, a (C 2 to C 6 alkynyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R e groups, a (C 1 to C 6 alkoxy)(C 2 to C 4 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R e groups, a (C 6 to C 10 aryl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R f groups, a (5- to 10-membered heteroaryl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R f groups, a C 3 to C 8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5
  • the "a C 1 to C 6 alkyl group substituted by 0, 1, 2, 3, 4 or 5R e groups" in R 4 is preferably C 2 to C 6 alkyl group substituted by 0, 1, 2, 3, 4 or 5R e and more preferably a tert-butylmethyl group or a 3,3,3-trifluoro-2,2-dimethylpropyl group.
  • the "a (C 2 to C 6 alkenyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R e groups" in R 4 is preferably one having 3 to 6 carbons in (C 2 to C 6 alkenyl)(C 1 to C 3 alkyl) and more preferably a 3-methyl-2-buten-1-yl group.
  • the "a (C 2 to C 6 alkynyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5R e groups" in R 4 is preferably one having 4 to 8 carbons in (C 2 to C 6 alkynyl)(C 1 to C 3 alkyl) and more preferably a 4,4-dimethyl-2-pentyn-1-yl group.
  • the "a (C 1 to C 6 alkoxy)(C 2 to C 4 alkyl) group substituted by 0, 1, 2, 3, 4 or 5R e groups" in R 4 is preferably one having 3 to 7 carbons in (C 1 to C 6 alkoxy)(C 2 to C 4 alkyl), more preferably a C 1 to C 4 alkoxyethyl group substituted by 0, 1, 2 or 3 alkyl groups, and even more preferably a 2,2-dirriethyl-2-methoxyethyl group or a 2-(tert-butoxy)ethyl group.
  • the "a (C 6 to C 10 aryl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R f groups" in R 4 is preferably a benzyl group substituted by 0, 1, 2, 3, 4 or 5 R f, s; more preferably a benzyl group substituted by 1, 2 or 3 groups selected from F and Cl, or a unsubstituted benzyl group; and even more preferable is a 4-fluorobenzyl group, a 3,5-difluorobenzyl group or a 4-(trifluoromethyl)benzyl group.
  • the "a (5- to 10-membered heteroaryl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R f groups" in R 4 is preferably a pyridylmethyl group, a thienylmethyl group, a thiazolylmethyl group or a furanylmethyl group.
  • the "a C 3 to C 8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups" in R 4 is preferably C 3 to C 6 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups and more preferably a 2,2-dimethylcyclobutyl group or a 4,4-dimethylcyclohexyl group.
  • the "a (C 3 to C 8 cycloalkyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R g groups" in R 4 is preferably a C 3 to C 6 cycloalkyl methyl group substituted by 0, 1, 2, 3 or 4 R g groups; and more preferable is a (1-fluorocyclopentyl)methyl group, a (3,3-dimethylcyclobutyl)methyl group, a (1-methylcyclobutyl)methyl group, a (1-(trifluoromethyl)cyclobutyl)methyl group, a (1-(trifluoromethyl)cyclopropyl)methyl group or a (1-methylcyclopropyl)methyl group.
  • the "a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups" in R 4 is preferably a 3- to 6-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups.
  • the "a (3- to 8-membered heterocycloalkyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R g groups" in R 4 is preferably a 3- to 6-membered heterocycloalkyl methyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups; more preferably a tetrahydrofuranylmethyl group substituted by 1, 2 or 3 groups selected from F, a C 1 to C 4 alkyl group and a C 1 to C 6 alkylene group substituted by 0, 1, 2 or 3 R l groups.
  • the "a C 6 to C 9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups" in R 4 is preferably a C 7 to C 8 spiroalkyl ring substituted by 0, 1, 2, 3, 4 or 5 R g groups; more preferably a spiro[2.5]octan-1-yl group, a spiro[3.5]nonan-1-yl group, a spiro[3.3]heptan-1-yl group or a spiro[3.3]heptan-2-yl group.
  • the "a (C 6 to C 9 spiroalkyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R g groups" in R 4 is preferably a C 6 to C 8 spiroalkyl methyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups; more preferably a spiro[2.5]octan-6-ylmethyl group substituted by 0, 1, 2 or 3 R g groups or a spiro[2.3]hexan-5-ylmethyl group substituted by 0, 1, 2 or 3 R g groups; and even more preferable is a spiro[2.5]octan-6-ylmethyl group, (5-fluoro-spiro[2.3]hexan)-5-ylmethyl group or spiro[2.3]hexan-5-ylmethyl group.
  • the "a C 6 to C 9 spiroheteroalkyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups" in R 4 is preferably a C 7 to C 8 spiroheteralkyl ring substituted by 0, 1, 2, 3, 4 or 5 R g groups.
  • the "a C 5 to C 9 bicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups" in R 4 is preferably a C 6 to C 8 bicycloalkyl ring substituted by 0, 1, 2, 3, 4 or 5 R g groups; more preferably a bicyclo[3.1.0]hexan-3-yl group substituted by 0, 1, 2 or 3 R g groups; and even more preferable is a 6,6-dimethylbicyclo[3.1.0]hexan-3-yl group.
  • the "a (C 5 to C 9 bicycloalkyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R g groups" in R 4 is preferably a C 5 to C 7 bicycloalkyl methyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups; more preferably a (bicyclo[1.1.1]pentan-1-yl)methyl group substituted by 0, 1, 2 or 3 R g groups or a (bicyclo[2.2.1]heptan-1-yl)methyl group substituted by 0, 1, 2 or 3 R g groups; and even more preferable is a (4-methylbicyclo[2.2.1]heptan-1-yl)methyl group or (bicyclo[1.1.1]pentan-1-yl)methyl group.
  • the "a (C 6 to C 9 heterobicycloalkyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R g groups" in R 4 is preferably a C 6 to C 7 heterobicycloalkyl methyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups; more preferably (7-oxabicyclo[2.2.1]heptan-1-yl)methyl group substituted by 0, 1, 2 or 3 R g groups; and, even more preferable is (4-methyl-7-oxabicyclo[2.2.1]heptan-1-yl)methyl group or (7-oxabicyclo[2.2.1]heptan-1-yl)methyl group.
  • R 5 is selected from a C 6 to C 10 aryl group substituted by 0, 1, 2, 3, 4 or 5 R i groups, a 5- to 10-membered heteroaryl group substituted by 0, 1, 2, 3, or 4 R i groups, a C 3 to C 8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 R j groups, a C 3 to C 8 cycloalkenyl group substituted by 0, 1, 2, 3, 4 or 5 R j groups and a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 R j groups; wherein R i is independently selected from F, Cl, Br, -OH, -CN, -NO 2 , -CO 2 H, a C 1 to C 6 alkyl group substituted by 0, 1, 2 or 3 R k groups, a C 2 to C 6 alkenyl group substituted by 0, 1, 2 or 3 R k groups, a C 2 to C 6 alkynyl group substituted by 0, 1, 1,
  • the "a C 6 to C 10 aryl group substituted by 0, 1, 2, 3, or 4 R i groups" in R 5 is preferably a phenyl group substituted by 2 to 4 groups selected from -OH, -NH 2 , Cl, F, -CN, -CF 3 , -OCF 3 , -OCF 2 H, a methyl group, a cyclopropyl group and a methoxy group; and more preferable is a 2,6-dichlorophenyl group, a 2,6-dichloro-4-fluorophenyl group, a 2,6-dichloro-4-methylphenyl group, a 2,4,6-trichlorophenyl group, a 2-chloro-6-fluorophenyl group or a 2,6-dichloro-3-fluorophenyl group.
  • the "a 5- to 10-membered heteroaryl group substituted by 0, 1, 2, 3, or 4 R i groups" in R 5 is preferably a pyridyl group substituted by 2 to 3 groups selected from -OH, -NH 2 , Cl, F, -CN, -CF 3 , a methyl group, and a methoxy group; and more preferable is a 3,5-dichloropyridin-4-yl group, a 3-chloro-5-methoxypyridin-4-yl group, a 3-chloro-5-fluoropyridin-4-yl group or a 2,4-dichloro-6-methylpyridin-3-yl group.
  • R 5 is preferably a phenyl group optionally substituted by 2, 3 or 4 R i groups or a 6-membered heteroaryl group optionally substituted by 2 or 3 R i groups.
  • R 8 and R 9 are independently selected from H, F, -OH, -NH 2 , a C 1 to C 3 alkyl group substituted by 0, 1, 2 or 3 R h groups, and a C 1 to C 6 alkoxy group substituted by 0, 1, 2 or 3 R h groups; or R 8 and R 9 together form an oxo group or a thioxo group; wherein R h is, independently selected from F, a C 1 to C 4 alkyl group, -OH, -CN, -NO 2 , -NH 2 , -CO 2 H, a C 1 to C 6 alkoxy group, a mono(C 1 to C 6 alkyl)amino group, a di(C 1 to C 6 alkyl)amino group, -CF 3 and an oxo group.
  • the "a C 1 to C 3 alkyl group substituted by 0, 1, 2 or 3 R h groups" in R 8 and R 9 is preferably methyl group substituted by 0, 1, 2 or 3 R h groups.
  • the "a C 1 to C 6 alkoxy group substituted by 0, 1, 2 or 3 R h groups" in R 8 and R 9 is preferably methoxy group substituted by 0, 1, 2 or 3 R h groups.
  • R 8 and R 9 are preferably H, F, -OH or an oxo group, anymore preferable are H or an oxo group.
  • R 12 is H; or R 4 and R 12 together are -CR m R m -CR 13 R 14 -CR m R m - or -CR 13 R 14 -CR m R m -CR m R m - to form a pyrrolidine ring.
  • R 13 is selected from H, a C 1 to C 6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 R e groups, a C 6 to C 10 aryl group substituted by 0, 1, 2, 3, 4 or 5 R f groups, a C 6 to C 10 aryloxy group substituted by 0, 1, 2, 3, 4 or 5 R f groups, a (C 2 to C 6 alkenyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R e groups, a (C 2 to C 6 alkynyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R e groups, a (C 1 to C 6 alkoxy)(C 2 to C 4 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R e groups, a (C 6 to C 10 aryl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R f groups, a (5- to 10-membered heteroaryl)
  • R 12 is H; or R 4 and R 12 together are -CH 2 -CR 13 R 14 -CH 2 - to form a pyrrolidine ring, more preferably R 12 is H.
  • R 13 is preferably a C 1 to C 6 alkyl group, a C 6 to C 10 aryl group, a C 6 to C 10 aryloxy group, a (C6 to C10 aryl)(C1 to C3 alkyl) group, or a C 3 to C 8 cycloalkenyl group.
  • R 14 is preferably H or CH 3 ; or R 13 and R 14 together form a C 3 to C 8 cycloalkane ring or a C 3 to C 8 cycloalkene ring.
  • a combination of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 12 , R 13 , R 14 Y, n, k, R a , R b , R c , R e , R f R g , R h , R i R j , R k , R l R m is preferably one where respective preferable components described above are combined; and more preferably one where components described above as more preferable are combined.
  • R l is a C 1 to C 6 alkyl group substituted by 0, 1, 2 or 3 R a groups.
  • R l is a C 1 alkyl group substituted by 0, 1, 2 or 3 R a groups.
  • R 1 is CF 3 .
  • R 2 is CO 2 H.
  • Y is selected from formula (II-a), formula (II-b), formula (II-c) and formula (II-d): wherein, k is 0, 1 or 2; and n is 1, 2 or 3.
  • Y is selected from formula (II-a) and formula (II-d); wherein in k is 0, 1 or 2; and n is 1, 2 or 3.
  • Y is selected from formula (II-a) and formula (II-d); wherein in k is 0; and n 2.
  • R 6 is selected from F, -OH, -NH 2 , -CN, a C 1 to C 6 alkyl group substituted by 0, 1, 2 or 3 R b groups and a C 1 to C 6 alkoxy group substituted by 0, 1, 2 or 3 R b groups.
  • R 6 is a C 1 to C 6 alkyl group substituted by 0, 1, 2 or 3 R b .
  • R 6 is CH 3 .
  • R 7 is independently selected from H, F and a C 1 to C 6 alkyl group substituted by 0, 1, 2 or 3 R b groups.
  • R 7 is H.
  • R 2 is selected from -OH, -CO 2 H -SO 3 H, -CONH 2 and -SO 2 NH 2 .
  • R 3 is H.
  • R 4 is selected from a C 1 to C 6 alkyl group substituted by 0, 1, 2 or 3 R e groups, a (C 6 to C 10 aryl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R f groups, a, C 3 to C 8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups, a (C 3 to C 8 cycloalkyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R g groups, a C 6 to C 9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups, a (C 6 to C 9 spiroalkyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R g groups, a C 5 to C 9 bicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups, a
  • R 4 is a C 1 to C 6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 R e groups.
  • R 4 is a (C 6 to C 10 aryl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R f groups.
  • R 4 is a C 3 to C 8 cycloalkyl group substituted by 0, 1, 2 or 3 R g groups.
  • R4 is a (C 5 to C 9 bicycloalkyl) group substituted by 0, 1, 2, 3, 4 or 5 R g groups.
  • R 4 is a (C 3 to C 8 cycloalkyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R g groups.
  • R 4 is a C 6 to C 9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 R g groups.
  • R 4 is a (C 6 to C 9 spiroalkyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R g groups.
  • R 4 is a (C 5 to C 9 bicycloalkyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R g groups.
  • R 4 is a (C 6 to C 9 heterobicycloalkyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R g groups.
  • R 8 and R 9 are independently selected from H and F.
  • R 8 and R 9 together form an oxo group.
  • R 5 is a C 6 to C 10 aryl group substituted by 0, 1, 2, 3, 4 or 5 R i groups.
  • R 5 is a phenyl group substituted by 0, 1, 2, 3, 4 or 5 R i groups.
  • R 5 is a 5- to 10-membered heteroaryl group substituted by 0, 1, 2, 3, or 4 R i groups.
  • R 5 is a 6-membered heteroaryl group substituted by 0, 1, 2, 3, or 4 R i groups.
  • R 5 is pyridyl substituted by 0, 1, 2, 3, or 4 R i groups.
  • R 12 is H.
  • R 4 and R 12 together are -CH 2 -CR 13 R 14 -CH 2 - to form a pyrrolidine ring.
  • R 14 is selected from H and CH 3 .
  • R 13 and R 14 together form a C 3 to C 8 cycloalkane ring substituted by 0, 1, 2, 3, 4 or 5 R g groups, C 3 to C 8 cycloalkene ring substituted by 0, 1, 2, 3, 4 or 5 R g groups, or a 3- to 8-membered heterocycloalkane ring substituted by 0, 1, 2, 3, 4 or 5 R g groups.
  • R 13 is selected from a C 1 to C 6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 R e groups, a C 6 to C 10 aryl group substituted by 0, 1, 2, 3, 4 or 5 R f groups, a C 6 to C 10 aryloxy group substituted by 0, 1, 2, 3, 4 or 5 R f groups, a (C 2 to C 6 alkenyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R e groups, a (C 2 to C 6 alkynyl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R e groups, a (C 1 to C 6 alkoxy)(C 2 to C 4 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R e groups, a (C 6 to C 10 aryl)(C 1 to C 3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 R f groups, a
  • R m is H
  • the present invention also relates to a pharmaceutically acceptable salt of a compound represented by formula (I).
  • a compound represented by formula (I) forms acid addition salts.
  • the pyrazole amide derivative forms salts with bases. These salts are not particularly limited as long as they are pharmaceutically acceptable ones.
  • the acid addition salts include mineral acid salts such as a hydrofluoride, a hydrochloride, a hydrobromide, a hydroiodide, a phosphate, a nitrate, a sulfate, and the like; organic sulfonate such as a methanesulfonate, an ethanesulfonate, a 2-hydroxyethanesulfonate, a p-toluenesufonate, a benzenesulfonate, an ethane-1,2-disulfonate ion, a 1,5-naphthalenedisulfonate ion, a naphthalene-2-sulfonate ion, and the like; and organic carboxylate such as an acetate, a trifluoroacetate, a propionate, an oxalate, a fumarate, a phthalate, a malonate, a succinate
  • salts with bases there are mentioned salts with inorganic bases such as a sodium salt, a potassium salt, a magnesium salt, a calcium salt, an aluminum salt, and the like; and salts with organic bases such as a methylamine salt, an ethylamine salt, a lysine salt, an ornithine salt, and the like.
  • a compound represented by formula (I) of the present invention contains isomers in some cases. Such isomers are included in a compound represented by formula (I) of the present invention.
  • isomers in the ring and condensed ring systems E-, Z-, cis-, and trans-forms
  • isomers due to the presence of chiral carbons R- and S-forms, ⁇ - and ⁇ -configurations, enantiomers, and diastereomers
  • optically active substances with optical rotation D-, L-, d-, and 1-forms
  • tautomers polar compounds obtained by chromatographic separation (a highly-polar compound and a lowly-polar compound), equilibrium compounds, rotamers, mixtures of these compounds in an arbitrary ratio, racemic mixtures, and the like.
  • the present invention also includes various deuterated forms of the compounds represented by formula (I). Each hydrogen atom attached to a carbon atom may be independently replaced with a deuterium atom.
  • the compound represented by formula (I) in the present invention can be produced by applying publicly known various synthesis methods with the use of characteristics based on types of basic structures or substituents.
  • the functional group may be protected with an appropriate protecting group or a group that can be easily converted to a functional group in the process of using a raw material and an intermediate depending on functional groups.
  • a functional group includes, for example, an amino group, a hydroxyl group, a carboxyl group, and the like.
  • the protecting groups thereof include, for example, protecting groups described in the " Protecting Groups in Organic Synthesis (the third edition, 1999)" written by T. W. Greene and P. G. M. Wuts . They may be suitably chosen and used depending on the reaction conditions. In these methods, the reaction is carried out by introducing the protecting group followed by eliminating the protecting group as necessary, or converting to an intended group to obtain an intended compound.
  • a compound (I-1) can be prepared, for example, by the following method: (wherein, R 8 and R 9 are independently H; F; a hydroxyl group; an amino group; a C 1 to C 3 alkyl group substituted by 0, 1, 2 or 3 R h groups; a C 1 to C 6 alkoxy group substituted by 0, 1, 2 or 3 R h groups; or R 8 and R 9 together form oxo group or thioxo group. Other symbols have the same meanings as described above.)
  • the present step is a method for producing a compound (I-1) by reacting a compound (1) or a reactive derivative thereof with a compound (2).
  • the reactive derivative of the compound (1) means a reactive derivative of a carboxyl group, and for example, acid chloride, acyl azide, mixed acid anhydride, symmetric acid anhydride, activated amide, activated ester, and the like are cited. These reactive derivatives can be optionally chosen depending on types of carboxylic acids used.
  • the present reaction may be carried out according to a general amide-forming reaction by methods described in the literature (e.g., Pepuchido Gousei no Kiso to Jikken by Nobuo Izumiya, etc., Maruzen, 1983 , Comprehensive Organic Synthesis, Vol. 6., Pergamon Press, 1991 , etc.), equivalent methods thereto or a combination of these methods and the conventional method.
  • the present reaction can be carried out by using a condensation agent that is well known to a person skilled in the art, or an ester activation method, a mixed acid anhydride method, an acid chloride method, a carbodiimide method and the like that are well known in the art.
  • the reagents used in such an amide-forming reaction include, for example, thionyl chloride, oxalyl chloride, N , N -dicyclohexylcarbodiimide, 1-methyl-2-bromopyridinium iodide, N,N' -carbonyldiimidazole, diphenylphosphoryl chloride, diphenylphosphoryl azide, N,N' -disuccinimidyl carbonate, N,N' -disuccinimidyl oxalate, 1-ethyl-3-(3-dimethylarninopropyl)carbodiimide hydrochloride, benzotriazol-1-yl-oxy-tris(pyrrolidinol)phosphonium hexafluorophosphate, 2-( 1H -benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, 2-(5-norborn
  • thionyl chloride oxalyl chloride, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride or 2-(7-aza- 1H -benzotriazol-1-yl)-1,1,3,3-tetramethyluronim hexafluorophosphate, and the like are preferable.
  • a base and/or a condensation agent may be used along with the above-mentioned amide-forming agent.
  • the amount of the condensation agent that is consumed is not strictly limited, and is generally 0.1 equivalents to 100 equivalents with respect to 1 equivalent of the compound (1), and preferably 0.1 equivalents to 10 equivalents.
  • a base used includes, for example, tertiary aliphatic amine such as trimethylamine, triethylamine, N,N -diisopropylethylamine, N -methylmorpholine, N -methylpyrrolidine, N -methylpiperidine, N,N -dimethylaniline, 1,8-diazabicyclo[5.4.0]undec-7-ene, 1,5-azabicyclo[4.3.0]non-5-ene, and the like; aromatic amines such as pyridine, 4-dimethylaminopyridine, picoline, lutidine, quinoline, or isoquinoline, and the like. Above all, tertiary aliphatic amine and the like are preferable, and triethylamine or N,N- diisopropylethylamine and the like are in particular preferable.
  • the amount of the base used varies depending on the compound used, types of solvents and other reaction conditions, however, it is generally 0.1 equivalents to 100 equivalents with respect to 1 equivalent of the compound (1), preferably 1 equivalent to 5 equivalents.
  • the condensation agent used includes, for example, N -hydroxybenzotriazole hydrate, N -hydroxysuccinimide, and the like.
  • the amount of the compound (2) used varies depending on the compound used, types of solvents and other reaction conditions, however, it is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (1) or a reactive derivative thereof, and preferably 1 equivalent to 3 equivalents.
  • the reaction is generally carried out in an inactive solvent
  • the inactive solvent include tetrahydrofuran, acetonitrile, N,N -dimethylformamide, 1,4-dioxane, benzene, toluene, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, pyridine, and the like, or mixtures thereof.
  • the reaction time is generally 0.5 hours to 96 hours, preferably 1 hour to 24 hours.
  • the reaction temperature is generally 0°C to the boiling point temperature of the solvent, and preferably room temperature to 80°C.
  • a base, an amide-forming reagent, and a condensation agent used in the present reaction can be used as a combination of one or more types thereof.
  • the compound (I-1) obtained in such a manner can be isolated and purified by an isolation and purification method that is well known to a person skilled in the art (e.g., concentration, concentration under reduced pressure, crystallization, solvent extraction, reprecipitation, chromatography, and the like; in the category of "general synthesis method", the term “isolation and purification method that is well known to a person skilled in the art” has the same meaning unless otherwise particularly specified).
  • an isolation and purification method that is well known to a person skilled in the art (e.g., concentration, concentration under reduced pressure, crystallization, solvent extraction, reprecipitation, chromatography, and the like; in the category of "general synthesis method", the term “isolation and purification method that is well known to a person skilled in the art” has the same meaning unless otherwise particularly specified).
  • compounds (I-2) and (I-3) can be produced, for example, by the following method: (wherein, other symbols have the same meanings as described above.)
  • the present step is a method for producing a compound (I-2) by reacting the compound (1) or a reactive derivative thereof with a compound (3).
  • the reaction in the present step can be carried out by the same method as in the step 1, an equivalent method thereto, or a combination of these methods and a conventional method.
  • the compound (I-2) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the present step is a method for producing a compound (I-3) by subjecting the compound (I-2) to an oxidation reaction.
  • the present step can be carried out according to a method well known to a person skilled in the art.
  • the PCC oxidation, the Swern oxidation, the MnO 2 oxidation, and the Dess-Martin oxidation, and the like are cited.
  • the Dess-Martin oxidation can be carried out by using the Dess-Martin reagent without solvent or in a solvent inert to the reaction.
  • the amount of the Dess-Martin reagent used is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (I-2), preferably 1 equivalent to 4 equivalents.
  • the reaction in the present step is generally carried out in an inactive solvent.
  • the inactive solvent for example, tetrahydrofuran, acetonitrile, N,N -dimethylformamide, dimethyl sulfoxide, 1,4-dioxane, benzene, toluene, dichloromethane, chloroform, carbon tetrachloride, 1, 2-dichloroethane, and the like; or mixtures thereof are cited.
  • the reaction time is generally 0.5 hours to 96 hours, and preferably 1 hour to 24 hours.
  • the reaction temperature is generally -78°C to the boiling point temperature of the solvent, and preferably -20°C to room temperature.
  • the compound (I-3) obtained in such a manner can be isolated and purified by an isolation and purification method that is well known to a person skilled in the art.
  • the carboxyl group is preferably protected in advance by a protecting group and then the protecting group is eliminated after completion of the reaction. Selection of such a protecting group and eliminating conditions can be conducted by referring to the method in previously mentioned " Protecting Groups in Organic Synthesis (the third edition, 1999 )".
  • a compound (I-3) can be prepared, for example, by the following method: Also, among the compounds (1) used to prepare the compounds in the present invention, a compound (1) wherein R 3 is H can be prepared, for example, by the following method: (wherein, R pro is a protecting group. Other symbols have the same meanings as described above.)
  • a compound represented by formula (a) can be synthesized according to a method well known to a person skilled in the art.
  • a compound represented by formula (c) can be synthesized according to a method well known to a person skilled in the art.
  • the present step is a method for producing a compound (b) by reacting a compound (a) with N,N -dimethylformamide dimethyl acetal in the presence or absence of a solvent.
  • N,N -dimethylformamide diethyl acetal, N,N -dimethylformamide diisopropyl acetal, or the like can be used instead of N,N -dimethylformamide dimethyl acetal.
  • the amount of N,N -dimethylformamide dimethyl acetal used is generally 1 equivalent to 10 equivalents with respect to equivalent of the compound (a).
  • the reaction solvent used is not in particular limited as far as it is inert to the reaction, and specifically includes, for example, methanol, ethanol, benzene, toluene, xylene, tetrahydrofuran, 1,4-dioxane, N,N -dimethylformamide, or mixtures thereof.
  • the reaction time is generally 0.5 hours to 96 hours, and preferably 1 hour to 24 hours.
  • the reaction temperature is generally 0°C to the boiling point temperature of the solvent, and preferably room temperature to 160°C.
  • the compound (b) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification means well known to a person skilled in the art.
  • the present step is a method for producing a compound (d) by reacting the compound (b) with a compound having a hydrazino group represented by formula (c).
  • the amount of the compound (c) used is generally 0.5 equivalents to 10 equivalents with respect to 1 equivalent of the compound (b), and preferably 0.7 equivalents to 3 equivalents.
  • the compound (c) when the compound (c) is a salt, it is necessary to use a base for neutralization.
  • a base include sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium acetate, potassium acetate, sodium hydroxide, potassium hydroxide, lithium hydroxide, triethylamine, N,N -diisopropylethylamine, pyridine, and the like.
  • the amount of the base used is generally 1 equivalent to 3 equivalents with respect to 1 equivalent of the compound (c).
  • the reaction solvent used is not in particular limited as far as it is inert to the reaction. Specifically, examples include, methanol, ethanol, n -propanol, n -butanol, isopropanol, acetonitrile, diethyl ether, tetrahydrofuran, 1,4-dioxane, N,N -dimethylformamide, dichloromethane, chloroform, benzene, toluene, xylene or mixtures thereof.
  • the reaction time is generally 0.5 hours to 96 hours, and preferably 1 hour to 24 hours.
  • the reaction temperature is generally 0°C to the boiling point temperature of the solvent, and preferably room temperature to 100°C.
  • the compound (d) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the present step is a method for producing a compound (1-a) by eliminating the protecting group R pro of the compound (d).
  • the elimination of the protecting group can be carried out by a method described in previously mentioned " Protecting Groups in Organic Synthesis (the third edition, 1999 )", an equivalent method thereto or a combination of these methods and the conventional method.
  • the protecting group is a benzyl group
  • the benzyl group can be eliminated by a catalytic reduction method with the use of hydrogen and palladium catalytic agent and the like.
  • the compound (1-a) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • a compound (2-a) wherein both R 8 and R 9 are H can be synthesized, for example, by the following method: (wherein, R 10 and R 11 each independently are H, a group having one less carbon atoms than the hydrocarbon chain of R 4 , or R 10 and R 11 are together form a lower cycloalkyl or cycloalkenyl group. Other symbols have the same meanings as described above.)
  • the compound represented by formula (f) can be synthesized according to a method well known to a person skilled in the art.
  • the present step is a method for producing a compound (g) by reacting an organic lithium compound (e) with ethylene oxide (f).
  • the amount of ethylene oxide (f) used is generally 0.1 equivalents to 10 equivalents with respect to 1 equivalent of the compound (e), and preferably 0.5 equivalents to 3 equivalents.
  • the reaction solvent is not in particular limited as far as it is inert to the reaction, and examples include, tetrahydrofuran, 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, n -hexane, n -heptane, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, benzene, toluene, xylene, and the like.
  • the reaction time is generally 0.5 hour to 48 hours, and preferably 1 hour to 24 hours.
  • the reaction temperature is generally -78°C to the boiling point temperature of the solvent, and preferably -78°C to room temperature.
  • the compound (g) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the present step is a method for producing a compound (h) by reacting the compound (g) with diphenylphosphoryl azide.
  • reaction in the present step can be carried out by the same method as in the step 16, an equivalent method thereto, or a combination of these methods and the conventional method.
  • the compound (h) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the present step is a method for producing a compound (i) by subjecting the compound (h) to a reduction reaction of the azide group.
  • the present step can be carried out according to methods well known to a person skilled in the art. These methods include, for example, a reduction method using phosphine; a catalytic reduction method using H and a palladium catalyst and the like; a reduction method using sodium borohydride; and the like.
  • the reduction method using phosphine can be carried out using triphenylphosphine and water in a solvent inert to the reaction.
  • examples include tetrahydrofuran, acetonitrile, N,N -dimethylformamide, 1,4-dioxane, benzene, toluene, dichloromethane, chloroform, carbon tetrachloride, 1, 2-dichloroethane, water, and the like; or mixtures thereof.
  • triphenylphosphine used is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (15), and preferably 1 to 4 equivalents.
  • the reaction time is generally 0.5 hours to 96 hours, and preferably 2 hours to 48 hours.
  • the reaction temperature is generally 0°C to the boiling point temperature of the solvent, and preferably room temperature to the boiling point temperature of the solvent.
  • the compound (i) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the present step is a method for producing a compound (2-a) by reacting the compound (i) with a compound (j) in the presence of a reducing agent.
  • the amount of the compound (i) used in the present step is generally 0.5 equivalents to 10 equivalents with respect to 1 equivalent of the compound (j), and preferably, 0.8 equivalents to 4 equivalents.
  • the reducing agents used include, for example, sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride, and the like.
  • the amount of the reducing agent used is generally 0.1 equivalents to 10 equivalents with respect to 1 equivalent of the compound (i), and preferably 0.3 equivalents to 5 equivalents.
  • the reaction solvent used is not in particular limited as far as it is inert to the reaction, and examples include methanol, ethanol, acetic acid, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, benzene, toluene, xylene, and the like.
  • the reaction time is generally 0.5 hours to 48 hours, and preferably, 1 hour to 24 hours.
  • the reaction temperature is generally 0°C to the boiling point temperature of the solvent.
  • the compound (2-a) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • a compound (2-b) wherein either R 8 or R 9 is F and the other is H can be synthesized, for example, by the following method: (wherein, each symbol has the same meanings as described above.)
  • a compound represented by formula (k) can be synthesized according to a method well known to a person skilled in the art.
  • the present step is a method for producing a compound (1) by reacting the compound (k) with trimethylsilyl cyanide in the presence of a zinc catalyst and subsequently reacting with a fluorinating agent.
  • the amount of trimethylsilyl cyanide used is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (k), and preferably, 1 equivalent to 5 equivalents.
  • the zinc catalyst used includes, for example, zinc iodide, zinc bromide, and the like.
  • the fluorinating agent used includes, for example, ( N,N- diethylamino)sulfur trifluoride, bis(2-methoxyethyl)aminosulfur trifluoride, 1,1,2,2-tetrafluoroethyl- N,N- dimethylamine, and the like.
  • the amount of fluorinating agent used is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (k), and preferably, 1 equivalent to 5 equivalents.
  • the reaction solvent that used is not in particular limited as far as it is inert to the reaction, and examples include tetrahydrofuran, acetonitrile, 1,4-dioxane, diethyl ether, dichloromethane, chloroform, 1,2-dichloroethane, carbon tetrachloride, benzene, toluene, N,N -dimethylformamide, and the like.
  • the reaction time is generally 30 minutes to 48 hours, and preferably, 1 hour to 24 hours.
  • the reaction temperature is generally 0°C to the boiling point temperature of the solvent.
  • the compound (1) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the present step is a method for producing a compound (m) by subjecting the compound (1) to a reduction reaction of the cyano group.
  • the reducing agents used include, for example, lithium aluminium hydride, sodium bis(2-methoxyethoxy)aluminumhydride, a borane-tetrahydrofuran complex, and the like.
  • the amount of the reducing agent used is generally 1 to 10 equivalents with respect to 1 equivalent of the compound (1).
  • reaction solvent that used is not in particular limited as far as it is inert to the reaction, and examples include tetrahydrofuran, 1,4-dioxane, dichloromethane, benzene, toluene, diethyl ether, and the like.
  • the reaction time is generally 1 hour to 24 hours.
  • the reaction temperature is generally 0°C to the boiling point temperature of the solvent.
  • the compound (m) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the present step is a method for producing a compound (2-b) by reacting the compound (m) with a compound (j) in the presence of a reducing agent.
  • the reaction in the present step can be carried out by the same method as in the step G, an equivalent method thereto, or a combination of these methods and the conventional method.
  • the compound (2-b) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • a compound (3-P) wherein either R 8 or R 9 is a hydroxyl group which is protected by a protecting group and the other is H can be synthesized, for example, by the following method: (wherein, R pro is a protecting group. Other symbols have the same meanings as described above.)
  • a compound represented by formula (n) can be synthesized according to a method well known to a person skilled in the art.
  • the present step is a method for producing a compound (o) by reacting an organic lithium compound (m) with ( tert -butyldimethylsilyloxy)acetaldehyde (n).
  • the reaction in the present step can be carried out by the same method as in the step D, an equivalent method thereto, or a combination of these methods and the conventional method.
  • the compound (o) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the present step is a method for introducing a protecting group to the hydroxyl group of the compound (o).
  • the introduction of the protecting group can be carried out by a method described in the previously mentioned " Protecting Groups in Organic Synthesis (the third edition, 1999 )", an equivalent method thereto, or a combination of these methods and the conventional method.
  • the compound (p) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the present step is a method for producing a compound (q) by eliminating the tert -butyldimethylsilyl group of the compound (p).
  • the elimination of the protecting group can be carried out by a method described in the previously-mentioned " Protecting Groups in Organic Synthesis (the third edition, 1999 )", an equivalent method thereto, or a combination of these methods and the conventional method, and for example, tetrabutylammonium fluoride can be used.
  • the compound (q) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the present step is a method for producing a compound (r) by subjecting the compound (q) to an oxidation reaction.
  • the reaction in the present step can be carried out by the same method as in the step 3, an equivalent method thereto, or a combination of these methods and the conventional method.
  • the compound (r) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the present step is a method for producing the compound (3-P) by reacting the compound (r) with a compound (s) in the presence of a reducing agent.
  • the reaction in the present step can be carried out by the same method as in the step G, an equivalent method thereto, or a combination of these methods and the conventional method.
  • the compound (3-P) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • a compound (2-c) wherein both R 8 and R 9 are F can be synthesized, for example, by the following method: _(wherein, X a and X b each independently are Br or I. Other symbols have the same meanings as described above.)
  • a compound represented by formula (u) can be synthesized according to a method well known to a person skilled in the art.
  • the present step is a method for producing a compound (v) by reacting the compound (t) with a compound (u) in the presence of copper to prepare.
  • the amount of the compound (t) used is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (u), and preferably 1 equivalent to 3 equivalents.
  • the amount of copper used is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (t), and preferably 1 equivalent to 5 equivalents.
  • the reaction solvent used is not in particular limited as far as it is inert to the reaction, and examples include tetrahydrofuran, acetonitrile, 1,4-dioxane, dimethyl sulfoxide, N,N -dimethylformamide, and the like.
  • the reaction time is generally 30 minutes to 48 hours.
  • the reaction temperature is generally room temperature to the boiling point temperature of the solvent.
  • the compound (v) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the present step is a method for producing a compound (w) by eliminating the protecting group R pro of the compound (v).
  • the reaction in the present step can be carried out by the same method as in the step C, an equivalent method thereto, or a combination of these methods and the conventional method.
  • the compound (w) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification means well known to a person skilled in the art.
  • the present step is a method for producing a compound (x) by reacting the compound (w) or a reactive derivative thereof with a compound (s).
  • the reaction in the present step can be carried out by the same method as in the step 1, an equivalent method thereto, or a combination of these methods and the conventional method.
  • the compound (x) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the present step is a method for producing a compound (2-c) by reducing the amide group of the compound (x).
  • reaction in the present step can be carried out by the same method as in the step I, an equivalent method thereto, or a combination of these methods and the conventional method.
  • the compound (2-c) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • the compound represented by formula (I) in the present invention may have a tautomer and/or optical isomer in some cases depending on types of substituents.
  • the present invention includes a mixture of these tautomers and isomers, and isolated ones.
  • the present invention relates to a pharmaceutically acceptable prodrug of the compound represented by formula (I).
  • pharmaceutically acceptable prodrug means a compound producing a compound represented by formula (I) by solvolysis or conversion to CO 2 H, NH 2 , OH, etc. under physiological conditions.
  • An example of the group that produces prodrug is found, for example, in Prog. Med., 5, 2157-2161 (1985 ), " Iyakuhin no Kaihatsu” (Hirokawa Shoten, 1990) Vol.7., Bunshi Sekkei 163-198 .
  • some of the compounds within the scope of formula (I) which have the group that produces a prodrug can serve as a prodrug of the corresponding compound of formula (I) which has CO 2 H, NH 2 , OH, etc.
  • a compound within the scope of formula (I) which has an alkoxycarbonyl group can be converted into a corresponding carboxyl acid derivative.
  • the present invention also relates to a pharmaceutically acceptable salt of the compound represented by formula (I) and a pharmaceutically acceptable prodrug thereof.
  • a salt includes, for example, hydrogen halides such as hydrochloric acid, hydrofluoric acid, hydrobromic acid, hydriodic acid, and the like; inorganic acids such as sulfuric acid, nitric acid, phosphoric acid, carbonic acid, and the like; lower alkyl sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, and the like; arylsulfonic acids such as benzenesulfonic acid, p-toluenesulfonic acid and the like; organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, and the like; and acid addition salts with amino acids including aspartic
  • the salt in the present invention may form a salt with a base.
  • examples include inorganic bases including metals such as sodium, potassium, magnesium, calcium, aluminum, lithium, and the like; salts with an organic base such as methyl amine, ethylamine, ethanolamine, guanidine, lysine, ornithine, and the like; and an ammonium salt, and the like.
  • the compound represented by formula (I) and the pharmaceutically acceptable salt thereof in the present invention (hereinafter, general term for these is referred to as the compound of the present invention) has an excellent ROR ⁇ inhibitory activity and can be used as a ROR ⁇ inhibitor that is clinically applicable to treat or prevent ROR ⁇ associated diseases and symptoms.
  • the compound of the present invention is useful as a therapeutic agent or preventive agent for, in particular, diseases selected from auto immune disease and inflammatory disease (e.g., multiple sclerosis, chronic rheumatoid arthritis, ankylosing spondylitis, systemic erythematodes, psoriasis, psoriatic arthritis, inflammatory bowel disease (e.g., Crohn's disease), and asthma), metabolic disease (especially, diabetes), and cancer (especially, malignant melanoma).
  • auto immune disease and inflammatory disease e.g., multiple sclerosis, chronic rheumatoid arthritis, ankylosing spondylitis, systemic erythematodes, psoriasis, psoriatic arthritis, inflammatory bowel disease (e.g., Crohn's disease), and asthma
  • metabolic disease especially, diabetes
  • cancer especially, malignant melanoma
  • prevention in the present invention means a procedure of administration of a pharmaceutical composition including the compound of the present invention or administration this to individuals who have not developed diseases or symptoms.
  • treatment means a procedure of administration of a pharmaceutical composition including the compound of the present invention or administration this to individuals who have already developed diseases or symptoms. Accordingly, a procedure of administration to individuals who have already developed diseases or symptoms in order to prevent aggravation or attacks is one aspect of the "treatment”.
  • the compound of the present invention can be mixed with a pharmaceutically acceptable carrier (diluting agent, bonding agent, disintegrant, flavoring substance, odor improving agent, emulsifying agent, diluent, solubilizing agent, and the like) and can be administered in the form of a pharmaceutical composition or drug formulation (oral preparation, injections, and the like) orally or parenterally.
  • a pharmaceutically acceptable carrier for example, a pharmaceutically acceptable carrier
  • the pharmaceutical composition can be formulated according to an ordinal method.
  • parenteral administration includes subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, infusion technique, and local administration (percutaneous administration, ophthalmic administration, pulmonary/bronchial administration, nasal administration, rectal administration, and the like), and the like.
  • the dosage form of oral administration includes, for example, tablets, pills, granules, powders, solvent, suspensions, syrups, capsules, and the like.
  • the amount of the compound of the present invention that can be combined with a carrier can be changed depending on a specific individual who receives treatment and on specific dosage forms.
  • the specific dosage for the specific patient is determined depending on various factors including age, body weight, overall health conditions, gender, diet, administration time, administration method, excretion rate, and the degree of the specified disease during treatment.
  • the dosage amount of the compound of the present invention is determined depending on age, body weight, general health conditions, gender, diet, administration time, administration method, excretion speed, the degree of a disease in a patient who is being treated, or in view of other factors.
  • the compound of the present invention can be administered in single or multiple times daily for adult in a range of 0.01 mg to 1000 mg, although the dosage is different depending on the conditions of the patient, body weight, types of the compound, administration route, and the like.
  • reagents, starting materials, and solvents were purchased from vendors (for example, Aldrich, Wako Junyaku, Tokyo Kasei, Fluka, Sigma, and the like) and used without further purification.
  • Step 4 2-(3,5-dichloropyridin-4-yl)-N-(4-fluorobenzyl)-2-((triethylsilyl)oxy)ethanamine (A1)
  • Step 1 4-(methoxymethylene)-1,1-dimethylcyclohexane (A12-1)
  • n-BuLi (2.6 M in hexane, 2.3 mL, 5.94 mmol) was added dropwisely to a stirred solution of (methoxymethyl)triphenylphosphonium chloride (2.04 g, 5.94 mmol) in THF (20 mL) at -78 °C and stirred for 10 min at the same temperature and then stirred for 2.5 h at room temperature.
  • the reaction mixture was cooled down to -78 °C, a solution of 4,4-dimethylcyclohexanone (500 mg, 3.96 mmol) in THF (5 mL) was added slowly at - 78 °C. The reaction mixture was allowed to warm to room temperature and stirred at room temperature for overnight.
  • reaction mixture was quenched with sat. NaHCO 3 aq. (20 mL) and extracted with EtOAc. The combined organic layers were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to provide compound A12-1 (512.2 mg, crude) as pale yellow oil. The crude product was used for next step without purification.
  • Step 3 2-(3,5-dichloropyridin-4-yl)-N-((4,4-dimethylcyclohexyl)methyl)-2-((triethylsilyl)oxy)etha namine (A12)
  • Step 3 2-(2,6-dichloro-4-fluorophenyl)-2-((triethylsilyl)oxy)ethanamine (A31-3)
  • Step 4 2-(2,6-dichloro-4-fluorophenyl)-N-(3,5-difluorobenzyl)-2-((triethylsilyl)oxy)ethanamine (A31)
  • Step 3 (1-(2,6-dichloro-4-iodophenyl)-2-nitroethoxy)triethylsilane (A35-3)
  • Step 4 2-(2,6-dichloro-4-iodophenyl)-2-((triethylsilyl)oxy)ethanamine (A35-4)
  • Step 5 2-(2,6-dichloro-4-iodophenyl)-N-((3,5-difluorophenyl)((triethylsilyl)oxy)methyl)ethanami ne (A35-5)
  • Step 6 tert-butyl (2-(2,6-dichloro-4-iodophenyl)-2-((triethylsilyl)oxy)ethyl)(3,5-difluorobenzyl)carbamate (A35-6)
  • Step 7 tert-butyl (2-(2,6-dichloro-4-cyanophenyl)-2-((triethylsilyl)oxy)ethyl)(3,5-difluorobenzyl)carbamate (A35-7)
  • the aqueous layer was acidified to pH ⁇ 5 and extracted with DCM (2 x 50 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 8% MeOH/DCM as eluent) to provide compound A56-1 (1.5 g, 70%) as a white solid.
  • Step 6 (1-(2,4-dimethylthiophen-3-yl)-2-nitroethoxy)triethylsilane (A56-6)
  • Step 7 2-(2,4-dimethylthiophen-3-yl)-2-((triethylsilyl)oxy)ethanamine (A56-7)
  • Step 8 N-(3,5-difluorobenzyl)-2-(2,4-dimethylthiophen-3-yl)-2-((triethylsilyl)oxy)ethanamine (A56)
  • Step 4 2-(2,6-dichloro-4-(methylthio)phenyl)-2-((triethylsilyl)oxy)ethanamine (A57-4)
  • Step 5 2-(2,6-dichloro-4-(methylthio)phenyl)-N-(3,5-difluorobenzyl)-2-((triethylsilyl)oxy)ethana mine (A57)
  • Step 2 N-(2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)-4,4-dimethylpent-2-yn-1-amine (A66)
  • Step 4 2-((triethylsilyl)oxy)-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)ethanamine (A75-4)
  • Step 5 N-(3,5-difluorobenzyl)-2-((triethylsilyl)oxy)-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-p yrazol-3-yl)ethanamine (A75)
  • Step 4 (S)-(5,5-dimethyltetrahydrofuran-2-yl)methyl methanesulfonate (A92-4)
  • Step 5 2-(3,5-dichloropyridin-4-yl)-N-(((S)-5,5-dimethyltetrahydrofuran-2-yl)methyl)-2-((triethyl silyl)oxy)ethanamine (A92)
  • Step 3 2-(2-chloro-6-methoxyphenyl)-2-((triethylsilyl)oxy)ethanamine (A93-3)
  • Step 4 2-(2-chloro-6-methoxyphenyl)-N-(3,5-difluorobenzyl)-2-((triethylsilyl)oxy)ethanamine (A93)
  • Step 4 2-(3,5-dichloropyridin-4-yl)-N-(((R)-5,5-dimethyltetrahydrofuran-2-yl)methyl)-2-((triethyl silyl)oxy)ethanamine (A94)
  • Step 1 N-methoxy-N-methyl-1-(trifluoromethyl)cyclopropanecarboxamide (A103-1)
  • Step 3 2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)-N-((1-(trifluoromethyl)cyclopropyl)met hyl)ethanamine (A103)
  • Step 7 2-(2,6-dichloro-4-(difluoromethyl)phenyl)-2-((trimethylsilyl)oxy)acetonitrile (A111-7)
  • Step 8 2-(2,6-dichloro-4-(difluoromethyl)phenyl)-2-((trimethylsilyl)oxy)ethanamine (A111-8)
  • Step 9 1-(2,6-dichloro-4-(difluoromethyl)phenyl)-2-((3,5-difluorobenzyl)amino)ethanol (A11)
  • Step 3 4-(((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)amino)methyl)-1-methylcycloh exanol (A112)
  • Step 2 dipentyl 3,3-dimethylcyclobutane-1,1-dicarboxylate (A119-2)
  • the sodium (0.98 g, 43.0 mmol) was added in portion to pentanol (25 mL) and the mixture was stirred at 50 °C to get a clear solution.
  • the reaction mixture was heated to 70 °C, and then diethyl malonate (3.50 g, 26.0 mmol) was added over a period of 5 min.
  • the reaction mixture was heated to 130 °C and compound A119-1 (5.0 g, 21 mmol) was added dropwise over a period of 10 min.
  • the reaction mixture was heated at 130 °C for 4 h.
  • the solvent was removed under vacuum at 100 °C.
  • the residue was quenched with water (100 mL) and extracted with EtOAc (2 x 50 mL).
  • the combined organic extracts were concentrated under reduced pressure to provide compound A119-2 (6 g, crude) as brown oil.
  • the crude product was used for next step without purification.
  • Step 7 2-(3,5-dichloropyridin-4-yl)-N-((3,3-dimethylcyclobutyl)methyl)-2-((triethylsilyl)oxy)etha namine (A119)
  • Lithium bis(trimethylsilyl)amide (1.0 M in THF, 15 mL, 15 mmol) was added dropwisely to a stirred solution of methyltriphenylphosphonium bromide (5.36 g, 15 mmol) in THF (50 mL) at 0 °C and stirred for 40 min at the same temperature.
  • a solution of ethyl 4-oxocyclohexanecarboxylate (2.04 g, 12 mmol) in THF (20 mL) was added slowly at 0 °C and stirred for 2 h from 0 °C to room temperature. The reaction was quenched with saturated NH 4 Cl aq. and extracted with hexane.
  • Step 2 ethyl 1-(bromomethyl)-4-methylenecyclohexanecarboxylate (A122-2)
  • n-BuLi (2.6 M in hexane, 2.5 mL, 6.6 mmoL) was added dropwisely to a solution of diisopropylamine (0.93 mL, 6.6 mmol) in THF (20 mL) at -78 °C and stirred for 30 min at the same temperature.
  • Hexamethylphosphoramide (4 mL) was added to the reaction mixture and stirred for 20 min at the same temperature.
  • a solution of compound A122-1 (1.01 g, 6 mmol) in THF (5 mL) was added and stirred for 1 h at the same temperature.
  • Step 3 ethyl 4-methylbicyclo[2.2.1]heptane-1-carboxylate (A122-3)
  • Step 7 2-(3,5-dichloropyridin-4-yl)-N-((4-methylbicyclo[2.2.1]heptan-1-yl)methyl)-2-((triethylsil yl)oxy)ethanamine (A122)
  • Step 1 ethyl cyclopentanecarboxylate (A124-1)
  • Step 2 ethyl 1-fluorocyclopentanecarboxylate (A 124-2)
  • n-BuLi (2.6 M in hexane, 4.0 mL, 10.5 mmoL) was added dropwisely to a solution of diisopropylamine (1.55 mL, 11 mmol) in THF (40 mL) at -78 °C and stirred for 30 min at the same temperature.
  • a solution of compound A 124-1 (1.00 g, 7 mmol) in THF (10 mL) was added to the mixture and the mixture was stirred for 50 min at the same temperature. The reaction mixture was allowed to warm to 0 °C for 1 h.
  • Step 4 1-fluoro-N-methoxy-N-methylcyclopentanecarboxamide (A 124-4)
  • Step 6 2-(3,5-dichloropyridin-4-yl)-N-((1-fluorocyclopentyl)methyl)-2-((triethylsilyl)oxy)ethana mine (A124)
  • Trimethylsilyldiazomethane (2.0 M in hexane, 25 mL, 50 mmol) was added to a stirred solution of compound A141-1 (4.64 g, 41.4 mmol) in DCM (25 mL) and MeOH (5 mL) dropwise at 0 °C for 5 min. The mixture was allowed to warm to room temperature and stirred at the same temperature for 30 min. The reaction mixture was quenched with AcOH (0.45 mL) and concentrated under reduced pressure. The residue was purified by silicagel chromatography (20% DCM/hexane as eluent) to provide compound A141-2 (3.8 g, 73%) as a colorless oil.
  • reaction mixture was quenched with saturated NH 4 Cl aq. (200 mL) and extracted with DCM. The collected organic layer was dried over MgSO 4 and concentrated under reduced pressure. The residue was purified by silicagel chromatography (20% EtOAc/hexane as eluent) to provide compound A141-3 (1.77 g, 63%) as a colorless oil.
  • Step 4 spiro[2.3]hexane-5-carboxylic acid (A141-4)
  • Step 6 spiro[2.3]hexane-5-carbaldehyde (A141-6)
  • Step 7 2-(2,4,6-trichlorophenyl)-N-(spiro[2.3]hexan-5-ylmethyl)-2-((triethylsilyl)oxy)ethanamine (A141)
  • Step 3 1-(2,6-dichloro-3-fluorophenyl)-2-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)ethanol
  • Step 2 2-(2,6-dichlorophenyl)-2-((trimethylsilyl)oxy)acetaldehyde.
  • Step 3 2-(2,6-dichlorophenyl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)-2-((trimethylsilyl)oxy) ethanamine.
  • Step 5 3-chloro-4-(2-nitro-1-((triethylsilyl)oxy)ethyl)quinoline (A275-5),
  • the solution was filtered and concentrated in vacuo to give the crude material as a yellow syrup.
  • the crude material was absorbed onto a plug of silica gel and purified by chromatography through a REDISEPTM pre-packed silica gel column (40 g), eluting with a gradient of 0% to 10% EtOAc in hexane, and dried under high vacuum to give 3-chloro-4-(2-nitro-1-((triethylsilyl)oxy)ethyl)quinoline (A275-5).
  • Step 6 2-(3-chloroquinolin-4-yl)-2-((triethylsilyl)oxy)ethanamine (A275-6)
  • Step 7 N-(2-(3-chloroquinolin-4-yl)-2-((triethylsilyl)oxy)ethyl)-2,2-dimethylpropan-1-amine (A275)
  • the reaction mixture was extracted with DCM (2 x 50 mL). The organic extract was washed with saturated NaCl (1 x 50 mL) and dried over Na 2 SO 4 . The solution was filtered and concentrated in vacuo to give the crude material as a yellow syrup.
  • the crude material was absorbed onto a plug of silica gel and purified by chromatography through a REDISEPTM pre-packed silica gel column (40 g), eluting with a gradient of 0% to 20% EtOAc in hexane, and dried under high vacuum to give N-(2-(3-chloroquinolin-4-yl)-2-((triethylsilyl)oxy)ethyl)-2,2-dimethylpropan-1-amine (A275) as colorless syrup.
  • the solution was filtered and concentrated in vacuo to give the crude material.
  • the crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 25% EtOAc in heptane to provide 2-(3,5-dichloropyridin-4-yl)-N-((5-methyltetrahydrofuran-2-yl)methyl)-2-((triethylsilyl)ox y)ethanamine (A281) as a light-yellow syrup.
  • Step 3 N-(2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)-3,3,3-trifluoro-2,2-dimethylpro pan-1-amine (A294)
  • the organic extract was dried over Na 2 SO 4 .
  • the solution was filtered and concentrated in vacuo to give the crude material as orange syrup.
  • the crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 20% EtOAc in heptane to provide N-(2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)-3,3,3-trifluoro-2,2-dimethylpro pan-1-amine (A294) (3.4393 g, 7.72 mmol, 69.5% yield) as colorless oil.
  • Step 1 1-(3,5-dichloropyridin-4-yl)-2-((3,5-difluorobenzyl)amino)ethanol (B13-1)
  • Step 2 tert-butyl (2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,5-difluorobenzyl)carbamate (B13-2)
  • Step 3 tert-butyl (2-(3,5-dichloropyridin-4-yl)-2-methoxyethyl)(3,5-difluorobenzyl)carbamate (B13-3)
  • Step 4 tert-butyl 2-(3,5-dichloropyridin-4-yl)-N-(3,5-difluorobenzyl)-2-methoxyethanamine (B13)
  • Step 2 ethyl-2-(3,5-dichloropyridin-4-yl)-2,2-difluoroacetate (B15-2)
  • Step 4 4-(2-azido-1,1-difluoroethyl)-3,5-dichloropyridine (B15-4)
  • Step 1 ( R )-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3 H )-one
  • Step 2 (7a R )-6-(2-hydroxypropan-2-yl)-3,3-dimethyltetrahydropyrrolo[1,2- c ]oxazol-5(3 H )-one
  • Step 4 ( R )-5-(hydroxymethyl)-3-(propan-2-ylidene)pyrrolidin-2-one
  • Step 5 (5 R )-5-(hydroxymethyl)-3-isopropylpyrolidin-2-one
  • Step 6 ((2 R )-4-isopropylpyrrolidin-2-yl)methanol
  • Step 7 (3a R )-5-isopropyltetrahydro-3H-pyrrolo[1,2- c ][1,2,3]oxathiazole 1,1-dioxide
  • reaction mixture was concentrated onto a plug of silica gel and purified by ISCO, chromatograph through a REDISEPTM pre-packed scilica gel column (40 g), eluting with a gradient of 0% to 10% MeOH (with 2 M NH 3 ) in DCM to give (3a R )-5-isopropyltetrahydro-3H-pyrrolo[1,2- c ][1,2,3]oxathiazole 1,1-dioxide (211.9 mg, 1.032 mmol, 9 %yield) as light yellow oil.
  • Step 8 3,5-dichloro-4-(((2 R )-4-isopropylpyrrolidin-2-yl)methyl)pyridine
  • reference example structure reference example structure B27 B34 B28 B35 B29 B36 B30 B37 B31 B38 B32 B39 B33 B40 B41 B48 B42 B49 B43 B50 B44 B51 B45 B52 B46 B53 B47 B54 B55 B62 B56 863 B57 B64 B58 B65 B59 B66 B60 B67 B61 B68 B69 B70
  • Step 6 (1R,3r,5S)-N-(2-(2,6-dichloro-4-fluorophenyl)-2-((triethylsilyl)oxy)ethyl)-6,6-dimethylbic yclo[3.1.0]hexan-3-amine (C22)
  • Step 3 2-(2,6-dichloro-4-methylphenyl)-2-((triethylsilyl)oxy)ethanamine (C45-3)
  • Step 4 (1R,3r,5S)-N-(2-(2,6-dichloro-4-methylphenyl)-2-((triethylsilyl)oxy)ethyl)-6,6-dimethylbi cyclo[3.1.0]hexan-3-amine (C45)
  • Stepp 4 (1R,3r,5S)-N-(2-(2,6-dichlorophenyl)-2-((triethylsilyl)oxy)ethyl)-6,6-dimethylbicyclo[3.1. 0]hexan-3-amine (C46)
  • Step 3 (1R,3r,5S)-N-(2-(2,6-dichloro-3-fluorophenyl)-2-((triethylsilyl)oxy)ethyl)-6,6-dimethylbic yclo[3.1.0]hexan-3-amine
  • reaction solution was quenched with saturated aqueous ammonium chloride (3 mL) and then basified with saturated NaHCO 3 .
  • the EtOH was then removed under reduced pressure, and the solution was diluted with water EtOAc. Celite was added and the solution was vigorously mixed for 15 min. The solution was then filtered through a pad of celite. The aqueous layer was extracted with EtOAc and the combined organic layers were washed with brine and dried over anhydrous Na 2 SO 4 , filtered and concentrated to afford a yellow oil.
  • Step 1 tert-butyl 2-(trans4-(ethoxycarbonyl)cyclohexyl)hydrazinecarboxylate (D1-1)
  • Step 2 ethyl trans-4-hydrazinylcyclohexanecarboxylate hydrochloride (D1-2)
  • Step 5 benzyl 1-(trans-4-(ethoxycarbonyl)cyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (D1-5)
  • reaction mixture was quenched with saturated aqueous NH 4 Cl and extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 2% EtOAc/hexane as eluent) to provide compound D2-2 (2.7 g, 50%) as colorless oil.
  • Step 5 ethyl trans-4-hydrazinyl-1-methylcyclohexanecarboxylate hydrochloride (D2-5)
  • Step 6 benzyl-1-(trans-4-(ethoxycarbonyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (D2-6)
  • Step 7 trans-4-(ethoxycarbonyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxyl ic acid (D2)
  • Step 3 tert-butyl 2-(trans-4-(hydroxymethyl)cyclohexyl)hydrazinecarboxylate (D19-3)
  • Step 5 ethyl-5-amino-1-(trans-4-(hydroxymethyl)cyclohexyl)-1H-pyrazole-4-carboxylate (D19-5)
  • Step 6 ethyl-5-chloro-1-(trans-4-(hydroxymethyl)cyclohexyl)-1H-pyrazole-4-carboxylate (D 19-6)
  • Step 7 trans-4-(5-chloro-4-(ethoxycarbonyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (D19-7)
  • Step 8 ethyl-1-(trans-4-(tert-butoxycarbonyl)cyclohexyl)-5-chloro-1H-pyrazole-4-carboxylate (D19-8)
  • Step 1 benzyl 3-cyclopropyl-3-oxopropanoate (D20-1)
  • Step 2 benzyl 2-(cyclopropanecarbonyl)-3-(dimethylamino)acrylate (D20-2)
  • Step 3 benzyl 5-cyclopropyl-1-(trans-4-(ethoxycarbonyl)cyclohexyl)-1H-pyrazole-4-carboxylate (D20-3)
  • Step 1 ethyl 8-ethyl-1,4-dioxaspiro[4.5]decane-8-carboxylate (D22-1)
  • Step 2 ethyl 1-ethyl-4-oxocyclohexanecarboxylate (D22-2)
  • Step 3 tert-butyl 2-(trans-4-(ethoxycarbonyl)-4-ethylcyclohexyl)hydrazinecarboxylate (D22-3)
  • Step 4 ethyl trans-1-ethyl-4-hydrazinylcyclohexanecarboxylate hydrochloride (D22-4)
  • Step 5 benzyl 1-(trans-4-(ethoxycarbonyl)-4-ethylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carbox ylate (D22-5)
  • Step 6 1-(trans-4-(ethoxycarbonyl)-4-ethylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carbox ylic acid (D22)
  • Step 2 benzyl-2-((dimethylamino)methylene)-4,4-difluoro-3-oxobutanoate (D26-2)
  • Step 3 benzyl-5-(difluoromethyl)-trans-4-(ethoxycarbonyl)cyclohexyl)-1H-pyrazole-4-carboxylat e (D26-3)
  • Step 1 benzyl 2-((dimethylamino)methylene)-3-oxobutanoate (D27-1)
  • Step 2 benzyl 1-((trans-4-(ethoxycarbonyl)cyclohexyl)-5-methyl-1H-pyrazole-4-carboxylate (D27-2)
  • Step 1 1,5-di-tert-butyl 3-ethyl 3-acetylpentane-1,3,5-tricarboxylate (D28-1)
  • Step 2 4-acetyl-4-(ethoxycarbonyl)heptanedioic acid (D28-2)
  • Step 3 ethyl-1-acetyl-4-oxocyclohexanecarboxylate (D28-3)
  • Step 4 ethyl 4-(benzylamino)-2-oxobicyclo[2.2.2]octane-1-carboxylate (D28-4)
  • Step 5 ethyl-4-(benzylamino)-2-hydroxybicyclo[2.2.2]octane-1-carboxylate (D28-5)
  • Step 6 ethyl-4-(benzylamino)-2-((methylsulfonyl)oxy)bicyclo[2.2.2]octane-1-carboxylate (D28-6)
  • Step 7 ethyl-4-(benzylamino)bicyclo[2.2.2]oct-2-ene-1-carboxylate (D28-7)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

    Technical Field
  • The present invention relates to novel compounds that modulate RORγ activity, pharmaceutical composition, and use in treatment or prevention of autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.
    • Background Art
  • Retinoid-related orphan receptor gamma (RORγ) is a nuclear receptor that binds to DNA and regulates transcription (NPL 1). Two isoforms of RORγ that differ only in the N- terminus are generated from the RORC gene; RORγ1 and RORγt (also referred to as RORγ2) (NPL 2). RORγ is used as a term to describe both isoforms of RORγ1 and RORγt.
  • RORγ1 is expressed in a variety of tissues including muscle, kidney, liver, and lung and is known to regulate adipogenesis (NPL 3). Loss of the RORC gene in mice accelerates preadipocyte differentiation to small adipocytes and protects against high fat diet induced insulin resistance. Consequently, by inhibiting the function of RORγ1, insulin resistance could be improved.
  • RORγt is expressed exclusively in cells of the immune system (NPLs 4 and 5) and is a master regulator of a Th17 cell-related transcriptional network associated with autoimmune pathology. Th17 cells are a subset of CD4+ helper T cells implicated as key drivers of the inflammatory process in autoimmunity and characterized by production of the pro-inflammatory cytokine IL-17A. Th17 cells also express CCR6, which mediates migration to sites of inflammation, are maintained and expanded by IL-23, through the IL-23 receptor (IL23R), and express other pro-inflammatory cytokines and chemokines, including IL-17F, IL-21, IL-22, CCL20 and GM-CSF, which together promote recruitment of other inflammatory cell types, especially neutrophils, to mediate pathology at the target tissue. RORγt is required for the differentiation of Th17 cells and directly and indirectly regulates expression of many of these pro-inflammatory mediators (NPL 6). RORγ-deficient mice have significantly reduced numbers of Th17 cells in vivo, lack the ability to produce IL-17A and other Th17-related cytokines ex vivo, and show resistance to induction of various disease models such as EAE, dermatitis, enteritis and nephritis (NPLs 6, and 12 to 14). Therefore, by inhibiting the function of RORγ, development of various autoimmune diseases and inflammatory diseases, in which the Th17 cell-related cytokines are involved, could be suppressed. Furthermore, expression of RORγt and the consequent expression of the Th17 cell-related transcriptional network has been observed in other immune cell types that may also be important in disease pathogenesis, namely CD8+ T cells, so called Tc17s, γδ T cells, natural killer T cells, innate lymphoid cells, natural killer cells, and mast cells (NPLs 7 and 8).
  • Th17 cell-related cytokines and chemokines have been implicated in the pathogenesis of various human autoimmune and inflammatory diseases including multiple sclerosis, rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, cystic fibrosis, asthma, chronic obstructive pulmonary disease, emphysema, lung fibrosis, systemic erythematodes, vasculitis, Wegener granuloma, polymyalgia rheumatica, giant cell arteritis, arteriosclerosis, autoimmune myositis, uveitis, dry eye, inflammatory bowel disease, alcohol-induced hepatitis, non-alcoholic steatohepatitis, primary biliary cirrhosis, viral hepatitis and type 1 diabetes. (NPLs 9 to 11).
  • RORγt is known to possess an inhibitory effect on the anti-tumorigenic activity of Th9 cells, a subtype of helper T cells (NPL 15). In the RORγ-deficient mice, production of IL-9 from Th9 cells is enhanced and tumor formation is delayed in mice injected with melanoma cells. Therefore, it is thought that, by inhibiting the function of RORγ, the function of Th9 cells is activated and formation of melanoma and other malignant tumors can be suppressed.
  • From the evidence described above, a RORγ modulator can be expected to show therapeutic or preventive benefit in treatment of; metabolic diseases such as diabetes; for autoimmune diseases or inflammatory diseases and; for melanoma and other cancer diseases.
  • Heterocyclic RORγ modulators are disclosed in WO 2014/023367 .
    • Citation List Non Patent Literature
    • NPL 1: Gigure, Endocrine. Reviews. 20: 689-725, 1999
    • NPL 2: Jetten, Nucl. Recept. Signal. 7:e003, 2009
    • NPL 3: Meissburger et al., EMBO Mol. Med. 3: 637-651, 2011
    • NPL 4: Hirose et al., Biochem. Biophys. Res. Commun. 30: 1976-1983, 1994
    • NPL 5: Eberl and Littman., Science. 9: 248-251, 2004
    • NPL 6: Ivanov et al., Cell 126: 1121-1133, 2006
    • NPL 7: Sutton et al., Eur. J. Immunol. 42: 2221-2231, 2012
    • NPL 8: Hueber et al., J. Immunol., 184: 3336-3340, 2010
    • NPL 9: Miossec et al., Nature Reviews Drug Discovery 11: 763-776,2012
    • NPL 10: Hammerich et al., Clin. Dev. Immunol. 2011: Article ID 345803, 2011
    • NPL 11: Ferraro et al., Diabetes 60: 2903-2913, 2011
    • NPL 12: Pantelyushin et al., J Clin Invest. 122: 2252-2256, 2012
    • NPL 13: Buonocore et al., Nature 464: 1371-1375, 2010
    • NPL 14: Steinmetz et al., J. Am. Soc. Nephrol. 22: 472-483, 2011
    • NPL 15: Purwar et al., Nat. Med. 18: 1248-1254, 2012
    Summary of Invention Technical Problem
  • The object of the present invention is to provide a compound having a function of inhibiting RORγ activity.
    • Solution to Problem
  • The present inventors conducted diligent research in order to achieve the above-described object and, as a result, found a novel compound represented by formula (I) or a pharmaceutically acceptable salt thereof, the compound or a pharmaceutically acceptable salt thereof having a function of inhibiting RORγ activity. That is, the present invention is as follows.
    1. (1) A compound represented by formula (I) or a pharmaceutically acceptable salt thereof:
      Figure imgb0001
       wherein:
      • R1 is selected from F, Cl, Br, a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Ra groups and a C3 to C8 cycloalkyl group substituted by 0, 1, 2 or 3 Ra groups;
      • Y is selected from a C4 to C6 cycloalkyl group, a C6 to C9 bicycloalkyl group and a C6 to C9 spiroalkyl group, all of which are substituted by a R2 group, 0 or 1 R6 group and 0, 1, 2 or 3 R7 groups;
      • R2 is selected from -OH, -CO2H, -SO3H, -CONH2, -SO2NH2, a (C1 to C6 alkoxy)carbonyl group substituted by 0, 1, 2 or 3 Rc groups, a (C1 to C6 alkyl)aminocarbonyl group substituted by 0, 1, 2 or 3 Rc groups, a C1 to C6 alkylsulfonyl group substituted by 0, 1, 2 or 3 Rc groups, a C1 to C6 alkylaminosulfonyl group substituted by 0, 1, 2 or 3 Rc groups, a (hydroxycarbonyl)(C1 to C3 alkyl) group substituted by 0, 1, 2 or 3 Rc groups, a (C1 to C6 alkoxy)carbonyl(C1 to C3 alkyl) group substituted by 0, 1, 2 or 3 Rc groups, a (C1 to C6 alkyl)sulfonyl(C1 to C3 alkyl) group substituted by 0, 1, 2 or 3 Rc groups and a (C2 to C6 alkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2 or 3 Rc groups;
      • R6 and R7 are independently selected from H, F, -OH, -NH2, -CN, a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Rb groups and a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rb groups;
      • R3 is selected from H, F, Cl, -CH3 and -CF3;
      • R4 is selected from a C1 to C6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C2 to C6 alkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C2 to C6 alkynyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C1 to C6 alkoxy)(C2 to C4 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C6 to C10 aryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a (5- to 10-membered heteroaryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C3 to C8 cycloalkenyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups and a (3- to 8-membered heterocycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C6 to C9 spiroalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroheteroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C5 to C9 bicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C5 to C9 bicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 heterobicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, and a (C6 to C9 heterobicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups;
      • R5 is selected from a C6 to C10 aryl group substituted by 0, 1, 2, 3, 4 or 5 Ri groups, a 5- to 10-membered heteroaryl group substituted by 0, 1, 2, 3, or 4 Ri groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rj groups, a C3 to C8 cycloalkenyl group substituted by 0, 1, 2, 3, 4 or 5 Rj groups and a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rj groups;
      • R8 and R9 are independently selected from H, F, -OH, -NH2, a C1 to C3 alkyl group substituted by 0, 1, 2 or 3 Rh groups, and a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rh groups; or R8 and R9 together form an oxo group or a thioxo group;
      • R12 is H; or R4 and R12 together are -CRmRm-CR13R14-CRmRm- or -CR13R14-CRmRm-CRmRm- to form a pyrrolidine ring;
      • R13 is selected from H, a C1 to C6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a C6 to C10 aryl group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a C6 to C10 aryloxy group substituted by 0, 1, 2, 3, 4 or 5 Rf groups,a (C2 to C6 alkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C2 to C6 alkynyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C1 to C6 alkoxy)(C2 to C4 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C6 to C10 aryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a (5- to 10-membered heteroaryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C3 to C8 cycloalkenyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups and a (3- to 8-membered heterocycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C6 to C9 spiroalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroheteroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 bicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C5 to C9 bicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 heterobicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, and a (C6 to C9 heterobicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups;
      • R14 is independently selected from H and a C1 to C6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 Re groups; or R13 and R14 together form a C3 to C8 cycloalkane ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups, C3 to C8 cycloalkene ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups, or a 3- to 8-membered heterocycloalkane ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups; Rm is independently selected from H, F, Cl, -CH3 and -CF3;
      • Rg and Rj are , independently selected from F, Cl, a C1 to C6 alkyl group, -OH, -CN, -NH2, -NO2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3, a C1 to C6 alkylene group substituted by 0, 1, 2 or 3 R1 groups, a C2 to C6 alkenylene group substituted by 0, 1, 2 or 3 R1 groups and an oxo group;
      • Rf and Ri are are independently selected from F, Cl, Br, -OH, -CN, -NO2, -CO2H, a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Rk groups, a C2 to C6 alkenyl group substituted by 0, 1, 2 or 3 Rk groups, a C2 to C6 alkynyl group substituted by 0, 1, 2 or 3 Rk groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2 or 3 Rk groups, a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rk groups, a C3 to C8 cycloalkyloxy group substituted by 0, 1, 2 or 3 Rk groups, -SH, a C1 to C6 alkylthio group substituted by 0, 1, 2 or 3 Rk groups, a C3 to C8 cycloalkylthio group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkyl)carbonyl group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkoxy)carbonyl group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkyl)aminocarbonyl group substituted by 0, 1, 2 or 3 Rk groups, a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2 or 3 Rk groups, a C1 to C6 alkylsulfonyl group substituted by 0, 1, 2 or 3 Rk groups, -NH2, a mono(C1 to C6 alkyl)amino group substituted by 0, 1, 2 or 3 Rk groups and a di(C1 to C6 alkyl)amino group substituted by 0, 1, 2 or 3 Rk groups; and
      • Ra, Rb, Rc, Re, Rh, Rk and Rl are independently selected from F, a C1 to C4 alkyl group, -OH, -CN, -NO2, -NH2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3 and an oxo group.
    2. (2) The compound according to section 1 or pharmaceutically acceptable salt thereof, wherein Y is selected from formula (II-a), formula (II-b), formula (II-c) and formula (II-d):
      Figure imgb0002
       wherein:
      • k is 0, 1 or 2;
      • and n is 1, 2 or 3.
    3. (3) The compound according to section 2 or pharmaceutically acceptable salt thereof, wherein Y is a group represented by formula (II-a):
      Figure imgb0003
    4. (4) The compound according to section 2 or pharmaceutically acceptable salt thereof, wherein Y is a group represented by formula (II-d):
      Figure imgb0004
       and n is 2.
    5. (5) The compound according to any one of sections 1 to 4 or pharmaceutically acceptable salt thereof, wherein R3 is H.
    6. (6) The compound according to any one of sections 1 to 5 or pharmaceutically acceptable salt thereof, wherein R2 is -CO2H or a hydroxycarbonylmethyl group substituted by 0, 1 or 2 Rc groups.
    7. (7) The compound according to any one of sections 1 to 6 or pharmaceutically acceptable salt thereof, wherein R12 is H.
    8. (8) The compound according to any one of sections 1 to 7 or pharmaceutically acceptable salt thereof, wherein R8 and R9 together form an oxo group or both R8 and R9 are H.
    9. (9) The compound according to any one of sections 1 to 8 or pharmaceutically acceptable salt thereof, wherein Rl is -CF3, -CF2H or Cl.
    10. (10) The compound according to any one of sections 1 to 9 or pharmaceutically acceptable salt thereof, wherein R5 is a C6 to C10 aryl group substituted by 0, 1, 2, 3, 4 or 5 Ri groups or a 5- to 10-membered heteroaryl group substituted by 0, 1, 2, 3, or 4 Ri groups.
    11. (11) The compound according to any one of sections 1 to 10 or pharmaceutically acceptable salt thereof, wherein R4 is a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Re groups, a (C6 to C10 aryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C6 to C9 spiroalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C5 to C9 bicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C5 to C9 bicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups or a (C6 to C9 heterobicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups.
    12. (12) A method of treating or preventing a disease using a compound according to any one of sections 1 to 11 or pharmaceutically acceptable salt thereof, wherein the disease is multiple sclerosis, chronic rheumatoid arthritis, ankylosing spondylitis, systemic erythematodes, psoriasis, psoriatic arthritis, inflammatory bowel disease or asthma.
    13. (13) A pharmaceutical composition comprising a compound according to any one of sections 1 to 11 or pharmaceutically acceptable salt thereof.
    Advantageous Effects of Invention
  • The present invention provides a novel compound having excellent activity of inhibiting RORγ and a method for producing the same. Further, the compound of the present invention or a pharmaceutically acceptable salt thereof is useful as a therapeutic agent or a preventive agent for autoimmune diseases, inflammatory diseases (for example, multiple sclerosis, chronic rheumatoid arthritis, ankylosing spondylitis, systemic erythematodes, psoriasis, psoriatic arthritis, inflammatory bowel disease, and asthma), metabolic diseases (especially diabetes), cancer diseases (especially malignant melanoma), or the like.
    • Description of Embodiments
  • In the following, terms used either independently or in combination in the present description will be explained. Unless particularly described, explanation of each substituent shall be common to each position. In addition, when any variable substituent (for example, Rj and the like) is present in respective arbitrary constituent elements (for example, Rf, Ri, and the like), its definition is independent in the respective constituent elements. Further, combination of substituents and variable substituents is allowed only when such combination provides a chemically stable compound. When a substituent itself is substituted by two or more groups, these plural groups can exist on the same carbon or different carbons as long as a stable structure is formed.
  • Each group of the compounds represented by formula (I) of the present invention is defined as described below. The writing order in each group indicates the order of the bonds in formula (I). For example, "a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group" in R4 is represented by group wherein "a C1 to C3 alkyl group" is bonded to nitrogen in formula (I) and "a C3 to C8 cycloalkyl group" and "a C1 to C3 alkyl group" are bonded. Additionally, the number situated to the right of carbon indicates the number of the carbon. For example, "C1 to C6" means a group having "1 to 6 carbons". It is a matter of course that, in the present invention, different number of carbons means a group having that number of carbons. For example, "a C1 to C4 alkyl group" means alkyl groups having 1 to 4 carbon among those defined by "C1 to C4 alkyl group". Treatment of the number of carbons in other groups is the same.
  • In the present invention, "a C1 to C6 alkyl, group" means a saturated linear or branched aliphatic hydrocarbon group having 1 to 6 carbons. For example, there may be mentioned a methyl group, an ethyl group, a n-propyl group, a n-butyl group, a n-pentyl group, a n-hexyl group, an isopropyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an isopentyl group, a 2-methylbutyl group, a 3-methylbutyl group, an 1-ethylpropyl group, an 1,1-dimethypropyl group, an 1,2-dimethylpropyl group, a neopentyl group, a 4-methylpentyl group, a 3-methylpentyl group, a 2-methylpentyl group, an 1-methylpentyl group, a 3,3-dimethylbutyl group, a 2,2-dimethylbutyl group, an 1,1-dimethylbutyl group, an 1,2-dimethylbutyl group, an 1,3-dimethylbutyl group, a 2,3-dimethylbutyl group, an 1-ethylbutyl group, a 2-ethylbutyl group, and the like.
  • In the present invention, "a C1 to C4 alkyl group" means a saturated linear or branched aliphatic hydrocarbon group having 1 to 4 carbons. For example, there may be mentioned a methyl group, an ethyl group, a n-propyl group, an isopropyl group a n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group and the like.
  • In the present invention, "a C2 to C4 alkyl group" means a saturated linear or branched aliphatic hydrocarbon group having 2 to 4 carbons. For example, there may be mentioned an ethyl group, a n-propyl group, an isopropyl group, a n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group and the like.
  • In the present invention, "a C1 to C3 alkyl group" means a saturated linear or branched aliphatic hydrocarbon group having 1 to 3 carbons. For example, there may be mentioned a methyl group, an ethyl group, a n-propyl group, an isopropyl group, and the like.
  • In the present invention, "a C2 to C6 alkenyl group" means a linear or branched aliphatic hydrocarbon group having 2 to 6 carbons with an unsaturated double bond. For example, there may be mentioned a vinyl group, an 1-propenyl group, a 2-propenyl group, a 2-methyl-1-propenyl group, a 2-methyl-2-propenyl group, a 2-buten-1-yl group, a 3-buten-1-yl group, a 2-penten-1-yl group, a 3-penten-1-yl group, a 4-penten-1-yl group, a 5-hexen-1-yl group, a 4-hexen-1-yl group, a 3-hexen-1-yl group, a 2-hexen-1-yl group, a 3-methyl-2-buten-1-yl group, a 3-methyl-3-penten-1-yl group, a 3-methyl-2-penten-1-yl group, a 4-methyl-3-penten-1-yl group, a 4-methyl-2-penten-1-yl group, a 2-methyl-2-penten-1-yl group, and the like.
  • In the present invention, "a C2 to C6 alkynyl group" means a linear or branched aliphatic hydrocarbon group having 2 to 6 carbons with an unsaturated triple bond. For example, there may be mentioned an ethynyl group, an 1-propyn-1-yl group, a 2-propyn-1-yl group, a 2-butyn-1-yl group, a 3-butyn-1-yl group, a 2-pentyn-1-yl group, a 3-pentyn-1-yl group, a 4-pentyn-1-yl group, a 5-hexyn-1-yl group, a 4-hexyn-1-yl group, a 3-hexyn-1-yl group, a 2-hexyn-1-yl group, and the like.
  • In the present invention, "a C1 to C6 alkylene group" means a bivalent group formed by removing hydrogen from "a C1 to C6 alkyl group". For example, there may be mentioned methylene, ethylene, propylene, butylene, pentylene, hexylene, and the like. The C1 to C6 alkylene group can be bonded to one carbon atom or two different carbon atoms to form a ring.
  • In the present invention, "a C2 to C6 alkenylene group" means a bivalent group having a double bond at arbitrary position of "a C2 to C6 alkylene group". There may be mentioned vinylene, propenylene, 1-butenylene, 2-butenylene, 1-pentenyene, 2-pentenyene, 1-hexenyene, 2-hexenyene, 3-hexenyene, and the like.
  • In the present invention, "a C3 to C8 cycloalkyl group" means a cyclic alkyl group having 3 to 8 carbons. For example, there may be mentioned a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, and the like.
  • In the present invention, "a C4 to C6 cycloalkyl group" means a cyclic alkyl group having 4 to 6 carbons. For example, there may be mentioned a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and the like.
  • In the present invention, "a C6 to C9 bicycloalkyl group" means a bicyclic alkyl group having 6 to 9 carbons. For example, there may be mentioned a bicyclo[3.1.0]hexanyl group, a bicyclo[2.2.0]hexanyl group, a bicyclo[2.1.1]hexanyl group, bicyclo[3.2.0]heptanyl group, a bicyclo[2.2.1]heptanyl group, a bicyclo[3.1.1]heptanyl group, a bicyclo[4.1.0]heptanyl group, an octahydropentalenyl group, a bicyclo[2.2.2]octanyl group, a bicyclo[3.2.1]octanyl group, a bicyclo[4.2.0]octanyl group, a bicyclo[4.1.1]octanyl group, a bicyclo[5.1.0]octanyl group, an octahydro-1H-indenyl group, a bicyclo[3.2.2]nonanyl group, a bicyclo[3.3.1]nonanyl group, a bicyclo[4.2.1]nonanyl group, a bicyclo[5.2.0]nonanyl group, and the like.
  • In the present invention, "a C5 to C9 bicycloalkyl group" means a bicyclic alkyl group having 5 to 9 carbons. For example, there may be mentioned a bicyclo[1.1.1]pentanyl group, bicyclo[3.1.0]hexanyl group, a bicyclo[2.2.0]hexanyl group, a bicyclo[2.1.1]hexanyl group, bicyclo[3.2.0]heptanyl group, a bicyclo[2.2.1]heptanyl group, a bicyclo[3.1.1]heptanyl group, a bicyclo[4.1.0]heptanyl group, an octahydropentalenyl group, a bicyclo[2.2.2]octanyl group, a bicyclo[3.2.1]octanyl group, a bicyclo[4.2.0]octanyl group, a bicyclo[4.1.1]octanyl group, a bicyclo[5.1.0]octanyl group, an octahydro-1H-indenyl group, a bicyclo[3.2.2]nonanyl group, a bicyclo[3.3.1]nonanyl group, a bicyclo[4.2.1]nonanyl group, a bicyclo[5.2.0]nonanyl group, and the like.
  • In the present invention, "spiroalkyl group" means a group consisting of two cycloalkyl moieties that have exactly one atom in common. "A C6 to C9 spiroalkyl group" means a spiroalkyl group having 6 to 9 carbons. For example, there may be mentioned a spiro[2.3]hexanyl group, a spiro[2.4]heptanyl group, a spiro[3.3]heptanyl group, a spiro[2.5]octanyl group, a spiro[3.4]octanyl group, a spiro[2.6]nonanyl group, a spiro[3.5]nonanyl group, a spiro[4.4]nonanyl group, and the like.
  • In the present invention, "a (C6 to C9 spiroalkyl)(C1 to C3 alkyl) group" means a group obtained by substituting "a C1 to C3 alkyl group" with "a (C6 to C9 spiroalkyl) group" at arbitrary position. For example, there may be mentioned a spiro[2.3]hexanyl methyl group, a spiro[2.4]heptanyl methyl group, a spiro[3.3]heptanyl methyl group, a spiro[2.5]octanyl methyl group, a spiro[3.4]octanyl methyl group, a spiro[2.6]nonanyl methyl group, a spiro[3.5]nonanyl methyl group, a spiro[4.4]nonanyl methyl group, and the like.
  • In the present invention, "a C3 to C8 cycloalkenyl group" means a group having a double bond at arbitrary position of "a C3 to C8 cycloalkyl group" having 3 to 8 carbons. For example, there may be mentioned a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a cyclooctenyl group, and the like.
  • In the present invention, "a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group" means a group obtained by substituting "a C1 to C3 alkyl group" with "a C3 to C8 cycloalkyl group" at arbitrary position. For example, there may be mentioned a cyclopropylmethyl group, a cyclopropylethyl group, a cyclopropylpropyl group, a cyclobutylmethyl group, a cyclobutylethyl group, a cyclopentylmethyl group, a cyclopentylethyl group, a cyclohexylmethyl group, a cyclohexylethyl group, a cycloheptylmethyl group, a cycloheptylethyl group, a cyclooctylmethyl group, and the like.
  • In the present invention, "a (C3 to C8 cycloalkenyl)(C1 to C3 alkyl) group" means a group obtained by substituting "a C1 to C3 alkyl group" with "a C3 to C8 cycloalkenyl group" at arbitrary position. For example, there may be mentioned a cyclopropenylmethyl group, a cyclopropenylethyl group, a cyclopropenylpropyl group, a cyclobutenylmethyl group, a cyclobutenylethyl group, a cyclopentenylmethyl group, a cyclopentenylethyl group, a cyclohexenylmethyl group, a cyclohexenylethyl group, a cycloheptenylmethyl group, a cycloheptenylethyl group, a cyclooctenylmethyl group, and the like.
  • In the present invention, "a (C2 to C6 alkenyl)(C1 to C3 alkyl) group" means a group obtained by substituting "a C1 to C3 alkyl group" with "a C2 to C6 alkenyl group" at arbitrary position. For example, there may be mentioned a 2-propenyl group, an 1-methyl-2-propenyl group, a 2-methyl-2-propenyl group, a 2-buten-1-yl group, a 3-buten-1-yl group, a 2-penten-1-yl group, a 3-penten-1-yl group, a 4-penyten-1-yl group, a 5-hexen-1-yl group, a 4-hexen-1-yl group, a 3-hexen-1-yl group, a 2-hexen-1-yl group, an 1-methyl-2-buten-1-yl group, an 1-ethyl-2-buten-1-yl group, a 2-methyl-2-buten-1-yl group, a 3-methyl-2-buten-1-yl group, a 3-methyl-3-penten-1-yl group, a 3-methyl-2-penten-1-yl group, a 3-ethyl-2-penten-1-yl group, a 4-methyl-3-penten-1-yl group, a 4-methyl-2-penten-1-yl group, a 2-methyl-2-penten-1-yl group, and the like.
  • In the present invention, "a (C2 to C6 alkynyl)(C1 to C3 alkyl) group" means a group obtained by substituting "a C1 to C3 alkyl group" with "a C2 to C6 alkynyl group" at arbitrary position. For example, there may be mentioned a 2-propyn-1-yl group, an 1-methyl-2-propyn-1-yl group, an 1-ethyl-2-propyn-1-yl group, a 2-butyn-1-yl group, an 1-methyl-2-butyn-1-yl group, an 1-ethyl-2-butyn-1-yl group, a 3-butyn-1-yl group, an 1-methyl-3-butyn-1-yl group, an 1-ethyl-3-butyn-1-yl group, a 2-pentyn-1-yl group, an 1-methyl-2-pentyn-1-yl group, a 3-pentyn-1-yl group, an 1-methyl-3-pentyn-1-yl group, a 4-pentyn-1-yl group, a 5-hexyn-1-yl group, a 4-hexyn-1-yl group, a 3-hexyn-1-yl group, a 2-hexyn-1-yl group, and the like.
  • In the present invention, "a C1 to C6 alkoxy group" means a group obtained by substituting an oxy group with "a C1 to C6 alkyl group". For example, there may be mentioned a methoxy group, an ethoxy group, a n-propoxy group, an isopropoxy group, a n-butoxy group, a sec-butoxy group, a 2-methylpropoxy group, a n-pentyloxy group, an isopentyloxy group, a 2-methylbutoxy group, an 1-ethylpropoxy group, a 2,2-dimethylpropoxy group, a n-hexyloxy group, a 4-methylpentoxy group, a 3-methylpentoxy group, a 2-methylpentoxy group, a 3,3-dimethylbutoxy group, a 2,2-dimethylbutoxy group, an 1,1-dimethylbutoxy group, a tert-butoxy group, and the like.
  • In the present invention, "a (C1 to C6 alkoxy)(C2 to C4 alkyl)" means a group obtained by substituting "a C2 to C4 alkyl group" with "a C1 to C6 alkoxy group" or, in other words, a group obtained by replacing one carbon of a C4 to C11 alkyl group with one oxygen at arbitrary chemically possible position. For example, there may be mentioned a methoxyethyl group, an ethoxyethyl group, a propyloxyethyl group, an isopropyloxyethyl group, a butyloxyethyl group, an isobutyloxyethyl group, a sec-butyloxyethyl group, a tert-butyloxyethyl group, an isopentyloxyethyl group, a 2-methylbutyloxyethyl group, a 3-methylbutyloxyethyl group, an 1-ethylpropyloxyethyl group, an 1,1-dimethylpropyloxyethyl group, an 1,2-dimethylpropyloxyethyl group, a neopentyloxyethyl group, a hexyloxyethyl group, a 4-methylpentyloxyethyl group, a 3-methylpentyloxyethyl group, a 2-methylpentyloxyethyl group, an 1-methylpentyloxyethyl group, a 3,3-dimethylbutyloxyethyl group, a 2,2-dimethylbutyloxyethyl group, an 1,1-dimethylbutyloxyethyl group, an 1,2-dimethylbutyloxyethyl group, an 1,3-dimethylbutyloxyethyl group, a 2,3-dimethylbutyloxyethyl group, an 1-ethylbutyloxyethyl group, a 2-ethylbutyloxyethyl group, a methoxypropyl group, an ethoxypropyl group, a propyloxypropyl group, an isopropyloxypropyl group, a butyloxypropyl group, an isobutyloxypropyl group, a sec-butyloxypropyl group, a tert-butyloxypropyl group, an isopentyloxypropyl group, a 2-methylbutyloxypropyl group, a 3-methylbutyloxypropyl group, an 1-ethylpropyloxypropyl group, an 1,1-dimethylpropyloxypropyl group, an 1,2-dimethylpropyloxypropyl group, a neopentyloxypropyl group, a hexyloxypropyl group, a 4-methylpentyloxypropyl group, a 3-methylpentyloxypropyl group, a 2-methylpentyloxypropyl group, an 1-methylpentyloxypropyl group, a 3,3-dimethylbutyloxypropyl group, a 2,2-dimethylbutyloxypropyl group, an 1,1-dimethylbutyloxypropyl group, an 1,2-dimethylbutyloxypropyl group, an 1,3-dimethylbutyloxypropyl group, a 2,3-dimethylbutyloxypropyl group, an 1-ethylbutyloxypropyl group, a 2-ethylbutyloxypropyl group, a methoxybutyl group, an ethoxybutyl group, a propyloxybutyl group, an isopropyloxybutyl group, a butyloxybutyl group, an isobutyloxybutyl group, a sec-butyloxybutyl group, a tert-butyloxybutyl group, an isopentyloxybutyl group, a 2-methylbutyloxybutyl group, a 3-methylbutyloxybutyl group, an 1-ethylpropyloxybutyl group, an 1,1-dimethylpropyloxybutyl group, an 1,2-dimethylpropyloxybutyl group, a neopentyloxybutyl group, a hexyloxybutyl group, a 4-methylpentyloxybutyl group, a 3-methylpentyloxybutyl group, a 2-methylpentyloxybutyl group, an 1-methylpentyloxybutyl group, a 3,3-dimethylbutyloxybutyl group, a 2,2-dimethylbutyloxybutyl group, an 1,1-dimethylbutyloxybutyl group, an 1,2-dimethylbutyloxybutyl group, an 1,3-dimethylbutyloxybutyl group, a 2,3-dimethylbutyloxybutyl group, an 1-ethylbutyloxybutyl group, a 2-ethylbutyloxybutyl group, and the like.
  • In the present invention, "a C1 to C6 alkylthio group" means a group obtained by substituting a thio group with "a C1 to C6 alkyl group". For example, there may be mentioned a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, a butylthio group, an isobutylthio group, a sec-butylthio group, a tert-butylthio group, a pentylthio group, a neopentylthio group, a tert-pentylthio group, a 2-methylbutylthio group, a hexylthio group, an isohexylthio group, and the like.
  • In the present invention, "a C3 to C8 cycloalkylthio group" means a group obtained by substituting a thio group with "a C3 to C8 cycloalkyl group". For example, there may be mentioned a cyclopropylthio group, a cyclobutylthio group, a cyclopentylthio group, a cyclohexylthio group, a cycloheptylthio group, a cyclooctylthio group, and the like.
  • In the present invention, "a (C1 to C6 alkyl)carbonyl group" means a group obtained by substituting a carbonyl group with "a C1 to C6 alkyl group". For example, there may be mentioned an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a n-pentylcarbonyl group, a sec-butylcarbonyl group, a tert-butylcarbonyl group, an isopentylcarbonyl group, a 2-methylbutylcarbonyl group, a 3-methylbutylcarbonyl group, an 1-ethylpropylcarbonyl group, an 1,1-dimethylpropylcarbonyl group, an 1,2-dimethylpropylcarbonyl group, a neopentylcarbonyl group, a 4-methylpentylcarbonyl group, a 3-methylpentylcarbonyl, a 2-methylpentylcarbonyl group, an 1-methylpentylcarbonyl group, a 3,3-dimethylbutylcarbonyl group, a 2,2-dimethylbutylcarbonyl group, an 1,1-dimethylbutylcarbonyl group, an 1,2-dimethylbutylcarbonyl group, an 1,3-dimethylbutylcarbonyl group, a 2,3-dimethylbutylcarbonyl group, an 1-ethylbutylcarbonyl group, a 2-ethylbutylcarbonyl group, a n-hexylcarbonyl group, and the like.
  • In the present invention, "a (C1 to C6 alkoxy)carbonyl group" means a group obtained by substituting a carbonyl group with "a C1 to C6 alkoxy group". For example, there may be mentioned a methoxycarbonyl group, an ethoxycarbonyl group, a n-propoxycarbonyl group, an isopropoxycarbonyl group, a n-butoxycarbonyl group, an isobutoxycarbonyl group, a sec-butoxycarbonyl group, a tert-butoxycarbonyl group, a n-pentoxycarbonyl group, an isopentoxycarbonyl group, a 2-methylbutoxycarbonyl group, a 3-methylbutoxycarbonyl group, an 1-ethylpropoxycarbonyl group, an 1,1-dimethylpropoxycarbonyl group, an 1,2-dimethylpropoxycarbonyl group, a neopentoxycarbonyl group, a 4-methylpentoxycarbonyl group, a 3-methylpentoxycarbonyl, a 2-methylpentoxycarbonyl group, an 1-methylpentoxycarbonyl group, a 3,3-dimethylbutoxycarbonyl group, a 2,2-dimethylbutoxycarbonyl group, an 1,1-dimethylbutoxycarbonyl group, an 1,2-dimethylbutoxycarbonyl group, an 1,3-dimethylbutoxycarbonyl group, a 2,3-dimethylbutoxycarbonyl group, an 1-ethylbutoxycarbonyl group, a 2-ethylbutoxycarbonyl group, a n-hexoxycarbonyl group, and the like.
  • In the present invention, "a C3 to C8 cycloalkyloxy group" means a group obtained by substituting an oxy group with "a C3 to C8 cycloalkyl group". For example, there may be mentioned a cyclopropyloxy group, a cyclobutyloxy group, a cyclopentyloxy group, a cyclohexyloxy group, a cycloheptyloxy group, a cyclooctyloxy group, and the like.
  • In the present invention, "a mono(C1 to C6 alkyl)amino group" means a group obtained by substituting an amino group with "a C1 to C6 alkyl group". For example, there may be mentioned a methylamino group, an ethylamino group, a propylamino group, an isopropylamino group, a butylamino group, an isobutylamino group, a sec-butylamino group, a tert-butylamino group, a pentylamino group, a hexylamino group, and the like.
  • In the present invention, "a di(C1 to C6 alkyl)amino group" means a group obtained by substituting an amino group with two of the same or different "a C1 to C6 alkyl group". For example, there may be mentioned a dimethylamino group, a diethylamino group, a dipropylamino group, a diisopropylamino group, a dibutylamino group, a diisobutylamino group, a di(sec-butyl)amino group, a di(tert-butyl)amino group, a dipentylamino group, a dihexylamino group, and the like.
  • In the present invention, "a (C1 to C6 alkyl)aminocarbonyl group" means a group obtained by substituting a carbonyl group with "a (C1 to C6 alkyl)amino group". For example, there may be mentioned a methylaminocarbonyl group, an ethylaminocarbonyl group, a propylaminocarbonyl group, an isopropylaminocarbonyl group, a butylaminocarbonyl group, an isobutylaminocarbonyl group, a sec-butylaminocarbonyl group, a tert-butylaminocarbonyl group, a pentylaminocarbonyl group, a hexylaminocarbonyl group, and the like.
  • In the present invention, "a C1 to C6 alkylsulfonyl group" means a group obtained by substituting a sulfonyl group with "a C1 to C6 alkyl group". For example, there may be mentioned a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, an isopropylsulfonyl group, a butylsulfonyl group, an isobutylsulfonyl group, a sec-butylsulfonyl group, a tert-butylsulfonyl group, a pentylsulfonyl group, a hexylsulfonyl group, and the like.
  • In the present invention, "a C1 to C6 alkylaminosulfonyl group" means a group obtained by substituting a sulfonyl group with "a mono(C1 to C6 alkyl)amino group". For example, there may be mentioned a methylaminosulfonyl group, an ethylaminosulfonyl group, a propylaminosulfonyl group, an isopropylaminosulfonyl group, a butylaminosulfonyl group, an isobutylaminosulfonyl group, a sec-butylaminosulfonyl group, a tert-butylaminosulfonyl group, a pentylaminosulfonyl group, a hexylaminosulfonyl group, and the like.
  • In the present invention, "a (hydroxycarbonyl)(C1 to C3 alkyl) group" means a group obtained by substituting "a C1 to C3 alkyl group" with "a (hydroxycarbonyl) group" at arbitrary position. For example, there may be mentioned a hydroxycarbonylmethyl group, a (1-hydroxycarbonyl)ethyl group, a (2-hydroxycarbonyl)ethyl group, a (3-hydroxycarbonyl)propyl group, an a (2-hydroxycarbonyl)propyl group, a (1-hydroxycarbonyl)propyl group, a (1-hydroxycarbonyl)(1-methyl)ethyl group, and the like.
  • In the present invention, "a (C1 to C6 alkoxy)carbonyl(C1 to C3 alkyl) group" means a group obtained by substituting "a C1 to C3 alkyl group" with "a (C1 to C6 alkoxy)carbonyl group" at arbitrary position. For example, there may be mentioned a methoxycarbonylmethyl group, a methoxycarbonylethyl group, a (3-methoxycarbonyl)propyl group, a (2-methoxycarbonyl)propyl group, a (1-methoxycarbonyl)propyl group, a (1-methoxycarbonyl)(1-methyl)ethyl group, an ethoxycarbonylmethyl group, an ethoxycarbonylethyl group, an (3-ethoxycarbonyl)propyl group, an (2-ethoxycarbonyl)propyl group, an (1-ethoxycarbonyl)propyl group, an (1-ethoxycarbonyl)(1-methyl)ethyl group, and the like.
  • In the present invention, "a (C1 to C6 alkyl)sulfonyl(C1 to C3 alkyl) group" means a group obtained by substituting "a C1 to C3 alkyl group" with "a (C1 to C6 alkyl)sulfonyl group" at arbitrary position. For example, there may be mentioned a methlsulfonyl methyl group, a methylsulfonylethyl group, a (3-methylsulfonyl)propyl group, a (2-methylsulfonyl)propyl group, a (1-methylsulfonyl)propyl group, a (1-methylsulfonyl)(1-methyl)ethyl group, an ethylsulfonylmethyl group, an ethylsulfonylethyl group, an (3-ethylsulfonyl)propyl group, an (2-ethylsulfonyl)propyl group, an (1-ethylsulfonyl)propyl group, an (1-ethylsulfonyl)(1-methyl)ethyl group , and the like.
  • In the present invention, "a C6 to C10 aryl group" means an aromatic hydrocarbon group having 6 to 10 carbons. For example, there may be mentioned a phenyl group, a naphthyl group, an indenyl group, a tetrahydronaphthyl group, an indanyl group, an azulenyl group, and the like.
    In the present invention, "a C6 to C10 aryloxy group" means a group obtained by substituting an oxy group with "a C6 to C10 aryl group". For example, there may be mentioned a phenyloxy group, a naphthyloxy group, an indenyloxy group, a tetrahydronaphthyloxy group, an indanyloxy group, an azulenyloxy group, and the like.
  • In the present invention, "a (C6 to C10 aryl)(C1 to C3 alkyl) group" means a group obtained by substituting "a C1 to C3 alkyl group" with "a C6 to C10 aryl group". For example, there may be mentioned a benzyl group, a phenethyl group, a phenylpropyl group, a naphthylmethyl group, and the like.
  • In the present invention, "a 5- to 10-membered heteroaryl group" means a 5- to 10-membered monocyclic or bicyclic heterocyclic group having aromaticity, wherein the heterocyclic group contains 1 to 5 heteroatoms selected from oxygen, sulfur and nitrogen. Further, in the case of a bicyclic aromatic heterocyclic group, if one ring is aromatic ring or aromatic heterocyclic ring, the other ring may be non-aromatic ring. In such aromatic heterocyclic group, the number of respective heteroatoms and combinations thereof are not particularly limited as long as ring having prescribed number of members can be formed and can exist chemically stably. As such "a 5- to 10-membered heteroaryl group", for example, there may be mentioned a pyridyl group, a pyrazyl group, a pyrimidyl group, a pyridazinyl group, a furyl group, a thienyl group, a pyrrole group, a pyrazolyl group, an 1,3-dioxaindanyl group, an isoxazolyl group, an isothiazolyl group, a benzofuranyl group, an isobenzofuryl group, a benzothienyl group, an indolyl group, an isoindolyl group, a chromanyl group, a benzothiazolyl group, a benzoimidazolyl group, a benzoxazolyl group, a pyranyl group, an imidazolyl group, an oxazolyl group, a thiazolyl group, a triazinyl group, a triazolyl group, a furazanyl group, a thiadiazolyl, a dihydrobenzofuryl group, a dihydroisobenzofuryl group, a dihydroquinolyl group, a dihydroisoquinolyl group, a dihydrobenzoxazolyl group, a dihydropteridinyl group, a benzoxazolyl group, a benzisoxazolyl group, a benzodioxazolyl group, a quinolyl group, an isoquinolyl group, a benzotriazolyl group, a pteridinyl group, a purinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a tetrazolyl group, and the like.
  • In the present invention, "a (5- to 10-membered heteroaryl)(C1 to C3 alkyl) group" means a group obtained by substituting "a C1 to C3 alkyl group" with "a 5- to 10-membered heteroaryl group". For example, there may be mentioned a pyridylmethyl group, a thienylmethyl group, a thiazolylmethyl group, a benzothiazolylmethyl group, a benzothiophenylmethyl group, and the like.
  • In the present invention, "a 3- to 8-membered heterocycloalkyl group" means a 3- to 8-membered aliphatic heterocyclic group which may be saturated or partially unsaturated, wherein the ring contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen. For example, there may be mentioned a piperidyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, a tetrahydrothienyl group, a morpholyl group, and the like.
  • In the present invention, "a (3- to 8-membered heterocycloalkyl)(C1 to C3 alkyl) group" means a group obtained by substituting "a C1 to C3 alkyl group" with "a 3- to 8-membered heterocycloalkyl group". For example, there may be mentioned a piperidylmethyl group, a tetrahydrofuranylmethyl group, a tetrahydropyranylmethyl group, a tetrahydrothienylmethyl group, a morpholinoethyl group, a oxetan-3-ylmethyl group, and the like.
  • In the present invention, "spiroheteroalkyl group" means a spiroalkyl group in which 1 to 4 carbon atoms replaced with 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen. "A C6 to C9 spiroheteroalkyl group" means a spiroalkyl group having 6 to 9 carbons. For example, there may be mentioned a 4-oxaspiro[2.4]heptanyl group, a 4-oxaspiro[2.5]octaneyl group, and the like.
  • In the present invention, "a (C5 to C9 bicycloalkyl)(C1 to C3 alkyl) group" means a group obtained by substituting "a C1 to C3 alkyl group" with "a C5 to C9 bicycloalkyl group" at arbitrary position. For example, there may be mentioned a bicyclo[1.1.1]pentanyl methyl group, a bicyclo[3.1.0]hexanyl methyl group, a bicyclo[3.1.0]hexanyl ethyl group, a bicyclo[2.2.0]hexanyl methyl group, a bicyclo[2.2.0]hexanyl ethyl group, a bicyclo[2.1.1]hexanyl methyl group, a bicyclo[2.1.1]hexanyl ethyl group, a bicyclo[3.2.0]heptanyl methyl group, a bicyclo[3.2.0]heptanyl ethyl group, a bicyclo[2.2.1]heptanyl methyl group, a bicyclo[2.2.1]heptanyl ethyl group, a bicyclo[3.1.1]heptanyl methyl group, a bicyclo[4.1.0]heptanyl methyl group, an octahydropentalenyl methyl group, a bicyclo[2.2.2]octanyl methyl group, a bicyclo[3.2.1]octanyl methyl group, a bicyclo[4.2.0]octanyl methyl group, a bicyclo[4.1.1]octanyl methyl group, a bicyclo[5.1.0]octanyl methyl group, an octahydro-1H-indenyl methyl group, a bicyclo[3.2.2]nonanyl methyl group, a bicyclo[3.3.1]nonanyl methyl group, a bicyclo[4.2.1]nonanyl methyl group, a bicyclo[5.2.0]nonanyl methyl group, and the like.
  • In the present invention, "heterobicycloalkyl group" means a bicycloalkyl group in which 1 to 4 carbon atoms replaced with 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen. "A C6 to C9 heterobicycloalkyl group" means a heterobicycloalkyl group having 6 to 9 carbons. For example, there may be mentioned a 7-oxabicyclo[2.2.1]heptanyl group and the like.
  • In the present invention, "a (C6 to C9 heterobicycloalkyl)(C1 to C3 alkyl) group" means a group obtained by substituting "a C1 to C3 alkyl group" with "a C6 to C9 heterobicycloalkyl group" at arbitrary position. For example, there may be mentioned a 7-oxabicyclo[2.2.1]heptanyl methyl group, a 7-oxabicyclo[2.2.1]heptanyl ethyl group, and the like.
  • In the present invention, in "a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Ra groups", when the C1 to C6 alkyl group is, substituted by a plurality of Ra groups, each Ra group can be selected independently and the C1 to C6 alkyl group can be substituted by the same Ra groups or by different Ra groups. In addition, meaning of other expressions such as "a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Rb groups" and the like mean similar situations.
  • The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof:
    Figure imgb0005
  • In the formula (I), R1 is selected from F, Cl, Br, a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Ra groups and a C3 to C8 cycloalkyl group substituted by 0, 1, 2 or 3 Ra groups; wherein Ra is, independently selected from F, C1 to C4 alkyl group, -OH, -CN, -NO2, -NH2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3 and an oxo group.
  • The "a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Ra groups" in R1 is preferably C1 to C3 alkyl group substituted by 0, 1, 2 or 3 Ra groups, and more preferable is a trifluoromethyl group or a difluoromethyl group.
  • The "a C3 to C8 cycloalkyl group substituted by 0, 1, 2 or 3 Ra groups" in R1 is preferably C3 to C4 cycloalkyl group substituted by 0, 1, 2 or 3 Ra groups, more preferable is a cyclopropyl group substituted by 0, 1, 2 or 3 Ra groups.
  • On the whole, R1 is preferably Cl, a C1 to C4 alkyl group substituted by 0, 1, 2 or 3 Ra groups or a cyclopropyl group substituted by 0, 1, 2 or 3 Ra groups, and more preferable is a trifluoromethyl group, a difluoromethyl group or Cl.
  • In the formula (I), Y is a C4 to C6 cycloalkyl group, a C6 to C9 bicycloalkyl group or a C6 to C9 spiroalkyl group, all of which are substituted by a R2 group, 0 or 1 R6 group and 0, 1, 2 or 3 R7 groups; wherein R2 is selected from -OH, -CO2H, -SO3H, -CONH2, -SO2NH2, a (C1 to C6 alkoxy)carbonyl group substituted by 0, 1, 2 or 3 Rc groups, a (C1 to C6 alkyl)aminocarbonyl group substituted by 0, 1, 2 or 3 Rc groups, a C1 to C6 alkylsulfonyl group substituted by 0, 1, 2 or 3 Rc groups, a C1 to C6 alkylaminosulfonyl group substituted by 0, 1, 2 or 3 Rc groups, a (hydroxycarbonyl)(C1 to C3 alkyl) group substituted by 0, 1,2 or 3 Rc groups, a (C1 to C6 alkoxy)carbonyl(C1 to C3 alkyl) group substituted by 0, 1, 2 or 3 Rc groups, a (C1 to C6 alkyl)sulfonyl(C1 to C3 alkyl) group substituted by 0, 1, 2 or 3 Rc groups and a (C2 to C6 alkenyl)(C1 to C3 alkyl) group substituted by 0, 1; 2 or 3 Rc groups; R6 and R7 are independently selected from H, F, -OH, -NH2, -CN, a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Rb groups and a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rb groups;
    wherein Rband Rc are , independently selected from F, a C1 to C4 alkyl group, -OH, -CN, -NO2, -NH2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3 and an oxo group;
    The "a C4 to C6 cycloalkyl group, a C6 to C9 bicycloalkyl group or a C6 to C9 spiroalkyl group, all of which are substituted by a R2 group, 0 or 1 R6 group and 0, 1, 2 or 3 R7 groups" in Y is preferably a group represented by formula (II-a), formula (II-b), formula (II-c) or formula (II-d):
    Figure imgb0006
     wherein:
    • k is 0, 1 or 2;
    • and n is 1, 2 or 3.
  • In the case of the group represented by formula (II-a), formula (II-b), formula (II-c) or formula (II-d), Y is preferably a group represented by formula (II-a), formula (II-c) or formula (II-d); and more preferably a group represented by formula (II-a) or formula (II-d).
  • The variable, n, is preferably 2 in a group represented by formula (II-d).
  • R2 in Y is preferably -CO2H, -SO3H -CONH2, -SO2NH2 a (C1 to C2 alkyl)aminocarbonyl group substituted by 0 or 1 Rc groups, a C1 to C2 alkylsulfonyl group substituted by 0 or 1 Rc groups, a C1 to C2 alkylaminosulfonyl group substituted by 0 or 1 Rc groups or a (hydroxycarbonyl)(C1 to C3 alkyl) group substituted by 0, 1, 2 or 3 Rc groups, and more preferable is -CO2H or a hydroxycarbonylmethyl group substituted by 0, 1 or 2 Rc groups.
  • R6 in Y is preferably H or a C1 to C4 alkyl group without Rb group, and more preferable is H, a methyl group or an ethyl group.
  • R7 in Y is preferably H or a C1 to C2 alkyl group without Rb group, and more preferable is H or a methyl group.
  • In the formula (I), R3 is selected from H, F, Cl, -CH3 and -CF3. R3 is preferably H.
  • In the formula (I), R4 is selected from a C1 to C6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C2 to C6 alkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C2 to C6 alkynyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C1 to C6 alkoxy)(C2 to C4 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C6 to C10 aryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a (5- to 10-membered heteroaryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C3 to C8 cycloalkenyl group substituted by 0, 1, 2, 3, 4 or 5Rg groups, a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (3- to 8-membered heterocycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4' or 5 Rg groups, a C6 to C9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C6 to C9 spiroalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroheteroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C5 to C9 bicycloalkyl group substituted by 0; 1, 2, 3, 4 or 5 Rg groups, a (C5 to C9 bicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 heterobicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups and a (C6 to C9 heterobicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups;
    wherein Re isindependently selected from F, a C1 to C4 alkyl group, -OH, -CN, -NO2, -NH2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3 and an oxo group;
    Rf is independently selected from F, Cl, Br, -OH, -CN, -NO2, -CO2H, a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Rk groups, a C2 to C6 alkenyl group substituted by 0, 1, 2 or 3 Rk groups, a C2 to C6 alkynyl group substituted by 0, 1,2 or 3 Rk groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2 or 3 Rk groups, a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rk groups, a C3 to C8 cycloalkyloxy group substituted by 0, 1, 2 or 3 Rk groups, -SH, a C1 to C6 alkylthio group substituted by 0, 1, 2 or 3 Rk groups, a C3 to C8 cycloalkylthio group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkyl)carbonyl group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkoxy)carbonyl group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkyl)aminocarbonyl group substituted by 0, 1, 2 or 3 Rk groups, a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2 or 3 Rk groups, a C1 to C6 alkylsulfonyl group substituted by 0, 1, 2 or 3 Rk groups, -NH2, a mono(C1 to C6 alkyl)amino group substituted by 0, 1, 2 or 3 Rk groups and a di(C1 to C6 alkyl)amino group substituted by 0, 1, 2 or 3 Rk groups;
    wherein, Rk is independently selected from F, a C1 to C4 alkyl group, -OH, -CN, -NO2, -NH2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3 and an oxo group;
    Rg is is independently selected from F, Cl, a C1 to C6 alkyl group, -OH, -CN, -NH2, -NO2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3, a C1 to C6 alkylene group substituted by 0, 1,2 or 3 Rl groups, a C2 to C6 alkenylene group substituted by 0, 1, 2 or 3 Rl groups and an oxo group;
    wherein Rl is independently selected from F, a C1 to C4 alkyl group, -OH, -CN, -NO2, -NH2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3 and an oxo group.
  • The "a C1 to C6 alkyl group substituted by 0, 1, 2, 3, 4 or 5Re groups" in R4 is preferably C2 to C6 alkyl group substituted by 0, 1, 2, 3, 4 or 5Re and more preferably a tert-butylmethyl group or a 3,3,3-trifluoro-2,2-dimethylpropyl group.
  • The "a (C2 to C6 alkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups" in R4 is preferably one having 3 to 6 carbons in (C2 to C6 alkenyl)(C1 to C3 alkyl) and more preferably a 3-methyl-2-buten-1-yl group.
  • The "a (C2 to C6 alkynyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5Re groups" in R4 is preferably one having 4 to 8 carbons in (C2 to C6 alkynyl)(C1 to C3 alkyl) and more preferably a 4,4-dimethyl-2-pentyn-1-yl group.
  • The "a (C1 to C6 alkoxy)(C2 to C4 alkyl) group substituted by 0, 1, 2, 3, 4 or 5Re groups" in R4 is preferably one having 3 to 7 carbons in (C1 to C6 alkoxy)(C2 to C4 alkyl), more preferably a C1 to C4 alkoxyethyl group substituted by 0, 1, 2 or 3 alkyl groups, and even more preferably a 2,2-dirriethyl-2-methoxyethyl group or a 2-(tert-butoxy)ethyl group.
  • The "a (C6 to C10 aryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups" in R4 is preferably a benzyl group substituted by 0, 1, 2, 3, 4 or 5 Rf,s; more preferably a benzyl group substituted by 1, 2 or 3 groups selected from F and Cl, or a unsubstituted benzyl group; and even more preferable is a 4-fluorobenzyl group, a 3,5-difluorobenzyl group or a 4-(trifluoromethyl)benzyl group.
  • The "a (5- to 10-membered heteroaryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups" in R4 is preferably a pyridylmethyl group, a thienylmethyl group, a thiazolylmethyl group or a furanylmethyl group.
  • The "a C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups" in R4 is preferably C3 to C6 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups and more preferably a 2,2-dimethylcyclobutyl group or a 4,4-dimethylcyclohexyl group.
  • The "a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups" in R4 is preferably a C3 to C6 cycloalkyl methyl group substituted by 0, 1, 2, 3 or 4 Rg groups; and more preferable is a (1-fluorocyclopentyl)methyl group, a (3,3-dimethylcyclobutyl)methyl group, a (1-methylcyclobutyl)methyl group, a (1-(trifluoromethyl)cyclobutyl)methyl group, a (1-(trifluoromethyl)cyclopropyl)methyl group or a (1-methylcyclopropyl)methyl group.
  • The "a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups" in R4 is preferably a 3- to 6-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups.
  • The "a (3- to 8-membered heterocycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups" in R4 is preferably a 3- to 6-membered heterocycloalkyl methyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups; more preferably a tetrahydrofuranylmethyl group substituted by 1, 2 or 3 groups selected from F, a C1 to C4 alkyl group and a C1 to C6 alkylene group substituted by 0, 1, 2 or 3 Rl groups.
  • The "a C6 to C9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups" in R4 is preferably a C7 to C8 spiroalkyl ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups; more preferably a spiro[2.5]octan-1-yl group, a spiro[3.5]nonan-1-yl group, a spiro[3.3]heptan-1-yl group or a spiro[3.3]heptan-2-yl group.
  • The "a (C6 to C9 spiroalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups" in R4 is preferably a C6 to C8 spiroalkyl methyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups; more preferably a spiro[2.5]octan-6-ylmethyl group substituted by 0, 1, 2 or 3 Rg groups or a spiro[2.3]hexan-5-ylmethyl group substituted by 0, 1, 2 or 3 Rg groups; and even more preferable is a spiro[2.5]octan-6-ylmethyl group, (5-fluoro-spiro[2.3]hexan)-5-ylmethyl group or spiro[2.3]hexan-5-ylmethyl group.
  • The "a C6 to C9 spiroheteroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups" in R4 is preferably a C7 to C8 spiroheteralkyl ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups.
  • The "a C5 to C9 bicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups" in R4 is preferably a C6 to C8 bicycloalkyl ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups; more preferably a bicyclo[3.1.0]hexan-3-yl group substituted by 0, 1, 2 or 3 Rg groups; and even more preferable is a 6,6-dimethylbicyclo[3.1.0]hexan-3-yl group.
  • The "a (C5 to C9 bicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups" in R4 is preferably a C5 to C7 bicycloalkyl methyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups; more preferably a (bicyclo[1.1.1]pentan-1-yl)methyl group substituted by 0, 1, 2 or 3 Rg groups or a (bicyclo[2.2.1]heptan-1-yl)methyl group substituted by 0, 1, 2 or 3 Rg groups; and even more preferable is a (4-methylbicyclo[2.2.1]heptan-1-yl)methyl group or (bicyclo[1.1.1]pentan-1-yl)methyl group.
  • The "a (C6 to C9 heterobicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups" in R4 is preferably a C6 to C7 heterobicycloalkyl methyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups; more preferably (7-oxabicyclo[2.2.1]heptan-1-yl)methyl group substituted by 0, 1, 2 or 3 Rg groups; and, even more preferable is (4-methyl-7-oxabicyclo[2.2.1]heptan-1-yl)methyl group or (7-oxabicyclo[2.2.1]heptan-1-yl)methyl group.
  • In the formula (I), R5 is selected from a C6 to C10 aryl group substituted by 0, 1, 2, 3, 4 or 5 Ri groups, a 5- to 10-membered heteroaryl group substituted by 0, 1, 2, 3, or 4 Ri groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rj groups, a C3 to C8 cycloalkenyl group substituted by 0, 1, 2, 3, 4 or 5 Rj groups and a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rj groups; wherein Ri is independently selected from F, Cl, Br, -OH, -CN, -NO2, -CO2H, a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Rk groups, a C2 to C6 alkenyl group substituted by 0, 1, 2 or 3 Rk groups, a C2 to C6 alkynyl group substituted by 0, 1, 2 or 3 Rk groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2 or 3 Rk groups, a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rk groups, a C3 to Cg cycloalkyloxy group substituted by 0, 1, 2 or 3 Rk groups, -SH, a C1 to C6 alkylthio group substituted by 0, 1, 2 or 3 Rk groups, a C3 to C8 cycloalkylthio group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkyl)carbonyl group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkoxy)carbonyl group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkyl)aminocarbonyl group substituted by 0, 1, 2 or 3 Rk groups, a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2 or 3 Rk groups, a C1 to C6 alkylsulfonyl group substituted by 0, 1, 2 or 3 Rk groups, -NH2, a mono(C1 to C6 alkyl)amino group substituted by 0, 1, 2 or 3 Rk groups and a di(C1 to C6 alkyl)amino group substituted by 0, 1, 2 or 3 Rk groups;
    Rj isindependently selected from F, Cl, a C1 to C6 alkyl group, -OH, -CN, -NH2, -NO2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3, a C1 to C6 alkylene group substituted by 0, 1, 2 or 3 R1 groups, a C2 to C6 alkenylene group substituted by 0, 1, 2 or 3 R1 groups and an oxo group;
    wherein, when Rj is a divalent group of a C1 to C6 alkylene group or a C2 to C6 alkenylene group, it is meant that each group forms bonds with atoms in R5; in this case, two bonds of each of these divalent groups are formed with the same atom or two different atoms in R5; wherein Rk and Rl are independently selected from F, a C1 to C4 alkyl group, -OH, -CN, -NO2, -NH2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3 and an oxo group.
  • The "a C6 to C10 aryl group substituted by 0, 1, 2, 3, or 4 Ri groups" in R5 is preferably a phenyl group substituted by 2 to 4 groups selected from -OH, -NH2, Cl, F, -CN, -CF3, -OCF3, -OCF2H, a methyl group, a cyclopropyl group and a methoxy group;
    and more preferable is a 2,6-dichlorophenyl group, a 2,6-dichloro-4-fluorophenyl group, a 2,6-dichloro-4-methylphenyl group, a 2,4,6-trichlorophenyl group, a 2-chloro-6-fluorophenyl group or a 2,6-dichloro-3-fluorophenyl group.
  • The "a 5- to 10-membered heteroaryl group substituted by 0, 1, 2, 3, or 4 Ri groups" in R5 is preferably a pyridyl group substituted by 2 to 3 groups selected from -OH, -NH2, Cl, F, -CN, -CF3, a methyl group, and a methoxy group; and more preferable is a 3,5-dichloropyridin-4-yl group, a 3-chloro-5-methoxypyridin-4-yl group, a 3-chloro-5-fluoropyridin-4-yl group or a 2,4-dichloro-6-methylpyridin-3-yl group.
  • On the whole, R5 is preferably a phenyl group optionally substituted by 2, 3 or 4 Ri groups or a 6-membered heteroaryl group optionally substituted by 2 or 3 Ri groups.
  • In the formula (I), R8 and R9 are independently selected from H, F, -OH, -NH2, a C1 to C3 alkyl group substituted by 0, 1, 2 or 3 Rh groups, and a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rh groups; or R8 and R9 together form an oxo group or a thioxo group;
    wherein Rh is, independently selected from F, a C1 to C4 alkyl group, -OH, -CN, -NO2, -NH2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3 and an oxo group.
  • The "a C1 to C3 alkyl group substituted by 0, 1, 2 or 3 Rh groups" in R8and R9 is preferably methyl group substituted by 0, 1, 2 or 3 Rh groups.
  • The "a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rh groups" in R8 and R9 is preferably methoxy group substituted by 0, 1, 2 or 3 Rh groups.
  • On the whole, R8 and R9 are preferably H, F, -OH or an oxo group, anymore preferable are H or an oxo group.
  • In the formula (I), R12 is H; or R4 and R12 together are -CRmRm-CR13R14-CRmRm- or -CR13R14-CRmRm-CRmRm- to form a pyrrolidine ring.
  • R13 is selected from H, a C1 to C6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a C6 to C10 aryl group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a C6 to C10 aryloxy group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a (C2 to C6 alkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C2 to C6 alkynyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C1 to C6 alkoxy)(C2 to C4 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C6 to C10 aryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a (5- to 10-membered heteroaryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C3 to C8 cycloalkenyl group substituted by 0, 1, 2, 3, 4 or 5 groups, a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups and a (3- to 8-membered heterocycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C6 to C9 spiroalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroheteroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 bicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C5 to C9 bicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, (C6 to C9 heterobicycloalkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, and a (C6 to C9 heterobicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups;
    R14 is selected from H and a C1 to C6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 Re groups; or R13 and R14 together form a C3 to C8 cycloalkane ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups, C3 to C8 cycloalkene ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups, or a 3- to 8-membered heterocycloalkane ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups; Rm is independently selected from H, F, Cl, -CH3 and -CF3;
    wherein Rg is selected from F, Cl, a C1 to C6 alkyl group, -OH, -CN, -NH2, -NO2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3, a C1 to C6 alkylene group substituted by 0, 1, 2 or 3 Rl groups, a C2 to C6 alkenylene group substituted by 0, 1, 2 or 3 Rl groups and an oxo group;
    Rf is independently selected from F, Cl, Br, -OH, -CN, -NO2, -CO2H, a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Rk groups, a C2 to C6 alkenyl group substituted by 0, 1, 2 or 3 Rk groups, a C2 to C6 alkynyl group substituted by 0, 1, 2 or 3 Rk groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2 or 3 Rk groups, a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rk groups, a C3 to C8 cycloalkyloxy group substituted by 0, 1, 2 or 3 Rk groups, -SH, a C1, to C6 alkylthio group substituted by 0, 1, 2 or 3 Rk groups, a C3 to C8 cycloalkylthio group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkyl)carbonyl group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkoxy)carbonyl group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkyl)aminocarbonyl group substituted by 0, 1, 2 or 3 Rk groups, a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2 or 3 Rk groups, a C1 to C6 alkylsulfonyl group substituted by 0, 1, 2 or 3 Rk groups, -NH2, a mono(C1 to C6 alkyl)amino group substituted by 0, 1, 2 or 3 Rk groups and a di(C1 to C6 alkyl)amino group substituted by 0, 1, 2 or 3 Rk groups; and
    Re and Rk are, independently selected from F, a C1 to C4 alkyl group, -OH, -CN, -NO2, -NH2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3 and an oxo group.
  • Preferably R12 is H; or R4 and R12 together are -CH2-CR13R14-CH2- to form a pyrrolidine ring, more preferably R12 is H.
  • R13 is preferably a C1 to C6 alkyl group, a C6 to C10 aryl group, a C6 to C10 aryloxy group, a (C6 to C10 aryl)(C1 to C3 alkyl) group, or a C3 to C8 cycloalkenyl group.
  • R14 is preferably H or CH3; or R13 and R14 together form a C3 to C8 cycloalkane ring or a C3 to C8 cycloalkene ring. In the formula (I), a combination of R1, R2, R3, R4, R5, R6, R7, R8, R9, R12 , R13, R14 Y, n, k, Ra, Rb, Rc, Re, Rf Rg, Rh, Ri Rj, Rk, Rl Rm is preferably one where respective preferable components described above are combined; and more preferably one where components described above as more preferable are combined.
  • In another embodiment, in conjunction with any above or below embodiments, Rl is a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Ra groups.
  • In another embodiment, in conjunction with any above or below embodiments, Rl is a C1 alkyl group substituted by 0, 1, 2 or 3 Ra groups.
  • In another embodiment, in conjunction with any above or below embodiments, R1 is CF3.
  • In another embodiment, in conjunction with any above or below embodiments, R2 is CO2H.
  • In another embodiment, in conjunction with any above or below embodiments, Y is selected from formula (II-a), formula (II-b), formula (II-c) and formula (II-d):
    Figure imgb0007
     wherein, k is 0, 1 or 2; and n is 1, 2 or 3.
  • In another embodiment, in conjunction with any above or below embodiments, Y is selected from formula (II-a) and formula (II-d);
    Figure imgb0008
     wherein in k is 0, 1 or 2; and n is 1, 2 or 3.
  • In another embodiment, in conjunction with any above or below embodiments, Y is selected from formula (II-a) and formula (II-d);
    Figure imgb0009
     wherein in k is 0; and n 2.
  • In another embodiment, in conjunction with any above or below embodiments, Y is
    Figure imgb0010
  • In another embodiment, in conjunction with any above or below embodiments, Y is
    Figure imgb0011
  • In another embodiment, in conjunction with any above or below embodiments, R6 is selected from F, -OH, -NH2, -CN, a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Rb groups and a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rb groups.
  • In another embodiment, in conjunction with any above or below embodiments, R6 is a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Rb.
  • In another embodiment, in conjunction with any above or below embodiments, R6 is CH3.
  • In another embodiment, in conjunction with any above or below embodiments, R7 is independently selected from H, F and a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Rb groups.
  • In another embodiment, in conjunction with any above or below embodiments, R7 is H.
  • In another embodiment, in conjunction with any above or below embodiments, R2 is selected from -OH, -CO2H -SO3H, -CONH2 and -SO2NH2.
  • In another embodiment, in conjunction with any above or below embodiments, R3 is H.
  • In another embodiment, in conjunction with any above or below embodiments, R4 is selected from a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Re groups, a (C6 to C10 aryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a, C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C6 to C9 spiroalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C5 to C9 bicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C5 to C9 bicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups or a (C6 to C9 heterobicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups.
  • In another embodiment, in conjunction with any above or below embodiments, R4 is a C1 to C6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 Re groups.
  • In another embodiment, in conjunction with any above or below embodiments, R4 is a (C6 to C10 aryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups.
  • In another embodiment, in conjunction with any above or below embodiments, R4 is a C3 to C8 cycloalkyl group substituted by 0, 1, 2 or 3 Rg groups.
  • In another embodiment, in conjunction with any above or below embodiments, R4 is a (C5 to C9 bicycloalkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups.
  • In another embodiment, in conjunction with any above or below embodiments, R4 is a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups.
  • In another embodiment, in conjunction with any above or below embodiments, R4 is a C6 to C9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups.
  • In another embodiment, in conjunction with any above or below embodiments, R4 is a (C6 to C9 spiroalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups.
  • In another embodiment, in conjunction with any above or below embodiments, R4 is a (C5 to C9 bicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups.
  • In another embodiment, in conjunction with any above or below embodiments, R4 is a (C6 to C9 heterobicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups.
  • In another embodiment, in conjunction with any above or below embodiments, R8 and R9 are independently selected from H and F.
  • In another embodiment, in conjunction with any above or below embodiments, R8 and R9 together form an oxo group.
  • In another embodiment, in conjunction with any above or below embodiments, R5 is a C6 to C10 aryl group substituted by 0, 1, 2, 3, 4 or 5 Ri groups.
  • In another embodiment, in conjunction with any above or below embodiments, R5 is a phenyl group substituted by 0, 1, 2, 3, 4 or 5 Ri groups.
  • In another embodiment, in conjunction with any above or below embodiments, R5 is a 5- to 10-membered heteroaryl group substituted by 0, 1, 2, 3, or 4 Ri groups.
  • In another embodiment, in conjunction with any above or below embodiments, R5 is a 6-membered heteroaryl group substituted by 0, 1, 2, 3, or 4 Ri groups.
  • In another embodiment, in conjunction with any above or below embodiments, R5 is pyridyl substituted by 0, 1, 2, 3, or 4 Ri groups.
  • In another embodiment, in conjunction with any above or below embodiments, R12 is H.
  • In another embodiment, in conjunction with any above or below embodiments, R4 and R12 together are -CH2-CR13R14-CH2- to form a pyrrolidine ring.
  • In another embodiment, in conjunction with any above or below embodiments, R14 is selected from H and CH3. In another embodiment, in conjunction with any above or below embodiments, R13 and R14 together form a C3 to C8 cycloalkane ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups, C3 to C8 cycloalkene ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups, or a 3- to 8-membered heterocycloalkane ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups.
  • In another embodiment, in conjunction with any above or below embodiments, R13 is selected from a C1 to C6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a C6 to C10 aryl group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a C6 to C10 aryloxy group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a (C2 to C6 alkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C2 to C6 alkynyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C1 to C6 alkoxy)(C2 to C4 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C6 to C10 aryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a (5- to 10-membered heteroaryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C3 to C8 cycloalkenyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups and a (3- to 8-membered heterocycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C6 to C9 spiroalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroheteroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 bicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C5 to C9 bicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 heterobicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, and a (C6 to C9 heterobicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups;
  • In another embodiment, in conjunction with any above or below embodiments, Rm is H;
  • The present invention also relates to a pharmaceutically acceptable salt of a compound represented by formula (I). For example, in the present invention, there are cases where a compound represented by formula (I) forms acid addition salts. Further, depending on the kind of substituent, there are cases where the pyrazole amide derivative forms salts with bases. These salts are not particularly limited as long as they are pharmaceutically acceptable ones. Specifically, the acid addition salts include mineral acid salts such as a hydrofluoride, a hydrochloride, a hydrobromide, a hydroiodide, a phosphate, a nitrate, a sulfate, and the like; organic sulfonate such as a methanesulfonate, an ethanesulfonate, a 2-hydroxyethanesulfonate, a p-toluenesufonate, a benzenesulfonate, an ethane-1,2-disulfonate ion, a 1,5-naphthalenedisulfonate ion, a naphthalene-2-sulfonate ion, and the like; and organic carboxylate such as an acetate, a trifluoroacetate, a propionate, an oxalate, a fumarate, a phthalate, a malonate, a succinate, a glutarate, an adipate, a tartrate, a maleate, a malate, a mandelate, a 1-hydroxy-2-naphthoate, and the like. As the salts with bases, there are mentioned salts with inorganic bases such as a sodium salt, a potassium salt, a magnesium salt, a calcium salt, an aluminum salt, and the like; and salts with organic bases such as a methylamine salt, an ethylamine salt, a lysine salt, an ornithine salt, and the like.
  • The various pharmaceutically acceptable salts of a compound represented by formula (I) can be produced suitably based on common knowledge in the present technical field.
  • A compound represented by formula (I) of the present invention contains isomers in some cases. Such isomers are included in a compound represented by formula (I) of the present invention. For example, there may be mentioned isomers in the ring and condensed ring systems (E-, Z-, cis-, and trans-forms), isomers due to the presence of chiral carbons (R- and S-forms, α- and β-configurations, enantiomers, and diastereomers), optically active substances with optical rotation (D-, L-, d-, and 1-forms), tautomers, polar compounds obtained by chromatographic separation (a highly-polar compound and a lowly-polar compound), equilibrium compounds, rotamers, mixtures of these compounds in an arbitrary ratio, racemic mixtures, and the like.
  • The present invention also includes various deuterated forms of the compounds represented by formula (I). Each hydrogen atom attached to a carbon atom may be independently replaced with a deuterium atom.
    • General synthesis method
  • The compound represented by formula (I) in the present invention can be produced by applying publicly known various synthesis methods with the use of characteristics based on types of basic structures or substituents. In this case, it may be effective in terms of manufacturing technology that the functional group may be protected with an appropriate protecting group or a group that can be easily converted to a functional group in the process of using a raw material and an intermediate depending on functional groups. Such a functional group includes, for example, an amino group, a hydroxyl group, a carboxyl group, and the like. The protecting groups thereof include, for example, protecting groups described in the "Protecting Groups in Organic Synthesis (the third edition, 1999)" written by T. W. Greene and P. G. M. Wuts. They may be suitably chosen and used depending on the reaction conditions. In these methods, the reaction is carried out by introducing the protecting group followed by eliminating the protecting group as necessary, or converting to an intended group to obtain an intended compound.
  • Among compound represented by formula (I) in the present invention, a compound (I-1) can be prepared, for example, by the following method:
    Figure imgb0012
     (wherein, R8 and R9 are independently H; F; a hydroxyl group; an amino group; a C1 to C3 alkyl group substituted by 0, 1, 2 or 3 Rh groups; a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rh groups; or R8 and R9 together form oxo group or thioxo group. Other symbols have the same meanings as described above.)
    • (Step 1)
  • The present step is a method for producing a compound (I-1) by reacting a compound (1) or a reactive derivative thereof with a compound (2).
  • The reactive derivative of the compound (1) means a reactive derivative of a carboxyl group, and for example, acid chloride, acyl azide, mixed acid anhydride, symmetric acid anhydride, activated amide, activated ester, and the like are cited. These reactive derivatives can be optionally chosen depending on types of carboxylic acids used.
  • The present reaction may be carried out according to a general amide-forming reaction by methods described in the literature (e.g., Pepuchido Gousei no Kiso to Jikken by Nobuo Izumiya, etc., Maruzen, 1983, Comprehensive Organic Synthesis, Vol. 6., Pergamon Press, 1991, etc.), equivalent methods thereto or a combination of these methods and the conventional method. Namely, the present reaction can be carried out by using a condensation agent that is well known to a person skilled in the art, or an ester activation method, a mixed acid anhydride method, an acid chloride method, a carbodiimide method and the like that are well known in the art. The reagents used in such an amide-forming reaction include, for example, thionyl chloride, oxalyl chloride, N,N-dicyclohexylcarbodiimide, 1-methyl-2-bromopyridinium iodide, N,N'-carbonyldiimidazole, diphenylphosphoryl chloride, diphenylphosphoryl azide, N,N'-disuccinimidyl carbonate, N,N'-disuccinimidyl oxalate, 1-ethyl-3-(3-dimethylarninopropyl)carbodiimide hydrochloride, benzotriazol-1-yl-oxy-tris(pyrrolidinol)phosphonium hexafluorophosphate, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, 2-(5-norbornene-2,3-dicarboximido)-1,1,3,3-tetramethyluronium tetrafluoroborate, O-(N-succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate, bromo-tris(pyrrolidino)phosphonium hexafluorophosphate, ethyl chloroformate, isobutyl chloroformate, or 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, and the like. Above all, for example, thionyl chloride, oxalyl chloride, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride or 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronim hexafluorophosphate, and the like are preferable. In the amide-forming reaction, a base and/or a condensation agent may be used along with the above-mentioned amide-forming agent.
  • The amount of the condensation agent that is consumed is not strictly limited, and is generally 0.1 equivalents to 100 equivalents with respect to 1 equivalent of the compound (1), and preferably 0.1 equivalents to 10 equivalents.
  • A base used includes, for example, tertiary aliphatic amine such as trimethylamine, triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, N-methylpyrrolidine, N-methylpiperidine, N,N-dimethylaniline, 1,8-diazabicyclo[5.4.0]undec-7-ene, 1,5-azabicyclo[4.3.0]non-5-ene, and the like; aromatic amines such as pyridine, 4-dimethylaminopyridine, picoline, lutidine, quinoline, or isoquinoline, and the like. Above all, tertiary aliphatic amine and the like are preferable, and triethylamine or N,N-diisopropylethylamine and the like are in particular preferable.
  • The amount of the base used varies depending on the compound used, types of solvents and other reaction conditions, however, it is generally 0.1 equivalents to 100 equivalents with respect to 1 equivalent of the compound (1), preferably 1 equivalent to 5 equivalents.
  • The condensation agent used includes, for example, N-hydroxybenzotriazole hydrate, N-hydroxysuccinimide, and the like.
  • The amount of the compound (2) used varies depending on the compound used, types of solvents and other reaction conditions, however, it is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (1) or a reactive derivative thereof, and preferably 1 equivalent to 3 equivalents.
  • The reaction is generally carried out in an inactive solvent, and examples of the inactive solvent include tetrahydrofuran, acetonitrile, N,N-dimethylformamide, 1,4-dioxane, benzene, toluene, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, pyridine, and the like, or mixtures thereof.
  • The reaction time is generally 0.5 hours to 96 hours, preferably 1 hour to 24 hours.
  • The reaction temperature is generally 0°C to the boiling point temperature of the solvent, and preferably room temperature to 80°C.
  • A base, an amide-forming reagent, and a condensation agent used in the present reaction can be used as a combination of one or more types thereof.
  • The compound (I-1) obtained in such a manner can be isolated and purified by an isolation and purification method that is well known to a person skilled in the art (e.g., concentration, concentration under reduced pressure, crystallization, solvent extraction, reprecipitation, chromatography, and the like; in the category of "general synthesis method", the term "isolation and purification method that is well known to a person skilled in the art" has the same meaning unless otherwise particularly specified).
  • Moreover, among all the compounds represented formula (I) in the present invention, compounds (I-2) and (I-3) can be produced, for example, by the following method:
    Figure imgb0013
     (wherein, other symbols have the same meanings as described above.)
    • (Step 2)
  • The present step is a method for producing a compound (I-2) by reacting the compound (1) or a reactive derivative thereof with a compound (3).
  • The reaction in the present step can be carried out by the same method as in the step 1, an equivalent method thereto, or a combination of these methods and a conventional method.
  • The compound (I-2) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
    • (Step 3)
  • The present step is a method for producing a compound (I-3) by subjecting the compound (I-2) to an oxidation reaction.
  • The present step can be carried out according to a method well known to a person skilled in the art. For example, the PCC oxidation, the Swern oxidation, the MnO2 oxidation, and the Dess-Martin oxidation, and the like are cited.
  • For example, the Dess-Martin oxidation can be carried out by using the Dess-Martin reagent without solvent or in a solvent inert to the reaction.
  • The amount of the Dess-Martin reagent used is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (I-2), preferably 1 equivalent to 4 equivalents.
  • The reaction in the present step is generally carried out in an inactive solvent. As the inactive solvent, for example, tetrahydrofuran, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, 1,4-dioxane, benzene, toluene, dichloromethane, chloroform, carbon tetrachloride, 1, 2-dichloroethane, and the like; or mixtures thereof are cited.
  • The reaction time is generally 0.5 hours to 96 hours, and preferably 1 hour to 24 hours.
  • The reaction temperature is generally -78°C to the boiling point temperature of the solvent, and preferably -20°C to room temperature.
  • The compound (I-3) obtained in such a manner can be isolated and purified by an isolation and purification method that is well known to a person skilled in the art.
  • Also, when the reactive substance has a carboxyl group that is not involved in the reaction in the first step, the second step and the third step, the carboxyl group is preferably protected in advance by a protecting group and then the protecting group is eliminated after completion of the reaction. Selection of such a protecting group and eliminating conditions can be conducted by referring to the method in previously mentioned "Protecting Groups in Organic Synthesis (the third edition, 1999)".
  • Moreover, among compounds represented by formula (I) in the present invention, a compound (I-3) can be prepared, for example, by the following method: Also, among the compounds (1) used to prepare the compounds in the present invention, a compound (1) wherein R3 is H can be prepared, for example, by the following method:
    Figure imgb0014
     (wherein, Rpro is a protecting group. Other symbols have the same meanings as described above.)
  • A compound represented by formula (a) can be synthesized according to a method well known to a person skilled in the art.
  • A compound represented by formula (c) can be synthesized according to a method well known to a person skilled in the art.
    • (Step A)
  • The present step is a method for producing a compound (b) by reacting a compound (a) with N,N-dimethylformamide dimethyl acetal in the presence or absence of a solvent.
  • Also, N,N-dimethylformamide diethyl acetal, N,N-dimethylformamide diisopropyl acetal, or the like can be used instead of N,N-dimethylformamide dimethyl acetal.
  • The amount of N,N-dimethylformamide dimethyl acetal used is generally 1 equivalent to 10 equivalents with respect to equivalent of the compound (a).
  • The reaction solvent used is not in particular limited as far as it is inert to the reaction, and specifically includes, for example, methanol, ethanol, benzene, toluene, xylene, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, or mixtures thereof.
  • The reaction time is generally 0.5 hours to 96 hours, and preferably 1 hour to 24 hours.
  • The reaction temperature is generally 0°C to the boiling point temperature of the solvent, and preferably room temperature to 160°C.
  • The compound (b) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification means well known to a person skilled in the art.
    • (Step B)
  • The present step is a method for producing a compound (d) by reacting the compound (b) with a compound having a hydrazino group represented by formula (c).
  • The amount of the compound (c) used is generally 0.5 equivalents to 10 equivalents with respect to 1 equivalent of the compound (b), and preferably 0.7 equivalents to 3 equivalents.
  • In the present step, when the compound (c) is a salt, it is necessary to use a base for neutralization. Examples of such a base include sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium acetate, potassium acetate, sodium hydroxide, potassium hydroxide, lithium hydroxide, triethylamine, N,N-diisopropylethylamine, pyridine, and the like. The amount of the base used is generally 1 equivalent to 3 equivalents with respect to 1 equivalent of the compound (c).
  • The reaction solvent used is not in particular limited as far as it is inert to the reaction. Specifically, examples include, methanol, ethanol, n-propanol, n-butanol, isopropanol, acetonitrile, diethyl ether, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, dichloromethane, chloroform, benzene, toluene, xylene or mixtures thereof.
  • The reaction time is generally 0.5 hours to 96 hours, and preferably 1 hour to 24 hours.
  • The reaction temperature is generally 0°C to the boiling point temperature of the solvent, and preferably room temperature to 100°C.
  • The compound (d) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
    • (Step C)
  • The present step is a method for producing a compound (1-a) by eliminating the protecting group Rpro of the compound (d).
  • The elimination of the protecting group can be carried out by a method described in previously mentioned "Protecting Groups in Organic Synthesis (the third edition, 1999)", an equivalent method thereto or a combination of these methods and the conventional method. For example, when the protecting group is a benzyl group, the benzyl group can be eliminated by a catalytic reduction method with the use of hydrogen and palladium catalytic agent and the like.
  • The compound (1-a) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • Moreover, among the compounds (2) used to prepare the compounds of the present invention, a compound (2-a) wherein both R8 and R9 are H can be synthesized, for example, by the following method:
    Figure imgb0015
     (wherein, R10 and R11 each independently are H, a group having one less carbon atoms than the hydrocarbon chain of R4, or R10 and R11 are together form a lower cycloalkyl or cycloalkenyl group. Other symbols have the same meanings as described above.)
  • The compound represented by formula (f) can be synthesized according to a method well known to a person skilled in the art.
    • (Step D)
  • The present step is a method for producing a compound (g) by reacting an organic lithium compound (e) with ethylene oxide (f).
  • The amount of ethylene oxide (f) used is generally 0.1 equivalents to 10 equivalents with respect to 1 equivalent of the compound (e), and preferably 0.5 equivalents to 3 equivalents.
  • The reaction solvent is not in particular limited as far as it is inert to the reaction, and examples include, tetrahydrofuran, 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, n-hexane, n-heptane, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, benzene, toluene, xylene, and the like.
  • The reaction time is generally 0.5 hour to 48 hours, and preferably 1 hour to 24 hours.
  • The reaction temperature is generally -78°C to the boiling point temperature of the solvent, and preferably -78°C to room temperature.
  • The compound (g) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
    • (Step E)
  • The present step is a method for producing a compound (h) by reacting the compound (g) with diphenylphosphoryl azide.
  • The reaction in the present step can be carried out by the same method as in the step 16, an equivalent method thereto, or a combination of these methods and the conventional method.
  • The compound (h) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
    • (Step F)
  • The present step is a method for producing a compound (i) by subjecting the compound (h) to a reduction reaction of the azide group.
  • The present step can be carried out according to methods well known to a person skilled in the art. These methods include, for example, a reduction method using phosphine; a catalytic reduction method using H and a palladium catalyst and the like; a reduction method using sodium borohydride; and the like.
  • For example, the reduction method using phosphine can be carried out using triphenylphosphine and water in a solvent inert to the reaction. Specifically, examples include tetrahydrofuran, acetonitrile, N,N-dimethylformamide, 1,4-dioxane, benzene, toluene, dichloromethane, chloroform, carbon tetrachloride, 1, 2-dichloroethane, water, and the like; or mixtures thereof.
  • The amount of triphenylphosphine used is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (15), and preferably 1 to 4 equivalents.
  • The reaction time is generally 0.5 hours to 96 hours, and preferably 2 hours to 48 hours.
  • The reaction temperature is generally 0°C to the boiling point temperature of the solvent, and preferably room temperature to the boiling point temperature of the solvent.
  • The compound (i) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
    • (Step G)
  • The present step is a method for producing a compound (2-a) by reacting the compound (i) with a compound (j) in the presence of a reducing agent.
  • The amount of the compound (i) used in the present step is generally 0.5 equivalents to 10 equivalents with respect to 1 equivalent of the compound (j), and preferably, 0.8 equivalents to 4 equivalents.
  • The reducing agents used include, for example, sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride, and the like.
  • The amount of the reducing agent used is generally 0.1 equivalents to 10 equivalents with respect to 1 equivalent of the compound (i), and preferably 0.3 equivalents to 5 equivalents.
  • The reaction solvent used is not in particular limited as far as it is inert to the reaction, and examples include methanol, ethanol, acetic acid, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, benzene, toluene, xylene, and the like.
  • The reaction time is generally 0.5 hours to 48 hours, and preferably, 1 hour to 24 hours.
  • The reaction temperature is generally 0°C to the boiling point temperature of the solvent.
  • The compound (2-a) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • A group represented by formula:
    Figure imgb0016
     (wherein, each symbol has the same meanings as described above) corresponds to the R4.
  • Moreover, among the compounds (2) used to prepare the compounds in the present invention, a compound (2-b) wherein either R8 or R9 is F and the other is H can be synthesized, for example, by the following method:
    Figure imgb0017
     (wherein, each symbol has the same meanings as described above.)
  • A compound represented by formula (k) can be synthesized according to a method well known to a person skilled in the art.
    • (Step H)
  • The present step is a method for producing a compound (1) by reacting the compound (k) with trimethylsilyl cyanide in the presence of a zinc catalyst and subsequently reacting with a fluorinating agent.
  • The amount of trimethylsilyl cyanide used is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (k), and preferably, 1 equivalent to 5 equivalents.
  • The zinc catalyst used includes, for example, zinc iodide, zinc bromide, and the like.
  • The fluorinating agent used includes, for example, (N,N-diethylamino)sulfur trifluoride, bis(2-methoxyethyl)aminosulfur trifluoride, 1,1,2,2-tetrafluoroethyl-N,N-dimethylamine, and the like.
  • The amount of fluorinating agent used is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (k), and preferably, 1 equivalent to 5 equivalents.
  • The reaction solvent that used is not in particular limited as far as it is inert to the reaction, and examples include tetrahydrofuran, acetonitrile, 1,4-dioxane, diethyl ether, dichloromethane, chloroform, 1,2-dichloroethane, carbon tetrachloride, benzene, toluene, N,N-dimethylformamide, and the like.
  • The reaction time is generally 30 minutes to 48 hours, and preferably, 1 hour to 24 hours.
  • The reaction temperature is generally 0°C to the boiling point temperature of the solvent.
  • The compound (1) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
    • (Step I)
  • The present step is a method for producing a compound (m) by subjecting the compound (1) to a reduction reaction of the cyano group.
  • The reducing agents used include, for example, lithium aluminium hydride, sodium bis(2-methoxyethoxy)aluminumhydride, a borane-tetrahydrofuran complex, and the like.
  • The amount of the reducing agent used is generally 1 to 10 equivalents with respect to 1 equivalent of the compound (1).
  • The reaction solvent that used is not in particular limited as far as it is inert to the reaction, and examples include tetrahydrofuran, 1,4-dioxane, dichloromethane, benzene, toluene, diethyl ether, and the like.
  • The reaction time is generally 1 hour to 24 hours.
  • The reaction temperature is generally 0°C to the boiling point temperature of the solvent.
  • The compound (m) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
    • (Step J)
  • The present step is a method for producing a compound (2-b) by reacting the compound (m) with a compound (j) in the presence of a reducing agent.
  • The reaction in the present step can be carried out by the same method as in the step G, an equivalent method thereto, or a combination of these methods and the conventional method.
  • The compound (2-b) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • Moreover, among the compounds (3) used to prepare the compounds of the present invention, a compound (3-P) wherein either R8 or R9 is a hydroxyl group which is protected by a protecting group and the other is H can be synthesized, for example, by the following method:
    Figure imgb0018
     (wherein, Rpro is a protecting group. Other symbols have the same meanings as described above.)
  • A compound represented by formula (n) can be synthesized according to a method well known to a person skilled in the art.
    • (Step K)
  • The present step is a method for producing a compound (o) by reacting an organic lithium compound (m) with (tert-butyldimethylsilyloxy)acetaldehyde (n).
  • The reaction in the present step can be carried out by the same method as in the step D, an equivalent method thereto, or a combination of these methods and the conventional method.
  • The compound (o) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
    • (Step L)
  • The present step is a method for introducing a protecting group to the hydroxyl group of the compound (o). The introduction of the protecting group can be carried out by a method described in the previously mentioned "Protecting Groups in Organic Synthesis (the third edition, 1999)", an equivalent method thereto, or a combination of these methods and the conventional method.
  • The compound (p) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
    • (Step M)
  • The present step is a method for producing a compound (q) by eliminating the tert-butyldimethylsilyl group of the compound (p).
  • The elimination of the protecting group can be carried out by a method described in the previously-mentioned "Protecting Groups in Organic Synthesis (the third edition, 1999)", an equivalent method thereto, or a combination of these methods and the conventional method, and for example, tetrabutylammonium fluoride can be used.
  • The compound (q) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
    • (Step N)
  • The present step is a method for producing a compound (r) by subjecting the compound (q) to an oxidation reaction.
  • The reaction in the present step can be carried out by the same method as in the step 3, an equivalent method thereto, or a combination of these methods and the conventional method.
  • The compound (r) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
    • (Step O)
  • The present step is a method for producing the compound (3-P) by reacting the compound (r) with a compound (s) in the presence of a reducing agent.
  • The reaction in the present step can be carried out by the same method as in the step G, an equivalent method thereto, or a combination of these methods and the conventional method.
  • The compound (3-P) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • Moreover, among the compounds (2) used to prepare the compounds in the present invention, a compound (2-c) wherein both R8 and R9 are F can be synthesized, for example, by the following method:
    Figure imgb0019
     _(wherein, Xa and Xb each independently are Br or I. Other symbols have the same meanings as described above.)
  • A compound represented by formula (u) can be synthesized according to a method well known to a person skilled in the art.
    • (Step P)
  • The present step is a method for producing a compound (v) by reacting the compound (t) with a compound (u) in the presence of copper to prepare.
  • The amount of the compound (t) used is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (u), and preferably 1 equivalent to 3 equivalents.
  • The amount of copper used is generally 1 equivalent to 10 equivalents with respect to 1 equivalent of the compound (t), and preferably 1 equivalent to 5 equivalents.
  • The reaction solvent used is not in particular limited as far as it is inert to the reaction, and examples include tetrahydrofuran, acetonitrile, 1,4-dioxane, dimethyl sulfoxide, N,N-dimethylformamide, and the like.
  • The reaction time is generally 30 minutes to 48 hours.
  • The reaction temperature is generally room temperature to the boiling point temperature of the solvent.
  • The compound (v) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
    • (Step Q)
  • The present step is a method for producing a compound (w) by eliminating the protecting group Rpro of the compound (v).
  • The reaction in the present step can be carried out by the same method as in the step C, an equivalent method thereto, or a combination of these methods and the conventional method.
  • The compound (w) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification means well known to a person skilled in the art.
    • (Step R)
  • The present step is a method for producing a compound (x) by reacting the compound (w) or a reactive derivative thereof with a compound (s).
  • The reaction in the present step can be carried out by the same method as in the step 1, an equivalent method thereto, or a combination of these methods and the conventional method.
  • The compound (x) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
    • (Step S)
  • The present step is a method for producing a compound (2-c) by reducing the amide group of the compound (x).
  • The reaction in the present step can be carried out by the same method as in the step I, an equivalent method thereto, or a combination of these methods and the conventional method.
  • The compound (2-c) obtained in such a manner can be subjected to a next step with or without isolation and purification by an isolation and purification method that is well known to a person skilled in the art.
  • Moreover, the compound represented by formula (I) in the present invention may have a tautomer and/or optical isomer in some cases depending on types of substituents. However, the present invention includes a mixture of these tautomers and isomers, and isolated ones.
  • Furthermore, the present invention relates to a pharmaceutically acceptable prodrug of the compound represented by formula (I). The term "pharmaceutically acceptable prodrug" means a compound producing a compound represented by formula (I) by solvolysis or conversion to CO2H, NH2, OH, etc. under physiological conditions. An example of the group that produces prodrug is found, for example, in Prog. Med., 5, 2157-2161 (1985), "Iyakuhin no Kaihatsu" (Hirokawa Shoten, 1990) Vol.7., Bunshi Sekkei 163-198. In the present invention, some of the compounds within the scope of formula (I) which have the group that produces a prodrug can serve as a prodrug of the corresponding compound of formula (I) which has CO2H, NH2, OH, etc. For example, a compound within the scope of formula (I) which has an alkoxycarbonyl group can be converted into a corresponding carboxyl acid derivative.
  • The present invention also relates to a pharmaceutically acceptable salt of the compound represented by formula (I) and a pharmaceutically acceptable prodrug thereof. Such a salt includes, for example, hydrogen halides such as hydrochloric acid, hydrofluoric acid, hydrobromic acid, hydriodic acid, and the like; inorganic acids such as sulfuric acid, nitric acid, phosphoric acid, carbonic acid, and the like; lower alkyl sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, and the like; arylsulfonic acids such as benzenesulfonic acid, p-toluenesulfonic acid and the like; organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, and the like; and acid addition salts with amino acids including aspartic acid, glutamic acid, and the like. Moreover, depending on types of substituents, the salt in the present invention may form a salt with a base. Examples include inorganic bases including metals such as sodium, potassium, magnesium, calcium, aluminum, lithium, and the like; salts with an organic base such as methyl amine, ethylamine, ethanolamine, guanidine, lysine, ornithine, and the like; and an ammonium salt, and the like.
  • The various pharmaceutically acceptable salts of compound represented by formula (I) can be synthesized based on general knowledge in the technical field in the art.
  • The compound represented by formula (I) and the pharmaceutically acceptable salt thereof in the present invention (hereinafter, general term for these is referred to as the compound of the present invention) has an excellent RORγ inhibitory activity and can be used as a RORγ inhibitor that is clinically applicable to treat or prevent RORγ associated diseases and symptoms. Among RORγ related diseases, the compound of the present invention is useful as a therapeutic agent or preventive agent for, in particular, diseases selected from auto immune disease and inflammatory disease (e.g., multiple sclerosis, chronic rheumatoid arthritis, ankylosing spondylitis, systemic erythematodes, psoriasis, psoriatic arthritis, inflammatory bowel disease (e.g., Crohn's disease), and asthma), metabolic disease (especially, diabetes), and cancer (especially, malignant melanoma).
  • Moreover, the term "prevention" in the present invention means a procedure of administration of a pharmaceutical composition including the compound of the present invention or administration this to individuals who have not developed diseases or symptoms. Moreover, the term "treatment" means a procedure of administration of a pharmaceutical composition including the compound of the present invention or administration this to individuals who have already developed diseases or symptoms. Accordingly, a procedure of administration to individuals who have already developed diseases or symptoms in order to prevent aggravation or attacks is one aspect of the "treatment".
  • When the compound of the present invention is used as medicine, the compound of the present invention can be mixed with a pharmaceutically acceptable carrier (diluting agent, bonding agent, disintegrant, flavoring substance, odor improving agent, emulsifying agent, diluent, solubilizing agent, and the like) and can be administered in the form of a pharmaceutical composition or drug formulation (oral preparation, injections, and the like) orally or parenterally. The pharmaceutical composition can be formulated according to an ordinal method.
  • In the present description, parenteral administration includes subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, infusion technique, and local administration (percutaneous administration, ophthalmic administration, pulmonary/bronchial administration, nasal administration, rectal administration, and the like), and the like. The dosage form of oral administration includes, for example, tablets, pills, granules, powders, solvent, suspensions, syrups, capsules, and the like.
  • The amount of the compound of the present invention that can be combined with a carrier can be changed depending on a specific individual who receives treatment and on specific dosage forms. In this regard, the specific dosage for the specific patient is determined depending on various factors including age, body weight, overall health conditions, gender, diet, administration time, administration method, excretion rate, and the degree of the specified disease during treatment.
  • The dosage amount of the compound of the present invention is determined depending on age, body weight, general health conditions, gender, diet, administration time, administration method, excretion speed, the degree of a disease in a patient who is being treated, or in view of other factors. The compound of the present invention can be administered in single or multiple times daily for adult in a range of 0.01 mg to 1000 mg, although the dosage is different depending on the conditions of the patient, body weight, types of the compound, administration route, and the like.
    • Abbreviations
    • Ac acetyl
    • aq. aqueous
    • Bn benzyl
    • Boc tert-butoxycarbonyl
    • BuOH butanol
    • Bzl benzyl
    • cat. catalytic
    • conc. concentrated
    • DAST N,N-diethylaminosulfur trifluoride
    • DBU 1,8-diazabicyclo[5.4.0]undec-7-ene
    • DCM dichloromethane
    • DIAD diisopropyl azodicarboxylate
    • DIPEA N,N-diisopropylethylamine
    • DMA N,N-dimethylacetoamide
    • DMAP 4-(N,N-dimethylamino)pyridine
    • DMF N,N-dimethylformamide
    • DMSO dimethyl sulfoxide
    • DPPA diphenylphosphoryl azide
    • Et2O dietylether
    • EtOAc ethyl acetate
    • EtOH ethanol
    • HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
    • LDA litium diisopropylamide
    • MeOH methanol
    • Ms methanesulfonyl (mesyl)
    • MTBE methyl tert-butyl ether
    • NBS N-Bromosuccinimide
    • NMO N-methylmorpholine N-oxide
    • quant. quantitative
    • sat. saturated
    • SEM 2-(trimethylsilyl)ethoxymethyl group
    • TBAF tetrabutylammonium fluoride
    • tert tertiary
    • TES triethylsilyl group
    • TFA trifluoroacetic acid
    • THF tetrahydrofuran
    • TLC thin layer chromatography
    • TMS trimethylsilyl group
    • TMSCN trimethylsilyl cyanide
    • TsOH toluenesulfonic acid
    Examples
  • Hereinafter, the present invention will be explained based on specific examples. However, the present invention is not limited to these examples.
  • Unless noted otherwise, reagents, starting materials, and solvents were purchased from vendors (for example, Aldrich, Wako Junyaku, Tokyo Kasei, Fluka, Sigma, and the like) and used without further purification.
  • The structure of the novel compound isolated was confirmed by and/or mass spectrometry using single quadrupole instrumentation equipped with an electron spray source and other appropriate analytical methods.
  • As for the compounds for which spectrum (300 MHz, 400 MHz or 500 MHz, MeOH-d4, DMSO-d6, CD3CN or CDCl3) was measured, the chemical shift (δ: ppm) and coupling constant (J: Hz) are shown. In addition, the following abbreviations represent the followings, respectively: s=singlet, d=doublet, t=triplet, q=quartet, brs=broad singlet, m=multiplet.
  • The compounds synthesized according to the following methods of examples were further analyzed by high performance liquid chromatography mass spectroscopy (LC/MS) analysis. As for the result of mass spectroscopy, the observed value of [M+H]+, that is, the observed value is shown as the value of the molecular mass of the compound (M) with a proton (H+).
    • LCMS Measurement Condition: (UPLC/MS)
    • LC Mass spectrometer: Waters Corporation AcquityUPLC™-SQD
    • Column: Acquity UPLC™ BEH C 18 1.7 µm 2.1 mm × 50 mm
    • UV: PDA detection (254 nm)
    • CAD:CORONA™ ULTRA detector
    • Column temperature: 40 °C
    • ES voltage: 3.0 kV(capillary)
    • Cone voltage: 30 V
    • Gradient conditions:
      • Solvents:
        1. A: H2O/MeCN = 95/5
          0.05% TFA
        2. B: H2O/MeCN = 5/95
          0.05% TFA
      • Flow rate: 0.6 mL/min
      • Gradients: 0.01 to 0.20 min, Solvent B: 2%, Solvent A: 98%
        0.20 to 3.0 min, Solvent B: 2% to 100%, Solvent A: 98% to 0%
        3.0 to 4.2 min, Solvent B: 100%, Solvent A: 0%
        4.2 to 4.21 min, Solvent B: 100% to 2%, Solvent A: 0% to 98%
        4.21 to 5.2 min, Solvent B: 2%, Solvent A: 98%
        5.2 to 5.5 min, Solvent B: 2%, Solvent A: 98%, Flow rate: 0.2 mL/min
    • LCMS Measurement Condition (LC/MS method A):
      • LC Mass spectrometer: Agilent Technologies Corporation 1260 INFINITY™ HPLC-6130MSD
      • Column: Phenomenex Gemini™ C18 A110 3 µm 4.6 mm × 30 mm
      • UV: PDA detection (254 nm)
      • Column temperature: 40 °C
      • Capillary voltage: 3.5 kV
      • Frag mentor voltage: 70 V
      • Gradient conditions:
      • Solvents:
        1. A: H2O/MeCN = 95/5
          0.05% TFA
        2. B: H2O/MeCN = 5/95
          0.05% TFA
      • Flow rate: 1.0 mL/min
      • Gradients: 0.01 to 0.30 min, Solvent B: 2% to 10%, Solvent A: 98% to 90%
        0.30 to 1.5 min, Solvent B: 10% to 100%, Solvent A: 90% to 0%
        1.5 to 3.5 min, Solvent B: 100%, Solvent A: 0%
        3.5 to 3.51 min, Solvent B: 100% to 2%, Solvent A:0% to 98%
        3.51 to 4.5 min, Solvent B: 2%, Solvent A: 98%
    • LCMS Measurement Condition(LC/MS method B):
      • LC Mass spectrometer: Shimadzu Corporation LCMS-2010 EV
      • Column: Shim-pack™ XR-ODII 2.0 mm × 75 mm
      • UV: PDA detection (254 nm)
      • Flow rate: 0.4 mL/min
      • Column temperature: 40 °C
      • Detection voltage: 1.20 kV
    • Gradient conditions:
      • Solvents:
        1. A: H2O/MeCN = 90/5
          0.1% HCO2H
        2. B: H2O/MeCN = 10/95
          0.1% HCO2H
      • Flow rate: 0.4 mL/min
      • Gradients: 0.01 to 0.50 min, Solvent B: 10%, Solvent A: 90%
        0.50 to 2.0 min, Solvent B: 10% to 95%, Solvent A: 90% to 5%
        2.0 to 3.8 min, Solvent B: 95%, Solvent A: 5%
        3.8 to 4.0 min, Solvent B: 95% to 10%, Solvent A: 5% to 90%
        4.0 to 5.0 min, Solvent B: 10%, Solvent A: 90%
    [Reference example A1]
  • Figure imgb0020
    • Step 1: 1-(3,5-dichloropyridin-4-yl)-2-nitroethanol (A1-1)
  • To a solution of 3,5-dichloro-4-pyridinecarboxyaldehyde (2.3 g, 13.3 mmol) in MeOH (25 mL) were added nitromethane (2.2 mL, 39.9 mmol) and sodium methoxide (861 mg, 15.9 mmol). After addition, the mixture was stirred for 1h. The reaction mixture was quenched by adding 2 M aqueous HCl (7 mL) and extracted with EtOAc. The organic layer was washed with brine x 2 and dried over MgSO4. After the solvent was removed, the residue was purified by column chromatography on silica gel to give compound A1-1 (2.8 g, 90%) as a white solid.
    • Step 2: 3,5-dichloro-4-(2-nitro-1-((triethylsilyl)oxy)ethyl)pyridine (A1-2)
  • To a solution of compound A1-1 (2.8 g, 11.9 mmol) in DMF (15 mL) were added imidazole (973 mg, 14.3 mmol) and triethylchlorosilane (2.2 mL, 13.1 mmol). After addition, the mixture was stirred for 1 h. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine x 2 and dried over MgSO4. After the solvent was removed, the residue was purified by column chromatography on silica gel to give compound A1-2 (4.1 g, 98%) as a colorless oil.
    • Step 3: 2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethanamine (A1-3)
  • Compound A1-2 (4.1 g, 11.6 mmol) and Raney nickel 2800 (690 mg, in water) in MeOH (50 mL) was hydrogenated in H2 atmosphere (1 atm) at room temperature for 8 h. The reaction mixture was filtered through a pad of celite and washed with EtOAc. After the solvent was removed, the residue was purified by column chromatography on silica gel to give compound A1-3 (1.9 g, 50%) as a white solid.
    • Step 4: 2-(3,5-dichloropyridin-4-yl)-N-(4-fluorobenzyl)-2-((triethylsilyl)oxy)ethanamine (A1)
  • To a solution of compound A1-3 (2.8 g, 11.9 mmol) in toluene (6 mL) and MeOH (6 mL) was added 4-fluorobenzaldehyde (360 µL, 3.4 mmol), and the mixture was stirred at 70 °C for 2 h. The reaction mixture was cooled to 0 °C, and NaBH4 was added gradually. The reaction mixture was allowed to warm to room temperature and stirred at room temperature for 12 h. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine x 2 and anhydrous Na2SO4. After the solvent was removed, the residue was purified by column chromatography on silica gel to give compound A1 (1.2 g, 88%) as a colorless oil.
    • [Reference example A12]
  • Figure imgb0021
    • Step 1: 4-(methoxymethylene)-1,1-dimethylcyclohexane (A12-1)
  • n-BuLi (2.6 M in hexane, 2.3 mL, 5.94 mmol) was added dropwisely to a stirred solution of (methoxymethyl)triphenylphosphonium chloride (2.04 g, 5.94 mmol) in THF (20 mL) at -78 °C and stirred for 10 min at the same temperature and then stirred for 2.5 h at room temperature. The reaction mixture was cooled down to -78 °C, a solution of 4,4-dimethylcyclohexanone (500 mg, 3.96 mmol) in THF (5 mL) was added slowly at - 78 °C. The reaction mixture was allowed to warm to room temperature and stirred at room temperature for overnight. The reaction mixture was quenched with sat. NaHCO3 aq. (20 mL) and extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to provide compound A12-1 (512.2 mg, crude) as pale yellow oil. The crude product was used for next step without purification.
    • Step 2: 4,4-dimethylcyclohexanecarbaldehyde (A12-2)
  • TFA (2 mL) was added to a stirred solution of compound A12-1 (512.2 mg, crude) in DCM (1 mL) at room temperature and stirred for 1.5 h at the same temperature. The reaction mixture was quenched with sat. NaHCO3 aq. (10 mL) and extracted with EtOAc. The combined organic layer was dried over anhydrous Na2SO4, and concentrated under reduced pressure to provide crude compound A12-2 as pale yellow oil. The crude product was used for next step without purification.
    • Step 3: 2-(3,5-dichloropyridin-4-yl)-N-((4,4-dimethylcyclohexyl)methyl)-2-((triethylsilyl)oxy)etha namine (A12)
  • Crude A12-2 (52 mg) and amine A1-3 (100 mg, 311.2 mmol) was added to a solution of MeOH (1 mL) and toluene (1 mL) and stirred at 80 °C for 4 h. The reaction mixture was cooled down to room temperature. MeOH (2 mL) was added to the reaction mixture and NaBH4 (100 mg) was added to reaction mixture at room temperature. The mixture was stirred at room temperature for 1 h. The reaction mixture was quenched with sat. NaHCO3 aq. (10 mL) and extracted with EtOAc (50 mL). The organic layer was washed with sat. NaHCO3 aq. and brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography (Merck KGaA, PLC Silicagel 60 F254, 1 mm, 20 x 20 cm with concentrating zone 20 x 4 cm, 20% EtOAc/hexane as eluent) to provide compound A 12 (58.6 mg, 42%) as pale yellow oil. 1H NMR (CDCl3, 400 MHz)): δ 8.42 (s, 2H), 5.49 (dd, J = 8.8, J = 4.4 Hz, 1H), 3.21 (dd, J = 12.5, J = 8.8 Hz, 1H), 2.77 (dd, J = 12.5, J = 4.4 Hz, 1H), 2.54-2.47 (m, 2H), 1.54-1.04 (m, 9H), 0.90-0.86 (m, 15H), 0.62-0.49 (m, 6H).
    • [Reference example A31]
  • Figure imgb0022
    • Step 1: 1-(2,6-dichloro-4-fluorophenyl)-2-nitroethanol (A31-1)
  • A mixture of 2,6-dichloro-4-fluorobenzaldehyde (10.0 g, 51.8 mmol), nitromethane (2 mL) and K2CO3 (3.57 g, 25.9 mmol) was stirred at room temperature for 2 h. The reaction mixture was quenched with water and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (2 x 50 mL) and brine (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to provide compound A31-1 (26.0 g, crude) as yellow gum. The crude product was used in the next step without purification.
    • Step 2: (1-(2,6-dichloro-4-fluorophenyl)-2-nitroethoxy)triethylsilane (A31-2)
  • To a stirred solution of compound A31-1 (26.0 g, 102.3 mmol) in DMF (100 mL) was added imidazole (20.9 g, 307.0 mmol) and TES-Cl (25.7 mL, 153.5 mmol) and the mixture was stirred at room temperature for 1 h. Upon reaction completion, the mixture was quenched with water (50 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with brine (2 x 50 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-10% EtOAc/hexane as eluent) to provide compound A31-2 (32.8 g, 74%) as colorless gum. 1H NMR (CDCl3, 400 MHz): δ 7.12 (s, 1H), 7.10 (s, 1H), 6.22 (dd, J = 9.2, J = 3.2 Hz, 1H), 5.22-5.11 (m, 1H), 4.42 (dd, J = 12.2, J = 3.6 Hz, 1H), 0.84 (t, J = 8.0 Hz, 9H), 0.55-0.50 (m, 6H).
    • Step 3: 2-(2,6-dichloro-4-fluorophenyl)-2-((triethylsilyl)oxy)ethanamine (A31-3)
  • To a stirred solution of compound A31-2 (15.0 g, 40.7 mmol) in EtOH/water (60 mL, 4:1) was added Fe powder (22.7 g, 407.6 mmol) and solid NH4Cl (21.8 g, 407.6 mmol). The mixture was stirred at 70 °C for 1 h. The reaction mixture was filtered through a pad of celite, washed with EtOAc (3 x 150 mL) and solvent was removed under reduced pressure. The residue was suspended in water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5% MeOH/DCM as eluent) to provide compound A31-3 (13.0 g, 94%) as colorless oil. 1H NMR (CDCl3, 400 MHz): δ 7.06 (s, 1H), 7.04 (s, 1H), 5.29 (dd, J = 8.4, J = 5.0 Hz, 1H), 3.25 (dd, J = 13.2, J = 8.8 Hz, 1H), 2.89 (dd, J = 13.2, J = 5.0 Hz, 1H), 0.88 (t, J = 8.0 Hz, 9H), 0.57-0.52 (m, 6H).
    • Step 4:2-(2,6-dichloro-4-fluorophenyl)-N-(3,5-difluorobenzyl)-2-((triethylsilyl)oxy)ethanamine (A31)
  • To a stirred solution of compound A31-3 (30.0 g, 88.7 mmol) in MeOH (200 mL) was added 3,5-difluorbenzaldehyde (12.6 g, 88.7 mmol) and the mixture was stirred at room temperature for 2 h. Upon completion of imine formation (monitored by TLC), solid NaBH4 (4.9 g, 133.1 mmol) was added in portions at 0 °C. The mixture was warmed to room temperature and stirred for 2 h. The reaction mixture was quenched with water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 75 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc/hexane as eluent) to provide compound A31 (30.0 g, 70%) as colorless gum.
    • [Reference example A35]
  • Figure imgb0023
    • Step 1: 2,6-dichloro-4-iodobenzaldehyde (A35-1)
  • To a stirred solution of 1,3-dichloro-5-iodobenzene (4.0 g, 14.6 mmol) in THF (30 mL), LDA (2.0 M in THF/heptane/ethylbenzene, 9.6 mL, 16.9 mmol) was added dropwise at -78 °C and stirred for 1 h at the same temperature. A solution of DMF (1.7 mL, 22.0 mmol) in THF (5 mL) was added slowly at -78 °C and stirred for 3 h. The reaction mixture was quenched with saturated NH4Cl (50 mL) and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with water (50 niL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to afford compound A35-1 (1.4 g, 32%) as colorless oil.
    • Step 2: 1-(2,6-dichloro-4-iodophenyl)-2-nitroethanol (A35-2)
  • Compound A35-2 (1.84 g, crude) was obtained as a colorless gum from the reaction of compound A35-1 (1.4 g, 4.8 mmol) and K2CO3 (0.23 g, 2.0 mmol) in CH3NO2 (10 mL) using a similar procedure to that described in reference example A1, step 1.
    • Step 3: (1-(2,6-dichloro-4-iodophenyl)-2-nitroethoxy)triethylsilane (A35-3)
  • Compound A35-3 (2.4 g, crude) was obtained as colorless gum from the reaction of compound A35-2 (1.84 g, 5.08 mmol), TES-Cl (1.02 mL, 6.12 mmol) and imidazole (1.03 g, 15.2 mmol) in DMF (10 mL) using a similar procedure to that described in reference example A1, step 2.
    • Step 4: 2-(2,6-dichloro-4-iodophenyl)-2-((triethylsilyl)oxy)ethanamine (A35-4)
  • Compound A35-4 (2.2 g, crude) was obtained as a brown oil from the reaction of compound A35-3 (2.4 g, 5.0 mmol), Fe (2.83 g, 50.0 mmol) and NH4Cl (2.68 g, 50.0 mmol) in EtOH/water (4:1, 20 mL) using a similar procedure to that described in reference example A31, step 3.
    • Step 5: 2-(2,6-dichloro-4-iodophenyl)-N-((3,5-difluorophenyl)((triethylsilyl)oxy)methyl)ethanami ne (A35-5)
  • Compound A35-5 (1.87 g, 67%) was obtained as a colorless gum from the reaction of compound A35-4 (2.2 g, 5.0 mmol), 3,5-difluorobenzaldehyde (0.55 mL, 5.0 mmol) and NaBH4 (0.38 g, 10.0 mmol) in MeOH (15 mL) using a similar procedure to that described in example A31, step4.
    • Step 6: tert-butyl (2-(2,6-dichloro-4-iodophenyl)-2-((triethylsilyl)oxy)ethyl)(3,5-difluorobenzyl)carbamate (A35-6)
  • To a stirred solution of compound A35-5 (1.87 g, 3.26 mmol) in DCM/water (4:1, 20 mL) was added NaHCO3 (0.55 g, 6.5 mmol) and (Boc)2O (1.07 g, 4.9 mmol) in DCM (8 mL) at 0 °C. The mixture was stirred at room temperature for 2 h. The reaction mixture was quenched in water (100 mL) and extracted with DCM (2 x 30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to get compound A35-6 (2.47 g, crude) as a colorless gum.
    • Step 7: tert-butyl (2-(2,6-dichloro-4-cyanophenyl)-2-((triethylsilyl)oxy)ethyl)(3,5-difluorobenzyl)carbamate (A35-7)
  • To a solution of compound A35-6 (2.0 g, 2.9 mmol) in DMA (10 mL) in sealed tube, Zn(CN)2 (0.7 g, 5.9 mmol) and Pd(PPh3)4 were added and stirred for 2 h at 80 °C. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to afford compound A35-7 (1.1 g, 61%) as colorless oil.
    • Steo 8: 3,5-dichloro-4-(2-((3,5-difluorobenzyl)amino)-1-hydroxyethyl)benzonitrile (A35)
  • To a stirred solution of compound A35-7 (0.2 g, 0.3 mmol) in EtOH (10 mL) was added 4 M HCl (5 mL) and the mixture was stirred at 80 °C for overnight. The reaction mixture was quenched with water (50 mL) and basified with 10% NaOH solution up to pH 9 and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel, 30% EtOAc/hexane as eluent) to afford compound A35 (0.12 g, 99%) as colorless oil.
    • [Reference example A56]
  • Figure imgb0024
    • Step 1: 4-methylthiophene-3-carboxylic acid (A56-1)
  • To a stirred solution of 3-bromo-4-methylthiophene (2.7 g, 15.6 mmol) in THF (35 mL) was added n-BuLi (1.6 M in hexane, 14.6 mL, 23.3 mmol) at -78 °C dropwise over a period of 15 min and the mixture was stirred at -78 °C for 30 min. The CO2 (gaseous) was passed through the reaction mixture for 10 min and the mixture was stirred at the same temperature for 20 min. Thereafter, the reaction mixture was warmed to 0 °C, quenched with aqueous 1 M NaOH (60 mL) and washed with EtOAc (2 x 50 mL). The aqueous layer was acidified to pH ∼ 5 and extracted with DCM (2 x 50 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 8% MeOH/DCM as eluent) to provide compound A56-1 (1.5 g, 70%) as a white solid.
    • Step 2: 2,4-dimethylthiophene-3-carboxylic acid (A56-2)
  • To a stirred solution of compound A56-1 (390 mg, 2.7 mmol) in THF (4 mL) was added n-BuLi (1.6 M in hexane, 3.8 mL, 6.0 mmol) dropwise at -78 °C for 10 min. The mixture was stirred at -78 °C for 5 min. A solution of iodomethane (0.4 mL, 6.8 mmol) in THF (1 mL) was added dropwise, and the reaction mixture was stirred at -78 °C for 30 min. The mixture was allowed to warm to room temperature and stirred at the same temperature for 15 h. The reaction mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc (2x25 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 2% MeOH/DCM as eluent) to provide compound A56-2 (246 mg, 57%) as a white solid.
    • Step 3: (2,4-dimethylthiophen-3-yl)methanol (A56-3)
  • To a stirred solution of compound A56-2 (246 mg, 1.5 mmol) in THF (3 mL) was added BH3·THF (1 M in THF, 5.5 mL, 5.5 mmol) dropwise at 0 °C for 15 min. The mixture was allowed to warm to room temperature and stirred at the same temperature for 15 h. The reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with EtOAc (2x30 mL). The combined organic layers were washed with brine (2x10 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 25% EtOAc/hexane as eluent) to provide compound A56-3 (201 mg, 90%) as a colorless gum.
    • Step 4: 2,4-dimethylthiophene-3-carbaldehyde (A56-4)
  • To a stirred solution of compound A56-3 (740 mg, 5.2 mmol) in DCM (18 mL) was added Dess-Martin periodinane (4.6 g, 10.9 mmol) at 0 °C and the mixture was stirred at room temperature for 3 h. The reaction mixture was quenched with saturated aqueous Na2S2O3 and NaHCO3, and extracted with EtOAc (2x50 mL). The combined organic layers were washed with brine (2x20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc/hexane as eluent) to provide compound A56-4 (275 mg, 38%) as a yellow solid.
    • Step 5: 1-(2,4-dimethylthiophen-3-yl)-2-nitroethanol (A56-5)
  • A mixture of compound A56-4 (133 mg, 0.95 mmol), nitromethane (2 mL) and K2CO3 (50 mg, 0.36 mmol) was stirred at room temperature for 60 h. The reaction mixture was quenched with water, and extracted with EtOAc (3x20 mL). The combined organic layers were washed with water (2x100 mL), and brine (100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 40% EtOAc/hexane as eluent) to provide compound A56-5 (80 mg, 42%) as a yellow gum.
    • Step 6: (1-(2,4-dimethylthiophen-3-yl)-2-nitroethoxy)triethylsilane (A56-6)
  • To a stirred solution of compound A56-5 (235 mg, 1.17 mmol) in DMF (4 mL) were added imidazole (238 mg, 3.5 mmol) and TES-Cl (0.23 mL, 1.4 mmol) and the mixture was stirred at room temperature for 4 h. Upon completion, the reaction mixture was quenched with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with brine (2x30 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5% EtOAc/hexane as eluent) to provide compound A56-6 (240 mg, 65%) as a colorless gum.
    • Step 7: 2-(2,4-dimethylthiophen-3-yl)-2-((triethylsilyl)oxy)ethanamine (A56-7)
  • To a stirred solution of compound A56-6 (240 mg, 0.76 mmol) in EtOH/water (10 mL, 4:1) were added powdered Fe (425 mg, 7.6 mmol) and solid NH4Cl (407 mg, 7.6 mmol). The mixture was stirred at 70 °C for 45 min. Upon completion, the reaction mixture was filtered through a pad of celite and washed with MeOH (3x15 mL). The solvent was removed under reduced pressure. The residue was suspended in EtOAc (100 mL) and washed with water (30 mL) and brine (30 mL). The organic layer was dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5% MeOH/DCM as eluent) to provide compound A56-7 (192 mg, 88%) as a yellow gum.
    • Step 8: N-(3,5-difluorobenzyl)-2-(2,4-dimethylthiophen-3-yl)-2-((triethylsilyl)oxy)ethanamine (A56)
  • To a stirred solution of compound A56-7 (192 mg, 0.67 mmol) in MeOH (5 mL) was added 3,5-difluorbenzaldehyde (95 mg, 0.67 mmol) and the mixture was stirred at room temperature for 2 h. Upon completion of imine formation (monitored by TLC), solid NaBH4 (51 mg, 1.3 mmol) was added in portions at 0 °C. The mixture was warmed to room temperature and stirred at the same temperature for 4 h. The reaction mixture was quenched with water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (2 x 30 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc/hexane as eluent) to provide compound A56 (200 mg, 72%) as a colorless gum. 1H NMR (CDCl3, 300 MHz): δ 6.90-6.77 (m, 3H), 6.71-6-60 (m, 1H), 5.09 (dd, J = 7.8, 4.2 Hz, 1H), 3.78 (s, 2H), 2.87 (dd, J = 12.0, 7.8 Hz, 1H), 2.71 (dd, J = 12.0, 4.5 Hz, 1H), 2.11 (d, J = 0.6, 3H), 2.06 (s, 3H), 1.65 (brs, 1H), 0.89 (t, J = 7.8 Hz, 9H), 0.62-0.50 (m, 6H).
    • [Reference example A57]
  • Figure imgb0025
    • Step 1: 2,6-dichloro-4-(methylthio)benzaldehyde (A57-1)
  • To a stirred solution of (3,5-dichlorophenyl)(methyl)sulfane (1.0 g, 5.1 mmol) in THF (15 mL), n-BuLi (1.6 M in THF, 4.8mL, 7.7 mmol) was added dropwise at -78 °C and stirred for 1 h at the same temperature. A solution of DMF (0.6 mL, 7.7 mmol) in THF (3 mL) was added slowly at -78 °C and stirred for 1 h. The reaction mixture was quenched with saturated NH4Cl aq. (50 mL) and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to afford compound A57-1 (1.4 g, 99%) as colorless oil.
    • Step 2: 1-(2,6-dichloro-4-(methylthio)phenyl)-2-nitroethanol (A57-2)
  • Compound A57-2 (0.71 g, crude) was obtained as a colorless gum from the reaction of compound A57-1 (0.5 g, 2.44 mmol) and K2CO3 (0.13 g, 0.92 mmol) in CH3NO2 (5 mL) using a similar procedure to that described in reference example A1, step 1. Step 3: (1-(2,6-dichloro-4-(methylthio)phenyl)-2-nitroethoxy)triethylsilane (A57-3)
  • Compound A57-3 (1.0 g, crude) was obtained as colorless gum from the reaction of compound A57-2 (0.71 g, 2.5 mmol), TES-Cl (0.5 mL, 3.02 mmol) and imidazole (0.51 g, 7.55 mmol) in DMF (10 mL) using a similar procedure to that described in reference example A1, step 2.
    • Step 4: 2-(2,6-dichloro-4-(methylthio)phenyl)-2-((triethylsilyl)oxy)ethanamine (A57-4)
  • Compound A57-4 (0.98 g, crude) was obtained as a brown color oil from the reaction of compound A57-3 (1.0 g, 2.53 mmol), Fe (1.42 g, 25.3 mmol) and NH4Cl (1.34 g, 25.3 mmol) in EtOH/water (4:1, 20 mL) using a similar procedure to that described in reference example A31, step 3.
    • Step 5: 2-(2,6-dichloro-4-(methylthio)phenyl)-N-(3,5-difluorobenzyl)-2-((triethylsilyl)oxy)ethana mine (A57)
  • Compound A57 (0.73 g, 55%) was obtained as a colorless gum from the reaction of compound A57-4 (0.98 g, 2.69 mmol), 3,5-difluorobenzaldehyde (0.29 mL, 2.69 mmol) and NaBH4 (0.2 g, 5.36 mmol) in MeOH (10 mL) using a similar procedure to that described in reference example A31, step 4. 1H NMR (CDCl3, 300 MHz): δ 7.10 (s, 2H), 6:8.7-6.61 (m, 3H), 5.53 (dd, J = 8.6, 4.8 Hz, 1H), 3.82 (s, 2H), 3.23 (dd, J = 12.1, 8.6 Hz, 1H), 2.78 (dd, J = 12.1,4.8 Hz, 1H), 2.49 (s, 3H), 0.90-0.85 (m, 9H), 0.58-0.50 (m, 6H).
    • [Reference example A58]
  • Figure imgb0026
    • 3,5-Dichloro-4-(2-((3,5-difluorobenzyl)amino)-1-hydroxyethyl)benzamide (A58)
  • To a stirred solution of compound A35 (0.12 g, 0.29 mmol) in THF/MeOH/water (2:2:1, 5 mL) was added LiOH (4 M aq. solution, 0.44 mL, 1.76 mmol) dropwise at 0 °C. The mixture was allowed to warm to room temperature while stirring continued for 4 h. The reaction mixture was acidified with HCl (1 M, 6 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with water (10 mL), brine (10 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to provide compound A58 (60 mg, 47%) as a yellow solid. LCMS (APCI): 391 (M+H)+.
    • [Reference example A59]
  • Figure imgb0027
    • Ethyl 3,5-dichloro-4-(2-((3,5-difluorobenzyl)amino)-1-hydroxyethyl)benzoate (A59)
  • To a stirred solution of compound A35-7 (0.2 g, 0.3 mmol) in EtOH (5 mL) was added conc. HCl (5 mL) and the mixture was stirred at reflux for overnight. The reaction mixture was quenched with water (50 mL) and basified with 10% NaOH solution up to pH 9 and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel, 30% EtOAc/hexane as eluent) to afford compound A59 (0.1 g, 92%) as a white solid.
    • [Reference example A66]
  • Figure imgb0028
    • Step 1: 4,4-dimethylpent-2-ynal (A66-1)
  • To a stirred solution of 3,3-dimethylbutan-1-yl (2.45 mL, 20 mmol) in THF (20 mL), n-BuLi (2.6 M in hexane, 8.46 mL, 22 mmol) was added at -78 °C dropwise and stirred for 1 h at the same temperature. A solution of DMF (3.85 mL, 50.0 mmol) was added slowly at -78 °C and the reaction mixture was allowed to warm to room temperature for overnight. The reaction mixture was quenched with saturated NH4Cl (100 mL) and extracted with hexane (2 x 100 mL). The collected organic layers were washed with water (3 x 200 mL) and concentrated under reduced pressure to provide compound A66-1. The crude product was used for next step without purification.
    • Step 2: N-(2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)-4,4-dimethylpent-2-yn-1-amine (A66)
  • Compound A66 (76.1 mg, 36.6%) was obtained as a pale yellow oil from the reaction of compound A1-3 (160 mg, 0.5 mmol), compound A66-1 (80 mg, 0.726 mmol), NaBH4 (120 mg) and MgSO4 (100mg) in MeOH (6 mL) and DCM (3mL) using a similar procedure to that described in reference example A31, step 4. 1H NMR (CDCl3, 400 MHz): δ 8.43 (s, 2H), 5.49 (dd, J = 8.5, J = 5.1 Hz, 1H), 3.48 (d, J = 16.4 Hz, 1H), 3.37 (d, J = 16.4 Hz, 1H), 3.32 (dd, J = 12.0, J = 8.5 Hz, 1H), 2.87 (dd, J = 12.0, J = 5.1 Hz, 1H), 1.21 (s, 9H), 0.89 (t, J = 7.8 Hz, 9H), 0.61-0.50 (m, 6H).
    • [Reference example A75]
  • Figure imgb0029
    • Step 1: 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carbaldehyde (A75-1)
  • To a stirred suspension of NaH (274 mg, 11.4 mmol) in DMF (20 mL) was added solution of 1H-pyrazole-3-carbaldehyde (1.0 g, 10.4 mmol) in DMF (10 mL) dropwise at 0 °C and the mixture was stirred at room temperature for 10 min. The reaction mixture was cooled to 0 °C and SEM-Cl (1.90 g, 11.4 mmol) was added dropwise. The mixture was warmed to room temperature and stirred at the same temperature for 16 h. The reaction mixture was quenched with water and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed water (20 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc/hexane as eluent) to provide compound A75-1 (350 mg, 29%) as colorless gum.
    • Step 2: 2-nitro-1-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)ethanol (A75-2)
  • Compound A75-2 (428 mg, 64%) was obtained as yellow gum from the reaction of compound A75-1 (350 mg, 1.54 mmol), CH3NO2 (1 mL) and K2CO3 (85 mg, 0.616 mol) using a similar procedure to that described in reference example A1, step 2. Step 3:
    • 3-(2-nitro-1-((triethylsilyl)oxy)ethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (A75-3)
  • Compound A75-3 (604 mg, crude) was obtained as yellow gum from the reaction of compound A75-2 (428 mg, 1.49 mmol), TES-Cl (0.280 mL, 1.78 mmol) and imidazole (303 mg, 4.47 mmol) using a similar procedure to that described in reference example A1, step 3.
    • Step 4: 2-((triethylsilyl)oxy)-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)ethanamine (A75-4)
  • Compound A75-4 (600 mg, crude) was obtained as colorless gum from the reaction of compound A75-3 (604 mg, 1.51 mmol), Fe powder (843 mg, 15.1 mmol) and NH4Cl (806 mg, 15.1 mmol) using a similar procedure to that described in reference example A31, step 3.
    • Step 5: N-(3,5-difluorobenzyl)-2-((triethylsilyl)oxy)-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-p yrazol-3-yl)ethanamine (A75)
  • Compound A75 (40 mg, 5%, over 3 steps) was obtained as colorless gum from the reaction of compound A75-4 (600 mg, 1.61 mmol), 3,5-diflurobenzaldehyde (206 mg, 1.45 mmol) and NaBH4 (119 mg, 3.22 mmol) using a similar procedure to that described in reference example A31, step 4. 1H NMR (CDCl3, 300 MHz): δ 7.59 (s, 0.7H), 7.48 (s, 0.3H), 6.39 (s, 1H), 5.38-5.71 (m, 2H), 4.91-5.08 (m, 1H), 3.54-3.61 (m, 2H), 2.95-3.04 (m, 2H), 0.85-0.95 (m, 9H), 0.59-0.62 (m, 6H); LCMS (APCI): 499 (M+H)+.
    • [Reference example A84]
  • Figure imgb0030
    • Step 1: 2-(2-chloro-6-nitrophenyl)-2-((trimethylsilyl)oxy)acetonitrile (A84-1)
  • To a stirred solution of 2-chloro-6-nitrobenzaldehyde (1.0 g, 5.4 mmol) in DCM (15 mL) were added TMSCN (1.0 mL, 8.1 mmol) and NMO (0.19 g, 1.6 mmol) at room temperature and stirred for 1 h. The reaction mixture was quenched with water (50 mL) and extracted with DCM (2 x 30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to get compound A84-1 (1.0 g, 67%) as a brown color oil.
    • Step 2: 2-(2-chloro-6-nitrophenyl)-2-((trimethylsilyl)oxy)ethanamine
  • To a stirred solution of compound A84-1 (0.85 g, 3.0 mmol) in THF (15 mL) was added BH3·THF (1.0 M in THF, 17.9 mL, 17.88 mmol) and stirred at room temperature for 16 h. The reaction mixture was quenched with MeOH and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to get compound A84-2 (0.65 g, 75%) as a brown color gum.
    • Step 3: 1-(2-chloro-6-nitrophenyl)-2-((3,5-difluorobenzyl)amino)ethanol (A84)
  • Compound A84 (0.57 g, 74%) was obtained as a yellow solid from the reaction of compound A84-2 (0.65 g, 2.24 mmol), 3,5-difluorobenzaldehyde (0.24 mL, 2.24 mmol) and NaBH4 (0.17 g, 4.49 mmol) in MeOH (10 mL) using a similar procedure to that described in reference example A56, step 8. 1H NMR (CDCl3, 300 MHz): δ 7.52-7.29 (m, 3H), 6.89-6.66 (m, 3H), 5.22 (dd, J = 10.0, 3.7 Hz, 1H), 3.88 (s, 2H), 3.27-3.19 (m, 1H), 3.07 (dd, J = 12.6, 3.7 Hz, 1H); LCMS (APCI): 343 (M+H)+.
    • [Reference example A92]
  • Figure imgb0031
    • Steep 1: (5S)-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)dihydrofuran-2(3H)-one (A92-1)
  • To a stirred solution of (S)-5-(hydroxymethyl)dihydrofuran-2(3H)-one (4.0 g, 34.45 mmol) in DCM (20 mL) was added 3,4-dihydro-2H-pyran (3.95 mL, 41.34 mmol) followed by pyridinium p-toluenesulfonate (0.86 g, 3.44 mmol) at room temperature and the mixture was stirred for 16 h. The reaction mixture was diluted with DCM (20 mL), quenched with water (40 mL) and extracted with DCM (2 x 50 mL). The combined organic layers were washed with brine (2 x 20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 50% EtOAc/hexane as eluent) to provide compound A92-1 (5.85 mg, 85%) as a colorless gum.
    • Step 2: (2S)-5-methyl-1-((tetrahydro-2H-pyran-2-yl)oxy)hexane-2,5-diol (A92-2)
  • To a stirred solution of compound A92-1 (5.85 g, 29.1 mmol) in THF (50 mL) was added methyl magnesium bromide (3.0 M in Et2O, 22.4 mL, 67.2 mmol) dropwise at 0 °C for 10 min and the mixture was stirred at 0 °C for 4 h. The mixture was allowed to warm to room temperature and stirred for 15 h. The reaction mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 90% EtOAc/hexane as eluent) to provide compound A92-2 (6.09 g, 90%) as a colorless gum.
    • Step 3: (S)-(5,5-dimethyltetrahydrofuran-2-yl)methanol (A92-3)
  • To a stirred solution of compound A92-2 (1.03 g, 4.43 mmol) in MeOH (8 mL) was added p-toluenesulfonic acid monohydrate (421 mg, 2.2 mmol) at room temperature and the mixture was refluxed for 5 h. The reaction mixture was cooled to room temperature, quenched with water (15 mL) and extracted with DCM (2 x 25 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 35% EtOAc/hexane as eluent) to provide compound A92-3 (330 mg, 57%) as a colorless gum.
    • Step 4: (S)-(5,5-dimethyltetrahydrofuran-2-yl)methyl methanesulfonate (A92-4)
  • To a stirred solution of compound A92-3 (300 mg, 2.30 mmol) in DCM (6 mL) was added Et3N (0.64 mL, 4.6 mmol) followed by methanesulfonyl chloride (0.21 mL, 2.76 mmol) at 0 °C. The mixture was stirred at 0 °C for 30 min. The mixture was allowed to warm to room temperature over a period of 2 h. The reaction mixture was quenched with water (10 mL) and extracted with DCM (2 x 20 mL). The combined organic layers were washed with water (20 mL), brine (20 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 35% EtOAc/hexane as eluent) to provide compound A92-4 (310 mg, 64%) as a colorless gum.
    • Step 5: 2-(3,5-dichloropyridin-4-yl)-N-(((S)-5,5-dimethyltetrahydrofuran-2-yl)methyl)-2-((triethyl silyl)oxy)ethanamine (A92)
  • A mixture of compound A92-4 (140 mg, 0.67 mmol), compound A1-3 (216 mg, 0.67 mmol), Na2CO3 (710 mg, 6.7 mmol) and isopropanol (4 mL) was taken in a microwave vial. The vial was capped and the mixture was subjected to microwave irradiation at 120 °C for 2 h. The reaction mixture was cooled to room temperature, quenched with water (15 mL) and extracted with DCM (2 x 25 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 2% MeOH/DCM as eluent) to provide compound A92 (40 mg, 14%) as a colorless gum.
    • [Reference example A93]
  • Figure imgb0032
    • Step 1: 1-(2-chloro-6-methoxyphenyl)-2-nitroethanol (A93-1)
  • Compound A93-1 (1.35 g, crude) was obtained as a colorless oil from the reaction of 2-chloro-6-methoxybenzaldehyde (1.0 g, 5.88 mmol) and K2CO3 (0.3 g, 2.2 mmol) in CH3NO2 (10 mL) using a similar procedure to that described in reference example A1, step 1.
    • Step 2: (1-(2-chloro-6-methoxyphenyl)-2-nitroethoxy)triethylsilane (A93-2)
  • Compound A93-2 (2.14 g, crude) was obtained as a colorless oil from the reaction of compoundA93-1 (1.35 g, 5.84 mmol), TES-Cl (1.17 mL, 7.01 mmol) and imidazole (1.19 g, 17.53 mmol) in DMF (10 mL) using a similar procedure to that described in reference example A1, step 2.
    • Step 3: 2-(2-chloro-6-methoxyphenyl)-2-((triethylsilyl)oxy)ethanamine (A93-3)
  • Compound A93-3 (1.6 g, 84%) was obtained as a colorless oil from the reaction of compound A93-2 (2.14 g, 6.2 mmol), Fe (3.48 g, 62.0 mmol) and NH4Cl (3.3 g, 62.0 mmol) in EtOH/water (4:1, 20 mL) using a similar procedure to that described in reference example A1, step 3.
    • Step 4: 2-(2-chloro-6-methoxyphenyl)-N-(3,5-difluorobenzyl)-2-((triethylsilyl)oxy)ethanamine (A93)
  • Compound A93 (1.2 g, 54%) was obtained as a colorless gum from the reaction of compound A93-3 (1.6 g, 5.16 mmol), 3,5-difluorobenzaldehyde (0.56 mL, 5.16 mmol) and NaBH4 (0.39 g, 10.2 mmol) in MeOH (10 mL) using a similar procedure to that described in reference example A1, step 4. 1H NMR (CDCl3, 300 MHz): δ 7.13 (t, J = 8.1 Hz, 1H), 6.95-6.60 (m, 5H), 5.58 (dd, J = 8.6, 4.7 Hz, 1H), 3.83-3.77 (m, 5H), 3.28 (dd, J = 12.0, 8.7 Hz, 1H), 2.78 (dd, J = 12.0, 4.7 Hz, 1H), 0.87-0.82 (m, 9H), 0.60-0.46 (m, 6H); LCMS (APCI):442 (M+H)+.
    • [Reference example A94]
  • Figure imgb0033
    • Step 1: (S)-(5-oxotetrahydrofuran-2-yl)methyl 4-methylbenzenesulfonate (A94-1)
  • To a stirred solution of (S)-5-(hydroxymethyl)dihydrofuran-2(3H)-one (2.0 g, 17.2 mmol) in DCM (20 mL) was added Et3N (4.8 mL, 34.44 mmol) followed by p-toluenesulfonyl chloride (3.61 g, 18.94 mmol) at 0 °C. The mixture was allowed to warm to room temperature and stirred at the same temperature for 15 h. The reaction mixture was quenched with water (100 mL) and extracted with DCM (2 x 50 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 50% EtOAc/hexane as eluent) to provide compound A94-1 (4.06 g, 87%) as a white solid.
    • Step 2: (R)-(5,5-dimethyltetrahydrofuran-2-yl)methanol (A94-2)
  • To a stirred solution of compound A94-1 (1.63 g, 6.03 mmol) in THF (20 mL) was added MeLi (3.0 M in diethoxymethane, 4.4 mL, 13.26 mmol) dropwise at -78 °C for 10 min and the mixture was stirred at -78 °C for 1 h. The mixture was allowed to warm to room temperature over a period of 4 h. The reaction mixture was quenched with saturated aqueous NaCl, diluted with water (30 mL) and extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 35% EtOAc/hexane as eluent) to provide compound A94-2 (220 mg, 28%) as a colorless gum.
    • Step 3: (R)-(5,5-dimethyltetrahydrofuran-2-yl)methyl methanesulfonate (A94-3)
  • Compound A94-3 (351 mg, 61 %) was obtained as a colorless gum from the reaction of compound A94-2 (360 mg, 2.76 mmol), Et3N (0.77 mL, 5.52 mmol) and methanesulfonyl chloride (0.25 mL, 3.31 mmol) in DCM (5.0 mL) using a similar procedure to that described in reference example A92, step 4.
    • Step 4: 2-(3,5-dichloropyridin-4-yl)-N-(((R)-5,5-dimethyltetrahydrofuran-2-yl)methyl)-2-((triethyl silyl)oxy)ethanamine (A94)
  • Compound A94 (32 mg, 8%) was obtained as a colorless gum from the reaction of compound A94-3 (200 mg, 0.96 mmol), compound A1-3 (247 mg, 0.77 mmol) and Na2CO3 (508 mg, 4.8 mmol) in isopropanol (3.0 mL) using a similar procedure to that described in reference example A92, step 5.
    • [Reference example A103]
  • Figure imgb0034
    • Step 1: N-methoxy-N-methyl-1-(trifluoromethyl)cyclopropanecarboxamide (A103-1)
  • To a mixture of 1-(trifluoromethyl)cyclopropanecarboxylic acid (150 mg, 0.974 mmol), 1-hydroxybenzotrizole monohydrate (224 mg, 1.46 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (280 mg, 1.46 mmol) and N,O-dimethylhydroxylamine hydrochloride (142 mg, 1.46 mmol) in DMF (5 mL) was added DIPEA (0.50 mL, 2.92 mmol) and the mixture was stirred at room temperature for overnight. The reaction mixture was quenched with water (30 mL) and extracted with EtOAc. The collected organic layer was washed with water and brine, dried over MgSO4 and concentrated under reduced pressure to provide compound A103-1 (164 mg, 85%) as a pale yellow oil.
    • Step 2: 1-(trifluoromethyl)cyclopropanecarbaldehyde (A103-2)
  • To a stirred solution of compound A103-1 (164 mg, 0.832 mmol) in DCM (2 mL) was added diisobutylaluminum hydride (1 M in hexane, 1.0 mL, 1.0 mmol) at -78 °C under nitrogen atmosphere. After 0.5 h, the mixture was allowed to warm to 0 °C and stirred for 0.5 h. The reaction mixture was quenched with sat. KHSO4 aq. (10 mL) and extracted with DCM (2 x 4 mL). The combined organic layers were directly used in the next step without further purification.
    • Step 3: 2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)-N-((1-(trifluoromethyl)cyclopropyl)met hyl)ethanamine (A103)
  • Compound A1-3 (0.20 g, 0.622 mmol) was dissolved in DCM solution containing compound A103-2. MgSO4 (0.2 g) was added to this solution and the mixture was stirred for 2 h. MeOH (10 mL) and NaBH4 (0.2 g) were added to the mixture and the mixture was stirred for 0.5 h. The reaction mixture was quenched with water and extracted with EtOAc. The collected organic layer was washed with brine, dried over MgSO4 and concentrated under reduced pressure. The crude material was purified by silicagel column chromatography eluting with 20% EtOAc in heptane to give compound A103 (87 mg, 32%) as a colorless oil. 1H NMR (CDCl3, 400 MHz) δ: 8.43 (2H, s), 5.45 (1H, dd, J = 8.5, 4.6 Hz), 3.24 (1H, dd, J = 12.2, 8.8 Hz), 2.86 (2H, dd, J = 24.4, 13.2 Hz), 2.76 (1H, dd, J = 12.2, 4.4 Hz), 0.97-0.86 (13H, m), 0.56-0.52 (6H, m).
    • [Reference example A111]
  • Figure imgb0035
    • Step 1: 2,6-dichloro-4-methylbenzoic acid (A111-1)
  • To a stirred solution of 1,3-dichloro-5-methylbenzene (2.0 g, 12.4 mmol) in THF (20 mL) was added n-BuLi (2.0 M in hexane, 9.3 mL, 18.6 mmol) at -78 °C dropwise over a period of 10 min and mixture was stirred at -78 °C for 30 min. A dry-ice was added to the reaction mixture slowly and the mixture was stirred at the same temperature for 20 min. Thereafter, the reaction mixture was slowly warmed to room temperature, quenched with 6 M HCl (10 mL) and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to get compound A111-1 (1.1 g, 44%) as a white solid.
    • Step 2: 2,6-dichloro-4-formylbenzoic acid (A111-2)
  • To a stirred solution of compound A111-1 (1.1 g, 5.3 mmol) in DCM (20 mL) was added NBS (2.3 g, 13.4 mmol) and diphenyl oxalate(65 mg, 0.27 mmol) and placed at reflux for 40 h. The reaction mixture was brought to room temperature and evaporated the solvent. To the residue, EtOAc (10 mL) was added and the obtained solids were filtered through Buckner funnel. The filtrate was evaporated and the crude product was dissolved in EtOH (20 mL) and heated to 50 °C. A solution of silver(I) nitrate (1.37 g, 8.0 mmol) in hot water (3 mL), was added to the reaction mixture dropwise and continued at the same temperature for 45 min. The reaction mixture was quenched with 1 M HCl (10 mL) and the obtained solids were filtered and washed with EtOH (30 mL). Filtrate was evaporated and remaining aqueous layer was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to get compound A111-2 (1.6 g, crude) as a brown oil.
    • Step 3: methyl 2,6-dichloro-4-formylbenzoate (A111-3)
  • To a stirred solution of compound A111-2 (1.1 g, 5.0 mmol) in DMF (10 mL) was added K2CO3 (1.0 g, 7.5 mmol) at 0 °C followed by slow addition of MeI (0.94 mL, 15.0 mmol) and the reaction mixture was stirred at the same temperature for 30 min. Then reaction mixture was quenched with water (50 mL) and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc/hexane as eluent) to provide compound A111-3 (0.59 g, 50%) as a white solid.
    • Step 4: methyl 2,6-dichloro-4-(difluoromethyl)benzoate (A111-4)
  • To a stirred solution of compound A111-3 (0.36 g, 1.5 mmol) in DCM (10 mL) was added DAST (0.37 mL, 2.8 mmol) at -78 °C dropwise followed by a drop addition of MeOH and the reaction was stirred at the same temperature for 15 min and brought to 0 °C. The reaction mixture was stirred for 30 min at the same temperature and 16 h at room temperature. The reaction mixture was quenched with saturated NaHCO3 (20 mL) at 0 °C and stirred for 20 min and extracted with DCM (2 x 30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to get compound A111-4 (0.37g, 94%) as a colorless oil.
    • Step 5: (2,6-dichloro-4-(difluoromethyl)phenyl)methanol (A111-5)
  • To a stirred solution of compound A111-4 (1.44 g, 5.64 mmol) in THF (10 mL) was added LiAlH4 (2.0 M in THF, 4.23 mL, 8.46 mmol) in THF (10 mL) at -78 °C dropwise for 15 min and brought to 0 °C. The reaction mixture was stirred for 30 min at the same temperature and 16 h at room temperature. The reaction mixture was quenched with 1 M HCl (20 mL) at 0 °C and stirred for 20 min and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to get compound A111-5 (0.59 g, 45%) as a colorless oil.
    • Step 6: 2,6-dichloro-4-(difluoromethyl)benzaldehyde (A111-6)
  • Compound A111-6 (0.38 g, 65%) was obtained as a colorless oil from the reaction of compound A111-5 (0.59 g, 2.46 mmol) and Dess-Martin periodinane (2.1 g, 4.92 mmol) in DCM (10 mL) using a similar procedure to that described in reference example A56, step 4.
    • Step 7: 2-(2,6-dichloro-4-(difluoromethyl)phenyl)-2-((trimethylsilyl)oxy)acetonitrile (A111-7)
  • To a stirred solution of compound A111-6 (0.38 g, 1.6 mmol) in DCM (15 mL) were added TMSCN (0.31 mL, 2.5 mmol) and NMO (60 mg, 0.5 mmol) at room temperature and stirred for 1 h. The reaction mixture was quenched with water (50 mL) and extracted with DCM (2 x 30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to get compound A111-7 (0.53 g, 97%) as a yellow solid.
    • Step 8 2-(2,6-dichloro-4-(difluoromethyl)phenyl)-2-((trimethylsilyl)oxy)ethanamine (A111-8)
  • To a stirred solution of compound A111-7 (0.53 g, 1.6 mmol) in THF (10 mL) was added BH3·THF (8.2 mL, 8.1 mmol) and stirred at room temperature for 16 h. The reaction mixture was quenched with MeOH and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to get compound A111-8 (0.5 g, crude) as a yellow oil.
    • Step 9: 1-(2,6-dichloro-4-(difluoromethyl)phenyl)-2-((3,5-difluorobenzyl)amino)ethanol (A11)
  • Compound A111 (0.21 g, 36%) was obtained as a colorless gum from the reaction of compound A111-8 (0.5 g, 1.52 mmol), 3,5-difluorobenzaldehyde (0.16 mL, 1.52 mmol) and NaBH4 (0.11 g, 3.0 mmol) in MeOH (5 mL) using a similar procedure to that described in reference example A56, step 8. 1H NMR (CDCl3, 400 MHz): δ 7.44 (s, 2H), 6.89-6.42 (m, 4H), 5.56-5.25. (m, 1H), 3.87 (s, 2H), 3.26 (dd, J = 12.8, 9.6 Hz, 1H), 2.91-2.86 (m, 1H).
    • [Reference example A112]
  • Figure imgb0036
    • Step 1: 4-(hydroxymethyl)-1-methylcyclohexanol (A112-1)
  • To a stirred solution of 4-(hydroxymethyl)cyclohexanone (1.0 g, 7.8 mmol) in THF (20 mL) was added methyl magnesium bromide (3.0 M in Et2O, 7.8 mL, 23.4 mmol) dropwise at 0 °C for 5 min. The mixture was allowed to warm to room temperature and stirred at the same temperature for 2 h. The reaction mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with water (20 mL), brine (20 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 80% EtOAc/hexane as eluent) to provide compound A112-1 (300 mg, 27%) as a white solid.
    • Step 2: 4-hydroxy-4-methylcyclohexanecarbaldehyde (A 112-2)
  • Compound A112-2 (49 mg, crude) was obtained as a yellow foam from the reaction of compound A112-1 (50 mg, 0.348 mmol) and Dess-Martin periodinane (206 mg, 0.48 mmol) in DCM (5.0 mL) using a similar procedure to that described in reference example A56, step 4.
    • Step 3: 4-(((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)amino)methyl)-1-methylcycloh exanol (A112)
  • To a stirred solution of compound A112-2 (49 mg, 0.34 mmol) in DCM (15 mL) was added compound A1-3 (109 mg, 0.34 mmol) followed by NaBH(OAc)3 (108 mg, 0.51 mmol) at room temperature. The mixture was stirred for 4 h at room temperature. The reaction mixture was quenched with aqueous saturated NaHCO3 (10 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layer was washed with water (20 mL), brine (20 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5% MeOH/DCM as eluent) to provide compound A112 (58 mg, 37% over two steps) as a yellow gum.
    • [Reference example A118]
  • Figure imgb0037
    • N-(2-bromobenzyl)-2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethanamine (A118)
  • Compound A118 (1.2 g, 79%) was obtained as a colorless oil from the reaction of compound A1-3. (1.0 g, 3.16 mmol), 2-bromobenzaldehyde (576 mg, 3.11 mmol) and NaBH4 (172 mg, 4.67 mmol) in MeOH (40 mL) using a similar procedure to that described in reference example A1, step 4. 1H NMR (CDCl3, 400 MHz): δ 8.41 (s, 2H), 7.53-7.51 (m, 1H), 7.37-7.35 (m, 1H), 7.28-7.25 (m, 1H), 7.13-7.08 (m, 1H), 5.55 (dd, J = 8.2, 5.2. Hz, 1H), 3.94-3.85 (m, 1H), 3.20 (dd, J = 12.1, 8.4 Hz, 1H), 2.88 (d, J = 4.8. Hz, 0.5H), 2.86 (dd, J = 12.1, 5.1 Hz, 0.5H), 0.89-0.86 (m, 9H), 0.58-0.51 (m, 6H).
    • [Reference example A119]
  • Figure imgb0038
    • Step 1: 1,3-dibromo-2,2-dimethylpropane (A119-1)
  • To a stirred solution of triphenylphosphine (26.2 g, 0.1 mol) in CH3CN (50 mL) was added a solution of bromine (5.13 mL, 0.10 mol) in CH3CN (30 mL) dropwise at 0 °C. 2,2-Dimethylpropane-1,3-diol (5.1 g, 0.05 mol) was added in portion to the reaction and the reaction mixture was stirred at 90 °C for 16 h. The solvent was removed under reduced pressure. The residue was suspended in MTBE (150 mL), and resulting solid was removed by filtration. The filtrate was concentrated under reduced pressure and the residue was dissolved in CH3CN and extracted with hexane (3 x 100 mL). The combined hexane extracts were concentrated under reduced pressure to provide compound A119-1 (6.5 g, 59%) as brown oil.
    • Step 2: dipentyl 3,3-dimethylcyclobutane-1,1-dicarboxylate (A119-2)
  • The sodium (0.98 g, 43.0 mmol) was added in portion to pentanol (25 mL) and the mixture was stirred at 50 °C to get a clear solution. The reaction mixture was heated to 70 °C, and then diethyl malonate (3.50 g, 26.0 mmol) was added over a period of 5 min. The reaction mixture was heated to 130 °C and compound A119-1 (5.0 g, 21 mmol) was added dropwise over a period of 10 min. The reaction mixture was heated at 130 °C for 4 h. The solvent was removed under vacuum at 100 °C. The residue was quenched with water (100 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were concentrated under reduced pressure to provide compound A119-2 (6 g, crude) as brown oil. The crude product was used for next step without purification.
    • Step 3: 3,3-dimethylcyclobutane-1,1-dicarboxylic acid (A119-3)
  • To a solution of compound A119-2 (6 g, crude) in EtOH/water (60 mL, 2:1) was added KOH solution (40% aqueous solution, 10 mL) and the reaction mixture was stirred at 100 °C for 4 h. After removing the solvent under reduced pressure, the residue was suspended in water (100 mL) and washed with MTBE. The aqueous layer was acidified to pH 1 and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to provide compound A119-3 (2.5 g, crude) as brown semi-solid gum. The crude product was used for next step without purification.
    • Step 4: 3,3-dimethylcyclobutanecarboxylic acid (A119-4)
  • Compound A119-3 (2.5 g, crude) was heated neat at 200 °C for 2 h to provide compound A119-4 (900 mg, crude) as light brown gum.
    • Step 5: (3,3-dimethylcyclobutyl)methanol (A119-5)
  • To a stirred suspension of LiAlH4 (534 mg, 14.0 mmol) in THF (20 mL) was added a solution of compound A119-4 (900 mg, 7.0 mmol) in THF (10 mL) at 0 °C and the mixture was stirred at the same temperature for 3 h. The reaction mixture was quenched with water (3 mL) and 20% aqueous NaOH (3 mL) and stirred at room temperature for 10 min. The solid was filtered over a pad of celite and the organic layer was washed with water (20 mL), brine (20 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to provide compound A119-5 (160 mg, 20%) as light yellow oil.
    • Step 6: 3,3-dimethylcyclobutanecarbaldehyde (A119-6)
  • To a stirred solution of compound A119-5 (160 mg, 1.4 mmol) in DCM (10 mL) was added Dess-Martin periodinane (1.20 g, 2.8 mmol) and the mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with DCM (10 mL) and quenched with aqueous Na2S2O8 (5 mL) and NaHCO3 solution (5 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to provide compound A119-6 (150 mg, quant.) as yellow oil. The crude product was used for next step without purification.
    • Step 7: 2-(3,5-dichloropyridin-4-yl)-N-((3,3-dimethylcyclobutyl)methyl)-2-((triethylsilyl)oxy)etha namine (A119)
  • The mixture of compound A119-6 (150 mg, 1.33 mmol) and compound A1-3 (300 mg, 0.97 mmol) in MeOH (10 mL) was stirred at room temperature for 3 h. NaBH4 (75 mg, 1.99 mmol) was added in portion and the mixture was stirred at room temperature for 3 h. The reaction mixture was quenched with water and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to provide compound A119 (190 mg, 36%) as yellow gum. 1H NMR (CDCl3, 400 MHz): δ 8.42 (s, 2H), 5.46-5.52 (m, 1H), 3.16-3.23 (m, 1H), 2.71-2.79 (m, 1H), 2.53-2.69 (m, 2H), 1.42-1.62 (m, 5H), 1.23-1.38 (m, 6H), 0.84-0.92 (m, 9H), 0.49-0.58 (m, 6H).
    • [Reference example A122]
  • Figure imgb0039
    • Step 1: ethyl 4-methylenecyclohexanecarboxylate (A 122-1)
  • Lithium bis(trimethylsilyl)amide (1.0 M in THF, 15 mL, 15 mmol) was added dropwisely to a stirred solution of methyltriphenylphosphonium bromide (5.36 g, 15 mmol) in THF (50 mL) at 0 °C and stirred for 40 min at the same temperature. A solution of ethyl 4-oxocyclohexanecarboxylate (2.04 g, 12 mmol) in THF (20 mL) was added slowly at 0 °C and stirred for 2 h from 0 °C to room temperature. The reaction was quenched with saturated NH4Cl aq. and extracted with hexane. The collected organic layer was dried over MgSO4 and concentrated under reduced pressure. The solvent (100 mL, hexane/Et2O = 5/1) was added to the residue and stirred for 30 min. The suspension was filtrated. The filtrate was concentrated under reduced pressure. The residue was purified by silicagel chromatography (5% EtOAc/hexane as eluent) to provide compound A122-1 (1.478 g, 73%) as a colorless oil.
    • Step 2: ethyl 1-(bromomethyl)-4-methylenecyclohexanecarboxylate (A122-2)
  • n-BuLi (2.6 M in hexane, 2.5 mL, 6.6 mmoL) was added dropwisely to a solution of diisopropylamine (0.93 mL, 6.6 mmol) in THF (20 mL) at -78 °C and stirred for 30 min at the same temperature. Hexamethylphosphoramide (4 mL) was added to the reaction mixture and stirred for 20 min at the same temperature. A solution of compound A122-1 (1.01 g, 6 mmol) in THF (5 mL) was added and stirred for 1 h at the same temperature. A solution of dibromomethane (2.1 mL, 30 mmol) was added to the reaction mixture and the mixture was allowed to warm to room temperature for 1.5 h. The reaction mixture was diluted hexane (80 mL) and AcOEt (20 mL). The collected organic layer was washed with water, saturated NH4Cl aq., brine, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by silicagel chromatography (10% EtOAc/hexane as eluent) to provide compound A122-2 (1.39 g, 89%) as a pale yellow oil.
    • Step 3: ethyl 4-methylbicyclo[2.2.1]heptane-1-carboxylate (A122-3)
  • To a stirred solution of compound A122-2 (783 mg, 3 mmol) in toluene (65 mL) was added tributyltin hydride (0.888 mL, 3.3 mmol) and 2,2'-azobis(isobutyronitrile) (25 mg) in toluene (20 mL) and the mixture was stirred at 110 °C for 1 h. The reaction mixture was cooled down and concentrated under reduced pressure. DCM (20 mL) and a solution of KF (1.0 g) in water (0.31 mL) were added to the residue and the mixture was stirred for 1 h. The reaction mixture was filtrated with anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silicagel chromatography (10% EtOAc/hexane as eluent) to provide compound A122-3 (501 mg, 92%) as a colorless oil.
    • Step 4: 4-methylbicyclo[2.2.1]heptane-1-carboxylic acid (A122-4)
  • To a stirred solution of compound A122-3 (500 mg, 2.74 mmol) in MeOH/water (8 mL, 3:1) was added a solution of LiOH aq. (4 M, 2 mL, 8 mmol). The mixture was stirred at room temperature for 2.5 h and stirred at 50 °C for 1.5 h. The organic solvent was removed under reduced pressure. The residue was diluted with water (10 mL) and hexane (10 mL). The aqueous layer was acidified with 6 M aqueous HCl to pH 1 and extracted with DCM. The organic layers were dried over MgSO4 and concentrated under reduced pressure to provide compound A122-4 (313 mg, 74%) as a pale yellow solid. Step 5: N-methoxy-N,4-dimethylbicyclo[2.2.1]heptane-1-carboxamide (A122-5)
  • To a mixture of compound A122-4 (302 mg, 1.96mmol), 1-hydroxybenzotrizole monohydrate (460 mg, 3 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (466 mg, 3 mmol) and N,O-dimethylhydroxylamine hydrochloride (293 mg, 3 mmol) in DMF (10 mL) was added DIPEA (1.03 mL, 6 mmol) and the mixture was stirred at room temperature for overnight. The reaction mixture was quenched with water (30 mL) and extracted with EtOAc. The collected organic layer was washed with saturated NH4Cl aq., brine, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by silicagel chromatography (30% EtOAc/hexane as eluent) to provide compound A122-5 (271.4 mg, 70%) as a colorless oil.
    • Step 6: 4-methylbicyclo[2.2.1]heptane-1-carbaldehyde (A122-6)
  • To a solution of compound A122-5 (271 mg, 1.37 mmol) in Et2O (5 mL) was added a suspension of LiAlH4 (52 mg, 1.37 mmol) in Et2O (2 mL) at 0 °C and stirred for 45 min at the same temperature. The reaction mixture was quenched with saturated KHSO4 aq. (5 mL) at 0 °C and stirred for 30 min at room temperature and extracted with Et2O. The organic layer was dried with MgSO4 and concentrated under reduced pressure to provide compound A122-6 (163 mg, 86%) as a colorless oil. The crude product was used for next step without purification.
    • Step 7: 2-(3,5-dichloropyridin-4-yl)-N-((4-methylbicyclo[2.2.1]heptan-1-yl)methyl)-2-((triethylsil yl)oxy)ethanamine (A122)
  • Compound A122 (177 mg, 80%) was obtained as a pale yellow oil from the reaction of compound A1-3 (160 mg, 0.50 mmol), compound A122-6 (82 mg, 0.59 mmol), NaBH4 (120 mg) and MgSO4 (200mg) in MeOH (4 mL) and DCM (3mL) using a similar procedure to that described in reference example A31, step 4. 1H NMR (CDCl3, 400 MHz): δ 8.42 (s, 2H), 5.50 (dd, J = 8.7, J = 4.6 Hz, 1H), 3.24 (dd, J = 12.6, J = 8.7 Hz, 1H), 2.78 (dd, J = 12.6, J = 4.6 Hz, 1H), 2.75 (d, J = 11.7 Hz, 1H), 2.67 (d, J = 11.7 Hz, 1H), 1.54-1.32 (m, 8H), 1.10-1.08 (m, 5H), 0.89 (t, J = 8.0 Hz, 9H), 0.58-0.49 (m, 6H).
    • [Reference example A124]
  • Figure imgb0040
    • Step 1: ethyl cyclopentanecarboxylate (A124-1)
  • To a solution of cyclopentanecarboxylate (1.14 g, 10 mmol) in EtOH (5mL) was added H2SO4 (0.1 mL) at room temperature. The mixture was allowed to warm to 80 °C and stirred at the same temperature for 3.5 h. The reaction mixture was cooled down to room temperature and poured into saturated NaHCO3 aq. (40 mL). The mixture was stirred at room temperature for 30 min and extracted with EtOAc. The organic layer was dried over MgSO4 and concentrated under reduced pressure to provide compound A 124-1 (1.01 g, 71 %) as a pale yellow oil. The crude product was used for next step without purification.
    • Step 2: ethyl 1-fluorocyclopentanecarboxylate (A 124-2)
  • n-BuLi (2.6 M in hexane, 4.0 mL, 10.5 mmoL) was added dropwisely to a solution of diisopropylamine (1.55 mL, 11 mmol) in THF (40 mL) at -78 °C and stirred for 30 min at the same temperature. A solution of compound A 124-1 (1.00 g, 7 mmol) in THF (10 mL) was added to the mixture and the mixture was stirred for 50 min at the same temperature. The reaction mixture was allowed to warm to 0 °C for 1 h. A solution of N-fluoro-N-(phenylsulfonyl)benzenesulfonamide (3.47 g, 10 mmol) in THF (10 mL) was added to the mixture and the mixture was stirred for 1 h at the same temperature. The reaction mixture was allowed to warm to room temperature for overnight. The reaction was quenched with saturated NH4Cl aq. and extracted with EtOAc. The collected organic layer was concentrated under reduced pressure. The residue was purified by silicagel chromatography (10% EtOAc/hexane as eluent) to provide compound A124-2 (911 m g, 81 %) as a yellow oil.
    • Step 3: 1-fluorocyclopentanecarboxylic acid (A124-3)
  • To a stirred solution of compound A124-2 (910 mg, 5.68 mmol) in EtOH/THF/water (7 mL, 4:2:1) was added a solution of LiOH aq. (4 M, 3 mL, 12 mmol). The mixture was stirred at room temperature for 2.5 h. The organic solvent was removed under reduced pressure. The residue was acidified with 2 M aqueous HCl to pH 1 and extracted with EtOAc. The organic layer was dried over MgSO4 and concentrated under reduced pressure to provide compound A124-3 (709 mg, 95%) as a brown oil. The crude product was used for next step without purification.
    • Step 4: 1-fluoro-N-methoxy-N-methylcyclopentanecarboxamide (A 124-4)
  • To a mixture of compound A 124-3 (709 mg, 5.37 mmol), 1-hydroxybenzotrizole (986 mg, 6.44 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.0 g, 6.44 mmol) and N,O-dimethylhydroxylamine hydrochloride (628 mg, 6.44 mmol) in DMF (10 mL) was added triethylamine (1.12 mL, 8.05 mmol) and the mixture was stirred at room temperature for overnight. The reaction mixture was quenched with 2 M aqueous HCl (30 mL) and extracted with EtOAc. The collected organic layer was washed with water, brine, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by silicagel chromatography (20% EtOAc/hexane as eluent) to provide compound A124-4 (543 mg, 58%) as a yellow oil.
    • Step 5: 1-fluorocyclopentanecarbaldehyde (A124-5)
  • To a solution of compound A124-4 (140 mg, 0.8 mmol) in Et2O (20 mL) was added LiAlH4 (33 mg, 0.88 mmol) at 0 °C and,stirred for 5 h at the same temperature. The reaction mixture was quenched with saturated KHSO4 aq. (5 mL) at 0 °C and extracted with Et2O. The combined organic layer was dried over MgSO4 and concentrated under reduced pressure to provide compound A124-5. The crude product was used for next step without purification.
    • Step 6: 2-(3,5-dichloropyridin-4-yl)-N-((1-fluorocyclopentyl)methyl)-2-((triethylsilyl)oxy)ethana mine (A124)
  • Compound A124 (207 mg, 68%) was obtained from the reaction of compound A1-3 (233 mg, 0.73 mmol), compound A124-5 (93 mg, 0.8 mmol), NaBH(OAc)3 (231 mg, 1.09 mmol), MgSO4 (93 mg) and AcOH (0.042 mL, 0.73 mmol) in DCM (2 mL) using a similar procedure to that described in reference example A31, step 4. 1H NMR (CDCl3, 400 MHz): δ 8.43 (s, 2H), 5.49 (dd, J = 8.5, J = 4.5 Hz, 1H), 3.26 (dd, J = 12.6, J = 8.5 Hz, 1H), 2.87 (d, J = 21.0 Hz, 2H), 2.83 (dd, J = 12.6, J = 4.5 Hz, 1H), 1.93-1.60 (m, 8H), 0.88 (t, J = 7.8 Hz, 9H), 0.60-0.49 (m, 6H).
    • [Reference example A141]
  • Figure imgb0041
    • Step 1: 3-methylenecyclobutanecarboxylic acid (A141-1)
  • To a stirred solution of KOH (10 g, 178 mmol) in water (15 mL) and EtOH (15 mL) was added 3-methylenecyclobutanecarbonitrile (3.92 g, 42 mmol) at room temperature for 10 min. The mixture was allowed to warm to 90 °C and stirred at the same temperature for 3.5 h. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in water (10 mL) at 0 °C. The mixture was acidified with 6 M aqueous HCl to pH 1 and extracted with DCM. The organic layer was dried over MgSO4 and concentrated under reduced pressure to provide compound A141-1 (4.65 g, 98%) as a colorless oil. The product was used for next step without futher purification.
    • Step 2: methyl 3-methylenecyclobutanecarboxylate (A141-2)
  • Trimethylsilyldiazomethane (2.0 M in hexane, 25 mL, 50 mmol) was added to a stirred solution of compound A141-1 (4.64 g, 41.4 mmol) in DCM (25 mL) and MeOH (5 mL) dropwise at 0 °C for 5 min. The mixture was allowed to warm to room temperature and stirred at the same temperature for 30 min. The reaction mixture was quenched with AcOH (0.45 mL) and concentrated under reduced pressure. The residue was purified by silicagel chromatography (20% DCM/hexane as eluent) to provide compound A141-2 (3.8 g, 73%) as a colorless oil.
    • Step 3: methyl spiro[2.3]hexane-5-carboxylate (A141-3)
  • To a solution of diethylzinc (1.0 M in hexane, 46 mL, 46 mmol) in DCM (200 mL) was added a solution of TFA (3.54 mL, 46 mmol) in DCM (50 mL) dropwise at 0 °C for 30 min. A solution of diiodomethane (3.7 mL, 46 mmol) in DCM (50 mL) was added dropwise at 0 °C for 45 min. The mixture was stirred at the same temperature for 1 h. A solution of compound A141-2 (2.52 g, 20 mmol) in DCM (30 mL) was added to the reaction mixture. The mixture was allowed to warm to room temperature for overnight. The reaction mixture was quenched with saturated NH4Cl aq. (200 mL) and extracted with DCM. The collected organic layer was dried over MgSO4 and concentrated under reduced pressure. The residue was purified by silicagel chromatography (20% EtOAc/hexane as eluent) to provide compound A141-3 (1.77 g, 63%) as a colorless oil.
    • Step 4: spiro[2.3]hexane-5-carboxylic acid (A141-4)
  • To a stirred solution of LiOH (4 M in water, 10 mL, 40 mmol) in water (10 mL) and MeOH (20 mL) was added compound A141-3 (1.76 g, 12.6 mmol) at room temperature. The mixture was stirred at room temperature for 40 min. The reaction mixture was concentrated under reduced pressure to ca. 20 mL of solution. The solution was acidified with 6 M aqueous HCl to pH 1 and extracted with DCM. The organic layer was dried over MgSO4 and concentrated under reduced pressure to provide compound A141-4 (1.51 g, 95%) as a colorless oil. The product was used for next step without futher purification. Step 5: N-methoxy-N-methylspiro[2.3]hexane-5-carboxamide (A141-5)
  • To a mixture of compound A141-4 (1.51 mg, 12.0 mmol), 1-hydroxybenzotrizole monohydrate (2.30 g, 15 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.33 g, 15 mmol) and N,O-dimethylhydroxylamine hydrochloride (1.46 g, 15 mmol) in DMF (20 mL) was added DIPEA (3.43 mL, 20 mmol) and the mixture was stirred at room temperature for overnight. The reaction mixture was quenched with water and extracted with hexane and EtOAc. The collected organic layer was washed with 1 M HCl aq. (100 mL), water, saturated Na2CO3 aq. (2 x 100 mL), brine, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by silicagel chromatography (75% EtOAc/hexane as eluent) to provide compound A141-5 (1.72 g, 84%) as a colorless oil.
    • Step 6: spiro[2.3]hexane-5-carbaldehyde (A141-6)
  • To a solution of compound A141-5 (677 mg, 4 mmol) in Et2O (15 mL) was added a suspension of LiAlH4 (152 mg, 4 mmol) in Et2O (5 mL) at 0 °C over 5 min and stirred for 2 h at the same temperature. The reaction mixture was quenched with saturated KHSO4 aq. (10 mL) at 0 °C and extracted with Et2O. The combined organic layer was dried with MgSO4 and concentrated under reduced pressure to provide compound A141-6 (351 mg, 80%) as a colorless oil. The crude product was used for next step without purification.
    • Step 7: 2-(2,4,6-trichlorophenyl)-N-(spiro[2.3]hexan-5-ylmethyl)-2-((triethylsilyl)oxy)ethanamine (A141)
  • Compound A141 (123 mg, 39%) was obtained as a pale yellow oil from the reaction of 2-(2,4,6-trichlorophenyl)-2-((triethylsilyl)oxy)ethanamine (248 mg, 0.7 mmol), compound A141-6 (100 mg, 0.91 mmol), NaBH4 (212 mg) and MgSO4 (100mg) in MeOH (1.4 mL) and THF (3.5 mL) using a similar procedure to that described in reference example A31, step 4. 1H NMR (CDCl3, 400 MHz): δ 7.29 (s, 2H), 5.53 (dd, J = 9.0, J = 4.6 Hz, 1H), 3.26 (dd, J = 12.2, J = 8.8 Hz, 1H), 2.85-2.71 (m, 3H), 2.62-2.51 (m, 1H), 2.17-2.10 (m, 2H), 1.86-1.81 (m, 2H), 0.87 (t, J = 7.8 Hz, 9H), 0.57-0.50 (m, 6H), 0.43-0.33 (m, 4H).
    • [Reference example A194] 1-(2,6-dichloro-3-fluorophenyl)-2-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)ethanol
  • Figure imgb0042
    • Step 1: 2-(2,6-dichloro-3-fluorophenyl)-2-((trimethylsilyl)oxy)acetonitrile
  • To a 200 ml RBF was charged with solution of 2,6-dichloro-3-fluorobenzaldehyde (2.29 g, 11.87 mmol), DCM (23 ml), TMSCN (1.9 ml, 14.24 mmol), and zinc iodide (0.379 g, 1.187 mmol) was added. The mixture was stirred at room temperature for 4 h. Then the mixture was washed with water (2x20 ml) and brine. Organic layer was concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, eluent: 0% to 30% EtOAc/heptane) to provide 2-(2,6-dichloro-3-fluorophenyl)-2-((trimethylsilyl)oxy)acetonitrile (1.435 g, 4.91 mmol, 41.4 % yield) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.32-7.42 (m, 1 H); 7.12-7.24 (m, 1 H); 6.17-6.30 (m, 1 H); 0.12-0.33 (m, 9 H).
    • Step 2: 2-(2,6-dichloro-3-fluorophenyl)-2-((trimethylsilyl)oxy)acetaldehyde
  • To a 100 mL three-necked RBF were added 2-(2,6-dichloro-3-fluorophenyl)-2-((trimethylsilyl)oxy)acetonitrile (0.50 g, 1.711 mmol) and DCM (9 ml). The reaction mixture was purged with nitrogen and cooled to -64 °C. Under a nitrogen atmosphere, diisobutylaluminum hydride, 1.0 M solution in hexane (2.6 ml, 2.6 mmol) was added dropwise. The mixture was stirred at -64 °C. After 2 h, the reaction was quenched. While maintaining temp <-65 °C, MeOH (1.4 ml, 34.2 mmol) was carefully added dropwise to the reaction mixture followed by saturated Rochelle salt solution (5mL). The mixture was allowed to reach room temperature and stirred for 30 min. Water and DCM were added and the aqueous layer was extracted with DCM. The combined organic layer was washed with brine, dried over anhydrous MgSO4, and concentrated to afford 2-(2,6-dichloro-3-fluorophenyl)-2-((trimethylsilyl)oxy)acetaldehyde as a colorless oil (0.517 g, crude).
    • Step 3: 1-(2,6-dichloro-3-fluorophenyl)-2-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)ethanol
  • To a solution of crude 2-(2,6-dichloro-3-fluorophenyl)-2-((trimethylsilyl)oxy)acetaldehyde (0.258 g, 0.874 mmol) in MeCN (9 ml) was added (1-(trifluoromethyl)cyclopropyl)methanamine (0.122 g, 0.874 mmol) followed by AcOH (0.050 ml, 0.874 mmol). The reaction mixture was stirred at room temperature for 1 h. Then NaBH(OAc)3 (0.370 g, 1.748 mmol) was added. The reaction mixture was stirred at room temperature for 23 h. Then it was quenched by adding saturated aqueous NaHCO3 solution and stirred for 30 min. It was extracted with DCM (2x5 mL). The combined organic layer was washed with brine, dried over anhydrous MgSO4, and concentrated under reduced pressure to provide a yellow oil. The yellow oil was dissolved in 2 mL of THF. Then TBAF, 1.0 M solution in THF (0.874 ml, 0.874 mmol) was added. The reaction mixture was stirred at room temperature for 15 min. It was quenched with saturated aqueous NaHCO3 and extracted with DCM. The combined organic layer was dried over anhydrous MgSO4 and concentrated under reduced pressure. The crude material was purified by column chromatography (silica gel, eluent: 0% to 50% EtOAc/heptane) to provide 1-(2,6-dichloro-3-fluorophenyl)-2-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)ethanol (116 mg, 0.335 mmol, 38.3% yield) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.25-7.31 (m, 1H), 7.06 (dd, J=8.9, 8.0 Hz, 1H), 5.45 (dd, J=9.7, 4.5 Hz, 1H), 3.45 (br. s., 1H), 3.28 (dd, J=12.6, 9.8 Hz, 1H), 2.89-2.92 (m, 3H), 0.99 - 1.04 (m, 2H), 0.69-0.76 (m, 2H); LCMS: 346.0 [M+H]+.
    • [Reference example A224] 2-(2,6-dichloro-4-fluorophenyl)-N-((1-methylcyclopropyl)methyl)-2-((triethylsilyl)oxy)eth anamine
  • Figure imgb0043
  • A mixture of 1-methylcyclopropanecarbaldehyde (31.6 mg, 0.375 mmol) and 2-(2,6-dichloro-4-fluorophenyl)-2-((triethylsilyl)oxy)ethanamine (127 mg, 0.375 mmol) in MeOH (1.9 ml) was stirred at room temperature for 3 h. NaBH4 (14.20 mg, 0.375 mmol) was added in portions and the mixture was stirred at room temperature for 40 min. The mixture was was concentrated and purified by prep TLC eluted with 5% MeOH/DCM to provide 2-(2.6-dichloro-4-fluorophenyl)-N-((1-methylcyclopropyl)methyl)-2-((triethylsilyl)oxy)eth anamine (111 mg, 0.273 mmol, 72.8% yield). 1H NMR (500 MHz, CDCl3) δ 7.29 (s, 1H), 7.06-7.10 (m, 2H), 5.56 (br. s., 1H), 3.33 (t, J=10.51 Hz, 1H), 2.81 (d, J=9.17 Hz, 1H), 2.60-2.67 (m, 1H), 2.44 (d, J=11.86 Hz, 1H), 1.46-1.59 (m, 1H), 1.13 (s, 3H), 0.85-0.96 (m, 9H), 0.50-0.63 (m, 6H), 0.36 (br. s., 2H), 0.30 (br. s., 2H); LCMS (ESI) m/z 406.0 (M+H)+.
    • [Reference example A258] 2-(2,6-dichlorophenyl)-N-((1-methylcyclopropyl)methyl)-2=((triethylsilyl)oxy)ethanamine
  • Figure imgb0044
  • To a mixture of 1-methylcyclopropanecarbaldehyde (32.8 mg, 0.390 mmol) in DCM (2.0 ml) was added 2-(2,6-dichlorophenyl)-2-((triethylsilyl)oxy)ethanamine (125 mg, 0.390 mmol) followed by NaBH(OAc)3 (124 mg, 0.585 mmol). After 45 min, this was quenched with sat. aq. NaHCO3. The layers were separated. The aqueous layer was extracted with DCM. The combined organic layers were concentrated then purified by prep TLC eluted with 5% MeOH/DCM to provide 2-(2,6-dichlorophenyl)-N-((1-methylcyclopropyl)methyl)-2-((triethylsilyl)oxy)ethanamine (95 mg, 0.245 mmol), 62.7 %yield). 1H NMR (500 MHz, CDCl3) δ 7.28-7.30 (m, 2H), 7.12-7.16 (m, 1H), 5.65 (br. s., 1H), 3.37-3.44 (m, 1H), 2.82-2.90 (m, 1H), 2.69 (br. s., 1H), 2.48 (d, J=11.86 Hz, 1H), 1.60 (br. s., 1H), 1.15 (s, 3H), 0.87-0.92 (m, 9H), 0.51-0.63 (m, 6H), 0.28-0.44 (m, 4H); LCMS (ESI) m/z 388.3 (M+H)+.
    • [Reference example A259]
  • Figure imgb0045
    • Step 1: 2-(2,6-dichlorophenyl)-2-((trimethylsilyl)oxy)acetonitrile
  • A 100 ml RBF was charged with solution of 2,6-dichlorobenzaldehyde (5.08 g, 29.0 mmol) and TMSCN (4.64 ml, 34.8 mmol) in DCM (60 ml). Zinc iodide (0.926 g, 2.90 mmol) was added and the mixture was stirred at ambient temperature for 3 h. Reaction mixture was diluted with DCM (200 mL). The organic layer was washed with water (2 x 20 mL) and brine (20 mL), organic layer was filtered through celite and concentrated. The residue was purified by flash chromatography on 100 g Biotage SNAP cartridge using 0-40% EtOAc in heptane to afford 2-(2,6-dichlorophenyl)-2-((trimethylsilyl)oxy)acetonitrile (3.01 g, 38%).
    • Step 2: 2-(2,6-dichlorophenyl)-2-((trimethylsilyl)oxy)acetaldehyde.
  • To a solution of 2-(2,6-dichlorophenyl)-2-((trimethylsilyl)oxy)acetonitrile (1.372 g, 5.00 mmol) in DCM (23.16 ml), diisobutylaluminum hydride 1.0 M solution in hexane (7.50 ml, 7.50 mmol) was added at -78 °C dropwise over 20 min. Reaction was carefully quenched first with MeOH (1 ml, 24.97 mmol) and then with Rochelle salt 1.5 M (5.00 ml, 7.50 mmol). The flask was removed from the bath and allowed to reach ambient temperature and extracted with EtOAc (20 ml). The organic layer was separated and washed with brine, filtered through celite pad and concentrated to obtain 2-(2,6-dichlorophenyl)-2-((trimethylsilyl)oxy)acetaldehyde (1.34 g, 97%) as a white solid.
    • Step 3: 2-(2,6-dichlorophenyl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)-2-((trimethylsilyl)oxy) ethanamine.
  • To a solution of crude 2-(2,6-dichlorophenyl)-2-((trimethylsilyl)oxy)acetaldehyde (0.35 g, 1.263 mmol) in DCM (6.31 ml) was added (1-(trifluoromethyl)cyclopropyl)methanamine (0.176 g, 1.263 mmol) and NaBH(OAc)3 (0.374 ml, 2.53 mmol) and stirred for 2 h at ambient temperature. The reaction was quenched with aqueous sat NH4Cl solution and diluted with DCM (50 mL). Organic layer was passed through phase seperator and concentrated to obtain 2-(2,6-dichlorophenyl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)-2-((trimethylsilyl)oxy) ethanamine (0.378 g, 70%) as light yellow oil. This was used in next step without further purification.
    • [Reference example A260] 2-(2,6-dichlorophenyl)-N-((1-methylcyclobutyl)methyl)-2-((triethylsilyl)oxy)ethanamine
  • Figure imgb0046
  • To a mixture of 1-methylcyclobutanecarbaldehyde (38.3 mg, 0.390 mmol) in DCM (2.0 ml) was added 2-(2,6-dichlorophenyl)-2-((triethylsilyl)oxy)ethanamine (125 mg, 0.390 mmol) followed by NaBH(OAc)3 (124 mg, 0.585 mmol). After 45 min, this was quenched with sat. aq. NaHCO3. The layers were separated. The aqueous layer was extracted with DCM. The combined organic layers were concentrated and then purified by prep TLC eluted with 5% MeOH/DCM to provide 2-(2,6-dichlorophenyl)-N-((1-methylcyclobutyl)methyl)-2-((triethylsilyl)oxy)ethanamine (89 mg, 0.221 mmol, 56.7% yield). 1H NMR (500 MHz, CDCl3) δ 7.18-7.22 (m, 2H), 6.98-7.10 (m, 1H), 5.57 (br. s., 1H), 3.30 (t, J=10.70 Hz, 1H), 2.74 (br. s., 1H), 2.60 (br. s., 1H), 2.51 (d, J=10.03 Hz, 1H), 1.68-1.89 (m, 4H), 1.60 (br. s., 2H), 1.47 (br. s., 1H), 1.03-1.14 (m, 3H), 0.76-0.84 (m, 9H), 0.41-0.54 (m, 6H); LCMS (ESI) m/z 402.4 (M+H)+.
    • [Reference example A262] 2-(2,6-dichlorophenyl)-N-((5-fluorospiro[2.3]hexan-5-yl)methyl)-2-((triethylsilyl)oxy)etha namine
  • Figure imgb0047
  • Spiro[2.3]hexane-5-carbaldehyde (300 mg, 2.72 mmol) and N-ethyl-N-isopropylpropan-2-amine (546 µl, 3.13 mmol) were combined in MeCN (5 mL) and trimethylsilyl trifluoromethanesulfonate (517 µl, 2.86 mmol) was added dropwise. The solution was stirred for 30 min and selectfluor (1061 mg, 3.00 mmol) in MeCN (5 mL) was added. The solution was stirred and sonicated for an additional 30 min. 2-(2,6-dichlorophenyl)-2-((triethylsilyl)oxy)ethanamine (785 mg, 2.451 mmol) and AcOH (187 µl, 3.27 mmol) were added. The solution was stirred for 30 min and NaBH(OAc)3 (1154 mg, 5.45 mmol) was added and the solution was stirred for an additional 2 h. The solution was quenched with saturated NaHCO3, the aqueous layer was extracted with ethyl aceate and the combined organic layers were washed with brine and dried over anhydrous Na2SO4, filtered and concentrated. The product was purified via silica gel column chromatography (40 g column) using 0-100% EtOAc in heptane to afford 2-(2,6-dichlorophenyl)-N-((5-fluorospiro[2.3]hexan-5-yl)methyl)-2-((triethylsilyl)oxy)etha namine (300 mg, 0.694 mmol, 25.5%yield). MS m/z = 432 [M+H]+.
    • [Reference example A267] 2-(2,6-dichlorophenyl)-N-(spiro[2.5]octan-6-ylmethyl)-2-((triethylsilyl)oxy)ethanamine
  • Figure imgb0048
  • To a solution of 2-(2,6-dichlorophenyl)-2-((triethylsilyl)oxy)ethanamine (248 mg, 0.774 mmol) in DCM (2581 µl) was added spiro[2.5]octane-6-carbaldehyde (107 mg, 0.774 mmol), AcOH (35.5 µl, 0.619 mmol) and NaBH(OAc)3 (246 mg, 1.161 mmol). The slurry mixture was stirred at room temperature for overnight. The mixture was quenched with 0.5 M NaOH and mixture was stirred at rt for 30 min. Evolution of gas was observed. The layers were separated. The organic layer was dried over Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with a gradient of 0% to 100% EtOAc in hexane to give 2-(2,6-dichlorophenyl)-N-(spiro[2.5]octan-6-ylmethyl)-2-((triethylsilyl)oxy)ethanamine.
    • [Reference example A275] N-(2-(3-chloroquinolin-4-yl)-2-((triethylsilyl)oxy)ethyl)-2,2-dimethylpropan-1-amine
  • Figure imgb0049
    • Step 1: 3-chloroquinolin-4(1H)-one (A275-1)
  • A mixture of 4-hydroxyquinoline (5.33 g, 36.7 mmol) in AcOH (184 mL) was treated with N-chlorosuccinimide (6.37 g, 47.7 mmol) and the yellow homogeneous mixture was stirred and heated at 60 °C. After 3 h, the mixture was cooled to room temperature and concentrated in vacuo. Saturated aqueous NaHCO3 solution (300 mL) was added until pH became ∼8.5. The resulting solid was collected by filtration, washed with water (300 mL), and dried under high vacuum to give 3-chloroquinolin-4(1H)-one (A275-1) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 12.28 (1H, br. s.), 8.40 (1H, d, J=6.5 Hz), 8.15 (1H, dd, J=8.2, 1.4 Hz), 7.65-7.73 (1H, m), 7.58-7.63 (1H, m), 7.39 (1H, ddd, J=8.1, 6.9, 1.2 Hz); LCMS (ESI) m/z 180.1 (M+H)+.
    • Step 2; 4-bromo-3-chloroquinoline (A275-2)
  • To a cooled suspension of 3-chloroquinolin-4(1H)-one (A275-1) (5.15 g, 28.7 mmol) in DMF (43.4 mL) at 0 °C was added phosphorous tribromide (2.77 mL, 29.5 mmol) dropwise over 3 min and then the mixture became orange homogenous mixture. After 4 min, yellow precipitates were formed and the yellow heterogeneous mixture was further stirred at 0 °C for 15 min. After 15 min, the cooling bath was removed and the yellow heterogeneous mixture was stirred at room temperature. After 15 h, the mixture was poured into ice water (300 mL) and stirred at 0 °C for 20 min. The mixture was then neutralized by the addition of 2 M NaOH solution (50 mL) until pH was >9 (pH paper). The resulting precipitate was collected by filtration, washed the solid with water (400 mL), and dried under high vacuum to give 4-bromo-3-chloroquinoline (A275-2) as off-white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.96 (1H, s), 8.20 (1H, dd, J=8.2, 1.6 Hz), 8.12 (1H, dd, J=8.3, 0.9 Hz), 7.81-7.93 (2H, m); LCMS (ESI) m/z 242.0 [M+H (79Br)]+ and 243.9 [M+H (81Br)]+.
    • Step 3: 3-chloroquinoline-4-carbaldehyde (A275-3)
  • A flask was charged with 4-bromo-3-chloroquinoline (A275-2) (1.00 g, 4.12 mmol) and THF (16.5 mL) under nitrogen, and the solution was cooled to -78 °C. To the cooled mixture was added n-butyllithium (2.5 M solution in hexane, 1.65 mL, 4.12 mmol) and the mixture was stirred at -78 °C for 1 hour. To the mixture was added DMF (1.60 mL, 20.6 mmol) dropwise, and the mixture was allowed to warm to room temperature. After 4 h, the mixture was quenched with saturated aqueous NH4Cl (20 mL). The mixture was was partitioned between water (50 mL) and EtOAc (50 mL). The aqueous layer was extracted with EtOAc (1 x 50 mL). The organic extract was dried over MgSO4. The solution was filtered and concentrated in vacuo to give the crude material as a brown syrup. The crude material was absorbed onto a plug of silica gel and purified by chromatography through a REDISEP™ pre-packed silica gel column (80 g), eluting with a gradient of 0% to 20% EtOAc in hexane, and dried under high vacuum to give 3-chloroquinoline-4-carbaldehyde (A275-3) as brown solid. 1H NMR (400 MHz, DMSO-d6) δ 10.74 (1H, s), 9.10 (1H, s), 8.68-8.73 (1H, m), 8.15 (1H, dd, J=8.5, 0.9 Hz), 7.79-7.92 (2H, m); LCMS (ESI) m/z 192.1 (M+H)+.
    • Steps 4: 1-(3-chloroquinolin-4-yl)-2-nitroethanol (A275-4)
  • To a brown clear solution of 3-chloroquinoline-4-carbaldehyde (A275-3) (0.362 g, 1.89 mmol) in THF (1.9 mL) at room temperature was added potassium carbonate (0.078 g, 0.566 mmol) and nitromethane (1.420 mL, 26.4 mmol). The brown homogeneous mixture was stirred at room temperature. After 4 h, the reaction mixture was quenched with water (50 mL) and extracted with EtOAc (2 x 50 mL). The organic extract was washed with saturated NaCl (1 x 50 mL), and dried over Na2SO4. The solution was filtered, concentrated in vacuo, and dried under high vacuum to give 1-(3-chloroquinolin-4-yl)-2-nitroethanol (A275-4) as a brown solid. 1H NMR (400 MHz, DMSO-d6) δ 8.88-8.93 (1H, m), 8.73 (1H, dd, J=8.6, 0.8 Hz), 8.08 (1H, dd, J=8.4, 1.0 Hz), 7.82 (1H, ddd, J=8.4, 6.9, 1.5 Hz), 7.72 (1H, ddd, J=8.5, 6.9, 1.4 Hz), 6.91 (1H, dd, J=4.5, 1.0 Hz), 6.26 (1H, ddd, J=10.0, 4.6, 3.6 Hz), 5.03-5.12 (1H, m), 4.94-5.01 (1H, m); LC-MS (ESI) m/z 253.1 (M+H)+.
    • Step 5: 3-chloro-4-(2-nitro-1-((triethylsilyl)oxy)ethyl)quinoline (A275-5),
  • To a brown clear solution of 1-(3-chloroquinolin-4-yl)-2-nitroethanol (A275-4) (0.423 g, 1.68 mmol) in DMF (4.19 mL) at room temperature was added imidazole (0.342 g, 5.03 mmol) and triethylsilyl chloride (0.341 mL, 2.01 mmol). The mixture was stirred at room temperature. After 2 h, the mixture was quenched with water (50 mL) and extracted with EtOAc (2 x 50 mL). The organic extract was washed with 1 M LiCl (1 x 50 mL) and brine (1 x 50 mL), and dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a yellow syrup. The crude material was absorbed onto a plug of silica gel and purified by chromatography through a REDISEP™ pre-packed silica gel column (40 g), eluting with a gradient of 0% to 10% EtOAc in hexane, and dried under high vacuum to give 3-chloro-4-(2-nitro-1-((triethylsilyl)oxy)ethyl)quinoline (A275-5). 1H NMR (400 MHz, DMSO-d6) δ 8.95 (1H, s), 8.67 (1H, d, J=7.4 Hz), 8.10 (1H, dd, J=8.4, 0.8 Hz), 7.84 (1H, td, J=7.6, 1.4 Hz), 7.71-7.79 (1H, m), 6.38 (1H, dd, J=9.8, 2.5 Hz), 5.14-5.23 (1H, m), 5.03-5.11 (1H, m), 0.65-0.74 (9H, m), 0.32-0.51 (6H, m); LCMS (ESI) m/z 367.1 (M+H)+.
    • Step 6: 2-(3-chloroquinolin-4-yl)-2-((triethylsilyl)oxy)ethanamine (A275-6)
  • To a clear yellow solution of 3-chloro-4-(2-nitro-1-((triethylsilyl)oxy)ethyl)quinoline (0.511 g, 1.39 mmol) in EtOH (7.96 mL) and water (1.99 mL) at room temperature was added iron powder (0.778 g, 13.9 mmol) and ammonium chloride (0.745 g, 13.9 mmol). The dark brown mixture was stirred and heated at 60 °C. After 4 h, the mixture was cooled to room temperature and filtered through a celite pad and washed the pad with MeOH (3 × 30 mL). The combined filtrates were concentrated in vacuo. The residue was partitioned between EtOAc (100 mL) and water (50 mL). The mixture (pH ∼4.0) was washed with saturated aqueous NaHCO3 (1 x 50 mL), water (1 x 50 mL), and brine (1 x 50 mL), dried over anhydrous Na2SO4, concentrated in vacuo, and dried under high vacuum to give 2-(3-chloroquiriolin-4-yl)-2-((triethylsilyl)oxy)ethanamine (A275-6) as a yellow syrup.
    1H NMR (400 MHz, DMSO-d6) δ 8.84 (1H, s), 8.72 (1H, d, J=8.2 Hz), 8.04 (1H, dd, J=8.4, 1.0 Hz), 7.76 (1H, ddd, J=8.4, 6.9, 1.4 Hz), 7.64 (1H, ddd, J=8.5, 7.0, 1.3 Hz), 5.52 (1H, dd, J=7.6, 5.5 Hz), 3.16 (1H, dd, J=13.0, 7.9 Hz), 2.88 (1H, dd, J=13.0, 5.4 Hz), 1.74 (1H, br. s.), 0.71-0.80 (1 H, m), 0.71-0.80 (9H, m), 0.37-0.57 (6H, m); LCMS (ESI) m/z 337.1 (M+H)+.
    • Step 7: N-(2-(3-chloroquinolin-4-yl)-2-((triethylsilyl)oxy)ethyl)-2,2-dimethylpropan-1-amine (A275)
  • To a yellow clear solution of 2-(3-chloroquinolin-4-yl)-2-((triethylsilyl)oxy)ethanamine (A275-6) (0.217 g, 0.644 mmol) in DCM (2.15 mL) was added trimethylacetaldehyde (0.077 mL, 0.71 mmol), AcOH (0.045 mL, 0.77 mmol), and NaBH(OAc)3 (0.205 g, 0.966 mmol). The yellow homogeneous mixture was stirred at room temperature. After 2 h, the mixture was quenched with water (20 mL) and neutralized with 0.5 M NaOH (10 mL) to pH ∼9.0. The reaction mixture was extracted with DCM (2 x 50 mL). The organic extract was washed with saturated NaCl (1 x 50 mL) and dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a yellow syrup. The crude material was absorbed onto a plug of silica gel and purified by chromatography through a REDISEP™ pre-packed silica gel column (40 g), eluting with a gradient of 0% to 20% EtOAc in hexane, and dried under high vacuum to give N-(2-(3-chloroquinolin-4-yl)-2-((triethylsilyl)oxy)ethyl)-2,2-dimethylpropan-1-amine (A275) as colorless syrup. 1H NMR (400 MHz, DMSO-d6) δ 8.84 (1H, s), 8.75 (1H, d, J=7.2 Hz), 8.04 (1H, dd, J=8.4, 1.0 Hz), 7.77 (1H, ddd, J=8.4, 6.9, 1.4 Hz), 7.61-7.68 (1H, m), 5.70 (1H, dd, J=7.7, 5.0 Hz), 3.26 (1H, dd, J=12.6, 8.1 Hz), 2.85 (1H, dd, J=12.6, 5.0 Hz), 2.23-2.39 (2H, m), 1.72 (1H, br. s.), 0.81 (9H, s), 0.72-0.79 (9H, m), 0.36-0.56 (6H, m); LCMS (ESI) m/z 407.1 (M+H)+.
    • [Reference example A281] 2-(3,5-dichloropyridin-4-yl)-N-((5-methyltetrahydrofuian-2-yl)methyl)-2-((triethylsilyl)ox y)ethanamine
  • Figure imgb0050
  • To a clear solution of 5-methyltetrahydrofuran-2-methanol in DCM was added Dess-Martin periodinane (1.2 eq.). The mixture was stirred at room temperature overnight. The crude mixture was directly added to a solution of 2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethanamine (1 eq.) in DCM followed by AcOH (1.2 eq.) and NaBH(OAc)3 (1.5 eq.). The reaction mixture was stirred at room temperature. After 2 h, the mixture was quenched with saturated aqueous Na2S2O3 and saturated NaHCO3. The reaction mixture was extracted with DCM. The organic extract was dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 25% EtOAc in heptane to provide 2-(3,5-dichloropyridin-4-yl)-N-((5-methyltetrahydrofuran-2-yl)methyl)-2-((triethylsilyl)ox y)ethanamine (A281) as a light-yellow syrup. 1H NMR (300 MHz, DMSO-d6) δ 8.58 (2H, s), 5.34-5.46 (1H, m), 3.71-3.90 (2H, m), 3.10 (1H, dt, J=12.5, 8.1 Hz), 2.90 (1H, td, J=12.1, 6.0 Hz), 2.52-2.67 (2H, m), 1.71-2.07 (3H, m), 1.47-1.64 (1H, m), 1.19-1.38 (1H, m), 1.11 (3H, t, J=6.3 Hz), 0.77-0.89 (9H, m), 0.40-0.62 (6H, m); LCMS (ESI) m/z 419.1 (M+H)+.
    • [Reference example A294] N-(2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)-3,3,3-trifluoro-2,2-dimethylpro pan-1-amine
  • Figure imgb0051
    • Step 1: 3,3,3-trifluoro-N-methoxy-N,2,2-trimethylpropanamide (A294-1)
  • To a clear solution of 3,3,3-trifluoro-2,2-dimethylpropionic acid (5.000 g, 32.0 mmol) in MeCN (22.88 ml) was added triethylamine (9.82 ml, 70.5 mmol) followed by HATU (12.79 g, 33.6 mmol) and the mixture was stirred at room temperature. After 15 min, to the dark clear mixture was added N,O-dimethylhydroxylamine hydrochloride (3.44 g, 35.2 mmol) and the mixture was stirred at room temperature. After 18 h, the reaction mixture was diluted with EtOAc (100 mL) and washed with 1 N HCl (2 x 100 mL), and sat. NaCl. (5 x 100 mL) and dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a orange solid. The orange solid was absorbed onto a plug of silica gel and purified by silica gel chromatography eluting with a gradient of 0% to 25% EtOAc in heptane to provide 3,3,3-trifluoro-N-methoxy-N,2,2-trimethylpropanamide (5.0503 g, 25.4 mmol, 79% yield) as yellow liquid. 1H NMR (300 MHz, CDCl3) δ 3.71 (3H, s), 3.22 (3H, s), 1.51 (6H, d, J=0.7 Hz); LCMS (ESI) m/z 200.1 (M+H)+.
    • Step 2: 3,3,3-trifluoro-2,2-dimethylpropanal
  • To a 250-mL of three neck round-bottomed flask equipped with goose neck for nitrogen and for thermocouple was added lithium aluminium hydride, 1 M solution in Et2O (25.3 ml, 25.3 mmol) at 0 °C. To the cooled mixture was added a solution of 3,3,3-trifluoro-N-methoxy-N,2,2-trimethylpropanamide (A294-1) (5.0325 g, 25.3 mmol) in Et2O (47.7 ml) dropwise over 35 min at 0 °C. After the completion of the addition, the reaction mixture was further stirred at 0 °C. After 2 h, the mixture was carefully quenched at 0 °C with water (0.96 mL), NaOH (15%, 0.96 mL) and water (2.88 mL) and the mixture was vigourouly stirred for 40 min. The reaction mixture was diluted with Et2O (50 mL), treated with Na2SO4 and then filtered through a Celite pad, washed with Et2O (100 mL). The filtrate was concentrated in vacuo to provide 3,3,3-trifluoro-2,2-dimethylpropanal (A294-2) (3.2304 g, 23.06 mmol, 91% yield) as yellow liquid. 1H NMR (400 MHz, CDCl3) δ 9.69 (1H, d, J=1.4 Hz), 1.31 (6H, s).
    • Step 3: N-(2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)-3,3,3-trifluoro-2,2-dimethylpro pan-1-amine (A294)
  • To a yellow clear mixture of 2-(3,5-dichloropyridiri-4-yl)-2-((triethylsilyl)oxy)ethanamine (3.57 g, 11.11 mmol) in DCM (37.0 mL) was added 3,3,3-trifluoro-2,2-dimethylpropanal (11.11 mmol) in DCM followed by AcOH (0.770 ml, 13.33 mmol) and NaBH(OAc)3 (3.53 g, 16.67 mmol). The yellow heterogeneous mixture was stirred at room temperature. After 8 h, the mixture was quenched with saturated NaHCO3 (100 mL). The reaction mixture was extracted with DCM (2 x 100 mL). The organic extract was dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as orange syrup. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 20% EtOAc in heptane to provide N-(2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)-3,3,3-trifluoro-2,2-dimethylpro pan-1-amine (A294) (3.4393 g, 7.72 mmol, 69.5% yield) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 8.44 (2H, s), 5.48 (1H, dd, J=7.7, 4.4 Hz), 3.27 (1H, dd, J=12.3, 8.4 Hz), 2.58-2.83 (3H, m), 1.25-1.44 (1H, m), 1.10 (6H, s), 0.85-0.94 (9H, m), 0.47-0.64 (6H, m);
    LCMS (ESI) m/z 445.1 (M+H)+.
  • The following secondary amines were prepared using similar procedure in reference examples described above:
    Figure imgb0052
    Figure imgb0053
    Figure imgb0054
    Figure imgb0055
    Figure imgb0056
    Figure imgb0057
    Figure imgb0058
    Figure imgb0059
    Figure imgb0060
    Figure imgb0061
    Figure imgb0062
    Figure imgb0063
    Figure imgb0064
    Figure imgb0065
    Figure imgb0066
    Figure imgb0067
    Figure imgb0068
    Figure imgb0069
    Figure imgb0070
    Figure imgb0071
    Figure imgb0072
    Figure imgb0073
    Figure imgb0074
    Figure imgb0075
    Figure imgb0076
    Figure imgb0077
    Figure imgb0078
    Figure imgb0079
    Figure imgb0080
    Figure imgb0081
    Figure imgb0082
    Figure imgb0083
    Figure imgb0084
    Figure imgb0085
    Figure imgb0086
    Figure imgb0087
    Figure imgb0088
    Figure imgb0089
    Figure imgb0090
    Figure imgb0091
    Figure imgb0092
    Figure imgb0093
    Figure imgb0094
    Figure imgb0095
    Figure imgb0096
    Figure imgb0097
    Figure imgb0098
    Figure imgb0099
    Figure imgb0100
    Figure imgb0101
    Figure imgb0102
    Figure imgb0103
    reference example structure reference example structure
    A185
    Figure imgb0104
         		A192
    Figure imgb0105
    A186
    Figure imgb0106
         		A193
    Figure imgb0107
    A187
    Figure imgb0108
         		A194
    Figure imgb0109
    A188
    Figure imgb0110
         		A195
    Figure imgb0111
    A189
    Figure imgb0112
         		A196
    Figure imgb0113
    A190
    Figure imgb0114
         		A197
    Figure imgb0115
    A191
    Figure imgb0116
         		A198
    Figure imgb0117
    A199
    Figure imgb0118
         		A206
    Figure imgb0119
    A200
    Figure imgb0120
         		A207
    Figure imgb0121
    A201
    Figure imgb0122
         		A208
    Figure imgb0123
    A202
    Figure imgb0124
         		A209
    Figure imgb0125
    A203
    Figure imgb0126
         		A210
    Figure imgb0127
    A204
    Figure imgb0128
         		A211
    Figure imgb0129
    A205
    Figure imgb0130
         		A212
    Figure imgb0131
    A213
    Figure imgb0132
         		A220
    Figure imgb0133
    A214
    Figure imgb0134
         		A221
    Figure imgb0135
    A215
    Figure imgb0136
         		A222
    Figure imgb0137
    A216
    Figure imgb0138
         		A223
    Figure imgb0139
    A217
    Figure imgb0140
         		A224
    Figure imgb0141
    A218
    Figure imgb0142
         		A225
    Figure imgb0143
    A219
    Figure imgb0144
         		A226
    Figure imgb0145
    A227
    Figure imgb0146
         		A234
    Figure imgb0147
    A228
    Figure imgb0148
         		A235
    Figure imgb0149
    A229
    Figure imgb0150
         		A236
    Figure imgb0151
    A230
    Figure imgb0152
         		A237
    Figure imgb0153
    A231
    Figure imgb0154
         		A238
    Figure imgb0155
    A232
    Figure imgb0156
         		A239
    Figure imgb0157
    A233
    Figure imgb0158
         		A240
    Figure imgb0159
    A241
    Figure imgb0160
         		A248
    Figure imgb0161
    A242
    Figure imgb0162
         		A249
    Figure imgb0163
    A243
    Figure imgb0164
         		A250
    Figure imgb0165
    A244
    Figure imgb0166
         		A251
    Figure imgb0167
    A245
    Figure imgb0168
         		A252
    Figure imgb0169
    A246
    Figure imgb0170
         		A253
    Figure imgb0171
    A247
    Figure imgb0172
         		A254
    Figure imgb0173
    A255
    Figure imgb0174
         		A262
    Figure imgb0175
    A256
    Figure imgb0176
         		A263
    Figure imgb0177
    A257
    Figure imgb0178
         		A264
    Figure imgb0179
    A258
    Figure imgb0180
         		A265
    Figure imgb0181
    A259
    Figure imgb0182
         		A266
    Figure imgb0183
    A260
    Figure imgb0184
         		A267
    Figure imgb0185
    A261
    Figure imgb0186
         		A268
    Figure imgb0187
    A269
    Figure imgb0188
         		A276
    Figure imgb0189
    A270
    Figure imgb0190
         		A277
    Figure imgb0191
    A271
    Figure imgb0192
         		A278
    Figure imgb0193
    A272
    Figure imgb0194
         		A279
    Figure imgb0195
    A273
    Figure imgb0196
         		A280
    Figure imgb0197
    A274
    Figure imgb0198
         		A281
    Figure imgb0199
    A275
    Figure imgb0200
         		A282
    Figure imgb0201
    A283
    Figure imgb0202
         		A290
    Figure imgb0203
    A284
    Figure imgb0204
         		A291
    Figure imgb0205
    A285
    Figure imgb0206
         		A292
    Figure imgb0207
    A286
    Figure imgb0208
         		A293
    Figure imgb0209
    A287
    Figure imgb0210
         		A294
    Figure imgb0211
    A288
    Figure imgb0212
         		A295
    Figure imgb0213
    A289
    Figure imgb0214
         		A296
    Figure imgb0215
    A297
    Figure imgb0216
         		A304
    Figure imgb0217
    A298
    Figure imgb0218
         		A305
    Figure imgb0219
    A299
    Figure imgb0220
         		A306
    Figure imgb0221
    A300
    Figure imgb0222
         		A307
    Figure imgb0223
    A301
    Figure imgb0224
         		A308
    Figure imgb0225
    A302
    Figure imgb0226
         		A309
    Figure imgb0227
    A303
    Figure imgb0228
         		A310
    Figure imgb0229
    A311
    Figure imgb0230
         		A318
    Figure imgb0231
    A312
    Figure imgb0232
    A313
    Figure imgb0233
    A314
    Figure imgb0234
    A315
    Figure imgb0235
    A316
    Figure imgb0236
    A317
    Figure imgb0237
    • [Reference example B1]
  • Figure imgb0238
    • Step 1: 2-(3,5-dichloropyridin-4-yl)ethanol (B1-1)
  • To a solution of 3,5-dichloropyridine (4.0 g, 27.0 mmol) in THF (70 mL) was added LDA (1.8 M in THF/heptane/ethylbenzene, 22.0 mL, 39.6 mmol) at -78 °C and the mixture was stirred at the same temperature for 2 h, and then ethylene oxide (1.2 M in THF, 25 ml, 30.0 mmol) was added. The reaction mixture was allowed to warm to room temperature gradually and stirred for 1 h at room temperature. The reaction mixture was quenched by adding saturated aqueous NH4Cl solution and extracted with EtOAc. The organic layer was washed with brine (2 times) and dried over MgSO4. After the solvent was removed, the residue was purified by column chromatography on silica gel to give compound B1-1(3.1 g, 60%) as a yellow solid.
    • Step 2: 4-(2-azidoethyl)-3,5-dichloropyridine (B1-2)
  • To a solution of compound B1-1 (3.1 g, 16.2 mmol) in THF (60 mL) were added DIAD (6.3 mL, 32.0 mmol), triphenylphosphine (8.52 g, 32.5 mmol) and DPPA (6.98 mL, 32.5 mmol) at 0 °C. The reaction mixture was allowed to warm to room temperature gradually and stirred at room temperature for 4.5 h. The reaction mixture was quenched by adding water and extracted with EtOAc. The organic layer was washed with brine (x 2) and dried over MgSO4. After the solvent was removed, the residue was purified by column chromatography on silica gel to give compound B1-2 (2.4 g, 68%) as a yellow oil.
    • Step 3: 2-(3,5-dichloropyridin-4-yl)ethanamine (B1-3)
  • To a solution of compound B1-2 (2.4 g, 11.1 mmol) in THF (25 mL) was added triphenylphosphine (2.9 g, 22.1 mmol) at 0°C. The mixture was stirred at room temperature for 2 h, and then water (2.5 mL) was added. The reaction mixture was allowed to warm to room temperature gradually and stirred at room temperature for 22 h. The reaction mixture was quenched by adding 2M aqueous HCl (10 mL) and diluted with EtOAc. The aqueous layer was washed with EtOAc x 3, and then basified with 2 M aqueous NaOH to pH 12. The aqueous layer was extracted with EtOAc, washed with brine (x 2) and dried over MgSO4. Drying the solution under high vacuum yielded compound B1-3 (1.9 g, 90%) as a white solid.
    • Step 4: 2-(3,5-dichloropyridin-4-yl)-N-(4-fluorobenzyl)ethanamine (B1)
  • To a solution of compound B1-3 (2.9 g, 15.2 mmol) in MeOH (30 mL) was added 4-fluorobenzaldehyde (1.89 g, 15.2 mmol), and the mixture was stirred at room temperature for 3 h. The reaction mixture was cooled to 0 °C and NaBH4 (1.16 g, 30.4 mmol) was added gradually. The reaction mixture was allowed to warm to room temperature and stirred at room temperature for 4 h. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine x 2 and dried over MgSO4. After the solvent was removed, the residue was purified by column chromatography on silica gel to give compound B1 (3.4 g, 75%) as a pale yellow solid.
    • [Reference example B2]
  • Figure imgb0239
    • Step 1: 1,3-dichloro-5-fluoro-2-(2-nitrovinyl)benzene (B2-1)
  • To a stirred solution of compound A31-1 (1.3 g, 5.1 mmol) in dioxane (10 mL) was added 6 M HCl (20 mL) at room temperature and the mixture was stirred at reflux for overnight. The reaction mixture was neutralized with 10% NaOH solution and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc/hexane as eluent) to provide compound B2-1 (0.22 g, 18%) as a colorless oil.
    • Step 2: 2-(2,6-dichloro-4-fluorophenyl)ethanamine (B2-2)
  • To a stirred solution of LiBH4 (3.0 M, 4.2 mL, 12.5 mmol) in THF (5 mL) was added TMS-Cl (3.2 mL, 25.2 mmol) dropwise at room temperature and the mixture was stirred at room temperature for 30 min. N2 gas was bubbled through the reaction mixture for 5 min to remove remaining trimethylsilane that had formed. A solution of compound B2-1 (0.22 g, 3.1 mmol) in THF (2 mL) was added dropwise to the mixture at room temperature and later refluxed for 1 h. The reaction mixture was cooled to 0 °C and quenched with MeOH (10 mL) carefully. Solvent was evaporated under reduced pressure and the residue was partitioned between 20% KOH (10 mL) and DCM (20 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to give compound B2-2 (0.21 g, 99%) as a colorless oil.
    • Step 3: 2-(2,6-dichloro-4-fluorophenyl)-N-(3,5-difluorobenzyl)ethanamine (B2)
  • Compound B2 (0.21 g, 69%) was obtained as a colorless gum from the reaction of compound B2-2 (0.19 g, 0.91 mmol), 3,5-difluorobenzaldehyde (0.1 mL, 0.91 mmol) and NaBH4 (70 mg, 1.8 mmol) in MeOH (5 mL) using a similar procedure to that described in reference example B1, step 4. 1H NMR (CDCl3, 300 MHz): δ 7.13-7.05 (m, 2H), 6.87-6.59 (m, 3H), 3.83 (s, 2H), 3.12-2.80 (m, 4H).
    • [Reference example B3]
  • Figure imgb0240
    • Step 1: 2-(3,5-dichloropyridin-4-yl)acetaldehyde (B3-1)
  • Compound B1-1 (1.0 g, 5.21 mmol) was dissolved in DCM (26.0 ml) and Dess-Martin periodinane (2.43 g, 5.73 mmol) was added. The solution was stirred for 1 h. The reaction mixture was quenched with 50 ml of 5% Na2S2O3, the organic layer was washed with saturated NaHCO3 dried with anhydrous Na2SO4 and concentrated. The product was purified by silica gel column chromatography (40 g column) using 0-100 % EtOAc in heptane to afford compound B3-1 (750 mg, 3.95 mmol, 76 % yield). LC/MS (ESI+) m/z = 189.9 (M+H)+.
    • Step 2: N-(2-(3,5-dichloropyridin-4-yl)ethyl)-2,2-dimethylpropan-1-amine (B3)
  • Compound B3-1 (0.65 g, 3.42 mmol) was dissolved in DCM (17 ml) under inert atmosphere, then 2,2-dimethylpropan-1-amine (0.605 ml, 5.13 mmol) was added followed by glacial AcOH (0.198 ml, 3.42 mmol). The solution was stirred for 15 min and then NaBH(OAc)3 (1.450 g, 6.84 mmol) was added. The solution was quenched with 15 ml of saturated NaHCO3 and stirred for 45 min. The organic layer was separated and concentrated. The product was purified via silica gel column chromatography (40 g column) using 0-100 % EtOAc in heptane to afford compound B3 (775 mg, 2.97 mmol, 87% yield). LC/MS (ESI+) m/z = 261.0 (M+H)+.
    • [Reference example B13]
  • Figure imgb0241
    • Step 1: 1-(3,5-dichloropyridin-4-yl)-2-((3,5-difluorobenzyl)amino)ethanol (B13-1)
  • To a stirred solution of 2-(3,5-dichloropyridin-4-yl)-N-(3,5-difluorobenzyl)-2-((triethylsilyl)oxy)ethanamine (0.2 g, 0.44 mmol) in THF (5 mL) was added TBAF (1.0 M in THF, 0.9 mL, 0.88 mmol) dropwise at 0 °C, and the mixture was allowed to warm up from 0 °C to room temperature while stirred for 2 h. The reaction mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc (2×20 mL). The combined organic layers were washed with water (20 mL), brine (20 mL) and dried over anhydrous Na2SO4. Solvent was evaporated under reduced pressure to provide compound B13-1 (0.2 g, crude) as brown color gum.
    • Step 2: tert-butyl (2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,5-difluorobenzyl)carbamate (B13-2)
  • To a stirred solution of compound B13-1 (0.2 g, 0.6 mmol) in DCM/water (4:1, 5 mL) were added NaHCO3 (0.1 g, 1.2 mmol) and (Boc)2O (0.19 g, 0.9 mmol) in DCM (2 mL) at 0 °C. The mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water (50 mL) and extracted with DCM (2x30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to provide compound B13-2, (0.17 g, 65%) as a colorless oil.
    • Step 3: tert-butyl (2-(3,5-dichloropyridin-4-yl)-2-methoxyethyl)(3,5-difluorobenzyl)carbamate (B13-3)
  • To a stirred solution of compound B13-2 (0.1 g, 0.2 mmol) in THF (5 mL) was added NaH (14 mg, 0.5 mmol) followed by dropwise addition of MeI (44 µL, 0.7 mmol) at 0 °C. The mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc/hexane as eluent) to provide compound B13-3 (0.11 g, 99%) as a colorless oil.
    • Step 4: tert-butyl 2-(3,5-dichloropyridin-4-yl)-N-(3,5-difluorobenzyl)-2-methoxyethanamine (B13)
  • To a stirred solution of compound B13-3 (0.28 g, 0.6 mmol) in dioxane (5 mL) was added 4 M HCl (in dioxane, 1.9 mL, 7.4 mmol) at room temperature and the mixture was stirred for overnight. Solvent was evaporated under reduced pressure to provide compound B13-3 (0.1 g, 48%) as a white solid. 1H NMR (CDCl3, 300 MHz): δ 8.45 (s, 2H), 6.90-6.63 (m, 3H), 5.14 (dd, J = 8.9, 4.1 Hz, 1H), 3.89-3.77 (m, 2H), 3.30-3.23 (m, 4H), 2.78 (dd, J = 12.6, 4.1 Hz, 1H).
    • [Reference example B15]
  • Figure imgb0242
    • Step 1: 3,5-dichloro-4-iodopyridine (B15-1)
  • To a stirred solution of 3,5-dichloropyridine (3.0 g, 20.4 mmol) in THF (15 mL) was added LDA (2.0 M solution in THF/heptane/ethylbenzene, 12.14 mL, 24.4 mmol) dropwise at 0 °C and the mixture was stirred at the same temperature for 1 h. A solution of iodine (2.7 g, 21.4 mmol) in THF (10 mL) added dropwise to above mixture. Upon completion of addition, the mixture was stirred at the same temperature for 1 h. The reaction mixture was quenched with water (40 mL) and extracted with EtOAc (4 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to provide compound B15-1 (3.2 g, 57%) as a yellow gum.
    • Step 2: ethyl-2-(3,5-dichloropyridin-4-yl)-2,2-difluoroacetate (B15-2)
  • The mixture of compound B15-1 (530 mg, 0.83 mmol), ethyl 2-bromo-2,2-difluoroacetate (0.12 ml, 1.38 mmol) and Cu (800 mg, 12.5 mmol) in DMSO (10 mL) was heated to 55 °C for 16 h. The reaction mixture was cooled to room temperature and quenched with saturated NH4Cl solution (100 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 30% EtOAc/hexane as eluent) to provide compound B15-2 (315 mg, 60%) as yellowish brown gum.
    • Step 3: 2-(3,5-dichloropyridin-4-yl)-2,2-difluoroethanol (B15-3)
  • To a stirred solution of compound B15-2 (315 mg, 1.16 mmol) in EtOH (10 mL) was added solid NaBH4 (16.2 mg, 1.74 mmol) in portions at 0 °C. The mixture was warmed to room temperature and stirred at the same temperature for 2 h. The reaction mixture was quenched with water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (2x30 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 55% EtOAc/hexane as eluent) to provide compound B15-3 (180 mg, 44%) as a colorless gum.
    • Step 4: 4-(2-azido-1,1-difluoroethyl)-3,5-dichloropyridine (B15-4)
  • To a stirred solution of compound B15-3 (140 mg, 0.72 mmol) in THF (5 mL) were added DIAD (0.31 mL, 1.60 mmol), DPPA (0.34 mL, 1.60 mmol) and PPh3 (420 mg, 1.60 mmol) at 0 °C. The mixture was warmed to room temperature and stirred at the same temperature for 16 h. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to provide compound B15-4 (80 mg, 55%) as a yellow gum.
    • Step 5: 2-(3,5-dichloropyridin-4-yl)-2,2-difluoroethanamine (B15-5)
  • To a stirred solution of compound B15-4 (80 mg, 0.31 mmol) in EtOAc (2 mL) were added (CH3)3P (0.47 mL, 0.47 mmol) and H2O (0.5 mL). The mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with EtOAc (10 mL) and washed with water (10 mL). The organic layer was washed with brine (10 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to provide compound B15-5 (60 mg) as a yellow gum. The crude residue was used for next step without purification.
    • Step 6: 2-(3,5-dichloropyridin-4-yl)-N-(3,5-difluorobenzyl)-2,2-difluoroethanamine (B15)
  • A mixture of compound B15-5 (113 mg, 0.49 mmol), 3,5-difluorobenzaldehyde (70 mg, 0.49 mmol) and NaBH(OAc)3 (316 mg, 1.49 mmol) in DCM was stirred at room temperature for 16 h. The reaction mixture was quenched with water (20 mL) and extracted with DCM (2 x 25 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to provide compound B15 (66 mg, 38%) as a white solid. 1H NMR (CDCl3, 300 MHz): δ 8.54-8.53 (m, 2H), 6.73-6.66 (m, 3H), 3.86 (s, 2H), 3.36-3.45 (t, J = 28.7 Hz, 2H); LCMS (APCI): 353 (M+H)+.
    • [Reference example B19]
  • Figure imgb0243
    • Step 1: (E)-4-chloro-3-(2-nitrovinyl)-1H-indole (B19-1)
  • A mixture of 4-chloroindole-3-carbaldehyde (314 mg, 1.75 mmol) and ammonium acetate (404 mg, 5.25 mmol) in nitromethane (6 mL) was stirred at 100 °C for 20 min. The reaction mixture was cooled, diluted with water and extracted with EtOAc (2 x 40 mL). The combined organic layers were washed with brine, dried over MgSO4 and concentrated under reduced pressure. The crude material was purified by silicagel column chromatography (50-100% EtOAc/heptane) to give compound B19-1 (224 mg, 58%) as an orange solid.
    • Step 2: 2-(4-chloro-1H-indol-3-yl)ethanamine (B19-2)
  • A solution of compound B19-1 (1.46 g, 6.56 mmol) in THF (25 mL) was added to a stirred slurry of lithium aluminum hydride (995 mg, 26.2 mmol) in THF (50 mL) at room temperature. The mixture was refluxed for 2 h and allowed to cool to room temperature. The reaction was quenched by dropwise addition of water (1.3 mL), followed by 15% NaOH aq. (1.3 mL), followed again by water (3.25 mL). After stirring vigorously for 14 h the mixture was filtered through Celite and the filtrate was concentrated. The residue was dissolved with EtOAc and then extracted with 2 N HCl aq. (2 x 20 mL). The combined aqueous layers were basified by adding 5 N NaOH aq. and extracted with EtOAc (2 x 40 mL). The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure to give compound B19-2 (1.02g, 80%) as a dark red syrup.
    • Step 3: (1R,3r,5S)-N-(2-(4-chloro-1H-indol-3-yl)ethyl)-6,6-dimethylbicyclo[3.1.0]hexan-3-amine (B19)
  • Compound B19 (22 mg, 14%) was obtained from the reaction of compound B19-2 (100 mg, 0.514 mmol), compound C22-5 (128 mg, 1.03 mmol), NaBH(OAc)3 (326 mg, 1.54 mmol) and AcOH (0.108 mL, 2.05 mmol) in DCM (2 mL) using a similar procedure to that described in reference example A31, step4. 1H NMR (CDCl3, 400 MHz) δ: 8.09 (1H, br s), 7.26-7.22 (1H, m), 7.07-7.05 (3H, m), 3.57-3.47 (1H, m), 3.13 (2H, t, J = 7.3 Hz), 2.89 (2H, t, J = 7.3 Hz), 2.17-2.10 (2H, m), 1.03-0.93 (10H, m).
    • [Reference example B50] 3,5-dichloro-4-(((2R)-4-isopropylpyrrolidin-2-yl)methyl)pyridine (B50)
  • Figure imgb0244
    • Step 1: (R)-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one
  • The reaction was equipped with a Dean-Stark then 2,2-dimethoxypropane (17.09 mL, 139 mmol) was added to a stirred mixture of (R)-(-)-5-(hydroxymethyl)-2-pyrrolidinone (5.353 g, 46.5 mmol) and p-toluenesulfonic acid monohydrate (0.126 g, 0.662 mmol) in toluene (100 mL). The reaction mixture was refluxed for 1.5 h and allowed to stir at room temperature overnight. Solvent was evaporated to afford (R)-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (7.22 g, 100% yield) as a light yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 4.18 (tt, J=8.8, 6.2 Hz, 1H), 4.00 (dd, J=8.1, 5.8 Hz, 1H), 3.40 (t, J=8.6 Hz, 1H), 2.69 (ddd, J=16.4, 12.1, 8.6 Hz, 1H), 2.33 (dd, J=16.3, 9.1 Hz, 1H), 2.02-2.11 (m, 1H), 1.73 (tt, J=12.1, 8.9 Hz, 1H), 1.53 (s, 3H), 1.33 (s, 3H). m/z (ESI, +ve) 156 (M+H).
    • Step 2: (7aR)-6-(2-hydroxypropan-2-yl)-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one
  • To a solution of (R)-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (6.68 g, 43.0 mmol) in THF (100 mL) cooled to -78 °C, was added lithium diisopropylamide, 2.0 M solution in THF/heptane/ethylbenzene (43.0 mL, 86 mmol) and stirred at -78 °C for 1 h. The resulting mixture was treated with acetone,99.8%, extra dry, acroseal (6.32 mL, 86 mmol) at -78 °C and then allowed to warm up to room temperature for 16 h. The reaction was quenched with sat. NH4Cl and extracted with EtOAc (2 x 200 mL). The combined extracts were washed with brine, dried over Na2SO4 filtered and concentrated to provide (7aR)-6-(2-hydroxypropan-2-yl)-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (6.088 g, 28.5 mmol, 66.3% yield) as a yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 4.50 (s, 1H), 4.07 - 4.18 (m, 1H), 3.98 (dd, J=8.0, 5.7 Hz, 1H), 3.32 - 3.35 (m, 1H), 2.50 - 2.56 (m, 1H), 2.22 (ddd, J=13.4, 7.2, 2.0 Hz, 1H), 1.83 (ddd, J=13.3, 10.4, 7.6 Hz, 1H), 1.54 (s, 3H), 1.32 (s, 3H), 1.21 (s, 3H), 1.14 (s, 3H). m/z (ESI, +ve) 214 (M+H). Step 3: (R)-3,3-dimethyl-6-(propan-2-ylidene)tetrahydropyrrolo[1,2-c]oxazol-5(3H)-one
  • To a solution of (7aR)-6-(2-hydroxypropan-2-yl)-3,3-dimethyltetrahydropyrrolo -[1,2-c]oxazol-5(3H-one (5.06 g, 23.73 mmol) in DCM (50 mL) at room temperature was added methanesulfonyl chloride (2.75 mL, 35.6 mmol) followed by triethylamine (16.50 mL, 119 mmol) and then heated at 55 °C for 1 h. The resulting mixture was treated with additional methanesulfonyl chloride (2.75 mL, 35.6 mmol) and heated for another 1 h. The reaction mixture was allowed to cool to room temperature, quenched with water (50 mL) and extracted with DCM (2 x 100 mL). The combined extracts were washed with brine, dried over MgSO4, filtered and concentrated to provide crude (R)-3,3-dimethyl-6-(propan-2-ylidene)tetrahydropyrrolo[1,2-c]oxazol-5(3H)-one as a brown oil, which was used in the next step without purification. m/z (ESI, +ve) 196 (M+H).
    • Step 4: (R)-5-(hydroxymethyl)-3-(propan-2-ylidene)pyrrolidin-2-one
  • To a solution of (R)-3,3-dimethyl-6-(propan-2-ylidene)tetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (4.63 g, 23.73 mmol) in MeOH (50 mL) at room temperature was added p-toluenesulfonic acid monohydrate (0.451 g, 2.373 mmol) and then heated at 60 °C for 45 min. The solvent was evaporated and the crude material was absorbed onto a plug of silica.gel and was purified by chromatography through a REDISEP™ pre-packed silica gel column (80 g), eluting with a gradient of 0% to 10% MeOH in DCM to give (R)-5-(hydroxymethyl)-3-(propan-2-ylidene)pyrrolidin-2-one (2.223 g, 14.32 mmol, 60.4% yield) as an yellow solid. 1NMR(400 MHz, CDCl3) δ 6.60 (br. s., 1H), 3.74 (td, J=8.0, 3.9 Hz, 1H), 3.67 (dd, J=11.1, 3.6 Hz, 1H), 3.44 (dd, J=11.1, 7.3 Hz, 1H), 2.75-2.86 (m, 1H), 2.81 (dd, J=16.5, 8.7 Hz, 1H), 2.33-2.43 (m, 1H), 2.23 (s, 3H), 1.77 (s, 3H). m/z (ESI, +ve) 156 (M+H).
    • Step 5: (5R)-5-(hydroxymethyl)-3-isopropylpyrolidin-2-one
  • A mixture of (R)-5-(hydroxymethyl)-3-(propan-2-ylidene)pyrrolidin-2-one (2.223 g, 14.32 mmol) and platinum (iv) oxide (0.325 g, 1.432 mmol) in EtOAc (40 mL)/MeOH (4 mL) at room temperature was stirred in the pressure bottle reactor under H2 (28 psi to 2 psi) overnight. The resulting mixture was filtered through a pad of Celite, washed with EtOAc, and concentrated to give (5R)-5-(hydroxymethyl)-3-isopropylpyrrolidin-2-one (2.251 g, 14.32 mmol, 90% yield) as a light yellow solid. 1H NMR (400 MHz, CDCl3) δ 6.56-6.71 (m, 1H), 3.64-3.80 (m, 2H), 3.37-3.53 (m, 1H), 2.48 (td, J=9.9, 45 Hz, 2H), 2.14-2.27 (m, 1H), 1.97-2.13 (m, 1H), 1.50 (ddd, J=12.7, 10.7, 8.3 Hz, 1H), 0.98 (d, J=6.8 Hz, 3H), 0.86 (d, J=6.8 Hz, 3H). m/z (ESI, +ve) 158 (M+H).
    • Step 6: ((2R)-4-isopropylpyrrolidin-2-yl)methanol
  • To a solution of (5R)-5-(hydroxymethyl)-3-isopropylpyrrolidin-2-one (2.251 g, 14.32 mmol) in THF (25 mL) was added lithium aluminium hydride, 1.0 M solution in THF (20.05 mL, 20.05 mmol) at room temperature dropwise slowly. The resulting mixture was then refluxed at 75 °C for 2 h. Additional lithium aluminium hydride, 1.0 M solution in THF (20.05 mL, 20.05 mmol) was added and the mixture was refluxed overnight. After 18 h, the reactiom mixture was allowed to cool to 0 °C. The reaction was quenched by adding saturated aqueous solution of Rochelle's salt. The reaction mixture was stirred vigorously for 1 h and the layers were separated. The aqueous layer was extracted with EtOAc twice and the organics were combined, washed with brine, dried over MgSO4, filtered and concentrated in vacuo to provide ((2R)-4-isopropylpyrrolidin-2-yl)methanol (1.645 g, 11.49 mmol, 80% yield) as a ligh yellow oil. The crude material was used in the next step without further purification. m/z (ESI, +ve) 144 (M+H).
    • Step 7:(3aR)-5-isopropyltetrahydro-3H-pyrrolo[1,2-c][1,2,3]oxathiazole 1,1-dioxide
  • A solution of ((2R)-4-isopropylpyrrolidin-2-yl)methanol (1.639 g, 11.44 mmol) and triethylamine (3.18 mL, 22.89 mmol) in DCM (100 m) was cooled to -78 °C. To this mixture was added sulfuryl chloride, 1.0 M solution in DCM (13.73 mL, 13.73 mmol) dropwise. The reaction mixture was allowed to warm to room temperature overnight. The reaction mixture was concentrated onto a plug of silica gel and purified by ISCO, chromatograph through a REDISEP™ pre-packed scilica gel column (40 g), eluting with a gradient of 0% to 10% MeOH (with 2 M NH3) in DCM to give (3aR)-5-isopropyltetrahydro-3H-pyrrolo[1,2-c][1,2,3]oxathiazole 1,1-dioxide (211.9 mg, 1.032 mmol, 9 %yield) as light yellow oil. m/z (ESI, +ve) 206 (M+H).
    • Step 8: 3,5-dichloro-4-(((2R)-4-isopropylpyrrolidin-2-yl)methyl)pyridine
  • To a solution of 3,5-dichloropyridine (228 mg, 1.542 mmol) in THF (2.6 mL) at -78 °C was added lithium diisopropylamide, 2.0 M heptane/THF/ethylbenzene (0.976 mL, 1.953 mmol) dropwise. After stirring for 45 min, a solution of (3aR)-5-isopropyltetrahydro-3H-pyrrolo[1,2-c][1,2,3]oxathiazole 1,1-dioxide (211 mg, 1.028 mmol) in THF (3.0 mL) was added dropwise at -78 °C. The resulting mixture was allowed to warm to room temperature and then stirred for 3 h. After evaporation of the solvent, the resulting brown solid was treated with 2 N HCl (3 mL) and EtOH (3 mL) and heated at 80 °C for 2 h. The reaction mixture was concentrated to remove the EtOH. The resulting mixture was treated with ice and basified with 2 N NaOH to pH∼10 and extracted with EtOAc (2 x 10 mL). The extracts were dried, evaporated and purified by ISCO, chromatograph through a REDISEP™ pre-packed scilica gel column (12 g), eluting with a gradient of 0% to 5% MeOH (with 2 M NH3) in DCM to give 3,5-dichloro-4-(((2R)-4-isopropylpyrrolidin-2-yl)methyl)pyridine (102 mg, 0.373 mmol, 36.3% yield) as an orange oil. 1H NMR (400 MHz, DMSO-d6) δ 8.56 (s, 2H), 3.35-3.51 (m, 1H), 2.84-3.08 (m, 3H), 2.35-2.44 (m, 1H), 1.80-1.93 (m, 1H), 1.55-1.69 (m, 1H), 1.31-1.49 (m, 2H), 1.02-1.17 (m, 1H), 0.85 (t, J=6.7 Hz, 6H). m/z (ESI, +ve) 273 (M+H).
    • [Reference example B52] (R)-3,5-dichloro-4-((4,4-diallylpyrrolidin-2-yl)methyl)pyridine
  • Figure imgb0245
    • Step 1: (R)-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one
  • To a stirred suspension of (R)-(-)-5-(hydroxymethyl)-2-pyrrolidinone (2.20 g, 19.11 mmol) and p-toluenesulfonic acid (0.018 g, 0.096 mmol) in toluene (54.6 ml), 2,2-dimethoxypropane (7.02 ml, 57.3 mmol) was added and the reaction was refluxed for 2 h. The reaction was equipped with a Dean-Stark then 2,2-dimethoxypropane (7.02 ml, 57.3 mmol) was added and the reaction was refluxed overnight. Solvent was evaporated to afford (R)-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (3.04 g, 19.59 mmol, 103% yield) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 4.27 (tt, J=6.01, 9.00 Hz, 1H), 4.09 (dd, J=5.65, 8.24 Hz, 1H), 3.43-3.50 (m, 1H), 2.81 (ddd, J=8.53, 12.19, 16.65 Hz, 1H), 2.55 (ddd, J=1.01, 9.15, 16.64 Hz, 1H), 2.13-2.23 (m, 1H), 1.72-1.80 (m, 1H), 1.66-1.72 (m, 3H), 1.48 (s, 3H).
    • Step 2: (R)-6,6-diallyl-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one
  • To a solution of (R)-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (2.55 g, 16.43 mmol) in THF (54.8 ml) cooled to -78 °C, was added lithium diisopropylamide (14.79 ml, 29.6 mmol) solution. The solution was stirred at this temperature for 1 h before adding allyl bromide (2.133 ml, 24.65 mmol). The reaction mixture was warmed to rt (1 h) then cooled to -78 °C prior addition of lithium diisopropylamide (14.79 ml, 29.6 mmol). The mixture was stirred at -78 °C for 1 h before adding allyl bromide (2.133 ml, 24.65 mmol). The mixture was slowly warm to rt and stirred overnight.The reaction was quenched with sat. NH4Cl and extracted with EtOAc. The combined extracts were washed with brine, dried and concentrated. The crude material was absorbed onto a plug of silica gel and purified by chromatography through a REDISEP™ pre-packed silica gel column (80 g), eluting with a gradient of 0% to 25% EtOAc in hexane, to provide (R)-6,6-diallyl-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (3.31 g, 14.07 mmol, 86% yield) as light-yellow, oil. 1H NMR (400 MHz, CDCl3) δ 5.66-5.90 (m, 2H), 5.06-5.19 (m, 4H), 4.01-4.11 (m, 2H), 3.29-3.38 (m, 1H), 2.32-2.48 (m, 2H), 2.20-2.29 (m, 1H), 2.12 (dd, J=8.97,13.79 Hz, 1H), 1.86-1.98 (m, 1H), 1.73-1.84 (m, 1H), 1.65 (s, 3H), 1.46 (s, 3H).
    • Step 3: (R)-3,3-diallyl-5-(hydroxymethyl)pyrrolidin-2-one
  • To a solution of (R)-6,6-diallyl-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (0.75 g, 3.19 mmol) in MeOH (12 ml) was added p-toluenesulfonic acid monohydrate (0.061 g, 0.319 mmol). The resulting mixture was heated at reflux for 2 h. TLC showed complete conversion. Solvent was evaporated and the crude material was absorbed onto a plug of silica gel and purified by chromatography through a REDISEP™ pre-packed silica gel column (12 g), eluting with a gradient of 0% to 6% MeOH in DCM, to provide (R)-3,3-diallyl-5-(hydroxymethyl)pyriolidin-2-one (0.62 g, 3.18 mmol, 100% yield) as white oil. 1H NMR (400 MHz, CDCl3) δ 6.68 (br. s., 1H), 5.67-5.86 (m, 2H), 5.06-5.20 (m, 4H), 3.62-3.74 (m, 2H), 3.36-3.45 (m, 1H), 2.37 (ddd, J=6.45, 11.86, 13.15 Hz, 2H), 2.19 (ddd, J=4.79, 8.40, 13.45 Hz, 2H), 1.99 (dd, J=7.72, 13.37 Hz, 1H), 1.69 (dd, J=7.44, 13.40 Hz, 1H).
    • Step 4: (R)-(4,4-diallylpyrrolidin-2-yl)methanol
  • To a solution of (R)-3,3-diallyl-5-(hydroxymethyl)pyrrolidin-2-one (0.43 g, 2.202 mmol) in THF (5.51 ml) cooled to 0 °C, lithium aluminum hydride, 1.0 M solution in THF (2.86 ml, 2.86 mmol) was added. The mixture was stirred at room temperature overnight. Extra lithium aluminum hydride, 1.0 M solution in THF (2.86 ml, 2.86 mmol) was added and it was refluxed for 6 h. More lithium aluminum hydride, 1.0 M solution in THF (2.86 ml, 2.86 mmol) was added and the mixture was refluxed overnight. The reaction mixture was cooled to 0 °C prior to addition of aq. Rochelle's salt into the mixture slowly. The resulting slurry solution was extracted with EtOAc (10 mL). The combined extracts were washed with brine, dried and concentrated to afford (R)-(4,4-diallylpyrrolidin-2-yl)methanol (0.34 g, 1.876 mmol, 85% yield) as colorless oil.
    1H NMR (400 MHz, CDCl3) δ 5.72-5.88 (m, 2H), 5.00-5.17 (m, 4H), 3.49-3.59 (m, 1H), 3.30-3.46 (m, 2H), 2.79 (d, J=11.30 Hz, 1H), 2.67 (d, J=11.35 Hz, 1H), 2.08-2.19 (m, 4H), 1.72 (dd, J=6.97, 13.04 Hz, 1H), 1.22-1.39 (m, 1H).
    • Step 5: (R)-5,5-diallyltetrahydro-3H-pyrrolo[1,2-c][1,2,3]oxathiazole 1,1-dioxide
  • A solution of triethylamine (2.460 ml, 17.65 mmol) and (R)-(4,4-diallylpyrrolidin-2-yl)methanol (1.60 g, 8.83 mmol) in DCM (44.1 ml) was cooled to -78 °C. To this mixture was added sulfuryl chloride (0.859 ml, 10.59 mmol) in DCM (44 mL) dropwise in 1h. The reaction was maintained at this temperature for 3 h, then allowed to warm to room temperature and stirred overnight. The mixture was washed with aq. 1N HCl (30 ml x 2), brine (30 ml), dried, filtered and concentrated. The crude material was absorbed onto a plug of silica gel and purified by chromatography through a REDISEP™ pre-packed silica gel column (40 g), eluting with a gradient of 0% to 30% EtOAc in hexane, to provide (R)-5,5-diallyltetrahydro-3H-pyrrolo[1,2-c][1,2,3]oxathiazole 1,1-dioxide (0.66 g, 2.71 mmol, 30.7% yield) as light-yellow oil. 1H NMR (400 MHz, CDCl3) δ 5.71-5.86 (m, 2H), 5.10-5.20 (m, 4H), 4.57 (dd, J=6.63, 8.76 Hz, 1H), 4.24-4.36 (m, 1H), 4.19 (dd, J=4.66, 8.76 Hz, 1H), 3.21-3.32 (m, 2H), 2.19-2.29 (m, 4H), 2.03-2.18 (m, 1H), 1.57-1.63 (m, 1H).
    • Step 6: (R)-3,5-dichloro-4-((4,4-diallylpyrrolidin-2-yl)methyl)pyridine
  • To a solution of 3,5-dichloropyridine (1.069 g, 7.22 mmol) in THF (12.04 ml) at -78 °C was added lithium diisopropylamide, 2.0 M heptane/THF/ethylbenzene (4.57 ml, 9.15 mmol) dropwise. After stirring for 1 h, a solution of (R)-5,5-diallyltetrahydro-3H-pyrrolo[1,2-c][1,2,3]oxathiazole 1,1-dioxide (1.172 g, 4.82 mmol) in THF (10 mL) was aded dropwise at -78 °C and the mixture was allowed to warm to room temperature with stirring for 6 h. After evaporatin of the solvent, the resulting beige foam was treated with hot 2 N HCl (12 ml) and EtOH (12 ml) overnight. The mixture was cooled to room temperature and basified with 1 N NaOH and extracted with EtOAc. The extracts were dried, evaporated and purified by chromatography through a REDISEP™ pre-packed silica gel column (40 g), eluting with a gradient of 1% to 6% MeOH in DCM, to provide (R)-3,5-dichloro-4-((4,4-diallylpyrrolidin-2-yl)methyl)pyridine (0.70 g, 2.249 mmol, 46.7% yield) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.46 (s, 2H), 5.66-5.86 (m, 2H), 5.03-5.18 (m, 4H), 3.59-3.72 (m, 1H), 3.25 (d, J=7.15 Hz, 1H), 2.97 (d, J=11.51 Hz, 1H), 2.82 (d, J=11.51 Hz, 1H), 2.10-2.28 (m, 4H), 1.78 (dd, J=13.06, 6.95 Hz, 1H), 1.51-1.61 (m, 1H); LCMS (ESI) m/z 311.0 (M+H)+.
    • [Reference example B53] (R)-3-((3,5-dichloropyridin-4-yl)methyl)-2-azaspiro[4.4]non-7-ene
  • Figure imgb0246
  • A mixture (R)-3,5-dichloro-4-((4,4-diallylpyrrolidin-2-yl)methyl)pyridine (3.1 g, 9.96 mmol) and grubbs catalyst 2nd generation (1.691 g, 1.992 mmol) in DCM (996 ml). The mixture was stirreded at 40 °C for 20 h. The mixture was concentrated and absorbed onto a plug of silica gel and purified by chromatography through a Biotage column (100 g), eluting with a gradient of 1% to 50% 1 M NH3·MeOH in DCM, to provide (R)-3-((3,5-dichloropyridin-4-yl)methyl)-2-azaspiro[4.4]non-7-ene (1.0 g, 3.53 mmol, 35.5% yield) as dark-brown oil. 1H NMR (400 MHz, CDCl3) δ 8.45 (s, 2H), 5.61-5.72 (m, 2H), 3.69-3.82 (m, 1H), 3.25 (br. s., 2H), 3.05 (d, J=10.47 Hz, 1H), 2.89-2.97 (m, 1H), 2.47 (br. s., 2H), 2.23-2.37 (m, 2H), 1.93 (dd, J=6.84, 12.59 Hz, 1H), 1.69-1.82 (m, 1H); LCMS (ESI) m/z 283.0 (M+H)+.
    • [Reference example B54] (R)-3-((3,5-dichloropyridin-4-yl)methyl)-2-azaspiro[4.4]non-7-ene
  • Figure imgb0247
  • A mixture of (R)-3-((3,5-dichloropyridin-4-yl)methyl)-2-azaspiro[4.4]non-7-ene (0.090 g, 0.318 mmol) and palladium 10 wt. % on activated carbon (0.034 g, 0.032 mmol) in EtOAc (4 ml) was stirred under hydrogen balloon at room temperature for 3 h. Starting material was converted to the desired project with mono-chloro product (∼4:1). The crude material was absorbed onto a plug of silica gel and purified by chromatography through a REDISEP™ pre-packed silica gel column (12 g), eluting with a gradient of 5% to 50% 1 M NH3·MeOH in DCM, to provide (R)-3-((3,5-dichloropyridin-4-yl)methyl)-2-azaspiro[4.4]nonane (0.053 g, 0.186 mmol, 58.5% yield) as a brown oil. 1H NMR (400 MHz, CDCl3) δ 8.42-8.50 (m, 2H), 3.63-3.83 (m, 1H), 3.28 (br. s., 2H), 3.02 (d, J=10.37 Hz, 1H), 2.87 (br. s., 1H), 1.73-1.83 (m, 1H), 1.54-1.72 (m, 9H), 1.42-1.53 (m, 1H); LCMS (ESI) m/z 285.0 (M+H)+.
  • The following secondary amines were prepared using similar procedure in reference examples disclibed above.
    Figure imgb0248
    Figure imgb0249
    Figure imgb0250
    Figure imgb0251
    Figure imgb0252
    Figure imgb0253
    Figure imgb0254
    reference example structure reference example structure
    B27
    Figure imgb0255
         		B34
    Figure imgb0256
    B28
    Figure imgb0257
         		B35
    Figure imgb0258
    B29
    Figure imgb0259
         		B36
    Figure imgb0260
    B30
    Figure imgb0261
         		B37
    Figure imgb0262
    B31
    Figure imgb0263
         		B38
    Figure imgb0264
    B32
    Figure imgb0265
         		B39
    Figure imgb0266
    B33
    Figure imgb0267
         		B40
    Figure imgb0268
    B41
    Figure imgb0269
         		B48
    Figure imgb0270
    B42
    Figure imgb0271
         		B49
    Figure imgb0272
    B43
    Figure imgb0273
         		B50
    Figure imgb0274
    B44
    Figure imgb0275
         		B51
    Figure imgb0276
    B45
    Figure imgb0277
         		B52
    Figure imgb0278
    B46
    Figure imgb0279
         		B53
    Figure imgb0280
    B47
    Figure imgb0281
         		B54
    Figure imgb0282
    B55
    Figure imgb0283
         		B62
    Figure imgb0284
    B56
    Figure imgb0285
         		863
    Figure imgb0286
    B57
    Figure imgb0287
         		B64
    Figure imgb0288
    B58
    Figure imgb0289
         		B65
    Figure imgb0290
    B59
    Figure imgb0291
         		B66
    Figure imgb0292
    B60
    Figure imgb0293
         		B67
    Figure imgb0294
    B61
    Figure imgb0295
         		B68
    Figure imgb0296
    B69
    Figure imgb0297
    B70
    Figure imgb0298
    • [Reference example C1]
  • Figure imgb0299
    • N-(2-(2,6-dichloro-4-fluorophenyl)-2-((triethylsilyl)oxy)ethyl)-4,4-dimethylcyclohexanami ne (C1)
  • To a stirred solution of compound A31-3 (107 mg, 0.32 mmol) in DCM (2 mL) were added 4,4-dimethylcyclohexanone (40 mg, 0.32 mmol), NaBH(OAc)3 (83 mg, 0.38 mmol) and AcOH (101 mg, 0.47 mmol). The resulting mixture was stirred at room temperature for 17 h, then quenched with 0.5 M NaOH aq. (10 mL) and extracted with EtOAc (2 × 20 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO4 and concentrated under reduced pressure. The residue was purified by silicagel column chromatography (eluent: 5% to 30% EtOAc/hexane) to yield compound C1 (122 mg, 86%) as colorless syrup.
    • [Reference example C22]
  • Figure imgb0300
    • Step 1: (1S,3R,4R,6R)-4-bromo-3,7,7-trimethylbicyclo[4.1.0]heptan-3-ol (C22-1)
  • A suspension of (+)-3-carene (4.09 g, 30 mmol), CaCO3 (3.90 g, 39 mmol) and NBS (6.94 g, 39 mmol) in water (15 mL) and 1,4-dioxane (30 mL) was stirred at room temperature for 1 h. The mixture was diluted with water (75 mL) and extracted with Et2O (100 mL). The organic layer was washed with water (3 x 50 mL), saturated Na2S2O3 aq. (50 mL), dried over MgSO4 and concentrated under reduced pressure. The residue was purified by silicagel chromatography (10% EtOAc/hexane as eluent) to provide compound C22-1 (4.53 g, 65%) as a white solid.
    • Step 2: 1-((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)ethanone (C22-2)
  • To a solution of compound C22-1 (4.53 g, 19.4 mmol) in water (9 mL) and 1,4-dioxane (127 mL) was added silver(I) oxide (12.16g, 52.5 mmol) and stirred at room temperature for 22 h. The mixture was filtered through a pad of celite and the filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with Et2O. The organic layer was washed with water, dried over MgSO4 and concentrated under reduced pressure to provide compound C22-2 (2.86 g, 99%) as a pale yellow oil. The crude product was used for next step without purification.
    • Step 3: (1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl acetate (C22-3)
  • To a solution of compound C22-2 (2.86 g, 18.8 mmol) in DCM (57 mL) was added m-chloroperoxybenzoic acid (6.02 g, 24.4 mmol) at 0 °C and stirred at room temperature for 15 h. The reaction mixture was quenched with 0.2 M aqueous NaOH and extracted with DCM (80 mL and 2 x 50 mL). The collected organic layers were washed with saturated NaHCO3 aq., water and brine, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by silicagel chromatography (10% EtOAc/hexane as eluent) to provide compound C22-3 (2.35 g, 74%) as a colorless gum.
    • Step 4: (1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-ol (C22-4)
  • To a solution of compound C22-3 (2.35 g, 14.0 mmol) in EtOH/water (63 mL, 2:1) was added a solution of LiOH aq. (4 M, 21mL, 84 mmol). The mixture was stirred at room temperature for 2.5 h. The mixture was diluted with water and extracted with EtOAc (2 x 80 mL). The combined organic layers were washed with brine, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by silicagel chromatography (35% EtOAc/hexane as eluent) to provide compound C22-4 (1.54 g, 88%) as a colorless oil.
    • Step 5: (1R,5S)- 6,6-dimethylbicyclo[3.1.0]hexan-3-one (C22-5)
  • Compound C22-4 (240 mg, 1.9 mmol) was dissolved in DCM (5 mL) and Dess-Martin periodinane (968 mg, 2.28 mmol) was added. The reaction mixture was stirred for 3 h. The reaction mixture was quenched with 5% Na2S2O3 and extracted with Et2O (30 mL). The organic layer was washed with saturated NaHCO3 aq. twice, dried over MgSO4 and concentrated under reduced pressure to provide compound C22-5 (261 mg, quant.) as a colorless gum. The crude product was used for next step without purification.
    • Step 6: (1R,3r,5S)-N-(2-(2,6-dichloro-4-fluorophenyl)-2-((triethylsilyl)oxy)ethyl)-6,6-dimethylbic yclo[3.1.0]hexan-3-amine (C22)
  • Compound C22 (75 mg, 74%) was obtained from the reaction of compound A31-3 (77 mg, 0.228 mmol), compound C22-5 (31 mg, 0.250 mmol), NaBH(OAc)3 (72 mg, 0.341 mmol) and AcOH (0.013 mL, 0.228 mmol) in DCM (2 mL) using a similar procedure to that described in reference example A31, step 4. NMR (CDCl3, 400 MHz): δ 7.04 (d, J = 8.3 Hz, 2H), 5.48 (dd, J = 9.2, J = 4.5 Hz, 1H), 3.60-3.51 (m, 1H), 3.19 (dd, J = 12.2, J = 9.2 Hz, 1H), 2.65 (dd, J = 12.2, J = 4.5 Hz, 1H), 2.17-2.07 (m, 2H), 1.06-0.97 (m, 10H), 0.87 (t, J = 8.0 Hz, 9H), 0.58-0.47 (m, 6H).
    • [Reference example C45]
  • Figure imgb0301
    • Step 1: 1-(2,6-dichloro-4-methylphenyl)-2-nitroethanol (C45-1)
  • Compound C45-1 (1.25 g, 96%) was obtained as a colorless gum from the reaction of 2,6-dichloro-4-methylbenzaldehyde (1.0 g, 5.3 mmol) and K2CO3 (0.28 g, 2.0 mmol) in CH3NO2 (10 mL) using a similar procedure to that described in example A1, step 2. Step 2: (1-(2,6-dichloro-4-methylphenyl)-2-nitroethoxy)triethylsilane (C45-2)
  • Compound C45-2 (1.8 g, crude) was obtained as colorless gum from the reaction of compound C45-1 (1.25 g, 1.0 mmol), TES-Cl (1.0 mL, 1.2 mmol) and imidazole (1.2 g, 3.0 mmol) in DMF (10 mL) using a similar procedure to that described in reference example A1, step 3.
    • Step 3: 2-(2,6-dichloro-4-methylphenyl)-2-((triethylsilyl)oxy)ethanamine (C45-3)
  • Compound C45-3 (1.56 g, 94%) was obtained as a brown color oil from the reaction of compound C45-2 (1.8 g, 4.9 mmol), Fe (2.76 g, 49.3 mmol) and NH4Cl (2.62 g, 49.3 mmol) in EtOH/water (4:1, 20 mL) using a similar procedure to that described in reference example A31, step 3.
    • Step 4: (1R,3r,5S)-N-(2-(2,6-dichloro-4-methylphenyl)-2-((triethylsilyl)oxy)ethyl)-6,6-dimethylbi cyclo[3.1.0]hexan-3-amine (C45)
  • Compound C45 (75 mg, 44%) was obtained from the reaction of C45-3 (130 mg, 0.389 mmol), ketone C22-5 (49 mg, 0.394 mmol), NaBH(OAc)3 (125 mg, 0.590 mmol) and AcOH (0.023 mL, 0.402 mmol) in DCM (3 mL) using a similar procedure to that described in reference example A31, step 4. 1H NMR (CDCl3, 400 MHz) δ: 7.07 (2H, s), 5.49 (1H, dd, J= 9.3, 4.4 Hz), 3.61-3.52 (1H, m), 3.20 (1H, dd, J = 12.2, 9.3 Hz), 2.64 (1H, dd, J= 12.2, 4.4 Hz), 2.27 (3H, s), 2.17-2.08 (2H, m), 1.08-0.97 (10H, m), 0.86 (9H, t, J = 7.8 Hz), 0.56-0.49 (6H, m).
    • [Reference example C46]
  • Figure imgb0302
    • Step 1: 1-(2,6-dichlorophenyl)-2-nitroethanol (C46-1)
  • Compound C46-1 (0.67 g, crude) was obtained as a yellow gum from the reaction of 2,6-dichlorobenzaldehyde (0.5 g, 2.85 mmol) and K2CO3 (0.15 g, 1.08 mmol) in CH3NO2 (10 mL) using a similar procedure to that described in reference example A1, step 2.
    • Step 2: (1-(2,6-dichlorophenyl)-2-nitroethoxy)triethylsilane (C46-2)
  • Compound C46-2 (0.95 g, 52%) was obtained as a colorless oil from the reaction of compound C46-1 (0.67 g, 2.83 mmol), TES-Cl (0.57 mL, 3.4 mmol) and imidazole (0.58 g, 8.5 mmol) in DMF (10 mL) using a similar procedure to that described in reference example A1, step 3.
    • Step 3: 2-(2,6-dichlorophenyl)-2-((triethylsilyl)oxy)ethanamine (C46-3)
  • Compound C46-3 (0.86 g, crude) was obtained as a colorless oil from the reaction of compound C46-2 (0.95 g, 2.84 mmol), Fe (1.59 g, 28.4 mmol) and NH4Cl (1.51 g, 28.4 mmol) in EtOH/water (4:1, 20 mL) using a similar procedure to that described in reference example A31, step 3.
    • Stepp 4: (1R,3r,5S)-N-(2-(2,6-dichlorophenyl)-2-((triethylsilyl)oxy)ethyl)-6,6-dimethylbicyclo[3.1. 0]hexan-3-amine (C46)
  • Compound C46 (94 mg, 78%) was obtained from the reaction of compound C46-3 (90 mg, 0.281 mmol), ketone C22-5 (42 mg, 0.337 mmol), NaBH(OAc)3 (89 mg, 0.421 mmol) and AcOH (0.016 mL, 0.281 mmol) in DCM (2 mL) using a similar procedure to that described in reference example A31, step 4. 1H NMR (CDCl3, 400 MHz) δ: 7.30-7.26 (2H, m), 7.09 (1H, t, J = 7.8 Hz), 5.53 (1H, dd, J = 9.3, 4.4 Hz), 3.62-3.53 (1H, m), 3.23 (1H, dd, J = 12.2, 9.3 Hz), 2.66 (1H, dd, J = 12.2, 4.4 Hz), 2.17-2.10 (2H, m), 1.04-0.99 (8H; m), 0.90-0.84 (11H, m), 0.60-0.45 (6H, m).
    • [Reference Example C80] (1R,3r,5S)-N-(2-(2,6-dichloro-3-fluorophenyl)-2-((triethylsilyl)oxy)ethyl)-6,6-dimethylbic yclo[3.1.0]hexan-3-amine
  • Figure imgb0303
    • Step 1: 1-(2,6-dichloro-3-fluorophenyl)-2-nitroethanol
  • In a 3-necked 100 mL RBF, freshly ground potassium carbonate (0.486 g, 3.51 mmol) was added to a solution of-2,6-dichloro-3-fluorobenzaldehyde (2.26 g, 11.71 mmol) in THF (12 ml) at room temperature. Then nitromethane (8.88 ml, 164 mmol) was added. The mixture was stirred at room temperature for 2 h. The mixture was quenched with water (15 mL) and extracted with EtOAc (3x15 mL). The combined organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to give 1-(2,6-dichloro-3-fluorophenyl)-2-nitroethanol (2.97 g, 11.69 mmol, 100% yield) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.36 (dd, J=8.9, 4.8 Hz, 1 H), 7.17 (dd, J=8.9, 7.8 Hz, 1 H), 6.27 (m, 1 H), 5.19 (dd, J=13.3, 10.1 Hz, 1 H), 4.57 (dd, J=13.3, 3.4 Hz, 1 H), 3.20 (br. s., 1 H).
    • Step 2: 2-(2,6-dichloro-3-fluorophenyl)-2-((triethylsilyl)oxy)ethanamine
  • To a 100 mL three-necked RBF were added (1-(2,6-dichloro-3-fluorophenyl)-2-nitroethoxy)triethylsilane (3.64 g, 9.88 mmol) in EtOH (16 ml) and water (4 ml) at room temperature followed by addition of iron (5.52 g, 99 mmol) and ammonium chloride (5.29 g, 99 mmol). The flask was purged with nitrogen and was heated to 60 °C under nitrogen for 3 h. The mixture was cooled to room temperature, diluted with 40 mL of MeOH, sonicated for 10 min. Then the solution was decanted through a pad of celite. This process was repeated for three times. The filtrate was concentrated to ∼30 mL and diluted with EtOAc (120 mL). The solid was filtered off and discarded. The filtrate was concentrated under reduced pressure. It was diluted with 50 mL of EtOAc, washed with water, brine, dried over anhydrous MgSO4, and concentrated to give 2-(2,6-dichloro-3-fluorophenyl)-2-((triethylsilyl)oxy)ethanamine hydrochloride as an off-white solid. The HCl salt was dissolved with 50 mL of DCM. The suspension was basicified w/ satd' aq NaHCO3 (pH=9). The organic layer was separated, washed with brine, dried over anhydrous MgSO4, and concentrated to give 2-(2,6-dichloro-3-fluorophenyl)-2-((triethylsilyl)oxy)ethanamine (2.73 g, 8.07 mmol, 82% yield) as a brown oil. 1H NMR (400 MHz, CDCl3) δ 7.23-7.29 (m, 1H), 6.99-7.06 (m, 1H), 5.35 (dd, J=8.6, 4.9 Hz, 1H), 3.29 (dd, J=13.1, 8.7 Hz, 1H), 2.92 (dd, J=13.2, 4.9 Hz, 1H), 0.83-0.93 (m, 9H), 0.46-0.61 (m, 6H); LCMS: 338.2 [M+H]+.
    • Step 3: (1R,3r,5S)-N-(2-(2,6-dichloro-3-fluorophenyl)-2-((triethylsilyl)oxy)ethyl)-6,6-dimethylbic yclo[3.1.0]hexan-3-amine
  • (1R,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-one (0.181, g, 1.457 mmol) and 2-(2,6-dichloro-3-fluorophenyl)-2-((triethylsilyl)oxy)ethanamine (0.493 g, 1.457 mmol) were combined in dry EtOH (7 ml) under nitrogen at room temperature and tetraisopropoxytitanium (0.86 ml, 2.91 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. Then, NaBH4 (0.083 g, 2.186 mmol) was added. After 2 h, the reaction solution was quenched with saturated aqueous ammonium chloride (3 mL) and then basified with saturated NaHCO3. The EtOH was then removed under reduced pressure, and the solution was diluted with water EtOAc. Celite was added and the solution was vigorously mixed for 15 min. The solution was then filtered through a pad of celite. The aqueous layer was extracted with EtOAc and the combined organic layers were washed with brine and dried over anhydrous Na2SO4, filtered and concentrated to afford a yellow oil. The crude material was purified by column chromatography (silica gel, eluent : 0% to 10% EtOAc / heptane) to provide (1R,3r,5S)-N-(2-(2,6-dichloro-3-fluorophenyl)-2-((triethylsilyl)oxy)ethyl)-6,6-dimethylbic yclo[3.1.0]hexan-3-amine (414 mg, 0.927 mmol, 63.6% yield) as colorless oil.
    1H NMR (400 MHz, CDCl3) δ 7.24 (dd, J=8.9, 4.9 Hz, 1H), 6.98-7.04 (m, 1H), 5.54 (br. s., 1H), 3.59 (t, J=8.8 Hz, 1H), 3.18-3.31 (m, 1H), 2.71 (d, J=12.3 Hz, 1H), 2.15 (d, J=8.1 Hz, 1H), 1.22-1.34 (m, 4H), 1.06 (d, J=5.8 Hz, 2H), 0.99 (d, J=5.0 Hz, 6H), 0.84-0.93 (m, 9H), 0.47-0.59 (m, 6 H); LCMS: 446.2 [M+H]+.
  • The following secondary amines were prepared using similar procedure in reference examples disclibed above.
    Figure imgb0304
    Figure imgb0305
    Figure imgb0306
    Figure imgb0307
    Figure imgb0308
    Figure imgb0309
    Figure imgb0310
    Figure imgb0311
    Figure imgb0312
    Figure imgb0313
    Figure imgb0314
    Figure imgb0315
    Figure imgb0316
    Figure imgb0317
    Figure imgb0318
    Figure imgb0319
    Figure imgb0320
    Figure imgb0321
    Figure imgb0322
    Figure imgb0323
    Figure imgb0324
    Figure imgb0325
    Figure imgb0326
    reference example structure reference example structure
    C80
    Figure imgb0327
         		C87
    Figure imgb0328
    C81
    Figure imgb0329
         		C88
    Figure imgb0330
    C82
    Figure imgb0331
         		C89
    Figure imgb0332
    C83
    Figure imgb0333
         		C90
    Figure imgb0334
    C84
    Figure imgb0335
    C85
    Figure imgb0336
    C86
    Figure imgb0337
    • [Reference example D1]
  • Figure imgb0338
    Figure imgb0339
    Figure imgb0340
    • Step 1: tert-butyl 2-(trans4-(ethoxycarbonyl)cyclohexyl)hydrazinecarboxylate (D1-1)
  • To a solution of 4-cyclohexanonecarboxylic acid ethyl ester (5.0 g, 29.0 mmol) and tert-butyl carbazate (3.9 g, 29.4 mmol) in dichlorometane (250 mL) and AcOH (4 mL) was added NaBH(OAc)3 (18.7 g, 88.0 mmol) gradually at 0 °C. After addition, the mixture was stirred at the same temperature for 3 h, then allowed to warm to room temperature and stirred for 20 h. The reaction mixture was poured into saturated aqueous Na2CO3 solution and extracted with DCM. The DCM extracts were washed with brine x 2 and dried over MgSO4. After the solvent was removed, the residue was purified by column chromatography on silica gel to give compound D1-1 (3.0 g, 36%) as a white solid. Step 2: ethyl trans-4-hydrazinylcyclohexanecarboxylate hydrochloride (D1-2)
  • To a solution of compound D1-1 in EtOH (25 mL) was added 4 M HCl (in THF, 25 mL, 100 mmol) and the mixture was stirred at room temperature for 16 h. Drying the solution under high vacuum yielded compound D1-2 (2.8 g, quant.) as a white solid.
    • Step 3: benzyl 4,4,4-trifluoro-3-oxobutanoate (D1-3)
  • To a solution of ethyl 4,4,4-trifluoro-3-oxobutanoate (17.0 g, 92.3 mmol) in toluene (80 mL) was added benzylalcohol (11.4 mL, 109.6 mmol). The mixture was stirred at 120 °C by using Dean-Stark for 5 h, and then the reaction mixture was cooled to 0 °C. Drying the solution under high vacuum yielded compound D1-3 (21.2 g, quant.) as a colorless oil, which was used to the next step without further purification. Step 4: benzyl 2-((dimethylamino)methylene)-4,4,4-trifluoro-3-oxobutanoate (D1-4)
  • To a solution of compound D1-3 (21.2 g, 92.3 mmol) and AcOH (10.6 mL, 184.7 mmol) in THF (100 mL) was added N,N-dimethylformamide diisopropyl acetal (38.6 mL, 184.7 mmol) dropwise over 25 min, and the mixture was stirred at room temperature for 16 h. The reaction mixture was poured into saturated aqueous NaHCO3 solution and extracted with EtOAc. The organic layer was washed with brine x 2 and dried over MgSO4. After the solvent was removed, the residue was purified by column chromatography on silica gel to give compound D1-4 (17.1 g, 91%) as a yellow oil.
    • Step 5: benzyl 1-(trans-4-(ethoxycarbonyl)cyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (D1-5)
  • To a solution of compound D1-2 (2.8 g, 10.5 mmol) in EtOH (50 mL) were added DIPEA(3.2mL, 12.6 mmol) and compound D1-4 (3.3 g, 11.0 mmol) and the mixture was stirred at room temperature for 1.5 h. The reaction was quenched by adding brine and extracted with EtOAc. The organic layer was washed with brine (x 2) and dried over MgSO4. After the solvent was removed, the residue was purified by column chromatography on silica gel to give compound D1-5 (3.5 g, 78%) as a colorless oil.
    • Step 6: 1-(trans-4-(ethoxycarbonyl)cyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid (D1)
  • Compound D1-5 (3.5 g, 8.2 mmol) and 10% Pd on carbon (300 mg) in EtOAc (40 mL) was hydrogenated in H2 atmosphere (1 atm) at room temperature for 25 h. The reaction mixture was filtered through a pad of celite and washed with EtOAc. Drying the solution under high vacuum yielded compound D1 (2.6 g, 95%) as a white solid.
    • [Reference example D2]
  • Figure imgb0341
    • Step 1: ethyl-1,4-dioxaspiro[4.5]decane-8-carboxylate (D2-1)
  • The mixture of ethyl-4-oxocyclohexanecarboxylate (10 g, 58.75 mmol), ethylene glycol (4.97 ml, 88.13 mmol) and p-TsOH (cat.) in toluene (80 mL) was refluxed for 16 h in a flask equipped with Dean-Stark adapter. Upon reaction completion, the mixture was cooled to room temperature and solvent was removed under reduced pressure to provide compound D2-1 (9.6 g, crude) as brown oil. The crude product was used in the next step without purification. 1H NMR (CDCl3, 400 MHz): δ 4.15-4.09 (m, 2H), 3.95 (s, 4H), 2.36-2.03 (m, 1H), 1.97-1.91 (m, 2H), 1.85-1.75 (m, 4H), 1.66-1.52 (m, 2H), 1.26-1.27 (m, 3H).
    • Step 2: ethyl-8-methyl-1,4-dioxaspiro[4.5]decane-8-carboxylate (D2-2)
  • To a stirred solution of compound D2-1 (5.1 g, 23.83 mmol) in THF (15 mL) was added LDA (2.0 M in THF/heptane/ethylbenzene, 17.8 mL, 35.74 mmol) dropwise at - 78 °C over a period of 15 min. The mixture was stirred at -78 °C for 30 min. A solution of iodomethane (2.23 mL; 35.74 mmol) in THF (1 mL) was added to the mixture dropwise, and the whole was stirred at -78 °C for 30 min. The mixture was allowed to warm to room temperature and stirred for 16 h. The reaction mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 2% EtOAc/hexane as eluent) to provide compound D2-2 (2.7 g, 50%) as colorless oil. 1H NMR (CDCl3, 400 MHz): δ 4.14 (q, J = 7.2 Hz, 2H), 3.93 (s, 4H), 2.15-2.10 (m, 2H), 1.65-1.60 (m, 4H), 1.54-1.49 (m, 2H), 1.25 (t, J = 7.2 Hz, 3H), 1.18 (s, 3H).
    • Step 3: ethyl-1-methyl-4-oxocyclohexanecarboxylate (D2-3)
  • To a solution of compound D2-2 (8.4 g, 36.84 mmol) in acetone (100 mL) was added HCl (3 M in water, 50 mL) dropwise at room temperature, and the whole was stirred at room temperature for 18 h. The reaction mixture was quenched with water (100 mL) and extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to provide compound D2-3 (6.3 g) as a light yellow oil. The crude product was used in the next step without purification. 1H NMR (CDCl3, 400 MHz): δ 4.22 (q, J = 7.0 Hz, 2H), 2.47-2.38 (m, 4H), 2.34-2.30 (m, 2H), 1.72-1.64 (m, 2H), 1.31-1.29 (m, 6H).
    • Step 4: tert-butyl-2-(trans-4-(ethoxycarbonyl)-4-methylcyclohexyl)hydrazinecarboxylate (D2-4)
  • To a mixture of compound D2-3 (30 g, 163.0 mmol) and tert-butylhydrazine carboxylate (21.5 g, 163.0 mmol) in isopropanol (200 mL) was added and AcOH (catalytic amount) and the mixture was stirred at room temperature for 2 h. Upon completion of imine formation (monitored by TLC), the mixture was cooled to 0 °C, and solid NaBH3CN (30.7 g, 489.1 mmol) was added in portions. The pH of reaction mixture was adjusted to 5-6 using AcOH, and stirring continued for 3 h at room temperature. The mixture was quenched with water (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 30% EtOAc/hexane) (Note: Polar spot was the trans-isomer) to provide compound D2-4 (12.0 g, 34%) as a white solid.
    • Step 5: ethyl trans-4-hydrazinyl-1-methylcyclohexanecarboxylate hydrochloride (D2-5)
  • To a solution of compound D2-4 (36.0 g, 120.0 mmol) in EtOH (100 mL) was added HCl (4 M in 1,4-dioxane, 350 mL) dropwise at 0 °C, and the whole was stirred at room temperature for 18 h. The solvent was removed under reduced pressure and residue was triturated with Et2O to get compound D2-5 (31.0 g, 95%) as white solid. The crude product was used in the next step without purification. 1H NMR (CDCl3, 400 MHz): δ 7.24-7.00 (brs, 4H), 4.13 (q, J = 7.2 Hz, 2H), 3.44 (brs, 1H), 2.08-2.05 (m, 2H), 1.97-1.90 (m, 2H), 1.81-1.80 (m, 4H), 1.30-1.26 (m, 6H).
    • Step 6: benzyl-1-(trans-4-(ethoxycarbonyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (D2-6)
  • To a solution of compound D2-5 (31.0 g, 113.9 mmol) in EtOH (150 mL) was added DIPEA (39.4 mL, 227.9 mmol) dropwise and the mixture was stirred at room temperature for 5 min. A solution of compound D1-4 (37.7 g, 125.3 mmol) in EtOH (10 mL) was added dropwise, and the whole was stirred at room temperature for 16 h. The reaction mixture was quenched with water (200 mL) and extracted with EtOAc (2 x 200 mL). The combined organic layer was washed with water (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 15% EtOAc/hexane as eluent) to provide compound D2-6 (20.0 g, 40%) as brown gum. 1H NMR (CDCl3, 400 MHz): δ 7.94 (s, 1H), 7.40-7.35 (m, 5H), 5.30 (s, 2H), 4.36 (m, 1H), 4.15 (q, J = 7.2 Hz, 2H), 2.24-2.19 (m, 2H), 1.88-1.87 (m, 6H), 1.3 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H).
    • Step 7: trans-4-(ethoxycarbonyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxyl ic acid (D2)
  • A mixture of compound D2-6 (20.0 g, 45.6 mmol)) and 5% Pd on carbon (10.0 g, 50% by weight) in MeOH (200 mL) was stirred under H2 atmosphere (1 atm) for 4h. The mixture was filtered through a pad of celite, washed with EtOAc (3 x 100 mL) and concentrated under reduced pressure. The residue was triturated with 10% EtOAc/hexane (2 x 25 mL) to provide compound D2 (13.0 g, 82%) as white solid. 1H NMR (CDCl3, 300 MHz): δ 8.03 (s, 1H), 4.42- 4.41 (m, 1H), 4.15 (q, J = 7.2 Hz, 2H), 2.25-2.21 (m, 2H), 1.92-1.88 (m, 6H), 1.35 (s, 3H), 1.27 (t, J = 7.0 Hz, 3H).
    • [Reference example D19]
  • Figure imgb0342
    Figure imgb0343
    Figure imgb0344
    • Step 1: 1,4-dioxaspiro[4.5]decan-8-ylmethanol (D19-1)
  • To a suspension of LiAlH4 (5.69 g, 150 mmol) in THF (100 mL) was added a solution of compound D2-1 (21.4 g, 100 mmol) in THF (100 mL) dropwise at 0 °C and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was cooled to 0 °C, quenched with water (7 mL) and 6 M NaOH (7 mL) and stirred at room temperature for 20 min. Na2SO4 (10 g) was added to the mixture, filtered over a pad of celite and washed with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (100 mL), water (100 mL) and concentrated under reduced pressure to provide compound D19-1 (17.0 g, quant) as colorless oil. The crude product was used for next step without purification.
    • Step 2: 4-(hydroxymethyl)cyclohexanone (D19-2)
  • To a stirred solution of compound D 19-1 (17.0 g, 9.88 mmol) in acetone (100 mL) was added aqueous HCl (2 M, 38 mL) and the mixture was stirred at room temperature for 18h. The solvent was removed under reduced pressure and then diluted with water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with water, dried over Na2SO4 and concentrated under reduced pressure to obtain compound D19-2 (7.5 g, 51%) as colorless gum.
    • Step 3: tert-butyl 2-(trans-4-(hydroxymethyl)cyclohexyl)hydrazinecarboxylate (D19-3)
  • A mixture of compound D19-2 (2.0 g, 15.5 mmol) and Boc-hydrzine (2.26 g, 17 mmol) in isopropanol (20 mL) was stirred at room temperature for 16 h. Na(CN)BH3 (2.92 g, 45.6 mmol) and AcOH (1 mL, cat.) were added and the mixture was stirred at room temperature for 16 h. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 50% EtOAc/hexane as eluent) to obtain compound D19-3 (820 mg, 22%) as a white semi solid.
    • Step 4: (trans-4-hydrazinylcyclohexyl)methanol hydrochloride (D19-4)
  • To a stirred mixture of compound D19-3 (1.8 g, 7.3 mmol) in dioxane (40 mL) was added HCl (20 mL, 73 mmol, 4 M in dioxane) and the mixture was stirred at room temperature for 16 h. The solvent was removed under reduced pressure, dried on high vacuum pump to provide compound D19-4 (1.7 g, crude) as an off white solid.
    • Step 5: ethyl-5-amino-1-(trans-4-(hydroxymethyl)cyclohexyl)-1H-pyrazole-4-carboxylate (D19-5)
  • To a solution of compound D 19-4 (720 mg, 3.31 mmol) in EtOH (20 mL) were added ethyl-2-cyano-3-ethoxyacrylate (448 mg, 2.65 mmol) and NaOAc (571 mg, 6.96 mmol) and the mixture was stirred at 70 °C for 18 h. The solvent was removed under reduced pressure, the residue was suspended in water (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with water, dried over Na2SO4. and concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (C18 silica gel, 30% CH3CN/water as eluent) to provide compound D19-5 (320 mg, 37%) as reddish brown solid.
    • Step 6: ethyl-5-chloro-1-(trans-4-(hydroxymethyl)cyclohexyl)-1H-pyrazole-4-carboxylate (D 19-6)
  • To a suspension of CuCl (103 mg, 1.04 mmol) in CH3CN (5 mL) was added tert-butyl nitrite (0.134 mL, 1.125 mmol) dropwise at 0 °C. A solution of compound D19-5 (200 mg, 0.749 mmol) in CH3CN (4 mL) was added dropwise to above mixture at 0 °C and stirred at the same temperature for 5 min. The mixture was stirred at room temperature for 30 min and at 70 °C for 30 min. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with water, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 40% EtOAc/hexane as eluent) to provide compound D19-6 (68 mg, 31%) as a brown semi solid.
    • Step 7: trans-4-(5-chloro-4-(ethoxycarbonyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (D19-7)
  • To a suspension of H5IO6 (159 mg, 0.698 mmol) in CH3CN was added CrO3 (0.6 mg, 0.0061 mmol) and the mixture was stirred at room temperature for 30 min. The mixture was cooled to 0 °C and a solution of compound D19-6 (100 mg, 0.349 mmol) was added dropwise. The reaction mixture was stirred at the same temperature for 30 min. The organic solvent was removed under reduced pressure, residue was suspended in water (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with water, dried over Na2SO4 and concentrated under reduced pressure to provide compound D19-7 (105 mg, quant) as an off-white solid.
    • Step 8: ethyl-1-(trans-4-(tert-butoxycarbonyl)cyclohexyl)-5-chloro-1H-pyrazole-4-carboxylate (D19-8)
  • To a mixture of compound D19-7 (105 mg, 0.35 mmol) and Boc anhydride (152 mg, 0.70 mmol) in t-BuOH (5 mL) was added DMAP (13 mg, 0.105 mmol) and the mixture was stirred at 35 °C for 16 h. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with water, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (C18 silica gel, 90% CH3CN/water as eluent) to provide compound D19-8 (70 mg, 56%) as colorless gum.
    • Step 9: 1-(trans-4-(tert-butoxycarbonyl)cyclohexyl)-5-chloro-1H-pyrazole-4-carboxylic acid (D 19)
  • To a stirred solution of compound D19-8 (70 mg, 0.233 mmol) in THF/MeOH (4 mL, 1:1) was added a solution of LiOH (44 mg, 1.86 mmol) in water (1 mL). The mixture was stirred at room temperature for 4 h. The organic solvent was removed under reduced pressure. The residue was diluted with water (5 mL), acidified with 20% aqueous KHSO4 to pH 4 and extracted with EtOAc (3 x 10 mL) to provide compound D 19 (62 mg, 90%) as white solid. 1H NMR (CDCl3, 300 MHz): δ 8.01 (s, 1H), 4.29-4.37 (m, 1H), 2.25-2.43 (m, 1H), 2.10-2.19 (m, 2H), 1.99-2.09 (m, 4H), 1.52-1.65 (m, 2H), 1.45 (s, 9H).
    • [Reference example D20]
  • Figure imgb0345
    • Step 1: benzyl 3-cyclopropyl-3-oxopropanoate (D20-1)
  • A mixture of ethyl 3-cyclopropyl-3-oxopropanoate (5.0 g, 32.0 mmol), benzyl alcohol (8.2 mL, 80.0 mmol) and LiOCl (680 mg, 6.4 mmol) in toluene (50 mL) was refluxed for 48 h in flask equipped with a Dean-stark apparatus. The reaction mixture was cooled to room temperature and solvent was removed under reduced pressure to provide compound D20-1 (5.2 g, crude) as a brown oil.
    • Step 2: benzyl 2-(cyclopropanecarbonyl)-3-(dimethylamino)acrylate (D20-2)
  • A mixture of compound D20-1 (1.0 g, 4.58 mmol) and dimethylformamide dimethylacetal (0.61 mL, 4.58 mmol) in 1,4-dioxane (25 mL) was stirred at 100 °C for 13 h. The reaction mixture was quenched with water (20 mL) and extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with water (25 mL), brine(25 mL), dried over Na2SO4 and concentrated under reduced pressure to provide compound D20-2 (1.2 g, crude) as a yellowish brown gum.
    • Step 3: benzyl 5-cyclopropyl-1-(trans-4-(ethoxycarbonyl)cyclohexyl)-1H-pyrazole-4-carboxylate (D20-3)
  • To a solution of compound D1-2 (809 mg, 2.67 mmol) in EtOH (20 mL) was added DIPEA (0.45 mL, 2.61 mmol) dropwise. The mixture was stirred at room temperature for 5 min, thereafter, a solution of compound D20-2 (600 mg, 2.18 mmol) in EtOH (5 mL) was added dropwise and reaction mixture was stirred at room temperature for 4 h. The reaction mixture was quenched with water (200 mL) and extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with water (25 mL), brine (25 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to provide compound D20-3 (425 mg, impure) as yellow gum. Step 4: 5-cyclopropyl-1-(trans-4-(ethoxycarbonyl)cyclohexyl)-1H-pyrazole-4-carboxylic acid (D20)
  • To a stirred solution of compound D20-3 (425 mg, 1.07 mmol) in THF/MeOH (20 mL, 1:1) was added 10% Pd on carbon (80 mg, 20% by weight) and the mixture was stirred under H2 atmosphere (1 atm) for 2 h. The mixture was filtered through pad of celite and washed with EtOAc (3 x 50 mL). The filtrate was concentrated under reduced pressure. The residue was triturated with 10% EtOAc/hexane (2 x 20 mL) to provide compound D20 (200 mg, crude) as white solid.
    • [Reference example D22]
  • Figure imgb0346
    • Step 1: ethyl 8-ethyl-1,4-dioxaspiro[4.5]decane-8-carboxylate (D22-1)
  • To a stirred solution of compound D2-1 (2.1 g, 9.80 mmol) in THF (24 mL) was added LDA (2.0 M in THF/heptane/ethylbenzene, 7.3 mL, 14.7 mmol) dropwise at -78 °C for 5 min. The mixture was stirred at -78 °C for 15 min before the addition of EtBr (1.09 mL, 14.7 mmol). The reaction mixture was stirred at -78 °C for 1 h. The mixture was allowed to warm to room temperature and stirred at the same temperature for 1 h. The reaction mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with water (20 mL), brine (20 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to provide compound D22-1 (2.07 g, 87%) as a colorless gum.
    • Step 2: ethyl 1-ethyl-4-oxocyclohexanecarboxylate (D22-2)
  • To a stirred solution of compound D22-1 (2.07 g, 8.54 mmol) in acetone (60 mL) was added aqueous HCl (2 M solution, 40 mL) at room temperature. The mixture was stirred at the same temperature for 16 h. Acetone was removed under reduced pressure. The residue was basified with aqueous NaHCO3 solution and extracted with DCM (2 x 30 mL). The combined organic layers were washed with water (20 mL), brine (20 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to give compound D22-2 (1.85 g, 99%) as a colorless gum.
    • Step 3: tert-butyl 2-(trans-4-(ethoxycarbonyl)-4-ethylcyclohexyl)hydrazinecarboxylate (D22-3)
  • Compound D22-3 (1.57 g, 53%) was obtained as a white solid from the reaction of compound D22-2 (1.87 g, 9.43 mmol), tert-butyl hydrazinecarboxylate (1.24 g, 9.4 mmol), AcOH (cat) and NaBH3CN (1.78. g, 28.29 mmol) in isopropanol (20 mL) using a similar procedure to that described in reference example D2, step 4.
    • Step 4: ethyl trans-1-ethyl-4-hydrazinylcyclohexanecarboxylate hydrochloride (D22-4)
  • Compound D22-4 (1.36 g, 100%) was obtained as a white solid from the reaction of compound D22-3 (1.50 g, 4.78 mmol) and HCl (4 M in 1,4-dioxane, 8.3 mL, 33.4 mmol) using a similar procedure to that described in reference example D2, step 5.
    • Step 5: benzyl 1-(trans-4-(ethoxycarbonyl)-4-ethylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carbox ylate (D22-5)
  • Compound D22-5 (820 mg, 86%) was obtained as a colorless gum from the reaction of compound D22-4 (600 mg, 2.1 mmol), compound D1-4 (669 mg, 2.2 mmol) and DIPEA (0.43 mL, 2.52 mmol) in EtOH (12 mL) using a similar procedure to that described in reference example D2, step 6.
    • Step 6: 1-(trans-4-(ethoxycarbonyl)-4-ethylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carbox ylic acid (D22)
  • Compound D22 (285 mg, 98%) was obtained as a white solid from the reaction of compound D22-5 (363 mg, 0.80 mmol), 5% Pd on carbon (85 mg, 30% by weight) and H2 (1 atm) in MeOH (6 mL) using a similar procedure to that described in reference example D2, step 7.
    • [Reference example D26]
  • Figure imgb0347
    • Step 1: benzyl-4,4-difluoro-3-oxobutanoate (D26-1)
  • Compound D26-1 (7.5 mg, crude) was obtained as a yellow oil from the reaction of ethyl-4,4-difluoro-3-oxobutanoate (5 g, 0.12 mmol) and BnOH (3.25 g, 30.0 mmol) in toluene (50 mL) using a similar procedure to that described in reference example D1, step 3.
    • Step 2: benzyl-2-((dimethylamino)methylene)-4,4-difluoro-3-oxobutanoate (D26-2)
  • Compound D26-2 (5.8 g, crude) was obtained as a yellow oil from the reaction of compound D26-1 (5.3 g, 23.2 mmol), dimethylformamide dimethylacetal (6.2 mL, 46.4 mmol) and AcOH (2.05 mL, 46.4 mmol) in THF (50 mL) using a similar procedure to that described in reference example D1, step 4.
    • Step 3: benzyl-5-(difluoromethyl)-trans-4-(ethoxycarbonyl)cyclohexyl)-1H-pyrazole-4-carboxylat e (D26-3)
  • Compound D26-3 (520 mg, 16%) was obtained as a pale yellow solid from the reaction of compound D26-2 (1.50 g, 5.28 mmol), compound D1-2 (1.6 g, 5.28 mmol) and DIPEA (1.8 mL, 10.5 mmol) in EtOH (30 mL) using a similar procedure to that described in reference example D1, step 5.
    • Step 4: 5-(difluoromethyl)-trans-4-(ethoxycarbonyl)cyclohexyl)-1H-pyrazole-4-carboxylic acid (D26)
  • Compound D26 (255 mg, 63%) was obtained as a white solid from the reaction of compound D26-3 (520 mg, 1.28 mmol) and 5% Pd on carbon (70 mg, 30% by weight) in EtOH (30 mL) using a similar procedure to that described in reference example D1, step 6. LCMS (APCI): 317 (M+H)+.
    • [Reference example D27]
  • Figure imgb0348
    • Step 1: benzyl 2-((dimethylamino)methylene)-3-oxobutanoate (D27-1)
  • To a stirred benzyl 3-oxobutanoate (1.1 g, 5.7 mmol), dimethylformamide dimethylacetal (1 mL, 7.4 mmol) was added dropwise at room temperature. The mixture was stirred for 16 h at room temperature. The reaction mixture was concentrated under reduced pressure and the residue was azeotroped with toluene (3 x 10 mL) to provide compound D27-1 as a brown oil (1.4 g, quant.).
    • Step 2: benzyl 1-((trans-4-(ethoxycarbonyl)cyclohexyl)-5-methyl-1H-pyrazole-4-carboxylate (D27-2)
  • To a solution of compound D1-2 (1.12 g, 4.3 mmol) in EtOH (10 mL) was added DIPEA (1.2 mL, 6.7 mmol) dropwise. The mixture was stirred at room temperature for 5 min. A solution of compound D27-1 (0.97 g, 3.94 mmol) in EtOH (5 mL) was added dropwise and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water (20 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to provide compound D27-2 (0.78 g, 54%) as a white solid.
    • Step 3: 1-((trans-4-(ethoxycarbonyl)cyclohexyl)-5-methyl-1H-pyrazole-4-carboxylic acid (D27)
  • To a stirred solution of compound D27-2 (0.78 g, 2.1 mmol) in MeOH (10 mL) was added 5% Pd on carbon (0.19 g, 25% by weight) and the mixture was stirred under H2 atmosphere (1 atm) for 2 h. The mixture was filtered through a pad of celite and washed with MeOH (3 x 20 mL). The filtrate was washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was triturated with 5% EtOAc/hexane (20 mL) to provide compound D27 (0.5 g, 85%) as a white solid. 1H NMR (300 MHz, DMSO-d6): δ 1.19 (t, J= 7.2 Hz), 1.56 (m, 2H), 1.88 (m, 4H), 2.00 (m, 2H), 2.35 (m, 1H), 2.50 (s, 3H), 4.07 (q, J=7.2 Hz, 2H), 4.20 (m, 1H), 7.72 (s, 1H), 12.10 (s, 1H).
    • [Reference example D28]
  • Figure imgb0349
    • Step 1: 1,5-di-tert-butyl 3-ethyl 3-acetylpentane-1,3,5-tricarboxylate (D28-1)
  • To a stirred solution of ethyl 3-oxobutanoate (45 g, 345 mmol) and Triton-B (40%, weight% solution in water, 1.08 mg, 6.90 mmol) in tert-BuOH (54 mL) was added tert-butyl acrylate (100.72 g, 691 mmol) dropwise over a period of 30 min under N2 atmosphere. The solution was stirred at room temperature for 24 h. The reaction mixture was partitioned between water (200 mL) and EtOAc (200 mL). The aqueous layer was washed with EtOAc (2 x 50 mL). The combined organic layers were washed with water (200 mL), brine (200 mL), dried over Na2SO4 and concentrated under reduced pressure to provide compound D28-1 (140 g, quant) as a pale yellow oil. 1H NMR (CDCl3, 400 MHz): δ 4.20 (q, J = 7.2 Hz 2H), 2.24-2.09 (m, 8H), 1.58 (s, 3H), 1.43 (s, 18Hz) 1.31 (t, J = 7.2 Hz, 3H).
    • Step 2: 4-acetyl-4-(ethoxycarbonyl)heptanedioic acid (D28-2)
  • To a stirred solution of compound D28-1 (140 g, 326 mmol) in DCM (350 mL) was added TFA (350 mL) in DCM (350 mL) at 0 °C and the mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure and the residue was co-evaporated with toluene (3 x 200 mL) to provide compound D28-2 (85 g, quant.) as an off-white solid.
    • Step 3: ethyl-1-acetyl-4-oxocyclohexanecarboxylate (D28-3)
  • To a stirred suspension of compound D28-2 (85 g, 310 mmol) in acetic anhydride (255 mL) was added pyridine (27 mL) and the mixture was stirred at 145 °C for 2 h. The solvent was removed under reduced pressure, the residue was suspended in water (200 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (14% EtOAc/hexane as eluent) to provide compound D28-3 (11 g, 17%) as brown gum. 1H NMR (CDCl3, 400 MHz): δ 4.28 (q, J = 7.2 Hz, 2H), 2.44-2.42 (m, 6H), 2.23-2.20 (m, 5H), 1.31 (t, J = 7.2 Hz, 3H).
    • Step 4: ethyl 4-(benzylamino)-2-oxobicyclo[2.2.2]octane-1-carboxylate (D28-4)
  • To a stirred mixture of compound D28-3 (25.0 g, 117 mol) and benzyl amine (38.6 mL, 353 mol) in toluene (250 mL) was added p-TsOH (0.22 g, 1.17 mmol), and the mixture was refluxed for 8 h in a flask equipped with a Dean-Stark adapter. The reaction mixture was cooled to room temperature. HCl (3 M, 250 mL) was added to the reaction mixture, and the whole was stirred for 30 min. The mixture was neutralized with aqueous solution of 6 M NaOH to pH 7. The reaction mixture was extracted with EtOAc (3 x 100 mL). The combined organic extracts were washed with water (100 mL), brine (100 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (50% EtOAc/hexane as eluent) to provide compound D28-4 (30 g, 85%) as an off-white solid. 1H NMR (CDCl3, 400 MHz): δ 7.40-7.21 (m, 5H), 6.44-6.32 (m, 2H), 4.20 (q, J = 7.2 Hz, 2H), 3.74 (s, 1H), 2.45 (s, 2H), 2.30-2.20 (m, 2H), 2.10-1.95 (m, 2H), 1.89-1.75 (m, 4H), 1.27 (t, J = 6.8 Hz, 3H).
    • Step 5: ethyl-4-(benzylamino)-2-hydroxybicyclo[2.2.2]octane-1-carboxylate (D28-5)
  • To a stirred solution of compound D28-4 (30.0 g, 99.0 mmol) in EtOH (300 mL) was added solid NaBH4 (5.64 g, 148 mmol) in portions at 0 °C. The whole was stirred at room temperature for 30 min. The mixture was quenched with water (100 mL) and extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with water (150 mL), brine (150 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (80% EtOAc/hexane as eluent) to provide compound D28-5 (14 g, 46%) as a white solid.
    • Step 6: ethyl-4-(benzylamino)-2-((methylsulfonyl)oxy)bicyclo[2.2.2]octane-1-carboxylate (D28-6)
  • To a stirred solution of compound D28-5 (14.0 g, 46.0 mmol) and Et3N (12.8 mL,57.5 mmol) in THF/toluene (125 mL, 1:4) was added MsCl (4.47 mL, 57.5 mmol) at 0 °C and the mixture was stirred at room temperature for 1 h. The reaction mixture was quenched with water (100 mL) and extracted with toluene (50 mL). The organic layer was separated, dried over Na2SO4 and concentrated under reduced pressure to provide compound D28-6 (14 g, crude). The crude product was used in the next step without purification.
    • Step 7: ethyl-4-(benzylamino)bicyclo[2.2.2]oct-2-ene-1-carboxylate (D28-7)
  • To a stirred solution of compound D28-6 (17.6 g, 46.3 mol) and NaI (1.38 g, 9.25 mmol) in toluene (170 mL) were added DBU (34.65 mL, 231 mmol) and DMA (50 mL), and the whole was stirred at 120 °C for 43 h. The reaction mixture was quenched with water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 50% EtOAc/hexane as eluent) to provide compound D28-7 (8 g, 61%, over two steps) as an off-white solid. 1H NMR (CDCl3, 400 MHz): δ 7.36-7.32 (m, 5H), 6.44 (d, J = 8.8 Hz, 1H), 6.32 (d, J = 8.8 Hz, 1H), 4.19 (q, J = 7.2 Hz, 2H), 3.86 (s, 2H), 2.04-1.97 (m, 2H), 1.65-1.50 (m, 6H), 1.28 (t, J = 7.2 Hz, 3H).
    • Step 8: ethyl-4-aminobicyclo[2.2.2]octane-1-carboxylate (D28-8)
  • To a stirred solution of compound D28-7 (8.0 g, 28.0 mmol) in MeOH (80 mL) was added 10% Pd on carbon (1.6 g, 20% by weight) and the whole was stirred for 5 h under H2 atmosphere (1 atm). The reaction mixture was filtered through a pad of celite and washed with MeOH (2 x 30 mL). The filtrate was concentrated under reduced pressure to provide compound D28-8 (5.2 g, 94%) as a colorless gum. 1H NMR (CDCl3, 400 MHz): δ 4.00 (q, J = 7.2 Hz, 2H), 1.88-1.84 (m, 4H), 1.56-1.55 (m, 8H), 1.15 (t, J = 7.2 Hz, 3H).
    • Step 9: tert-butyl 4-cyanobenzylidenecarbamate (D28-9)
  • A mixture of 4-formylbenzonitrile (12.0 g, 9.16 mol) and tert-butyl (triphenylphosphoranylidene)carbamate (36.3 g, 9.61 mol) in toluene (60 mL) was refluxed for 18 h. The precipitated solid was filtered off. The filtrate was concentrated under reduced pressure to provide compound D28-9 (13 g, crude) as a colorless gum. Step 10: tert-butyl 3-(4-cyanophenyl)-1,2-oxaziridine-2-carboxylate (D28-10, mixture of cis- and trans- isomer)
  • To a stirred solution of compound D28-9 (13 g, 1.67 mmol) in CHCl3 (220 mL) was added a pre-cooled solution of K2CO3 (50 g) in water (400 mL) at 0 °C, and the mixture was stirred vigorously. A pre-cooled solution of Oxone (80 g) in water (800 mL) was added, and the whole was stirred at 0 °C for 50 min. The reaction mixture was subjected to ten such cycles. The combined organic layer was separated, washed with water (200 mL), brine (200 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (C18 silica gel, 45-50% CH3CN/water as eluent) to provide compound D28-10 (1.3 g, 14% over two steps) as a white solid. 1H NMR (CDCl3, 400 MHz, mixture of cis- and trans-): δ 7.73-7.58 (m, 6.5H), 5.29 (s, 0.3H), 5.06 (s, 1H), 1.57 (s, 3H), 1.55 (s, 9H).
    • Step 11: tert-butyl 2-(4-(ethoxycarbonyl)bicyclo[2.2.2]octan-1-yl)hydrazinecarboxylate (D28-11)
  • A mixture of compound D28-8 (0.8 g, 4.04 mmol) and compound D28-10 (1.03 g, 4.24 mmol) in DCM (20 mL) was stirred for 3 h at 0 °C. The reaction mixture was quenched with water (10 mL) and extracted with DCM (2 x 10 mL). The combined organic layers were washed with water (10 mL), brine (10 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc/hexane as eluent) to provide compound D28-11 (0.6 g, 50%) as a white solid.
    • Step 12: ethyl-4-hydrazinylbicyclo [2.2.2] octane-1-carboxylate hydrochloride (D28-12)
  • A mixture of compound D28-11 (0.6 g, 1.92 mmol) and 4 M HCl in dioxane (4.80 mL, 19.2 mmol) was stirred at room temperature for 18 h. The solvent was removed under reduced pressure. The residue was co-evaporated with hexane twice to provide compound D28-12 (0.58 g, crude) as a white solid.
    • Step 13: benzyl 1-(4-(ethoxycarbonyl)bicyclo[2.2.2]octan-1-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxy late (D28-13)
  • To a stirred mixture of compound D28-12 (0.58 g, 2.04 mmol) and DIPEA (0.69 mL, 4.08 mmol) in EtOH (10 mL) was added a solution of compound D1-4 (0.64 g, 2.15 mmol) in EtOH (10 mL). The mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with water (20 mL), brine (20 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc/hexane as eluent) to provide compound D28-13 (0.2 g, 21%) as a light yellow gum. 1H NMR (CDCl3, 400 MHz): δ 7.81-7.80 (s, 1H), 7.39-7.25 (m, 5H), 5.29 (s, 2H), 4.11 (q, J = 7.2 Hz, 2H), 2.27-2.23 (m, 6H), 2.02-1.99 (m, 6H), 1.25 (t, J = 7.2 Hz, 3H).
    • Step 14: 1-(4-(ethoxycarbonyl)bicyclo[2.2.2]octan-1-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxy lic acid (D28)
  • To a stirred solution of compound D28-13 (0.2 g, 0.44 mmol) in MeOH was added 10% Pd on carbon (40 mg, 30% by weight), and the whole was stirred under H2 atmosphere (1 atm) for 5 h. The reaction mixture was filtered through a pad of celite, washed with MeOH (3 x 30 mL). The fitrate was concentrated under reduced pressure. The residue was triturated with hexane (2 x 10 mL) and the resulting solid was filtered to provide compound D28 (0.15 g, 93%) as a white solid. 1H NMR (CDCl3, 400 MHz): δ 7.90 (s, 1H), 4.14 (q, J = 7.2 Hz, 2H), 2.30-2.26 (m, 6H), 2.04-2.00 (m, 6H), 1.25 (t, J = 7.2 Hz, 3H).
    • [Reference example D30]
  • Figure imgb0350
    • Step 1: benzyl-5-(difluoromethyl)-trans-4-(ethoxycarbonyl)-4-methylcyclohexyl)-1H-pyrazole-4-c arboxylate (D30-1)
  • Compound D30-1 (1.91 g, 50%) was obtained as a pale yellow solid from the reaction of compound D26-2 (2.7 g, 9.55 mmol), compound D2-5 (2.6 g, 9.55 mmol) and DIPEA (3.3 mL, 19.1 mmol) in EtOH (50 mL) using a similar procedure to that described in reference example D1, step 5. 1H NMR (CDCl3, 400 MHz): δ 7.94 (s, 1H). 7.40-7.35 (m, 6H), 5.30 (s, 2H), 4.36 (m, 1H), 4.15 (q, J = 7.2 Hz, 2H), 2.24-2.19.(m, 2H), 1.88-1.87 (m, 6H), 1.3 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H).
    • Step 2: 1-trans-4-(ethoxycarbonyl)cyclohexyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid (D30)
  • Compound D30 (1.19 g, 79%) was obtained as a white solid from the reaction of compound D30-1 (1.91 g, 4.54 mmol) and 5% Pd on carbon (200 mg, 10% by weight) in EtOH (30 mL) using a similar procedure to that described in reference example D1, step 6. 1H NMR (CDCl3, 300 MHz): δ 8.03 (s, 1H), 7.51 (t, J = 51.6 Hz), 4.4-4.42 (m, 1H), 4.15 (q, J = 7.2 Hz, 2H), 2.2-2.25 (m. 2H), 1.88-1.92 (m, 6H), 1.35 (s, 3H), 1.27 (t, J = 7.0 Hz, 3H).
    • [Reference example D33]
  • Figure imgb0351
    • Step 1: Ethyl 5-amino-1-(trans-4-(ethoxycarbonyl)-4-methylcyclohexyl)-1H-pyrazole-4-carboxylate (D33-1)
  • To a solution of ethyl 2-cyano-3-ethoxyacrylate (19 g, 70 mmol) and compound D2-5 (11.96 g, 70 mmol) in EtOH (100 mL) was added sodium acetate (11.54 g, 140 mmol) and the mixture was refluxed for 6 h. The reaction mixture was quenched with water and extracted with DCM. The organic layer was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 30% EtOAc/hexane as eluent) to provide compound D33-1 (16 g, 45%) as a yellow solid.
    • Step 2: ethyl 5-chloro-1-(trans-4-(ethoxycarbonyl)-4-methylcyclohexyl)-1H-pyrazole-4-carboxylate (D33-2)
  • To a stirred mixture of copper (I) chloride (0.77 g, 7.8 mmol) in CH3CN (10 mL) at 0 °C was added tert-butyl nitrite (0.92 mL, 7.8 mmol). A solution of compound D33-1 (1.26 g, 3.9 mmol) in CH3CN (10 mL) was added dropwise to the mixture at the same temperature. The reaction mixture was warmed to room temperature and stirred at the same temperature for 1 h and at 60 °C for another 1 h. The reaction mixture was quenched with 6 M HCl (10 mL) at 0 °C and extracted with DCM (3 x 100 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 30% EtOAc/hexane as eluent) to provide compound D33-2 (0.3 g, 37%) as a colourless gum.
    • Step 3: 5-chloro-1-(trans-4-(ethoxycarbonyl)-4-methylcyclohexyl)-1H-pyrazole-4-carboxylic acid (D33)
  • To a solution of compound D33-2 (0.6 g, 1.75 mmol) in EtOH (10 mL) was added 1 N NaOH solution dropwise at room temperature. The mixture was stirred for 45 min. The reaction mixture pH was adjusted to 3 and extracted with EtOAc (2 x 200 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (C18 silica gel, 80% CH3CN/water as eluent) to provide compound D33 (0.4 g, 55%) as an off-white solid.
    • [Reference example D41] 1-((1S,3R,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylic acid
  • Figure imgb0352
    • Step 1: (1S,2R)-ethyl 2-methyl-4-oxocyclohexanecarboxylate (Racemic)
  • To a Parr flask was added 10% palladium on carbon (wet degussa type) (4.47 g, 4.20 mmol) in EtOH (378 ml). Then ethyl 2-methyl-4-oxo-2-cyclohexene-1-carboxylate (23.65 ml, 140 mmol) and 5 N hydrochloric acid (1.679 ml, 8.40 mmol) were added into the reaction mixture. The atmosphere of the flask was degassed, and then filled with hydrogen (50 psi). The mixture was allowed to stir under hydrogenation conditions 30 min. The progress of the reaction was monitored by LC/MS and TLC (50% EtOAc/hexane; potassium permanganate stain), which suggested reaction completion. The mixture was filtered through a pad of celite and the filter cake was rinsed with EtOH. The mixture was concentrated in-vacuo. The crude material was purified by chromatography through an Interchim (15 micron) silica-gel column (220 g), eluting with a gradient of 0-50% EtOAc in hexane, to provide (1S,2R)-ethyl 2-methyl-4-oxocyclohexanecarboxylate (18.277 g, 99 mmol, 70.9% yield) (Racemic) as light-yellow oil. 1H NMR (400 MHz, CDCl3) δ 4.19 (dtt, 2H), 2.85 (td, J=4.25, 8.31 Hz, 1H), 2.43-2.58 (m, 4H), 2.31 (ddd, J=6.06, 8.75, 14.72 Hz, 1H), 2.01-2.21 (m, 2H), 1.29 (t, J=7.14 Hz, 3H), 0.98 (d, J=6.85 Hz, 3H); LCMS (ESI) m/z 185.0 (M+H)+.
    • Step 2: (1S,2R)-ethyl 2-methyl-4-oxocyclohexanecarboxylate (Chiral)
  • (1S,2R)-ethyl 2-methyl-4-oxocyclohexanecarboxylate (Racemic) was separated into chiral peak 1 and chiral peak 2 by normal phase HPLC ; Varian Cardinals SD1 normal phase system (10 x 50 cm ; 20 micron AS column). Method : 10% EtOH in Heptane Flow Rate : 400 ml/min. Detection : 220 nm, 300 nm. This purification method provided peak 1 (1S,2R)-ethyl 2-methyl-4-oxocyclohexanecarboxylate (>98% ee) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 4.19 (ddquin, 2H), 2.85 (td, J=4.25, 8.31 Hz, 1H), 2.43-2.58 (m, 4H), 2.31 (ddd, J=6.16, 8.66, 14.72 Hz, 1H), 2.01-2.21 (m, 2H), 1.24-1.32 (m, 3H), 0.98 (d, J=6.85 Hz, 3H); LCMS (ESI) m/z 185.0 (M+H)+. Peak 2 (1R,2S)-ethyl 2-methyl-4-oxocyclohexanecarboxylate (>95% ee) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 4.19 (ddquin, 2H), 2.85 (td, J=4.13, 8.36 Hz, 1H), 2.43-2.58 (m, 4H), 2.31 (ddd, J=6.16, 8.66, 14.72 Hz, 1H), 2.01-2.21 (m, 2H), 1.29 (t, J=7.14 Hz, 3H), 0.98 (d, J=6.85 Hz, 3H); LCMS (ESI) m/z 185.0 (M+H)+.
    • Step 3: tert-butyl 2-((1S,3R,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl) hydrazinecarboxylate
  • To a 500-mL 3-neck round-bottomed flask was added (1S,2R)-ethyl 2-methyl-4-oxocyclohexanecarboxylate (10.00 g, 54.3 mmol) in chloroform (201 ml). Then AcOH, glacial (3.13 ml, 54.3 mmol), and tert-butyl carbazate (7.89 g, 59.7 mmol) was added into the reaction mixture. The flask was placed into a pre-heated bath (30 °C) and allowed to stir 10 min. Then NaBH(OAc)3 (34.5 g, 163 mmol) was slowly added into the reaction mixture in small portions. The bath was removed after the addition and the overall mixture was allowed to stir under inert atmosphere 16 h. The progress of the reaction was monitored by LC/MS and TLC (30% EtOAc/DCM; Ninhydrin stain) which suggested reaction completion. The mixture was neutralized with the slow addition of sat. aq. NaHCO3 to the reaction mixture. After the material was neutralized, the layers were separated and the aqueous layer was extracted with DCM (3x). The combined organic extracts were dried over Na2SO4, filtered and concentrated in-vacuo. The crude sample was analyzed by TLC (30% EtOAc/hexane; ninhydrin stain; Peak 1: Rf= 0.46 & Peak 2: Rf= 0.38) The crude material was divided into two portions and purified by chromatography through an Interchim (25 micron) silica-gel column (300 g) *(Two 300 Gram Columns were used), eluting with a gradient of 0-30% EtOAc in hexane, to provide tert-butyl 2-((1R,3R,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl) hydrazinecarboxylate (8.512 g, 28.3 mmol, 52.2% yield) (Peak 1; Cis) 1H NMR (400 MHz, CDCl3) δ 6.03-6.28 (m, 1H), 4.07-4.16 (m, 2H), 3.59-3.90 (m, 1H), 2.76-2.97 (m, 1H), 2.55 (d, J=2.74 Hz, 1H), 2.01 (dd, J=3.03, 13.40 Hz, 1H), 1.59-1.77 (m, 3H), 1.49-1.56 (m, 2H), 1.46 (s, 10H), 1.19-1.31 (m, 3H), 1.02 (d, J=7.04 Hz, 3H); LCMS (ESI) m/z 301.1 (M+H)+ and tert-butyl 2-((1S,3R,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl) hydrazinecarboxylate (5.089 g, 16.94 mmol, 31.2% yield) (Peak 2; trans) 1H NMR (400 MHz, DMSO-d6) δ 7.89-8.27 (m, 1H), 5.75 (s, 1H), 4.08-4.19 (m, 1H), 2.74-2.93 (m, 1H), 2.21-2.46 (m, 2H), 1.99 (s, 1H), 1.66 (d, J=3.91 Hz, 3H), 1.38 (s, 9H), 1.14-1.26 (m, 5H), 0.79 (d, J=7.04 Hz, 3H); LCMS (ESI) m/z 301.1 (M+H)+.
    • Step 4: (1S,2R,4S)-ethyl 4-hydrazinyl-2-methylcyclohexanecarboxylate hydrochloride
  • To a 250-mL round-bottomed flask was added tert-butyl 2-((1S,3R,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)hydrazinecarboxylate (5.089 g, 16.94 mmol) in EtOH (56.5 ml). Then hydrogen chloride, 4.0 M solution in 1,4-dioxane (72.0 ml, 288 mmol) was added into the reaction mixture. The overall mixture was allowed to stir under inert atmosphere overnight. The progress of the reaction was monitored by TLC (30% EtOAc in hexane; ninhydrin stain), which suggested reaction completion. The mixture was concentrated in-vacuo. The residue was diluted with hexane and concentrated in-vacuo. This gave (1S,2R,4S)-ethyl 4-hydrazinyl-2-methylcyclohexanecarboxylate hydrochloride (4.60 g) as white solid. This material was carried into the next step of the synthesis, without further purification. LCMS (ESI) m/z 201.2 (M+H)+.
    • Step 5: benzyl 1-((1S,3R,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylate
  • To a 250-mL) round-bottomed flask was added (1S,2R,4S)-ethyl 4-hydrazinyl-2-methylcyclohexanecarboxylate hydrochloride (4.00 g, 16.90 mmol) and DIPEA (4.43 ml, 25.3-mmol)) in EtOH (84 ml). Then a solution of (Z)-benzyl 2-((dimethylamino)methylene)-4,4,4-trifluoro-3-oxobutanoate (5.09 g, 16.90 mmol) in EtOH (84 ml) was added dropwise into the reaction mixture. The overall reaction mixture was allowed to stir under inert atmosphere, while at ambient temperature overnight. The progress of the reaction was monitored by LC/MS and TLC (30% EtOAc/hexane) which showed mostly desired material LCMS (ESI) m/z 461.2 (M+Na)+, without any starting material remaining. The reaction mixture was concentrated in-vacuo. The crude material was purified by chromatography through an Interchim (25 micron) silica-gel column (200 g), eluting with a gradient of 0-30% EtOAc in hexane, to provide benzyl 1-((1S,3R,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylate (5.631 g, 12.84 mmol, 76% yield) as light-yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 8.14 (s, 1H), 7.32-7.45 (m, 5H), 5.30 (s, 2H), 4.55-4.65 (m, 1H), 4.02-4.15 (m; 2H), 2.65 (td, J=4.50, 11.54 Hz, 1H), 2.13 (dt, J=4.50, 12.42 Hz, 1H), 1.95-2.04 (m, 2H), 1.73 (d, J=4.89 Hz, 3H), 1.16-1.23 (m, 3H), 0.92 (d, J=7.04 Hz, 3H) ; LCMS (ESI) m/z 461.2 (M+Na)+.
    • Step 6: 1-((1S,3R,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylic acid *(Hydrogenation was performed with suitcase apparatus)
  • A pressurized vial was charged with palladium 10 wt. % (dry basis) on activated carbon, wet (1.367 g, 1.284 mmol) while under a stream of N2 (gas). Then a solution of benzyl 1-((1S,3R,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylate (5.631 g, 12.84 mmol) in a 1:1 mixture of EtOH (32.1 ml)/EtOAc (32.1 ml) was added into the vial. The reaction mixture atmosphere was purged with hydrogen gas (3x). The reaction was stirred vigourously under hydrogenation (35 psi) conditions for 2.5 h. The progress of the reaction was monitored by LC/MS, which suggested reaction completion LCMS (ESI) m/z 371.2 (M+Na)+. The mixture was filtered through a plug of celite and the filtrate was concentrated in-vacuo. The residue was diluted with hexane and agitated. The precipitate was collected by filtration and the solids were rinsed with hexane. This gave 1-((1S,3R,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylic acid (3.810 g, 10.94 mmol, 85% yield) as white solid. 1H NMR (400 MHz, DMSO-d6) δ 7.91-8.21 (m, 1H), 4.47-4.69 (m, 1H), 4.01-4.16 (m, 2H), 2.56-2.70 (m, 1H), 2.12 (dt, J=4.21, 12.37 Hz, 1H), 1.93-2.06 (m, 2H), 1.71-1.90 (m, 3H), 1.19 (t, J=7.04 Hz, 3H), 0.92 (d, J=7.04 Hz, 3H); LCMS (ESI) m/z 371.2 (M+Na)+.
    • [Reference example D43] 1-((1R,3R,4R)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid compound with 1-((1S,3S,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylic acid (1:1) (D43)
  • Figure imgb0353
    • Step 1: tert-butyl 2-((1R,3R,4R)-4-(ethoxycarbonyl-)-3-methylcyclohexyl)hydrazinecarboxylate compound with tert-butyl 2-((1S,3S,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)hydrazinecarboxylate (1:1) (D43-1)
  • To a homogeneous racemic mixture of (1R,2R)-ethyl 2-methyl-4-oxocyclohexanecarboxylate compound with (1S,2S)-ethyl 2-methyl-4-oxocyclohexanecarboxylate (1:1) (1.600 g, 8.68 mmol) was added tert-butyl carbazate (1.263 g, 9.55 mmol), AcOH (1.038 ml, 17.98 mmol), and NaBH(OAc)3 (6.00 g, 28.3 mmol). The light-yellow heterogeneous mixture was stirred at room temperature. After 24 h, LCMS (ESI) and TLC indicated that the reaction was complete, two peaks with 323.1 (M+Na).
    • [TLC]: (30% of EtOAc in Hexane, stained with phosphomolybdic acid in EtOH) Rf of reactant=0.47, Rf of 1,4-cis-desired product=0.42, Rf of 1,4-trans-desired product=0.25. The reaction mixture was poured into saturated aqueous NaHCO3 solution (150 mL). The reaction mixture was extracted with DCM (2 x 100 mL). The organic extract was dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a colorless oil. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 25% EtOAc in hexane to provide two fractions:
      • First fraction for higher spot (1,4-cis): (Rf=0.42 at 30% of EtOAc in Hexane) tert-butyl 2-((1R,3S,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)hydrazinecarboxylate compound with tert-butyl 2-((1S,3R,4R)-4-(ethoxycarbonyl)-3-methylcyclohexyl)hydrazinecarboxylate (1:1) (1.4418 g, 4.80 mmol, 55.3% yield) as light-yellow syrup: 1H NMR (300 MHz, CDCl3) δ 6.05 (1 H, br. s.), 4.14 (2 H, q, J=7.1 Hz), 3.25 (1 H, br. s.), 1.12 - 2.22 (21 H, m), 0.88 (3 H, d, J=6.6 Hz); LCMS (ESI) m/z 301.1 (M+H)+ and m/z 323.1 (M+Na)+.
      • Second fraction for lower spot (1,4-trans): Desired product (Rf=0.25 at 30% of EtOAc in Hexane) tert-butyl 2-((1R,3R,4R)-4-(ethoxycarbonyl)-3-methylcyclohexyl)hydrazinecarboxylate compound with tert-butyl 2-((1S,3S,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)hydrazinecarboxylate (1:1) (D43-1) (0.5467 g, 1.820 mmol, 20.96% yield) as off-white syrupy solid. 1H NMR (300 MHz, CDCl3) δ 6.05 (1H, br. s.), 4.06-4.23 (2H, m), 2.81-2.99 (1H, m), 1.65-2.07 (5H, m), 1.39-1.56 (10H, m), 1.20-1.31 (4H, m), 0.99-1.16 (1H, m), 0.79-0.96 (4H, m); LCMS (ESI) m/z 323.1 (M+Na)+.
    • [NOTE]: The second fraction was used in Step 2.
    Step 2: (1R,2R,4R)-ethyl 4-hydrazinyl-2-methylcyclohexanecarboxylate compound with (1S,2S,4S)-ethyl 4-hydrazinyl-2-methylcyclohexanecarboxylate (1:1) dihydrochloride (D43-2)
  • To a mixture of tert-butyl 2-((1R,3R,4R)-4-(ethoxycarbonyl)-3-methylcyclohexyl)hydrazinecarboxylate compound with tert-butyl 2-((1S,3S,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)hydrazinecarboxylate (1:1) (D42-1) (0.5245 g, 1.746 mmol) in EtOH (4.37 ml) was added hydrogen chloride, 4 M in 1,4-dioxane (4.37 ml, 17.46 mmol). The clear light-yellow mixture was stirred at room temperature. After 42 h (white heterogeneous mixture), LC-MS (ESI) showed that the reaction was complete, the desired product (m/z 201.2 (M+1)) was formed. The mixture was concentrated in vacuo to provide (1R,2R,4R)-ethyl 4-hydrazinyl-2-methylcyclohexanecarboxylate compound with (1S,2S,4S)-ethyl 4-hydrazinyl-2-methylcyclohexanecarboxylate (1:1) dihydrochloride (D43-2) as light-yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 4.07 (2H, q, J=7.0 Hz), 2.88-3.05 (1H, m), 2.04 (2H, t, J=11.6 Hz), 1.80-1.96 (2H, m), 1.52-1.73 (1H, m), 1.12-1.46 (5H, m), 0.78-1.08 (4H, m); LCMS (ESI) m/z 201.2 (M+H)+.
    • Step 3: benzyl 1-((1R,3R,4R)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate compound with benzyl 1-((1S,3S,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylate (1:1) (D43-3)
  • To a mixture of (1R,2R,4R)-ethyl 4-hydrazinyl-2-methylcyclohexanecarboxylate compound with (1S,2S,4S)-ethyl 4-hydrazinyl-2-methylcyclohexanecarboxylate (1:1) dihydrochloride (D42-2) (0.413 g, 1.745 mmol) in EtOH (13.42 ml) was added DIPEA (0.669 ml, 3.84 mmol) followed by a solution of (Z)-benzyl 2-((dimethylamino)methylene)-4,4,4-trifluoro-3-oxobutanoate (0.526 g, 1.745 mmol) in EtOH (5 mL). The clear brown mixture was stirred at room temperature. After 15 h, LC-MS (ESI) showed that the reaction wasa complete, the desired product (m/z 439.1 (M+1)) was formed. The reaction mixture was concentrated in vacuo. The residue was diluted with water (50 mL) and extracted with EtOAc (2 x 100 mL). The organic extract was washed with satd NaCl (1 x 100 mL) and dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a brown syrup. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 10% EtOAc in hexane to give benzyl 1-((1R,3R,4R)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate compound with benzyl 1-((1S,3S,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylate (1:1) (D43-3) (0.4258 g, 0.971 mmol, 55.7% yield) as yellow syrup: 1H NMR (300 MHz, DMSO-d6) δ 8.06-8.17 (1H, m), 7.29-7.50 (5H, m), 5.29 (2H, s), 4.42-4.60 (1H, m), 4.10 (2H, q, J=7.1 Hz), 1.48-2.13 (8H, m), 1.19 (3H, t, J=7.1 Hz), 0.89 (3H, d, J=6.0 Hz); LCMS (ESI) m/z 439.1 (M+H)+.
    • Step 4: 1-((1R,3R,4R)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid compound with 1-((1S,3S,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylic acid (1:1) (D43)
  • A pressurized vial was charged with palladium 10 wt. % on activated carbon (0.103 g, 0.097 mmol) while under a stream of nitrogen gas. Then a solution of benzyl 1-((1R,3R,4R)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate compound with benzyl 1-((1S,3S,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylate (1:1) (D43-3) (0.4258 g, 0.971 mmol) in a 1:1 mixture of EtOH (2.428 ml)/EtOAc (2.428 ml) was added into the vial. The reaction atmosphere was purged with hydrogen gas (3 times). The reaction was stirred vigourously under hydrogenation (33 psi) at 21 °C. After 3 h, LCMS (ESI) showed that the reaction was complete. The reaction mixture was purged with nitrgen gas for 30 min. The mixture was filtered through a pad of celite and the filter cake was rinsed with EtOAc. The filtrate was concentrated in vacuo to give 1-((1R,3R,4R)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid compound with 1-((1S,3S,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylic acid (1:1) (D43) (0.3224 g, 0.926 mmol, 95% yield) as light-yellow solid:
    1H NMR (300 MHz, DMSO-d6) δ 13.14.(1H, br. s.), 8.01 (1H, s), 4.40-4.59 (1H, m), 4.10 (2H, q, J=7.0 Hz), 1.48-2.16 (8H, m), 1.20 (3H, t, J=7.1 Hz), 0.89 (3H, d, J=6.0 Hz); LCMS (ESI) m/z 349.1 (M+H)+
    • [Reference example D48] 1-(((3aS,5R,7aS)-3a-(methoxycarbonyl)octahydro-1H-inden-5-yl)-5-(trifluoromethyl)-1H-p yrazole-4-carboxylic acid
  • Figure imgb0354
    • Step 1: methyl 2-oxo-1-(3-oxobutyl)cyclopentanecarboxylate
  • A solution of methyl 2-oxocyclopentanecarboxylate (2.000 ml, 14.07 mmol), methyl vinyl ketone (1.381 ml, 16.88 mmol) and triethylamine (2.94 ml, 21.10 mmol) in toluene (20 mL) was heated at 40 °C for 24 h. The reaction was brought to room temperature, diluted with EtOAc, washed with sat. NH4Cl, dried over Na2SO4, filtered, concentrated and chromatographed on silica gel using 0-50% heptane/EtOAc to afford a colorless oil as methyl 2-oxo-1-(3-oxobutyl)cyclopentanecarboxylate (2.0 g, 9.42 mmol, 67.0% yield). Step 2: methyl 5-(pyrrolidin-1-yl)-2,6,7,7a-tetrahydro-1H-indene-7a-carboxylate
  • A solution of methyl 2-oxo-1-(3-oxobutyl)cyclopentanecarboxylate (2.0 g, 9.42 mmol, 67.0 % yield) and pyrrolidine (2.354 ml, 28.1 mmol) in dry toluene (25 mL) was heated to reflux under N2 atmosphere in a Dean-Stark trap for 16 h. The reaction went to completion and concentrated. The residue was dissolved in EtOAc, washed with water, brine, dried over Na2SO4, filtered and concentrated to afford a greenish oil as methyl 5-(pyrrolidin-1-yl)-2,6,7,7a-tetrahydro-1H-indene-7a-carboxylate (3.3 g, 13.34 mmol, 95% yield) to be used as is.
    • Step 3: methyl 6-oxo-2,3,3a,4,5,6-hexahydro-1H-indene-3a-carboxylate
  • The crude enamine from Step 2 was dissolved in toluene (20 mL) and a solution of sodium acetate (1.360 ml, 25.3 mmol) in AcOH/water (4/4 mL) was added and the resulting mixture was heated to reflux under N2 atmosphere for 2 h. The reaction went to completion, diluted with EtOAc, washed with water, sat. NH4Cl, sat. NaHCO3, brine, dried over Na2SO4, filtered, concentrated and chromatographed on silica gel using 0-30% heptane/EtOAc to afford methyl 6-oxo-2,3,3a,4,5,6-hexahydro-1H-indene-3a-carboxylate (1.32 g, 6.80 mmol, 48.3% yield) as a bright yellow oil. MS m/z=195.2 [M+H]+.
    • Step 4: (3aS,7aR)-methyl 6-oxooctahydro-1H-indene-3a-carboxylate
  • To a stirred solution of methyl 6-oxo-2,3,3a,4,5,6-hexahydro-1H-indene-3a-carboxylate (1.32 g, 6.80 mmol) in EtOH (30 mL) was added palladium, 10 wt.%(dry basis) on activated carbon, wet, degussa type e101 ne/w (0.120 ml, 6.80 mmol) and the resulting mixture underwent hydrogenation using the hydrogenation kit for 3 h. The mixture was filtered through celite, concentrated and chromatographed on silica gel using 0-25% heptane/hexane to afford (3aS,7aR)-methyl 6-oxooctahydro-1H-indene-3a-carboxylate (0.278 g, 1.417 mmol, 20.84% yield) and (3aS,7aS)-methyl 6-oxooctahydro-1H-indene-3a-carboxylate (0.394 g, 2.008 mmol, 29.5% yield) as colorless oil. MS m/z=181.2 [M+H]+.
    • Steps 5 through 8.
  • 1-((3aS,5R,7aS)-3a-(methoxycarbonyl)octahydro-1H-inden-5-yl)-5-(trifluoromethyl)-1 H-p yrazole-4-carboxylic acid was prepared from (3aS,7aR)-methyl 6-oxooctahydio-1H-indene-3a-carboxylate using similar procedures as in example D22. MS m/z=361.2 [M+H]+.
    • [Example D55] trans-1-(4-(Ethoxycarbonyl)-3,3-dimethylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid (racemic mixture)
  • Figure imgb0355
    • Step 1: Ethyl 2,2-dimethyl-4-oxocyclohexanecarboxylate (racemic mixture)
  • Methyllithium (170 mL of a 1.6 M solution with Et2O, 260 mmol) was added to a stirring mixture of copper (I) iodide (25 g, 130 mmol) and Et2O (130 mL), at -40 °C under a nitrogen atmosphere. After stirring for 10 min at -40 °C, ethyl 2-methyl-4-oxo-2-cyclohexene-1-carboxylate (12 g, 66 mmol) was added. After stirring for 30 min at -40 °C, the reaction mixture was allowed to warm to -20 °C. After stirring for 90 min at -20 °C, saturated aqueous ammonium chloride and EtOAc were added sequentially, the mixture was partitioned between more saturated aqueous ammonium chloride and EtOAc, the layers were separated, the organic material was washed sequentially with saturated aqueous ammonium chloride (2x) and brine, dried (Na2SO4), filtered, and the filtrate was concentrated. The residue was dissolved with DCM, silica gel (39 g) was added to the solution, and the volatiles were removed under reduced pressure. The residue was subjected to flash chromatography on silica gel (gradient elution; 19:1 to 9:1 hexane-EtOAc) to give ethyl 2,2-dimethyl-4-oxocyclohexanecarboxylate (8.9 g, 68% yield; racemic mixture) as a clear yellow oil.
    • Step 2: tert-Butyl trans-2-4-(ethoxycarbonyl)-3,3-dimethylcyclohexyl)hydrazinecarboxylate (racemic mixture)
  • NaBH(OAc)3 (29 g, 140 mmol) was added to a stirring solution of ethyl 2,2-dimethyl-4-oxocyclohexanecarboxylate (8.9 g, 45 mmol, from Step 1; racemic material), tert-butyl carbazate (6.5 g, 49 mmol), glacial AcOH (7.8 mL, 140 mmol), and THF (90 mL). After stirring for 26 h, the reaction mixture was added to saturated aqueous NaHCO3, the mixture was stirred for 60 min, partitioned between EtOAc and more saturated aqueous NaHCO3, the layers were separated, the organic material was washed sequentially with saturated aqueous NaHCO3 and brine, dried (Na2SO4), filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved with DCM, silica gel (42 g) was added to the solution, and the volatiles were removed under reduced pressure. The residue was subjected to flash chromatography on silica gel (gradient elution; 9:1 to 4:1 hexane-EtOAc) and the isolated material containing the desired product was re-subjected to flash chromatography on silica gel (5:1 hexane-EtOAc) to give tert-butyl trans-2-4-(ethoxycarbonyl)-3,3-dimethylcyclohexyl)hydrazinecarboxylate (0.79 g, 5.6% yield; racemic mixture) as a clear colorless oil.
    • Step 3: Ethyl trans-4-hydrazinyl-2,2-dimethylcyclohexanecarboxylate hydrochloride (racemic mixture)
  • Hydrogen chloride (3.1 mL of a 4.0 M solution with 1,4-dioxane, 13 mmol) was added to a stirring solution of tert-butyl trans-2-4-(ethoxycarbonyl)-3,3-dimethylcyclohexyl)hydrazinecarboxylate (0.79 g, 2.5 mmol, from Step 2; racemic material) and EtOH (5.0 mL), and then the reaction mixture was heated at 60 °C. After stirring for 3 h at 60 °C, the reaction mixture was allowed to cool to room temperature and then concentrated under reduced pressure to give ethyl trans-4-hydrazinyl-2,2-dimethylcyclohexanecarboxylate hydrochloride (0.63 g, 100% yield; racemic mixture) as an off-white solid.
    • Step 4: Benzyl trans-1-4-(ethoxycarbonyl)-3,3-dimethylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-ca rboxylate (racemic mixture)
  • A solution of (Z)-benzyl 2-((dimethylamino)methylene)-4,4,4-trifluoro-3-oxobutanoate (0.76 g, 2.5 mmol) and EtOH (2.4 mL) was added to a stirring solution of ethyl trans-4-hydrazinyl-2,2-dimethylcyclohexanecarboxylate hydrochloride (0.63 g, 2.5 mmol, from Step 3; racemic mixture), DIPEA (0.96 mL, 5.5 mmol), and EtOH (6.0 mL). After stirring for 20 h, the reaction mixture was concentrated under reduced pressure, the residue was partitioned between EtOAc and saturated aqueous NaHCO3, the layers were separated, the organic material was washed sequentially with saturated aqueous NaHCO3 and brine, dried (Na2SO4), filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved with DCM, silica gel (5.0 g) was added to the solution, and the volatiles were removed under reduced pressure. The residue was subjected to flash chromatography on silica gel (19:1 hexane-EtOAc) to give benzyl trans-1-4-(ethoxycarbonyl)-3,3-dimethylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-ca rboxylate (0.76 g, 67% yield; racemic mixture) as a clear colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 7.46-7.29 (m, 5H), 5.30 (s, 2H), 4.67-4.52 (m, 1H), 4.25-4.05 (m, 2H), 2.35-2.23 (m, 1H), 2.12-1.84 (m, 5H), 1.69 (dd, J = 3.2, 12.8 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.09 (s, 3H), 1.07 (s, 3H). LCMS (ESI): 453.0 (M+H)+.
    • Step 5: trans-1-(4-(Ethoxycarbonyl)-3,3-dimethylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid (racemic mixture)
  • A stirring mixture of benzyl trans-1-4-(ethoxycarbonyl)-3,3-dimethylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-ca rboxylate (0.76 g, 1.7 mmol, from Step 4; racemic mixture), palladium (0) (10 wt. % dry basis, wet) on activated carbon (0.18 g, 0.17 mmol), EtOAc (4.2 mL), and EtOH (4.2 mL) was exposed to gaseous hydrogen (33 psi). After stirring for 2 h, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give trans-1-(4-(ethoxycarbonyl)-3,3-dimethylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid (0.59 g, 97% yield; racemic mixture) as a colorless solid. LCMS (ESI): 363.0 (M+H)+.
    • [Reference example D60] 1-(((+/-)-cis)-2-allylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid as a racemate (D60)
  • Figure imgb0356
    • Step 1: tert-butyl 2-(((+/-)cis)-2-allylcyclohexyl)hydrazinecarboxylate as a racemate
  • To a solution of tert-butyl carbazate (0.966 g, 7.31 mmol), 2-allylcyclohexanone (1.00 g, 7.24 mmol), and AcOH (1.00 ml, 17.47 mmol) at 0 °C was added NaBH(OAc)3 (4.60 g, 21.71 mmol) and the mixturew was stirred at room temperature overnight. The reaction mixture was added slowly to a saturated aqueous solution of Na2CO3. The layers were separated and the aqueous layer was extracted with DCM twice. The organics were pooled, washed with brine, dried over Na2SO4, decanted and concentrated in vacuo to provide a colorless syrup. NMR indicated ∼0.16:1 mixture of isomers. The syrup was purified by silical gel column chromatography eluting with a gradient of 0% to 50% EtOAc in hexane. The first eluting peak was collected and concentrated in vacuo to provide tert-butyl 2-(((+/-)cis)-2-allylcyclohexyl)hydrazinecarboxylate as a racemate. Step 2: (((+/-)cis)-2-allylcyclohexyl)hydrazine dihydrochloride as a racemate
  • 4 M HCl in dioxane (11.79 ml, 47.2 mmol) was added to a solution of tert-butyl 2-(((+/-)cis)-2-allylcyclohexyl)hydrazinecarboxylate as a racemate (1.20 g, 4.72 mmol) in EtOH (11.79 ml) and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo to provide (((+/-)cis)-2-allylcyclohexyl)hydrazine dihydrochloride as a racemic, white solid.
    • Step 3: ethyl 1-(((+/-)cis)-2-allylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate as a racemate
  • A solution of (Z)-ethyl 2-((dimethylamino)methylene)-4,4,4-trifluoro-3-oxobutanoate (1.073 g, 4.49 mmol) in EtOH (11 mL) was added slowly to a solution of (((+/-)cis)-2-allylcyclohexyl)hydrazine dihydrochloride as a racemate (1.07 g, 4.71 mmol) and DIPEA (1.724 ml, 9.87 mmol) in EtOH (22.43 ml) at room temperature. After 6 h, the reaction mixture was concentrated in vacuo, diluted with water and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na2SO4, decanted and concentrated in vacuo to provide an orange oil. The mixture was purified by silica gel column chromatography eluting with a gradient of 0% to 35% EtOAc in hexane to provide ethyl 1-(((+/-)cis)-2-allylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate as a racemate as a pale yellow oil.
    • Step 4: 1-(((+/-)-cis)-2-allylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid as a racemate
  • A solution of lithium hydroxide hydrate (1.265 g, 30.2 mmol) in water was added to a solution of ethyl 1-(((+/-)cis)-2-allylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate as a racemate (0.996 g, 3.02 mmol) in THF and MeOH and the mixture was stirred at room temperature overnight. The mixture was concentrated in vacuo. The resulting turbid solution was diluted with water to provide a clear solution. The pH was adjusted to 1 by adding 1 M HCl and the mixture was stirred vigorously for 30 min. The resulting precipitate was collected by vacuum filtration to provide 1-(((+/-)-cis)-2-allylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid as a racemate (D60) as a white solid.
    • [Reference example D68 (cis and trans)] 1-((1r,4r)-4-(2-ethoxy-2-oxoethyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylic acid and 1-((1s,4s)-4-(2-ethoxy-2-oxoethyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid
  • Figure imgb0357
    • Step 1: ethyl 2-(8-methyl-1,4-dioxaspiro[4.5]decan-8-yl)acetate
  • To a solution of CuI (5.8 g, 30 mmol, 3.24 eq) in Et2O (100 mL) maintained under N2 at 0 °C was added a solution of 3.0 M MeLi (21.3 mL, 64 mmol, 6.8 eq) in dimethoxyethane dropwise. The resulting solution was stirred at 0 °C for 10 min and the ether solvent was removed from the reaction under vacuum (120 torr) at 0 °C. DCM (100 mL) was then added to the residue and the reaction was cooled to -78 °C. TMSCl (4.4 mL, 35 mmol, 3.7 eq) was added followed by ethyl 2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetate (JW Pharmlab, Levittown, PA; 2.127 g, 9.4 mmol) in DCM (10 mL). The reaction mixture was stirred overnight and quenched with aqueous NH4Cl solution. The black suspension was filtered through celite and the organic layer was separated, washed, dried and purified by silica gel chromatography (EtOAc/hexane, up to 15%) on 80 g gold column to give ethyl 2-(8-methyl-1,4-dioxaspiro[4.5]decan-8-yl)acetate (1.6 g, 6.60 mmol, 70.2% yield) as a colorless liquid: 1H NMR (500 MHz, CDCl3) δ 1.07 (s, 3H), 1.19-1.33 (m, 3H), 1.49-1.67 (m, 8H), 2.27 (s, 2H), 3.94 (s, 4H), 4.09-4.16 (m, 2H).
    • Step 2: ethyl 2-(1-methyl-4-oxocyclohexyl)acetate
  • Water (0.5 mL) was added to a stirring solution of ethyl 2-(8-methyl-1,4-dioxaspiro[4.5]decan-8-yl)acetate (1.6 g, 6.60 mmol) and formic acid (10 mL) at room temperature. Analysis of the reaction mixture by LCMS indicated that the starting material was consumed and the desired product had formed. The reaction mixture was concentrated under reduced pressure, and the residue was partitioned between EtOAc and brine, the layers were separated, the organic material was washed with brine (2x), dried (Na2SO4) filtered, and the filtrate was concentrated under reduced pressure to give a pale yellow liquid ethyl 2-(1-methyl-4-oxocyclohexyl)acetate (1.6 g, 8.07 mmol, 86% yield): 1H NMR (500 MHz, CDCl3) δ 1.22-1.31 (m, 6H), 1.77-1.91 (m, 4H), 2.39-2.43 (m, 6H), 4.12-4.23 (m, 2H).
    • Step 3: tert-butyl 2-(4-(2-ethoxy-2-oxoethyl)-4-methylcyclohexyl)hydrazinecarboxylate
  • Ethyl 2-(1-methyl-4-oxocyclohexyl)acetate (1.5 g, 7.57 mmol) and tert-butyl carbazate (1.100 g, 8.32 mmol) were dissolved in chloroform (30 mL), and AcOH (1.0 mL) and NaBH(OAc)3 (5.65 g) were added under ice-cooling. The mixture was allowed to gradually return to room temperature, and the mixture was stirred for 4 h. The reaction mixture was poured into saturated aqueous NaHCO3 solution, and the mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane:EtOAc, 100%-35%) to give tert-butyl 2-(4-(2-ethoxy-2-oxoethyl)-4-methylcyclohexyl)hydrazinecarboxylate (1.72 g, 5.47 mmol, 72.3% yield) as a mixture of isomers (colorless oil). LCMS = 315.4 (M+H)+.
    • Step 4: ethyl 2-(4-hydrazinyl-1-methylcyclohexyl)acetate hydrochloride
  • tert-Butyl 2-(4-(2-ethoxy-2-oxoethyl)-4-methylcyclohexyl)hydrazinecarboxylate (1.7 g, 5.41 mmol) in EtOH (5 mL) was added HCl (4 M in 1,4-dioxane, 10 mL) dropwise at 0 °C. The mixture was stirred at room temperature for 4 h and concentrated to give a white solid, used without further purification in the next step.
    • Step 5: benzyl 1-(4-(2-ethoxy-2-oxoethyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carbo xylate
  • A solution of (Z)-benzyl 2-((dimethylamino)methylene)-4,4,4-trifluoro-3-oxobutanoate (2.018 g, 6.70 mmol) in EtOH (20 mL) was added dropwise to a solution of ethyl 2-(4-hydrazinyl-1-methylcyclohexyl)acetate hydrochloride (1.6 g, 6.38 mmol) and DIPEA (2.452 ml, 14.04 mmol) in EtOH (31.9 ml) at ambient temperature. The reaction was allowed to stir overnight. The solvent was removed and the residual oil was purified using a 40 g REDISEP™ Gold SiO2 column eluting with 0-25% EtOAc/hexane using the Gold resolution method. Fractions containing the desired product were combined and concentrated in vacuo to provide benzyl 1-(4-(2-ethoxy-2-oxoethyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carbo xylate (2.12 g, 4.69 mmol, 73.4% yield) as a mixture of isomers (colorless syrup). LCMS = 453.4 (M+H)+.
    • Step 6: 1-((1r,4r)-4-(2-ethoxy-2-oxoethyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylic acid and 1-((1s,4s)-4-(2-ethoxy-2-oxoethyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid
  • Benzyl 1-(4-(2-ethoxy-2-oxoethyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carbo xylate (2.1 g, 4.64 mmol) was dissolved in EtOH (10 mL) and EtOAc (10 mL) and added to wet Pd/C (10%, 210 mg) in a pressure flask under N2. The reaction mixture was equipped with a pressure gauge and one arm was connected vacuum and the other to hydrogen cylinder. The pressure was set to 20 psi and the reaction system was connected to hydrogen and open to vacuum twice. Then the valves were closed and the reaction mixture was stirred for 2 h. The pressure of the gauge was 5 psi and LCMS showed completion. Filtration through celite and removal of solvents gave an oil (1.5 g). The material was separated by prep SFC: 150x50 mm AD-H column with 18 mL/min MeOH (20 mM NH3) + 162 g/min CO2, 10% co-solvent at 180 g/min. Temp. = 29°C, Outlet pressure = 100 bar, Wavelength = 230 nm. Injected 0.5 mL of 1,500 mg sample dissolved in 20 mL 1:1 MeOH:DCM; c= 75 mg/mL and 37.5 mg per injection. Cycle time 11 min, run time 15 min, to give Peak 1: white solid 1-((1r,4r)-4-(2-ethoxy-2-oxoethyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylic acid (600 mg, 1.656 mmol, 35.7% yield): 1H NMR (500 MHz, CD2Cl2) δ 1.14 (s, 3H), 1.23-1.28 (m, 3H), 1.46-1.58 (m, 2H), 1.67-1.77 (m, 2H), 1.79-1.87 (m, 2H), 2.16-2.28 (m, 4H), 4.08-4.14 (m, 2H), 4.32 (tt, J=11.7, 4.1 Hz, 1H), 6.76 (br. s, 1H), 7.94 (s, 1H). LCMS = 363.3 (M+H)+; Peak 2:
    1-((1s,4s)-4-(2-ethoxy-2-oxoethyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid (700 mg, 1.932 mmol, 41.6% yield): 1H NMR (500 MHz, CDCl3) δ 1.09 (s, 3H), 1.25-1.28 (m, 3H), 1.33-1.43 (m, 2H), 1.82-1.88 (m, 4H), 2.17-2.32 (m, 2H), 2.47 (s, 2H), 4.12-4.17 (m, 2H), 4.35 (tt, J=11.7, 3.9 Hz, 1H), 6.72 (br. s, 1H), 7.98 (s, 1H).
    LCMS = 363.4 (M+H)+.
  • The following pyrazole carboxylic acids were prepared using similar procedure in reference examples described above.
    Figure imgb0358
    Figure imgb0359
    Figure imgb0360
    Figure imgb0361
    Figure imgb0362
    Figure imgb0363
    Figure imgb0364
    Figure imgb0365
    Figure imgb0366
    Figure imgb0367
    reference example structure reference example structure
    D40
    Figure imgb0368
         		D46
    Figure imgb0369
    D40b
    Figure imgb0370
         		D47
    Figure imgb0371
    D41
    Figure imgb0372
         		D48
    Figure imgb0373
    D42
    Figure imgb0374
         		D49
    Figure imgb0375
    D43
    Figure imgb0376
         		D50
    Figure imgb0377
    D44
    Figure imgb0378
         		D51
    Figure imgb0379
    D45
    Figure imgb0380
         		D52
    Figure imgb0381
    D53
    Figure imgb0382
         		D60
    Figure imgb0383
    D54
    Figure imgb0384
         		D61
    Figure imgb0385
    D55
    Figure imgb0386
         		D62
    Figure imgb0387
    D56
    Figure imgb0388
         		D63
    Figure imgb0389
    D57
    Figure imgb0390
         		D64
    Figure imgb0391
    D58
    Figure imgb0392
         		D65
    Figure imgb0393
    D59
    Figure imgb0394
         		D66
    Figure imgb0395
    D67
    Figure imgb0396
    D68
    Figure imgb0397
    D69
    Figure imgb0398
    D70
    Figure imgb0399
    D71
    Figure imgb0400
    D72
    Figure imgb0401
    • [Example 1] trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluo romethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0402
    • Step 1: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-(triethylsilyloxy)ethyl)(4-fluorobenzyl)carbamo yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (1-1)
  • To a mixture of acid D1 (6.22 g, 18.6 mmol) and amine A1 (8.67 g, 20.4 mmol) in DMF (100 mL) were added HATU (8.48 g, 22.3 mmol) and DIPEA (4.74 mL, 27.9 mmol) and the mixture was stirred at room temperature for 5 h. The reaction mixture was quenched with water (200 mL) and extracted with EtOAc (2×100 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over Na2SO4 and concentrated under reduced pressure to afford compound 1-1 (15 g, crude) as a brown gum.
    • Step 2: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(4-fluorobenzyl)carbamoyl)-5-(tri fluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (1-2)
  • To a stirred solution of compound 1-1 (15 g, 20.2 mmol) in THF (20 mL) was added TBAF (1.0 M in THF, 40.4 mL, 40.4 mmol) dropwise at 0 °C, and the mixture was allowed to warm up from 0 °C to room temperature while stirred for 2 h. The reaction mixture was quenched with saturated aqueous NH4Cl (100 mL) and extracted with EtOAc (2×150 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, eluent: 70% EtOAc/hexane) to provide compound 1-2 (9.9 g, 84% over two steps) as a yellow-brown gum. 1H NMR (CDCl3) rotomers present δ 8.42 and 8.38 (2H, 2xs) ; 7.57 and 7.53 (1H, 2xs); 7.41-7.35 and 7.14-7.09 (4H, 2xm) ; 5.61-5.45 (1H, m); 5.10-4.50 (3H, m); 4.25-3.90 (4H, m); 3.31-3.15 (1H, m); 2.23-2.16 (6H, m) ; 1.65-1.51 (2H, m) ; 1.28-1.23 (3H, m); LCMS: 631 (M+H)+.
    • Step 3: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluo romethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (1-3)
  • To a stirred solution of compound 1-2 (9.9 g, 15.6 mmol) in DCM (120 mL) was added Dess-Martin periodinane (21.9 g, 21:9 mmol) in portions, and the mixture was stirred at room temperature for 3 h. The reaction mixture was quenched with NaHCO3 (50 mL, sat. aq.) and Na2S2O3 (50 mL, sat. aq.), then extracted with DCM (2×150 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, eluent: 10% EtOAc/hexane) to yield compound 1-3 (9.12 g, 92%) as a white solid. 1H NMR (CDCl3) rotomers present δ 8.74 and 8.67 (2H, 2xs); 7.85 and 7.79 (1H, 2xs); 7.30-7.26 (1H, m); 7.41-7.37 and 7.22-7.15 (3H, 2xm); 4.73-4.51 (4H, m) ; 4.27-4.21 (1H, m) ; 4.07 (2H, q, J = 7.2 Hz) ; 2.50-2.48 (1H, m) ; 2.06-1.93 (6H, m) ; 1.59-1.54 (2H, m) ; 1.18 (3H, t, J = 6.9 Hz); LCMS: 629 (M+H)+.
    • Step 4: trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluo romethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (1)
  • To a stirred solution of compound 1-3 (9.12 g, 14.5 mmol) in a mixture of THF/water/EtOH (77 mL, 7:1:7) was added LiOH (4.0 M aq. solution, 4.45 mL, 57.9 mmol) dropwise at 0 °C. The mixture was allowed to warm to room temperature while stirring continued for 4 h. The reaction mixture was acidified with HCl (1 M, 60 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over Na2SO4 and concentrated under reduced pressure to provide the compound of example 1 (8.0 g, 94%) as a white solid. 1H NMR (CDCl3) rotomers present δ 8.53 and 8.47 (2H, 2xs) ; 7.69 and 7.60 (1H, 2xs) ; 7.31-7.28 (1H, m) ; 7.16-7.12 (1H, m) ; 7.06-7.02 (2H, m) ; 4.83 and 4.65 (2H, 2xs) ; 4.61 and 4.30 (2H, 2xs), 4.27-4.21 (1H, m); 2.78 (1H, m) ; 2.44-2.40 (2H, m) ; 2.26-2.15 (2H, m) ; 1.96-1.86 (2H, m) ; 1.74-1.67 (2H, m); LCMS (ESI): 601.2 (M+H)+.
    • [Example 2] trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • Figure imgb0403
    • Step 1: ethyl trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-((triethylsilyl)oxy)ethyl)(3,5-difluorobenzyl )carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (2-1)
  • To a solution of acid D2 (12.5 g, 35.9 mmol) and (COCl)2 (4.62 mL, 39.51 mmol) in DCM (150 mL) was added DMF (catalytic amount), and the whole was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure and dried under high vacuum. The residue was dissolved in DCM (10 mL) and added dropwise to a mixture of amine A31 (18.3 g, 39.5 mmol) and Et3N (10.0 mL, 71.8 mmol) in DCM (150 mL) at 0 °C. Upon completion of reaction (monitored by TLC), the mixture was quenched with water (50 mL) and extracted with DCM (2 x 100 mL). The combined organic layer was washed with brine (20 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-10% EtOAc/hexane as eluent) to provide compound 2-1 (27.0 g, 91%) as a colorless gum. 1H NMR (CDCl3) rotomers present δ 7.54 and 7.47 (1H, 2xs); 7.02-6.98 (2H, m) ; 6.87-6.86 and 6.56-6.54 (2H, 2xm); 6.73-6.71 (1H, m) ; 5.90-5.88 and 5.50-5.47 (1H, 2xm); 4.99-4.29 (2H, m) ; 4.18-4.12 and 3.30-3.26 (4H, 2xm) ; 3.87-3.81 (1H, m) ; 2.21-2.16 (2H, m) ; 1.89-1.88 (6H, m) ; 1.35-1.24 (6H, m); 0.91-0.84 (9H, m); 0.58-0.48 (6H, m).
    • Step 2: ethyl trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-hydroxyethyl)(3,5-difluorobenzyl)carbamoy 1)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (2-2)
  • Compound 2-2 was prepared using a similar procedure to that described in example 1, step 2.
    • Step 3: ethyl trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (2-3)
  • Compound 2-3 was prepared using a similar procedure to that described in example 1, step 3.
    • Step 4: trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid (2)
  • The compound of example 2 was prepared using a similar procedure to that described in example 1, step 4. 1H NMR (CDCl3) rotomers present δ 8.55 and 8.49 (2H, 2xs) ; 7.66 and 7.62 (1H, 2xs); 6.85-6.69 (3H, m) ; 4.83 and 4.70 (2H, 2xs) ;4.62 and 4.34 (2H; 2xs) ; 4.29-4.21 (1H, m); 2.25-2.17 (2H, m) ; 1.94-1.88 (6H, m); 1.41 and 1.40 (3H, 2xs) LCMS (ESI): 650.2 (M+H)+.
    • [Example 3] trans-4-(4-((3,5-difluorobenzyl)(2-(2,4-dimethylthiophen-3-yl)-2-oxoethyl)carbamoyl)-5-(t rifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0404
    • Step 1 and 2: ethyl trans-4-(4-((3,5-difluorobenzyl)(2-(2,4-dimethylthiophen-3-yl)-2-hydroxyethyl)carbamoyl) -5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (3-2)
  • To a mixture of acid D1 (162 mg, 0.48 mmol) and amine A56 (200 mg, 0.48 mmol) in DMF (4 mL) were added DIPEA (0.12 mL, 0.72 mmol) and HATU (221 mg, 0.58 mmol) at room temperature and stirred at the same temperature for 4 h. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (2x20 mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4 and concentrated under reduced pressure to provide a yellow residue.
  • To a stirred solution of the yellow residue was added TBAF (1 M in THF, 0.96 mL, 0.96 mmol) dropwise at room temperature. The mixture was stirred at the same temperature for 1 h. The reaction mixture was quenched with saturated aqueous NaHCO3 solution and extracted with EtOAc (2x20 mL). The organic layers were washed with brine (2 x 10 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc/hexane as eluent) to provide compound 3-2 (290 mg, 97%) as a colorless gum.
    • Step 3: ethyl trans-4-(4-((3,5-difluorobenzyl)(2-(2,4-dimethylthiophen-3-yl)-2-oxoethyl)carbamoyl)-5-(t rifluoromethyl)-1H-pyrazol-1-yl)cyelohexanecarboxylate (3-3)
  • To a stirred solution of compound 3-2 (290 mg, 0.47 mmol) in DCM (8 mL) was added Dess-Martin periodinane (401 mg, 0.94 mmol) at 0 °C and the mixture was stirred at room temperature for 3 h. The reaction mixture was quenched with saturated aqueous Na2S2O3 and NaHCO3, and extracted with EtOAc (2x20 mL). The combined organic layers were washed with brine (2 x 10 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 30% EtOAc/hexane as eluent) to provide compound 3-3 (220 mg, 78%) as a colorless gum.
    • Step 4: trans-4-(4-((3,5-difluorobenzyl)(2-(2,4-dimethylthiophen-3-yl)-2-oxoethyl)carbamoyl)-5-(t rifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (3)
  • To a solution of compound 3-3 (220 mg, 0.37 mmol) in EtOH (1 mL), THF (1 mL) and H2O (0.2 mL) was added LiOH (4 M aqueous solution, 0.55 mL, 2.2 mmol) dropwise, and the mixture was stirred at room temperature for 2 h. The reaction mixture was quenched by dropwise addition of 1 M aqueous HCl (pH was adjusted to 4.0) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (2 x 10 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (C18 silica gel, 56% water/CH3CN as eluent) to provide the compound of example 3 (56 mg, 26%) as a white solid. 1H NMR (DMSO-d6) rotamers present δ 7.63 and 7.50 (1H, 2xs) ; 7.14 and 7.09 (1H, 2xs) ; 6.83-6.81 (1H, m) ; 6.77-6.68 (2H, m) ; 4.78 and 4.69 (2H, 2xs) ; 4.59 and 4.28 (2H, 2xs) ; 4.27-4.18 (1H, m) ; 2.49-2.38 (4H, m) ; 2.25-2.18 (5H, m) ; 2.10-1.97 (4H, m) ; 1.70-1.57 (2H, m); LCMS (APCI): 584 (M+H)+.
    • [Example 4] trans-4-(4-((2-(2;6-dichloro-4-(methylsulfonyl)phenyl)-2-xoethyl)(3,5-difluorobenzyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0405
    • Step 1: ethyl trans-4-(4-((2-(2,6-dichloro-4-(methylthio)phenyl)-2-((triethylsilyl)oxy)ethyl)(3,5-difluoro benzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (4-1)
  • Compound 4-1 (0.44 g, crude) was obtained as a brown color gum from the reaction of amine A57 (0.26 g, 0.52 mmol), acid D1 (0.17 g, 0.52 mmol), HATU (0.24 g, 0.63 mmol) and DIPEA (0.13 mL, 0.79 mmol) in DMF (5 mL) using a similar procedure to that described in example 1.
    • Step 2: ethyl trans-4-(4-((2-(2,6-dichloro-4-(methylthio)phenyl)-2-hydroxyethyl)(3,5-difluorobenzyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (4-2)
  • Compound 4-2 (0.38 g, 91%) was obtained as brown color gum from the reaction of compound 4-1 (0.44 g, 0.59 mmol) and TBAF (1.0 M in THF, 0.31 mL, 1.19 mmol) in THF (10 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-((2-(2,6-dichloro-4-(methylthio)phenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbam oyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (4-3)
  • Compound 4-3 (0.1 g, 26%) was obtained as a colorless gum from the reaction of compound 4-2 (0.38 g, 0.61 mmol) and Dess-Martin periodinane (0.52 g, 1.22 mmol) in DCM (10 mL) using a similar procedure to that described in example 1.
    • Step 4: ethyl trans-4-(4-((2-(2,6-dichloro-4-(methylsulfonyl)phenyl)-2-oxoethyl)(3,5-difluorobenzyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (4-4)
  • To a stirred solution of compound 4-3 (0.1 g, 0.1 mmol) in DCM (5 mL) was added m-CPBA (84 mg, 0.48 mmol) at room temperature. The mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water (30 mL) and extracted with DCM (2 x 20 mL). The combined organic layers were washed with 10% NaOH solution (20 mL), water (30 mL), brine (30 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to provide compound 4-4 (0.17 g, 65%) as a colorless oil.
    • Step 5: trans-4-(4-((2-(2,6-dichloro-4-(methylsulfonyl)phenyl)-2-oxoethyl)(3,5-difluorobenzyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (4)
  • The compound of example 4 (50 mg, 52%) was obtained as a white solid from the reaction of compound 4-4 (0.1 g, 0.13 mmol) and LiOH (20 mg, 0.82 mmol) in THF/MeOH/water (2:2:1, 5 mL) using a similar procedure to that described in example 1.
    1H NMR (DMSO-d6) rotamers present δ 12.21 (1H, brs) ; 8.10 and 8.03 (2H, 2xs) ; 7.88 and 7.86 (1H, 2xs); 7.20-7.14 (1H, m); 7.11-7.08 and 6.95-6.92 (2H, 2xm) ; 4.85 and 4.73 (2H, 2xs) ; 4.69 and 4.57 (2H, 2xs); 4.28-4.17 (1H, m) ; 3.37 and 3.32 (3H, 2xs) ; 2.35-2.29 (1H, m) ; 2.07-2.02 (2H, m) ; 1.98-1.90 (4H, m) ; 1.60-1.49 (2H, m); LCMS (APCI): 696 (M+H)+.
    • [Example 5] N-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-N-(3,5-difluorobenzyl)-1-(trans-4-(hydroxyca rbamoyl)cyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
  • Figure imgb0406
    • Step 1: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)(3,5-difluorobenzyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (5-1)
  • Compound 5-1 (633 mg, crude) was obtained as a brown gum from the reaction of acid D1, amine A18 (400 mg, 0.89 mmol), HATU (408 mg, 1.07 mmol) and DIPEA (0.23 mL, 1.34 mmol) in DMF (6.0 mL) using a similar procedure to that described in example 1.
    • Step 2: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,5-difluorobenzyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (5-2)
  • Compound 5-2 (410 mg, 71%) was obtained as a yellow solid from the reaction of compound 5-1 (633 mg, 0.83 mmol) and TBAF (1 M in THF, 1.65 mL, 1.65 mmol) in THF (3.0 mL) using a similar procedure to that described in example 1. LCMS: 649 (M+H)+.
    • Step 3: trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,5-difluorobenzyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (5-3)
  • Compound 5-3 (185 mg, 86%) was obtained as a white solid from the reaction of compound 5-2 (224 mg, 0.34 mmol) and LiOH·H2O (87 mg, 2.06 mmol) in THF (3.0 mL), EtOH (2.0 mL) and water (2.0 mL) using a similar procedure to that described in example 1.
    • Step 4: 1-(trans-4-(((tert-butyldimethylsilyl)oxy)carbamoyl)cyclohexyl)-N-(2-(3,5-dichloropyridin -4-yl)-2-hydroxyethyl)-N-(3,5-difluorobenzyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxa mide (5-4)
  • Compound 5-4 (173 mg, 84%) was obtained as a white solid from the reaction of compound 5-3 (170 mg, 0.27 mmol), O-(tert-butyldimethylsilyl)hydroxylamine (41 mg, 0.27 mmol), HATU (124 mg, 0.32 mmol) and DIPEA (0.07 mL, 0.41 mmol) in DMF (3.0 mL) using a similar procedure to that described in example 1. LCMS: 750 (M+H)+.
    • Step 5: 1-(trans-4-(((tert-butyldimethylsilyl)oxy)carbamoyl)cyclohexyl)-N-(2-(3,5-dichloropyridin -4-yl)-2-oxoethyl)-N-(3,5-difluorobenzyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide (5-5)
  • Compound 5-5 (100 mg, 58%) was obtained as a colorless gum from the reaction of compound 5-4 (173 mg, 0.23 mmol) and Dess-Martin periodinane (117 mg, 0.27 mmol) in DCM (20.0 mL) using a similar procedure to that described in example 1. LCMS: 748 (M+H)+.
    • Step 6: N-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-N-(3,5-difluorobenzyl)-1-(trans-4-(hydroxyca rbamoyl)cyclohexyl)-5-(trifluorome,thyl)-1H-pyrazole-4-carboxamide (5)
  • To a stirred solution of compound 5-5 (100 mg, 0.13 mmol) in THF (8 mL) was added TBAF (1 M in THF, 0.20 mL, 0.20 mmol) dropwise and the mixture was stirred at room temperature for 1 h. The reaction mixture was quenched with MeOH (2 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (2 x 10 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 7% MeOH/DCM as eluent) to provide the compound of example 5 (19 mg, 22%) as a white solid. 1H NMR (CDCl3) rotamers present δ 8.54 and 8.48 (2H, 2xs); 7.64 and 7.60 (1H, 2xs) ; 6.84-6.68 (3H, m) ; 4.82-4.25 (5H, m) ; 2.23-2.04 (7H, m); 1.83-1.73 (2H, m); LCMS (APCI): 634 (M+H)+.
    • [Example 6] N-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-N-(3,5-difluorobenzyl)-1-(trans-4-(methoxyca rbamoyl)cyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
  • Figure imgb0407
    • Step 1: N-(2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)-N-(3,5-difluorobenzyl)-1-(trans-4-(metho xycarbamoyl)cyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide (6-1)
  • To a mixture of compound 5-3 (75 mg, 0.12 mmol) and O-methylhydroxylamine hydrochloride (10 mg, 0.12 mmol) in DMF (3 mL) were added HATU (55 mg, 0.14 mmol) and DIPEA (0.05 mL, 0.30 mmol) and mixture was stirred at room temperature for 5 h. The reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with water, brine, dried over Na2SO4 and concentrated under reduced pressure to afford crude compound 6-1 (65 mg, 82%) as a white foam. LCMS: 650 (M+H)+.
    • Step 2: N-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-N-(3,5-difluorobenzyl)-1-(trans-4-(methoxyca rbamoyl)cyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide (6)
  • The compound of example 6 (15 mg, 23%) was obtained as a white solid from the reaction of compound 6-1 (65 mg, 0.099 mmol) and Dess-Martin periodinane (85 mg, 0.19 mmol) in DCM (5.0 mL) using a similar procedure to that described in example 1. 1H NMR (CDCl3) rotamers present δ 8.54 and 8.48 (2H, 2xs) ; 8.07 (1H, brs) ; 7.64 and 7.60 (1H, 2xs) ; 6.84-6.68 (3H, m) ; 4.82-4.25 (5H, m) ; 3.81 and 3.78 (3H, 2xs) ; 2.10-2.01 (7H, m) ; 1.84-1.75 (2H, m); LCMS (APCI): 648 (M+H)+.
    • [Example 7] trans-4-(4-((3,5-difluorobenzyl)(2-(2-hydroxy-6-methoxyphenyl)-2-oxoethyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0408
    • Step 1: ethyl trans-4-(4-((3,5-difluorobenzyl)(2-(2,6-dimethoxyphenyl)-2-((triethylsilyl)oxy)ethyl)carba moyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (7-1)
  • Compound 7-1 (0.23 g, crude) was obtained as a brown color gum from the reaction of amine A67 (0.13 g, 0.3 mmol), acid D1 (0.1 g, 0.3 mmol), HATU (0.13 g, 0.35 mmol) and DIPEA (76 µL, 0.44 mmol) in DMF (5 mL) using a similar procedure to that described in example 1.
    • Step 2: ethyl trans-4-(4-((3,5-difluorobenzyl)(2-(2,6-dimethoxyphenyl)-2-hydroxyethyl)carbamoyl)-5-(t rifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (7-2)
  • Compound 7-2 (0.22 g, crude) was obtained as brown color gum from the reaction of compound 7-1 (0.23 g, 0.3 mmol) and TBAF (1.0 M in THF), 0.61 mL, 0.6 mmol) in THF (5 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-((3,5-difluorobenzyl)(2-(2,6-dimethoxyphenyl)-2-oxoethyl)carbamoyl)-5-(triflu oromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (7-3)
  • Compound 7-3 (0.16 g, 73%) was obtained as a colorless gum from the reaction of compound 7-2 (0.22 g, 0.34 mmol) and Dess-Martin periodinane (0.29 g, 0.69 mmol) in DCM (10 mL) using a similar procedure to that described in example 1.
    • Step 4: ethyl trans-4-(4-((3,5-difluorobenzyl)(2-(2-hydroxy-6-methoxyphenyl)-2-oxoethyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (7-4)
  • To a stirred solution of compound 7-3 (50 mg, 0.07 mmol) in DCM (5 mL) was added BBr3 (1.0 M in DCM, 1.5 mL, 1.4 mmol) at room temperature and the mixture was stirred for 16 h. Solvent was evaporated under reduced pressure and the obtained residue was purified by column chromatography (silica gel, 30% EtOAc/hexane as eluent) to provide compound 7-4 (32 mg, 65%) as a brown color gum.
    • Step 5: trans-4-(4-((3,5-difluorobenzyl)(2-(2-hydroxy-6-methoxyphenyl)-2-oxoethyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (7)
  • The compound of example 7 (15 mg, 50%) was obtained as a white solid from the reaction of compound 7-4 (32 mg, 0.05 mmol) and LiOH (6.2 mg, 0.25 mmol) in THF/MeOH/water (2:2:1, 5 mL) using a similar procedure to that described in example 1.
    1H NMR (DMSO-d6) rotamers present δ 11.81 (1H, brs) ; 10.89 (1H, brs) ; 7.76 and 7.64 (1H, 2xs) ; 7.42-7.23 (1H, m) ; 7.18-6.86 (3H, m) ; 6.61-6.46 (2H, m) ; 4.82-4.51 (4H, m) ; 4.25-4.13 (1H, m) ; 3.84 and 3.65 (3H, 2xs); 2.28-2.21 (1H, m) ; 2.03-1.89 (6H, m) ; 1.55-1.44 (2H, m); LCMS (APCI): 596 (M+H)+.
    • [Example 8] trans-4-(4-((3,5-difluorobenzyl)(2-oxo-2-(1H-pyrazol-3-yl)ethyl)carbamoyl)-5-(trifluorom ethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0409
    • Step 1: ethyl trans-4-(4-((3,5-difluorobenzyl)(2-((triethylsilyl)oxy)-2-(1-((2-(trimethylsilyl)ethoxy)meth yl)-1H-pyrazol-3-yl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecar boxylate (8-1)
  • Compound 8-1 (34 mg, impure) was obtained as a colorless gum from the reaction of amine A75 (40 mg, 0.080 mmol), acid D1 (26 mg, 0.080 mmol), HATU (36.4 mg, 0.096 mmol) and DIPEA (0.020 mL, 0.120 mmol) in DMF (5 mL) using a similar procedure to that described in example 1.
    • Step 2: ethyl trans-4-(4-((3,5-difluorobenzyl)(2-hydroxy-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyr azol-3-yl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (8-2)
  • Compound 8-2 (25 mg, crude) was obtained as a colorless gum from the reaction of compound 8-1 (34 mg, 0.048 mmol) and TBAF (1 M in THF, 0.10 mL, 0.10 mmol) in THF (3 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-((3,5-difluorobenzyl)(2-oxo-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol -3-yl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (8-3)
  • Compound 8-3 (40 mg, 50%) was obtained as an off-white solid from the reaction of compound 8-2 (80 mg, 0.114 mmol) and Dess-Martin periodinane (97 mg, 0.228 mmol) in DCM (5 mL) using a similar procedure to that described in example 1.
    • Step 4: trans-4-(4-((3,5-difluorobenzyl)(2-oxo-2-(1H-pyrazol-3-yl)ethyl)carbamoyl)-5-(trifluorom ethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (8)
  • To a stirred solution of compound 8-3 (75 mg, 0.107 mmol) in 1,4-dioxane (2 mL) was added HCl (12 M, 0.5 mL). The mixture was stirred at 80 °C for 2 h. The solvent was removed under reduced pressure. The residue was dissolved in 1,4-dioxane (2 mL) and NH4OH (0.5 mL) was added. The reaction mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the residue was purified by reverse phase column chromatography (C18 silica gel, 70% CH3CN/water as eluent) to provide the compound of example 8 (10 mg, 16%) as a white solid. 1H NMR (CD3OD) rotamers present δ 7.74-7.50 (2H, m) ; 6.98-6.95 (1H, m) ; 6.87-6.78 (3H, m) ; 5.00 and 4.78 (2H, 2xs) ; 4.74 and 4.64 (2H, 2xs) ; 4.28-4.21 (1H, m) ; 2.36-2.28 (1H, m) ; 2.17-2.09 (2H, m); 2.02-1.93 (4H, m); 1.62-1.55 (2H, m); LCMS (APCI): 540 (M+H)+.
    • [Example 9] 4-(4-((3,5-difluorobenzyl)(2-(2,6-dihydroxyphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromet hyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0410
    • Step 1: ethyl trans-4-(4-((3,5-difluorobenzyl)(2-(2-hydroxy-6-methoxyphenyl)-2-oxoethyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (9-1)
  • To a solution of compound 7-4 (50 mg, 0.082 mmol) in dichloroethane (3 mL) was added BBr3 (0.822 mL, 0.822 mmol, 1 M in DCM) dropwise, and the mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure to yield compound 9-1 as a brown oil (50 mg, quant.).
    • Step 2: 4-(4-((3,5-difluorobenzyl)(2-(2,6-dihydroxyphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromet hyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (9)
  • To compound 9-1 (50 mg, 0.082 mmol) was added excess BBr3 (1 M in DCM) dropwise, and the mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (C18 silica gel, 55% water/CH3CN as eluent) to provide the compound of example 9 (3 mg, 6%) as a white solid. 1H NMR (DMSO-d6) rotamers present δ 11.91 (1H, brs) ; 7.79 and 7.61 (1H, 2xs); 7.28-6.88 (4H, m) ; 6.36-6.02 (2H, m) ; 4.89-4.13 (5H, m) ; 2.29-2.22 (1H, m); 2.05-1.83 (6H, m) ; 1.55-1.46 (2H, m) ; LCMS (ESI): 582 (M+H)+.
    • [Example 10] trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2,2-difluoroethyl)(3,5-difluorobenzyl)carbamoyl) -5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0411
    • Step 1: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2,2-difluoroethyl)(3,5-difluorobenzyl)carbamoyl) -5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (10-1)
  • To a mixture of acid D1 (56.7 mg, 0.16 mmol) and amine B15 (60 mg, 0.016 mmol) in pyridine (4 mL) was added POCl3 (0.02 mL, 0.25 mmol) dropwise at 0 °C and stirred at the same temperature for 1 h. The reaction mixture was quenched with saturated KHPO4 solution (5 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 15% EtOAc/hexane as eluent) to provide compound 10-1 (25 mg, 22%) as a pale yellow solid.
    • Step 2: trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2,2-difluoroethyl)(3,5-difluorobenzyl)carbamoyl) -5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (10)
  • The compound of example 10 (11 mg, 46%) was obtained as a white solid from the reaction of compound 10-1 (25 mg, 0.37 mmol) and LiOH (27 mg, 0.11 mmol) in EtOH (0.5 mL), THF (0.5 mL) and H2O (0.2 mL) using a similar procedure to that described in example 1. 1H NMR (DMSO-d6) rotamers present δ 8.75 and 8.69 (2H, 2xs); 7.91 and 7.74 (1H, 2xs) ; 7.21-6.75 (3H, m) ; 4.86 and 4.76 (2H, 2xs) ; 4.63-4.00 (3H, m) ; 2.34-2.23 (1H, m) ; 2.09-1.77 (6H, m) ; 1.61-1.44 (2H, m) ; LCMS (APCI): 641 (M+H)+.
    • [Example 11] trans-4-(4-((2-(2-amino-6-chloiophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(tri fluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0412
    • Step 1 ethyl trans-4-(4-((2-(2-chloro-6-nitrophenyl)-2-hydroxyethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (11-1)
  • Compound 11-1 (0.40 g, crude) was obtained as a pale yellow color gum from the reaction of amine A84 (0.2 g, 0.58 mmol), acid D1 (0.19 g, 0.58 mmol), HATU (0.26 g, 0.7 mmol) and DIPEA (0.14 mL, 0.87 mmol) in DMF (10 mL) using a similar procedure to that described in example 1.
    • Step 2: ethyl trans-4-(4-((2-(2-chloro-6-nitrophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifl uoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (11-2)
  • Compound 11-2 (0.28 g, 70%) was obtained as a colorless gum from the reaction of compound 11-1 (0.40 g, 0.6 mmol) and Dess-Martin periodinane (0.51 g, 1.2 mmol) in DCM (10 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-((2-(2-amino-6-chlorophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(tri fluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (11-3)
  • Compound 11-3 (70 mg, 74%) was obtained as a yellow color gum from the reaction of compound 11-2 (0.1 g, 0.15 mmol), Fe (85 mg, 1.52 mmol) and NH4Cl (81 mg, 1.52 mmol) in EtOH/water (4:1, 5 mL) using a similar procedure to that described in reference example A5 6, step 7.
    • Step 4: trans-4-(4-((2-(2-amino-6-chlorophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(tri fluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (11)
  • The compound of example 11 (8 mg, 33%) was obtained as a yellow solid from the reaction of compound 11-3 (20 mg, 0.03 mmol) and LiOH (3.8 mg, 0.16 mmol) in THF/MeOH/water (2:2:1, 5 mL) using a similar procedure to that described in example 1.
    1H NMR (DMSO-d6) rotamers present δ 12.17 (1H, brs) ; 7.79 and 7.79 (1H, 2xs) ; 7.17-6.93 (4H, m) ; 6.70-6.54 (2H, m) ; 5.80 (1H, brs) ; 5.53 (1H, brs) ; 4.77-4.59 (4H, m) ; 4.23-4.16 (1H, m) ; 2.29-2.22 (1H, m) ; 2.06-1.88 (6H, m) ; 1.57-1.46 (2H, m) ; LCMS (APCI): 599 (M+H)+.
    • [Example 12] trans-4-(4-((3,5-difluorobenzyl)(2-oxo-2-(2,4,6-trihydroxypyrimidin-5-yl)ethyl)carbamoyl) -5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0413
    • Step 1: ethyl trans-4-(4-((3,5-difluorobenzyl)(2-((triethylsilyl)oxy)-2-(2,4,6-tris(benzyloxy)pyrimidin-5-yl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (12-1)
  • Compound 12-1 was obtained (0.45 g, crude) as a brown color gum from the reaction of amine A85 (0.3 g, 0.4 mmol), acid D1 (0.14 g, 0.4 mmol), HATU (0.19 g, 0.5 mmol) and DIPEA (0.11 mL, 0.6 mmol) in DMF (5 mL) using a similar procedure to that described in example 1.
    • Step 2: ethyl trans-4-(4-((3,5-difluorobenzyl)(2-hydroxy-2-(2,4,6-tris(benzyloxy)pyrimidin-5-yl)ethyl)c arbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (12-2)
  • Compound 12-2 was obtained (0.31 g, 79%) as a brown color gum from the reaction of compound 12-1 (0.45 g, 0.4 mmol) and TBAF (1 M in THF, 0.9 mL, 0.8 mmol) in THF (10 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-((3,5-difluorobenzyl)(2-oxo-2-(2,4,6-tris(benzyloxy)pyrimidin-5-yl)ethyl)carba moyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (12-3)
  • Compound 12-3 was obtained (0.31 g, quant.) as a colorless gum from the reaction of compound 12-2 (0.31 g, 0.3 mmol) and Dess-Martin periodinane (0.29 g, 0.7 mmol) in DCM (10 mL) using a similar procedure to that described in example 1.
    • Step 4: trans-4-(4-((3,5-difluorobenzyl)(2-oxo-2-(2,4,6-trihydroxypyrimidin-5-yl)ethyl)carbamoyl) -5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (example 12)
  • To a stirred solution of compound 12-3 (0.1 g, 0.1 mmol) in dioxane (5 mL) was added 6 M HCl (5 mL) at room temperature and the mixture was stirred at 80 °C for 2 h. 10% NaOH solution was added to the reaction mixture up to pH 5 and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (C18 silica gel, 75% water/CH3CN as eluent) to provide the compound of example 12 (8 mg, 12%) as a white solid. 1H NMR (DMSO-d6) rotamers present δ 7.78 and 7.72 (1H, 2xs) ; 7.18-6.89 (3H, m) ; 4.92-4.56 (4H, m); 4.22-4.15 (1H, m); 2.33-2.25 (1H, m); 2.05-1.87 (6H, m) ; 1.57-1.46 (2H, m) ; LCMS (APCI): 600 (M+H)+.
    • [Example 13] trans-4-(4-((2-(2-acetamido-6-chlorophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0414
    • Step 1: ethyl trans-4-(4-((2-(2-acetamido-6-chlorophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (13-1)
  • To a stirred solution of compound 11-3 (45 mg, 0.07 mmol) in 1:1 mixture of pyridine and DCM (5 mL) was added CH3COCl (6 µL, 0.08 mmol) at 0 °C and stirred for 2 h. The reaction mixture was quenched with water (20 mL) and extracted with DCM (2 x 10 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20% EtOAc/hexane as eluent) to provide compound 13-1 (50 mg, quant.) as a yellow solid.
    • Step 2: trans-4-(4-((2-(2-acetamido-6-chlorophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (13)
  • The compound of example 13 (25 mg, 52%) was obtained as a white solid from the reaction of compound 13-1 (50 mg, 0.07 mmol) and LiOH (9 mg, 0.37 mmol) in THF/MeOH/water (2:2:1, 5 mL) using a similar procedure to that described in example 1.
    1H NMR (DMSO-d6) rotamers present δ 10.10 and 9.74 (1H, 2xs), 7.80 and 7.78 (1H, 2xs) ; 7.59-6.91 (6H, m) ; 4.82-4.61 (4H, m) ; 4.26-4.15 (1H, m) ; 2.34-2.24 (1H, m) ; 2.07-1.89 (9H, m) ; 1.58-1.47 (2H, m); LCMS (APCI): 641 (M+H)+.
    • [Example 14] trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(((S)-5,5-dimethylTHF-2-yl)methyl)c arbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0415
    • Step 1: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)(((S)-5,5-dimethylTHF -2-yl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyctohexanecarboxylate (14-1)
  • Compound 14-1 (42 mg, 61%) was obtained as a yellow foam from the reaction of acid D1 (31 mg, 0.09 mmol), amine A92 (40 mg, 0.09 mmol), HATU (42 mg, 0.11 mmol) and DIPEA (0.024 mL, 0.138 mmol) in DMF (3.0 mL) using a similar procedure to that described in example 1. LCMS (APCI): 749 (M+H)+.
    • Step 2: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(((S)-5,5-dimethylTHF-2-yl)meth yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (14-2)
  • Compound 14-2 (22 mg, 62%) was obtained as a colorless gum from the reaction of compound 14-1 (42 mg, 0.056 mmol) and TBAF (1 M in THF, 0.11 mL, 0.11 mmol) in THF (3.0 mL) using a similar procedure to that described in example 1.
    LCMS (APCI): 635 (M+H)+.
    • Step 3: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(((S)-5,5-dimethylTHF-2-yl)methyl)c arbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (14-3)
  • Compound 14-3 (15 mg, 70%) was obtained as a colorless gum from the reaction of compound 14-2 (22 mg, 0.034 mmol) and Dess-Martin periodinane (29 mg, 0.069 mmol) in DCM (4.0 mL) using a similar procedure to that described in example 1. LCMS (APCI): 633 (M+H)+.
    • Step 4: trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(((S)-5,5-dimethylTHF-2-yl)methyl)c arbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (14)
  • The compound of example 14 (7.5 mg, 54%) was obtained as a white solid from the reaction of compound 14-3 (15 mg, crude) and LiOH·H2O (8 mg, 0.19 mmol) in MeOH/THF/H2O (4 mL, 1:1:0.5) using a similar procedure to that described in example 1.
    1H NMR (DMSO-d6) rotamers present δ 12.16 (1H, brs), 8.79 and 8.72 (2H, 2xs); 7.84 and 7.69 (1H, 2xs); 5.01-4.76 (2H, m); 4.30-3.81 (3H, m); 2.33-2.26 (1H, m); 2.06-1.45 (13H, m) ; 1.19-1.04 (6H, m) ; LCMS (APCI): 605 (M+H)+.
    • [Example 15] trans-4-(4-((2-(2-chloro-6-hydroxyphenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(t rifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0416
    • Step 1: ethyl trans-4-(4-((2-(2-chloro-6-methoxyphenyl)-2-((triethylsilyl)oxy)ethyl)(3,5-difluorobenzyl) carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (15-1)
  • Compound 15-1 (0.41 g, crude) was obtained as a brown color gum from the reaction of amine A93 (0.23 g, 0.52 mmol), acid D1 (0.17 g, 0.52 mmol), HATU (0.23 g, 0.62 mmol) and DIPEA (0.133 mL, 0.78 mmol) in DMF (10 mL) using a similar procedure to that described in example 1.
    • Step 2: ethyl trans-4-(4-((2-(2-chloro-6-methoxyphenyl)-2-hydroxyethyl)(3,5-difluorobenzyl)carbamoyl )-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (15-2)
  • Compound 15-2 (0.36 g, crude) was obtained as a yellow color gum from the reaction of compound 15-1 (0.41 g, 0.54 mmol) and TBAF (1.0 M in THF, 1.1 mL, 1.08 mmol) in THF (10 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-((2-(2-chloro-6-methoxyphenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-( trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (15-3)
  • Compound 15-3 (0.25 g, 70%) was obtained as a white solid from the reaction of compound 15-2 (0.36 g, 0.56 mmol) and Dess-Martin periodinane (0.47 g, 1.12 mmol) in DCM (10 mL) using a similar procedure to that described in example 1.
    • Step 4: ethyl trans-4-(4-((2-(2-chloro-6-hydroxyphenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(t rifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (15-4)
  • To a stirred solution of compound 15-3 (0.25 g, 0.39 mmol) in DCM (10 mL) was added BBr3 (1.0 M in DCM, 3.9 mL, 3.9 mmol) at room temperature and the mixture was stirred for 16 h. Solvent was evaporated under reduced pressure and the obtained residue was purified by column chromatography (silica gel, 30% EtOAc/hexane as eluent) to provide compound 15-4 (85 mg, 35%) as a yellow oil.
    • Step 5: trans-4-(4-((2-(2-chloro-6-hydroxyphenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(t rifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (15)
  • The compound of example 15 (55 mg, 68%) was obtained as a white solid from the reaction of compound 15-4 (85 mg, 0.13 mmol) and LiOH (16.3 mg, 0.67 mmol) in THF/MeOH/water (2:2:1, 5 mL) using a similar procedure to that described in example 1.
    1H NMR (DMSO-d6) rotamers present δ 7.76 and 7.74 (1H, 2xs) ; 7.28-6.78 (6H, m) ; 4.75-4.52 (4H, m); 4.26-4.15 (1H, m); 2.33-2.26 (1H, m); 2.07-1.90 (6H, m); 1.58-1.47 (2H, m); LCMS (APCI): 600 (M+H)+.
    • [Example 16] trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(((R)-5,5-dimethylTHF-2-yl)methyl)c arbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0417
    • Step 1: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)(((R)-5,5-dimethylTHF -2-yl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (16-1)
  • Compound 16-1 (29 mg, 52%) was obtained as a colorless gum from the reaction of acid D1 (25 mg, 0.074 mmol), amine A94 (32 mg, 0.074 mmol), HATU (34 mg, 0.088 mmol) and DIPEA (0.019 mL, 0.11 mmol) in DMF (3.0 mL) using a similar procedure to that described in example 1. LCMS (APCI): 749 (M+H)+.
    • Step 2: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(((R)-5,5-dimethylTHF-2-yl)met hyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (16-2)
  • Compound 16-2 (25 mg, crude) was obtained as a colorless gum from the reaction of compound 16-1 (29 mg, 0.038 mmol) and TBAF (1 M in THF, 0.076 mL, 0.076 mmol) in THF (3.0 mL) using a similar procedure to that described in example 1. LCMS (APCI): 635 (M+H)+.
    • Step 3: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(((R)-5,5-dimethylTHF-2-yl)methyl)c arbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (16-3)
  • Compound 16-3 (23 mg, crude) was obtained as a colorless gum from the reaction of compound 16-2 (25 mg, crude) and Dess-Martin periodinane (33 mg, 0.078 mmol) in DCM (4.0 mL) using a similar procedure to that described in example 1. LCMS (APCI): 633 (M+H)+.
    • Step 4: trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(((R)-5,5-dimethylTHF-2-yl)methyl)c arbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecaiboxylic acid (16)
  • The compound of example 16 (8.5 mg, 39%) was obtained as a white solid from the reaction of compound 16-3 (23 mg, crude) and LiOH·H2O (12 mg, 0.29 mmol) in MeOH/THF/H2O (4 mL, 1:1:0.5) using a similar procedure to that described in example 1.
    1H NMR (DMSO-d6) rotamers present δ 12.19 (1H, brs), 8.79 and 8.72 (2H, 2xs) ; 7.84 and 7.69 (1H, 2xs) ; 5.01-4.76 (2H, m) ; 4.27-3.80 (3H, m) ; 2.33-2.26 (1H, m) ; 2.06-1.45 (13H, m); 1.19-1.04 (6H, m); LCMS (APCI): 605 (M+H)+.
    • [Example 17] trans-4-(5-cyclopropyl-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,5-difluorobenzyl)car bamoyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0418
    • Step 1: ethyl traris-4-(5-cyclopropyl-4-((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)(3,5-difl uorobenzyl)carbambyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (17-1)
  • Compound 17-1 (130 mg, crude) was obtained as a colorless gum from the reaction of acid D20 (200 mg, 0.56 mmol), amine A18 (233 mg, 0.52 mmol), HATU (296 mg, 0.78 mmol) and DIPEA (0.165 mL, 0.97 mmol) in DMF (10 mL) using a similar procedure to that described in example 1.
    • Step 2: ethyl trans-4-(5-cyclopropyl-4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,5-difluorobenzy l)carbamoyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (17-2)
  • Compound 17-2 (80 mg, impure) was obtained as a colorless gum from the reaction of compound 17-1 (80 mg, 0.128 mmol) and TBAF (1 M in THF, 0.190 mL, 0.190 mmol) in THF (4 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(5-cyclopropyl-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,5-difluorobenzyl)car bamoyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (17-3)
  • Compound 17-3 (60 mg, 75%) was obtained as an off-white solid from the reaction of compound 17-2 (80 mg, 0.128 mmol) and Dess-Martin periodinane (110 mg, 0.250 mmol) in DCM (10 mL) using a similar procedure to that described in example 1.
    • Step 4: trans-4-(5-cyclopropyl-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,5-difluorobenzyl)car bamoyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (17)
  • The compound of example 17 (8 mg, 12%) was obtained as a white solid from the reaction of compound 17-3 (70 mg, 0.113 mmol) and LiOH (8.4 mg, 0.330 mmol) in EtOH/THF/water (5mL, 2:2:1) using a similar procedure to that described in example 1.
    1H NMR (DMSO-d6) rotamers present δ 8.76 and 8.69 (2H, 2xs) ; 7.46 and 7.35 (1H, 2xs) ; 7.18-7.12 and 6.95-6.91 (3H, m) ; 4.76-4.62 (4H, m) ; 4.44-4.36 (1H, m) ; 2.26-2.17 (1H, m); 2.03-2.00 (2H, m); 1.87-1.83 (5H, m); 1.57-1.47 (2H, m); 0.95-0.90 (2H, m); 0.68-0.64 (2H, m); LCMS (APCI): 591 (M+H)+.
    • [Example 18] trans-4-(4-((2-(2,6-dichloro-4-(difluoromethyl)phenyl)-2-oxoethyl)(3,5-difluorobenzyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0419
    • Step 1: ethyl trans-4-(4-((2-(2,6-dichloro-4-(difluoromethyl)phenyl)-2-hydroxyethyl)(3,5-difluorobenzyl )carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (18-1)
  • Compound 18-1 (0.18 g, crude) was obtained as a brown color gum from the reaction of amine A111 (0.10 g, 0.26 mmol), acid D1 (87 mg, 0.26 mmol), HATU (0.12 g, 0.31 mmol) and DIPEA (67 µL, 0.39 mmol) in DMF (5 mL) using a similar procedure to that described in example 1.
    • Step 2: ethyl trans-4-(4-((2-(2,6-dichloro-4-(difluoromethyl)phenyl)-2-oxoethyl)(3,5-difluorobenzyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (18-2)
  • Compound 18-2 (0.12 g, 67%) was obtained as a colorless gum from the reaction of compound 18-1 (0.18 g, 0.26 mmol) and Dess-Martin periodinane (0.22 g, 0.52 mmol) in DCM (5 mL) using a similar procedure to that described in example 1.
    • Step 3: trans-4-(4-((2-(2,6-dichloro-4-(difluoromethyl)phenyl)-2-oxoethyl)(3,5-difluorobenzyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (18)
  • The compound of example 18 (15 mg, 26%) was obtained as a white solid from the reaction of compound 18-2 (60 mg, 0.08 mmol) and LiOH (11 mg, 0.43 mmol) in THF/MeOH/water (2:2:1, 5 mL) using a similar procedure to that described in example 1.
    1H NMR (DMSO-d6) rotamers present δ 12.20 (1H, brs) ; 7.87-7.75 (3H, m) ; 7.21-6.88 (4H, m); 4.84 and 4.72 (2H, 2xs) ; 4.68 and 4.57 (2H, 2xs); 4.28-4.17 (1H, m) ; 2.34-2.27 (1H, m) ; 2.07-1.90 (6H, m) ; 1.59-1.49 (2H, m) ; LCMS (APCI): 668 (M+H)+.
    • [Example 19] trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)((4-hydroxy-4-methylcyclohexyl)met hyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0420
    • Step 1: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)((4-hydroxy-4-methylc yclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylat e (19-1)
  • Compound 19-1 (72 mg, crude) was obtained as a colorless gum from the reaction of acid D1 (44 mg, 0.129 mmol), amine A112 (58 mg, 0.129 mmol), HATU (59 mg, 0.155 mmol) and DIPEA (0.034 mL, 0.194 mmol) in DMF (4.0 mL) using a similar procedure to that described in example 1.
    • Step 2: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)((4-hydroxy-4-methylcyclohexyl) methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (19-2)
  • Compound 19-2 (46 mg, 55% over two steps) was obtained as a colorless gum from the reaction of compound 19-1 (72 mg, crude) and TBAF (1 M in THF, 0.18 mL, 0.18 mmol) in THF (4.0 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)((4-hydroxy-4-methylcyclohexyl)met hyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (19-3)
  • Compound 19-3 (45 mg, crude) was obtained as a colorless gum from the reaction of compound 19-2 (46 mg, 0.071 mmol) and Dess-Martin periodinane (60 mg, 0.14 mmol) in DCM (5.0 mL) using a similar procedure to that described in example 1.
    • Step 4: trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)((4-hydroxy-4-methylcyclohexyl)met hyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (19)
  • The compound of example 19 (16 mg, 38%) was obtained as a white solid from the reaction of compound 19-3 (45 mg, 0.069 mmol) and LiOH·H2O (18 mg, 0.41 mmol) in EtOH/THF/H2O (4 mL, 1:1:0.5) using a similar procedure to that described in example 1.
    1H NMR (DMSO-d6) rotamers present δ 12.24 (1H, brs) ; 8.80 and 8.73 (2H, 2xs) ; 7.80 and 7.70 (1H, 2xs) ; 4.83 and 4.67 (2H, 2xs) ; 4.28-4.18 (1H, m) ; 3.93 and 3.87 (1H, 2xs) ; 3.49-3.47 and 3.18-3.11 (1H, 2xm) ; 2.33-2.25 (1H, m) ; 2.06-1.90 (6H, m) ; 1.58-1.01 (14H, m) ; LCMS (APCI): 617 (M-H)-.
    • [Example 20] trans-4-(4-((2-(3,5-Dichloropyridin-4-yl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(di fluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0421
    • Step 1: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)(3,5-difluorobenzyl)car bamoyl)-5-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (20-1)
  • Compound 20-1 (130 mg, 55%) was obtained as a white solid from the reaction of acid D26 (100 mg, 0.31 mmol), amine A18 (105 mg, 0.31 mmol), (COCl)2 (0.03 mL, 0.37 mmol), Et3N (0.08 mL, 0.63 mmol) and DMF (cat) in DCM using a similar procedure to that described in example 2.
    • Step 2: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,5-difluorobenzyl)carbamoyl)-5 -(difluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (20-2)
  • Compound 20-2 (101 mg, 91 %) was obtained as an off-white solid from the reaction of compound 20-1 (130 mg, 0.54 mmol) and TBAF (1.0 M solution in THF, 0.24 mL, 0.24 mmol) in THF (4 mL) using a similar procedure to that described in example 2.
    • Step 3: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(dif luoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (20-3)
  • Compound 20-3 (30 mg, 33%) was obtained as an off-white solid from the reaction of Compound 20-2 (101 mg, 0.15 mmol) and Dess-Martin periodinane (101 mg, 0.23 mmol) in DCM (8 mL) using a similar procedure to that described in example 2.
    • Step 4: trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(dif luoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (20)
  • To a solution of compound 20-3 (106 mg, 0.17 mmol) in dioxane (6 mL) was added 6 M HCl (6 mL) and heated at 80 °C for 16 h. The reaction mixture was cooled to room temperature, added H2O and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with brine (2 x 10 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (C18 silica gel, 75% CH3CN /water as eluent) to provide the compound of example 20 (36 mg, 62%) as a white solid. 1H NMR (DMSO-d6) rotamers present δ 8.76 and 8.69 (2H, 2xs); 7.77 and 7.67 (1H, 2xs); 7.45-7.00 (4H, m) ; 4.91-4.70 (4H, m); 4.36-4.29 (1H, m) ; 2.31-2.24 (1H, m); 2.06-2.02 (2H, m); 1.94-1.89 (4H, m); 1.56-1.45 (2H, m); LCMS (ESI): 599 (M+H)+.
    • [Example 21] trans-4-(4-((2-(2-amino-4-chloropyridin-3-yl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0422
    • Step 1: ethyl trans-4-(4-((2-(2-azido-4-chloropyridin-3-yl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (21-1)
  • To a stirred solution of ethyl trans-4-(4-((2-(2,4-dichloropyridin-3-yl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trif luoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (100 mg, 0.15 mmol) in DMF (5 mL) was added NaN3 (50 mg, 0.7 mmol) and the mixture was stirred at room temperature for 3 h. The reaction mixture was quenched with water (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 30% EtOAc/hexane as eluent) to provide compound 21-1 (60 mg, 59%) as a brown oil.
    • Step 2: ethyl trans-4-(4-((2-(2-amino-4-chloropyridin-3-yl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (21-2)
  • To a stirred solution of compound 21-1 (60 mg, 0.09 mmol) in THF (5 mL) was added Me3P (1.0 M in THF, 0.18 mL, 0.18 mmol) at 0 °C and mixture was stirred at room temperature for 2 h. H2O (0.06 mL) was added to the reaction mixture at 0 °C and the mixture was stirred at room temperature for 16 h. The solvent was removed under reduced pressure and the residue was purified by column chromatography (silica gel, 30% EtOAc/hexane as eluent) to provide compound 21-2 (40 mg, 69%) as a yellow oil.
    • Step 3: trans-4-(4-((2-(2-amino-4-chloropyridin-3-yl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (21)
  • To a stirred solution of compound 21-2 (40 mg, 0.06 mmol) in THF/MeOH (4 mL, 1:1) was added a solution of LiOH (7.7 mg, 0.3 mmol) in water (1 mL). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with water (10 mL), acidified with 0.5 M HCl (to pH 5) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with water (10 mL), brine (10 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (C18 silica gel, 70% CH3CN/water as eluent) to provide the compound of example 21 (25 mg, 66%) as a white solid. 1H NMR (DMSO-d6) rotamers present δ 12.14 (1H, brs) ; 8.75 and 8.46 (1H, 2xs) ; 7.91 (2H, brs) ; 7.73 and 7.49 (1H, 2xs) ; 7.16-7.01 (2H, m) ; 6.89-6.85 (1H, m) ; 6.78 and 6.73 (1H, 2xs) ; 5.02 and 4.83 (2H, 2xs) ; 4.65 and 4.55 (2H, 2xs) ; 4.20-4.12 (1H, m) ; 2.33-2.21 (1H, m) ; 2.04-1.79 (6H, m) ; 1.56-1.43 (2H, m); LCMS (APCI): 600 (M+H)+.
    • [Example 22] trans-4-(4-((2-cyanobenzyl)(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluo romethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0423
    • Step 1: ethyl trans-4-(4-((2-bromobenzyl)(2-(3,5-dichloropyndin-4-yl)-2-((triethylsilyl)oxy)ethyl)carba moyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyelohexanecarboxylate (22-1)
  • Compound 22-1 (310 mg, crude) was obtained as a yellow oil from the reaction of amineA118 (200 mg, 0.40 mmol), acid D1 (136 mg, 0.40 mmol), HATU (232 mg, 0.61 mmol) and DIPEA (0.14 mL, 0.81 mmol) in DMF (5 mL) using a similar procedure to that described in example 1.
    • Step 2: ethyl trans-4-(4-((2-bromobenzyl)(2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)carbamoyl)-5-(tr ifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (22-2)
  • Compound 22-2 (175 mg, 73%) was obtained as an off-white solid from the reaction of compound 22-1 (310 mg, 0.38 mmol) and TBAF (1.0 M solution in THF, 0.57 mL, 0.57 mmol) in THF (4 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-((2-bromobenzyl)(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluo romethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (22-3)
  • Compound 22-3 (150 mg, 86%) was obtained as an off-white solid from the reaction of compound 22-2 (175 mg, 0.25 mmol) and Dess-Martin periodinane (161 mg, 0.37 mmol) in DCM (10 mL) using a similar procedure to that described in example 1.
    • Step 4: ethyl trans-4-(4-((2-cyanobenzyl)(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluo romethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (22-4)
  • A mixture of compound 22-3 (100 mg, 0.14 mmol) and Zn(CN)2 (34 mg, 0.28 mmol) in DMA (8 mL) was purged with argon for 10 min. Pd(PPh3)4 (33.4 mg, 0.02 mmol) was added and the mixture was heated at 100 °C for 3 h. The reaction mixture was cooled to room temperature, quenched with water (10 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with water (10 mL) and brine (10 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 30% EtOAc/hexane) to provide compound 22-4 (27 mg, 29%) as an off-white solid.
    • Step 5: trans-4-(4-((2-cyanobenzyl)(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluo romethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (22)
  • The compound of example 22 (15 mg, 39%) was obtained as a white solid from the reaction of compound 22-4 (40 mg, 0.06 mmol) and LiOH (4.3 mg, 0.03 mmol) in EtOH (2 mL), THF (2 mL) and H2O (1 mL) using a similar procedure to that described in example 1. 1H NMR (DMSO-d6) rotamers present δ 8.56-8.50 (2H, m); 7.91 (2H, brs) ; 7.94 (1H, s); 7.54-7.42 and 7.17 (3H, m and s); 7.08 (1H, s); 5.62-5.58 and 4.64-4.59 (1H, 2xm); 4.33-4.17 (1H, m); 2.39-2.33 (1H, m); 2.10-1.93 (7H, m); LCMS (APCI): 608 (M+H)+.
    • [Example 23] trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carb amoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
  • Figure imgb0424
    • Step 1: ethyl trans-4-(4=((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)((3,3-dimethylcyclobut yl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (23-1)
  • Compound 23-1 (180 mg, crude) was obtained as a yellow gum from the reaction of amineA119 (190 mg, 0.455 mmol), acid D1 (167 mg, 0.50 mmol), oxaly chloride (0.086 mL, 1.0 mmol), Et3N (0.10 ml, 0.68 mmol) and DMF (cat) in DCM (10 mL) using a similar procedure to that described in example 2.
    • Step 2: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)((3,3-dimethylcyclobutyl)methyl) carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (23-2)
  • Compound 23-2 (60 mg, 20%, over 2 steps) was obtained as a colorless gum from the reaction of compound 23-1 (180 mg, 0.245 mmol) and TBAF (0.5 mL, 0.5 mmol, 1 M in THF) in THF (3 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carb amoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylate (23-3)
  • Compound 23-3 (60 mg, quant) was obtained as a white solid from the reaction of compound 23-2 (60 mg, 0.096mmol) and Dess-Martin periodinane (83 mg, 0.193 mmol) in DCM (10 mL) using a similar procedure to that described in example 1.
    • Step 4: tans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carba moyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid (23)
  • The compound of example 23 (30 mg, 52%) was obtained as an off-white solid from the reaction of compound 23-3 (60 mg, 0.097 mmol) and LiOH (19 mg, 0.048 mmol) in THF/water/MeOH (5 mL, 2:2:1) using a similar procedure to that described in example 1.
    1H NMR (CD3OD) rotamers present δ 8.65 and 8.58 (2H, 2xs) ; 7.74 and 7.57 (1H, 2xs) ; 4.81 and 4.63 (2H, 2xs) ; 4.36-4.24 (1H, m); 3.62 and 3.42 (2H, 2xd, J=7.5 Hz) ; 2.67-2.34 (2H, m) ; 2.21-2.02 (6H, m) ; 1.92-1.81 (2H, m) ; 1.70-1.56 (3H, m) ; 1.37-1.29 (1H, m) ; 1.15-0.93 (6H, m); LCMS (APCI): 591 (M+H)+.
    • [Example 186] trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(tr ifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
  • Figure imgb0425
    • Step 1: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)(neopentyl)carbamoyl) -5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (186-1)
  • Compound 186-1 was obtained from the reaction of amine A3 (60 mg, 0.153 mmol), acid D2 (56 mg, 0.161 mmol), oxaly chloride (0.028 mL, 0.322 mmol), 1 N NaOH (0.92 mL, 0.920 mmol) and DMF (cat) in DCM (1 mL) using a similar procedure to that described in example 2.
    • Step 2: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(neopentyl)carbamoyl)-5-(trifluor omethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (186-2)
  • Compound 186-2 (89 mg, 96% over 2 steps) was obtained as a colorless syrup from the reaction of compound 186-1 (crude) and TBAF (0.169 mL, 0.169 mmol), 1 M in THF) in THF (1 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluorome thyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (186-3)
  • Compound 186-3 (69 mg, 78%) was obtained as a white solid from the reaction of compound 186-2 (89 mg, 0.147 mmol) and Dess-Martin periodinane (87 mg, 0.205 mmol) in DCM (2 mL) using a similar procedure to that described in example 1.
    • Step 4: trans-4-(4-((2-(3,5-Dichloropyridin-4-yl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(t rifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid (186)
  • The compound of example 186 (51 mg, 77%) was obtained as a white solid from the reaction of compound 186-3 (69 mg, 0.114 mmol) and 4 N LiOH (0.228 mL, 0.912 mmol) in THF/water/MeOH (1 mL, 2:1:2) using a similar procedure to that described in example 1. 1H NMR (CDCl3) rotamers present δ 8.57 and 8.50 (2H, 2xs) ; 7.71 and 7.57 (1H, 2xs) ; 4.87 and 4.53 (2H, 2xs) ; 4.25-4.18 (1H, m) ; 3.43-3.35 (2H, m); 2.25-2.15 (2H, m) ; 1.95-1.85 (6H, m); 1.42 and 1.40 (3H, 2xs); 1.01 and 0.85 (9H, 2xs); LCMS (ESI) : 577.2 (M+H)+.
    • [Example 233] 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluor omethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
  • Figure imgb0426
    • Step 1: ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)(neopentyl)carbamoyl)-5-(tri fluoromethyl)-1H-pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylate (233-1)
  • Compound 233-1 was obtained from the reaction of amine A3 (58 mg, 0.148 mmol), acid D28 (50 mg, 0.139 mmol), oxaly chloride (0.024 mL, 0.278 mmol), 1 N NaOH (0.833 mL, 0.833 mmol) and DMF (cat) in DCM (1 mL) using a similar procedure to that described in example 2.
    • Step 2: ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(neopentyl)carbamoyl)-5-(trifluoromet hyl)-1H-pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylate (233-2)
  • Compound 233-2 (67 mg, 78% over 2 steps) was obtained as a colorless syrup from the reaction of compound 233-1 (crude) and TBAF (0.148 mL, 0.148 mmol, 1 M in THF) in THF (1 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylate (233-3)
  • Compound 233-3 (56 mg, 84%) was obtained as a white solid from the reaction of compound 233-2 (67 mg, 0.108 mmol) and Dess-Martin periodinane (64 mg, 0.151 mmol) in DCM (2 mL) using a similar procedure to that described in example 1.
    • Step 4: 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluor omethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid (233)
  • The compound of example 233 (27 mg, 51%) was obtained as a white solid from the reaction of compound 233-3 (56 mg, 0.091 mmol) and 4 N LiOH (0.091 mL, 0.363 mmol) in THF/water/MeOH (0.7 mL, 3:1:3) using a similar procedure to that described in example 1. 1H NMR (CDCl3) rotamers present δ 8.57 and 8.50 (2H, 2xs) ; 7.64 and 7.49 (1H, 2xs) ; 4.84 and 4.50 (2H, 2xs) ; 3.61-3.26 (2H, m) ; 2.32-2.22 (6H, m); 2.08-2.04 (6H, m) ; 1.01 and 0.85 (9H; 2xs) ; LCMS (ESI) : 589.2 (M+H)+.
    • [Example 276] trans-4-(5-chloro-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2,2-dimethylpropyl)carbam oyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
  • Figure imgb0427
    • Step 1: ethyl trans-4-(5-chloro-4-((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)(neopentyl)ca rbamoyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (276-1)
  • Compound 276-1 was obtained from the reaction of amine A3 (124 mg, 0.31 mmol), acid D33 (100 mg, 0.31 mmol), oxaly chloride (0.082 mL, 0.95 mmol), Et3N (0.088 ml, 0.66 mmol) and DMF (cat) in DCM (5 mL) using a similar procedure to that described in example 2.
    • Step 2: ethyl trans-4-(5-chloro-4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(neopentyl)carbamoyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (276-2)
  • Compound 276-2 (160 mg, 88%, over 2 steps) was obtained as white solid from the reaction of compound 276-1 (crude) and TBAF (0.5 mL, 0.5 mmol, 1 M in THF) in THF (2 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(5-chloro-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-1H-p yrazol-1-yl)-1-methylcyclohexanecarboxylate (276-3)
  • Compound 276-3 (130 mg, 81%) was obtained as an off-white solid from the reaction of compound 276-2 (160 mg, 0.279 mmol) and Dess-Martin periodinane (233 mg, 0.56 mmol) in DCM (10 mL) using a similar procedure to that described in example 1.
    • Step 4: trans-4-(5-chloro-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2,2-dimethylpropyl)carbam oyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid (276)
  • The compound of example 276 (60 mg, 47%) was obtained as a white solid from the reaction of compound 276-3 (130 mg, 0.224 mmol) and LiOH (26.9 mg, 1.123 mmol) in THF/EtOH/water (11 mL, 5:5:1) using a similar procedure to that described in example 1.
    1H NMR (DMSO-d6) rotamers present δ 12.25 (1H, brs) ; 8.77 and 8.72 (2H, 2xs) ; 7.79 and 7.73 (1H, 2xs) ; 4.84 and 4.77 (2H, 2xs) ; 4.36-4.28 (1H, m) ; 2.02-1.72 (8H, m) ; 1.21 (3H, s); 0.95 and 0.74 (9H, 2xs); LCMS (APCI): 545 (M+H)+.
    • [Example 277] trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[ 3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexaneca rboxylic acid
  • Figure imgb0428
    • Step 1: ethyl trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-((triethylsilyl)oxy)ethyl)((1R,3r,5S)-6,6-di methylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methy lcyclohexanecarboxylate (277-1)
  • Compound 277-1 was obtained from the reaction of amine C45 (74 mg, 0.167 mmol), acid D2 (55 mg, 0.158 minol), HATU (72 mg, 0.190 mmol) and DIPEA (0.055 mL, 0.320 mmol) in DMF (2 mL) using a similar procedure to that described in example 1.
    • Step 2: ethyl trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicy clo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexa necarboxylate (277-2)
  • Compound 277-2 (85 mg, 82% over 2 steps) was obtained as a yellow semi-solid from the reaction of compound 277-1 (crude) and TBAF (0.3 mL), 0.3 mmol, 1 M in THF) in THF (2 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[ 3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexaneca rboxylate (277-3)
  • Compound 277-3 (80 mg, 95%) was obtained as a pale yellow semi- solid from the reaction of compound 277-2 (85 mg, 0.129mmol) and Dess-Martin periodinane (66 mg, 0.155 mmol) in DCM (2 mL) using a similar procedure to that described in example 1.
    • Step 4: trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-((triethylsilyl)oxy)ethyl)((1R,3r,5S)-6,6-di methylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methy lcyclohexanecarboxylate (277)
  • The compound of example 277 (58 mg, 75%) was obtained as a white solid from the reaction of compound 277-3 (80 mg, 0.122 mmol) and 4 N LiOH (0.31 mL, 1.22 mmol) in THF/water/MeOH (1.5 mL, 2:1:2) using a similar procedure to that described in example 1.
    1H NMR (CDCl3) rotamers present δ 7.69 and 7.54 (1H, 2xs) ; 7.16 and 7.08 (2H, 2xs); 5.10-5.00 and 4.36-4.14 (2H, 2xm) ; 4.59 and 4.39 (2H, 2xs) ; 2.35 and 2.31 (3H, 2xs) ; 2.31-1.85 (10H, m) ; 1.42 and 1.39 (3H, 2xs); 1.39-1.23 (2H, m) ; 1.09-0.95 (8H, m) ; LCMS (ESI) : 628.3 (M+H)+.
    • [Example 278] trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexa n-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • Figure imgb0429
    • Step 1: ethyl trans-4-(4-((2-(2,6-dichlorophenyl)-2-((triethylsilyl)oxy)ethyl)((1R,3r,5S)-6,6-dimethylbic yclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohex anecarboxylate (278-1)
  • Compound 278-1 was obtained from the reaction of amine C46 (94 mg, 0.219 mmol), acid D2 (76 mg, 0.219 mmol), oxaly chloride (0.038 mL, 0.438 mmol), DIPEA (0.114 mL, 0.657 mmol) and DMF (cat) in DCM (1 mL) using a similar procedure to that described in example 2.
    • Step 2: ethyl trans-4-(4-((2-(2,6-dichlorophenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0] hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxy late (278-2)
  • Compound 278-2 (102 mg, 72% over 2 steps) was obtained as a colorless oil from the reaction of compound 278-1 (crude) and TBAF (0.22 mL, 0.22 mmol), 1 M in THF) in THF (1 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexa n-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (278-3)
  • Compound 278-3 (84 mg, 83%) was obtained as a white solid from the reaction of compound 278-2 (102 mg, 0.158mmol) and Dess-Martin periodinane (100 mg, 0.237 mmol) in DCM (1 mL) using a similar procedure to that described in example 1.
    • Step 4: trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R;3r,5S)-6,6-dimethylbicyclo[3.1.0]hexa n-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid (278)
  • The compound of example 278 (35 mg, 44%) was obtained as a white solid from the reaction of compound 278-3 (84 mg, 0.131 mmol) and 4 N LiOH (0.33 mL, 1.31 mmol) in THF/water/MeOH (1.5 mL, 2:1:2) using a similar procedure to that described in example 1.
    1H NMR (CDCl3) rotamers present δ 7.70 and 7.55 (1H, 2xs) ; 7.36-7.26 (3H, m) ; 5.10-5.00 and 4.37-4.15 (2H, 2xm); 4.61 and 4.42 (2H, 2xs) ; 2.31-1.87 (10H, m) ; 1.42 and 1.39 (3H, 2xs) ; 1.39-1.23 (2H, m) ; 1.09-0.95 (8H, m) ; LCMS (ESI) : 614.2 (M+H)+.
    • [Example 330] trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-(trifluoromethyl)cyclopropyl)met hyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
  • Figure imgb0430
    • Step 1: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)(((1-(trifluoromethyl)cy clopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanec arboxylate (330-1)
  • Compound 330-1 was obtained from the reaction of amine A103 (44 mg, 0.098 mmol), acid D2 (34 mg, 0.098 mmol), oxaly chloride (0.017 mL, 0.196 mmol), 1 N NaOH (0.49 mL, 0.491 mmol) and DMF (cat) in DCM (1 mL) using a similar procedure to that described in example 2.
    • Step 2: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)((1-(trifluoromethyl)cyclopropyl) methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (330-2)
  • Compound 330-2 (37 mg, 58% over 2 steps) was obtained as a colorless oil from the reaction of compound 330-1 (crude) and TBAF (0.098 mL, 0.098 mmol, 1 M in THF) in THF (1 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl)meth yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (330-3)
  • Compound 330-3 (31 mg, 83%) was obtained as a colorless oil from the reaction of 330-2 (37 mg, 0.056 mmol) and Dess-Martin periodinane (36 mg, 0.085 mmol) in DCM (1 mL) using a similar procedure to that described in example 1.
    • Step 4: trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-(trifluoromethyl)cyclopropyl)met hyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid (330)
  • The compound of example 330 (17 mg, 58%) was obtained as a white solid from the reaction of compound 330-3 (31 mg, 0.047 mmol) and 4 N LiOH (0.12 mL, 0.467 mmol) in THF/water/MeOH (0.75 mL, 2:1:2) using a similar procedure to that described in example 1. 1H NMR (CDCl3) rotamers present δ 8.59 and 8.52 (2H, 2xs) ; 7.65 and 7.54 (1H, 2xs) ; 4.95 and 4.58 (2H, 2xs) ; 4.28-4.20 (1H, m) ; 3.84 and 3.74 (2H, 2xs) ; 2.26-2.16 (2H,m); 1.95-1.85 (6H, m) ; 1.42 and 1.41 (3H, 2xs) ; 1.12-1.06 (4H, m) ;
    LCMS (ESI) : 629.2 (M+H)+.
    • [Example 343] trans-4-(4-((2-(4-chloro-1H-indol-3-yl)ethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • Figure imgb0431
    • Step 1: ethyl trans-4-(4-((2-(4-chloro-1H-indol-3-yl)ethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (343-1)
  • Compound 343-1 (42 mg, 91%) was obtained as a yellow gum from the reaction of amine B19 (22 mg, 0.073 mmol), acid D2 (25 mg, 0.073 mmol), HATU (33 mg, 0.087 mmol) and DIPEA (0.037 mL, 0.218 mmol) in DMF (1 mL) using a similar procedure to that described in example 1.
    • Step 2: trans-4-(4-((2-(4-chloro-1H-indol-3-yl)ethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid (343)
  • The compound of example 343 (31 mg, 78%) was obtained as a white solid from the reaction of compound 343-1 (42 mg, 0.066 mmol) and 4 N LiOH (0.066 mL, 0.265 mmol) in THF/water/MeOH (0.5 mL, 2:1:2) using a similar procedure to that described in example 1. 1H NMR (CDCl3) rotamers present δ 8.20 (1H, brs) ; 7.53-6.90 (5H, m) ; 4.68-4.61 and 4.29-4.02 (2H, 2xm) ; 3.64-3.61 and 3.53-3.49 (2H, 2xm); 3.35-3.32 and 3.04-3.00 (2H, 2xm) ; 2.28-1.86 (8H, m) ; 1.70-1.60 (2H, m) ; 1.41 and 1.39 (3H, 2xs) ; 1.28-0.85 (10H, m); LCMS (ESI) : 606.0 (M+H)+.
    • [Example 361 and 362] trans-4-(4-(((2R)-2-(2,6-dichloro-4-fluorophenyl)-2-hydroxyethyl)-(4,4-dimethylcyclohexy l)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid or trans-4-(4-(((2S)-2-(2,6-dichloro-4-fluorophenyl)-2-hydroxyethyl)-(4,4-dimethylcyclohexy l)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
  • Figure imgb0432
    • Step 1: ethyl trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-((triethylsilyl)oxy)ethyl)(4,4-dimethylcyclo hexyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (361-1)
  • Compound 361-1 was obtained from the reaction of amine C1 (89 mg, 0.199 mmol), acid D2 (60 mg, 0.172mmol), oxaly chloride (0.044 mL, 0.517 mmol), DIPEA (0.090 mL, 0.517 mmol) and DMF (cat) in DCM (2 mL) using a similar procedure to that described in example 2.
    • Step 2: ethyl trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-hydroxyethyl)(4,4-dimethylcyclohexyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (377-2)
  • Compound 361-2 (100 mg, 88% over 2 steps) was obtained from the reaction of 361-1 (crude) and TBAF (0.26 mL, 0.258 mmol, 1 M in THF) in THF (2 mL) using a similar procedure to that described in example 1.
    • Step 3: ethyl trans-4-(4-(((S)-2-(2,6-dichloro-4-methylphenyl)-2-hydroxyethyl)(4,4-dimethylcyclohexyl) carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate and ethyl trans-4-(4-(((R)-2-(2,6-dichloro-4-methylphenyl)-2-hydroxyethyl)(4,4-dimethylcyclohexyl )carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (361-3 and 362-1)
  • Compound 361-2 (100 mg, 0.151 mmol) was purified by chiral HPLC (250 x 20 mm DAICEL CHIRALPAK™ IA 5 µm column with 16 mL/min n-hexane/IPA (96/4)) to give 361-3 (49 mg, 49%) as the first eluting isomer and compound 362-1 (48 mg, 48%) as the second eluting isomer.
    • Step 4: trans-4-(4-(((2R)-2-(2,6-dichloro-4-fluorophenyl)-2-hydroxyethyl)-(4,4-dimethylcyclohexy l)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid or trans-4-(4-(((2S)-2-(2,6-dichloro-4-fluorophenyl)-2-hydroxyethyl)-(4,4-dimethylcyclohexy l)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid (361)
  • The compound of example 361 (37 mg, 79%) was obtained as a white solid from the reaction of compound 361-3 (49 mg, 0.074 mmol) and 4 N LiOH (0.25 mL, 1.00 mmol) in EtOH/water (1.5 mL, 2:1) using a similar procedure to that described in example 1.
    LCMS (ESI): 636.3 (M+H)+.
    • Step 5: trans-4-(4-(((2R)-2-(2,6-dichloro-4-fluorophenyl)-2-hydroxyethyl)-(4,4-dimethylcyclohexy l)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid or trans-4-(4-(((2S)-2-(2,6-dichloro-4-fluorophenyl)-2-hydroxyethyl)-(4,4-dimethylcyclohexy l)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid (362)
  • The compound of example 362 (39 mg, 85%) was obtained as a white solid from the reaction of compound 362-1 (48 mg, 0.073 mmol) and 4 N LiOH (0.25 mL, 1.00 mmol) in EtOH/water (1.5 mL, 2:1) using a similar procedure to that described in example 1. 1H NMR (CDCl3) rotamers present δ 7.57 and 7.56 (1H, 2xs) ; 7.11 and 7.05 (2H, 2xd, J=7.8 Hz) ; 5.62-5.47 (1H, m) ; 4.86 (1H, brs) ; 4.70-4.64 and 4.09-4.02 (1H, 2xm) ; 4.30-4.20 (1H, m) ; 3.46-3.26 (2H, m); 2.31-2.18 (2H, m) ; 1.99-1.66 (8H, m); 1.47-1.26 (7H, m); 1.12-0.86 (8H, m); LCMS (ESI): 636.0 (M+H)+.
    • [Example 569] trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(spiro[25]oct-6-ylmethyl)carbamoyl)-5-(tri fluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • Figure imgb0433
    • Step 1 and Step 2: ethyl trans-4-(4-((2-(2,6-dichlorophenyl)-2-hydroxyethyl)(spiro[2.5]octan-6-ylmethyl)carbamoyl )-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • To a solution of 1-((trans)-4-(ethoxycarbonyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-car boxylic acid (0.157 g, 0.452 mmol) and oxalyl chloride (0.049 ml, 0.565 mmol) in DCM (4.52 ml) was added DMF (1 drop) and the mixture was stirred at room temperature. After 1 h, the reaction mixture was concentrated in vacuo. To the residue was added a solution of 2-(2,6-dichlorophenyl)-N-(spiro[2.5]octan-6-ylmethyl)-2-((triethylsilyl)oxy)ethanamine (0.200 g, 0.452 mmol) in THF (4.5 mL) followed by DIPEA (0.158 ml, 0.904 mmol) and the mixture was stirred at room temperature. After 17 h, to the reaction mixture was added TBAF solution, 1.0 M in THF (0.904 ml, 0.904 mmol) and the mixture was stirred at room temperature. After 7 h, the reaction mixture was diluted with water (50 mL) and brine (50 mL). The reaction mixture was extracted with EtOAc (2 x 50 mL). The organic extract was washed with satd NaCl (1 x 50 mL) and dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a light-yellow syrup. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 50% EtOAc in heptane to provide ethyl trans-4-(4-((2-(2,6-dichlorophenyl)-2-hydroxyethyl)(spiro[2.5]octan-6-ylmethyl)carbamoyl )-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (0.0815 g, 0.124 mmol, 27.4% yield) a colorless gum.
    • Step 3: ethyl trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(spiro[2.5]octan-6-ylmethyl)carbamoyl)-5-( trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • To a solution of ethyl trans-4-(4-((2-(2,6-dichlorophenyl)-2-hydroxyethyl)(spiro[2.5]octan-6-ylmethyl)carbamoyl )-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (0.0815 g, 0.124 mmol) in DCM (1.238 ml) was added Dess-Martin periodinane (0.079 g, 0.186 mmol) and the mixture was stirred at room temperature. After 6 h, the mixture was quenched with saturated aqueous Na2S2O3 (50 mL) and saturated aqueous NaHCO3 (50 mL). The reaction mixture was extracted with DCM (2 x 100 mL). The organic extract was dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a white solid. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 35% EtOAc in heptane to provide ethyl trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(spiro[2.5]octan-6-ylmethyl)carbamoyl)-5-( trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (0.0685 g, 0.104 mmol, 84% yield) as a colorless syrup.
    • Step 4: trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(spiro[25]oct-6-ylmethyl)carbamoyl)-5-(tri fluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • To a solution of ethyl trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(spiro[2.5]octan-6-ylmethyl)carbamoyl)-5-( trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (0.0685 g, 0.104 mmol) in THF (0.750 mL) was added a solution of lithium hydroxide hydrate (0.044 g, 1.043 mmol) in water (0.500 mL) and the mixture was stirred and heated at 50 °C overnight. The THF and MeOH were removed in vacuo and the turbid solution was diluted with water (3 mL) to provide a clear solution. 1 M HCl was added to adjust the pH to 1. The mixture was stirred for 30 min before collecting the precipitate by vacuum filtration to provide a white solid. The solid was purified by silica gel column chromatography eluting with a gradient of 0% to 5% MeOH in DCM to provide Example 569 (0.0457 g, 0.073 mmol, 69.7% yield) as white solid. 1H NMR (400 MHz, CD3OD) δ 7.40-7.79 (4H, m), 5.30-5.54 (1H, m), 4.87 (1H, s), 4.64 (1H, s), 4.22-4.36 (1H, m), 3.50 (2H, d, J=7.2 Hz), 2.12-2.30 (2H, m), 1.54-1.98 (10H, m), 1.27-1.41 (5H, m), 0.78-1.05 (3H, m), 0.07-0.37 (4H, m), (rotamers present); LCMS (ESI) m/z 628.2 (M+H)+.
    • [Example 688] trans-4-(4-(((2R)-2-((3,5-dichloro-4-pyridinyl)methyl)-4,4-dimethyl-1-pyrrolidinyl) carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • Figure imgb0434
    • Step 1: Prepared according to WO patent: 2013004290A1 . To a stirred suspension of (R)-(-)-5-(hydroxymethyl)-2-pyrrolidinone (Sigma Aldrich Chemical Company, St. Louis, MO, 5.36 g, 46.5 mmol) and p-toluenesulfonic acid (44 mg, 0.233 mmol) in toluene (100 mL), 2,2-dimethoxypropane (17.1 mL, 140 mmol) was added and the reaction was refluxed for 1.5 h. The reaction was equipped with a Dean-Stark apparatus then additional 2,2-dimethoxypropane (17.1 mL, 140 mmol) was added and the reaction was refluxed for 36 h. The solvent was evaporated to afford (R)-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one as an orange waxy solid. MS (ESI) 156.1 [M + H]+. The crude material was taken to the next step without further purification.
    • Step 2: Prepared according to WO patent: WO2013004290A1 . To a solution of (R)-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (3.50 g, 22.55 mmol) in THF (75 mL) cooled to -78 °C, was added lithium diisopropylamide (2.0M heptane/THF/ethylbenzene, 20.30 mL, 40.6 mmol) solution. The solution was stirred at this temperature for 1 h before adding iodomethane (2.12 mL, 33.8 mmol). The reaction mixture was warmed to room temperature and stirred for 1 h, then cooled to -78 °C prior addition of lithium diisopropylamide (2.0 M heptane/THF/ethylbenzene, 20.30 mL, 40.6 mmol). The mixture was stirred at -78 °C for 1 h before adding additional iodomethane (2.12 mL, 33.8 mmol). The mixture was slowly warmed to room temperature and stirred overnight (16 h). The reaction was quenched with a saturated solution of ammonium chloride and extracted with EtOAc (2 x 75 mL). The combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated to provide crude (R)-3,3,6,6 tetramethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one as an orange tar. MS (ESI) 184.1 [M + H]+.
    • Step 3: Prepared according to WO patent: 2013004290 . To a solution of (R)-3,3,6,6-tetramethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (4.13 g, 22.54 mmol) in MeOH (90 mL) was added p-toluenesulfonic acid monohydrate (0.429 g, 2.254 mmol). The resulting mixture was heated at reflux for 2 h. The solvent was removed under reduced pressure (rotary evaporator) and the crude material was absorbed onto a plug of silica gel and purified by chromatography on an ISCO Combiflash™ RF (40 g Grace Reverlis column, using a gradient of 0-20% MeOH in DCM) affording (R)-5-(hydroxymethyl)-3,3-dimethylpyrrolidin-2-one (2.91 g, 20.31 mmol, 90% yield) as a white semi-solid. MS (ESI) 144.1 [M + H]+.
    • Step 4: Prepared according to US patent: 20070032433A1 . To a solution of (R)-5-(hydroxymethyl)-3,3-dimethylpyrrolidin-2-one (2.91 g, 20.30 mmol) in THF (50.8 mL) cooled to 0 °C, lithium aluminum hydride (2.0 M solution in THF, 12.18 mL, 24.36 mmol) was added. The mixture was stirred at room temperature overnight (16 h). Additional lithium aluminum hydride (2.0 M solution in THF, 12.18 mL, 24.36 mmol) was added and the solution was refluxed for 6 h. The reaction mixture was cooled and additional lithium aluminum hydride (2.0 M solution in THF, 12.18 mL, 24.36 mmol) was added and the mixture was refluxed overnight. The reaction mixture was cooled to 0 °C in an ice bath prior to addition of water (3.67 mL) followed by 15% aqueous NaOH (3.67 mL) and water (10.9 mL). It was then stir vigorously at room temperature for 1 h and filtered on a medium porosity sintered glass frit with cotton and celite washing with EtOAc. The solution was then concentrated affording crude (R)-(4,4-dimethylpyrrolidin-2-yl)methanol (2.29 g, 17.73 mmol, 87% yield) as yellow viscous oil. MS (ESI) 130.1 [M + H]+. Step 5: A solution of triethylamine (4.94 mL, 35.4 mmol) and (R)-(4,4-dimethylpyrrolidin-2-yl)methanol (2.29 g, 17.72 mmol) in DCM (89 mL) was cooled to -78 °C. To this mixture was added sulfuryl chloride (1.0 M in DCM, 21.27 mL, 21.27 mmol) over 15 seconds. The reaction was maintained at this temperature for ∼ 3 h, allowed to warm to room temperature and stirred overnight (16 h). The mixture was washed with aqueous 1 N HCl (30 mL x 2), brine (40 mL), dried over MgSO4, filtered and concentrated affording crude product as a brown-orange oil that crystallized upon standing. The crude material was absorbed onto a plug of silica gel and purified by chromatography on an ISCO Combiflash™ RF (40 g Grace Reverlis column, using a gradient of 0-60% EtOAc in heptane) affording (R)-5,5-dimethyltetrahydro-3H-pyrrolo[1,2-c][1,2,3]oxathiazole 1,1-dioxide (708 mg, 3.70 mmol, 21% yield) as a white crystalline solid. MS (ESI) 192.1 [M + H]+.
    • Step 6: To a solution of 3,5-dichloropyridine (796 mg, 5.38 mmol) in THF (9.0 mL) at -78 °C was added lithium diisopropylamide (2.0 M heptane/THF/ethylbenzene, 3.41 mL, 6.82 mmol) dropwise. After stirring for 1 h at this temperature, a solution of (R)-5,5-dimethyltetrahydro-3H-pyrrolo[1,2-c][1,2,3]oxathiazole 1,1-dioxide (686 mg, 3.59 mmol) in THF (9.0 mL) was added dropwise at -78 °C and the mixture was allowed to warm to room temperature over 3 h and then stirred at room temperature for 4 h. After evaporation of the solvent, the resulting beige foam was treated with hot (80 °C) 2 N HCl (8 mL) and EtOH (8 mL) overnight. The reaction mixture was concentrated under reduced pressure (rotary evaporator) and the mixture was treated with ice and basified with 5 N NaOH (8 mL) and extracted with EtOAc (2 x 75 mL). The organic extracts were dried, evaporated and purified by chromatography on an ISCO Combiflash™ RF (25 g Thomson SingleStep column, using a gradient of 0-10% MeOH in DCM) affording (R)-3,5-dichloro-4-((4,4-dimethylpyrrolidin-2-yl)methyl)pyridine (748 mg, 2.89 mmol, 80% yield) as an orange oil. MS (ESI) 259.1, 261.0 [M + H]+.
    • Step 7: 1-((1r,4r)-4-(ethoxycarbonyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1 H-pyrazole-4-car boxylic acid (445 mg, 1.28 mmol) was treated with DCM (8 mL) and three drops of DMF, cooled to 0 °C in an ice bath and treated with oxalyl chloride (0.16 mL, 1.82 mmol) slowly dropwise. The reaction mixture was removed from the ice bath and allowed to stir at room temperature for 1.5 h. The volatiles were removed under reduced pressure (rotary evaporator) and the crude acid chloride was treated with DCM (10 mL), cooled in an ice bath and treated with (R)-3,5-dichloro-4-((4,4-dimethylpyrrolidin-2-yl)methyl)pyridine (315 mg, 1.22 mmol) (in DCM 5 mL) slowly dropwise followed by DIPEA (0.64 mL, 3.65 mmol). The solution was removed from the ice bath and allowed to warm to rt and stirred for 1 h. The solvent was evaporated and the crude material was absorbed onto a plug of silica gel and purified by chromatography on an ISCO Combiflash™ RF (40 g Thomson SingleStep column, using a gradient of 0-40% EtOAc in heptane) to provide (1R,4r)-ethyl 4-(4-((R)-2-((3,5-dichloropyridin-4-yl)methyl)-4,4-dimethylpyrrolidine-1-carbonyl)-5-(trifl uororriethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (489 mg, 0.83 mmol, 68% yield) as a light yellow amorphous solid after drying in a vacuum oven over 48hrs at 40 °C. MS (ESI) 589.3/591.2 [M + H]+.
    • Step 8: To a mixture of (1R,4r)-ethyl 4-(4-((R)-2-((3,5-dichloropyridin-4-yl)methyl)-4,4-dimethylpyrrolidine-1-carbonyl)-5-(trifl uoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (464 mg, 0.787 mmol) in THF (3.9 mL) and MeOH (3.9 mL) was added lithium hydroxide monohydrate (1.0 M aqueous solution, 3.9 mL, 3.94 mmol). The mixture was stirred at room temperature overnight (16 h). The organics were removed under reduced pressure (rotary evaporator) and the aqueous solution was acidified with 1 N HCl leading to the formation of a precipitate. The mixture was extracted with EtOAc (2 x 40 mL). The combined extracts were washed with brine, dried over anhydrous MgSO4, filtered and concentrated. The crude material was absorbed onto a plug of silica gel and purified by chromatography on an ISCO Combiflash™ RF (40 g Thomson SingleStep column, using a gradient of 0-8% MeOH in DCM) affording (1R,4r)-4-(4-((R)-2-((3,5-dichloropyridin-4-yl)methyl)-4,4-dimethylpyrrolidine-1-carbonyl )-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid (258 mg, 0.46 mmol, 59% yield) as white amorphous foam. MS (ESI) 561.0, 563.1 [M + H]+.
    [Example 692] trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)ca rbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • Figure imgb0435
    • Step 1 and Step 2: ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,3,3-trifluoro-2,2-dimethylprop yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • To a slightly cloudy solution of 1-((1r,4r)-4-(ethoxycarbonyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-car boxylic acid (1.0102 g, 2.90 mmol) in DCM (29.0 ml) was added oxalyl chloride (0.307 ml, 3.63 mmol) followed by DMF (1 drop) and the light-yellow slightly cloudy reaction mixture was stirred at room temperature. After 3 h, the mixture was concentrated in vacuo to give ethyl trans-4-(4-(chlorocarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecar boxylate as light-yellow syrup. To the residue was added a solution of N-(2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)-3,3,3-trifluoro-2,2-dimethylpro pan-1-amine (1.292 g, 2.90 mmol) in THF (29.0 ml) followed by DIPEA (2.021 ml, 11.60 mmol) and the mixture was stirred at room temperature. After 19 h, LCMS (ESI) showed that ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)(3,3,3-trifluoro-2,2-dim ethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarbox ylate was formed: LCMS (ESI) m/z 775.1 (M+H)+.
  • To the reaction mixture was added TBAF solution, 1.0 M in THF (11.60 ml, 11.60 mmol) and the mixture was stirred at room temperature. After 30 min, LC-MS (ESI) showed that the reaction was complete. The reaction mixture was diluted with water (100 mL) and brine (100 mL). The reaction mixture was extracted with EtOAc (2 x 100 mL). The organic extract was washed with satd NaCl (1 x 100 mL) and dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a light-yellow syrup. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 50% EtOAc in heptane to provide ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,3,3-trifluoro-2,2-dimethylprop yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (1.6938 g, 2.56 mmol, 88% yield) as a white gummy solid. 1H NMR (400 MHz, DMSO-d6) δ 8.46-8.63 (2H, m), 7.71-7.83 (1H, m), 6.11 (1H, d, J=4.1 Hz), 5.19-5.33 (1H, m), 4.27 (1H, t, J=11.0 Hz), 4.09 (2H, q, J=7.2 Hz), 3.39-3.97 (4H, m), 2.02-2.19 (2H, m), 1.66-1.97 (6H, m), 1.14-1.30 (12H, m), NMR showed several peak sets due to diastereomers and rotamers; LCMS (ESI) m/z 661.1 (M+H)+.
    • Step 3: ethyl trans-4-(4-((2-(3;5-dichloropyridin-4-yl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)ca rbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • To a clear solution of ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,3,3-trifluoro-2,2-dimethylprop yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (1.6826 g, 2.54 mmol) in DCM (25.4 ml) was added Dess-Martin periodinane (1.618 g, 3.82 mmol). The white cloudy mixture was stirred at room temperature. After 1 h, the mixture was quenched with saturated aqueous Na2S2O3 (50 mL) and saturated aqueous NaHCO3 (50 mL). The reaction mixture was extracted with DCM (2 x 100 mL). The organic extract was dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a white solid. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 30% EtOAc in heptane to provide ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)ca rbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (1.5825 g, 2.400 mmol, 94% yield) as a white gummy solid. 1H NMR (400 MHz, CDCl3) δ 8.45-8.64 (2H, m), 7.51-7.78 (1H, m), 4.52 (2H, s), 4.09-4.30 (3H, m), 3.70 (2H, br. s.), 2.12-2.32 (2H, m), 1.79-2.00 (6H, m), 1.02-1.46 (12H, m), rotamers present; LCMS (ESI) m/z 659.0 (M+H)+.
    • Step 4: trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)ca rbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • To a clear mixture of ethyl trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)ca rbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (1.5739 g, 2.387 mmol) in THF (9.55 ml), EtOH (9.55 ml), and water (4.77 ml) was added 2 M LiOH in water (11.93 ml, 23.87 mmol). After adding 2 M LiOH solution, the white heterogeneous mixture became yellow cloudy mixture. The yellow cloudy mixture was stirred and heated at 60 °C. After 15 h, the reaction mixture was concentrated in vacuo to remove THF and EtOH. The resulting aqueous solution was diluted with water (30 mL). The pH of the solution was adjusted to ∼3.0 with 1 N HCl and the resulting precipitate was collected by vacuum filtration, wash with water, and freeze-dried on lyophilizer overnight to provide example 692 (1.3955 g, 2.210 mmol, 93% yield) as white solid. 1NMR (400 MHz, DMSO-d6) δ 12.27 (1H, br. s.), 8.58-8.83 (2H, m), 7.75-8.02 (1H, m), 4.68-5.43 (2H, m), 4.26 (1H, t, J=11.0 Hz), 3.46-3.90 (2H, m), 1.97-2.17 (2H, m), 1.69-1.92 (6H, m), 1.00-1.39 (9H, m), rotamers present; LCMS (ESI) m/z 631.0 (M+H)+.
    • [Example 713] (1r,4r)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((5-fluorospiro[2.3]hexan-5-yl)methyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • Figure imgb0436
    • Step 1: ethyl trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-((triethylsilyl)oxy)ethyl)(3,5-difluorobenzyl )carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • 1-((1r,4r)-4-(ethoxycarbonyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid (3.48g, 9.99 mmol) was dissolved in DCM (30 ml) and thionyl chloride (0.875 ml, 11.99 mmol) was added followed by 1 drop of DMF. The reaction was rrefluxed for 2.5 h. The solvents were removed in vacuo and the residue was placed in the freezer overnight. The solidified material was then dried under vacuo for 1 h to afford (1s,4s)-ethyl 4-(4-(chlorocarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxyl ate. 2-(2,6-dichlorophenyl)-N-((5-fluorospiro[2.3]hexan-5-yl)methyl)-2-((triethylsilyl)oxy)etha namine (150 mg, 0.347 mmol) was dissolved in 2 ml of DCM and (1s,4s)-ethyl 4-(4-(chlorocarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxyl ate (127 mg, 0.347 mmol) dissolved in 2 ml of DCM was added, followed by triethylamine (242 µl, 1.734 mmol). The solution was stirred for 1 h and was concentrated to afford crude (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-((triethylsilyl)oxy)ethyl)((5-fluorospiro[2.3]hexan-5-yl)me thyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (265 mg, 0.347 mmol, 100% yield).
    • Step 2: (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-hydroxyethyl)((5-fluorospiro[2.3]hexan-5-yl)methyl)carba moyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • To a stirred solution of (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-((triethylsilyl)oxy)ethyl)((5-fluorospiro[2.3]hexan-5-yl)me thyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (265 mg, 0.347 mmol) in 2 ml of THF was added TBAF (695 µl, 0.695 mmol), and the mixture was stirred for 1 h. The reaction mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford crude (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-hydroxyethyl)((5-fluorospiro[2.3]hexan-5-yl)methyl)carba moyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (225 mg, 0.347 mmol, 100% yield). MS m/z =648 [M+H]+.
    • Step 3: (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((5-fluorospiro[2.3]hexan-5-yl)methyl)carbamoy l)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-hydroxyethyl)((5-fluorospiro[2.3]hexan-5-yl)methyl)carba moyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (225 mg, 0.347 mmol) was dissolved in 10 ml of DCM and Dess-Martin periodane (184 mg, 0.434 mmol) was added. The solution was stirred for 1 h. The solution was quenched with 5% Na2S2O3, washed with saturated NaHCO3, dried with Na2SO4 and concentrated. The product was purified via silica gel column chromatography (40 g column) using 0-100 % EtOAc in heptane to afford (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((5-fluorospiro[2.3]hexan-5-yl)methyl)carbamoy l)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (140 mg, 0.217 mmol, 62.4% yield). MS m/z =646 [M+H]+.
    • Step 4: (1r,4r)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((5-fluorospiro[2.3]hexan-5-yl)methyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((5-fluorospiro[2.3]hexan-5-yl)methyl)carbarbamoy l)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (140 mg, 0.217 mmol) and lithium hydroxide (100 mg, 4.18 mmol) were combined in 5 ml of MeOH, 5 ml of THF, and 2 ml of water. The solution was heated at 50 °C for 3 h. The solution was made acidic with 6 N HCl and diluted with water. The product was extracted with EtOAc, dried with Na2SO4, filtered and concentrated to afford (1r,4r)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((5-fluorospiro[2.3]hexan-5-yl)methyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid (115mg, 0.186 mmol), 86% yield). 1H NMR (400 MHz, CD3OD, mixture of rotamers) δ 7.88 (s, 0.2H) 7.66 (s, 0.8H) 7.40-7.50 (m, 3H) 4.11 (m, 3H) 2.43-2.61 (m, 2H) 2.15-2.32 (m, 3H) 1.81-2.05 (m, 7H) 1.17-1.43 (m, 5H) 0.42 - 0.70 (m, 4H) LC/MS (ESI+) m/z = 618 (M+H)+.
    • [Example 716] trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)((1-methylcyclopropyl)methyl) carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • Figure imgb0437
    • Step 1: ethyl trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-((triethylsilyl)oxy)ethyl)((1-methylcyclopro pyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxy late
  • This compound was prepared using similar procedure described for examples 1, step 1 without chromatography purification. LCMS (ESI) m/z 735.8 (M+H)+.
    • Step 2: ethyl trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-hydroxyethyl)(((1-methylcyclopropyl)methy l)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • This compound was prepared using similar procedure described for examples 1, step 2 without chromatography purification. LCMS (ESI) m/z 623.9 (M+H)+.
    • Step 3: ethyl trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)(((1-methylcyclopropyl)methyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • This compound was prepared using similar procedure described for examples 1, step 3. 1H NMR (500 MHz, CDCl3) rotamers present δ 7.65 and 7.58 (2xs, 1H), 7.16 and 7.15 (2xs, 1H), 7.09 and 7.08 (2xs, 1H), 4.98 (s, 1H), 4.60 (s, 1H), 4.22-4.33 (m, 1H), 4.15-4.22 (m, 2H), 3.36 (s, 1H), 2.15-2.31 (m, 2H), 1.84-1.99 (m, 6H), 1.39 and 1.37 (2xs, 3H), 1.30 (td, J=7.09, 2.32 Hz, 3H), 1.12 and 0.98 (2xs, 3H), 0.48-0.56 (m, 1H), 0.34-0.43 (m, 3H); LCMS (ESI) m/z 619.8 (M+H)+.
    • Step 4: trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)(((1-methylcyclopropyl)methyl) carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • This compound was obtained as a white solid using similar procedures described for example 1, step 4. 1H NMR (500 MHz, DMSO-d6) rotamers present δ 12.29 (s, 1H), 7.52-7.82 (m, 3H), 5.17 and 4.87 (2xs, 1H), 4.69 (s, 1H), 4.18-4.32 (m, 1H), 3.52 and 3.38 (2xs, 1H), 3.32 and 3.22 (2xs, 1H), 2.00-2.16 (m, 2H), 1.73-1.91 (m, 6H), 1.24 and 1.08 (2xs, 3H), 1.05 and 0.91 (2xs, 3H), 0.44-0.57 (m, 1H), 0.23-0.38 (m, 3H); LCMS (ESI) m/z 592.1 (M+H)+.
    • [Example 729]
  • Figure imgb0438
    • Step 1: (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-((trimethylsilyl)oxy)ethyl)((1-(trifluoromethyl)cyclopropyl )methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylat e.
  • To a solution of 2-(2,6-dichlorophenyl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)-2-((trimethylsilyl)oxy) ethanamine (0.15 g, 0.375 mmol) in DCM (3 mL) was added ethyl 4-(4-(chlorocarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxyl ate (0.137 g, 0.375 mmol) followed by triethylamine (0.104 mL, 0.749 mmol) and stirred at ambient temperature for 15 min. Reaction mixture was loaded on a 25 g column (MPLC) and eluted with Hex:EtOAc (0-50%) to obtain (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-((trimethylsilyl)oxy)ethyl)((1-(trifluoromethyl)cyclopropyl )methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylat e (0.177 g, 0.242 mmol, 65%) as clear oil.
    • Step 2 : (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-hydroxyethyl)((1-(trifluoromethyl)cyclopropyl)methyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • To a solution of (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-((trimethylsilyl)oxy)ethyl)((1-(trifluoromethyl)cyclopropyl )methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylat e (0.177 g, 0.242 mmol) in 2-Me-THF (0.808 ml) was added tetra-n-butylammonium fluoride (0.291 ml, 0.291 mmol) The mixture was stirred at ambient temperature for 1h. The reaction mixture was quenched with saturated aqueous NH4Cl (1 mL) and diluted with EtOAc (50 mL) and water (20 mL). The organic layer was concentrated under reduced pressure to afford (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-hydroxyethyl)((1-(trifluoromethyl)cyclopropyl)methyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate as an off-white solid. This was dissolved in DCM (3 mL) and dess-martin periodinane (0.134 g, 0.315 mmol) was added and the reaction mixture was stirred at ambient temperature for 16h. To this was then added Na2S2O3 (5 mL) followed by saturated NaHCO3 (2 mL) and DCM (20 mL) and stirred for 15 min. Organic layer was passed through phase seperator and concentrated. The crude mixture was purified by MPLC (25 g column) and eluting with Hex:EtOAc (10-40%) to obtain (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-(trifiuoromethyl)cyclopropyl)methyl)carbam oyl)=5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexahecarboxylate (0.13 g, 82%) as amorphous white solid.
    • Step 3: (1r,4r)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl)methyl) carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid.
  • To a solution of (1r,4r)-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl)methyl)carbam oyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (0.13 g, 0.198 mmol) in 2Me-THF (0.660 ml), MeOH (0.660 ml) and water (0.660 ml) was added lithium hydroxide (0.047 g, 1.980 mmol) and stirred at 40 °C for 1 h. Reaction mixture was acidified with 2 N HCl to pH 2 and extracted with EtOAc (2 x 30 mL). Organic layer was dried on anhydrous Na2SO4 filtered and concentrated to obtain (1r,4r)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl)methyl) carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid (0.1g, 75%) as amorphous white solid. 1H NMR δ (DMSO-d6) rotamers present 12.22 (1H, brs) ; 9.79 (1H, 2x) ; 7.69 and 7.67 (1H, 2xs) ; 7.55 and 7.54 (1H, 2xs) ; 7.46 and 7.44 (1H, 2xs) ; 5.19 (1H, m) ; 4.30-4.20 (2H, m) ; 3.78 (2H, m) ; 2.28-2.20 (2H, m) ; 2.18-1.98 (3H, m) ; 1.88-1.47 (8H, m); 1.24 and 1.23 (3H, 2xs) LCMS (ESI): 628.0 (M+H)+.
    • [Example 759] trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • Figure imgb0439
    • Step 1: trans-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-hydroxyethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5 -(trifluoromethyl)-1 H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • To a solution of 1-(trans-4-(ethoxycarbonyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carbo xylic acid (2.88 g, 8.27 mmol) in DCM thionyl chloride (0.663 ml, 9.10 mmol) was added followed by 1 drop of DMF. The flask was then equipped with reflux condenser and the mixture was then stirred for 4 h at 40 °C and then stirred overnight at rt. The solvents were removed in vacuo and the residue was dried in vacuo to afford trans-ethyl 4-(4-(chlorocarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxyl ate (2.87 g, 95% yield) which was used without further purification. To a solution of 2-(2,6-dichlorophenyl)-N-((1-methylcyclopropyl)methyl)-2-((triethylsilyl)oxy)ethanamine (95 mg, 0.245 mmol) in DCM (1.2 ml) was added DIPEA (85 µl, 0.489 mmol) and trans-ethyl 4-(4-(chlorocarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxyl ate (90 mg, 0.245 mmol). After 45 min, TBAF (1 M solution in THF) (905 µl, 0.905 mmol) was added. After 2 h, 1 M aq. HCl was added to the reaction mixture. Organic layer was separated, and the aqueous layer was extracted with DCM. The combined organic layers were washed with sat. aq. NaHCO3, dried with Na2SO4 and concentrated to provide crude trans-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-hydroxyethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (206 mg) which was used without purification in the next step.
    • Step 2: trans-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trif luoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • To a solution of trans-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-hydroxyethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (206 mg, 0.341 mmol) in DCM (3.5 ml) was added Dess-Martin periodinane (217 mg, 0.511 mmol). After 40 min 1 M aq. Na2S2O3 and sat. aq. NaHCO3 were added. The mixture was stirred for 1 h, organic layer was separated, the aqueous layer was extracted with DCM. The combined organic layers were concentrated. The residue was purified by preparative TLC eluted with 30% EtOAc/hexane to provide trans-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trif luoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (100 mg, 0.166 mmol, 48.7% yield).
    • Step 3: trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • To a mixture of trans-ethyl 4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trif luoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (100 mg, 0.166 mmol) in MeOH (1.5 mL), THF (1.5 mL), and water (1 mL) was added lithium hydroxide monohydrate (69 mg, 1.66 mmol). The mixture was heated at 50 °C for 90 min. Most of the MeOH and THF were removed in vacuo. The mixture was brought to pH 1 with 1 M aq. HCl. The mixture was stirred for 15 min, precipitated solid was filtered, washed with water and dried in vacuo to afford trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid (82 mg, 0.143 mmol, 86% yield). 1H NMR (400 MHz, DMSO-d6) mixture of rotamers and keto-enol tautomers δ 12.24 (br. s, 1H), 9.59 (s, 0.2H), 7.80 (s, 0.2H), 7.73 (s, 0.55H), 7.72 (s, 0.25H), 7.32-7.63 (m, 3H), 5.15 (s, 0.2H), 4.88 (br. s, 0.5H), 4.70 (br. s, 1.1H), 4.15-4.35 (m, 1H), 3.52 (s, 0.4H), 3.32 (s, 1.1H), 3.22 (s, 0.5H), 1.99-2.16 (m, 2H), 1.70-1.93 (m, 6H), 1.21-1.28 (m, 3H), 0.88-1.11 (m, 3H), 0.45-0.58 (m, 2H), 0.23-0.35 (m, 2H). LCMS (APCI): 574.3 (M+H)+.
    • [Example 760] trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • Figure imgb0440
    • Step 1: ethyl trans-4-(4-((2-(2,6-dichlorophenyl)-2-((triethylsilyl)oxy)ethyl)((1-methylcyclobutyl)methy l)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • This compound was prepared using similar procedure described for example 1, step 1 without chromatography purification.
    • Step 2: ethyl trans-4-(4-((2-(2,6-dichlorophenyl)-2-hydroxyethyl)((1-methylcyclobutyl)methyl)carbamo yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • This compound was prepared using similar procedure described for example 1, step 2 without chromatography purification. LCMS (ESI) m/z 618.3 (M+H)+.
    • Step 3: ethyl trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5 -(trifluoromethyl)-1 H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • This compound was prepared using similar procedure described for example 1, step 3. 1H NMR (500 MHz, DMSO-d6) rotamers present δ 7.44-7.77 (m, 4H), 4.63 (2xs, 2H), 4.26 (m, 1H), 4.09 (q, J=7.13 Hz, 2H), 3.48 (br. s., 2H), 1.98-2.13 (m, 4H), 1.82-1.96 (m, 3H), 1.74-1.82 (m, 5H), 1.58-1.67 (m, 2H), 1.14-1.28 (m, 9H); LCMS (ESI) m/z 616.3 (M+H)+.
    • Step 4: trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5 -(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • This compound was obtained as a white solid using similar procedure described for example 1, step 4. 1H NMR (500 MHz, DMSO-d6) rotamers present δ 12.18 (br. s., 1H), 9.58 (d, J=1.10 Hz, 1H), 7.66 (s, 1 H), 7.27-7.48 (m, 3H), 5.05 (d, J=1.22 Hz, 1H), 4.09-4.22 (m, 1H), 3.55-3.61 (m, 1H), 1.91-2.05 (m, 4H), 1.67-1.85 (m, 8H), 1.44-1.61 (m, 2H), 1.16 (s, 3H), 1.10 (s, 3H); LCMS (ESI) m/z 588.3 (M+H)+.
    • [Example 785] (1S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylic acid
  • Figure imgb0441
    • Step 1: Ethyl trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(tr ifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylate (racemic mixture).
  • Oxalyl chloride (64 µL, 0.72 mmol) and DMF (1 drop) were added sequentially to a stirring solution of trans-1-(4-(ethoxycarbonyl)-3,3-dimethylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid (0.20 g, 0.55 mmol; racemic mixture) and DCM (5.5 mL). After stirring for 2 h, the reaction mixture was concentrated under reduced pressure. The residue was dissolved with THF (4.5 mL), and then a solution of N-(2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)-2,2-dimethylpropan-1-amine (0.22 g, 0.55 mmol) and THF (1.0 mL) was added followed by DIPEA (0.29 mL, 1.7 mmol). After stirring for 30 min, TBAF (1.7 mL of a 1.0 M solution with THF, 1.7 mmol) was added. After stirring for 1 h, the reaction mixture was partitioned between EtOAc and saturated aqueous NaHCO3, the layers were separated, the organic material was washed sequentially with saturated aqueous NaHCO3 (2x) and brine, dried (Na2SO4), filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved with DCM (5.5 mL) and the resulting solution was treated with Dess-Martin periodinane (0.26 g, 0.60 mmol). After stirring for 10 min, the reaction mixture was concentrated under reduced pressure, the residue was partitioned between THF-EtOAc (1:1 vol/vol) and saturated aqueous NaHCO3, the layers were separated, the organic material was washed sequentially with saturated aqueous NaHCO3 and brine, dried (Na2SO4), filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved with DCM, silica gel (1.0 g) was added to the solution, and the volatiles were removed under reduced pressure. The residue was subjected to flash chromatography on silica gel (gradient elution; 9:1 to 4:1 hexane-EtOAc) to give ethyl trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(tr ifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylate (0.27 g, 80% overall yield; racemic mixture) as a colorless solid.
    • Step 2: Ethyl (1S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylate.
  • Ethyl trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(tr ifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylate (0.22 g, from Step 1; racemic mixture) was resolved using preparative high-performance liquid chromatography (CHIRALPAK™ AD-H column from Chiral Technologies, Inc., West Chester, PA (250 mm x 30 mm, 5 µm column) eluting with a mixture of heptane/EtOH (90:10 v/v) at a flow rate of 50 mL/min) to give two products in greater than 97% enantiomeric excess.
    Peak 1 : Ethyl
    (1R,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylate (0.10 g) as a colorless solid. Peak 2: Ethyl
    (1S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylate (0.098 g) as a colorless solid.
    • Step 3: (1S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylic acid
  • NaOH (1.6 mL of a 1.0 M aqueous solution, 1.6 mmol) was added to a stirring solution of ethyl (1S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylate (0.098 g, 0.16 mmol, from Step 2), THF (1.6 mL), and EtOH (1.6 mL), and then the reaction mixture was heated at 60 °C. After stirring for 40 h, the reaction mixture was allowed to cool to room temperature and then concentrated under reduced pressure. The residue was dissolved with water (10 mL), concentrated hydrochloric acid (10 drops) was added to the solution, the resulting heterogeneous mixture was filtered, the filter cake was washed with water, dissolved with Et2O, the solution was filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved with DCM, the solution was filtered, and the filtrate was concentrated under reduced pressure to give (1S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylic acid (0.082 g, 88% yield) as a colorless solid.
    1H NMR (400 MHz, CDCl3) major rotamer/tautomer (carboxylic acid proton not observed) δ 8.50 (s, 2H), 7.55 (s, 1H), 4.61-4.35 (m, 3H), 3.70-3.16 (m, 2H), 2.47-2.31 (m, 1H), 2.16-1.86 (m, 5H), 1.81-1.57 (m, 1H), 1.17 (br. s., 3H), 1.10 (br. s., 3H), 1.01 (br. s., 9H);
    LCMS (ESI): 591.0 (M+H)+.
    [Example 754]: made from the racemic ethyl ester from Step 1 of example 785.
    [Example 784]: made from the (1R,4R)-ethyl ester from Step 2 example 785.
    [Example 807]: made in the same manner as example 754.
    • [Example 791] (trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(tr ifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexyl)acetic acid
  • Figure imgb0442
    • Steps 1 and 2: 2-((1r,4r)-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(neopentyl)carbamoyl)-5-(tri fluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexyl)acetate
  • Steps 1 and 2 were conducted in a similar manner to Example 1 to give ethyl 2-((1r,4r)-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(neopentyl)carbamoyl)-5-(tri fluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexyl)acetate.
    • Step 3: ethyl 2-((1r,4r)-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluor omethyl)-1H-pyrazol-1-yl)-1-methylcyclohexyl)acetate
  • To a solution of ethyl 2-((1r,4r)-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(neopentyl)carbamoyl)-5-(tri fluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexyl)acetate (134.7 mg, 0.217 mmol) in DCM (2 mL) was added Dess-Martin periodinane (129 mg, 0.303 mmol). The resulting mixture was stirred at ambient temperature for 30 min. The reaction mixture was quenched with NaHCO3 (5 mL, sat. aq.) and Na2S2O3 (5 mL, sat. aq.), then extracted with CH2Cl2 (2×15 mL). The combined organic layers were washed with water (10 mL), brine (10 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (24 g Gold, 0% -50% EtOAc/Hexane) to yield pure white solid as ethyl 2-((1r,4r)-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluor omethyl)-1H-pyrazol-1-yl)-1-methylcyclohexyl)acetate (85.5 mg, 0.138 mmol, 63.7% yield). LCMS = 618 (M+H)+.
    • Step 4: (trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(tr ifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexyl)acetic acid.
  • To solution of ethyl 2-((1r,4r)-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluor omethyl)-1H-pyrazol-1-yl)-1-methylcyclohexyl)acetate (85.5 mg, 0.138 mmol) in THF (2 mL)/EtOH (0.500 mL) was added LiOH, 1 M aqueous (0.552 mL, 0.552 mmol). The reaction mixture was stirred at ambient temperature overnight. Solvent was partially removed. The aqueous solution was acidified to pH 2. The resulting precipitate was filtered, washed with water and allowed to dry in the open air to afford pure white solid as 2-((1r,4r)-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluor omethyl)-1H-pyrazol-1-yl)-1-methylcyclohexyl)acetic acid (82 mg, 0.139 mmol, 100% yield) as mixture of tautomers. 1H NMR (500 MHz, DMSO-d6) δ 0.90-1.01 (m, 9H) 1.05-1.14 (m, 3H) 1.46-1.59 (m, 2H) 1.61-1.83 (m, 4H) 2.00-2.21 (m, 2H) 3.49 (s, 2H) 4.05-4.23 (m, 1H) 5.34 (s, 1H) 7.75 (s, 1H) 8.62 (s, 2H) 9.88 (s, 1H). LCMS = 590.0 (M+H)+.
    • [Example 795]
  • Figure imgb0443
    • trans-4-(4-(((2S,4S)-2-((3,5-dichloro-4-pyridinyl)carbonyl)-4-phenoxy-1-pyrrolidinyl) carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid.
  • The title compound was prepared according to example 822 using (2S,4S)-Boc-4-phenoxy-pyrrolidine-2-carboxylic acid (Chem Impex Int'l, Wood Dale, IL, 2.07 g, 6.74 mmol). The mixture of epimers was separated using prepartory SFC under the following conditions. Step 1: Preparative SFC: OX-H (5 um, 21 mm x 25 cm), Organic modifier: 15% MeOH. F=70 ml/min, T=40 °C, BPR=100 bar, 220 nm. P=151 bar. All sample (605 mg) dissolved in MeOH (10 mL) ∼60 mg/ml, 0.5 ml inj.
    Step 2: Preparative SFC: Reprocessing Peak 2. OX-H (5 um, 21 mm x 25 cm), Organic modifier: 25% MeOH. F=70 ml/min, T=40 °C, BPR=100 bar, 220 nm. P=165 bar. All sample dissolved in MeOH (10 mL), ∼60 mg/ml), 1.0 mL inj.
    Step 3: Preparative SFC: Recycling Peak 1 collection. OX-H (5 um, 21 mm x 25 cm) Organic modifier: 25% MeOH. F=70 ml/min, T=40 °C, BPR=100 bar, 220 nm. P=165 bar. All sample dissolved in MeOH (10 mL), 1.0 ml inj. MS (ESI) 639.0, 641.0 [M + H]+. Note: this epimer was the second eluting peak under the separation conditions described above.
    • [Example 796]
  • Figure imgb0444
    • trans-4-(4-(((2R,4S)-2-((3,5-dichloro-4-pyridinyl)carbonyl)-4-phenoxy-1-pyrrolidinyl) carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid.
  • The title compound was isolated (107 mg, 0.17 mmol, 11% yield) as a light yellow amorphous solid following preparatory SFC separation of the mixture of epimers (at the C2 position of the pyrrolidine) from Example 712. MS (ESI) 639.0, 641.0 [M + H]+. Note: this epimer was the third eluting peak under the separation conditions described above for example 795.
    • [Example 797]
  • Figure imgb0445
    • trans-4-(4-(((2S,4R)-2-((3,5-dichloro-4-pyridinyl)carbonyl)-4-phenoxy-1-pyrrolidinyl) carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid.
  • The title compound was isolated (6.7 mg, 10.48 µmol, 0.7% yield) as a light yellow amorphous solid following preparatory SFC separation of the mixture of epimers (at the C2 position of the pyrrolidine) from example 795. MS (ESI) 639.0, 641.0 [M + H]+. Note: this epimer was the first eluting peak under the separation conditions described above for example 795.
    • [Example 798] (1r,4r)-4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl )methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • Figure imgb0446
    • Step 1: (1r,4r)-ethyl 4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-hydroxyethyl)((1-(trifluoromethyl)cyclopropyl)m ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • To a solution of 1-(2,6-dichloro-3-fluorophenyl)-2-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)ethanol (116 mg, 0.335 mmol) and (1r,4r)-ethyl 4-(4-(chlorocarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxyl ate (147 mg, 0.402 mmol) in DCM (2.3 mL) was added DIPEA (117 µl, 0.670 mmol). The reaction mixture was stirred at room temperature. After 1.5 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with DCM. The combined organic layers were washed with water, brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford a light-yellow oil. The crude material was purified by column chromatography (silica gel, eluent: 10% to 70%. EtOAc/heptane), to provide (1r,4r)-ethyl 4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-hydroxyethyl)((1-(trifluoromethyl)cyclopropyl)m ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (150 mg, 0.222 mmol, 66.2% yield) as a white solid. LCMS: 675.9 (M+H)+.
    • Step 2: (1r,4r)-ethyl 4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl)methyl )carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate
  • A mixture of (1r,4r)-ethyl 4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-hydroxyethyl)((1-(trifluoromethyl)cyclopropyl)m ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (150 mg, 0.222 mmol), TEMPO (3.46 mg, 0.022 mmol), DCM (2.2 mL) and 1 M aq NaHCO3 (554 µl, 0.554 mmol) was stirred at 0 °C. Then sodium hypochlorite, 5.65-6% (1.5 ml, 1.1 mmol) was added slowly. After 1 h, the reaction was quenched with saturated aqueous Na2S2O3 at 0 °C and extracted with DCM (10 mL). The organic layer was dried over anhydrous MgSO4, and concentrated under reduced pressure to afford colorless residue. The crude material was purified by column chromatography (silica gel, eluent : 0% to 40% EtOAc/heptane) to provide (1r,4r)-ethyl 4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl)methyl )carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (113 mg, 0.168 mmol, 76% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 7.25-7.30 (m, 1H), 7.15-7.21 (m, 1H), 4.57 (s, 2H), 4.12-4.20 (m, 3H), 3.86 and 3.75 (2H, 2xs,), 2.12-2.29 (m, 2H), 1.81-1.97 (m, 6H), 1.34-1.39 (m, 3H), 1.25-1.31 (m, 3H), 1.07 (d, J=6.4 Hz, 4H); LCMS: 674.1[M+H]+.
    • Step 3: (1r,4r)-4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl )methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • To a mixture of (1r,4r)-ethyl 4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl)methyl )carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (113 mg, 0.168 mmol) in MeOH (0.4 mL) and THF (0.4 mL) (1:1 ratio) was added 2 N aqueous NaOH (0.42 µl, 0.838 mmol). The reaction mixture was heated to 50 °C for 2 h. It was concentrated, cooled to 0 °C and acidified with 1 N aqueous HCl solution. The white solid was collected, washed with water and dried under reduced pressure to provide (1r,4r)-4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl )methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid (86 mg, 0.133 mmol, 79% yield). 1H NMR (400 MHz, DMSO-d6) δ 12.26 (br. s., 1H), 7.68 (s, 1H), 7.62 (d, J=6.5 Hz, 2H), 4.88 and 4.71 (2H, 2xs), 4.27 (m, 1H), 3.77 and 3.67 (2H, 2xm), 1.98-2.16 (m, 2H), 1.69-1.90 (m, 6H), 1.20-1.27 (m, 3H), 1.01 (br. s., 4H); LCMS: 645.9[M+H]+.
    • [Example 813] (1S,2S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl) -5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
  • Figure imgb0447
    • Step 1 and Step 2: (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(neopentyl)carbamoyl)-5-(trifluoromet hyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate with its (1R,2R,4R)-isomer
  • To a light-yellow clear solution of 1-((1S,3S,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylic, acid with its (1R,3R,4R)-isomer (0.3128 g, 0.898 mmol) in DCM (8.98 ml) was added oxalyl chloride (0.095 ml, 1.123 mmol) followed by DMF (1 drop) and the light-yellow clear reaction mixture was stirred at room temperature. After 2 h, The mixture was concentrated in vacuo to give (1S,2S,4S)-ethyl 4-(4-(chlorocarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxyl ate with its (1R,2R,4R)-isomer as brown syrupy solid. To the residue was added a solution of N-(2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)-2,2-dimethylpropan-1-amine (0.352 g, 0.898 mmol) in THF (8.98 ml) followed by DIPEA (0.626 ml, 3.59 mmol). The brown heterogeneous mixture was stirred at room temperature. After 3 h, LC-MS (ESI) showed that the intermediate (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)(neopentyl)carbamoyl)-5-(tri fluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate with its (1R,2R,4R)-isomer was formed: LCMS (ESI) m/z 721.1 (M+H)+.
  • To the reaction mixture was added TBAF solution, 1.0 M in THF (3.59 ml, 3.59 mmol). After 1 hour, the reaction mixture was diluted with water (30 mL) and brine (30 mL). The reaction mixture was extracted with EtOAc (2 x 50 mL). The organic extract was washed with satd NaCl (1 x 100 mL) and dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a orange syrup. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 50% EtOAc in hexane to provide (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(neopentyl)carbamoyl)-5-(trifluoromet hyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate with its (1R,2R,4R)-isomer (0.4742 g, 0.781 mmol, 87% yield) as off-white syrupy solid: 1H NMR (300 MHz, DMSO-d6) δ 8.44-8.63 (2H, m), 7.57-7.71 (1H, m), 6.01 (1H, d, J=4.4 Hz), 5.28 (1H, dt, J=9.0, 4.5 Hz), 4.32 (1H, d, J=7.2 Hz), 4.11 (2H, q, J=7.1 Hz), 3.85 (1H, dd, J=14.6, 9.2 Hz), 3.53 (2H, d, J=13.0 Hz), 3.32-3.41 (1H, m), 1.49-2.16 (8H, m), 1.21 (3H, t, J=7.1 Hz), 0.63-0.98 (12H, m), (several peak sets due to diastereomers and rotamers); LCMS (ESI) m/z 607.1 (M+H)+.
    • Step 3: (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate
  • To a light-yellow clear solution of (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(neopentyl)carbamoyl)-5-(trifluoromet hyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate with its (1R,2R,4R)-isomer (0.4702 g, 0.774 mmol) in DCM (12.90 ml) was added Dess-Martin periodinane (0.492 g, 1.161 mmol). The white cloudy mixture was stirred at room temperature. After 2 h, the mixture was quenched with saturated aqueous NaHCO3 (30 mL) and saturated aqueous Na2S2O3 (30 mL). The reaction mixture was extracted with DCM (2 x 50 mL). The organic extract was dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a colorless syrup. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 50% EtOAc in hexane to give (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate with its (1R,2R,4R)-isomer (0.437 g, 0.722 mmol, 93% yield): 1H NMR (400 MHz, CDCl3) δ 8.46-8.61 (2H, m), 7.51-7.74 (1H, m), 4.49-4.92 (2H, m), 4.25-4.39 (1H, m), 4.18 (2H, q, J=7.1 Hz), 3.29-3.61 (2H, m), 1.63-2.18 (8H, m), 1.29 (3H, t, J=7.1 Hz), 0.81-1.06 (12H, m), rotamers present; LCMS (ESI) m/z 605.0 (M+H)+.
    The racemic mixture was separated by SFC to give two fractions:
    The stereochemisty of each fraction was arbitrarily assigned.
    • First peak on SFC IA column: (1R,2R,4R)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate (0.1588 g, 0.262 mmol, 33.9% yield) as white solid: 1H NMR (300 MHz, DMSO-d6) δ 8.68-8.87 (2H, m), 7.71-7.89 (1H, m), 4.65-4.92 (2H, m), 4.33 (1H, br. s.), 4.10 (2H, q, J=7.0 Hz), 3.24-3.30 (2H, m), 1.49-2.17 (8H, m), 1.20 (3H, t, J=7.1 Hz), 0.73-1.00 (12H, m) ; LCMS (ESI) m/z 605.0 (M+H)+.
    • Second peak on SFC IA column: (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate (0:1526 g, 0.252 mmol, 32.6% yield) as white solid: 1H NMR (300 MHz, DMSO-d6) δ 8.70-8.87 (2H, m), 7.72-7.89 (1H, m), 4.64-4.93 (2H, m), 4.34 (1H, d, J=5.1 Hz), 4.10 (2H, q, J=7.0 Hz), 3.27 (2H, br. s.), 1.50-2.18 (8H, m), 1.20 (3H, t, J=7.1 Hz), 0.72-1.01 (12H, m) ; LCMS (ESI) m/z 605.0 (M+H)+.
    Step 4: (1S,2S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl) -5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid.
  • To a mixture of the racemic mixture of (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate (0.1245 g, 0.206 mmol) in THF (1.645 ml), EtOH (1.645 ml), and water (0.822 ml) was added 2 M LiOH in water (1.028 ml, 2.056 mmol). The yellow homogeneous mixture was stirred and heated at 60 °C. After 17 h, the reaction mixture was concentrated in vacuo to remove THF and EtOH. The resulting aqueous solution was diluted with water (10 mL). The pH of the solution was adjusted to ∼3.0 with 2 N HCl and the resulting precipitate was collected by vacuum filtration and freeze-dried on lyophilizer overnight to provide example 813 (0.0939 g, 0.163 mmol, 79% yield) as white solid. 1H NMR (300 MHz, DMSO-d6) δ 12.19 (1H, br. s.), 8.57-9.91 (2H, m), 7.72-7.88 (1H, m), 4.65-5.39 (2H, m), 4.32 (1H, d, J=4.5 Hz), 3.22-3.53 (2H, m), 1.46-2.10 (8H, m), 0.72-1.03 (12H, m), rotamers present; LC-MS (ESI) m/z 577.1 (M+H)+. The stereochemisty was arbitrarily assigned as (1S,2S,4S).
    • [Example 822]
  • Figure imgb0448
    • trans-4-(4-(((2R,4S)-4-cyclohexyl-2-((3,5-dichloro-4-pyridinyl)carbonyl)-1-pyrrolidinyl) carbonyl)-5-(trifluoromethyl)-1H-pyiazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • Figure imgb0449
    • Step 1: (2S,4S)-Boc-4-cyclohexyl-pyrrolidine-2-carboxylic acid (Chem Impex Int'l, Wood Dale, IL, 997 mg, 3.35 mmol) was treated with DCM (25 mL) followed by 1,1'-carbonyldiimidazole (598 mg, 3.69 mmol). The solution was allowed to stir at room temperature for 1.5 h then the reaction mixture was then treated with N,O-dimethyl hydroxylamine hydrochloride (360 mg, 3.69 mmol) and allowed to stir over the weekend at room temperature. The reaction mixture was diluted with EtOAc (50 mL), washed with a saturated solution of NaHCO3 (30 mL) and brine (30 mL), dried over MgSO4, filtered and concentrated affording crude (2S,4S)-tert-butyl 4-cyclohexyl-2-(methoxy(methyl)carbamoyl)pyrrolidine-1-carboxylate (1.14 g, 3.35 mmol, 99% yield) as a clear, colorless viscous oil. MS (ESI) 363.2 [M + Na]+. The crude material was used in the next step without further purification.
    • Step 2: (2S,4S)-tert-butyl 4-cyclohexyl-2-(methoxy(methyl)carbamoyl)pyrrolidine-1-carboxylate (1.14 g, 3.35 mmol) was treated with THF (20 mL), cooled to 0 °C in an ice bath and then treated with lithium aluminum hydride (1.0M solution in THF, 3.35 mL, 3.35 mmol) slowly dropwise over 3 min. The solution was then stirred at 0 °C for 45 min. The reaction mixture was quenched with a solution of sodium potassium tartrate, stirred at room temperature for 20 min, then extracted with EtOAc (3 x 50 mL), washed with brine and dried over MgSO4, filtered and concentrated affording crude (2S,4S)-tert-butyl. 4-cyclohexyl-2-formylpyrrolidine-1-carboxylate as a clear, viscous oil. MS (ESI) 304.1 [M + Na]+. The crude material was used in the next step without further purification.
    • Step 3: (2S,4S)-tert-butyl 4-cyclohexyl-2-formylpyrrolidine-1-carboxylate (943 mg, 3.35 mmol) was treated with THF (20 mL) and DBU (1.0 mL, 6.70 mmol) and allowed to stir at room temperature overnight. The reaction mixture was concentrated to dryness on the rotovap, treated with DCM and a saturated solution of NH4Cl and extracted, washed with brine, dried over MgSO4, filtered and concentrated affording a mixture of crude (2S,4S)-tert-butyl 4-cyclohexyl-2-formylpyrrolidine-1-carboxylate and (2R,4S)-tert-butyl 4-cyclohexyl-2-formylpyrrolidine-1-carboxylate (470 mg, 1.67 mmol, 99% yield) as a clear, colorless viscous oil. MS (ESI) 304.1 [M + Na]+.
    • Step 4: Lithium diisopropylamide (2.0 M solution in heptane/THF/ ethylbenzene, 3.51 mL, 7.02 mmol) was added to 3,5-dichloropyridine (820 mg, 5.54 mmol) dissolved in THF (15 mL) cooled at -78 °C and stirred at this temperature for 1 h. (2S,4S)-tert-butyl 4-cyclohexyl-2-formylpyrrolidine-1-carboxylate (1.04 g, 3.70 mmol) and its epimer at C2 of the pyrrolidine in THF (11 mL) was added and the solution was removed from the cooling bath and allowed to warm to room temperature and stirred for 2 h. The solution was quenched with saturated ammonium chloride, the aqueous layer was extracted with EtOAc (2 x 50 mL) and the organic layer was washed with brine (30 mL) and dried over anhydrous magnesium sulfate, filtered and concentrated. The crude product was purified on an ISCO Combiflash™ RF (40 g Grace Reverlis column, using a gradient of 0-80% EtOAc in heptane) affording (2S,4S)-tert-butyl 4-cyclohexyl-2-((S)-(3,5-dichloropyridin-4-yl)(hydroxy)methyl)pyrrolidine-1-carboxylate (1.20 g, 2.79 mmol, 76% yield) as a mixture of epimers. MS (ESI) 451.1,453.1 [M + Na]+.
    • Step 5: (2S,4S)-tert-butyl 4-cyclohexyl-2-((S)-(3,5-dichloropyridin-4-yl)(hydroxy)methyl)pyrrolidine-1-carboxylate (1.20 g, 2.79 mmol) and its epimer at C2 of the pyrrolidine was treated with DCM (10 mL) and TFA (7 mL, 91 mmol) and allowed to stir at room temperature for 1.5 h. The reaction mixture was concentrated on the rotovap and the crude residue purified on an ISCO Combiflash™ RF (40 g Grace Reveleris column, using a gradient of 0-20% 2M NH3/MeOH in DCM) affording (S)-((2S,4S)-4-cyclohexylpyrrolidin-2-yl)(3,5-dichloropyridin-4-yl)methanol 2,2,2-trifluoroacetate (755 mg, 1.705 mmol, 61% yield) along with its epimer at C2 of the pyrrolidine as a light tan-colored foam. MS (ESI) 329.0, 331.1 [M + H]+.
    • Step 6: Oxalyl chloride (0.22 mL, 2.55 mmol) was added to a solution of 1-((1r,4r)-4-(ethoxycarbonyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-car boxylic acid (593 mg, 1.70 mmol) in DCM (10.0 mL), followed by 2 drops of DMF while cooling in an ice bath. The solution was then removed from the ice bath and allowed to stir at room temperature for 1 h. The reaction mixture was concentrated to dryness on the rotovap and the crude residue was treated with DCM (10.0 mL) and cooled to 0 °C. The stirring solution was then treated with (S)-((2S,4S)-4-cyclohexylpyrrolidin-2-yl)(3,5-dichloropyridin-4-yl)methanol 2,2,2-trifluoroacetate (755 mg, 1.70 mmol) and DIPEA (0.89 mL, 5.11 mmol) in DCM (10 mL) and allowed to warm to room temperature and stirred for 1 h. The reaction mixture was concentrated to dryness under reduced pressure (rotary evaporator) and the crude residue was purified on an ISCO Combiflash™ RF (40 g Grace Reveleris column, using a gradient of 0-100% EtOAc in heptane) affording (1S,4r)-ethyl 4-(4-((2S,4S)-4-cyclohexyl-2-((S)-(3,5-dichloropyridin-4-yl)(hydroxy)methyl)pyrrolidine-1 -carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (640 mg, 0.970 mmol, 57% yield) along with its epimer at C2 of the pyrrolidine as a light tan foam. MS (ESI) 659.2, 661.1 [M + H]+.
    • Step 7: Dess-Martin Periodinane (823 mg, 1.94 mmol) and (1R,4r)-ethyl 4-(4-((2R,4S)-4-cyclohexyl-2-((R)-(3,5-dichloropyridin-4-yl)(hydroxy)methyl)pyrrolidine-1-carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (640 mg, 0.97 mmol) as a mixture with its epimer at C2 of the pyrrolidine were treated with DCM (10 mL) and allowed to stir at room temperature for 3 h. The reaction was treated with a saturated solution of NaHCO3 and solid sodium metabisulfite. The reaction mixture was then extracted with DCM (2 x 75 mL), dried over MgSO4, filtered and concentrated affording crude product as a light orange foam. This residue was purified on an ISCO Combiflash™ RF (25 g Grace Reverlis column, using a gradient of 0-70% EtOAc in heptane) affording (1R,4r)-ethyl 4-(4-((2R,4S)-4-cyclohexyl-2-(3,5-dichloroisonicotinoyl)pyrrolidine-1-carbonyl)-5-(trifluo romethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (605 mg, 95%) along with its epimer at C2 of the pyrrolidine as a light yellow foam. MS (ESI) 657.0, 659.0 [M + H]+.
    • Step 8: (1S,4r)-ethyl 4-(4-((2S,4S)-4-cyclohexyl-2-(3,5-dichloroisonicotinoyl)pyrrolidine-1-carbonyl)-5-(trifluor omethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylate (454 mg, 0.69 mmol) and its epimer at C2 of the pyrrolidine in THF (3.5 mL) and MeOH (3.5 mL) was treated with lithium hydroxide monohydrate (1.0 M solution, 3.5 mL, 3.45 mmol). The mixture was stirred at room temperature overnight (16 h), the organics were removed under reduced pressure (rotary evaporator) and the resulting aqueous solution was acidified with 1 N HCl leading to the formation of a precipitate. The mixture was extracted with EtOAc (2 x 40 mL). The combined extracts were washed with brine, dried over anhydrous MgSO4, filtered and concentrated. The crude material was absorbed onto a plug of silica gel and purified by chromatography on an ISCO Combiflash™ RF (25 g Thomson SingleStep column, using a gradient of 0-100% [10% MeOH in DCM] in DCM) affording a mixture of two products epimeric at C2 of the pyrrolidine. This material was subjected to separation on a preparatory SFC using the following conditions: OX column (SN=2121, 5 um, 21 mm x 25 cm, 50/50/50 p=172), Organic modifier: 25% MeOH with 20 mM NH3. F=70 ml/min, T=40 °C, BPR=100 bar, 220 nm. P=165 bar, all sample (416 mg) dissolved in 8 mL of MeOH, ∼ 52 mg/ml), 1.0 mL inj. affording trans-4-(4-(((2R,4S)-4-cyclohexyl-2-((3,5-dichloro-4-pyridinyl)carbonyl)-1-pyrrolidinyl)ca rbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid (55.3 mg, 0.088 mmol, 13% yield) as a light yellow amorphous solid. MS (ESI) 629.1, 631.1 [M + H]+. Note: this epimer was the first eluting peak under the separation conditions described above.
    [Example 823]
  • Figure imgb0450
    • trans-4-(4-(((2S,4S)-4-cyclohexyl-2-((3,5-dichloro-4-pyridinyl)carbonyl)-1-pyrrolidinyl) carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid.
  • The title compound was isolated (291 mg, 0.46 mmol, 67% yield) as a light yellow amorphous solid following preparatory SFC separation of the mixture of epimers (at the C2 position of the pyrrolidine) from Example 739. MS (ESI) 629.1, 631.1 [M + H]+. Note: this epimer was the second eluting peak under the separation conditions described above.
    • [Example 827]
  • Figure imgb0451
    • trans-4-(4-(((2S,4R)-2-((3,5-dichloro-4-pyridinyl)carbonyl)-4-phenyl-1-pyrrolidinyl) carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • The title compound was prepared according to example 822 using (2S,4R)-1-(tert-butoxycarbonyl)-4-phenylpyrrolidine-2-carboxylic acid (Frontier Scientific, Newark, DE, 1.00 g, 3.43 mmol) and isolated (63.7 mg, 0.10 mmol, 18% yield) as a white amorphous solid. The mixture of epimers was separated using preparative SFC under the following conditions. Column: CHIRALPAK™ AZ-H (Reversed) (250 x 21 mm, 5 µm), Mobile Phase: 82:18 (A:B), A: Liquid CO2, B: EtOH. Flow Rate: 70 mL/min. Column/Oven temp.: 40 °C, 186 - 193 bar inlet pressure. SN: 403121. MS (ESI) 623.0, 625.0 [M + H]+. Note: this epimer was the second eluting peak under the separation conditions described above.
    • [Example 828]
  • Figure imgb0452
    • trans-4-(4-(((2R,4R)-2-((3,5-dichloro-4-pyridinyl)carbonyl)-4-phenyl-1-pyrrolidinyl) carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid.
  • The title compound was isolated (135 mg, 0.217 mmol, 39% yield) as a white foam following preparatory SFC separation of the mixture of epimers (at the C2 position of the pyrrolidine) from example 827. MS (ESI) 623.0, 625.0 [M + H]+. Note: this epimer was the third eluting peak under the separation conditions described above for example 827.
    • [Example 845]: (1S,2R,4S)-4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbic yclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohex anecarboxylic acid.
  • Figure imgb0453
    • Step 1: (1S,2R,4S)-ethyl 4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3. 1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarb oxylate.
  • To a solution of (1R,3r,5S)-N-(2-(2,6-dichloro-3-fluorophenyl)-2-((triethylsilyl)oxy)ethyl)-6,6-dimethylbic yclo[3.1.0]hexan-3-amine (97 mg, 0.217 mmol) and (1S,2R,4S)-ethyl 4-(4-(chlorocarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxyl ate (96 mg, 0.261 mmol) in DCM (0.8 mL) was added DIPEA (76 µl, 0.434 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with saturated aqueous NaHCO3 solution and extracted with DCM (3x10 mL). The organic layer was combined, dried over anhydrous MgSO4, filtered, and concentrated to afford product as yellow residue. The residue was dissolved with THF (0.75 mL), then added TBAF solution, 1.0 M in THF (434 µl, 0.434 mmol). The mixture was stirred at room temperature for 0.5 h. It was quenched with saturated aqueous NaHCO3 and extracted with DCM. The combined organic layer was washed with water, brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford a light-yellow oil. The crude material was purified by column chromatography (silica gel, elutent: 0% to 40% EtOAc/heptane) to provide (1S,2R,4S)-ethyl 4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3. 1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarb oxylate (96 mg, 0.145 mmol, 66.7% yield) as a white solid. LCMS: 662.1[M+H]+
    • Step 2: (1S,2R,4S)-ethyl 4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]h exan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxyl ate
  • (1S,2R,4S)-ethyl 4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3. 1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarb oxylate (96 mg, 0.145 mmol) was dissolved in DCM (3 mL) and Dess-Martin periodane (77 mg, 0.181 mmol) was added. It was stirred at room temperature for 3 h. The reaction mixture was quenched with 5% Na2S2O3, washed with saturated NaHCO3, dried with anhydrous Na2SO4 and concentrated. The crude product was purified by column chromatography (silica gel, eluent: 0-40% EtOAc / heptane) to afford (1S,2R,4S)-ethyl 4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]h exan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxyl ate (90 mg, 0.136 mmol, 94% yield) as a viscous white oil.
    LCMS 660.0 [M+H]+.
    • Step 3: (1S,2R,4S)-4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbic yclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohex anecarboxylic acid.
  • To a mixture of (1S,2R,4S)-ethyl 4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]h exan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxyl ate (90 mg, 0.136 mmol) in MeOH (0.34 mL) and THF (0.34 mL) (1:1 ratio) was added 2 N aq. NaOH (0.34mL, 0.68 mmol). The reaction mixture was heated to 50 °C for 3 h. It was concentrated, cooled to 0 °C and acidified with 1 N aqueous HCl. The white solid was collected, washed with water and dried under reduced pressure to provide (1S,2R,4S)-4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbic yclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohex anecarboxylic acid (58 mg, 0.092 mmol, 67.3% yield). 1H NMR (500 MHz, DMSO-d6) δ 12.18 (br. s., 1H), 7.87-7.56 (m, 2H), 7.40-7.51 (m, 1H), 4.96-5.10 (m, 1H), 4.53-4.77 (m, 1H), 4.11-4.52 (m, 2H), 2.54-2.64 (m, 1H), 1.66-2.24 (m, 10H), 1.35-1.59 (m, 2H), 1.19-1.29 (m, 1H), 0.82-1.14 (m, 15H); LCMS: 632.2 [M+H]+
    • [Example 853] trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1s,4s)-7-oxabicyclo[221]hept-1-ylm ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • Figure imgb0454
    • Step 1 and Step 2: ethyl trans-4-(4-(((1s,4S)-7-oxabicyclo[2.2.1]heptan-1-ylmethyl)(2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarbo xylate.
  • To a clear solution of 1-((1r,4r)-4-(ethoxycarbonyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-car boxylic acid (0.121 g, 0.348 mmol) in DCM (3.48 ml) was added oxalyl chloride (0.037 ml, 0.435 mmol) followed by DMF (1 drop) and the clear reaction mixture was stirred at room temperature. After 5 h, the mixture was concentrated in vacuo to give (1r,4r)-ethyl 4-(4-(chlorocarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxyl ate as light-yellow syrup. To the residue was added a solution of N-((1s,4s)-7-oxabicyclo[2.2.1]heptan-1-ylmethyl)-2-(3,5-dichloropyridin-4-yl)-2-((triethyl silyl)oxy)ethanamine (0.150 g, 0.348 mmol) in THF (3.48 ml) followed by DIPEA (0.242 ml, 1.391 mmol). The yellow heterogeneous mixture was stirred at room temperature. After 13 h, LCMS showed that the intermediate ethyl trans-4-(4-(((1s,4S)-7-oxabicyclo[2.2.1]heptan-1-ylmethyl)(2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohe xanecarboxylate was formed: LCMS (ESI) m/z 761.2 (M+H)+. To the reaction mixture was added TBAF solution, 1.0 M in THF (1.391 ml, 1.391 mmol). After 4 h, the reaction mixture was diluted with water (30 mL) and brine (30 mL). The reaction mixture was extracted with EtOAc (2 x 50 mL). The organic extract was washed with satd NaCl (1 x 100 mL) and dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a light-yellow syrup. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 50% EtOAc in heptane to provide ethyl trans-4-(4-(((1s,4S)-7-oxabicyclo[2.2.1]heptan-1-ylmethyl)(2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarbo xylate (0.1083 g, 0.167 mmol, 48.1 % yield) as colorless syrupy solid:
    1H NMR (400 MHz, DMSO-d6) δ 8.43-8.59 (2H, m), 7.49-7.84 (1H, m), 5.95-6.04 (1H, m), 5.32-5.63 (1H, m), 3.51-4.54 (8H, m), 1.11-2.22 (22H, m), (diastereomers and rotamers present); LCMS (ESI) m/z 647.2 (M+H)+.
    • Step 3: ethyl trans-4-(4-(((1s,4S)-7-oxabicyclo[2.2.1]heptan-1-ylmethyl)(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxyla te
  • To a clear solution of ethyl trans-4-(4-(((1s,4S)-7-oxabicyclo[2.2.1]heptan-1-ylmethyl)(2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarbo xylate (0.1015 g, 0.157 mmol) in DCM (2.61 ml) was added Dess-Martin periodinane (0.100 g, 0.235 mmol). The cloudy mixture was stirred at room temperature. After 2 h, the mixture was quenched with saturated aqueous Na2S2O3 (30 mL) and saturated aqueous NaHCO3 (30 mL). The reaction mixture was extracted with DCM (2 x 50 mL). The organic extract was dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a light-yellow syrup. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 50% EtOAc in heptane to provide ethyl trans-4-(4-(((1s,4S)-7-oxabicyclo[2.2.1]heptan-1-ylmethyl)(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxyla te (0.0841 g, 0.130 mmol, 83% yield) as colorless syrup. 1H NMR (400 MHz, CDCl3) δ 8.43-8.60 (2H, m), 7.51-7.68 (1H, m), 3.71-5.12 (8H, m), 1.21-2.36 (22H, m), rotamers present; LC-MS (ESI) m/z 645.0 (M+H)+.
    • Step 4: trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1s,4s)-7-oxabicyclo[221]hept-1-ylm ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • To clear solution of ethyl trans-4-(4-(((1s,4S)-7-oxabicyclo[2.2.1]heptan-1-ylmethyl)(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxyla te (0.0786 g, 0.122 mmol) in THF (0.974 ml), EtOH (0.974 ml), and water (0.487 ml) was added 2 M LiOH in water (0.609 ml, 1.218 mmol). The yellow homogeneous mixture was stirred and heated at 60 °C. After 10 h, the reaction mixture was concentrated in vacuo to remove THF and EtOH. The resulting aqueous solution was diluted with water (10 mL). The pH of the solution was adjusted to ∼3.0 with 2 N HCl and the resulting precipitate was collected by vacuum filtration, wash with water, and freeze-dried on lyophilizer overnight to provide example 853 as white solid. 1H NMR (400 MHz, DMSO-d6) δ 12.25 (1H, br. s.), 8.57-8.84 (2H, m), 7.69-7.86 (1H, m), 4.77-5.00 (2H, m), 4.40-4.53 (1H, m), 4.25 (1H, t, J=11.3 Hz), 3.64-4.06 (2H, m), 1.10-2.20 (19H, m), rotamers present; LCMS (ESI) m/z 617.0 (M+H)+.
    • [Example 872]
  • Figure imgb0455
    • trans-4-(4-((2-(3,5-dichloro-2-methoxy-4-pyridinyl)ethyl)(2,2-dimethylpropyl) carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid.
  • The title compound was prepared from N-(2-(3,5-dichloro-2-methoxypyridin-4-yl)ethyl)-2,2-dimethylpropan-1-amine and 1-((1r,4r)-4-(ethoxycarbonyl)-4-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-car boxylic acid by procedures similar to those described in example 545. MS (ESI) 593.2, 595.1 [M + H]+.
    • [Example 879] (1S,2S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpro pyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
  • Figure imgb0456
    • Step 1 and Step2: (1R,2R,4R)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate compound with (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate (1:1)
  • To a slightly cloudy mixture of 1-((1R,3R,4R)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid compound with 1-((1S,3S,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4 -carboxylic acid (1:1) (0.300 g, 0.431 mmol) in DCM (17.23 ml) was added oxalyl chloride (0.091 ml, 1.077 mmol) followed by DMF (1 drop) and the light-yellow slightly cloudy reaction mixture was stirred at room temperature. After 1.5 h, the mixture was concentrated in vacuo to give (1R,2R,4R)-ethyl 4-(4-(chlorocarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxyl ate compound with (1S,2S,4S)-ethyl 4-(4-(chlorocarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxyl ate (1:1) as light-yellow syrup.
  • To the yellow syrup was added a solution of N-(2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)-3,3,3-trifluoro-2,2-dimethylpro pan-1-amine (0.384 g, 0.862 mmol) in THF (17.23 ml) followed by DIPEA (0.600 ml, 3.45 mmol). The yellow homogeneous mixture was stirred at room temperature. After 4 h, LCMS (ESI) showed that the intermediate (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-((triethylsilyl)oxy)ethyl)(3,3,3-trifluoro-2,2-dimethyl propyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate including its isomer (1R,2R,4R) was formed: LCMS (ESI) m/z 775.1 (M+H)+.
  • To the reaction mixture was added TBAF solution, 1.0 M in THF (3.45 ml, 3.45 mmol) and the yellow homogeneous mixture was stirred at room temperature. After 20 min, the reaction mixture was diluted with water (50 mL) and brine (50 mL). The reaction mixture was extracted with EtOAc (2 x 50 mL). The organic extract was washed with satd NaCl (1 x 100 mL) and dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a light-yellow syrup. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 50% EtOAc in heptane to provide (1R,2R,4R)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate compound with (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate (1:1) (0.4648 g, 0.351 mmol, 82% yield) as colorless syrup: 1H NMR (400 MHz, DMSO-d6) δ 8.46-8.63 (2H, m), 7.70-7.82 (1H, m), 6.11 (1H, d, J=3.3 Hz), 5.20-5.32 (1H, m), 4.34 (1H, d, J=8.0 Hz), 4.06-4.16 (2H, m), 3.43-3.97 (4H, m), 1.53-2.15 (8H, m), 0.82-1.31 (12H, m), (diastereomers and rotamers); LCMS (ESI) m/z 661.1 (M+H)+.
    • Step 3: (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)carbam oyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate
  • To a clear solution of (1R,2R,4R)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate compound with (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate (1:1) (0.458 g, 0.346 mmol) in DCM (11.54 ml) was added Dess-Martin periodinane (0.441 g, 1.039 mmol). The white cloudy mixture was stirred at room temperature. After 14 h, the mixture was quenched with saturated aqueous Na2S2O3 (50 mL) and saturated aqueous NaHCO3 (50 mL). The reaction mixture was extracted with DCM (2 x 50 mL). The organic extract was dried over Na2SO4. The solution was filtered and concentrated in vacuo to give the crude material as a white solid. The crude material was absorbed onto a plug of silica gel and purified by silica gel column chromatography eluting with a gradient of 0% to 50% EtOAc in hexane to provide (1R,2R,4R)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)carbam oyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate compound with (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)carbam oyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate (1:1) (0.3795 g, 0.288 mmol, 83% yield) as white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.70-8.85 (2H, m), 7.73-7.99 (1H, m), 4.69-4.93 (2H, m), 4.35 (1H, d, J=3.7 Hz), 4.10 (2H, q, J=7.0 Hz), 3.51-3.87 (2H, m), 1.51-2.15 (8H, m), 0.87-1.23 (12H, m), rotamers present; LCMS (ESI) m/z 659.0 (M+H)+.
    The racemic mixture was separated by SFC to give two fractions where the stereochemisty of each fraction was arbitrarily assigned.
    • First peak on SFC IA column: (1R,2R,4R)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)carbam oyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate (0.1371 g, 0.208 mmol, 43.4% yield) as white solid: 1H NMR (400 MHz, CDCl3) δ 8.47-8.63 (2H, m), 7.51-7.77 (1H, m), 4.52 (2H, s), 4.26-4.39 (1H, m), 4.18 (2H, q, J=7.1 Hz), 3.70 (2H, br. s.), 1.62-2.17 (8H, m), 1.29 (3H, t, J=7.1 Hz), 1.24 (6H, s), 1.00 (3H, d, J=6.1 Hz), rotamers present; LCMS (ESI) m/z 659.0 (M+H)+.
    • Second peak on SFC IA column: (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)carbam oyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate (0.1447 g, 0.219 mmol, 45.8% yield) as white powder: 1H NMR (400 MHz, CDCl3) δ 8.44-8.64 (2H, m), 7.51-7.77 (1H, m), 4.52 (2H, s), 4.25-4.38 (1H, m), 4.18 (2H, q, J=7.1 Hz), 3.57-3.98 (2H, m), 1.63-2.14 (8H, m), 1.29 (3H, t, J=7.1 Hz), 1.24 (6H, s), 1.00 (3H, d, J=6.1 Hz), rotamers present; LCMS (ESI) m/z 659.0 (M+H)+.
    Step 4: (1S,2S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpro pyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
  • To a clear solution of (1S,2S,4S)-ethyl 4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)carbam oyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate (0.1345 g, 0.204 mmol) in THF (1.632 ml), EtOH (1.632 ml), and water (0.816 ml) was added 2 M LiOH in water (1.020 ml, 2.040 mmol). The light-yellow slightly cloudy mixture was stirred and heated at 60 °C. After 4 h, the reaction mixture was concentrated in vacuo to remove THF and EtOH. The resulting aqueous solution was diluted with water (10 mL). The pH of the solution was adjusted to ∼3.0 with 1 N HCl and the resulting precipitate was collected by vacuum filtration, wash with water, and freeze-dried on lyophilizer overnight to provide example 879 (0.1151 g, 0.182 mmol, 89% yield) as white solid: 1H NMR (400 MHz, DMSO-d6) δ 12.18 (1H, br. s.), 8.59-8.86 (2H, m), 7.73-8.02 (1H, m), 4.65-5.49 (2H, m), 4.33 (1H, d, J=8.4 Hz), 3.44-3.94 (2H, m), 1.48-2.10 (8H, m), 0.85-1.36 (9H, m), rotamers present; LCMS (ESI) m/z 631.1 (M+H)+. The stereochemisty was arbitrarily assigned as (1S,2S,4S).
    • [Example 885]
  • Figure imgb0457
    • trans-4-(4-((2-(3,5-dichloro-2-oxo-1,2-dihydro-4-pyridinyl)ethyl)(2,2-dimethylpropyl), carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid.
  • The title compound was prepared in an analogous manner to example 886 and isolated (36.7 mg, 0.063 mmol, 54% yield) as a white amorphous solid. MS (ESI) 579.0, 581.0 [M + H]+.
    • [Example 886]
  • Figure imgb0458
    • (1S,2R,4S)-4-(4-((2-(3,5-dichloro-2-oxo-1,2-dihydro-4-pyridinyl)ethyl)(2,2-dimethylpropy l)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
  • Figure imgb0459
    • Step 1: Oxalyl chloride (2.0M in DCM, 0.52 mL, 1.03 mmol) was added to a solution of 1-((1S,3R,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid (239 mg, 0.687 mmol) in DCM (2.0 mL) followed by 1 drop of DMF while cooling in an ice bath. The solution was removed from the ice bath and allowed to stir at room temperature for 1 h. The reaction mixture was concentrated to dryness under reduced pressure (rotary evaporator) and the crude residue was treated with DCM (2.0 mL) and cooled to 0 °C. The stirring solution was then treated with N-(2-(3,5-dichloro-2-methoxypyridin-4-yl)ethyl)-2,2-dimethylpropan-1-amine (200 mg, 0.687 mmol) in DCM (2 mL) followed by the addition of DIPEA (0.36 mL, 2.06 mmol) and allowed to warm to room temperature and stirred overnight (16 h). The reaction mixture was concentrated to dryness under reduced pressure (rotary evaporator) and the crude residue was purified on an ISCO Combiflash™ RF (25 g Grace Reveleris column, using a gradient of 0-50% EtOAc in heptane) affording (1S,2R,4S)-ethyl-4-(4-((2-(3,5-dichloro-2-methoxypyridin-4-yl)ethyl)(neopentyl)carbamoyl)-5-(trifluoromet hyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate (350 mg, 0.56 mmol, 82% yield) as a white crystalline solid. MS (ESI) 621.2, 623.2 [M + H]+.
    • Step 2: (1S,2R,4S)-ethyl 4-(4-((2-(3,5-dichloro-2-methoxypyridin-4-yl)ethyl)(neopentyl)carbamoyl)-5-(trifluoromet hyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylate (109 mg, 0.175 mmol) was treated with aqueous hydrochloric acid (5.0 N, 3.00 mL, 15.00 mmol) and hydrochloric acid (4.0 N in 1,4-dioxane, 3.00 mL, 12.00 mmol), fitted with a reflux condenser and heated to 120 °C for 3 h. The reaction mixture was concentrated to dryness under reduced pressure (rotary evaporator) and the crude residue was purified on a Gilson (Gemini™ Phenomenex; 30 x 150 mm, 5 u, using a gradient of 10-95% 0.1%TFA/CH3CN in 0.1%TFA/water), concentrated in a genevac overnight affording (1S,2R,4S)-4-(4-((2-(3,5-dichloro-2-oxo-1,2-dihydropyridin-4-yl)ethyl)(neopentyl)carbamo yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid (57 mg, 0.098 mmol, 56% yield) as a white amorphous solid. MS (ESI) 579.0, 581.2 [M + H]+.
    [Example 887]
  • Figure imgb0460
    • (1S,2R,4S)-4-(4-((2-(3,5-dichloro-2-methoxy-4-pyridinyl)ethyl)(2,2-dimethylpropyl) carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
  • The title compound was prepared from N-(2-(3,5-dichloro-2-methoxypyridin-4-yl)ethyl)-2,2-dimethylpropan-1-amine and 1-((1S,3R,4S)-4-(ethoxycarbonyl)-3-methylcyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid by procedures similar to those described in example 872. MS (ESI) 593.2, 595.1 [M + H]+.
  • The following examples were synthesized similar procedures described above.
    example structure name
    24
    Figure imgb0461
         		4-(4-((2-(3,5-dichloropyridin-4-yl)ethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluocomethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    25
    Figure imgb0462
         		cis-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    26
    Figure imgb0463
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(isobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    27
    Figure imgb0464
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    28
    Figure imgb0465
         		trans-4-(4-((cyclobutylmethyl)(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    29
    Figure imgb0466
         		trans-4-(4-((cyclopentylmethyl)(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    30
    Figure imgb0467
         		trans-4-(4-((cyclohexylmethyl)(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    31
    Figure imgb0468
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    32
    Figure imgb0469
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(isopentyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    33
    Figure imgb0470
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,3-dimethylbutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    34
    Figure imgb0471
         		trans-4-(4-((2-cyclopropylethyl)(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    35
    Figure imgb0472
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3-methylbut-2-en-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    36
    Figure imgb0473
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)((4,4-dimethylcyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    37
    Figure imgb0474
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(spiro[2.5]octan-6-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    38
    Figure imgb0475
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(((S)-tetrahydrofuran-3-yl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    39
    Figure imgb0476
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(((R)-tetrahydrofuran-3-yl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    40
    Figure imgb0477
         		trans-4-(4-(benzyl(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    41
    Figure imgb0478
         		trans-4-(4-((4-chlorobenzyl)(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    42
    Figure imgb0479
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    43
    Figure imgb0480
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(2,3-difluorobenzyl)carbamoyl)-5-(trifluocomethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    44
    Figure imgb0481
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,4-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    45
    Figure imgb0482
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(2,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    46
    Figure imgb0483
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(furan-2-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    47
    Figure imgb0484
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(furan-3-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    48
    Figure imgb0485
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(pyrazin-2-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    49
    Figure imgb0486
         		trans-4-(4-((2-(3-chloro-5-methylpyridin-4-yl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    50
    Figure imgb0487
         		trans-4-(4-((2-(3-chloro-5-fluoropyridin-4-yl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    51
    Figure imgb0488
         		trans-4-(4-((3,5-difluorobenzyl)(2-(3,5-difluoropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    52
    Figure imgb0489
         		trans-4-(4-((3,5-difluorobenzyl)(2-(3,5-dimethylpyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    53
    Figure imgb0490
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    54
    Figure imgb0491
         		trans-4-(4-((2-(2-chloro-6-methoxyphenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    55
    Figure imgb0492
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    56
    Figure imgb0493
         		trans-4-(4-((3,5-difluorobenzyl)(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    57
    Figure imgb0494
         		trans-4-(4-((2-(2,6-dichloro-4-(trifluoromethyl)phenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    58
    Figure imgb0495
         		trans-4-(4-((2-(2,6-dichloro-4-cyanophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    59
    Figure imgb0496
         		trans-4-(4-((2-(3,5-dichlorophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    60
    Figure imgb0497
         		trans-4-(4-((3,5-difluorobenzyl)(2-(3,5-difluorophenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    61
    Figure imgb0498
         		trans-4-(4-((2-(2-chloro-4-fluorophenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    62
    Figure imgb0499
         		trans-4-(4-((3,5-difluorobenzyl)(2-oxo-2-(pyridin-4-yl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    63
    Figure imgb0500
         		trans-4-(4-((3,5-difluorobenzyl)(2-(2,4-dimethylfuran-3-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    64
    Figure imgb0501
         		trans-4-(4-((3,5-difluorobenzyl)(2-(3,5-dimethylisoxazol-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    65
    Figure imgb0502
         		trans-4-(4-((2-cyclohexyl-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    66
    Figure imgb0503
         		trans-4-(4-((2-(2,6-dichloro-4-cyclopropylphenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    67
    Figure imgb0504
         		trans-4-(4-((2-(2,6-dichloro-4-methoxyphenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    68
    Figure imgb0505
         		trans-4-(4-((2-(2-chloro-6-ethynylphenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    69
    Figure imgb0506
         		trans-4-(4-((3,5-difluorobenzyl)(2-(4-hydroxyphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    70
    Figure imgb0507
         		trans-4-(4-((2-(2,6-dichloro-4-hydroxyphenyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    71
    Figure imgb0508
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanetarboxylic acid
    72
    Figure imgb0509
         		trans-4-(4-((cyclopropylmethyl)(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    73
    Figure imgb0510
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(2-fluoro-2-methylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    74
    Figure imgb0511
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(2-methoxy-2-methylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    75
    Figure imgb0512
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(2,2,2-trifluoroethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    76
    Figure imgb0513
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(pyridin-4-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    77
    Figure imgb0514
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    78
    Figure imgb0515
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    79
    Figure imgb0516
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    80
    Figure imgb0517
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-fluorocyclohexanecarboxylic acid
    81
    Figure imgb0518
         		cis-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-fluorocyclohexanecarboxylic acid
    82
    Figure imgb0519
         		trans-3-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclobutanecarboxylic acid
    83
    Figure imgb0520
         		cis-3-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclobutanecarboxylic acid
    84
    Figure imgb0521
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(4-fluorobenzyl)carbamoyl)-5-(1,1-difluoroethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    85
    Figure imgb0522
         		N-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-N-(3,5-difluorobenzyl)-1-(trans-4-hydroxycyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
    86
    Figure imgb0523
         		N-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-N-(4-fluorobenzyl)-1-(cis-4-(methylsulfonyl)cyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
    87
    Figure imgb0524
         		N-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-N-(4-fluorobenzyl)-1-(trans-4-(methylsulfonyl)cyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
    88
    Figure imgb0525
         		1-(trans-4-carbamoylcyclohexyl)-N-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-N-(4-fluorobenzyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
    89
    Figure imgb0526
         		N-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-N-(4-fluorobenzyl)-1-(trans-4-((2-hydroxyethyl)carbamoyl)cyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
    90
    Figure imgb0527
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-hydroxyethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    91
    Figure imgb0528
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-fluoroethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluocomethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    92
    Figure imgb0529
         		(1S,3S)-3-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclopentane-1-carboxylic acid
    93
    Figure imgb0530
         		(1R,3S)-3-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclopentane-1-carboxylic acid
    94
    Figure imgb0531
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    95
    Figure imgb0532
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2-((2-methy)propan-2-yl)oxy)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    96
    Figure imgb0533
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2,2-difluoroethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    97
    Figure imgb0534
         		trans-4-(4-((2-(4-carbamoyl-2,6-dichlorophenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    98
    Figure imgb0535
         		trans-4-(2-((1-(4-carboxycyclohexyl)-5-(trifluoromethyl)pyrazole-4-carbonyl)-((3,5-difluorophenyl)methyl)amino)acetyl)-3,5-dichlorobenzoic acid
    99
    Figure imgb0536
         		trans-4-(4-((2-(2-chlorophenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    100
    Figure imgb0537
         		trans-4-(4-(2-(2,6-dichlorophenyl)propyl-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    101
    Figure imgb0538
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((4,4-difluorocyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    102
    Figure imgb0539
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-methylcyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    103
    Figure imgb0540
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(pyridin-2-ylmethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    104
    Figure imgb0541
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(pyridin-3-ylmethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    105
    Figure imgb0542
         		cis-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-hydroxycyclohexane-1-carboxylic acid
    106
    Figure imgb0543
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-hydroxycyclohexane-1-carboxylic acid
    107
    Figure imgb0544
         		trans-4-(4-((2-(2,5-dichlorophenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    108
    Figure imgb0545
         		trans-4-(4-(2-(2,6-dichlorophenyl)propyl-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    109
    Figure imgb0546
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-methoxyethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    110
    Figure imgb0547
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(4,4-dimethylpent-2-ynyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    111
    Figure imgb0548
         		trans-4-(4-((3,5-difluorophenyl)methyl-(2-(2,6-dimethoxyphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    112
    Figure imgb0549
         		trans-4-(4-((2-(2,4-dichloro-6-methoxyphenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    113
    Figure imgb0550
         		trans-4-(4-((2-cyclopentyl-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    114
    Figure imgb0551
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((2S)-3,3-dimethylbutan-2-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    115
    Figure imgb0552
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((2R)-3;3-dimethylbutan-2-yl)carbamoyl)-5-,(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    116
    Figure imgb0553
         		cis-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-aminocyclohexane-1-carboxylic acid
    117
    Figure imgb0554
         		cis-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-aminocyclohexane-1-carboxylic acid
    118
    Figure imgb0555
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-methylpropyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    119
    Figure imgb0556
         		trans-4-(4-((3,5-difluorophenyl)methyl-(2-(3,5-dimethoxypyridin-4-yl)-2-oxoethyl)carbamoyl)-5 , (trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    120
    Figure imgb0557
         		trans-4-(4-(2-(2,6-dichloro-4-fluorophenyl)ethyl-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    121
    Figure imgb0558
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(piperidin-2-ylmethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    122
    Figure imgb0559
         		trans-4-(4-((3,5-difluorophenyl)methyl-(2-(2,4-dimethyl-6-oxo-1H-pyridin-3-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    123
    Figure imgb0560
         		trans-4-(4-(1-adamantylmethyl-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    124
    Figure imgb0561
         		trans-4-(4-((2-(2-chloro-6-(trifluoromethyl)phenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    125
    Figure imgb0562
         		trans-4-(4-((3-tert-butylcyclobutyl)methyl-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    126
    Figure imgb0563
         		trans-4-(4-((3-tert-butylcyclobutyl)methyl-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    127
    Figure imgb0564
         		trans-4-(4-((2-(2,6-dichloro-4-(trifluoromethoxy)phenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    128
    Figure imgb0565
         		trans-4-(4-((2-(3,5-dichloropyridin-4-y))-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-cyanocyclohexane-1-carboxylicacid
    129
    Figure imgb0566
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-cyanocyclohexane-1-carboxylic acid
    130
    Figure imgb0567
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((6,6-dimethyloxan-3-yl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    131
    Figure imgb0568
         		trans-4-(4-((3-tert-butylcyclobutyl)-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    132
    Figure imgb0569
         		trans-4-(4-((3-tert-butylcyclobutyl)-(2-(3,5-dichloropyridin-4-yl)2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    133
    Figure imgb0570
         		trans-4-(4-((3,5-difluoropheny))methyl-(2-(4,6-dimethylpyrimidin-5-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    134
    Figure imgb0571
         		trans-4-(4-((3,5-difluorophenyl)methyl-(2-(2,4-dimethylpyridin-3-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    135
    Figure imgb0572
         		trans-4-(5-chloro-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    136
    Figure imgb0573
         		trans-4-(4-((2-(2-chloro-4-(trifluoromethyl)phenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    137
    Figure imgb0574
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluorormethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    138
    Figure imgb0575
         		trans-4-(4-(((2R)-2-(2,6-dichlorophenyl)-2-fluoroethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    139
    Figure imgb0576
         		trans-4-(4-(((2S)-2-(2,6-dichlorophenyl)-2-fluoroethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    140
    Figure imgb0577
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((3-(2,2-dimethylpropyl)cyclobutyl)methyl)carbamoyl) -5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    141
    Figure imgb0578
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((4-hydroxyphenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    142
    Figure imgb0579
         		trans-4-(4-((2-(2-aminophenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    143
    Figure imgb0580
         		trans-4-(4-((2-(2-amino-5-methylphenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    144
    Figure imgb0581
         		trans-4-(4-((2-(2,6-dichloro-4-(trifluoromethyl)phenyl)-2-oxoethyl)-(2-((2-methylpropan-2-yl)oxy)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    145
    Figure imgb0582
         		trans-4-(4-((2-(3-chloro-5-hydroxypyridin-4-yl)-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    146
    Figure imgb0583
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)-(pyrimidin-5-ylmethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    147
    Figure imgb0584
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((2-hydroxyphenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    148
    Figure imgb0585
         		trans-4-(5-tert-butyl-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    149
    Figure imgb0586
         		trans-4-(4-((2-(2,6-dichloro-4-(trifluoromethyl)phenyl)-2-oxoethyl)-(2-((2-methylpropan-2-yl)oxy)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    150
    Figure imgb0587
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-(trifluoromethyl)cyclopropyl)methyl)carbamo yl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    151
    Figure imgb0588
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)-(pyridazin-4-ylmethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    152
    Figure imgb0589
         		trans-4-(4-((2-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    153
    Figure imgb0590
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((3-hydroxyphenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    154
    Figure imgb0591
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-methylpiperidin-4-yl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    155
    Figure imgb0592
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(3-((2-methylpropan-2-yl)oxy)cyclobutyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    156
    Figure imgb0593
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-ethylcyclohexane-1-carboxylic acid
    157
    Figure imgb0594
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(((2S)-5-oxopyrrolidin-2-yl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    158
    Figure imgb0595
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(((2R)-5-oxopyrrolidin-2-yl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    159
    Figure imgb0596
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(hydroxymethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    160
    Figure imgb0597
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-methyl-7-oxabicyclo[2.2.1]heptan-4-yl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    161
    Figure imgb0598
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1S,2R)-2-phenylcyclopropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    162
    Figure imgb0599
         		trans-4-(4-((2-(3,5-dichtoropyridin-4-yl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-propan-2-ylpyrazol-1-yl)cyclohexane-1-carboxylic acid
    163
    Figure imgb0600
         		trans-4-(5-(aminomethyl)-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    164
    Figure imgb0601
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-methylpyrazol-1-yl)cyclohexane-1-carboxylic acid
    165
    Figure imgb0602
         		trans-4-(4-((4-chloro-1,3-thiazol-2-yl)methyl-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    166
    Figure imgb0603
         		4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    167
    Figure imgb0604
         		trans-4-(4-((2-chloro-1,3-thiazol-4-yl)methyl-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    168
    Figure imgb0605
         		trans-4-(4-((5-chloro-1,3-thiazol-2-yl)methyl-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    169
    Figure imgb0606
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    170
    Figure imgb0607
         		trans-4-(4-((3-cyanophenyl)methyl-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    171
    Figure imgb0608
         		trans-4-(4-((4-cyanophenyl)methyl-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    172
    Figure imgb0609
         		trans-4-(4-((1-acetylazetidin-3-yl)-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    173
    Figure imgb0610
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(1-(2,2-dimethylpropanoyl)azetidin-3-yl)carbamoyl)-5-(triffuoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    174
    Figure imgb0611
         		trans-4-(4-(cyclohexyl-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    175
    Figure imgb0612
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(4,4-difluorocyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    176
    Figure imgb0613
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(3-((2-methylpropan-2-yl)oxy)cyclobutyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    177
    Figure imgb0614
         		4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.1]heptane-1-carboxylic acid
    178
    Figure imgb0615
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(difluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    179
    Figure imgb0616
         		trans-4-(4-((2-(2-chloro-4,6-difluorophenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    180
    Figure imgb0617
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2,3-dihydro-1H-inden-2-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    181
    Figure imgb0618
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(oxan-4-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    182
    Figure imgb0619
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-spiro[2.5]octan-6-ylcarbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    183
    Figure imgb0620
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1S)-3,3-dimethylcyclopentyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    184
    Figure imgb0621
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1S)-3,3-dimethylcyclopentyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    185
    Figure imgb0622
         		trans-4-(4-(cyclopentyl-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(triftuoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    187
    Figure imgb0623
         		trans-4-(4-(1-cyclopentylethyl-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    188
    Figure imgb0624
         		trans-4-(4-((2-(3-chloro-5-methoxypyridin-4-yl)-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluorormethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    189
    Figure imgb0625
         		trans-4-(4-((4,4-dimethylcyclohexyl)-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    190
    Figure imgb0626
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    191
    Figure imgb0627
         		trans-4-(4-((4,4-dimethylcyclohexyl)-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluocomethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    192
    Figure imgb0628
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-methyl-4-bicyclo[2.2.1]heptanyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    193
    Figure imgb0629
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-((1-methyl-4-bicyclo[2.2.1]heptanyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    194
    Figure imgb0630
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    195
    Figure imgb0631
         		trans-4-(4-((2-(4-chloro-2-oxo-1H-pyridin-3-yl)-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    196
    Figure imgb0632
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(difluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    197
    Figure imgb0633
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(difluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    198
    Figure imgb0634
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(oxolan-3-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    199
    Figure imgb0635
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethy))-((1R,3r,5S)-6,6-dimethy)-3-bicyclo[3.1.0]hexenyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    200
    Figure imgb0636
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(spiro[2.3]hexan-5-ylmethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    201
    Figure imgb0637
         		trans-4-(4-((2-(3,5-dichloro-1-methylpyrazol-4-yl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    202
    Figure imgb0638
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(spiro[2.3]hexan-5-ylmethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    203
    Figure imgb0639
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(3-(2,2-dimethylpropyl)cyclobutyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    204
    Figure imgb0640
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(1-spiro[2.3]hexan-5-ylethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    205
    Figure imgb0641
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(3,3-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    206
    Figure imgb0642
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)-(4,4-dimethylpent-2-ynyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    207
    Figure imgb0643
         		trans-4-(4-(4,4-dimethylpent-2-ynyl-(2-oxo-2-(2,4,6-trichlorophenylphethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    208
    Figure imgb0644
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(5,5-dimethyloxolan-3-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    209
    Figure imgb0645
         		trans-4-(4-((2-(3,5-dichloro-1H-pyrazol-4-yl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    210
    Figure imgb0646
         		trans-4-(4-((3-cyano-3-methylcyclopentyl)-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    211
    Figure imgb0647
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1R,3r,5S)-6,6-dimethyl-3-bicyclo[3.1.0]hexanyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    212
    Figure imgb0648
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(4-(trifluoromethyl)cyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    213
    Figure imgb0649
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(4-(trifluoromethyl)cyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    214
    Figure imgb0650
         		trans-4-(4-((2-(2-chloro-6-methoxyphenyl)-2-oxoethyl)-(4,4-dimethylpent-2-ynyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    215
    Figure imgb0651
         		trans-4-(4-(3-bicyclo[2.2.1]heptanyl-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    216
    Figure imgb0652
         		trans-4-(4-((2-(3,5-dichloro-1,2-thiazol-4-yl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    217
    Figure imgb0653
         		trans-4-(4-((2-(2-chloro-6-(trifluoromethyl)phenyl)-2-oxoethyl)-(4,4-dimethylpent-2-ynyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    218
    Figure imgb0654
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(4,4-dimethylpent-2-ynyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    219
    Figure imgb0655
         		trichlorophenyl)ethyl)carbamoyl)-5-trans-4-(4-(((1R,3r,5S)-6,6-dimethyl-3-bicyclo[3.1.0]hexanyl)-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    220
    Figure imgb0656
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-((4,4-dimethylcyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    221
    Figure imgb0657
         		trans-4-(4-(2,2-dimethylpropyl-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    222
    Figure imgb0658
         		trans-4-(4-((2-(2-chloro-6-(trifluoromethyl)phenyl)-2-oxoethyl)-((1R,3r,5S)-6,6-dimethyl-3-bicyclo[3.1.0]hexanyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    223
    Figure imgb0659
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1R)-3,3-dimethylcyclopentyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    224
    Figure imgb0660
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    225
    Figure imgb0661
         		trans-4-(4-((1-fluorocyclopentyl)methyl-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    226
    Figure imgb0662
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)-((1-methyl-7-oxabicyclo[2.2.1]heptan-4-yl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    227
    Figure imgb0663
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    228
    Figure imgb0664
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((4-fluorophenyl)methyl)carbamoyl)-5-(2,2,2-trifluoroethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    229
    Figure imgb0665
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    230
    Figure imgb0666
         		4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    231
    Figure imgb0667
         		4-(4-((4,4-dimethylcyclohexyl)-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    232
    Figure imgb0668
         		trans-4-(4-((2-(2-chloro-6-methoxyphenyl)-2-oxoethyl)-((1R,3r,5S)-6,6-dimethyl-3-bicyclo(3.1.0)hexanyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    234
    Figure imgb0669
         		trans-4-(4-((2-oxo-2-(2,4,6-trichlorophenyl)ethyl)-(spiro[2.3]hexan-5-ylmethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    235
    Figure imgb0670
         		trans-4-(4-((2-(2-chloro-6-(trifluoromethyl)phenyl)-2-oxoethyl)-(spiro[2.3]hexan-5-ylmethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    236
    Figure imgb0671
         		4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    237
    Figure imgb0672
         		4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)-((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    238
    Figure imgb0673
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)-((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    239
    Figure imgb0674
         		trans-4-(4-((4,4-dimethylcyclohexyl)methyl-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    240
    Figure imgb0675
         		4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-((1R,3r,5S)-6,6-dimethyl-3-bicyclo[3.1.0]hexanyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo(2.2.2)octane-1-carboxylic acid
    241
    Figure imgb0676
         		4-(4-(((1R,3r,5S)-6,6-dimethyl-3-bicyclo[3.1.0]hexanyl)-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo(2.2.2)octane-1-carboxylic acid
    242
    Figure imgb0677
         		4-(4-((2-(2-chloro-6-(trifluoromethyl)phenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    243
    Figure imgb0678
         		4-(4-((2-(2-chloro-6-methoxyphenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazo)-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    244
    Figure imgb0679
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-((1-methyl-7-oxabicyclo[2.2.1]heptan-4-yl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    245
    Figure imgb0680
         		4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    246
    Figure imgb0681
         		4-(4-(2,2-dimethylpropyl-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    247
    Figure imgb0682
         		4-(4-((2-(2-chloro-6-(trifluoromethyl)phenyl)-2-oxoethyl)-((1R,3r,5S)-6,6-dimethyl-3-bicyclo[3.1.0]hexanyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    248
    Figure imgb0683
         		4-(4-((2-(2-chloro-6-methoxyphenyl)-2-oxoethyl)-((1R,3r,5S)-6,6-dimethyl-3-bicyclo[3.1.0]hexanyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    249
    Figure imgb0684
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    250
    Figure imgb0685
         		trans-4-(4-((3,3-dimethylcyclobutyl)methyl-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    251
    Figure imgb0686
         		trans-4-(4-((2-(2-chloro-6-(trifluoromethyl)phenyl)-2-oxoethyl)-((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    252
    Figure imgb0687
         		trans-4-(4-((2-(2-chloro-6-methoxyphenyl)-2-oxoethyl)-((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    253
    Figure imgb0688
         		trans-4-(4-((2-(2-chloro-6-methoxyphenyl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    254
    Figure imgb0689
         		trans-4-(4-((2-(2-chloro-6-(trifluoromethyl)phenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    255
    Figure imgb0690
         		trans-4-(4-((2-(2-chloro-6-methoxyphenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    256
    Figure imgb0691
         		4-(4-((3,3-dimethylcyclobutyl)methyl-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    257
    Figure imgb0692
         		4-(4-((2-(2-chloro-6-methoxyphenyl)-2-oxoethyl)-((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    258
    Figure imgb0693
         		4-(4-((2-(2-chloro-6-(trifluoromethyl)phenyl)-2-oxoethyl)-((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    259
    Figure imgb0694
         		trans-4-(4-((2-(2-chloro-6-methoxyphenyl)-2-oxoethyl)-((4,4-dimethylcyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    260
    Figure imgb0695
         		trans-4-(4-((1-methyl-7-oxabicyclo[2.2.1]heptan-4-yl)methyl-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    261
    Figure imgb0696
         		4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)-((1-methyl-7-oxabicyclo[2.2.1]heptan-4-yl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    262
    Figure imgb0697
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(7-oxabicyclo[2.2.1]heptan-4-ylmethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    263
    Figure imgb0698
         		4-(4-((2-(2-chloro-6-(trifluoromethyl)phenyl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylicacid
    264
    Figure imgb0699
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1R,3r,55)-6,6-dimethyl-3-bicyclo[3.1.0]hexanyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid,
    265
    Figure imgb0700
         		trans-4-(4-((2-(2-chloro-6-(trifluoromethyl)phenyl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluorormethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    266
    Figure imgb0701
         		4-(4-((2-(2/6-dichloro-4-fluorophenyl)-2-oxoethyl)-((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    267
    Figure imgb0702
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-methyl-4-bicyclo[2.2.1]heptanyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    268
    Figure imgb0703
         		trans-4-(4-((2-(4-chloro-2,6-dimethylphenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    269
    Figure imgb0704
         		trans-4-(4-((2-(2-chloro-4,6-dimethylphenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    270
    Figure imgb0705
         		trans-4-(4-((2-(2-chloro-6-(trifluoromethyl)phenyl)-2-oxoethyl)-((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    271
    Figure imgb0706
         		4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    272
    Figure imgb0707
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    273
    Figure imgb0708
         		4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(difluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    274
    Figure imgb0709
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-((1-methyl-4-bicyclo[2.2.1]heptanyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    275
    Figure imgb0710
         		trans-4-(4-((1-methyl-4-bicyclo[2.2.1]heptanyl)methyl-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    279
    Figure imgb0711
         		trans-4-(4-((2-(2-chloro-4,6-dimethylphenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    280
    Figure imgb0712
         		trans-4-(4-((2-(4-chloro-2,6-dimethylphenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    281
    Figure imgb0713
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)-((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    282
    Figure imgb0714
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)-((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    283
    Figure imgb0715
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    284
    Figure imgb0716
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    285
    Figure imgb0717
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-methyl-7-oxabicyclo[2.2.1]heptan-4-yl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    286
    Figure imgb0718
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2,2-dimethylbutyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    287
    Figure imgb0719
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-pentan-3-ylcarbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    288
    Figure imgb0720
         		4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2,2-dimethylbutyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    289
    Figure imgb0721
         		trans-1-methyl-4-(4-(2-oxaspiro[3.5]nonan-7-yl-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    290
    Figure imgb0722
         		trans-3-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclobutane-1-carboxylic acid
    291
    Figure imgb0723
         		cis-3-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclobutane-1-carboxylic acid
    292
    Figure imgb0724
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(2-((2-methylpropan-2-yl)oxy)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    293
    Figure imgb0725
         		trans-1-methyl-4-(4-(2-((2-methylpropan-2-yl)oxy)ethyl-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    294
    Figure imgb0726
         		trans-4-(4-((2-(3-chloro-5-fluoropyridin-4-yl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    295
    Figure imgb0727
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(1-methylpiperidin-4-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    296
    Figure imgb0728
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(1-propan-2-ylpiperidin-4-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    297
    Figure imgb0729
         		trans-4-(4-((2-(2-chloro-6-fluorophenyl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    298
    Figure imgb0730
         		4-(4-((1-fluorocyclopentyl)methyl-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    299
    Figure imgb0731
         		4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    300
    Figure imgb0732
         		4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)-((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    301
    Figure imgb0733
         		cis-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    302
    Figure imgb0734
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(2,2-dimethylbutyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    303
    Figure imgb0735
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    304
    Figure imgb0736
         		trans-4-(4-(8-azabicyclo[3.2.1]octan-3-yl-(2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    305
    Figure imgb0737
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(8-propan-2-yl-8-azabicyclo[3.2.1]octan-3-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    306
    Figure imgb0738
         		trans-4-(4-(2,2-dimethylbutyl-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    307
    Figure imgb0739
         		trans-4-(4-((2-(2-chloro-6-cyano-4-methylphenyl)-2-oxoethyl)-((3,5-difluorophenyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    308
    Figure imgb0740
         		4-(4-(2,2-dimethylbutyl-(2-oxo-2-(2,4,6-trichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    309
    Figure imgb0741
         		4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(2,2-dimethylbutyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    310
    Figure imgb0742
         		trans-4-(5-cyano-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    311
    Figure imgb0743
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(1,2,2;6,6-pentamethylpiperidin-4-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    312
    Figure imgb0744
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(4-methylpentan-2-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    313
    Figure imgb0745
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(1-methoxypropan-2-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    314
    Figure imgb0746
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(3-methylbut-2-enyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    315
    Figure imgb0747
         		trans-4-(4-((2-(3-chloro-5-methoxypyridin-4-yl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    316
    Figure imgb0748
         		4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-methylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    317
    Figure imgb0749
         		4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    318
    Figure imgb0750
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2-((2-methylpropan-2-yl)oxy)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    319
    Figure imgb0751
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(1-(2-methylpropyl)cyclopropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    320
    Figure imgb0752
         		4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    321
    Figure imgb0753
         		4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    322
    Figure imgb0754
         		4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((2,2,3,3-tetramethylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    323
    Figure imgb0755
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(6,6-dimethyloxan-3-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    324
    Figure imgb0756
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-hydroxycyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    325
    Figure imgb0757
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((2,2,3,3-tetramethylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    326
    Figure imgb0758
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2-fluoro-2-methylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    327
    Figure imgb0759
         		4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2-fluoro-2-methylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    328
    Figure imgb0760
         		trans-4-(4-(2,2-dimethylpropyl-(2-(1H-indol-3-yl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    329
    Figure imgb0761
         		4-(4-((2-(3,5-dichloropyridin=4-yl)-2-oxoethyl)-((1-(trifluoromethyl)cyclopropyl)methyl)carbamo yl)-5-(trifluoromethyl)pyrazol-1-yl)bicyclo[2.2.2]octane-1-carboxylic acid
    331
    Figure imgb0762
         		trans-4-(4-(((1R,2S)-2-tert-butylcyclopropyl)-(2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    332
    Figure imgb0763
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(1-((2-methylpropan-2-yl)oxy)propan-2-yl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    333
    Figure imgb0764
         		trans-4-(4-((2-(3-chloro-5-fluoropyridin-4-yl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    334
    Figure imgb0765
         		trans-4-(4-(2-(4-chloro-1H-indol-3-yl)ethyl-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    335
    Figure imgb0766
         		4-(4-((2-(3-chloro-5-fluoropyridin-4-yl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)Carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)bicyclo(2.2.2)octane-1-carboxylic acid
    336
    Figure imgb0767
         		trans-4-(4-((2-(2-chloro-6-methoxyphenyl)-2-hydroxyethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    337
    Figure imgb0768
         		trans-4-(4-((2-(3-chloro-5-fluoropyridin-4-yl)-2-oxoethyl)-(2,2-dimethylbutyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    338
    Figure imgb0769
         		trans-4-(4-((4,4-dimethylcyclohexyl)-(2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    339
    Figure imgb0770
         		trans-3-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclobutane-1-carboxylic acid
    340
    Figure imgb0771
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1S,2S)-2-propan-2-ylcyclopropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    341
    Figure imgb0772
         		trans-4-(4-((2-(2-chloro-6-methoxyphenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    342
    Figure imgb0773
         		trans-4-(4-((2-(2-chloro-6-methoxyphenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    344
    Figure imgb0774
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((3-((2-methylpropan-2-yl)oxy)cyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    345
    Figure imgb0775
         		trans-4-(5-chloro-4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    346
    Figure imgb0776
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1S,2R)-2-propan-2-ylcyclopropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    347
    Figure imgb0777
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)-5-propan-2-ylpyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    348
    Figure imgb0778
         		trans-4-(4-(2-tert-butylsulfanylethyl-(2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    349
    Figure imgb0779
         		trans-4-(4-(2-(4-chloro-1H-indol-3-yl)ethyl-(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    350
    Figure imgb0780
         		trans-4-(4-(2-tert-butylsulfonylethyl-(2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    351
    Figure imgb0781
         		trans-4-(4-(2-tert-butylsulfinylethyl-(2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    352
    Figure imgb0782
         		trans-4-(4-((2-(4-chloro-1H-indol-3-yl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    353
    Figure imgb0783
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)-(2-(3-fluoropiperidin-1-yl)ethyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    354
    Figure imgb0784
         		trans-4-(4-((2-(2-chloro-6-fluorophenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    355
    Figure imgb0785
         		trans-4-(4-((2-(2-chloro-6-fluorophenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    356
    Figure imgb0786
         		trans-4-(4-(((2R)-2-(2-chloro-6-methoxyphenyl)-2-hydroxyethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    357
    Figure imgb0787
     I    		 trans-4-(4-(((2S)-2-(2-chloro-6-methoxyphenyl)-2-hydroxyethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    358
    Figure imgb0788
         		trans-4-(5-chloro-4-((2-(2,6-dichlorophenyl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    359
    Figure imgb0789
         		trans-4-(5-chloro-4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    360
    Figure imgb0790
         		trans=4-(4-(2-(4-chloro-2-methyt-1H-indol-3-yl)ethyl-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    363
    Figure imgb0791
         		trans-4-(5-chloro-4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    364
    Figure imgb0792
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-methyl-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    365
    Figure imgb0793
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-methyl-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    366
    Figure imgb0794
         		trans-4-(5-chloro-4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    367
    Figure imgb0795
         		trans-4-(5-chloro-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    368
    Figure imgb0796
         		trans-4-(4-((2-(2-chlorophenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    369
    Figure imgb0797
         		trans-4-(4-((2-(2-chlorophenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    370
    Figure imgb0798
         		trans-4-(4-(((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)(2-hydroxy-2-(2-methoxyphenyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    371
    Figure imgb0799
         		trans-4-(4-(((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)(2-hydroxy-2-(2-methoxyphenyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    372
    Figure imgb0800
         		trans-4-(4-(((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)(2-hydroxy-2-(2-(trifluoromethyl)phenyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    373
    Figure imgb0801
         		trans-4-(4-(((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)(2-hydroxy-2-(2-(trifluoromethyl)phenyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    374
    Figure imgb0802
         		trans-4-(5-chloro-4-((2-(2-chloro-6-methoxyphenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    375
    Figure imgb0803
         		trans-4-(5-chloro-4-((2-(2-chloro-6-methoxyphenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    376
    Figure imgb0804
         		trans-4-(4-((2-(4-chloro-1H-indazol-3-yl)ethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    377
    Figure imgb0805
         		trans-4-(4-((2-(4-chloro-1H-indol-3-yl)propyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    378
    Figure imgb0806
         		trans-4-(5-chloro-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-methylcyclopropyl)methyl)carbamoyl)pyrazol -1-yl)-1-methylcyclohexane-1-carboxylic acid
    379
    Figure imgb0807
         		trans-4-(4-((2-(3-chloro-5-methylpyridin-4-yl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    380
    Figure imgb0808
         		trans-4-(4-((2-(4-chloro-1H-pyrrolo(2,3-c)pyridin-3-yl)ethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    381
    Figure imgb0809
         		trans-4-(5-chloro-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((3,3-dimethylcyclobutyl)methyl)carbamoyl)pyrazo l-1-yl)-1-methylcyclohexane-1-carboxylic acid
    382
    Figure imgb0810
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-methylpyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    383
    Figure imgb0811
         		trans-4-(4-((2-(3-chloro-5-fluoropyridin-4-yl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    384
    Figure imgb0812
         		trans-4-(4-((2-(3-chloro-5-fluoropyridin-4-yl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    385
    Figure imgb0813
         		trans-4-(5-cyclopropyl-4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    386
    Figure imgb0814
         		trans-4-(5-chloro-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-methyl-7-oxabicyclo[2.2.1]heptan-4-yl)methyl)carbamoyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    387
    Figure imgb0815
         		trans-4-(4-((2-(3-chloro-5-methylpyridin-4-yl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    388
    Figure imgb0816
         		trans-4-(5-chloro-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-((1-(trifluoromethyl)cyclopropyl)methyl)carbamo yl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    389
    Figure imgb0817
         		trans-4-(5-chloro-4-((2-(2,6-dichlorophenyl)-2-oxoethyl)-(4,4-dimethylcyclohexyl)carbamoyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    390
    Figure imgb0818
         		trans-4-(4-((2-(3-chloropyridin-2-yl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    391
    Figure imgb0819
         		trans-4-(4-((2-(3-chloropyridin-2-yl)-2-hydroxyethyl)(((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(triffuoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    392
    Figure imgb0820
         		trans-4-(4-((2-(4-chloro-2-methyl-1H-indol-3-yl)ethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    393
    Figure imgb0821
         		trans-4-(4-((2-(2-chlorophenyl)-2-hydroxypropyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    394
    Figure imgb0822
         		trans-4-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2-ethyl-2-fluorobutyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    395
    Figure imgb0823
         		trans-4-(5-chloro-4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)-(2-ethyl-2-fluorobutyl)carbamoyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    396
    Figure imgb0824
         		trans-4-(4-((2-(3-chlorothiophen-2-yl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    397
    Figure imgb0825
         		trans-4-(4-((2-(3-chlorothiophen-2-yl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    398
    Figure imgb0826
         		trans-4-(4-((2-(3-chloropyridin-2-yl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    399
    Figure imgb0827
         		trans-4-(4-((2-(2-chloro-6-(difluoromethoxy)phenyl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    400
    Figure imgb0828
         		trans-4-(4-((2-(2-chloro-6-(difluoromethoxy)phenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    401
    Figure imgb0829
         		trans-4-(4-(((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)(2-hydroxy-2-(pyridin-2-yl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    402
    Figure imgb0830
         		trans-4-(4-((2-(3-chloropyridin-2-yl)-2-hydroxyethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    403
    Figure imgb0831
         		trans-4-(4-((2-(3-chloropyridin-2-yl)-2-hydroxyethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    404
    Figure imgb0832
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(1-fluorocyclopropyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    405
    Figure imgb0833
         		trans-4-(4-((2-(7-chloro-1H-benzo(d)imidazol-1-yl)ethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    406
    Figure imgb0834
         		trans-4-(4-((2-(2-chloro-6-(difluoromethoxy)phenyl)-2-oxoethyl)-(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)pyrazol-1-yl)-1-methylcyclohexane-1-carboxylic acid
    407
    Figure imgb0835
         		trans-4-(4-((2-(5-chloro-2-methylpyrimidin-4-yl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    408
    Figure imgb0836
         		trans-4-(4-((2-(5-chloropyrimidin-4-yl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    409
    Figure imgb0837
         		trans-4-(4-((2-amino-2-(2-chloro-6-fluorophenyl)ethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    410
    Figure imgb0838
         		trans-4-(4-(((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)(2-hydroxy-2-(3-methylpyrazin-2-yl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    411
    Figure imgb0839
         		trans-4-(4-((2-(2-chlorothiophen-3-yl)-2-hydroxyethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    412
    Figure imgb0840
         		trans-4-(4-(2-(3,5-dichloropyridin-4-yl)ethyl-((4-fluorophenyl)methyl)carbamoyl)-3,5-bis(trifluoromethyl)pyrazol-1-yl)cyclohexane-1-carboxylic acid
    example structure name
    500
    Figure imgb0841
         		trans-4-(4-((4-chlorobenzyl)(2-(2-chlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    501
    Figure imgb0842
         		trans-4-(4-((4-chlorobenzyl)(2-(2,6-dichlorophenyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    502
    Figure imgb0843
         		trans-4-(4-((4-chlorobenzyl)(2-phenylethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    503
    Figure imgb0844
         		trans-4-(4-((4-chlorobenzyl)(2-(1H-indol-6-yl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    504
    Figure imgb0845
         		trans-4-(4-((4-chlorobenzyl)(2-(2,4-d ichloro phenyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    505
    Figure imgb0846
         		trans-4-(4-((4-chlorobenzyl)(2-(2,4-dimethylphenyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    506
    Figure imgb0847
         		trans-4-(4-((4-chlorobenzyl)(2-(1H-indol-4-yl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    507
    Figure imgb0848
         		trans-4-(4-((4-chlorobenzyl)(2-(1H-indol-3-yl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    508
    Figure imgb0849
         		trans-4-(4-((4-chlorobenzyl)(2-(1H-indol-7-yl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    509
    Figure imgb0850
         		trans-4-(4-((4-chlorobenzyl)(2-(2-methylphenyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    510
    Figure imgb0851
         		trans-4-(4-((cyclohexylmethyl)(2-(2,6-dichloro-4-methylphenyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    511
    Figure imgb0852
         		trans-4-(4-((2-(2,6-d dichloro-4-methylphenyl)ethyl)((1-methylcyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    512
    Figure imgb0853
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)ethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    513
    Figure imgb0854
         		trans-4-(4-((4-chlorobenzyl)(2-(2-methyl-1H-indol-3-yl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    514
    Figure imgb0855
         		trans-4-(4-((cyclohexylmethyl)(2-(2,6-dichloro-4-methylphenyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    515
    Figure imgb0856
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)ethyl)(2,2-d imethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    516
    Figure imgb0857
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(4,4-d imethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    517
    Figure imgb0858
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(2,2-d imethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    518
    Figure imgb0859
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(spiro[2.5]oct-6-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    519
    Figure imgb0860
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1-methylcyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    520
    Figure imgb0861
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    521
    Figure imgb0862
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    522
    Figure imgb0863
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(3,5-difluoro-4-(trifluoromethyl)benzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    523
    Figure imgb0864
         		trans-4-(4-((2-(2,6-d ichlorophenyl)ethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    524
    Figure imgb0865
         		trans-4-(4-(((2R)-2-(2,6-dichlorophenyl)-2-hydroxyethyl)(2,2-d imethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    525
    Figure imgb0866
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(4,4-d imethylcyclo hexyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    526
    Figure imgb0867
         		trans-4-(4-((2-(2,6-dichlorophenyl)ethyl)(4-(trifluoromethyl)benzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    527
    Figure imgb0868
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(4-(trifluoromethyl)benzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    528
    Figure imgb0869
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(4-(trifluoromethyl)benzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    529
    Figure imgb0870
         		trans-4-(4-(((2R/S)-2-(2,6-dichloro-4-methylphenyl)-2-methoxyethyl)(2,2-d imethylp ro pyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    530
    Figure imgb0871
         		trans-4-(4-(((2S)-2-(2,6-dichloro-4-methylphenyl)-2-methoxyethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    531
    Figure imgb0872
         		trans-4-(4-(((2R)-2-(2,6-dichloro-4-methylphenyl)-2-methoxyethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    532
    Figure imgb0873
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((4,4-dimethylcyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    533
    Figure imgb0874
         		trans-4-(4-((cyclohexylmethyl)(2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    534
    Figure imgb0875
         		trans-4-(4-((2-(2,6-dichlorophenyl)ethyl)(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    535
    Figure imgb0876
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((4,4-dimethylcyclohexyl)methyl)carbamoyl )-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    536
    Figure imgb0877
         		trans-4-(4-((2-(2,6-d ichloro-4-methylphenyl)-2-oxoethyl)(trans-3-(2-methyl-2-propanyl)cyclobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    537
    Figure imgb0878
         		trans-4-(4-((cyclohexylmethyl)(2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    538
    Figure imgb0879
         		trans-4-(4-((2-(3-chloro-4-quinolinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    539
    Figure imgb0880
         		trans-4-(4-((2-(3-chloro-4-quinolinyl)-2-oxoethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    541
    Figure imgb0881
         		trans-4-(4-((4-chlorobenzyl)(2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    542
    Figure imgb0882
         		trans-4-(4-((2-(2,4-dichloro-6-methyl-3-pyrid inyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    543
    Figure imgb0883
         		trans-4-(4-((4-chlorobenzyl)(2-(2,4-dichloro-6-methyl-3-pyridinyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    544
    Figure imgb0884
         		trans-4-(4-((4-chlorobenzyl)(2-(4,6-dimethyl-2-oxo-1(2H)-pyridinyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    545
    Figure imgb0885
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    546
    Figure imgb0886
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)((4,4-dimethylcyclohexyl)methyl)carbamoyl )-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    547
    Figure imgb0887
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    548
    Figure imgb0888
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)(4,4-dimethyl-2-pentyn-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    549
    Figure imgb0889
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)((1-methylcyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    550
    Figure imgb0890
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    552
    Figure imgb0891
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)(((2S)-2-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    553
    Figure imgb0892
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    554
    Figure imgb0893
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)(((1R)-2,2-dimethylcyclopropyl)methyl)carbamo yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    555
    Figure imgb0894
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1R,3s,5S)-6,6-dimethylbicyclo[3:1.0]hex-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    556
    Figure imgb0895
         		trans-4-(4-((2-(3,5-dichloro-4-pyrid inyl)ethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    557
    Figure imgb0896
         		trans-4-(4-((2-(3,5-dichloro-pyridinyl)ethyl)((1-methylcyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    558
    Figure imgb0897
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    559
    Figure imgb0898
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    560
    Figure imgb0899
         		cis-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    561
    Figure imgb0900
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((4,4-dimethylcyclohexyl)methyl)carbamoyl )-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    562
    Figure imgb0901
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    563
    Figure imgb0902
         		cis-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    564
    Figure imgb0903
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    565
    Figure imgb0904
         		cis-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(spiro[2.3]hex-5-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    566
    Figure imgb0905
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(spiro[2.3]hex-5-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    567
    Figure imgb0906
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(spiro[2:3]hex-5-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    568
    Figure imgb0907
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(2,2-d imethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    569
    Figure imgb0908
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(spiro[2.5]oct-6-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    570
    Figure imgb0909
         		(1S,2R,4R)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    571
    Figure imgb0910
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1-methylcyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    572
    Figure imgb0911
         		(1S,2R,4S)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    573
    Figure imgb0912
         		trans-4-(4-(((2R)-2-(2,6-dichlorophenyl)-2-hydroxyethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    574
    Figure imgb0913
         		trans-4-(4-(((2S)-2-(2,6-dichlorophenyl)-2-hydroxyethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    575
    Figure imgb0914
         		trans-4-(4-((2-(2,6-dichloro-4-methoxyphenyl)-2-oxoethyl)(4,4-d imethylcyclo hexyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    576
    Figure imgb0915
         		trans-4-(4-(((3R)-3-((3,5-dichloro-4-pyridinyl)methyl)-2-azaspiro[4.4]non-7-en-2-yl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    577
    Figure imgb0916
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    578
    Figure imgb0917
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1S)-2,2-d imethylcyclobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    579
    Figure imgb0918
         		trans-4-(4-((2-(2,6-dichloro-4-methoxyphenyl)-2-oxoethyl)(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    580
    Figure imgb0919
         		trans-4-(4-((2-(2,6-dichloro-4-methoxyphenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    581
    Figure imgb0920
         		trans-4-(4-((2-(2,6-dichloro-4-methoxyphenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    582
    Figure imgb0921
         		trans-4-(4-(((3R)-3-((3,5-dichloro-4-pyridinyl)methyl)-2-azaspiro[4.4]non-2-yl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    583
    Figure imgb0922
         		trans-4-(4-((2-(2,6-dichloro-4-, methylphenyl)-2-oxoethyl)(spiro[2.3]hex-5-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    584
    Figure imgb0923
         		trans-4-(4-((2-(2,6-dichloro-4-methoxyphenyl)-2-oxoethyl)((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    585
    Figure imgb0924
         		cis-4-(4-((2-(2-bromophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    586
    Figure imgb0925
         		N-(2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)-N-(2,2-dimethylpropyl)-1-((1S,2S)-2-(2-propen-1-yl)cyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
    587
    Figure imgb0926
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3-dimethylcyclobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    588
    Figure imgb0927
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-methylcyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    589
    Figure imgb0928
         		trans-4-(4-((2-(2-bromophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    590
    Figure imgb0929
         		cis-4-(4-((2-(2,6-dichloro-4-methoxyphenyl)-2-oxoethyl)((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    591
    Figure imgb0930
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)((1-methylcyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    592
    Figure imgb0931
         		trans-4-(4-((cyclopentylmethyl)(2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    593
    Figure imgb0932
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-fluorocyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    594
    Figure imgb0933
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((3,3-difluorocyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    595
    Figure imgb0934
         		trans-4-(4-((2-(2-chloro-6-fluorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    596
    Figure imgb0935
         		cis-4-(4-((2-(2-chloro-6-fluorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    597
    Figure imgb0936
         		cis-4-(4-((2-(2,6-difluorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    598
    Figure imgb0937
         		trans-4-(4-((2-(2,6-difluorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluororpethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    599
    Figure imgb0938
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(3,3-dimethylcyclobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    600
    Figure imgb0939
         		cis-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(3,3-dimethylcyclobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1 yl)cyclohexanecarboxylic acid
    601
    Figure imgb0940
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(((2R)-4,4-dimethyl-2-oxetanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    602
    Figure imgb0941
         		trans-4-(4-(((3,3-dimethylcyclobutyl)methyl)(2-(2-fluoro-6-methoxyphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    603
    Figure imgb0942
         		cis-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    604
    Figure imgb0943
         		trans-4-(4-((2-(2-cyanophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    605
    Figure imgb0944
         		trans-4-(4-((2-(2,6-dichlorophenyl)ethyl)((2R)-1-hydroxy-4,4-dimethyl-2-pentanyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    606
    Figure imgb0945
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    607
    Figure imgb0946
         		trans-4-(4-((4,4-dimethylcyclohexyl)(2-(2-fluoro-6-methoxyphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    608
    Figure imgb0947
         		trans-4-(4-(((1-fluorocyclopentyl)methyl)(2-(2-fluoro-6-methoxyphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    609
    Figure imgb0948
         		cis-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    610
    Figure imgb0949
         		cis-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    611
    Figure imgb0950
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-fluorocyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    612
    Figure imgb0951
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(((1r,4r)-4-methylbicyclo[2.2.1]hept-1-yl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    613
    Figure imgb0952
         		cis-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(spiro[3.3]hept-2-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    614
    Figure imgb0953
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((2R,5R)-5-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    615
    Figure imgb0954
         		cis-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(((1r,4r)-4-methylbicyclo[2.2.1]hept-1-yl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    616
    Figure imgb0955
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1R)-2,2-dimethylcyclobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    617
    Figure imgb0956
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1S)-2,2-d imethylcyclobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    618
    Figure imgb0957
         		trans-4-(4-(((2R)-2-((3,5-dichloro-4-pyridinyl)methyl)-4,4-di(2-propen-1-yl)-1-pyrrolidinyl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    619
    Figure imgb0958
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1S)-spiro[2.4]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    620
    Figure imgb0959
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1S)-spiro[2.4]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    621
    Figure imgb0960
         		cis-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)((1R)-spiro[3.3]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    622
    Figure imgb0961
         		trans-4-(4-((3-cyano-3-methylbutyl)(2-(2,6-dichlorophenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    623
    Figure imgb0962
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1S)-2,2-d imethylcyclopropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    624
    Figure imgb0963
         		cis-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1S)-spiro[2.4]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    625
    Figure imgb0964
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1S)-spiro[2.4]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    626
    Figure imgb0965
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1S)-spiro[3.4]oct-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    627
    Figure imgb0966
         		cis-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R)-spiro[3.4]oct-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    628
    Figure imgb0967
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(((2R)-4,4-dimethyl-2-oxetanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    629
    Figure imgb0968
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(((2S)-4,4-dimethyl-2-oxetanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    630
    Figure imgb0969
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1-fluorocyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    631
    Figure imgb0970
         		cis-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    632
    Figure imgb0971
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(spiro[3.3]hept-2-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    633
    Figure imgb0972
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(spiro[3.3]hept-2-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    634
    Figure imgb0973
         		cis-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1R)-2,2-d imethylcyclobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    635
    Figure imgb0974
         		cis-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1S)-2,2-d imethylcyclobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    636
    Figure imgb0975
         		cis-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R)-2,2-d imethylcyclobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    637
    Figure imgb0976
         		cis-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1S)-2,2-dimethylcyclobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    638
    Figure imgb0977
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-methoxycyclopentyl)methyl)carbamo yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    639
    Figure imgb0978
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R)-spiro[3.3]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    640
    Figure imgb0979
         		cis-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R)-spiro[3.3]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    641
    Figure imgb0980
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1S)-spiro[3.3]hept-1- yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    642
    Figure imgb0981
         		cis-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1S)-spiro[3.3]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    643
    Figure imgb0982
         		trans-4-(4-((2-(2-chloro-6-fluorophenyl)-2-oxoethyl)((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    644
    Figure imgb0983
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-diethylbutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    645
    Figure imgb0984
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-methoxycyclohexyl)methyl)carbamoyl )-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    646
    Figure imgb0985
         		cis-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-methoxycyclopentyl)methyl)carbamo yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    647
    Figure imgb0986
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1S)-2,2-d imethylcyclopropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    648
    Figure imgb0987
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1R)-2,2-dimethylcyclopropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    649
    Figure imgb0988
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1S)-spiro[3.4]oct-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    650
    Figure imgb0989
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R)-spiro[3.4]oct-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    651
    Figure imgb0990
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1S)-spiro[2.4]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    652
    Figure imgb0991
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R)-spiro[2.4]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    653
    Figure imgb0992
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((8S)-5-oxaspiro[3.5]non-8-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    654
    Figure imgb0993
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((8R)-5-oxaspiro[3.5]non-8-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    655
    Figure imgb0994
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((2R)-5,5-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    656
    Figure imgb0995
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1S)-2,2-dimethylcyclopropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    657
    Figure imgb0996
         		trans-4-(4-((2-(2-chloro-6-fluorophenyl)-2-oxoethyl)(2,2-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    658
    Figure imgb0997
         		trans-4-(4-((2-(2-chloro-6-fluorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    659
    Figure imgb0998
         		((1S,2R)-2-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)acetic acid
    660
    Figure imgb0999
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((2S)-2-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    661
    Figure imgb1000
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((2R)-2-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    662
    Figure imgb1001
         		(1R,2S,4R)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    663
    Figure imgb1002
         		(1S,2R,4S)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    664
    Figure imgb1003
         		trans-4-(4-((cyclohexylmethyl)(2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    665
    Figure imgb1004
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1-fluorocyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    666
    Figure imgb1005
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-fluorocyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    667
    Figure imgb1006
         		cis-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    668
    Figure imgb1007
         		(trans-3-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclobutyl)acetic acid
    669
    Figure imgb1008
         		(cis-3-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclobutyl)acetic acid
    670
    Figure imgb1009
         		cis-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(2,2-d imethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    671
    Figure imgb1010
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)((1-methylcyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    672
    Figure imgb1011
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    673
    Figure imgb1012
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((2S)-5,5-dimethyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    674
    Figure imgb1013
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((2S)-5,5-dimethyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    675
    Figure imgb1014
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((3-methyl-3-oxetanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    676
    Figure imgb1015
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((3-methyl-3-oxetanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    677
    Figure imgb1016
         		trans-4-(4-((1S,2R,4R)-bicyclo[2.2.1]hept-2-yl(2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    678
    Figure imgb1017
         		trans-4-(4-((1S,2S,4R)-bicyclo[2.2.1]hept-2-yl(2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    679
    Figure imgb1018
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)(((2R)-5,5-dimethyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    680
    Figure imgb1019
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)(((2S)-5,5-dimethyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    681
    Figure imgb1020
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)(((2R)-2-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    682
    Figure imgb1021
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)ethyl)(((2S)-2-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    683
    Figure imgb1022
         		(1S,2R,4R)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    684
    Figure imgb1023
         		(1R,2S,4S)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    685
    Figure imgb1024
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((2R)-4,4-dimethyl-2-oxetanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    686
    Figure imgb1025
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((2S)-4,4-dimethyl-2-oxetanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    687
    Figure imgb1026
         		trans-4-(4-((2-(2,4-dichloro-6-methyl-3-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    688
    Figure imgb1027
         		trans-4-(4-(((2R)-2-((3,5-dichloro-4-pyridinyl)methyl)-4,4-dimethyl-1-pyrrolidinyl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    689
    Figure imgb1028
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(cis-3-(2-methyl-2-propanyl)cyclobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    690
    Figure imgb1029
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)((1-fluorocyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    691
    Figure imgb1030
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    692
    Figure imgb1031
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3,3-trifluoro-2,2-d imethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    693
    Figure imgb1032
         		trans-4-(4-((2-(2-chloro-4,6-dimethyl-3-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    694
    Figure imgb1033
         		trans-4-(4-((cyclobutylmethyl)(2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    695
    Figure imgb1034
         		trans-4-(4-((cyclopropylmethyl)(2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    696
    Figure imgb1035
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)((1-methylcyclohexyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    697
    Figure imgb1036
         		trans-4-(4-((2,2-dimethylpropyl)(2-oxo-2-(2,3,5-trichloro-4-pyridinyl)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    698
    Figure imgb1037
         		trans-4-(4-((cyclopentylmethyl)(2-(2,6-d ichloro-4-fluorophenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    699
    Figure imgb1038
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(cis-3-(2-methyl-2-propanyl)cyclobutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    700
    Figure imgb1039
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3-methylbutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    701
    Figure imgb1040
         		trans-4-(4-(((2R,4R)-2-((3,5-dichloro-4-pyridinyl)methyl)-4-(2-propanyl)-1-pyrrolidinyl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    702
    Figure imgb1041
         		trans-4-(4-((2-(2-chloro-4,6-dimethyl-3-pyridinyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    703
    Figure imgb1042
         		trans-4-(4-((2-(2,4-dichloro-6-methyl-3-pyridinyl)-2-oxoethyl)((1-fluorocyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    704
    Figure imgb1043
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(3-methylbutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    705
    Figure imgb1044
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((2R,5S)-5-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    706
    Figure imgb1045
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((2S,5R)-5-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    707
    Figure imgb1046
         		trans-4-(4-((cyclopropylmethyl)(2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    708
    Figure imgb1047
         		(1R,3r,5S,6s)-3-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)bicyclo[3.1.0]hexane-6-carboxylic acid
    709
    Figure imgb1048
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1-methylcyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    710
    Figure imgb1049
         		trans-4-(4-((cyclopropylmethyl)(2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    711
    Figure imgb1050
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-methylcyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    712
    Figure imgb1051
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((5-fluorospiro[2.3]hex-5-yl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    713
    Figure imgb1052
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((5-fluorospiro[2.3]hex-5-yl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    714
    Figure imgb1053
         		trans-4-(4-((2-(2,4-d ichloro-6-methyl-3-pyridinyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    715
    Figure imgb1054
         		trans-4-(4-((2-(3,5-dichloro-2-methyl-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    716
    Figure imgb1055
         		trans-4-(4-((2-(2,6-dichloro-4-fluorophenyl)-2-oxoethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    717
    Figure imgb1056
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    718
    Figure imgb1057
         		trans-4-(4-((cyclopentylmethyl)(2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    719
    Figure imgb1058
         		(trans-4-(4-((2-(3,5-d ichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)acetic acid
    720
    Figure imgb1059
         		(cis-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-d imethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)acetic acid
    721
    Figure imgb1060
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1S)-spiro[3.3]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    722
    Figure imgb1061
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1R)-spiro[3.3]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    723
    Figure imgb1062
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(((2S)-4,4-dimethyl-2-oxetanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    724
    Figure imgb1063
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(((2R)-4,4-dimethyl-2-oxetanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    725
    Figure imgb1064
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(((2S)-2-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    726
    Figure imgb1065
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(((2R)-2-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    727
    Figure imgb1066
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(((2S)-2-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    728
    Figure imgb1067
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(((2R)-2-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    729
    Figure imgb1068
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl)methyl)ca rbamoyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    730
    Figure imgb1069
         		trans-4-(4-((2-(3,5-d ichloro-4-pyridinyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    731
    Figure imgb1070
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    732
    Figure imgb1071
         		trans-4-(4-((2-(2,4-dichloro-6-methyl-3-pyrid inyl)-2-oxoethyl)(4,4-dimethylcyclohexyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    733
    Figure imgb1072
         		trans-4-(4-((cyclobutylmethyl)(2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    734
    Figure imgb1073
         		trans-4-(4-((cyclobutylmethyl)(2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    735
    Figure imgb1074
         		trans-4-(4-((cyclohexylmethyl)(2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    736
    Figure imgb1075
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-fluorocyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    737
    Figure imgb1076
         		(1R,2S,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-fluorocyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    738
    Figure imgb1077
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    739
    Figure imgb1078
         		(1R,2S,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    740
    Figure imgb1079
         		(trans-4-(4-((2-(2,4-dichloro-6-methyl-3-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)acetic acid
    741
    Figure imgb1080
         		trans-4-(4-((2-(2-chloro-6-fluorophenyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl)methyl)ca rbamoyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    742
    Figure imgb1081
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-ethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    743
    Figure imgb1082
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((1S)-2,2-dimethylcyclopropyl)methyl)carbamo yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    744
    Figure imgb1083
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1- ethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    745
    Figure imgb1084
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(((1R)-2,2-dimethylcyclopropyl)methyl)carbamo yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    746
    Figure imgb1085
         		trans-4-(4-(((2R,4S)-2-((3,5-dichloro-4-pyridinyl)methyl)-4-(2-propanyl)-1-pyrrolidinyl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    747
    Figure imgb1086
         		trans-4-(4-(((2R,4R)-2-((3,5-dichloro-4-pyridinyl)methyl)-4-(2-propanyl)-1-pyrrolidinyl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    748
    Figure imgb1087
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1S)-spiro[3.3]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    749
    Figure imgb1088
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1R)-spiro[3.3]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    750
    Figure imgb1089
         		(trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)acetic acid
    751
    Figure imgb1090
         		trans-4-(4-((2-(2,4-dichloro-6-methyl-3-pyridinyl)-2-oxoethyl)((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    752
    Figure imgb1091
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(3-methylbutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    753
    Figure imgb1092
         		trans-4-(4-((2-(3,5-dichloro-2-methoxy-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    754
    Figure imgb1093
         		(1R,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylic acid
    755
    Figure imgb1094
         		(trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)acetic acid
    756
    Figure imgb1095
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((3,3-dimethylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    757
    Figure imgb1096
         		trans-4-(4-((2-(2-chloro-4,6-dimethyl-3-pyridinyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    758
    Figure imgb1097
         		trans-4-(4-((2-(3,5-dichloro-2-methyl-4-pyridinyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    759
    Figure imgb1098
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    760
    Figure imgb1099
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    761
    Figure imgb1100
         		cis-4-(4-((2-(2,4-dichloro-6-methyl-3-pyrid inyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    762
    Figure imgb1101
         		trans-4-(4-((2-(2,4-dichloro-6-methyl-3-pyridinyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    763
    Figure imgb1102
         		trans-4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    764
    Figure imgb1103
         		trans-4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    765
    Figure imgb1104
         		(1R,3r,5S,6r)-3-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3-methylbutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)bicyclo[3.1.0]hexane-6-carboxylic acid
    766
    Figure imgb1105
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3,3-trifluoropropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    767
    Figure imgb1106
         		(1R,2S,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3,3-trifluoropropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    768
    Figure imgb1107
         		trans-4-(4-((2-(3,5-dichloro-2-methyl-4-pyridinyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    769
    Figure imgb1108
         		(1R,3r,5S,6s)-3-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)bicyclo[3.1.0]hexane-6-carboxylic acid
    770
    Figure imgb1109
         		(1R,3r,5S,6s)-3-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)bicyclo[3.1.0]hexane-6-carboxylic acid
    771
    Figure imgb1110
         		(4r)-6-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)spiro[3.3]heptane-2-carboxylic acid
    772
    Figure imgb1111
         		(S)-2-((1R,3S)-3-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hexan-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclobutyl)propanoic acid
    773
    Figure imgb1112
         		(1R,2S,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((2S)-5,5-dimethyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    774
    Figure imgb1113
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((2S)-5,5-dimethyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    775
    Figure imgb1114
         		(trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)acetic acid
    776
    Figure imgb1115
         		trans-4-(4-((2-cyclopropylethyl)(2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    777
    Figure imgb1116
         		trans-4-(4-((2-cyclopropylethyl)(2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    778
    Figure imgb1117
         		trans-4-(4-((2-(2-chloro-6-fluoro-4-methylphenyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    779
    Figure imgb1118
         		trans-4-(4-((2-(2,4-dichloro-6-methyl-3-pyridinyl)-2-oxoethyl)(2-((2-methyl-2-propanyl)oxy)ethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    780
    Figure imgb1119
         		2-(trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3-,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)propanoic acid
    781
    Figure imgb1120
         		(1S,2R,4S)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    782
    Figure imgb1121
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    783
    Figure imgb1122
         		trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)(((2S)-5,5-dimethyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    784
    Figure imgb1123
         		(1R,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylic acid
    785
    Figure imgb1124
         		(1S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylic acid
    786
    Figure imgb1125
         		2-(cis-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)propanoic acid
    787
    Figure imgb1126
         		(1S,2R,4S)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    788
    Figure imgb1127
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-methylcyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    789
    Figure imgb1128
         		(trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexyl)acetic acid
    790
    Figure imgb1129
         		(cis-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,5-difluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexyl)acetic acid
    791
    Figure imgb1130
         		(trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexyl)acetic acid
    792
    Figure imgb1131
         		(cis-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexyl)acetic acid
    793
    Figure imgb1132
         		(1R,2R,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    794
    Figure imgb1133
         		(1S,2R,4S)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    795
    Figure imgb1134
         		trans-4-(4-(((2S,4S)-2-((3,5-dichloro-4-pyridinyl)carbonyl)-4-phenoxy-1-pyrrolidinyl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    796
    Figure imgb1135
         		trans-4-(4-(((2R,4S)-2-((3,5-dichloro-4-pyridinyl)carbonyl)-4-phenoxy-1-pyrrolid inyl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    797
    Figure imgb1136
         		trans-4-(4-(((2S,4R)-2-((3,5-dichloro-4-pyridinyl)carbonyl)-4-phenoxy-1-pyrrolidinyl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    798
    Figure imgb1137
         		trans-4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl)methyl)ca rbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    799
    Figure imgb1138
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-(trifluoromethyl)cyclobutyl)methyl)car bamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    800
    Figure imgb1139
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-(fluoromethyl)cyclobutyl)methyl)carba moyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    801
    Figure imgb1140
         		trans-4-(4-((cyclohexylmethyl)(2-(2,4-dichloro-6-methyl-3-pyridinyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    802
    Figure imgb1141
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    803
    Figure imgb1142
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3-methylbutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    804
    Figure imgb1143
         		(1S,2R,4S)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(3-methylbutyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    805
    Figure imgb1144
         		trans-4-(4-((2-(2-chloro-6-fluoro-4-methylphenyl)-2-oxoethyl)(((2S)-2-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    806
    Figure imgb1145
         		trans-4-(4-((2-(2-chloro-6-fluoro-4-methylphenyl)-2-oxoethyl)(((2R)-2-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    807
    Figure imgb1146
         		(1R,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylic acid
    808
    Figure imgb1147
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((2R)-tetrahydro-2-furanylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    809
    Figure imgb1148
         		(1S,2R,4S)-4-(4-(((3R)-3-((3,5-dichloro-4-pyrid inyl)methyl)-2-azaspiro[4.4]non-7-en-2-yl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    810
    Figure imgb1149
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    811
    Figure imgb1150
         		(1S,2R,4S)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl)methyl)ca rbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    812
    Figure imgb1151
         		(1R,2R,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    813
    Figure imgb1152
         		(1S,2S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    814
    Figure imgb1153
         		trans-4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)(((2R)-2-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    815
    Figure imgb1154
         		trans-4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)(((2S)-2-methyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    816
    Figure imgb1155
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1S)-spiro[3.3]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    817
    Figure imgb1156
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1R)-spiro[3.3]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    818
    Figure imgb1157
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((1S)-2,2-difluorocyclopropyl)methyl)carbamoyl )-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    819
    Figure imgb1158
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((1R)-2,2-difluorocyclopropyl)methyl)carbamoyl )-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    820
    Figure imgb1159
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((2R)-tetrahydro-2-furanylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    821
    Figure imgb1160
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(((2R)-5,5-dimethyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    822
    Figure imgb1161
         		trans-4-(4-(((2R,4S)-4-cyclohexyl-2-((3,5-dichloro-4-pyridinyl)carbonyl)-1-pyrrolidinyl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    823
    Figure imgb1162
         		trans-4-(4-(((2S,4S)-4-cyclohexyl-2-((3,5-dichloro-4-pyridinyl)carbonyl)-1-pyrrolidinyl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    824
    Figure imgb1163
         		(1R,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylic acid
    825
    Figure imgb1164
         		(1S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-dimethylcyclohexanecarboxylic acid
    826
    Figure imgb1165
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(((2R)-5,5-dimethyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    827
    Figure imgb1166
         		trans-4-(4-(((2S,4R)-2-((3,5-dichloro-4-pyridinyl)carbonyl)-4-phenyl-1-pyrrolidinyl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    828
    Figure imgb1167
         		trans-4-(4-(((2R,4R)-2-((3,5-dichloro-4-pyridinyl)carbonyl)-4-phenyl-1-pyrrolidinyl)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    829
    Figure imgb1168
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2-fluoro-2-methylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    830
    Figure imgb1169
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-(trifluoromethyl)cyclopropyl)methyl)ca rbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    831
    Figure imgb1170
         		(1S,2R,4S)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(2-fluoro-2-methylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    832
    Figure imgb1171
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(2-fluoro-2-methylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    833
    Figure imgb1172
         		cis-4-(4-((2-(2,4-dichloro-6-methyl-3-pyridinyl)-2-oxoethyl)((4,4-dimethylcyclohexyl)methyl)carbamoyl )-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    834
    Figure imgb1173
         		cis-4-(4-((cyclohexylmethyl)(2-(2,4-dichloro-6-methyl-3-pyridinyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexanecarboxylic acid
    835
    Figure imgb1174
         		trans-4-(4-((2-(2,4-dichloro-6-methyl-3-pyridinyl)-2-oxoethyl)((4,4-dimethylcyclohexyl)methyl)carbamoyl )-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    836
    Figure imgb1175
         		(4R/S)-6-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)spiro[3.3]heptane-2-carboxylic acid
    837
    Figure imgb1176
         		(4R)-6-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)spiro[3.3]heptane-2-carboxylic acid
    838
    Figure imgb1177
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(((2S)-5,5-dimethyttetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    839
    Figure imgb1178
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(((2R)-5,5-dimethyltetrahydro-2-furanyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    840
    Figure imgb1179
         		trans-4-(4-(((2R)-2-(3,5-dichloro-4-pyridinyl)-2-hydroxyethyl)((1-fluorocyclopropyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    841
    Figure imgb1180
         		N-(2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)-N-(2,2-dimethylpropyl)-1-(cis-4-((methylsulfonyl)methyl)cyclohexyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
    842
    Figure imgb1181
         		(1R,3S,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1,3-dimethylcyclohexanecarboxylic acid
    843
    Figure imgb1182
         		(1S,3S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1,3-dimethylcyclohexanecarboxylic acid
    844
    Figure imgb1183
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1-methoxycyclopropyl)methyl)carbamo yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    845
    Figure imgb1184
         		(1S,2R,4S)-4-(4-((2-(2,6-dichloro-3-fluorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    846
    Figure imgb1185
         		(cis-3-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclobutyl)acetic acid
    847
    Figure imgb1186
         		(4s)-6-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2-fluoro-2-methylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)spiro[3.3]heptane-2-carboxylic acid
    848
    Figure imgb1187
         		(1S,2R,4S)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1S)-spiro[3.3]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    849
    Figure imgb1188
         		(1S,2R,4S)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R)-spiro[3.3]hept-1-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    850
    Figure imgb1189
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2-ethoxy-2-methylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    851
    Figure imgb1190
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(spiro[2.5]oct-6-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    852
    Figure imgb1191
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(spiro[2.5]oct-6-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    853
    Figure imgb1192
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1s,4s)-7-oxabicyclo[2.2.1]hept-1-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    854
    Figure imgb1193
         		trans-4-(4-((bicyclo[1.1.1]pent-1-ylmethyl)(2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    855
    Figure imgb1194
         		(1R,3R,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1,3-dimethylcyclohexanecarboxylic acid
    856
    Figure imgb1195
         		(1S,3S,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1,3-dimethylcyclohexanecarboxylic acid
    857
    Figure imgb1196
         		(1R,3R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1,3-dimethylcyclohexanecarboxylic acid
    858
    Figure imgb1197
         		(trans-3-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclobutyl)acetic acid
    859
    Figure imgb1198
         		(cis-3-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1R,3r,5S)-6,6-dimethylbicyclo[3.1.0]hex-3-yl)carbamoyl)-5-(frifluoromethyl)-1H-pyrazol-1-yl)cyclobutyl)acetic acid
    860
    Figure imgb1199
         		(1R,3r,6R)-6-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-y)spiro[2.5]octane-1-carboxytic acid
    861
    Figure imgb1200
         		(1S,2S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1,2-dimethylcyclohexanecarboxylic acid
    862
    Figure imgb1201
         		(1S,2S,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1,2-dimethylcyclohexanecarboxylic acid
    863
    Figure imgb1202
         		trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((3,3-difluoro-1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    864
    Figure imgb1203
         		(1S,2S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    865
    Figure imgb1204
         		(1R,4R)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-d imethylcyclohexanecarboxylic acid
    866
    Figure imgb1205
         		(1S,4S)-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2,2-d imethylcyclohexanecarboxylic acid
    867
    Figure imgb1206
         		(1S,2S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1s,4s)-7-oxabicyclo[2.2.1]hept-1-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    868
    Figure imgb1207
         		(1S,3R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-3-fluoro-1-methylcyclohexanecarboxylic acid
    869
    Figure imgb1208
         		(1R,3S,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-d imethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-3-fluoro-1-methylcyclohexanecarboxylic acid
    870
    Figure imgb1209
         		(1R,3S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-3-fluoro-1-methylcyclohexanecarboxylic acid
    871
    Figure imgb1210
         		(3aR,6R,7aR)-6-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)((2,2-d imethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)octahydro-1H-indene-3a-carboxylic acid
    872
    Figure imgb1211
         		trans-4-(4-((2-(3,5-dichloro-2-methoxy-4-pyridinyl)ethyl)(2,2-d imethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    873
    Figure imgb1212
         		(1S,2S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1,2-dimethylcyclohexanecarboxylic acid
    874
    Figure imgb1213
         		(1R,2R,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1,2-dimethylcyclohexanecarboxylic acid
    875
    Figure imgb1214
         		(1R,2S,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    876
    Figure imgb1215
         		(3aS,6S,7aS)-6-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)octahydro-1H-indene-3a-carboxylic acid
    877
    Figure imgb1216
         		(3aR,6R,7aR)-6-(4-((2-(3,5-dichloropyridin-4-yl)-2-oxoethyl)(neopentyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)octahydro-1H-indene-3a-carboxylic acid
    878
    Figure imgb1217
         		(1R,2R,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    879
    Figure imgb1218
         		(1S,2S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    880
    Figure imgb1219
         		(1R,2R,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1s,4s)-7-oxabicyclo[2.2.1]hept-1-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    881
    Figure imgb1220
         		(1S,2S,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)((1s,4s)-7-oxabicyclo[2.2.1]hept-1-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    882
    Figure imgb1221
         		(1S,3R,4S)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1,3-dimethylcyclohexanecarboxylic acid
    883
    Figure imgb1222
         		(1R,3S,4R)-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1,3-dimethylcyclohexanecarboxylic acid
    884
    Figure imgb1223
         		(trans-4-(4-((2-(3,5-dichloro-4-pyridinyl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)carbamoyl)-5-(trifluorormethyl)-1H-pyrazol-1-yl)cyclohexyl)acetic acid
    885
    Figure imgb1224
         		trans-4-(4-((2-(3,5-dichloro-2-oxo-1,2-dihydro-4-pyridinyl)ethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    886
    Figure imgb1225
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-2-oxo-1,2-dihydro-4-pyridinyl)ethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    887
    Figure imgb1226
         		(1S,2R,4S)-4-(4-((2-(3,5-dichloro-2-methoxy-4-pyridinyl)ethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-2-methylcyclohexanecarboxylic acid
    888
    Figure imgb1227
         		(trans-4-(4-((2-(2,6-dichloro-4-methoxyphenyl)-2-oxoethyl)((1-fluorocyclopentyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)acetic acid
    889
    Figure imgb1228
         		(trans-4-(4-((2-(2,6-dichloro-4-methoxyphenyl)-2-oxoethyl)(4-fluorobenzyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)acetic acid
    890
    Figure imgb1229
         		(trans-4-(4-((2-(2,6-dichloro-4-methylphenyl)-2-oxoethyl)((1-methylcyclobutyl)methyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)acetic acid
    891
    Figure imgb1230
         		trans-4-(4-((2-(2,6-dichloro-4-methoxyphenyl)-2-oxoethyl)(spiro[3.5]non-7-ylmethyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    892
    Figure imgb1231
         		trans-4-(4-((2-(6,8-dichloro[1,2,4]triazolo[1,5-a]pyridin-7-yl)ethyl)(2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
    893
    Figure imgb1232
         		trans-4-(4-((2-(2,6-dichlorophenyl)-2-oxoethyl)(3,3,3-trifluoro-2,2-dimethylpropyl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-methylcyclohexanecarboxylic acid
  • The results of high performance liquid chromatography mass spectroscopy (LC/MS) analysis for the above examples were shown in the following tables.
    example Exact Mass Obs. Mass example Exact Mass Obs. Mass
    24 586.1 587.1 60 585.1 586
    25 600.1 601.2 61 601.1 602
    26 548.1 549.0 62 550.2 551
    27 562.1 563.1 63 567.2 568
    28 560.1 561.1 64 568.2 569
    29 574.1 575.1 65 555.2 554
    30 588.2 569.1 66 657.1 658
    31 560.1 561.0 67 647.1 648
    32 562.1 563.0 68 607.1 608
    33 576.2 579.1 69 565.2 566
    34 560.1 561.2 70 633.1 634
    35 560.1 561.2 71 590.1 593.0
    36 616.2 617.1 72 546.1 547.0
    37 614.2 615.1 73 566.1 567.0
    38 576.1 577.0 74 578.1 579.1
    39 576.1 577.0 75 574.1 575.0
    40 582.1 583.0 76 583.1 584.0
    41 616.1 617.0 77 614.1 615.0
    42 618.1 619.0 78 632.1 633.0
    43 618.1 619.0 79 614.1 615.0
    44 618.1 619.0 80 618.1 619.0
    45 618.1 619.0 81 618.1 619.0
    46 572.1 573.0 82 572.1 573.0
    47 572.1 573.0 83 572.1 573.0
    48 584.1 585.0 84 596.1 597.1
    49 598.1 599 85 590.1 591
    50 602.1 603 86 634.1 635.0
    51 586.1 587 87 634.1 635.0
    52 578.2 579 88 599.1 600.0
    53 617.1 618 89 643.1 644.1
    54 613.1 614 90 602.1 603.0
    55 635.1 636 91 603.1 604.0
    56 651.1 652 92 586.1 587.0
    57 685.1 686 93 586.1 587.0
    58 642.1 643 94 593.1 594.2
    59 617.1 618 95 592.1 593.1
    96 621.1 622.0 132 602.2 603.1
    97 660.1 661 133 579.2 580
    98 661.1 662 134 578.2 579
    99 583.1 584 135 584.1 587
    100 599.1 600.1 136 651.1 652
    101 624.1 625.1 137 631.1 632
    102 602.2 603.1 138 635.1 636.2
    103 583.1 584.0 139 635.1 636.2
    104 583.1 584.0 140 630.2 631
    105 616.1 617.0 141 598.1 599
    106 616.1 617.0 142 564.2 565
    107 617.1 618 143 578.2 579
    108 617.1 618 144 659.1 660.1
    109 634.1 635 145 582.1 583.1
    110 586.1 587.1 146 583.1 584
    111 609.2 610 147 598.1 599
    112 647.1 649 148 606.2 607
    113 541.2 542 149 673.2 674.1
    114 576.2 577.1 150 614.1 615.0
    115 576.2 577.1 151 583.1 585
    116 615.1 616.2 152 652.1 653
    117 615.1 616.2 153 598.1 599
    118 631.1 632 154 603.2 604.3
    119 610.2 611 155 618.2 619.1
    120 621.1 622 156 646.1 647
    121 589.1 590.0 157 589.1 590
    122 594.2 595 158 589.1 590
    123 640.2 641.1 159 580.1 581.0
    124 651.1 652 160 616.1 617.1
    125 616.2 617.1 161 608.1 609.0
    126 616.2 617.1 162 592.1 593
    127 701.1 702 163 579.1 580.0
    128 625.1 626.2 164 564.1 565
    129 625.1 626.0 165 623.0 624
    130 618.2 619.1 166 626.1 627.0
    131 602.2 603.1 167 623.0 624
    168 623.0 624 205 602.2 603.3
    169 602.2 603.1 206 613.2 614.2
    170 607.1 608 207 633.1 634.2
    171 607.1 608 208 590.1 591.2
    172 589.1 590.0 209 607.1 608.2
    173 631.2 632.1 210 599.1 600.2
    174 574.1 575.1 211 600.2 601.3
    175 610.1 611.0 212 642.1 643.2
    176 618.2 619.1 213 642.1 643.2
    177 612.1 613.0 214 595.2 596.3
    178 614.1 615 215 586.1 587
    179 619.1 620 216 624.0 625
    180 608.1 609.0 217 633.2 634.3
    181 576.1 577.0 218 617.1 618.3
    182 600.2 601.1 219 647.1 648.2
    183 588.2 589 220 647.2 648.3
    184 588.2 589.2 221 609.1 610.2
    185 560.1 561.2 222 647.2 648.3
    187 588.2 589.2 223 588.2 589.3
    188 596.1 597.1 224 623.1 624.2
    189 635.1 636.0 225 639.1 640.2
    190 633.2 634.3 226 643.2 645
    191 649.1 650.2 227 629.2 630
    192 614.2 615.3 228 614.1 615
    193 631.2 632.2 229 616.2 617.3
    194 592.1 593.2 230 645.2 646.3
    195 582.1 583.2 231 661.1 662.2
    196 598.2 597 232 609.2 610.3
    197 631.1 632.2 234 633.1 634.2
    198 562.1 563.2 235 633.2 634.3
    199 631.2 632.3 236 641.2 642
    200 586.1 587.2 237 627.2 628
    201 621.1 622.2 238 615.2 616
    202 617.1 618.2 239 663.2 664.3
    203 647.2 648.3 240 643.2 644.3
    204 600.2 601.3 241 659.1 660.2
    242 661.2 662.3 281 605.1 606.2
    243 623.2 624.3 282 619.2 620.2
    244 647.2 648.3 283 615.2 616.3
    245 605.1 606.3 284 575.2 576.2
    246 621.1 622.2 285 630.2 631.3
    247 659.2 660.3 286 590.2 591.3
    248 621.2 622.3 287 576.2 579.2
    249 619.2 620.3 288 602.2 603.2
    250 635.1 636.2 289 663.1 664
    251 635.2 636.3 290 591.1 592
    252 597.2 598.3 291 591.1 592
    253 571.2 572.3 292 623.2 624
    254 649.2 650.3 293 639.1 642
    255 611.2 612.3 294 560.2 561.2
    256 647.1 648.3 295 620.2 621
    257 609.2 610.3 296 648.2 649
    258 647.2 648.3 297 559.2 560.3
    259 625.3 626.4 298 651.1 652.2
    260 663.1 664.2 299 618.1 619.2
    261 655.2 656 300 631.2 632.2
    262 602.1 603 301 633.2 634
    263 621.2 622.3 302 607.2 608.3
    264 600.2 601.2 303 646.2 647
    265 609.2 610.2 304 632.2 633
    266 631.2 632.2 305 674.2 675
    267 628.2 629.3 306 623.1 626.1
    268 611.2 612 307 622.1 623
    269 611.2 612 308 635.1 636.1
    270 639.2 640.3 309 619.2 620.1
    271 635.1 636.2 310 533.2 534.5
    272 606.1 607.2 311 659.2 660
    273 627.2 628.3 312 590.2 591
    274 645.2 646.2 313 578.1 579
    275 661.1 662.2 314 574.1 575
    279 609.3 610 315 572.2 573.3
    280 609.3 610 316 586.1 587.2
    317 587.2 588.2 355 599.2 600.3
    318 606.2 606.6 356 573.2 574.3
    319 602.2 603.6 357 573.2 574.3
    320 625.2 626.2 358 541.1 544
    321 639.2 640.3 359 555.1 558
    322 628.2 629.2 360 580.2 581
    323 618.2 619.8 363 579.1 580
    324 604.1 605.2 364 559.2 560
    325 616.2 617.3 365 573.2 574
    326 580.1 581.2 366 593.2 594
    327 592.1 593.2 367 580.1 581
    328 532.3 533.7 368 581.2 583.0
    329 640.1 641.2 369 581.2 582.9
    331 602.2 603 370 577.3 578.9
    332 620.2 619 371 577.3 579.0
    333 598.2 599.3 372 615.3 616.9
    334 566.2 567.7 373 615.3 617.0
    335 610.2 611.3 374 577.2 578.9
    336 613.3 614.3 375 577.2 578.9
    337 574.2 575.2 376 605.2 607.0
    338 551.3 552 377 618.3 620.0
    339 605.1 606 378 540.1 541.2
    340 588.2 589 379 556.2 557.3
    341 611.2 612.3 380 605.2 606.3
    342 611.2 612.9 381 568.1 569.2
    344 646.2 645 382 548.2 549.3
    345 599.2 600 383 600.2 601
    346 588.2 589 384 600.2 601
    347 607.2 606 385 585.2 586
    348 639.1 640 386 596.1 597.8
    349 606.3 608 387 594.2 595.9
    350 671.1 672 388 594.1 595.1
    351 655.1 656 389 581.2 582.3
    352 580.2 581.8 390 582.2 583
    353 652.2 653 391 582.2 583
    354 599.2 600.3 392 618.3 619
    example Exact Mass Obs. Mass
    393 595.2 596.3
    394 608.2 609.3
    395 574.1 575.2
    396 587.2 588
    397 587.2 588
    398 580.2 581.3
    399 647.2 648
    400 645.2 646
    401 548.3 549
    402 544.2 545
    403 544.2 545
    404 603.2 604
    405 605.2 606
    406 607.2 608
    407 597.2 598
    408 583.2 584
    409 598.2 599
    410 563.3 564
    411 587.2 588
    412 654.1 655.2
    example Exact Mass Obs. Mass example Exact Mass Obs. Mass
    500 567.1 568.1 535 629.2 629.8
    501 601.1 602.0, 604.0 536 615.2 616
    502 533.2 534.2 536 615.2 615.7
    503 572.2 573.2 537 601.2 601.7
    504 601.1 602.0, 604.1 537 601.2 602
    505 561.2 562.2 538 592.2 593
    506 572.2 573.2 539 616.1 617.2
    507 572.2 573.1 541 633.1 634.0
    508 572.2 573.2 542 576.2 577.1
    509 547.2 548 543 630.1 629.0, 631.0
    510 587.2 588 544 578.2 579
    511 601.2 602.2 545 561.1 562
    512 561.2 562.1 546 602.2 603.0
    513 586.2 587.2 547 548.2 549.0
    514 601.2 602.2 548 572.2 573
    515 575.2 576.2 549 588.2 589
    516 615.2 616 550 588.2 589.2
    517 575.2 575.8 552 576.2 577
    518 627.2 628 553 574.2 575.0
    519 615.2 615.7 554 560.2 561
    520 601.2 601.7 555 600.2 601.0
    521 587.2 587.8 556 588.2 589
    522 699.1 699.5 557 574.2 575.2
    523 547.2 547.7 558 614.2 615.1
    524 563.2 564 559 602.2 603.0, 605.0
    525 601.2 601.7 560 560.2 561.2
    526 635.1 635.6 561 630.2 631.0
    527 649.1 649.5 562 574.2 575
    528 663.1 664 563 546.1 547
    529 591.2 591.7 564 560.2 561.2
    530 591.2 592 565 599.2 600
    531 591.2 591.7 566 599.2 600.1
    532 643.2 644.2 567 585.1 586.0
    533 615.2 616.1 568 589.2 590
    534 587.2 587.7 569 627.2 628.2
    534 587.2 587.7 570 601.2 604.3
    535 629.2 629.8
    571 629.2 630.2 608 585.2 586.1
    572 601.2 602.2 609 578.1 579
    573 563.2 564.2 610 599.2 600.2
    574 563.2 564.0 611 577.1 577.8
    575 631.2 632.2 612 627.2 628.2
    576 584.2 585 612 627.2 628.2
    577 574.1 577 613 585.1 586.1
    578 588.2 589.0 614 604.1 604.8
    579 645.2 648 615 613.2 614
    580 617.2 618 615 613.2 614.1
    581 631.2 632.2 616 588.2 589.0
    582 586.2 587.0 617 588.2 589.0
    583 613.2 614.0 618 612.2 613.1
    584 635.2 636.0 619 615.2 588.0
    585 597.1 598.2 620 615.2 588.0
    586 558.2 559.1 621 572.2 573.2
    587 588.2 589 622 600.2 601
    588 616.2 617 623 574.1 575.2
    589 611.2 612 624 585.1 586.2
    590 621.1 622 625 599.2 600.2
    591 588.2 589 626 613.2 614
    592 588.2 589.0 627 599.2 600
    593 578.1 578.9 628 603.2 604.0
    594 610.1 611 629 603.2 604
    595 585.2 586 630 591.1 592.0
    596 571.2 572 631 605.1 606
    597 555.2 556 632 599.2 600.2
    598 569.2 570 633 600.2 601.1
    599 587.2 588.1 634 574.1 575
    600 573.1 574 634 574.1 575
    601 603.2 604 635 574.1 575.0
    602 581.3 582 635 574.1 575.0
    603 591.1 592.0 636 573.1 574.0
    604 558.2 587.2 636 573.1 574.0
    605 605.2027 606.1 637 573.1403 574
    606 592.1625 593 637 573.1403 574
    607 595.266 596.2 638 618.1617 619
    639 599.2 600.2 675 590.1 591
    640 585.1 586 676 603.2 604
    641 599.2 600 677 600.2 601.1
    642 585.1 586 678 613.2 614.1
    643 589.2 590.2 679 604.2 605.2
    644 618.2 619.2 680 604.2 605.2
    645 632.2 632.9 681 590.2 591.2
    646 604.1 604.8 682 590.2 591.2
    647 574.1 575.1 683 601.2 602.2
    648 574.1 575 684 601.2 602.2
    649 613.2 614.2 685 604.1 605.1
    650 613.2 614.2 686 604.1 605.2
    651 599.2 600.2 687 590.2 590.9
    652 599.2 600.2 688 560.2 561.0,563.1
    653 629.2 630.2 689 629.2 630.2
    654 629.2 630.2 690 595.1 596.0
    655 618.2 619.0 691 605.1 606.1
    656 560.1 561.2 692 630.1 631.0
    657 573.2 574.2 693 570.2 570.8
    658 597.2 598.2 694 591.1 591.8
    659 576.2 577.1 694 591.1 591.8
    660 604.1 605.2 695 577.1 577.8
    661 604.1 605.2 695 577.1 577.8
    662 601.2 602.2 696 633.2 633.8
    663 601.2 603 696 633.2 633.8
    664 619.2 620.2 697 610.1 611.2
    665 633.2 634.2 698 605.1 605.8
    666 620.2 621.2 698 605.1 605.8
    667 592.1 593 699 616.2 617.2
    667 592.1 593 700 576.2 577.2
    668 573.1 574 701 574.2 574.9
    669 573.1 573.9 702 626.2 627.3
    670 561.1 562,562 703 592.1 592.8
    671 619.2 620.2 704 589.2 590.2
    672 601.2 604 705 604.1 605.0
    673 618.2 619.1 706 604.1 605.0
    674 618.2 619.1 707 573.1 574.0
    708 597.1 598.2 737 578.1 580
    709 615.2 616.2 738 576.2 578
    710 560.1 561.0 739 576.2 578
    711 602.2 603.0 740 590.2 591
    712 618.1 619 741 611.1 612.2
    712 618.1 619 742 602.2 603
    713 617.1 618 743 588.2 589.2
    713 617.1 618 744 615.2 616.2
    714 628.2 629.2 745 601.2 602.1
    715 590.2 591 746 574.2 574.9
    716 591.1 592.1 747 574.2 574.9
    716 591.1 592.1 748 600.2 601.2
    717 587.2 588.1 749 600.2 601.2
    717 587.2 588.1 750 627.2 628.4
    718 601.2 602.2 751 620.2 621.3
    718 601.2 602.2 752 575.2 612.2
    719 576.2 577.3 753 606.2 607.3
    720 576.2 577.3 754 590.2 591
    721 613.2 614.2 755 632.1 633.2
    722 613.2 614.2 756 602.2 604
    723 617.2 618.2 757 608.2 609.3
    724 617.2 618.2 758 628.2 629.3
    725 617.2 618.2 759 573.1 574.3
    726 617.2 618.2 759 573.1 574.3
    727 603.2 604.2 760 587.2 588.3
    728 603.2 604.2 760 587.2 588.3
    729 627.1 628 761 632.1 632.2 (M-H)-
    730 588.2 589.1 762 646.1 646.2 (M-H)-
    731 601.2 602.1 763 631.2 632.2
    732 630.2 631.3 764 593.1 594.2
    733 587.2 588.1 765 560.1 561.2
    733 587.2 588.1 766 602.1 604
    734 574.1 575 767 602.1 604
    734 574.1 575 768 646.1 647.3
    735 602.2 603 769 589.1 570.2
    735 602.2 603 770 560.1 561.2
    736 578.1 580 771 574.1 575.2
    772 599.2 600 809 584.2 585.2
    773 618.2 619.1 810 606.1 607
    774 618.2 619.1 810 606.1 607
    775 588.2 587.9 811 627.1 628
    776 574.1 575.2 812 576.2 577.1
    777 587.2 588 813 576.2 577.1
    778 585.2 586.2 814 621.1 622.2
    779 620.2 619.8 815 621.1 622.2
    780 646.1 645.7 816 600.2 601.2
    781 587.2 589 817 600.2 601.2
    782 588.2 590 818 596.1 597
    783 631.2 632.0 819 596.1 597
    784 590.2 591 820 590.1 591.2
    785 590.2 591 821 617.2 618.2
    786 646.1 646.3 822 628.2 629.1,631.1
    787 613.2 614.2 823 628.2 629.1,631.1
    788 574.1 575.2 824 602.2 604
    789 646.1 646.3 825 602.2 604
    790 646.1 645.5 826 618.2 619.1
    791 590.2 590 827 622.1 623.0,625.0
    792 590.2 590 828 622.1 623.0,625.0
    793 576.2 577.1 829 580.1 581.2
    794 575.2 577 830 628.1 629.2, 631.2
    795 638.1 639.0,641.0 831 579.1 580.2
    796 638.1 639.0,641.0 832 579.1 580.2
    797 638.1 639.0,641.0 833 630.2 631.2
    798 645.1 645.9 834 602.2 605.2
    799 642.1 642.9 835 644.2 647.2
    800 606.1 606.9 836 574.1 575.2
    801 616.2 619.0 837 574.1 575.2
    802 630.1 632 838 617.2 618.2
    803 576.2 577.2 839 617.2 618.2
    804 575.2 576.2 840 580.1 581.2
    805 601.2 602.2 841 610.1 611.0
    806 601.2 602.2 842 590.2 591.2
    807 602.2 602.9 843 590.2 591.2
    808 590.1 591.0 844 590.1 591.0
    845 631.2 632.2 876 602.2 603
    846 585.1 586.2 876 602.2 603
    847 578.1 579 877 602.2 603
    848 599.2 600 877 602.2 603
    849 599.2 600 878 630.1 631.1
    850 606.2 607.1 879 630.1 631.1
    851 628.2 629.2, 631.2 880 616.1 617.2
    852 628.2 629.2, 631.2 881 616.1 617.2
    853 616.1 617.0 882 590.2 591.2
    854 586.1 587.2 883 590.2 591.2
    855 590.2 591.2 884 630.1 631.0
    856 590.2 591.2 885 578.2 579.0,581.0
    857 590.2 591.2 886 578.2 579.0,581.2
    858 585.1 586.2 887 592.2 593.2,595.1
    859 585.1 586.2 888 635.2 636
    860 588.2 589.2 888 635.2 636
    861 590.2 591 889 643.1 644
    861 590.2 591 889 643.1 644
    862 590.2 591 890 601.2 602
    862 590.2 591 890 601.2 602
    863 624.1 625 891 671.2 672
    863 624.1 625 891 671.2 672
    864 630.1 631.1 892 602.2 603.2
    865 601.2 603 893 629.1 630.2
    866 601.2 603
    867 616.1 617.2
    868 594.1 595.2
    869 594.1 595.2
    870 594.1 595.2
    871 602.2 603
    871 602.2 603
    872 592.2 593.2,595.1
    873 590.2 591
    873 590.2 591
    874 590.2 591
    874 590.2 591
    875 630.1 632
    As for the examples, the results of spectrum were shown in the following tables.
    example
    25 δ (400 MHz, CDCl3) rotomers present 8.53 and 8.47 (2H, 2xs); 7.69 and 7.59 (1H, 2xs); 7.31-7.28 (1H, m); 7.16-7.12 (1H, m); 7.06-7.02 (2H, m); 4.83 and 4.65 (2H, 2xs); 4.61 and 4.30 (2H, 2xs), 4.27-4.21 (1H, m); 2.78 (1H, m); 2.44-2.40 (2H, m); 2.26-2.15 (2H, m) 1.96-1.86 (2H, m); 1.74-1.67 (2H, m)
    26 δ (400 MHz, CDCl3) rotomers present 8.58 and 8.51 (2H, 2xs); 7.63 and 7.55 (2H, 2xs); 4.77 and 4.44 (2H, 2xs); 4.28-4.19 (1H, m); 3.44(1H, d, J = 6.8Hz) and 3.21(1H, d, J = 7.6Hz); 2.52-2.42 (1H, m); 2.26-2.23 (2H, m); 2.14-2.03 (4H, m); 1.88-1.59 (1H, m); 0.99 and 0.84 (6H, 2xd, J = 6.6Hz)
    27 δ (400 MHz, CDCl3) rotomers present 8.57 and 8.50 (2H, 2xs); 7.71 and 7.56 (2H, 2xs); 4.87 and 4.53 (2H, 2xs); 4.25-4.19 (1H, m); 3.43-3.34 (2H, m); 2.49-2.43 (1H, m); 2.26-2.23 (2H, m); 2.10-2.03 (4H, m); 1.70-1.59 (2H, m); 1.01 and 0.85 (9H, 2xs)
    28 δ (400 MHz, CDCl3) rotomers present 8.58 and 8.50 (2H, 2xs); 7.64 and 7.54 (2H, 2xs); 4.71 and 4.40 (2H, 2xs); 4.28-4.17 (1H, m); 3.66 and 3.40 (2H, 2xd, J = 7.3Hz); 2.71-2.42 (2H, m); 2.27-2.22 (2H, m); 2.15-1.99 (6H, m); 1.94-1.52 (6H, m)
    29 δ (400 MHz, CDCl3) rotomers present 8.58 and 8.51 (2H, 2xs); 7.63 and 7.55 (1H, 2xs); 4.79 and 4.46 (2H, 2xs); 4.30-4.1.8 (1H, m); 3.57 and 3.32 (2H, 2xd, J = 7.8Hz); 2.50-2.42 (1H, m); 2.27-2.22 (2H, m); 2.13-2.04 (4H, m); 1.78-1.49 (9H, m); 1.31-1.27 (1H, m); 1.07-1.03 (1H, m)
    30 δ (400 MHz, CDCl3) rotomers present 8.58 and 8.51 (2H, 2xs); 7.62 and 7.55 (1H, 2xs); 4.76 and 4.44 (2H, 2xs); 4.28-4.19 (1H, m); 3.45 and 3.22 (2H, 2xd, J = 7.8Hz); 2.51-2.42 (1H, m); 2.27-2.23 (2H, m); 2.14-2.03 (4H, m); 1.75-1.64 (9H, m); 1.54-1.46 (1H, m); 1.16-1.10 (1H, m); 1.07-1.01 (1H, m); 0.77-0.71 (1H, m)
    31 δ (400 MHz, CDCl3) rotomers present 8.58 and 8.51 (2H, 2xs); 7.62 and 7.55 (1H, 2xs); 4.95 and 4.60 (2H, 2xs); 4.30-4.22 (1H, m); 3.57 and 3.34 (2H, 2xs); 2.52-2.43 (1H, m); 2.27-2.24 (2H, m); 2.15-2.04 (4H, m); 1.72-1.62 (2H, m); 1.09 and 0.97 (3H, 2xs); 0.51-0.32 (4H, m)
    32 δ (400 MHz, CDCl3) rotomers present 8.58 and 8.51 (2H, 2xs); 7.65 and 7.55 (1H, 2xs); 4.74 and 4.42 (2H, 2xs); 4.30-4.17 (1H, m); 3.61 and 3.34 (2H, 2xt, J = 7.7Hz); 2.50-2.43 (1H, m); 2.27-2.24 (2H, m); 2.12-2.03 (4H, m); 1.72-1.38 (5H, m); 0.96 (3H, d, J = 6.6Hz); 0.77 (3H, d, J = 6.3Hz)
    33 δ (400 MHz, CDCl3) rotomers present 8.58 and 8.52 (2H, 2xs); 7.65 and 7.54 (1H, 2xs); 4.74 and 4.41 (2H, 2xs); 4.30-4.20 (1H, m); 3.62-3.58 and 3.33-3.29 (2H, 2xm); 2.50-2.43 (1H, m); 2.26-2.23 (2H, m); 2.12-2.04 (4H, m); 1.72-1.62 (2H, m); 1.56-1.51 and 1.42-1.38 (2H, 2xm); 0.97 and 0.76 (9H, 2xs)
    35 δ (400 MHz, CDCl3) rotomers present 8.56 and 8.49 (2H, 2xs); 7.63 and 7.55 (1H, 2xs); 5.19-5.16 and 5.10-5.06 (1H, 1xm); 4.29-4.27 and 3.99-3.97 (2H, 2xm); 2.50-2.43 (1H, m); 2.26-2.23 (2H, m); 2.13-2.03 (4H, m); 1.72 and 1.52 (3H, 2xs); 1.70-1.63 (2H, m)
    36 δ (400 MHz, CDCl3) rotomers present 8.58 and 8.51 (2H, 2xs); 7.63 and 7.55 (1H, 2xs); 4.76 and 4.44 (2H, 2xs); 4.28-4.17 (1H, m); 3.49 and 3.26 (2H, 2xd, J = 6.8Hz); 2.51-2.42 (1H, m); 2.27-2.23 (2H, m); 2.14-2.03 (4H, m); 1.71-0.97 (11H, m); 0.90-0.78 (6H, m)
    37 δ (400 MHz, CDCl3) rotomers present 8.58 and 8.51 (2H, 2xs); 7.64 and 7.55 (1H, 2xs); 4.77 and 4.45 (2H, 2xs); 4.29-4.19 (1H, m); 3.51 and 3.28 (2H, 2xd, J = 6.8Hz); 2.51-2.43 (1H, m); 2.27-2.23 (2H, m); 2.14-2.03 (4H, m); 1.73-1.54 (7H, m); 1.27-1.18 (1H, m); 0.98-0.84 (3H, m), 0.30-0.10 (4H, m)
    40 δ (400 MHz, CDCl3) rotomers present 8.52 and 8.45 (2H, 2xs); 7.69 and 7.60 (1H, 2xs); 7.37-7.29 (4H, m); 7.17-7.15 (1H, m); 4.87 and 4.66 (2H, 2xs); 4.64 and 4.30 (2H, 2xs); 4.30-4.21 (1H, m); 2.49-2.42 (1H, m); 2.25-2.22 (2H, m); 2.09-2.04 (4H, m); 1.71-1.64 (2H, m)
    41 δ (400 MHz, CDCl3) rotomers present 8.53 and 8.47 (2H, 2xs); 7.68 and 7.60 (1H, 2xs); 7.33 (2H, d, J = 8.3Hz); 7.25 and 7.10 (2H, d, J = 8.3Hz); 4.82 and 4.65 (2H, 2xs); 4.61 and 4.29 (2H, 2xs); 4.29-4.20 (1H, m); 2.50-2.42 (1H, m); 2.27-2.23 (2H, m); 2.11-2.03 (4H, m); 1.70-1.59 (2H, m)
    42 δ (400 MHz, CDCl3) rotomers present 8.55 and 8.49 (2H, 2xs); 7.66 and 7.61 (1H, 2xs); 6.85-6.69 (3H, m); 4.83 and 4.70 (2H, 2xs); 4.62 and 4.34 (2H, 2xs); 4.28-4.21 (1H, m); 2.49-2.43 (1H, m); 2.27-2.23 (2H, m); 2.10-2.04 (4H, m); 1.71-1.60 (2H, m)
    43 δ (400 MHz, CDCl3) rotomers present 8.54 and 8.48 (2H, 2xs); 7.67 and 7.59 (1H, 2xs); 7.26-7.21, 7.15-7.70 and 6.93-6.89 (3H, 3xm); 4.92 and 4.71 (2H, 2xs); 4.71 and 4.42 (2H, 2xs); 4.28-4.18 (1H, m); 2.50-2.43 (1H, m); 2.26-2.23 (2H, m); 2.12-2.03 (4H, m); 1.71-1.59 (2H, m)
    44 δ (400 MHz, CDCl3) rotomers present 8.54 and 8.48 (2H, 2xs); 7.67 and 7.60 (1H, 2xs); 7.19-7.12 and 7.05-6.89 (3H, 2xm); 4.80 and 4.67 (2H, 2xs); 4.60 and 4.32 (2H, 2xs); 4.27-4.19 (1H, m); 2.49-2.42 (1H, m); 2.26-2.23 (2H, m); 2.11-2.04 (4H, m); 1.70-1.63 (2H, m)
    45 δ (400 MHz, CDCl3) rotomers present 8.55 and 8.48 (2H, 2xs); 7.68 and 7.60 (1H, 2xs); 7.19-7.14, 7.06-6.95 and 6.82-6.78 (3H, 3xm); 4.87 and 4.73 (2H, 2xs); 4.66 and 4.42 (2H, 2xs); 4.28-4.19 (1H, m); 2.50-2.43 (1H, m); 2.26-2.23 (2H, m); 2.13-2.03 (4H, m); 1.70-1.60 (2H, m)
    46 δ (400 MHz, CDCl3) rotomers present 8.56 and 8.49 (2H, 2xs); 7.78 and 7.75 (1H, 2xs); 7.39 (1H, m); 6.35 (1H, m); 6.33-6.32 and 6.22-6.21 (1H, 2xm); 4.84 and 4.73 (2H, 2xs); 4.56 and 4.44 (2H, 2xs); 4.33-4.19 (1H, m); 2.50-2.42 (1H, m); 2.27-2.23 (2H, m); 2.14-2.03 (4H, m); 1.73-1.62 (2H, m)
    47 δ (400 MHz, CDCl3) rotomers present 8.55 and 8.49 (2H, 2xs); 7.70 and 7.58 (1H, 2xs); 7.41-7.33 (2H, m); 6.40 and 6.26 (1H, 2xs); 4.70 (2H, s); 4.46 and 4.35 (2H, 2xs); 4.32-4.18 (1H, m); 2.50-2.42 (1H, m); 2.27-2.23 (2H, m); 2.14-2.03 (4H, m); 1.72-1.59 (2H, m)
    48 δ (400 MHz, CDCl3) rotomers present 8.76-8.36 (5H, m); 7.71 and 7.60 (1H, 2xs); 4.94 and 4.85 (2H, 2xs); 4.74 and 4.66 (2H, 2xs); 4.26-4.18 (1H, m); 2.49-2.42 (1H, m); 2.25-2.22 (2H, m); 2.11-2.03 (4H, m); 1.70-1.59 (2H, m)
    49 δ (400 MHz, DMSO-d6) rotamers present 12.16 (1H, brs); 8.56-8.51 and 8.49-8.43 (2H, 2xm); 7.88 and 7.82 (1H, 2xs); 7.16-6.92 (3H, m); 4.78 and 4.77 (2H, 2xs); 4.72 and 4.60 (2H, 2xs); 4.28-4.17 (1H, m); 2.33-2.29 (1H, m); 2.28 and 1.83 (3H, 2xs); 2.07-2.03 (2H, m); 1.94-1.91 (4H, m); 1.60-1.49 (2H, m)
    50 δ (400 MHz, DMSO-d6) rotamers present 8.78 and 8.71 (1H, 2xs); 8.69 and 8.62 (1H, 2xs); 7.81 and 7.78 (1H, 2xs); 7.18-6.90 (3H, m); 4.84 and 4.81 (2H, 2xs); 4.70 and 4.59 (2H, 2xs); 4.23-4.14 (1H, m); 2.33-2.26 (1H, m); 2.09-2.02 (2H, m); 1.99-1.90 (4H, m); 1.58-1.46 (2H, m)
    51 δ (400 MHz, DMSO-d6) rotamers present 12.20 (1H, brs); 8.72 and 8.66 (2H, 2xs); 7.74 and 7.72 (1H, 2xs); 7.18-7.10 (1H, m); 7.07 and 6.90 (2H, 2xd, J=6.4 Hz); 4.84 and 4.82 (2H, 2xs); 4.71 and 4.60 (2H, 2xs); 4.22-4.17 (1H, m); 2.33-2.27 (1H, m); 2.09-1.92 (6H, m); 1.55-1.49 (2H, m)
    52 δ (400 MHz, CDCl3) rotamers present 8.31 and 8.24 (2H, 2xs); 7.67 and 7.63 (1H, 2xs); 6.83-6.72 (3H, m); 4.84 and 4.63 (2H, 2xs); 4.47 and 4.20 (2H, 2xs); 4.27-4.25 (1H, m); 2.49-2.43 (1H, m); 2.27-2.23 (2H, m); 2.23 and 1.86 (6H, 2xs); 2.11-2.06 (4H, m); 1.68-1.64 (2H, m)
    53 δ (400 MHz, DMSO-d6) rotamers present 12.20 (1H, brs); 7.86 and 7.84 (1H, 2xs); 7.57-7.49 (3H, m); 7.19-7.13 (1H, m); 7.11-7.08 and 6.93-6.91 (2H, 2xm); 4.81 and 4.72 (2H, 2xs); 4.67 and 4.56 (2H, 2xs); 4.27-4.19 (1H, m); 2.34-2.27 (1H, m); 2.06-2.03 (2H, m); 1.98-1.92 (4H, m); 1.58-1.50 (2H, m)
    54 δ (400 MHz, DMSO-d6) rotamers present 12.20 (1H, brs); 7.75 (1H, s); 7.47-7.38 (1H, m); 7.18-6.88 (5H, m); 4.71 and 4.67 (2H, 2xs); 4.53 and 4.52 (2H, 2xs); 4.25-4.23 (1H, m); 3.77 and 3.67 (3H, 2xs); 2.34-2.28 (1H, m); 2.06-1.90 (6H, m); 1.59-1.49 (2H, m)
    55 δ (400 MHz, DMSO-d6) rotamers present 12.20 (1H, brs); 7.86 and 7.84 (1H, 2xs); 7.68 and 7.62 (2H, 2xd, J=8.4 Hz); 7.19-6.91 (3H, m); 4.80 and 4.71 (2H, 2xs); 4.65 and 4.55 (2H, 2xs); 4.26-4.21 (1H, m); 2.35-2.28 (1H, m); 2.07-2.06 (2H, m); 1.97-1.92 (4H, m); 1.60-1.49 (2H, m)
    56 δ (400 MHz, DMSO-d6) rotamers present 7.86 and 7.84 (1H, 2xs); 7.84 and 7.76 (2H, 2xs); 7.19-6.91 (3H, m); 4.80 and 4.71 (2H, 2xs); 4.65 and 4.56 (2H, 2xs); 4.27-4.17 (1H, m); 2.34-2.27 (1H, m); 2.06-2.02 (2H, m); 1.97-1.91 (4H, m); 1.59-1.49 (2H, m)
    57 δ (400 MHz, DMSO-d6) rotamers present 12.18 (1H, brs); 8.08 and 8.02 (2H, 2xs); 7.88 and 7.85 (1H, 2xs); 7.19-6.92 (3H, m); 4.84 and 4.72 (2H, 2xs); 4.68 and 4.57 (2H, 2xs); 4.27-4.18 (1H, m); 2.35-2.27 (1H, m); 2.07-2.03 (2H, m); 1.98-1.93 (4H, m); 1.60-1.51 (2H, m)
    58 δ (400 MHz, CD3CN) rotamers present 7.88-7.68 (3H, m); 7.02-6.86 (3H, m); 4.79 and 4.76 (2H, 2xs); 4.62 and 4.56 (2H, 2xs); 4.35-4.29 (1H, m); 2.47-2.40 (1H, m); 2.17-2.12 (2H, m); 2.08-2.02 (4H, m); 1.67-1.62 (2H, m)
    59 δ (400 MHz, DMSO-d6) rotamers present 12.20 (1H, brs); 8.04-7.87 (3H, m); 7.75 and 7.52 (1H, 2xs); 7.17-7.10 (1H, m); 7.06-7.05 and 6.89-6.88 (2H, 2xm); 5.08 and 4.96 (2H, 2xs); 4.67 and 4.57 (2H, 2xs); 4.18-4.17 (1H, m); 2.32-2.25 (1H, m); 2.04-1.98 (2H, m); 1.95-1.81 (4H, m); 1.55-1.47 (2H, m)
    60 δ (400 MHz, DMSO-d6) rotamers present 12.20 (1H, brs); 7.77-7.51 (4H, m); 7.17-7.07 (1H, m); 7.05 and 6.89 (2H, 2xd, J=1.6 Hz); 5.07 and 4.93 (2H, 2xs); 4.68 and 4.57 (2H, 2xs); 4.18-4.17 (1H, m); 2.29-2.25 (1H, m); 2.05-1.98 (2H, m); 1.95-1.81 (4H, m); 1.53-1.47 (2H, m)
    61 δ (400 MHz, CDCl3) rotamers present 7.76-7.72 and 7.38-7.34 (1H, 2xm); 7.58 and 7.50 (1H, 2xs); 7.18-7.02 (2H, m); 6.83-6.71 (3H, m); 4.78 and 4.71 (2H, 2xs); 4.62 and 4.51 (2H, 2xs); 4.25-4.22 (1H, m); 2.45-2.41 (1H, m); 2.24-2.21 (2H, m); 2.10-2.02 (4H, m); 1.66-1.62 (2H, m)
    62 δ (400 MHz, DMSO-d6) rotamers present 8.84 and 8.77 (2H, 2xdd, J=4.8, 1.6 Hz); 7.89 and 7.71 (2H, 2xdd, J=4.8, 1.6 Hz); 7.76 and 7.55 (1H, 2xs); 7.15-7.10 (1H, m); 7.08-7.06 and 6.91-6.89 (2H, 2xm); 5.08 and 4.95 (2H, 2xs); 4.70 and 4.59 (2H, 2xs); 4.18-4.15 (1H, m); 2.33-2.21 (1H, m); 2.04-1.79 (6H, m); 1.53-1.45 (2H, m)
    63 δ (400 MHz, DMSO-d6) rotamers present 12.10 (1H, brs); 7.74 and 7.61 (1H, 2xs); 7.40 and 7.34 (1H, 2xs); 7.16-6.88 (3H, m); 4.74 and 4.68 (2H, 2xs); 4.55 and 4.53 (2H, 2xs); 4.21-4.12 (1H, m); 2.56 and 2.39 (3H, 2xs); 2.33-2.21 (1H, m); 2.14 and 1.97 (3H, 2xs); 2.01-1.99 (2H, m); 1.93-1.85 (4H, m); 1.55-1.47 (2H, m)
    64 δ (400 MHz, DMSO-d6) rotamers present 12.20 (1H, brs); 7.73 and 7.62 (1H, 2xs); 7.16-6.89 (3H, m); 4.81 and 4.67 (2H, 2xs); 4.61 and 4.55 (2H, 2xs); 4.20-4.11 (1H, m); 2.73 and 2.49 (3H, 2xs); 2.39 and 2.28 (3H, 2xs); 2.26-2.17 (1H, m); 2.02-1.99 (2H, m); 1.96-1.85 (4H, m); 1.53-1.43 (2H, m)
    65 δ (400 MHz, CDCl3) rotamers present 7.57 and 7.40 (1H, 2xs); 6.78-6.65 (3H, m); 4.69 and 4.49 (2H, 2xs); 4.27 and 3.95 (2H, 2xs); 4.25-4.21 (1H, m); 2.47-2.37 (2H, m); 2.24-2.21 (2H, m); 2.09-2.03 (4H, m); 1.86-1.77 (2H, m); 1.68-1.60 (4H, m); 1.51-1.26 (6H, m)
    66 δ (400 MHz, DMSO-d6) rotamers present 7.83 and 7.82 (1H, 2xs); 7.28 and 7.21 (2H, 2xs); 7.18-7.12 (1H, m); 7.07 and 6.90 (2H, 2xd, J=1.6 Hz); 4.78 and 4.70 (2H, 2xs); 4.61 and 4.54 (2H, 2xs); 4.26-4.20 (1H, m); 2.28-2.21 (1H, m); 2.04-2.01 (2H, m); 1.99-1.89 (5H, m); 1.54-1.50 (2H, m); 1.04-0.96 (2H, m); 0.82-0.74 (2H, m)
    67 δ (400 MHz, DMSO-d6) rotamers present 12.20 (1H, brs); 7.84 and 7.82 (1H, 2xs); 7.18-7.09 (3H, m); 7.08 and 6.91 (2H, 2xd, J=1.6 Hz); 4.78 and 4.70 (2H, 2xs); 4.61 and 4.54 (2H, 2xs); 4.26-4.20 (1H, m); 3.83 and 3.78 (3H, 2xs); 2.33-2.27 (1H, m); 2.05-2.02 (2H, m); 1.97-1.91 (4H, m); 1.58-1.50 (2H, m)
    68 δ (400 MHz, DMSO-d6) rotamers present 7.98 (1H, s); 7.76-7.74 (1H, m); 7.52-7.50 (1H, m); 7.45-7.41 (1H, m); 7.12-7.05 (3H, m); 6.70 (1H, s); 5.10-4.76 (4H, m); 4.23-4.19 (1H, m); 2.27-2.21 (1H, m); 2.01-1.98 (2H, m); 1.91-1.85 (4H, m); 1.55-1.44 (2H, m)
    69 δ (400 MHz, DMSO-d6) rotamers present 7.92-7.90 and 7.75-7.73 (2H, 2xm); 7.75 and 7.49 (1H, 2xs); 7.15-7.08 (1H, m); 7.06 and 6.89 (2H, 2xd, J=1.6 Hz); 6.88-6.86 and 6.81-6.78 (2H, 2xm); 4.96 and 4.76 (2H, 2xs); 4.66 and 4.55 (2H, 2xs); 4.17-4.14 (1H, m); 2.29-2.23 (1H, m); 2.04-1.96 (2H, m); 1.91-1.83 (4H, m); 1.53-1.45 (2H, m)
    70 δ (400 MHz, DMSO-d6) rotamers present 7.82 (1H, s); 7.18-7.12 (1H, m); 7.07 and 6.90 (2H, 2xd, J=1.6 Hz); 6.85 and 6.75 (2H, 2xs); 4.75 and 4.68 (2H, 2xs); 4.58 and 4.53 (2H, 2xs); 4.25-4.19 (1H, m); 2.30-2.26 (1H, m); 2.07-2.02 (2H, m); 1.96-1.90 (4H, m); 1.58-1.48 (2H, m)
    71 δ (400 MHz, CDCl3) rotomers present 8.59 and 8.52 (2H, 2xs); 7.64 and 7.55 (1H, 2xs); 4.76 and 4.45 (2H, 2xs); 4.28-4.19 (1H, m); 4.02-3.93 (2H, m); 3.50-3.28 (4H, m); 2.26-2.23 (2H, m); 2.13-2.03 (5H, m); 1.76-1.59 (5H, m); 1.46-1.36 (1H, m); 1.16-1.06 (1H, m)
    72 δ (400 MHz, CDCl3) rotomers present 8.58 and 8.51 (2H, 2xs); 7.64 and 7.56 (1H, 2xs); 4.91 and 4.57 (2H, 2xs); 4.31-4.18 (1H, m); 3.54 and 3.26 (2H, d, J = 6.9 Hz); 2.50-2.43 (1H, m); 2.27-2.23 (2H, m); 2.14-2.04 (4H, m); 1.72-1.60 (2H, m); 1.09-1.01 and 0.91-0.85 (1H, 2xm); 0.61-0.56 (2H, m); 0.36-0.32 (1H, m); 0.15-0.10 (1H, m)
    73 δ (400 MHz, CDCl3) rotomers present 8.57 and 8.50 (2H, 2xs); 7.66 and 7.56 (1H, 2xs); 5.00 and 4.68 (2H, 2xs); 4.27-4.19 (1H, m); 3.83-3.57 (2H, m); 2.50-2.42 (1H, m); 2.27-2.23 (2H, m); 2.13-2.04 (4H, m); 1.71-1.60 (2H, m); 1.43 and 1.28 (6H; d, J = 21.6Hz)
    74 δ (400 MHz, CDCl3) rotomers present 8.56 and 8.48 (2H, 2xs); 7.66 and 7.54 (1H, 2xs); 5.12 and 4.82 (2H, 2xs); 4.27-4.18 (1H, m); 3.46 and 3.13 (2H, 2xs); 3.17(3H, s); 2.49-2.43 (1H, m); 2.26-2.23 (2H, m); 2.12-2.03 (4H, m); 1.70-1.59 (2H, m); 1.22 and 1.04 (6H, 2xs)
    75 δ (400 MHz, CDCl3) rotomers present 8.60 and 8.53 (2H, 2xs); 7.66 and 7.57 (1H, 2xs); 4.94 and 4.62 (2H, 2xs); 4.30-4.22 (2H, m); 4.04-3.98 (1H, m); 2.51-2.43 (1H, m); 2.27-2.24 (2H, m); 2.14-2.05 (4H, m); 1.71-1.62 (2H, m)
    76 δ (400 MHz, CDCl3) rotomers, present 8.62 (2J, d, J = 5.2 Hz); 8.54 and 8.48 (2H, 2xs); 7.65 and 7.62 (1H, 2xs); 7.25 and 7.13 (2H, 2xd, J = 5.2 Hz); 4.86 and 4.70 (2H, 2xs); 4.66 and 4.34 (2H, 2xs); 4.27-4.22 (1H, m); 2.49-2.42 (1H, m); 2.27-2.24 (2H, m); 2.10-2.05 (4H, m); 1.71-1.61 (2H, m)
    77 δ (400 MHz, CDCl3) rotomers present 8.53 and 8.47 (2H, 2xs); 7.70 and 7.61 (1H, 2xs); 7.31-7.25 (1H, m); 7.16-7.13 (1H, m); 7.07-7.03 (2H, m); 4.83 and 4.65 (2H, 2xs); 4.62 and 4.30 (2H, 2xs); 4.30-4.19 (1H, m); 2.26-2.16 (2H, m); 1.94-1.86 (6H, m); 1.40 (3H, s)
    78 δ (400 MHz, CDCl3) rotomers present 8.55 and 8.49 (2H, 2xs); 7.66 and 7.62 (1H, 2xs); 6.85-6.69 (3H, m); 4.83 and 4.70 (2H, 2xs); 4.62 and 4.34 (2H, 2xs); 4.29-4.21 (1H, m); 2.25-2.17 (2H, m); 1.94-1.88 (6H, m); 1.41 and 1.40 (3H, 2xs)
    79 δ (400 MHz, CDCl3) rotomers present 8.53 and 8.47 (2H, 2xs); 7.68 and 7.59 (1H, 2xs); 7.31-7.26 (1H, m); 7.15-7.12 (1H, m); 7.06-7.02 (2H, m); 4.83 and 4.65 (2H, 2xs); 4.61 and 4.30 (2H, 2xs); 4.25-4.17 (1H, m); 2.43-2.40 (2H, m); 2.19-2.11 (2H, m); 1.97-1.88 (2H, m); 1.41-1.34 (2H, m); 1.31 (3H, s)
    80 δ (400 MHz, CDCl3) rotomers present 8.53 and 8.48 (2H, 2xs); 7.73 and 7.64 (1H, 2xs); 7.31-7.27 (1H, m); 7.17-7.13 (1H, m); 7.07-7.03 (2H, m); 4.83 and 4.65 (2H, 2xs); 4.62 and 4.30 (2H, 2xs); 4.58-4.51 (1H, m); 2.67-2.56 (2H, m); 2.25-2.14 (4H, m); 2.02-1.93 (2H, m)
    81 δ (400 MHz, CDCl3) rotomers present 8.54 and 8.48 (2H, 2xs); 7.72 and 7.63 (1H, 2xs); 7.31-7.27 (1H, m); 7.17-7.13 (1H, m); 7.07-7.03 (2H, m); 4.83 and 4.65 (2H, 2xs); 4.62 and 4.30 (2H, 2xs); 4.41-4.34 (1H, m); 2.46-2.38 (2H, m); 2.33-2.27 (2H, m); 2.18-1.94 (4H, m)
    82 δ (400 MHz, CDCl3) rotomers present 8.53 and 8.47 (2H, 2xs); 7.74 and 7.66 (1H, 2xs); 7.30-7.27 (1H, m); 7.16-7.13 (1H, m); 7.07-7.02 (2H, m); 5.26-5.14 (1H, m); 4.83 and 4.64 (2H, 2xs); 4.61 and 4.29 (2H, 2xs); 3.34-3.27 (1H, m); 3.10-2.98 (2H, m); 2.86-2.77 (2H, m)
    83 δ (400 MHz, CDCl3) rotomers present 8.53 and 8.47 (2H, 2xs); 7.74 and 7.65 (1H, 2xs); 7.30-7.26 (1H, m); 7.16-7.12 (1H, m); 7.07-7.02 (2H, m); 4.90-4.82 (1H, m); 4.82 and 4.64 (2H, 2xs); 4.61 and 4.30 (2H, 2xs); 3.12-3.04 (3H, m); 2.82-2.76 (2H, m)
    84 δ (400 MHz, CDCl3) rotomers present 8.53 and 8.47 (2H, 2xs); 7.58 and 7.48 (1H, 2xs); 7.31-7.28 (1H, m); 7.19-7.15 (1H, m); 7.07-7.02 (2H, m); 4.82 and 4.66 (2H, 2xs); 4.64 and 4.40 (2H, 2xs); 4.36-4.30 (1H, m); 2.50-2.42 (1H, m); 2.24-2.03 (9H, m), 1.71-1.59 (2H, m)
    85 δ (400 MHz, DMSO-d6) rotamers present 8.77 and 8.70 (2H, 2xs); 7.87 and 7.83 (1H, 2xs); 7.20-7.14 (1H, m); 7.10 and 6.92 (2H, 2xd, J=1.6 Hz); 4.86 and 4.72 (2H, 2xs); 4.72 and 4.57 (2H, 2xs); 4.51-4.49 (1H, m); 4.26-4.21 (1H, m); 3.87 (1H, brs); 2.32-2.29 (2H, m); 1.81-1.78 (2H, m); 1.60-1.58 (4H, m)
    86 δ (400 MHz, CDCl3) rotamers present 8.53 and 8.48 (2H, 2xs); 7.69 and 7.60 (1H, 2xs); 7.31-7.26 (1H, m); 7.16-7.13 (1H, m); 7.07-7.02 (2H, m); 4.83 and 4.65 (2H, 2xs); 4.61 and 4.29 (2H, 2xs); 4.60-4.52 (1H, m); 3.04-2.97 (1H, m); 2.91 and 2.90 (3H, 2xs); 2.54-2.34 (4H, m); 2.13-2.06 (2H, m); 2.01-1.91 (2H, m)
    87 δ (400 MHz, CDCl3) rotamers present 8.53 and 8.47 (2H, 2xs); 7.70 and 7.61 (1H, 2xs); 7.30-7.26 (1H, m); 7.16-7.12 (1H, m); 7.07-7.03 (2H, m); 4.82 and 4.65 (2H, 2xs); 4.60 and 4.29 (2H, 2xs); 4.33-4.23 (1H, m); 3.01-2.93 (1H, m); 2.90 (3H, s); 2.44-2.41 (2H, m); 2.26-2.09 (4H, m); 1.87-1.76 (2H, m)
    88 δ (400 MHz, CDCl3) rotamers present 8.53 and 8.47 (2H, 2xs); 7.69 and 7.60 (1H, 2xs); 7.30-7.26 (1H, m); 7.16-7.12 (1H, m); 7.07-7.02 (2H, m); 5.45 and 5.29 (2H, 2xs); 4.83 and 4.64 (2H, 2xs); 4.61 and 4.29 (2H, 2xs); 4.29-4.21 (1H, m); 2.30-2.24 (1H, m); 2.14 -2.03 (6H, m); 1.77-1.67 (2H, m)
    89 δ (400 MHz, CDCl3) rotamers present 8.52 and 8.47 (2H, 2xs); 7.68 and 7.59 (1H, 2xs); 7.30-7.26 (1H, m); 7.16-7.12 (1H, m); 7.06-7.02 (2H, m); 5.93 (1H, t, J = 5.9Hz); 4.82 and 4.64 (2H, 2xs); 4.60 and 4.29 (2H, 2xs); 4.29-4.23 (1H, m); 3.77-3.73 (2H, m); 2.30-2.17 (2H, m); 2.10 -2.03 (6H, m); 1.78-1.71 (2H, m)
    90 δ (400 MHz, CDCl3) rotamers present 8.43 and 8.39 (2H, 2xs); 7.59 and 7.55 (1H, 2xs); 7.38-7.35 and 7.16-7.12 (2H, 2xm); 7.07-7.02 (2H, m); 5.60-5.45 (1H, m); 5.08-5.04, 4.75-4.71 and 3.98-3.88 (1H, 3xm); 4.60-4.54 (2H, m); 4.29-4.21 (1H, m); 3.32-3.20 (1H, m); 2.48-2.42 (1H, m); 2.25 -2.22 (2H, m); 2.10-2.04 (4H, m); 1.70-1.60 (2H, m)
    91 δ (400 MHz, CDCl3) rotamers present 7.58 and 7.52 (1H, 2xs); 7.38-7.31 (2H, m); 7.26-7.17 (2H, m); 7.12-7.00 (3H, m); 6.53 and 6.13 (1H, 2xddd, J = 47.5, 9.8, 3.2Hz); 5.40, 4.80, 4.63 and 4.58 (2H, 4xd J = 15.1Hz); 4.25-3.92 and 3.34-3.22 (3H, 2xm); 2.49-2.43 (1H, m); 2.26 -2.22 (2H, m); 1.70-1.59 (2H, m)
    92 δ (400 MHz, CDCl3) rotamers present 8.53 and 8.47 (2H, 2xs); 7.67 and 7.59 (1H, 2xs); 7.30-7.26 (1H, m); 7.16-7.13 (1H, m); 7.07-7.02 (2H, m); 5.05-4.93 (1H, m); 4.83 and 4.64 (2H, 2xs); 4.61 and 4.29 (2H, 2xs), 3.35-3.27 (1H, m); 2.50-2.25 (4H, m); 2.23-2.09 (1H, m); 2.04-1.95 (1H, m)
    93 δ (400 MHz, CDCl3) rotamers present 8.53 and 8.48 (2H, 2xs); 7.71 and 7.62 (1H, 2xs); 7.31-7.26 (1H, m); 7.16-7.13 (1H, m); 7.07-7.02 (2H, m); 4.94-4.78 (2H, m); 4.65 (1H, s); 4.61 and 4.30 (2H, 2xs); 3.08-3.00 (1H, m); 2.58-2.50 (2H, m); 2.26-2.12 (4H, m)
    94 δ (400 MHz, CDCl3) rotamers present 7.73 and 7.57 (1H, 2xs); 7.13 and 7.06 (2H, 2xd, J=7.8 Hz); 4.88 and 4.51 (2H, 2xs); 4.24-4.16 (1H, m); 3.52-3.32 (2H, m); 2.25-2.15 (2H, m); 1.94-1.84 (6H, m); 1.42 and 1.40 (3H, 2xs); 1.01 and 0.83 (9H, 2xs)
    95 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.50 (2H, 2xs); 7.68 and 7.54 (1H, 2xs); 4.94 and 4.74 (2H, 2xs); 4.28-4.19 (1H, m); 3.77-3.74 (1H, m); 3.63 (1H, t, J=4.9 Hz); 3.53 (1H, t, J=5.4 Hz); 3.41 (1H, t, J=5.4 Hz); 2.50-2.42 (1H, m); 2.26-2.23 (2H, m); 2.13-2.03 (4H, m); 1.72-1.60 (2H, m); 1.16 and 1.15 (9H, 2xs)
    96 δ (400 MHz, CDCl3) rotamers present 7.39-7.22 (5H, m); 7.10-7.01 (3H, m); 5.03 and 4.74 (2H, 2xs); 4.32 and 3.85 (2H, 2xt, J=13.6 Hz); 4.20-4.16 (1H, m); 2.49-2.42 (1H, m); 2.25-2.23 (2H, m); 2.09-2.04 (4H, m); 1.69-1.59 (2H, m)
    97 δ (400 MHz, DMSO-d6) rotamers present 8.23-8.17 (1H, m); 7.98 and 7.91 (2H, 2xs); 7.87 and 7.84 (1H, 2xs); 7.77-7.75 (1H, m); 7.19-7.13 (1H, m); 7.12-7.08 and 6.93-6.91 (2H, m); 4.84 and 4.72 (2H, 2xs); 4.68 and 4.57 (2H, 2xs); 4.26-4.17 (1H, m); 2.34-2.25 (1H, m); 2.07-2.01 (2H, m); 1.99-1.90 (4H, m); 1.59-1.49 (2H, m)
    98 δ (400 MHz, DMSO-d6) rotamers present 12.16 (1H, brs); 7.95-7.85 (3H, m); 7.19-7.13 (1H, m); 7.12-7.08 and 6.94-6.91 (2H, m); 4.84 and 4.72 (2H, 2xs); 4.69 and 4.57 (2H, 2xs); 4.28-4.17 (1H, m); 2.37-2.28 (1H, m); 2.07-2.02 (2H, m); 1.98-1.90 (4H, m); 1.60-1.49 (2H, m)
    99 δ (400 MHz, DMSO-d6) rotamers present 12.17 (1H, brs); 7.81-7.41 (5H, m); 7.17-6.88 (3H, m); 4.88 and 4.83 (2H, 2xs); 4.72 and 4.60 (2H, 2xs); 4.25-4.12 (1H, m); 2.30-2.23 (1H, m); 2.05-2.00 (2H, m); 1.97-1.88 (4H, m); 1.56-1.46 (2H, m)
    100 δ (400 MHz, CDCl3) rotamers present 7.39-7.30 (3H, m); 7.14-6.97 (5H, m); 4.89-3.46 (6H, m); 2.49-2.40 (1H, m); 2.26-2.20 (2H, m); 2.12-2.03 (4H, m); 1.70-1.60 (2H, m); 1.46 and 1.28 (3H, 2xd, J=7.3 Hz)
    101 δ (400 MHz, CDCl3) rotamers present 8.59 and 8.52 (2H, 2xs); 7.63 and 7.55 (1H, 2xs); 4.74 and 4.44 (2H, 2xs); 4.28-4.17 (1H, m); 3.49 and 3.30 (2H, 2xd, J=6.7 Hz); 2.50-2.43 (1H, m); 2.26-2.23 (2H, m); 2.13-1.35 (15H, m)
    102 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.50 (2H, 2xs); 7.72 and 7.56 (1H, 2xs); 4.86 and 4.54 (2H, 2xs); 4.27-4.17 (1H, m); 3.45-3.35 (2H, m); 2.50-2.42 (1H, m); 2.26-2.23 (2H, m); 2.11-2.02 (4H, m); 1.70-1.12 (12H, m); 0.99 and 0.83 (3H, 2xs)
    103 δ (400 MHz, CDCl3) rotamers present 8.58-8.47 (3H, m); 7.76-7.47 (2H, m); 7.26-7.11 (2H, m); 4.94 and 4.82 (2H, 2xs); 4.71 and 4.65 (2H, 2xs); 4.27-4.18 (1H, m); 2.48-2.42 (1H, m); 2.25-2.22 (2H, m); 2.09-2.05 (4H, m); 1.71-1.57 (2H, m)
    104 δ (400 MHz, CDCl3) rotamers present 8.63-8.44 (2H, m); 8.54 and 8.49 (2H, 2xs); 7.97-7.93 (1H, m); 7.71 and 7.61 (1H, 2xs); 7.52-7.34 (1H, m); 4.89 and 4.68 (2H, 2xs); 4.68 and 4.39 (2H, 2xs); 4.28-4.18 (1H, m); 2.49-2.43 (1H, m); 2.26-2.23 (2H, m); 2.12-2.03 (4H, m); 1.71-1.60 (2H, m)
    105 δ (400 MHz, CDCl3) rotamers present 8.53 and 8.47 (2H, 2xs); 7.71 and 7.62 (1H, 2xs); 7.31-7.26 (1H, m); 7.16-7.13 (1H, m); 7.07-7.02 (2H, m); 4.83 and 4.65 (2H, 2xs); 4.62 and 4.30 (2H, 2xs); 4.36-4.28 (1H, m); 2.50-2.46 (2H, m); 2.10-1.88 (6H, m)
    106 δ (400 MHz, CDCl3) rotamers present 8.53 and 8.47 (2H, 2xs); 7.92 and 7.80 (1H, 2xs); 7.31-7.26 (1H, m); 7.17-7.14 (1H, m); 7.07-7.03 (2H, m); 4.84 and 4.65 (2H, 2xs); 4.62 and 4.31 (2H, 2xs); 4.49-4.39 (1H, m); 2.43-2.31 (4H, m); 2.11-2.03 (2H, m); 1.84-1.75 (2H, m)
    107 δ (400 MHz, DMSO-d6) rotamers present 12.14 (1H, brs); 7.90-7.53 (4H, m); 7.17-6.86 (3H, m); 4.90 and 4.86 (2H, 2xs); 4.72 and 4.60 (2H, 2xs); 4.26-4.12 (1H, m); 2.34-2.26 (1H, m); 2.05-2.01 (2H, m); 1.98-1.89 (4H, m); 1.58-1.46 (2H, m)
    108 δ (400 MHz, DMSO-d6) rotamers present 12.15 (1H, brs); 7.58-6.70 (7H, m); 4.88-3.62 (6H, m); 2.35-2.29 (1H, m); 2.09-1.86 (6H, m); 1.59-1.45 (2H, m); 1.40 and 1.22 (3H, 2xd, J=7.0 Hz)
    109 δ (400 MHz, DMSO-d6) rotamers present 8.62 and 8.53 (2H, 2xs); 7.81 and 7.68 (1H, 2xs); 7.21-6.81 (3H, m); 5.32-3.40 (6H, m); 3.18 and 2.93 (3H, 2xs); 2.34-2.26 (1H, m); 2.08-1.90 (6H, m); 1.60-1.47 (2H, m)
    110 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.52 (2H, 2xs); 7.73 and 7.56 (1H, 2xs); 4.89 and 4.63 (2H, 2xs); 4.49 and 4.14 (2H, 2xs); 4.32-4.20 (1H, m); 2.50-2.43 (1H, m); 2.27-2.24 (2H, m); 2.14-2.04 (4H, m); 1.72-1.62 (2H, m); 1.20 (9H, s)
    111 δ (400 MHz, DMSO-d6) rotamers present 7.73 and 7.63 (1H, 2xs); 7.39-7.30 (1H, m); 7.19-6.85 (3H, m); 6.71 and 6.64 (2H, 2xd, J=8.4 Hz); 4.64-4.38 (4H, m); 4.27-4.15 (1H, m); 3.70 and 3.62 (6H, 2xs); 2.35-2.23 (1H, m); 2.09-1.90 (6H, m); 1.58-1.47 (2H, m)
    112 δ (400 MHz, CD3OD) rotamers present 7.71 and 7.62 (1H, 2xs); 7.12-6.80 (5H, m); 4.76-4.47 (4H, m); 4.34-4.26 (1H, m); 3.82 and 3.74 (3H, 2xs); 2.42-2.35 (1H, m); 2.19-2.03 (6H, m); 1.67-1.56 (2H, m)
    113 δ (400 MHz, CDCl3) rotamers present 7.57 and 7.41 (1H, 2xs); 6.79-6.65 (3H, m); 4.70 and 4.50 (2H, 2xs); 4.28-3.95 (3H, m); 2.92-2.84 and 2.66-2.58 (1H, 2xm); 2.47-2.40 (1H, m); 2.24-2.21 (2H, m); 2.09-2.03 (4H, m); 1.85-1.42 (10H, m)
    114 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.49 (2H, 2xs); 7.68 and 7.54 (1H, 2xs); 5.02 and 4.62 (1H, 2xd, J=19.0 Hz); 4.48 and 4.33 (1H, 2xd, J=19.0 Hz); 4.31-4.19 (1H, m); 3.80 (1H, q, J=7.0 Hz); 2.51-2.42 (1H, m); 2.27-2.24 (2H, m); 2.12-2.04 (4H, m); 1.72-1.62 (2H, m); 1.30 and 1.22 (3H, 2xd, J=7.0 Hz); 0.99 and 0.88 (9H, 2xs)
    115 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.49 (2H, 2xs); 7.68 and 7.54 (1H, 2xs); 5.02 and 4.62 (1H, 2xd, J=19.0 Hz); 4.48 and 4.33 (1H, 2xd, J=19.0 Hz); 4.31-4.20 (1H, m); 3.80 (1H, q, J=7.0 Hz); 2.50-2.43 (1H, m); 2.27-2.23 (2H, m); 2.12-2.04 (4H, m); 1.69-1.63 (2H, m); 1.30 and 1.22 (3H, 2xd, J=7.0 Hz); 0.99 and 0.88 (9H, 2xs)
    116 δ (400 MHz, DMSO-d6) rotamers present 8.74 and 8.67 (2H, 2xs); 7.83 and 7.77 (1H, 2xs); 7.40-7.11 (4H, m); 6.80 (2H, brs); 4.73 and 4.67 (2H, 2xs); 4.59 and 4.50 (2H, 2xs); 4.15-4.09 (1H, m); 2.56-2.49 (2H, m); 2.14-2.11 (2H, m); 1.76-1.72 (2H, m); 1.48-1.42 (2H, m)
    117 δ (400 MHz, DMSO-d6) rotamers present 8.74 and 8.67 (2H, 2xs); 7.87 and 7.81 (1H, 2xs); 7.65 (2H, brs); 7.40-7.13 (4H, m); 4.72 and 4.68 (2H, 2xs); 4.59 and 4.51 (2H, 2xs); 4.27-4.21 (1H, m); 2.18-2:07 (4H, m); 1.81-1.78 (4H, m)
    118 δ (400 MHz, CD3OD) rotamers present 7.59 (1H, s); 7.38 and 7.33 (2H, 2xd, J=8.0 Hz); 7.17 (1H, t, J =8.0 Hz); 6.83-6.78 (1H, m); 6.49 and 6.35 (2H, 2xd, J=6.0 Hz); 4.57 and 4.34 (2H, 2xs); 4.25 and 4.10 (2H, 2xs); 4.25-4.17 (1H, m); 2.17-1.84 (9H, m); 1.65-1.54 (4H, m); 1.30-1.28 (2H, m)
    119 δ (400 MHz, CDCl3) rotamers present 8.07 and 8.02 (2H, 2xs); 7.63 and 7.53 (1H, 2xs); 6.85-6.67 (3H, m); 4.81-4.21 (5H, m); 3.89 and 3.83 (6H, 2xs); 2.48-2.42 (1H, m); 2.25-2.22 (2H, m); 2.11-2.06 (4H, m); 1.71-1.60 (2H, m)
    120 δ (400 MHz, DMSO-d6) rotamers present 7.81 and 7.79 (1H, 2xs); 7.50 and 7.44 (2H, 2xd, J=8.6 Hz); 7.21-6.83 (3H, m); 4.80 and 4.52 (2H, 2xs); 4.27-4.15 (1H, m); 3.62-2.89 (4H, m); 2.34-2.24 (1H, m); 2.07-1.88 (6H, m); 1.60-1.49 (2H, m)
    121 δ (400 MHz, DMSO-d6) rotamers present 9.33-8.95 (2H, m); 8.81-8.64 (2H, m); 8.11 and 7.91 (1H, 2xs); 5.32-4.59 (4H, m); 4.26-4.18 (1H, m); 3.67-3.25 (3H, m); 2.87-2.79 (1H, m); 2.34-2.28 (1H, m); 2.05-1.43 (13H, m)
    122 δ (400 MHz, DMSO-d6) rotamers present 11.61 (1H, brs); 7.79 and 7.75 (1H, 2xs); 7.16-7.07 (2H, m); 6.89 (1H, d, J=6.4 Hz); 6.04 and 5.97 (1H, 2xs) ; 4.67 and 4.62 (2H, 2xs); 4.59 and 4.58 (2H, 2xs); 4.24-4.13 (1H, m); 2.26-2.18 (1H, m); 2.20 and 2.03 (3H, 2xs); 2.03-2.00 (2H, m); 1.90-1.88 (4H, m); 1.71 and 1.61 (3H, 2xs); 1.56-1.47 (2H, m)
    123 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.50 (2H, 2xs); 7.70 and 7.56 (1H, 2xs); 4.84 and 4.50 (2H, 2xs); 4.29-4.19 (1H, m); 3.40-3.12 (2H, m); 2.49-2.42 (1H, m); 2.26-2.23 (2H, m); 2.13-1.94 (6H, m); 1.74-1.36 (15H, m)
    124 δ (400 MHz, DMSO-d6) rotamers present 7.93-7.68 (4H, m); 7.18-6.90 (3H, m); 4.88-4.14 (5H, m); 2.34-2.26 (1H, m); 2.09-1.88 (6H, m); 1.59-1.49 (2H, m)
    125 δ (400 MHz, CDCl3) rotamers present 8.57-8.50 (2H, m); 7.65-7.53 (1H, m); 4.72-4.42 (2H, m); 4.30-4.18 (1H, m); 3.78-3.32 (2H, m); 2.51-1.19 (15H, m); 0.82-0.69 (9H, m)
    126 δ (400 MHz, CDCl3) rotamers present 8.57-8.50 (2H, m); 7.66-7.53 (1H, m); 4.73-4.42 (2H, m); 4.30-4.19 (1H, m); 3.78-3.32 (2H, m); 2.48-1.19 (15H, m); 0.82-0.69 (9H, m)
    127 δ (400 MHz, DMSO-d6) rotamers present 12.16 (1H, brs); 7.86-7.74 (3H, m); 7.19-6.91 (3H, m); 4.82-4.56 (4H, m); 4.28-4.17 (1H, m); 2.35-2.27 (1H, m); 2.07-1.92 (6H, m); 1.60-1.49 (2H, m)
    129 δ (400 MHz, CDCl3) rotamers present 8.54 and 8.48 (2H, 2xs); 7.73 and 7.63 (1H, 2xs); 7.31-7.26 (1H, m); 7.14-7.03 (3H, m); 4.83 and 4.65 (2H, 2xs); 4.62 and 4.31 (2H, 2xs); 4.31-4.23 (1H, m); 2.60-2.41 (4H, m); 2.17-2.01 (4H, m)
    130 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.51 (2H, 2xs) ; 7.66 and 7.54 (1H, 2xs) ; 4.83-4.45 (2H, m); 4.29-4.17 (1H, m); 3.73-3.21 (4H, m) ; 2.50-2.41 (1H, m); 2.26-2.22 (2H, m); 2.13-1.94 (4H, m); 1.74-1.34 (7H, m) ; 1.23-1.06 (6H, m)
    131 δ (400 MHz, CDCl3) rotamers present 8.60-8.50 (2H, m) ; 7.6.5-7.54 (1H, m); 4.80-4.46 (2H, m); 4.31-3.99 (2H, m); 2.51-2.43, (1H, m) ; 2.27-1.93 (9H, m); 1.81-1.56 (4H, m); 0.89-0.76 (9H, m)
    132 δ (400 MHz, CDCl3) rotamers present 8.60-8.50 (2H, m); 7.65-7.54 (1H, m); 4.86-4.46 (2H, m); 4.31-3.98 (2H, m); 2.50-2.44 (1H, m); 2.27-1.99 (9H, m); 1.82-1.62 (4H, m); 0.89-0.76 (9H, m)
    133 δ (400 MHz, CDCl3) rotamers present 8.98 and 8.93 (1H, 2xs); 7.66 and 7.63 (1H, 2xs); 6.84-6.74 (3H, m); 4.84-4.23 (5H, m); 2.45 and 2.04 (6H, 2xs); 2.28-2.02 (7H, m); 1.71-1.60 (2H, m)
    134 δ (400 MHz, DMSO-d6) rotamers present 8.37 and 8.31 (1H, 2xd, J=5.1 Hz); 7.89 and 7.81 (1H, 2xs); 7.18-6.92 (4H, m); 4.75-4.61 (4H, m); 4.27-4.14 (1H, m); 2.37 and 2.22 (3H, 2xs); 2.33-2.25 (1H, m); 2.06-1.87 (6H, m); 1.89 and 1.73 (3H, 2xs); 1.58-1.46 (2H, m)
    135 δ (400 MHz, CDCl3) rotamers present 8.52 (2H, s); 7.62 (1H, s); 6.86-6.74 (3H, m); 4.79 (2H, s); 4.67 and 4.49 (2H, 2xs); 4.35-4.30 (1H, m); 2.47-2.41 (1H, m); 2.26-2.23 (2H, m); 2.07-1.93 (4H, m); 1.72-1.62 (2H, m)
    136 δ (400 MHz, DMSO-d6) rotamers present 8.02-7.72 (4H, m); 7.17-6.87 (3H, m); 4.88-4.62 (4H, m); 4.26-4.12 (1H, m); 2.33-2.24 (1H, m); 2.05-1.89 (6H, m); 1.57-1.47 (2H, m)
    137 δ (400 MHz, DMSO-d6) rotamers present 7.85 and 7.83 (1H, 2xs); 7.42 and 7.25 (2H, 2xd, J=0.7 Hz); 7.18-6.90 (3H, m); 4.79-4.55 (4H, m); 4.27-4.16 (1H, m); 2.34-2.28 (4H, m); 2.07-1.90 (6H, m); 1.59-1.48 (2H, m)
    138 δ (400 MHz, CDCl3) rotamers present 7.57 and 7.55 (1H, 2xs); 7.35-7.18 (3H, m); 6.92 and 6.65 (2H, 2xd, J=5.7 Hz); 6.78-6.72 (1H, m); 6.61-6.46 and 6.19-6.04 (1H, 2xm); 5.01-4.62 (2H, m); 4.27-4.15 (2H, m); 4.02-3.93 and 3.39-3.26 (1H, 2xm); 2.28-2.18 (2H, m); 1.96-1.90 (6H, m); 1.42 and 1.39 (3H, 2xs)
    139 δ (400 MHz, CDCl3) rotamers present 7.57 and 7.55 (1H, 2xs); 7.35-7.18 (3H, m); 6.92 and 6.65 (2H, 2xd, J=6.1 Hz); 6.78-6.72 (1H, m); 6.61-6.46 and 6.19-6.04 (1H, 2xm); 5.01-4.62 (2H, m); 4.27-4.15 (2H, m); 4.02-3.93 and 3.39-3.26 (1H, 2xm); 2.26-2.19 (2H, m); 1.96-1.90 (6H, m); 1.42 and 1.39 (3H, 2xs)
    141 δ (400 MHz, DMSO-d6) rotamers present 9.45 (1H, brs); 8.74 and 8.68 (2H, 2xs); 7.86 and 7.74 (1H, 2xs); 7.13 and 6.98 (2H, 2xd, J=8.5 Hz); 6.75-6.69 (2H, m); 4.66 and 4.58 (2H, 2xs); 4.50 and 4.39 (2H, 2xs); 4.27-4.19 (1H, m); 2.34-2.27 (1H, m); 2.07-1.90 (6H, m); 1.59-1.48 (2H, m)
    142 δ (400 MHz, DMSO-d6) rotamers present 12.16 (1H, brs); 7.82-7.79 and 7.52-7.50 (1H, 2xm); 7.75 and 7.50 (1H, 2xs); 7.30-6.87 (6H, m); 6.80-6.74 (1H, m); 6.57-6.52 and 6.45-6.41 (1H, 2xm); 4.98 and 4.76 (2H, 2xs); 4.66 and 4.55 (2H, 2xs); 4.21-4.12 (1H, 2xm); 2.33-2.19 (1H, m); 2.05-1.77 (6H, m); 1.56-1.42 (2H, m)
    143 δ (400 MHz, DMSO-d6) rotamers present 12.16 (1H, brs); 7.75 and 7.48 (1H, 2xs); 7.62 and 7.32 (1H, 2xs); 7.16-6.86 (6H, m); 6.73-6.67 (1H, m); 4.97 and 4.75 (2H, 2xs); 4.65 and 4.55 (2H, 2xs); 4.22-4.11 (1H, m); 2.33-2.22 (1H, m); 2.19 and 2.09 (3H, 2xs); 2.05-1.78 (6H, m); 1.56-1.42 (2H, m)
    144 δ (400 MHz, CDCl3) rotamers present 7.69-7.52 (3H, m); 4.97 and 4.73 (2H, 2xs); 4.28-4.18 (1H, m); 3.94-3.40 (4H, m); 2.49-2.43 (1H, m); 2.25-2.22 (2H, m); 2.13-2.03 (4H, m); 1.70-1.62 (2H, m); 1.31-1.14 (9H, m)
    145 δ (400 MHz, CDCl3) rotamers present 8.36 (1H, s); 8.18 (1H, s); 7.63 (1H, s), 7.26-7.06 (4H, m); 4.76-4.54 (4H, m); 4.30-4.25 (1H, m); 2.49-2.42 (1H, m); 2.26-2.23 (2H, m); 2.12-2.05 (4H, m); 1.68-1.58 (2H, m)
    146 δ (400 MHz, DMSO-d6) rotamers present 9.11 and 9.08 (1H, 2xs); 8.82 and 8.60 (2H, 2xs); 7.94 and 7.88 (1H, 2xs); 7.59-7.46 (3H, m); 4.87 and 4.78 (2H, 2xs); 4.74 and 4.61 (2H, 2xs); 4.26-4.19 (1H, m); 2.35-2.27 (1H, m); 2.07-1.88 (6H, m); 1.59-1.48 (2H, m)
    147 δ (400 MHz, DMSO-d6) rotamers present 12.17 (1H, brs); 9.68 (1H, brs); 8.74 and 8.68 (2H, 2xs); 7.76 and 7.75 (1H, 2xs); 7.20-7.08 and 6.92-6.71 (4H, m); 4.73-4.45 (4H, m); 4.27-4.19 (1H, m); 2.34-2.26 (1H, m); 2.07-1.90 (6H, m); 1.59-1.49 (2H, m)
    148 δ (400 MHz, DMSO-d6) rotamers present 12.11 (1H, brs); 8.75 and 8.70 (2H, 2xs); 7.36 and 7.26 (1H, 2xs); 7.20-7.14 (1H, m); 7.08-7.06 and 6.98-6.95 (2H, 2xm); 5.00-4.50 (4H, m); 4.37-4.31 (1H, m); 2.31-2.24 (1H, m); 2.03-1.91 (4H, m); 1.87-1.78 (2H, m); 1.63-1.53 (2H, m); 1.38 and 1.33 (9H, 2xs)
    149 δ (400 MHz, CDCl3) rotamers present 7.69-7.52 (3H, m); 4.97 and 4.74 (2H, 2xs); 4.29-4.19 (1H, m); 3.94-3.37 (4H, m); 2.25-2.15 (2H, m); 1.95-1.86 (6H, m); 1.41 and 1.40 (3H, 2xs); 1.16 and 1.14 (9H, 2xs)
    150 δ (400 MHz, CDCl3) rotamers present 8.59 and 8.52 (2H, 2xs); 7:64 and 7.52 (1H, 2xs); 4.94 and 4.57 (2H, 2xs); 4.28-4.19 (1H, m); 3.84 and 3.73 (2H, 2xs); 2.49-2.43 (1H, m); 2.26-2.23 (2H, m); 2.14-2.03 (4H, m); 1.73-1.60 (2H, m); 1.10-1.06 (4H, m)
    151 δ (400 MHz, DMSO-d6) rotamers present 12.12 (1H, brs); 9.26-9.25 and 9.05-9.04 (1H, 2xm); 9.21-9.20 and 9.16-9.15 (1H, 2xm); 7.92 and 7.85 (1H, 2xs); 7.66-7.46 (4H, m); 4.85 and 4.78 (2H, 2xs); 4.75 and 4.63 (2H, 2xs); 4.28-4.17 (1H, m); 2.33-2.26 (1H, m); 2.06-2.02 (2H, m); 1.97-1.90 (4H, m); 1.59-1.48 (2H, m)
    152 δ (400 MHz, DMSO-d6) rotamers present 12.18 (1H, brs); 9.09-8.98 (1H, m); 8.68-8.63 (1H, m); 7.75 and 7.70 (1H, 2xs); 7.18-7.10 (1H, m); 7.08-7.06 (1H, m); 6.94-6.91 (1H, m); 5.02 and 4.96 (2H, 2xs); 4.73 and 4.60 (2H, 2xs); 4.24-4.13 (1H, m); 2.33-2.22 (1H, m); 2.05-1.99 (2H, m); 1.94-1.86 (4H, m); 1.56-1.45 (2H, m)
    153 δ (400 MHz, DMSO-d6) rotamers present 12.07 (1H, brs); 9.50 (1H, brs); 8.74 and 8.68 (2H, 2xs); 7.82 and 7.75 (1H, 2xs); 7.17-7.10 (1H, m); 6.79-6.58 (3H, m); 4.70 and 4.61 (2H, 2xs); 4.53 and 4.43 (2H, 2xs); 4.28-4.21 (1H, m); 2.35-2.26 (1H, m); 2.07-2.03 (2H, m); 1.98-1.91 (4H, m); 1.60-1.48 (2H, m)
    155 δ (400 MHz, CDCl3) rotamers present 8.59 and 8.50 (2H, 2xs); 7.65 and 7.54 (1H, 2xs); 4.83 and 4.54 (2H, 2xs); 4.54-4.46 and 3.75-3.68 (1H, 2xm); 4.30-4.21 (1H, m); 3.96-3.87 (1H, m); 2.74-2.72 and 2.51-2.40 (3H, m); 2.27-2.24 (2H, m); 2.14-2.00 (6H, m) ; 1.72-1.61 (2H, m); 1.18 and 1.12 (9H, 2xs)
    156 δ (400 MHz, DMSO-d6) rotamers present 12.40 (1H, brs); 8.77 and 8.70 (2H, 2xs); 7.84 and 7.80 (1H, 2xs) ; 7.19-7.08 and 6.92-6.90 (3H, m); 4.85-4.56 (4H, m); 4.27-4.14 (1H, m); 2.20-2.17 (2H, m); 2.04-1.95 (2H, m); 1.78-1.75 (2H, m); 1.48-1.43 (2H, m); 1.33-1.24 (2H, m) ; 0.80 (3H, t, J=7.5 Hz)
    157 δ (400 MHz, DMSO-d6) rotamers present 12.15 (1H, brs) ; 8.81 and 8.74 (2H, 2xs); 7.85-7.74 (2H, m); 4.95-4.76 (2H, m); 4.26-4.19 (1H, m); 3.88-3.25 (3H, m); 2.34-1.73 (11H, m); 1.59-1.49 (2H, m)
    158 δ (400 MHz, DMSO-d6) rotamers present 12.17 (1H, brs) ; 8.81 and 8.74 (2H, 2xs); 7.85-7.74 (2H, m); 4.93-4.76 (2H, m); 4.26-4.19 (1H, m); 3.86-3.25 (3H, m); 2.35-1.73 (11H, m); 1.59-1.49 (2H, m)
    159 δ (400 MHz, CDCl3) rotamers present 8.55 and 8.52 (2H, 2xs); 7.56 and 7.43 (1H, 2xs); 6.86-6.77 (3H, m); 4.91-4.67 (6H, m); 4.32-4.23 (1H, m); 2.48-2.42 (1H, m); 2.25-2.22 (2H, m); 2.07-1.99 (4H, m) ; 1.72-1.61 (2H, m)
    160 δ (400 MHz, CDCl3) rotamers present 8.55 and 8.48 (2H, 2xs); 7.64 and 7.56 (1H, 2xs); 5.09 and 4.80 (2H, 2xs); 4.28-4.18 (1H, m) ; 3.96 and 3.75 (2H, 2xs); 2.50-2.42 (1H, m); 2.26-2.23 (2H, m); 2.13-2.03 (4H, m); 1.69-1.42 (10H, m); 1.40 and 1.39 (3H, 2xs)
    161 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.48 (2H, 2xs); 7.67 and 7.59 (1H, 2xs); 7.19-7.13 (3H, m); 6.73 (2H, d, J=6.8 Hz); 4.93 and 4.72 (2H, 2xd, J=18.8 Hz); 4.12-4.04 (1H, m); 3.50 (1H, brs); 3.18-3.14 (1H, m); 2.43-2.37 (1H, m); 2.21-2.07 (4H, m); 1.92-1.52 (4H, m); 1.35-1.30 (1H, m); 1.14-1.09 (1H, m)
    162 δ (400 MHz, CDCl3) rotamers present 8.50 (2H, brs); 7.43 (1H, s); 6.90-6.72 (3H, m) ; 4.79-4.72 (2H, m) ; 4.68 and 4.59 (2H, 2xs) ; 4.15-4.08 (1H, m) ; 3.35-3.25 (1H, m); 2.50-2.43 (1H, m); 2.25-2.22 (2H, m); 2.10-1.90 (6H, m); 1.40-1.38 (6H, m)
    164 δ (400 MHz, DMSO-d6) rotamers present 12.17 (1H, brs); 8.71 (2H, s); 7.57-6.99 (4H, m); 5.00-4.68 (4H, m); 4.20-4.12 (1H, m); 2.38-2.21 (4H, m); 2.02-1.95 (2H, m); 1.86-1.80 (4H, m); 1.59-1.48 (2H, m)
    165 δ (400 MHz, DMSO-d6) rotamers present 12.16 (1H, brs) ; 9.12 (1H, s) ; 8.78 and 8.72 (2H, 2xs); 7.86 and 7.77 (1H, 2xs); 4.97 and 4.84 (2H, 2xs); 4.77 and 4.74 (2H, 2xs); 4.25-4.18 (1H, m); 2.28-2.22 (1H, m) ; 2.05-1.90 (6H, m); 1.57-1.48 (2H, m)
    166 δ (400 MHz, CDCl3) rotamers present 8.52 and 8.47 (2H, 2xs); 7.63 and 7.54 (1H, 2xs); 7.30-7.26 (1H, m); 7.16-7.13 (1H, m); 7.07-7.00 (2H, m); 4.82 and 4.63 (2H, 2xs) ; 4.57 and 4.26 (2H, 2xs); 2.31-2.22 (6H, m) ; 2.07-2.04 (6H, m)
    167 δ (400 MHz, DMSO-d6) rotamers present 12.19 (1H, brs); 8.77 and 8.71 (2H, 2xs); 7.88 and 7.80 (1H, 2xs); 7.62 and 7.54 (1H, 2xs); 4.80-4.52 (4H, m); 4.28-4.20 (1H, m) ; 2.34-2.28 (1H, m) ; 2.07-1.92 (6H, m) ; 1.59-1.49 (2H, m)
    168 δ (400 MHz, DMSO-d6) rotamers present 12.25 (1H, brs); 8.78 and 8.71 (2H, 2xs); 7.81-7.77 (2H, m); 5.03-4.81 (4H, m); 4.26-4.19 (1H, m); 2.32-2.24 (1H, m); 2.06-1.93 (6H, m); 1.57-1.48 (2H, m)
    169 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.50 (2H, 2xs); 7.65 and 7.55 (1H, 2xs); 4.66-4.18 (4H, m); 2.51-2.42 (1H, m); 2.27-2.24 (2H, m); 2.15-2.03 (4H, m); 1.73-1.42 (9H, m); 1.14-1.07 (1H, m); 0.94-0.87 (6H, m)
    170 δ (400 MHz, DMSO-d6) rotamers present 12.10 (1H, brs) ; 8.76 and 8.69 (2H, 2xs) ; 7.87-7.52 (5H, m); 4.84 and 4.75 (2H, 2xs); 4.72 and 4.60 (2H, 2xs); 4.28-4.17 (1H, m) ; 2.36-2.26 (1H, m) ; 2.07-2.02 (2H, m); 1.98-1.91 (4H, m) ; 1.60-1.49 (2H, m)
    171 δ (400 MHz, DMSO-d6) rotamers present 12.14 (1H, brs); 8.75 and 8.69 (2H, 2xs); 7.87-7.80 (3H, m); 7.56 and 7.41 (2H, 2xd, J=8.3 Hz); 4.80 and 4.78 (2H, 2xs); 4.69 and 4.63 (2H, 2xs) ; 4.28-4.18 (1H, m) ; 2.36-2.26 (1H, m); 2.07-2.02 (2H, m); 1.98-1.90 (4H, m) ; 1.60-1.49 (2H, m)
    172 δ (400 MHz, CDCl3) rotamers present 8.61 and 8.53 (2H, 2xs); 7.66 and 7.57 (1H, 2xs); 5.03-4.93 (1H, m); 4.80-4.72 (1H, m); 4.63-3.99 (6H, m); 2.51-2.43 (1H, m); 2.28-2.24 (2H, m); 2.14-2.04 (4H, m); 1.91 and 1.87 (3H, 2xs); 1.72-1.59 (2H, m)
    173 δ (400 MHz, CDCl3) rotamers present 8.61 and 8.52 (2H, 2xs); 7.65 and 7.57 (1H, 2xs); 5.00-4.19 (8H, m); 2.50-2.43 (1H, m); 2.27-2.24 (2H, m); 2.14-2.04 (4H, m) ; 1.72-1.61 (2H, m); 1.23-1.1-7 (9H, m)
    174 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.50 (2H, 2xs); 7.65 and 7.55 (1H, 2xs); 4.62 and 4.42 (2H, 2xs); 4.31-4.18 (1H, m) ; 3.55-3.50 (1H, m) ; 2.52-2.41 (1H, m); 2.27-2.23 (2H, m); 2.15-2.03 (4H, m) ; 1.88-1.30 (10H, m); 1.19-0.97 (2H, m)
    175 δ (400 MHz, CDCl3) rotamers present 8.59 and 8.51 (2H, 2xs); 7.67 and 7.56 (1H, 2xs); 4.86-4.78 and 3.74-3.66 (1H, 2xm) ; 4.63 and 4.43 (2H, 2xs); 4.32-4.17 (1H, m); 2.53-2.42 (1H, m) ; 2.28-1.59 (16H, m)
    177 δ (400 MHz, CDCl3) rotamers present 8.53 and 8.47 (2H, 2xs); 7.64 and 7.55 (1H, 2xs); 7.32-7.26 (1H, m); 7.17-7.13 (1H, m); 7.07-7.02 (2H, m); 4.83 and 4.64 (2H, 2xs); 4.60 and 4.29 (2H, 2xs); 2.57 and 2.53 (2H, 2xs); 2.33-2.25 (4H, m); 2.21-1.99 (2H, m) ; 1.95-1.88 (2H, m)
    178 δ (400 MHz, CDCl3) rotamers present 8.56-8.51 (2H, m); 7.56-7.46 (1H, m); 7.12-6.76 (4H, m); 4.82-4.78 (2H, m); 4.67-4.57 (2H, m); 4.53-4.38 (1H, m); 2.41-2.38 (2H, m); 2.18-2.08 (2H, m); 1.99-1.93 (2H, m); 1.43-1.36 (2H, m); 1.30 (3H, s)
    179 δ (400 MHz, DMSO-d6) rotamers present 12.16 (1H, brs); 7.79 and 7.78 (1H, 2xs); 7.56-7.45 (2H, m); 7.18-6.88 (3H, m); 4.78 and 4.73 (2H, 2xs); 4.69 and 4.56 (2H, 2xs); 4.26-4.14 (1H, m); 2.33-2.26 (1H, m); 2.09-1.90 (6H, m); 1.58-1.46 (2H, m)
    180 δ (400 MHz, CDCl3) rotamers present 8.50 and 8.42 (2H, 2xs) ; 7.72 and 7.58 (1H, 2xs); 7.23-7.15 (4H, m); 5.62-5.54 and 4.80-4.72 (1H, 2xm); 4.58 and 4.42 (2H, 2xs); 4.31-4.23 (1H, m); 3.42-3.02 (m, 4H); 2.50-2.43 (1H, m); 2.26-2.23 (2H, m); 2.14-2.03 (4H, m); 1.71-1.61 (2H, m)
    181 δ (400 MHz, CDCl3) rotamers present 8.59 and 8.51 (2H, 2xs); 7.66 and 7.56 (1H, 2xs) ; 4.99-4.91 and 3.84-3.76 (1H, 2xm) ; 4.65 and 4.45 (2H, 2xs) ; 4.33-4.17 (1H, m); 4.08-3.98 (2H, m); 3.59-3.53 and 3.28-3.22 (2H, 2xm); 2.52-2.41 (1H, m); 2.28-2.22 (2H, m); 2.16-2.03 (4H, m); 1.82-1.59 (6H, m)
    182 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.50 (2H, 2xs) ; 7.66 and 7.56 (1H, 2xs) ; 4.76-4.67 and 3.62-3.56 (1H, 2xm); 4.67 and 4.46 (2H, 2xs); 4.31-4.19 (1H, m); 2.51-2.42 (1H, m); 2.27-2.23 (2H, m) ; 2.17-1.96 (4H, m); 1.83-1.55 (8H, m) ; 0.94-0.86 (2H, m); 0.38-0.29 (2H, m); 0.19-0.15 (2H, m)
    183 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.50 (2H, 2xs); 7.66 and 7.55 (1H, 2xs); 5.23-5.14 and 4.31-4.18 (2H, m); 4.65-4.42 (2H, m); 2.51-2.43 (1H, m); 2.27-2.24 (2H, m); 2.14-2.03 (4H, m); 1.97-1.32 (8H, m); 1.08-0.87 (6H, m)
    185 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.50 (2H, 2xs); 7.66 and 7.56 (1H, 2xs); 5.01-4.95 and 4.17-4.09 (1H, 2xm) ; 4.58 and 4.42 (2H, 2xs); 4.30-4.17 (1H, m); 2.51-2.42 (1H, m); 2.27-2.23 (2H, m); 2.14-1.50 (14H, m)
    187 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.50 (2H, 2xs); 7.65 and 7.56 (1H, 2xs); 4.95-4.17 and 3.57-3.50 (4H, m); 2.51-2.43 (1H, m); 2.27-2.24 (2H, m); 2.15-2.03 (4H, m); 1.94-0.98 (14H, m)
    189 δ (400 MHz, CDCl3) rotamers present 7.65 and 7.55 (1H, 2xs); 7.39 and 7.31 (2H, 2xs); 4.66 and 4.42 (2H, 2xs); 4.61-4.52 and 3.49-3.43 (1H, 2xm); 4.31-4.14 (1H, m); 2.51-2.42 (1H, m); 2.27-2.22 (2H, m); 2.15-2.02 (4H, m) ; 1.72-1.40 (9H, m); 1.13-1.05 (1H, m); 0.94-0.87 (6H, m)
    190 δ (400 MHz, CDCl3) rotamers present 7.67 and 7.56 (1H, 2xs); 7.14 and 7.06 (2H, 2xd, J=8.1 Hz); 4.67 and 4.43 (2H, 2xs); 4.61-4.53 and 3.52-3.44 (1H, 2xm) ; 4.30-4.15 (1H, m); 2.29-2.14 (2H, m); 1.99-1.85 (6H, m); 1.65-1.39 (10H, m); 1.13-1.06 (1H, m) ; 0.94-0.87 (6H, m)
    191 δ (400 MHz, CDCl3) rotamers present 7.66 and 7.56 (1H, 2xs) ; 7.39 and 7.31 (2H, 2xs); 4.66 and 4.43 (2H, 2xs); 4.61-4.53 and 3.52-3.44 (1H, 2xm); 4.30-4.15 (1H, m); 2.29-2.14 (2H, m); 1.99-1.86 (6H, m); 1.65-1.40 (10H, m); 1.13-1.02 (1H, m); 0.94-0.87 (6H, m)
    192 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.50 (2H, 2xs); 7.66 and 7.55 (1H, 2xs) ; 4.81 and 4.47 (2H, 2xs); 4.28-4.17 (1H, m) ; 3.71-3.59 (2H, m); 2.50-2.42 (1H, m) ; 2.26-2.23 (2H, m) ; 2.12-2.03 (4H, m) ; 1.72-1.06 (15H, m)
    193 δ (400 MHz, CDCl3) rotamers present 7.68 and 7.52 (1H, 2xs); 7.14-7.05 (2H, m); 4.82 and 4.45 (2H, 2xs) ; 4.27-4.17 (1H, m) ; 3.70-3.57 (2H, m) ; 2.46-2.42 (1H, m) ; 2.25-2.22 (2H, m); 2.12-2.02 (4H, m); 1.78-1.05 (15H, m)
    194 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.49 (2H, 2xs); 7.67 and 7.56 (1H, 2xs); 5.00 and 4.69 (2H, 2xs); 4.29-4.19 (1H, m) ; 3.98-3.70 (2H, m) ; 2.50-2.42 (1H, m); 2.27-2.23 (2H, m) ; 2.13-2.03 (4H, m); 1.94-1.52 (10H, m)
    195 δ (400 MHz, CDCl3) 12.80 (1H, brs); 7.52 (1H, s); 7.33 (1H, d, J=7.1 Hz); 7.26-7.23 (2H, m); 7.03-7.00 (2H, m); 6.46 (1H, d, J=7.1 Hz); 4.79 (2H, s); 4.43 (2H, s); 4.26-4.19 (1H, m) ; 2.39-2.32 (1H, m) ; 2.23-2.19 (2H, m) ; 2.14-2.09 (4H, m); 1.60-1.53 (2H, m)
    196 δ (400 MHz, DMSO-d6) 8.80 and 8.73 (2H, 2xs); 7.72 and 7.59 (1H, 2xs); 7.37-7.04 (1H, m) ; 4.78 (2H, s) ; 4.39-4.24 and 3.72-3.64 (2H, m) ; 2.21-2.15 (2H, m) ; 2.04-1.91 (2H, m); 1.83-1.23 (11H, m); 1.15-1.10 (4H, m); 0.91-0.84 (6H, m)
    197 δ (400 MHz, CDCl3) rotamers present 7.57-6.77 (7H, m) ; 4.82-4.38 (5H, m); 2.41-2.37 (2H, m); 2.17-2.09 (2H, m); 1.98-1.91 (2H, m); 1.43-1.35 (2H, m); 1.30 (3H, s)
    198 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.50 (2H, 2xs); 7.67 and 7.55 (1H, 2xs); 5.38-5.33 and 4.52-4.47 (1H, 2xm); 4.73 and 4.58 (2H, 2xs); 4.31-4.17 (1H, m) ; 4.10-4.03 (1H, m) ; 3.91-3.84 (1H, m) ; 3.79-3.52 (2H, m) ; 2.51-2.43 (1H, m) ; 2.28-1.91 (6H, m) ; 1.73-1.59 (4H, m)
    199 δ (400 MHz, CDCl3) rotamers present 7.68 and 7.53 (1H, 2xs) ; 7.12 and 7.05 (2H, 2xd, J=8.0 Hz); 5.09-4.99 and 4.58-4.15 (4H, m); 2.31-1.89 (10H, m); 1.42 and 1.39 (3H, 2xs) ; 1.30-1.24 (2H, m); 1.07-0.96 (8H, m)
    200 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.51 (2H, 2xs); 7.67 and 7.54 (1H, 2xs); 4.73 and 4.43 (2H, 2xs) ; 4.32-4.16 (1H, m); 3.79 and 3.59 (2H, 2xd, J=7.7 Hz); 2.85-2.77 and 2.64-2.57 (1H, 2xm) ; 2.51-2.42 (1H, m); 2.28-2.23 (2H, m) ; 2.19-1.97 (7H, m); 1.73-1.59 (3H, m); 0.42-0.17 (4H, m)
    201 δ (400 MHz, CDCl3) rotamers present 7.63 and 7.44 (1H, 2xs); 6.82-6.69 (3H, m); 4.78 and 4.75 (2H, 2xs) ; 4.57 and 4.41 (2H, 2xs); 4.28-4.19 (1H, m) ; 3.85 and 3.83 (3H, 2xs); 2.49-2.38 (1H, m); 2.24-2.21 (2H, m); 2.09-1.97 (4H, m); 1.69-1.59 (2H, m)
    202 δ (400 MHz, CDCl3) rotamers present 7.69 and 7.55 (1H, 2xs); 7.14-7.06 (2H, m); 4.75 and 4.41 (2H, 2xs); 4.30-4.16 (1H, m); 3.79 and 3.58 (2H, 2xd, J=7.6 Hz); 2.86-2.78 and 2.65-2.57 (1H, 2xm); 2.54-2.12 (4H, m); 2.05-1.84 (7H, m); 1.66-1.58 (1H, m); 1.42 and 1.40 (3H, 2xs); 0.42-0.16 (4H, m)
    204 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.50 (2H, 2xs); 7.70-7.55 (1H, 2xs); 5.01-4.94 and 3.96-3.88 (1H, 2xm); 4.78-4.73 and 4.39-4.15 (3H, m); 2.55-2.40 (2H, m) ; 2.28-2.23 (2H, m); 2.16-1.94 (7H, m); 1.82-1.78 and 1.71-1.67 (3H, m); 1.18-1.15 (3H, m) ; 0.43-0.22 (4H, m)
    205 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.50 (2H, 2xs); 7.65 and 7.55 (1H, 2xs); 4.88-4.81 and 3.76-3.69 (1H, 2xm) ; 4.65-4.40 (2H, m) ; 4.30-4.20 (1H, m) ; 2.51-2.44 (1H, m); 2.27-2.24 (2H, m) ; 2.13-2.04 (4H, m); 1.87-0.65 (16H, m)
    206 δ (400 MHz, CDCl3) rotamers present 7.74 and 7.58 (1H, 2xs); 7.17 and 7.10 (2H, 2xs) ; 4.91 and 4.60 (2H, 2xs); 4.48 and 4.13 (2H, 2xs); 4.31-4.18 (1H, m); 2.37 and 2.33 (3H, 2xs); 2.28-2.17 (2H, m); 1.97-1.83 (6H, m); 1.41 and 1.40 (3H, 2xs); 1.20 and 1.19 (9H, 2xs)
    207 δ (400 MHz, CDCl3) rotamers present 7.73 and 7.57 (1H, 2xs); 7.39 and 7.32 (2H, 2xs); 4.90 and 4.60 (2H, 2xs); 4.48 and 4.13 (2H, 2xs); 4.31-4.18 (1H, m); 2.28-2.15 (2H, m); 1.98-1.86 (6H, m) ; 1.41 and 1.39 (3H, 2xs); 1.20 and 1.19 (9H, 2xs)
    208 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.50 (2H, 2xs) ; 7.65 and 7.54 (1H, 2xs); 4.70-4.47 (3H, m); 4.31-4.18 (1H, m); 4.07-3.76 (2H, m); 2.51-2.45 (1H, m); 2.28-2.05 (7H, m); 1.75-1.62 (3H, m) ; 1.36-1.13 (6H, m)
    210 δ (400 MHz, CDCl3) rotamers present 8.59 and 8.51 (2H, 2xs) ; 7.65 and 7.55 (1H, 2xs); 4.77-4.19 (4H, m) ; 2.48-1.89 (13H, m) ; 1.75-1.39 (5H, m) (cis-, trans- mixture in AreaB)
    211 δ (400 MHz, CDCl3) rotamers present 8.59 and 8.51 (2H, 2xs); 7.63 and 7.53 (1H, 2xs); 5.13-5.05 and 4.19-4.11 (1H, 2xm); 4.60 and 4.43 (2H, 2xs); 4.29-4.21 (1H, m); 2.50-2.43 (1H, m); 2.26-2.23 (2H, m); 2.11-2.02 (4H, m); 1.87-1.84 (4H, m) ; 1.72-1.59 (2H, m); 1.25-1.19 (2H, m); 0.98-0.68 (6H, m)
    212 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.49 (2H, 2xs); 7.66 and 7.55 (1H, 2xs); 4.81-4.75 and 3.65-3.56 (1H, 2xm); 4.63 and 4.42 (2H, 2xs); 4.31-4.16 (1H, m) ; 2.51-2.03 (8H, m) ; 1.84-1.43 (10H, m)
    213 δ (400 MHz, CDCl3) rotamers present 8.59 and 8.51 (2H, 2xs) ; 7.65 and 7.55 (1H, 2xs); 4.60 and 4.41 (2H, 2xs); 4.60-4.54 and 3.62-3.55 (1H, 2xm); 4.32-4.16 (1H, m) ; 2.52-2.42 (1H, m) ; 2.28-2.24 (2H, m) ; 2.18-1.91 (6H, m) ; 1.73-1.21 (9H, m)
    214 δ (400 MHz, CDCl3) rotamers present 7.70 and 7.55 (1H, 2xs); 7.3.4-7.23 (1H, m); 7.03-6.79 (2H, m); 4.86 and 4.54 (2H, 2xs); 4.45 and 4.10 (2H, 2xs); 4.27-4.23 (1H, m); 3.87 and 3.75 (3H, 2xs); 2.27-2.17 (2H, m) ; 1.98-1.87 (6H, m); 1.41-1.40 (3H, m); 1.19 (9H, s)
    215 δ (400 MHz, DMSO-d6) 12.22 (1H, brs); 8.79-8.60 (2H, m); 7.85-7..69 (1H, m); 5.19-4.78 (2H, m); 4.50-4.39 and 4.09-4.02 (1H, 2xm); 4.27-4.18 (1H, m); 2.67-2.57 (1H, m); 2.33-2.26 (1H, m); 2.23-2.19 (1H, m); 2.07-1.90 (6H, m); 1.59-1.16 (10H, m)
    216 δ (400 MHz, CDCl3) rotamers present 7.61 and 7.50 (1H, 2xs); 6.84-6.71 (3H, m) ; 4.80 and 4.73 (2H, 2xs); 4.60 and 4.48 (2H, 2xs); 4.29-4.19 (1H, m); 2.49-2.42 (1H, m); 2.25-2.22 (2H, m); 2.10-2.02 (4H, m); 1.70-1.59 (2H, m)
    217 δ (400 MHz, CDCl3) rotamers present 7.75-7.49 (4H, m) ; 4.98 and 4.66 (2H, 2xs); 4.47 and 4.13 (2H, 2xs) ; 4.31-4.20 (1H, m) ; 2.29-2.18 (2H, m) ; 1.99-1.89 (6H, m) ; 1.42 and 1.41 (3H, 2xs) ; 1.20 and 1.19 (9H, 2xs)
    218 δ (400 MHz, CDCl3) rotamers present 7.74 and 7.58 (1H, 2xs); 7.14 and 7.07 (2H, 2xd, J=8.0 Hz) ; 4.90 and 4.61 (2H, 2xs); 4.48 and 4.14 (2H, 2xs) ; 4.31-4.19 (1H, m) ; 2.28-2.16 (2H, m) ; 1.99-1.86 (6H, m) ; 1.41 and 1.40 (3H, 2xs); 1.20 and 1.20 (9H, 2xs)
    219 δ (400 MHz, CDCl3) rotamers present 7.68 and 7.53 (1H, 2xs) ; 7.38 and 7.30 (2H, 2xs); 5.08-4.98 and 4.36-4.14 (2H, m); 4.57 and 4.38 (2H, 2xs); 2.31-1.84 (10H, m); 1.42 and 1.39 (3H, 2xs); 1.35-1.24 (2H, m); 1.10-0.95 (8H, m)
    220 δ (400 MHz, CDCl3) rotamers present 7.65 and 7.56 (1H, 2xs); 7.13 and 7.07 (2H, 2xd, J=8.1 Hz); 4.77 and 4.42 (2H, 2xs); 4.29-4.17 (1H, m); 3.50-3.47 and 3.26-3.25 (2H, 2xm); 2.28-2.14 (2H, m); 1.96-1.85 (6H, m); 1.57-1.05 (11H, m) ; 0.96-0.78 (7H, m)
    221 δ (400 MHz, CDCl3) rotamers present 7.73 and 7.57 (1H, 2xs); 7.38 and 7.31 (2H, 2xs) ; 4.87 and 4.50 (2H, 2xs) ; 4.25-4.15 (1H, m) ; 3.49-3.31 (2H, m); 2.25-2.14 (2H, m); 1.94-1.83 (6H, m); 1.41 and 1.40 (3H, 2xs); 1.00 and 0.83 (9H, 2xs)
    222 δ (400 MHz, CDCl3) rotamers present 7.69-7.49 (4H, m); 4.61-4.15 (4H, m); 2.31-2.17 (2H, m); 1.99-1.87 (8H, m); 1.42 and 1.40 (3H, 2xs); 1.30-1.19 (2H, m); 1.07-0.95 (8H, m)
    224 δ (400 MHz, CDCl3) rotamers present 7.69 and 7.57 (1H, 2xs) ; 7.12 and 7.05 (2H, 2xd, J=8.0 Hz); 5.01 and 4.67 (2H, 2xs); 4.25-4.17 (1H, m); 4.07-3.70 (2H, m); 2.25-2.15 (2H, m) ; 1.94-1.71 (14H, m) ; 1.41 and 1.40 (3H, 2xs)
    225 δ (400 MHz, CDCl3) rotamers present 7.68 and 7.56 (1H, 2xs) ; 7.37 and 7.30 (2H, 2xs); 5.01 and 4.66 (2H, 2xs); 4.25-4.17 (1H, m); 4.01-3.88 and 3.77-3.70 (2H, m); 2.25-2.15 (2H, m) ; 1.94-1.71 (14H, m) ; 1.41 and 1.40 (3H, 2xs)
    226 δ (400 MHz, CD3CN) rotamers present 7.55 and 7.46 (1H, 2xs); 7.20 and 7.12 (2H, 2xs); 4.91 and 4.67 (2H, 2xs); 4.22-4.16 (1H, m) ; 3.80 and 3.62 (2H, 2xs) ; 2.26 and 2.21 (3H, 2xs); 1.82-1.33 (16H, m); 1.27 and 1.25 (3H, 2xs); 1.23 and 1.21 (3H, 2xs)
    227 δ (400 MHz, CD3OD) rotamers present 7.76 and 7.59 (1H, 2xs) ; 7.33 and 7.25 (2H, 2xs); 4.75 and 4.63 (2H, 2xs); 4.43-4.28 (1H, m); 4.30-4.23 and 3.52-3.47 (1H, 2xm); 2.38 and 2.33 (3H, 2xs); 2.30-2.15 (2H, m); 1.98-1.38 (13H, m); 1.36 and 1.34 (3H, 2xs) ; 1.16-1.05 (1H, m) ; 0.95-0.86 (6H, m)
    228 δ (400 MHz, DMSO-d6) rotamers present 12.07 (1H, brs); 8.72 and 8.61 (2H, 2xs); 7.66 and 7.63 (1H, 2xs); 7.38-7.17 (4H, m); 4.73-4.67 (4H, m); 4.43-4.36 (1H, m); 4.26-4.08 (2H, m); 2.33-2.25 (1H, m); 2.03-1.76 (6H, m); 1.61-1.51 (2H, m)
    229 δ (400 MHz, CDCl3) rotamers present 8.59 and 8.50 (2H, 2xs); 7.66 and 7.56 (1H, 2xs); 4.66 and 4.45 (2H, 2xs) ; 4.64-4.56 and 3.54-3.46 (1H, 2xm); 4.31-4.17 (1H, m); 2.29-2.16 (2H, m); 1.99-1.86 (6H, m); 1.63-1.27 (10H, m); 1.15-1.07 (1H, m); 0.95-0.88 (6H, m)
    230 δ (400 MHz, CDCl3) rotamers present 7.59 and 7.50 (1H, 2xs); 7.14 and 7.06 (2H, 2xd, J=8.0 Hz); 4.65 and 4.40 (2H, 2xs); 4.61-4.53 and 3.46-3.38 (1H, 2xm); 2.33-2.18 (6H, m); 2.09-2.03 (6H, m); 1.64-1.39 (7H, m); 1.12-1.02 (1H, m); 0.93-0.86 (6H, m)
    231 δ (400 MHz, CDCl3) rotamers present 7.59 and 7.50 (1H, 2xs); 7.39 and 7.31 (2H, 2xs) ; 4.64 and 4.39 (2H, 2xs); 4.61-4.53 and 3.46-3.38 (1H, 2xm) ; 2.33-2.21 (6H, m) ; 2.09-2.02 (6H, m) ; 1.63-1.39 (7H, m) ; 1.12-1.04 (1H, m); 0.93-0.86 (6H, m)
    234 δ (400 MHz, CDCl3) rotamers present 7.68 and 7.55 (1H, 2xs) ; 7.38 and 7.32 (2H, 2xs); 4.74 and 4.41 (2H, 2xs); 4.30-4.16 (1H, m); 3.78 and 3.58 (2H, 2xd, J=7.8 Hz); 2.85-2.78 and 2.64-2.57 (1H, 2xm); 2.28-2.12 (4H, m); 2.02-1.85 (7H, m); 1.66-1.61 (1H, m) ; 1.42 and 1.39 (3H, 2xs); 0.43-0.16 (4H, m)
    235 δ (400 MHz, CDCl3) rotamers present 7.71-7.48 (4H, m); 4.84 and 4.49 (2H, 2xs); 4.31-4.17 (1H, m); 3.83-3.59 (2H, m); 2.86-2.78 and 2.62-2.55 (1H, 2xm); 2.28-2.10 (4H, m); 2.01-1.87 (7H, m); 1.64-1.59 (1H, m); 1.42 and 1.41 (3H, 2xs); 0.43-0.16 (4H, m)
    236 δ (400 MHz, DMSO-d6) rotamers present 12.30 (1H, brs); 7.77 and 7.54 (1H, 2xs); 7.45 and 7.38 (2H, 2xs); 4.68 and 4.58 (2H, 2xs); 4.32-4.26 (1H, m); 2.36 and 2.30 (3H, 2xs); 2.21-2.18 (2H, m) ; 2.14-2.10 (4H, m) ; 1.94-1.88 (6H, m); 1.72-1.59 (2H, m) ; 1.47-1.24 (m, 5H); 1.00-0.92 (1H, m); 0.98-0.80 (6H, m)
    237 δ (400 MHz, DMSO-d6) rotamers present 12.25 (1H, brs) ; 7.76 and 7.54 (1H, 2xs) ; 7.44 and 7.38 (2H, 2xs) ; 4.70 and 4.50 (2H, 2xs) ; 3.50-3.25 (2H, m); 2.59-2.53 and 2.45-2.37 (1H, 2xm) ; 2.35 and 2,31 (3H, 2xm); 2.21-2.10 (6H, m); 1.94-1.88 (6H, m); 1.82-1.70 (2H, m); 1.59-1.54 and 1.27-1.22 (2H, 2xm); 1.10-0.87 (6H, m)
    238 δ (400 MHz, DMSO-d6) rotamers present 7.66 and 7.55 (1H, 2xs); 7.16 and 7.09 (2H, 2xs); 4.74 and 4.38 (2H, 2xs); 4.31-4.15 (1H, m); 3.65 and 3.40 (2H, 2xd, J=7.1 Hz); 2.66-2.13 (6H, m); 1.97-1.78 (8H, m); 1.65-1.58 and 1.36-1.29 (2H, m) ; 1.42 and 1.40 (3H, 2xs); 1.14-0.93 (6H, m)
    239 δ (400 MHz, CDCl3) rotamers present 7.65 and 7.56 (1H, 2xs); 7.38 and 7.31 (2H, 2xs); 4.77 and 4.41 (2H, 2xs); 4.30-4.16 (1H, m); 3.48 and 3.25 (2H, 2xd, J=7.0 Hz) ; 2.28-2.14 (2H, m); 1.96-1.84 (6H, m) ; 1.57-1.05 (11H, m) ; 0.96-0.78 (7H, m)
    240 δ (400 MHz, CDCl3) rotamers present 7.61 and 7.46 (1H, 2xs) ; 7.12 and 7.05 (2H, 2xd, J=7.6 Hz); 5.09-4.99 and 4.31-4.21 (1H, 2xm) ; 4.57 and 4.35 (2H, 2xs); 2.34-2.21 (6H, m); 2.09-2.03 (6H, m); 1.94-1.87 and 1.40-1.33 (2H, m); 1.29-1.22 (2H, m) ; 1.09-0.95 (8H, m)
    241 δ (400 MHz, CDCl3) rotamers present 7.60 and 7.46 (1H, 2xs); 7.37 and 7.30 (2H, 2xs); 5.08-4.99 and 4.30-4.21 (1H, 2xm); 4.56 and 4.35 (2H, 2xs); 2.33-2.20 (6H, m); 2.09-2.02 (6H, m); 1.93-1.86 and 1.39-1.33 (2H, m) ; 1.28-1.21 (2H, m); 1.10-0.95 (8H, m)
    242 δ (400 MHz, CDCl3) rotamers present 7.68-7.47 (4H, m); 4.71 and 4.48 (2H, 2xs) ; 4.31-4.22 and 3.46-3.39 (1H, 2xm) ; 2.33-2.24 (6H, m) ; 2.11-2.03 (6H, m); 1.87-1.77 (1H, m); 1.67-1.34 (6H, m) ; 1.11-1.03 (1H, m); 0.93-0.86 (6H, m)
    243 δ (400 MHz, CDCl3) rotamers present 7.61 and 7.52 (1H, 2xs); 7.32-7.23 (1H, m) ; 7.04-6.80 (2H, m); 4.64 and 4.33 (2H, 2xs) ; 4.63-4.56 and 3.43-3.35 (1H, 2xm) ; 3.86 and 3.76 (3H, 2xs); 2.33-2.22 (6H, m) ; 2.09-2.02 (6H, m) ; 1.62-1.38 (7H, m); 1.11-1.04 (1H, m); 0.94-0.86 (6H, m)
    244 δ (400 MHz, CDCl3) rotamers present 7.66 and 7.57 (1H, 2xs) ; 7.11 and 7.04 (2H, 2xd, J=8.1 Hz); 5.09 and 4.77 (2H, 2xs); 4.29-4.18 (1H, m); 3.96-3.76 (2H, m) 2.21-2.14 (2H, m); 1.96-1.84 (6H, m); 1.68-1.39 (14H, m)
    245 δ (400 MHz, CDCl3) rotamers present 7.66 and 7.49 (1H, 2xs) ; 7.13 and 7.06 (2H, 2xd, J=8.1 Hz); 4.86 and 4.48 (2H, 2xs); 3.79-3.25 (2H, m); 2.31-2.21 (6H, m); 2.07-2.03 (6H, m); 1.01 and 0.84 (9H, 2xs)
    246 δ (400 MHz, CDCl3) rotamers present 7.66 and 7.49 (1H, 2xs) ; 7.38 and 7.31 (2H, 2xs); 4.86 and 4.48 (2H, 2xs) ; 3.75-3.25 (2H, m) ; 2.32-2.21 (6H, m) ; 2.07-2.03 (6H, m); 1.00 and 0.84 (9H, 2xs)
    247 δ (400 MHz, CDCl3) rotamers present 7.66-7.47 (4H, m); 4.60 and 4.42 (2H, 2xs); 4.31-4.18 (1H, m); 2.34-2.22 (6H, m); 2.09-2.02 (6H, m); 1.92-1.83 (2H, m); 1.29-0.95 (10H, m)
    248 δ (400 MHz, CDCl3) rotamers present 7.62 and 7.47 (1H, 2xs); 7.31-7.23 (1H, m); 7.03-6.78 (2H, m); 5.19-5.09 and 4.28-4.19 (1H, 2xm); 4.56 and 4.30 (2H, 2xs); 3.84 and 3.73 (3H, 2xs) ; 2.33-2.21 (6H, m); 2.09-2.01 (7H, m) ; 1.91-1.84 (1H, m); 1.33-1.24 (2H, m); 1.10-0.93 (8H, m)
    249 δ (400 MHz, CDCl3) rotamers present 7.66 and 7.54 (1H, 2xs); 7.13 and 7.07 (2H, 2xd, J=8.0 Hz); 4.72 and 4.39 (2H, 2xs); 4.29-4.16 (1H, m); 3.64 and 3.40 (2H, 2xd, J=7.6 Hz); 2.63-2.55 and 2.44-2.36 (1H, 2xm); 2.25-2.14 (2H, m); 1.95-1.80 (8H, m); 1.64-1.58 and 1.35-1.30 (2H, 2xm); 1.42 and 1.39 (3H, 2xs); 1.14-0.93 (6H, m)
    250 δ (400 MHz, CDCl3) rotamers present 7.65 and 7.54 (1H, 2xs); 7.38 and 7.31 (2H, 2xs) ; 4.71 and 4.38 (2H, 2xs) ; 4.29-4.17 (1H, m) ; 3.64 and 3.40 (2H, 2xd, J=7.6 Hz); 2.62-2.54 and 2.43-2.35 (1H, 2xm); 2.28-1.79 (10H, m); 1.63-1.58 and 1.34-1.29 (2H, 2xm); 1.41 and 1.39 (3H, 2xs); 1.14-0.93 (6H, m)
    251 δ (400 MHz, CDCl3) rotamers present 7.68-7.48 (4H, m) ; 4.82 and 4.46 (2H, 2xs); 4.27-4.17 (1H, m); 3.66-3.39 (2H, m); 2.63-2.55 and 2.41-2.33 (1H, 2xm); 2.29-2.17 (2H, m); 1.95-1.76 (8H, m); 1.63-1.58 and 1.33-1.27 (2H, 2xm); 1.42 and 1.41 (3H, 2xs); 1.14-0.93 (6H, m)
    252 δ (400 MHz, CDCl3) rotamers present 7.62 and 7.53 (1H, 2xs); 7.33-7.26 (1H, m) ; 7.03-6.79 (2H, m); 4.71 and 4.35 (2H, 2xs); 4.29-4.18 (1H, m); 3.86 and 3.76 (3H, 2xs) ; 3.64 and 3.37 (2H, 2xd, J=7.3 Hz) ; 2.63-2.55 and 2.44-2.36 (1H, 2xm); 2.26-2.14 (2H, m); 1.94-1.79 (8H, m) ; 1.63-1.58 and 1.35-1.30 (2H, 2xm); 1.41 and 1.39 (3H, 2xs) ; 1.14-0.94 (6H, m)
    253 δ (400 MHz, CDCl3) rotamers present 7.70 and 7.55 (1H, 2xs); 7.33-7.25 (1H, m); 7.03-6.78 (2H, m) ; 4.86 and 4.46 (2H, 2xs) ; 4.24-4.18 (1H, m); 3.85 and 3.75 (3H, 2xs); 3.42 and 3.33 (2H, 2xs); 2.26-2.18 (2H, m); 1.93-1.87 (6H, m) ; 1.41 and 1.39 (3H, 2xs) ; 1.01 and 0.83 (9H, 2xs)
    254 δ (400 MHz, CDCl3) rotamers present 7.68-7.47 (4H, m); 4.73 and 4.51 (2H, 2xs); 4.27-4.17 and 3.52-3.44 (2H, 2xm); 2.26-2.21 (2H, m) ; 1.98-1.78 (7H, m); 1.68-1.40 (9H, m) ; 1.12-1.04 (1H, m) ; 0.94-0.86 (6H, m)
    255 δ (400 MHz, CDCl3) rotamers present 7.68 and 7.58 (1H, 2xs); 7.32-7.25 (1H, m); 7.04-6.80 (2H, m); 4.66 and 4.36 (2H, 2xs); 4.62-4.58 and 3.48-3.42 (1H, 2xm); 4.29-4.15 (1H, m); 3.87 and 3.77 (3H, 2xs); 2.28-2.16 (2H, m); 1.98-1.86 (6H, m); 1.66-1.39 (10H, m); 1.13-1.05 (1H, m); 0.94-0.87 (6H, m)
    256 δ (400 MHz, CDCl3) rotamers present 7.57 and 7.47 (1H, 2xs); 7.38 and 7.31 (2H, 2xs) ; 4.70 and 4.35 (2H, 2xs); 3.62-3.34 (2H, m); 2.62-2.54 and 2.43-2.35 (1H, 2xm); 2.32-2.21 (6H, m); 2.08-2.02 (6H, m); 1.89-1.79 (2H, m); 1.63-1.58 and 1.35-1.30 (2H, 2xm) ; 1.14-0.94 (6H, m)
    257 δ (400 MHz, CDCl3) rotamers present 7.54 and 7.45 (1H, 2xs); 7.32-7.26 (1H, m) ; 7.03-6.78 (2H, m); 4.70 and 4.32 (2H, 2xs) ; 3.86 and 3.75 (3H, 2xs); 3.63-3.32 (2H, m) ; 2.63-2.55 and 2.44-2.36 (1H, 2xm) ; 2.32-2.22 (6H, m); 2.08-2.02 (6H, m); 1.90-1.79 (2H, m); 1.63-1.58 and 1.36-1.31 (2H, 2xm); 1.14-0.95 (6H, m)
    258 δ (400 MHz, CDCl3) rotamers present 7.67-7.48 (4H, m); 4.81 and 4.44 (2H, 2xs); 3.93-3.13 (2H, m); 2.63-2.23 (7H, m); 2.09-2.03 (6H, m); 1.88-1.76 (2H, m); 1.63-1.58 and 1.33-1.28 (2H, 2xm); 1.14-0.94 (6H, m)
    259 δ (400 MHz, CDCl3) rotamers present 7.61 and 7.55 (1H, 2xs); 7.33-7:26 (1H, m); 7.03-6.78 (2H, m); 4.76 and 4.38 (2H, 2xs); 4.28-4.18 (1H, m); 3.86 and 3.75 (3H, 2xs); 3.48 and 3.23 (2H, 2xd, J=7.1 Hz); 2.27-2.16 (2H, m); 1.95-1.87 (6H, m); 1.67-1.05 (11H, m) ; 0.96-0.78 (7H, m)
    260 δ (400 MHz, CDCl3) rotamers present 7.65 and 7.57 (1H, 2xs); 7.36 and 7.29 (2H, 2xs); 5.08 and 4.76 (2H, 2xs) ; 4.29-4.17 (1H, m); 3.96 and 3.75 (2H, 2xs); 2.25-2.14 (2H, m) ; 1.95-1.84 (6H, m); 1.68-1.39 (14H, m)
    261 δ (400 MHz, DMSO-d6) rotamers present 12.20 (1H, brs); 7.71 and 7.61 (1H, 2xs); 7.42 and 7.37 (2H, 2xs) ; 4.92 and 4.70 (2H, 2xs) ; 3.83 and 3.61 (2H, 2xs); 2.35 and 2.30 (3H, 2xs); 2.21-2.12 (6H, m) ; 1.93-1.89 (6H, m); 1.69-1.50 (6H, m); 1.45-1.38 (2H, m); 1.34 and 1.31 (3H, 2xs)
    262 δ (400 MHz, DMSO-d6) rotamers present 11.97 (1H, brs); 8.77 and 8.70 (2H, 2xs); 7.81 and 7.71 (1H, 2xs); 4.95 and 4.82 (2H, 2xs); 4.48-4.42 (1H, m); 4.27-4.19 (1H, m); 3.87 and 3.71 (2H, 2xs); 2.34-2.26 (1H, m); 2.07-1.90 (6H, m); 1.67-1.30 (10H, m)
    264 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.49 (2H, 2xs) ; 7.66 and 7.52 (1H, 2xs); 5.14-5.04 and 4.37-4.16 (2H, m); 4.57 and 4.40 (2H, 2xs); 2.52-2.44 (1H, m); 2.28-2.25 (2H, m); 2.17-2.02 (4H, m) ; 1.96-1.89 (1H, m); 1.73-1.62 (2H, m,); 1.36-0.96 (11H, m)
    265 δ (400 MHz, CDCl3) rotamers present 7.78 and 7.48 (4H, m) ; 4.97 and 4.60 (2H, 2xs); 4.24-4.18 (1H, m); 3.72-3.12 (2H, m); 2.27-2.19 (2H, m); 1.94-1.88 (6H, m); 1.41 and 1.25 (3H, 2xs); 1.00 and 0.82 (9H, 2xs)
    266 δ (400 MHz, CDCl3) rotamers present 7.58 and 7.47 (1H, 2xs) ; 7.13 and 7.06 (2H, 2xd, J=8.0 Hz); 4.71 and 4.36 (2H, 2xs); 3.70-3.35 (2H, m) ; 2.63-2.55 and 2.43-2.35 (1H, 2xm) ; 2.32-2.21 (6H, m); 2.08-2.02 (6H, m); 1.89-1.79 (2H, m); 1.63-1.58 and 1.36-1.30 (2H, 2xm); 1.14-0.94 (6H, m)
    267 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.50 (2H, 2xs); 7.67 and 7.56 (1H, 2xs) ; 4.81 and 4.47 (2H, 2xs) ; 4.29-4.18 (1H, m) ; 3.72 and 3.59 (2H, 2xs) ; 2.28-2.15 (2H, m) ; 1.95-1.85 (6H, m); 1.67-1.06 (16H, m)
    268 δ (400 MHz, DMSO-d6) rotamers present 12.23 (1H, brs) ; 7.90 and 7.81 (1H, 2xs); 7.19-7.09 (4H, m); 6.93-6.91 (1H, m); 4.72-4.59 (4H, m); 4.27-4.13 (1H, m); 2.33-2.29 (1H, m); 2.19 (3H, s); 2.05-2.02 (2H, m); 1.96-1.90 (4H, m); 1.70 (3H, s); 1.58-1.46 (2H, m)
    269 δ (300 MHz, DMSO-d6) rotamers present 12.15 (1H, brs); 7.85 and 7.81 (1H, 2xs); 7.17-6.91 (5H, m); 4.71-4.58 (4H, m); 4.28-4.13 (1H, m); 2.34-2.23 (4H, m); 2.22 and 1.77 (3H, 2xs); 2.08-1.90 (6H, m); 1.60-1.47 (2H, m)
    270 δ (400 MHz, CDCl3) rotamers present 7.65-7.47 (4H, m) ; 5.11 and 4.75 (2H, 2xs); 4.25-4.19 (1H, m); 4.02-3.70 (2H, m); 2.28-2.18 (2H, m); 1.95-1.73 (14H, m); 1.41 (3H, s)
    272 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.49 (2H, 2xs); 7.67 and 7.56 (1H, 2xs); 5.00 and 4.69 (2H, 2xs); 4.26-4.19 (1H, m) ; 3.98-3.92 (2H, m) ; 2.28-2.16 (2H, m) ; 1.95-1.74 (14H, m) ; 1.41 (3H, s)
    275 δ (400 MHz, CDCl3) rotamers present 7.68 and 7.56 (1H, 2xs) ; 7.38 and 7.31 (2H, 2xs) ; 4.82 and 4.44 (2H, 2xs) ; 4.29-4.17 (1H, m) ; 3.71 and 3.58 (2H, m) ; 2.24-2.14 (2H, m) ; 1.96-1.84 (6H, m); 1.66-1.05 (16H, s)
    279 δ (300 MHz, DMSO-d6) rotamers present 12.22 (1H, brs) ; 7.85 and 7.68 (1H, 2xs); 7.22 and 7.15 (1H, 2xs); 7.11 and 7.05 (1H, 2xs); 4.61 and 4.59 (2H, 2xs); 4.32-4.17 and 3.39-3.30 (2H, 2xm); 2.30-1.98 (7H, m); 1.90-1.58 (9H, m); 1.50-1.31 (4H, m); 1.25 and 1.22 (3H, 2xs) ; 1.04-0.82 (8H, m)
    280 δ (400 MHz, CD3OD) rotamers present 7.76 and 7.62 (1H, 2xs); 7.13 and 7.07 (2H, 2xs); 4.61 and 4.54 (2H, 2xs); 4.35-4.27 and 3.57-3.45 (2H, 2xm); 2.36-2.20 (7H, m) ; 1.95-1.81 (7H, m); 1.77-1.07 (11H, m); 0.95-0.86 (6H, m)
    281 δ (400 MHz, CDCl3) rotamers present 7.70 and 7.58 (1H, 2xs) ; 7.36-7.23 (3H, m); 5.05 and 4.69 (2H, 2xs) ; 4.25-4.18 (1H, m); 4.00-3.95 (2H, m); 2.26-2.16 (2H, m); 1.94-1.73 (14H, m); 1.40 (3H, s)
    282 δ (400 MHz, CDCl3) rotamers present 7.69 and 7.58 (1H, 2xs) ; 7.15 and 7.07 (2H, 2xs); 5.02 and 4.66 (2H, 2xs); 4.25-4.17 (1H, m); 3.98-3.70 (2H, m) ; 2.35 and 2.32 (3H, 2xs) ; 2.25-2.15 (2H, m); 1.94-1.73 (14H, m); 1.41 and 1.40 (3H, 2xs)
    283 δ (400 MHz, CDCl3) rotamers present 7.68 and 7.58 (1H, 2xs) ; 7.38-7.23 (3H, m); 4.70 and 4.46 (2H, 2xs); 4.61-4.53 and 3.52-3.44 (1H, 2xm); 4.30-4.15 (1H, m); 2.29-2.16 (2H, m); 1.98-1.86 (6H, m); 1.68-1.40 (10H, m); 1.13-1.06 (1H, m); 0.94-0.87 (6H, m)
    284 δ (400 MHz, CDCl3) rotamers present 7.75 and 7.59 (1H, 2xs) ; 7.36-7.23 (3H, m); 4.92 and 4.53 (2H, 2xs); 4.24-4.16 (1H, m) ; 3.44-3.36 (2H, m); 2.25-2.15 (2H, m) ; 1.94-1.85 (6H, m); 1.42 and 1.40 (3H, 2xs); 1.01 and 0.84 (9H, 2xs)
    287 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.50 (2H, 2xs); 7.65 and 7.57 (1H, 2xs); 4.64-4.57 and 3.55-3.48 (1H, 2xm); 4.54 and 4.35 (2H, 2xs); 4.30-4.21 (1H, m) ; 2.28-2.18 (2H, m); 1.97-1.87 (6H, m); 1.62-1.49 (4H, m); 1.42 and 1.40 (3H, 2xs); 0.99 and 0.90 (6H, 2xt, J=7.5 Hz)
    288 δ (400 MHz, DMSO-d6) rotamers present 12:24 (1H, brs); 8.78 and 8.72 (2H, 2xs); 7.65 and 7.62 (1H, 2xs); 4.82 and 4.66 (2H, 2xs); 3.49-3.22 (2H, m) ; 2.15-2.11 (6H, m) ; 1.93-1.89 (6H, m); 1.30-1.24 (2H, m); 0.89-0.72 (9H, m)
    289 δ (400 MHz, CDCl3) rotamers present 7.66 and 7.55 (1H, 2xs); 7.39 and 7.31 (2H, 2xs); 4.57-4.52 (1.5H, m); 4.39-4.15 (6H, m); 3.53-3.48 (0.5H, m); 2.27-2.13 (4H, m); 1.95-1.75 (8H, m); 1.65-1.58 (1H, m); 1.45-1.28 (6H, m)
    290 δ (400 MHz, DMSO-d6) rotamers present 12.47 (1H, brs) ; 7.91 and 7.76 (1H, 2xs); 7.72 and 7.65 (2H, 2xd, J=8.6 Hz); 5.14-4.98 (1H, m); 4.73 and 4.65 (2H, 2xs); 4.34-4.28 and 3.43-3.38 (1H, 2xm); 3.17-3.09 (1H, m); 2.92-2.75 (2H, m); 2.71-2.59 (2H, m); 1.71-1.61 (2H, m); 1.48-1.24 (5H, m); 1.06-1.00 (1H, m); 0.91-0.81 (6H, m)
    291 δ (400 MHz, DMSO-d6) rotamers present 12.38 (1H, brs); 7.89 and 7.75 (1H, 2xs); 7.72 and 7.66 (2H, 2xd, J=8.6 Hz) ; 4.98-4.85 (1H, m) ; 4.72 and 4.64 (2H, 2xs); 4.35-4.28 and 3.43-3.37 (1H, 2xm); 3.02-2.96 (1H, m); 2.81-2.59 (4H, m); 1.70-1.60 (2H, m) ; 1.48-1.27 (5H, m); 1.07-1.00 (1H, m) ; 0.91-0.82 (6H, m)
    292 δ (400 MHz, CD3OD) rotamers present 7.81 and 7.59 (1H, 2xs); 7.40 and 7.34 (2H, 2xd, J=8.6 Hz); 4.96 and 4.78 (2H, 2xs); 4.35-4.25 (1H, m); 3.72-3.63 and 3.51-3.46 (4H, 2xm); 2.31-2.13 (2H, m); 1.93-1.84 (6H, m) ; 1.35 and 1.33 (3H, 2xs); 1.19 and 1.16 (9H, 2xs)
    293 δ (400 MHz, CD3OD) rotamers present 7.81 and 7.59 (1H, 2xs) ; 7.61and 7.55 (2H, 2xs) ; 4.96 and 4.78 (2H, 2xs); 4.36-4.26 (1H, m) ; 3.72-3.63 and 3.52-3.45 (4H, 2xm); 2.35-2.13 (2H, m); 1.94-1.85 (6H, m) ; 1.36 and 1.34 (3H, 2xs) ; 1.19 and 1.16 (9H, 2xs)
    294 δ (400 MHz, CDCl3) rotamers present 8.54-8.44 (2H, m); 7.61 and 7.51 (1H, 2xs); 4.71 and 4.54 (2H, 2xs); 4.27-4.19 (1H, m) ; 3.40-3.33 (2H, m) ; 2.27-2.17 (2H, m) ; 1.94-1.87 (6H, m); 1.41 and 1.40 (3H, 2xs); 1.01 and 0.86 (9H, 2xs)
    295 δ (400 MHz, CD3OD) rotamers present 7.81 and 7.63 (1H, 2xs); 7.41 and 7.34 (2H, 2xd, J=6.3 Hz); 4.79-3.93 (4H, m); 3.31-3.12 (2H, m); 2.99-2.94 (1H, m); 2.80-2.68 (4H, m); 2.46-2.37 (2H, m); 2.28-2.15 (2H, m); 1.95-1.72 (8H, m); 1.32 and 1.30 (3H, 2xs)
    296 δ (400 MHz, DMSO-d6) rotamers present 7.88-7.69 (3H, m); 4.69-4.19 (4H, m) ; 3.12-2.73 (4H, m); 2.13-2.02 (3H, m); 1.91-1.65 (10H, m); 1.25 and 1.22 (3H, 2xs) ; 1.05-0.90 (6H, m)
    297 δ (400 MHz, CDCl3) rotamers present 7.64 and 7.52 (1H, 2xs) ; 7.39-6.99 (3H, m) ; 4.78 and 4.53 (2H, 2xs) ; 4.25-4.18 (1H, m) ; 3.41-3.33 (2H, m) ; 2.26-2.16 (2H, m) ; 1.94-1.87 (6H, m); 1.41 and 1.40 (3H, 2xs); 1.01 and 0.85 (9H, 2xs)
    298 δ (400 MHz, CDCl3) rotamers present 7.61 and 7.49 (1H, 2xs); 7.37 and 7.30 (2H, 2xs) ; 4.99 and 4.64 (2H, 2xs) ; 3.94-3.66 (2H, m) ; 2.31-2.22 (6H, m) ; 2.07-2.03 (6H, m) ; 1.93-1.73 (8H, m)
    299 δ (400 MHz, CDCl3) rotamers present 8.56 and 8.49 (2H, 2xs) ; 7.60 and 7.49 (1H, 2xs) ; 4.99 and 4.67 (2H, 2xs) ; 3.94-3.66 (2H, m) ; 2.31-2.23 (6H, m) ; 2.08-2.04 (6H, m) ; 1.99-1.74 (8H, m)
    300 δ (400 MHz, CDCl3) rotamers present 7.62 and 7.50 (1H, 2xs); 7.15 and 7.07 (2H, 2xs); 5.01 and 4.64 (2H, 2xs); 3.95-3.67 (2H, m); 2.35 and 2.32 (3H, 2xs); 2.26-2.22 (6H, m); 2.07-2.03 (6H, m) ; 1.94-1.73 (8H, m)
    301 δ (400 MHz, DMSO-d6) rotamers present 12.40 (1H, brs); 7.80 and 7.63 (1H, 2xs); 7.71 and 7.67 (2H, 2xd, J=8.6 Hz); 4.72 and 4.65 (2H, 2xs); 4.34-4.17 (2H, m); 2.20-2.14 (2H, m); 2.03-1.62 (6H, m); 1.48-1.24 (7H, m); 1.14 and 1.12 (3H, 2xs); 1.02-0.95 (1H, m); 0.90-0.81 (6H, m)
    302 δ (400 MHz, DMSO-d6) rotamers present 12.26 (1H, brs); 7.88 and 7.75 (1H, 2xs); 7.70 and 7.65 (2H, 2xd, J=8.5 Hz); 4.81 and 4.63 (2H, 2xs); 4.25-4.20 (1H, m); 3.82-3.75 and 3.38-3.23 (2H, 2xm) ; 2.09-1.98 (2H, m); 1.87-1.72 (6H, m) ; 1.30-1.15 (5H, m); 0.87-0.70 (9H, m)
    303 δ (400 MHz, DMSO-d6) rotamers present 12.26 (1H, brs); 9.41 and 9.14 (1H, 2xbrs); 7.89 and 7.76 (1H, 2xs); 7.75 and 7.69 (2H, 2xd, J=8.6 Hz) ; 4.80-4.73 (2.5H, m); 4.36-4.31 (0.5H, m); 4.26-4.20 (1H, m); 3.90-3.88 and 3.81-3.78 (2H, 2xm); 2.63 and 2.56 (3H, 2xd, J=4.5 Hz); 2.49-2.42 (2H, m); 2.29-2.27 (2H, m); 2.14-1.63 (12H, m) ; 1.25 and 1.23 (3H, 2xs)
    304 δ (400 MHz, CD3OD) rotamers present 7.82 and 7.62 (1H, 2xs) ; 7.43 and 7.37 (2H, 2xd, J=8.0 Hz); 4.79 and 4.70 (2H, 2xs); 4.45-4.36 (1H, m); 4.30-4.25 (1H, m); 4.11-4.02 (2H, m) ; 2.64-2.48 (2H, m); 2.26-2.06 (8H, m) ; 1.99-1.74 (7H, m) ; 1.36 and 1.34 (3H, 2xs)
    305 δ (400 MHz, CD3OD) rotamers present 7.66 and 7.63 (1H, 2xs) ; 7.37 and 7.29 (2H, 2xd, J=8.2 Hz); 4.77 and 4.72 (2H, 2xs); 4.29-4.17 (4H, m); 3.26-3.20 (1H, m); . 2.79-2.71 (2H, m); 2.33-2.15 (8H, m); 1.95-1.82 (6H, m); 1.47-1.34 (9H, m)
    306 δ (400 MHz, DMSO-d6) rotamers present 7.94-7.72 (3H, m); 4.80 and 4.63 (2H, 2xs); 4.16-4.09 (1H, m) ; 3.48-3.20 (2H, m) ; 2.07-1.96 (2H, m) ; 1.80-1.63 (6H, m) ; 1.29-1.22 (2H, m); 1.12 (3H, s) ; 0.87-0.69 (9H, m)
    307 δ (400 MHz, DMSO-d6) 12.11 (1H, brs); 8.32 (2H, s); 7.49 (1H, s); 7.37 (1H, s) ; 7.18-7.13 (2H, m); 7.10-7.03 (2H, m); 5.13 (1H, d, J=15.7 Hz); 4.30 (1H, d, J=15.7 Hz) ; 4.16-4.08 (1H, m) ; 2.28 (3H, s); 2.24-2.18 (1H, m); 2.00-1.82 (4H, m); 1.75-1.69 (2H, m); 1.52-1.40 (2H, m)
    308 δ (400 MHz, DMSO-d6) rotamers present 7.84 and 7.79 (2H, 2xs) ; 7.64 and 7.61 (1H, 2xs); 4.79 and 4.59 (2H, 2xs); 3.50-3.32 (2H, m) ; 2.19-2.10 (6H, m); 1.92-1.88 (6H, m); 1.29-1.22 (2H, m); 0.88-0.71 (9H, m)
    309 δ (400 MHz, DMSO-d6) rotamers present 7.80-7.61 (3H, m); 4.79 and 4.59 (2H, 2xs); 3.50-3.22 (2H, m); 2.18-2.10 (6H, m) ; 1.91-1.88 (6H, m); 1.29-1.23 (2H, m) ; 0.87-0.71 (9H, m)
    310 δ (400 MHz, DMSO-d6) rotamers present 12.30 (1H, brs); 8.78 and 8.73 (2H, 2xs); 8.13 and 8.04 (1H, 2xs) ; 4.86 (2H, s); 4.50-4.43 (1H, m) ; 3.41-3.28 (2H, m); 2.04-1.95 (2H, m); 1.88-1.83 (4H, m); 1.74-1.71 (2H, m); 1.20 and 1.14 (3H, 2xs); 0.94 and 0.76 (9H, 2xs)
    312 δ (400 MHz, CD3OD) rotamers present 8.65 and 8.58 (2H, 2xs); 7.79 and 7.61 (1H, 2xs); 4.95-4.88 and 3.99-3.91 (1H, 2xm); 4.80-4.63 (2H, m) ; 4.37-4.25 (1H, m); 2.33-2.14 (2H, m); 1.93-1.85 (7H, m); 1.68-1.40 (2H, m); 1.36 and 1.34 (3H, 2xs); 1.32-1.27 (1H, m) ; 1.23 and 1.21 (3H, 2xs); 0.99-0.93 (3H, m); 0.75 and 0.73 (3H, 2xs)
    313 δ (400 MHz, DMSO-d6) rotamers present 12.21 (1H, brs); 8.80 and 8.72 (2H, 2xs); 7.81 and 7.70 (1H, 2xs); 4.88-4.57 (2.5H, m); 4.31-4.21 (1H, m); 3.96-3.91 (0.5H, m); 3.54-3.22 (2H, m); 3.25 and 3.16 (3H, 2xs); 2.15-2.01 (2H, m) ; 1.88-1.76 (6H, m); 1.24 and 1.23 (3H, 2xs) ; 1.16 and 1.08 (3H, 2xd, J=6.8 Hz)
    314 δ (400 MHz, DMSO-d6) rotamers present 12.27 (1H, brs); 8.79 and 8.72 (2H, 2xs); 7.85 and 7.75 (1H, 2xs); 5.17-5.11 (1H, m); 4.75 and 4.60 (2H, 2xs); 4.30-4.22 (1H, m) ; 4.11 and 3.86 (2H, 2xd, J=6.7 Hz); 2.14-2.01 (2H, m) ; 1.88-1.74 (6H, m) ; 1.70 and 1.66 (3H, 2xs) ; 1.64 and 1.37 (3H, 2xs) ; 1.24 and 1.23 (3H, 2xs)
    315 δ (400 MHz, CDCl3) rotamers present 8.33-8.23 (2H, m); 7.68 and 7.53 (1H, 2xs); 4.80 and 4.47 (2H, 2xs) ; 4.24-4.19 (1H, m); 3.98 and 3.88 (3H, 2xs); 3.41-3.31 (2H, m); 2.27-2.16 (2H, m); 1.94-1.86 (6H, m); 1.41 and 1.40 (3H, 2xs); 1.01 and 0.85 (9H, 2xs)
    316 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.51 (2H, 2xs); 7.54 and 7.48 (1H, 2xs) ; 4.94 and 4.58 (2H, 2xs); 3.55-3.30 (2H, m) ; 2.33-2.23 (6H, m) ; 2.09-2.05 (6H, m); 1.09 and 0.98 (3H, 2xs); 0.49-0.34 (4H, m)
    317 δ (400 MHz, CDCl3) rotamers present 7.68 and 7.51 (2H, 2xs); 7.37-7.25 (3H, m); 4.91 and 4.51 (2H, 2xs) ; 3.49-3.33 (2H, m) ; 2.32-2.22 (6H, m); 2.07-2.03 (6H, m) ; 1.01 and 0.84 (9H, 2xs)
    318 δ (400 MHz, CDCl3) rotamers present 7.71 and 7.60 (1H, 2xs); 7.37-7.27 (2H, m) ; 4.96 and 4.72 (2H, 2xs); 4.29-4.18 (1H, m); 3.77-3.40 (4H, m) ; 2.25-2.17 (2H, m); 1.93-1.87 (6H, m); 1.41 and 1.40 (3H, 2xs); 1.16 and 1.15 (9H, 2xs)
    319 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.50 (2H, 2xs) ; 7.71 and 7.52 (1H, 2xs); 5.19-5.15 and 4.53-4.15 (3H, m) ; 2.28-2.14 (2H, m) ; 1.95-1.55 (8H, m) ; 1.42-0.55 (14H, m)
    320 δ (400 MHz, CDCl3) rotamers present 7.62 and 7.48 (1H, 2xs); 7.36-7.26 (3H, m); 5.10-5.00 and 4.31-4.22 (1H, 2xm); 4.60 and 4.38 (2H, 2xs); 2.34-2.21 (6H, m); 2.09-1.88 (8H, m); 1.43-1.23 (2H, m); 1.08-0.95 (8H, m)
    321 δ (400 MHz, CDCl3) rotamers present 7.62 and 7.47 (1H, 2xs) ; 7.16 and 7.08 (2H, 2xs); 5.11-5.01 and 4.30-4.21 (1H, 2xm); 4.57 and 4.35 (2H, 2xs); 2.35-2.21 (9H, m) ; 2.09-2.02 (7H, m) ; 1.93-1.85 (1H, m) ; 1.40-1.23 (2H, m) ; 1.10-0.95 (8H, m)
    322 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.51 (2H, 2xs); 7.55 and 7.48 (1H, 2xs); 4.74 and 4.45 (2H, 2xs); 3.68 (1H, brs); 3.32 (1H, d, J=5.9 Hz) ; 2.31-2.23 (6H, m) ; 2.08-2.05 (6H, m); 1.09 (3H, s) ; 1.05 (3H, s) ; 1.03 (3H, s); 0.80 (3H, s) ; 0.55-0.51 and 0.31-0.28 (1H, m)
    325 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.51 (2H, 2xs); 7.64 and 7.55 (1H, 2xs); 4.76 and 4.48 (2H, 2xs); 4.29-4.18 (1H, m); 3.68 and 3.37 (2H, 2xd, J=6.5 Hz); 2.31-2.16 (2H, m); 1.95-1.86 (6H, m); 1.42 and 1.41 (3H, 2xs); 1.09 (3H, s); 1.06 (3H, s); 1.04 (3H, s) ; 0:80 (3H, s); 0.53 and 0.31 (1H, 2xt, J=6.5 Hz)
    326 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.50 (2H, 2xs) ; 7.67 and 7.57 (1H, 2xs); 5.00 and 4.68 (2H, 2xs); 4.26-4.20 (1H, m); 3.83-3.58 (2H, m); 2.26-2.16 (2H, m); 1.95-1.86 (6H, m); 1.46-1.23 (9H, m)
    327 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.50 (2H, 2xs); 7.59 and 7.50 (1H, 2xs); 4.99 and 4.66 (2H, 2xs); 3.80-3.54 (2H, m) ; 2.32-2.23 (6H, m); 2.08-2.04 (6H, m) ; 1.46-1.26 (6H, m)
    329 δ (400 MHz, CDCl3) rotamers present 8.59 and 8.52 (2H, 2xs); 7.56 and 7.46 (1H, 2xs) ; 4.94 and 4.55 (2H, 2xs); 3.84 and 3.70 (2H, 2xs) ; 2.33-2.22 (6H, m) ; 2.08-2.04 (6H, m); 1.10-1.06 (4H, m)
    331 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.50 (2H, 2xs) ; 7.75 and 7.55 (1H, 2xs) ; 4.78 and 4.45 (2H, 2xs); 4.29-4.24 (1H, m) ; 2.83-2.79 (1H, m) ; 2.28-2.20 (2H, m) ; 1.95-1.90 (6H, m) ; 1.42 (3H, s) ; 1.04-0.99 (1H, m) ; 0.95 and 0.70 (9H, 2xs); 0.64-0.55 (2H, m)
    332 δ (400 MHz, DMSO-d6) rotamers present 12.27 (1H, brs); 8.80 and 8.73 (2H, 2xs); 7.81 and 7.66 (1H, 2xs); 4.89-4.57 (2.5H, m); 4.30-4.21 (1H, m); 3.87-3.82 (0.5H, m); 3.50-3.18 (2H, m); 2.13-2.04 (2H, m); 1.88-1.75 (6H, m); 1.24-1.07 (15H, m)
    333 δ (400 MHz, CDCl3) rotamers present 8.54-8.44 (2H, m); 7.64 and 7.49 (1H, 2xs) ; 5.26-5.20 and 4.34-4.17 (2H, 2xm); 4.52 and 4.36 (2H, 2xs) ; 2.31-1.88 (10H, m); 1.42 and 1.40 (3H, 2xs); 1.27-1.12 (2H, m); 1.04-0.97 (8H, m)
    337 δ (400 MHz, CDCl3) rotamers present 8.54-8.44 (2H, m); 7.62 and 7.50 (1H, 2xs); 4.71 and 4.53, (2H, 2xs); 4.26-4.19 (1H, m); 3.41 and 3.34 (2H, 2xs); 2.26-2.16 (2H, m) ; 1.94-1.86 (6H, m) ; 1.40-1.14 (5H, m) ; 0.95-0.68 (9H, m)
    338 δ (400 MHz, DMSO-d6) rotamers present 12.11 (2H, brs); 7.89 and 7.80 (1H, 2xs); 4.29-4.23 (1H, m); 4.17-4.09 (1H, m) ; 3.26-3.16 (1H, m); 3.04-3.00 (1H, m); 2.57-2.53 (1H, m); 2.36-2.32 (1H, m); 2.15 (3H, s); 2.13-2.05 (2H, m); 1.88-1.64 (11H; m); 1.58-1.55 (1H, m); 1.48-1.30 (4H, m) ; 1.24 (3H, s); 1.00-0.82 (7H, m)
    339 δ (400 MHz, CD3OD) rotamers present 7.79 and 7.64 (1H, 2xs) ; 7.40 and 7.34 (2H, 2xd, J=8.5 Hz); 5.15-5.00 (1H, m); 4.77 and 4.64 (2H, 2xs); 4.44-4.36 and 3.55-3.47 (1H, 2xm) ; 2.99-2.87 (2H, m) ; 2.73-2.58 (2H, m) ; 1.83-1.70 (2H, m) ; 1.63-1.37 (8H, m); 1.15-1.08 (1H, m); 0.94-0.86 (6H, m)
    340 δ (400 MHz, DMSO-d6) rotamers present 12.27 (1H, brs) ; 8.81 and 8.73 (2H, 2xs) ; 7.95 and 7.73 (1H, 2xs); 4.88-4.56 (2H, m); 4.31-4.20 (1H, m); 2.71-2.60 (1H, m); 2.15-2.05 (2H, m) ; 1.90-1.75 (6H, m) ; 1.24 and 1.22 (3H, 2xs) ; 1.08-1.07 (1H, m) ; 0.92-0.76 (2H, m) ; 0.67-0.59 (6H, m); 0.52-0.48 (1H, m)
    341 δ (400 MHz, DMSO-d6) rotamers present 12.24 (1H, brs); 7.69 and 7.52 (1H, 2xs); 7.26-6.90 (3H, m); 5.47-4.96 (2H, m); 4.34-3.96 (2H, m); 3.79-3.50 (4H, m); 2.09-0.88 (23H, m)
    342 δ (400 MHz, DMSO-d6) rotamers present 12.24 (1H, brs) ; 7.69 and 7.52 (1H, 2xs) ; 7.26-6.90 (3H, m); 5.47-4.96 (2H, m); 4.34-3.96 (2H, m) ; 3.79-3.50 (4H, m); 2.09-0.88 (23H, m)
    345 δ (400 MHz, DMSO-d6) rotamers present 12.25 (1H, brs); 7.77 and 7.65 (3H, m) ; 4.70 (2H, s); 4.39-4.24 and 3.70-3.62 (2H, 2xm) ; 2.03-1.64 (10H, m); 1.51-1.09 (10H, m); 0.91-0.85 (6H, m)
    346 δ (400 MHz, DMSO-d6) rotamers present 12.19 (1H, brs) ; 8.81 and 8.74 (2H, 2xs) ; 8.09 and 7.73 (1H, 2xs); 4.96-4.56 (2H, m); 4.31-4.23 (1H, m); 3.22-3.04 (1H, m); 2.17-2.03 (2H, m); 1.88-1.73 (6H, m) ; 1.24 and 1.22 (3H, 2xs) ; 1.19-1.07 (1H, m); 0.99-0.48 (9H, m)
    348 δ (400 MHz, DMSO-d6) rotamers present 12.29 (1H, brs) ; 7.96 and 7.73 (1H, 2xs) ; 7.73 and 7.68 (2H, 2xd, J=8.6 Hz); 4.86 and 4.74 (2H, 2xs); 4.32-4.21 (1H, m) ; 3.57-3.53 and 3.39-3.35 (2H, 2xm); 2.76-2.72 and 2.63-2.59 (2H, 2xm); 2.13-1.99 (2H, m); 1.88-1.72 (6H, m); 1.30 and 1.09 (9H, 2xs); 1.23 and 1.22 (3H, 2xs)
    350 δ (400 MHz, DMSO-d6) rotamers present 12.28 (1H, brs) ; 8.02 and 7.73 (1H, 2xs); 7.74 and 7.68 (2H, 2xd, J=8.8 Hz) ; 4.93 and 4.79 (2H, 2xs); 4.32-4.22 (1H, m) ; 3.89-3.85 and 3.70-3.66 (2H, 2xm); 3.42-3.38 and 3.35-3.31 (2H, 2xm); 2.11-2.00 (2H, m); 1.88-1.73 (6H, m) ; 1.33-1.22 (12H, m).
    351 δ (400 MHz, DMSO-d6) rotamers present 12.28 (1H, brs) ; 7.95 and 7.74 (1H, 2xs) ; 7.73 and 7.67 (2H, 2xd, J=8.6 Hz); 4.91-4.70 (2H, m); 4.31-4.21 (1H, m); 3.91-3.64 (2H, m); 2.98-2.64 (2H, m) ; 2.11-1.99 (2H, m); 1.87-1.72 (6H, m); 1.23 and 1.22 (3H, 2xs); 1.17 and 1.10 (9H, 2xs)
    352 δ (400 MHz, DMSO-d6) rotamers present 12.28-12.23 (1H, m); 8.56 and 8.23 (1H, 2xd, J=2.0 Hz); 7.85 and 7.50 (1H, 2xs); 7.46-7.40 and 7.26-7.13 (3H, 2xm); 4.83 and 4.65 (2H, 2xs); 4.27-4.07 (1H, m) ; 3.41-3.28 (2H, m); 2.11-1.63 (8H, m); 1.23 and 1.13 (3H, 2xs); 0.96 and 0.77 (9H, 2xs)
    358 δ (300 MHz, DMSO-d6) rotamers present 12.24 (1H, brs) ; 7.80 and 7.73 (1H, 2xs) ; 7.58-7.51 (3H, m); 4.84 and 4.72 (2H, 2xs); 4.34-4.27 (1H, m); 1.98-1.72 (8H, m); 1.21 (3H, s); 0.95 and 0.74 (9H, 2xs)
    359 δ (300 MHz, DMSO-d6) rotamers present 12.30 (1H, brs) ; 7.79 and 7.72 (1H, 2xs) ; 7.43 and 7.38 (2H, 2xs) ; 4.82 and 4.68 (2H, 2xs) ; 4.36-4.27 (1H, m) ; 2.31 (3H, s) ; 2.02-1.72 (8H, m); 1.21 (3H, s) ; 0.95 and 0.74 (9H, 2xs)
    360 δ (400 MHz, DMSO-d6) rotamers present 12.42 (1H, brs) ; 11.20 and 11.13 (1H, 2xs); 7.77 and 7.63 (1H, 2xs) ; 7.24-7.17 (1H, m); 6.96-6.85 (2H, m) ; 4.25-4.20 (1H, m); 3.64-3.42 (4H, m); 3.11-3.07 and 2.91-2.87 (2H, 2xm); 2.10-1.99 (5H, m) ; 1.87-1.75 (6H, m); 1.24 (3H, s); 0.95 and 0.74 (9H, 2xs)
    363 δ (400 MHz, DMSO-d6) rotamers present 12.23 (1H, brs); 7.83-7.29 (4H, m); 4.90-4.34 (4H, m) ; 1.93-1.76 (10H, m) ; 1.45-1.41 (2H, m); 1.22 (3H, s); 1.05-0.95 (8H, m)
    364 δ (400 MHz, DMSO-d6) rotamers present 12.20 (1H, brs); 7.55-7.28 (4H, m); 4.62-4.55 (3H, m) ; 4.25-4.15 (1H, m) ; 2.33-2.30 (3H, m) ; 2.09-1.81 (6H, m) ; 1.73-1.71 (4H, m); 1.32-1.27 (2H, m) ; 1.22 (3H, s); 1.05-0.90 (8H, m)
    365 δ (300 MHz, DMSO-d6) rotamers present 12.19 (1H, brs); 7.51-7.33 (3H, m); 4.64-4.57 (3H, m) ; 4.16-4.05 (1H, m) ; 2.35-2.26 (5H, m) ; 2.02-1.81 (6H, m) ; 1.74-1.71 (4H, m); 1.38-1.31 (2H, m) ; 1.22 (3H, s); 1.04-0.90 (8H, m)
    366 δ (300 MHz, DMSO-d6) rotamers present 12.23 (1H, brs); 7.80-7.41 (3H, m); 4.59-4.34 (4H, m); 2.33 (3H, s); 2.07-1.76 (10H, m); 1.31-1.21 (5H, m); 1.05-0.94 (8H, m)
    367 δ (400 MHz, DMSO-d6) rotamers present 12.23 (1H, brs); 8.77 and 8.61 (2H, 2xs); 7.83 and 7.68 (1H, 2xs); 4.65-4.36 (4H, m); 1.97-1.78 (10H, m); 1.30-1.21 (5H, m) ; 1.05-0.95 (8H, m)
    378 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.51 (2H, 2xs) ; 7.69 and 7.62 (1H, 2xs); 4.96 and 4.72 (2H, 2xs); 4.35-4.27 (1H, m); 3.57 and 3.48 (2H, 2xs) ; 2.18-2.12 (2H, m) ; 1.95-1.84 (6H, m) ; 1.40 (3H, s) ; 1.13 and 0.96 (3H, 2xs) ; 0.49-0.39 (4H, m)
    379 δ (400 MHz, CDCl3) rotamers present 8.48-8.35 (2H, m); 7.70 and 7.58 (1H, 2xs) ; 4.76 and 4.51 (2H, 2xs) ; 4.28-4.19 (1H, m) ; 3.43-3.35 (2H, m) ; 2.40 and 1.90 (3H, 2xs); 2.28-2.16 (2H, m); 1.95-1.85 (6H, m); 1.41 and 1.40 (3H, 2xs); 1.01 and 0.86 (9H, 2xs)
    381 δ (400 MHz, CDCl3) rotamers present 8.56 and 8.53 (2H, 2xs) ; 7.68 and 7.59 (1H, 2xs); 4.70 and 4.54 (2H, 2xs) ; 4.32-4.27 (1H, m); 3.63-3.56 (2H, m) ; 2.59-2.45 (1H, m) ; 2.17-2.11 (2H, m) ; 1.94-1.88 (8H, m) ; 1.39-0.96 (11H, m)
    382 δ (400 MHz, CDCl3) 8.55 (2H, s); 7.56 (1H, s); 4.68 (2H, s); 4.06-3.99 (1H, m); 3.61 (2H, d, J=6.8 Hz) ; 2.57-2.40 (4H, m) ; 2.22-2.16 (2H, m) ; 1.94-1.82 (8H, m) ; 1.40-1.00 (11H, m)
    383 δ (300 MHz, CD3OD) rotamers present 8.43-8.33 (2H, m) ; 7.65 and 7.52 (2H, 2xs) ; 5.63-5.59 and 5.23-5.21 (1H, 2xm); 4.54-4.12 (2H, m); 3.90-3.73 and 3.48-3.44 (2H, 2xm); 2.29-1.56 (12H, m); 1.35 (3H, s); 1.26-0.93 (8H, m)
    387 δ (400 MHz, CDCl3) 8.53 (1H, s); 8.46 (1H, s) ; 7.67 (1H, s) ; 4.51 (2H, s) ; 4.38-4.26 (2H, m); 2.49 (3H, s); 2.32-2.21 (2H, m); 2.01-1.94 (8H, m); 1.42 (3H, s); 1.30-1.24 (2H, m); 1.06-0.97 (8H, m)
    388 δ (400 MHz, CDCl3) rotamers present 8.58 and 8.52 (2H, 2xs); 7.70 and 7.60 (1H, 2xs) ; 4.93 and 4.70 (2H, 2xs); 4.33-4.25 (1H, m); 3.86 (2H, s); 2.18-2.08 (2H, m); 1.94-1.82 (6H, m) ; 1.39 (3H, s) ; 1.09-1.05 (4H, m)
    389 δ (400 MHz, CDCl3) rotamers present 7.71 and 7.61 (1H, 2xs); 7.37-7.27 (3H, m); 4.72 and 4.57 (2H, 2xs); 4.57-4.49 and 3.87-3.81 (1H, 2xm); 4.38-4.21 (1H, m); 2.20-2.11 (2H, m) ; 1.94-1.83 (6H, m) ; 1.70-1.40 (10H, m); 1.27-1.23 (1H, m); 0.94-0.90 (6H, m)
    390 δ (300 MHz, DMSO-d6) rotamers present 12.19 (1H, brs); 8.56-8.46 (1H, m); 7.91-7.85 (1H, m); 7.74 and 7.63 (1H, 2xs); 7.40-7.35 (1H, m); 5.53-5.44 and 4.98-4.93 (2H, 2xm); 4.29-3.98 (2H, m); 3.61-3.49 (1H, m); 2.13-1.73 (10H, m); 1.56-1.37 (1H, m); 1.23-0.82 (12H, m)
    392 δ (300 MHz, DMSO-d6) rotamers present 12.24 (1H, brs) ; 11.19 and 11.14 (1H, 2xs); 7.83 and 7.66 (1H, 2xs); 7.24-7.16 (1H, m); 6.95-6.83 (2H, m); 4.47-4.00 (2H, m) ; 3.41-2.85 (4H, m) ; 2.50 and 2.41 (3H, 2xs) ; 2.12-1.66 (11H, m); 1.31-1.10 (6H, m) ; 0.99-0.88 (6H, m)
    393 δ (400 MHz, CDCl3) 8.06 (1H, d, J=7.3 Hz) ; 7.52 (1H, s); 7.35-7.20 (3H, m); 5.91 (1H, s); 4.30-4.23 (1H, m); 4.16-4.06 (1H, m); 3.99 (1H, d, J=14.4 Hz); 3.89 (1H, d, J=14.4Hz) ; 2.28-2.17 (2H, m) ; 1.96-1.22 (14H, m) ; 1.10-0.83 (10H, m)
    394 δ (400 MHz, CDCl3) rotamers present 8.57 and 8.49 (2H, 2xs) ; 7.69 and 7.57 (1H, 2xs); 5.00 and 4.69 (2H, 2xs); 4.25-4.20 (1H, m) ; 3.85-3.61 (2H, m) ; 2.26-2.16 (2H, m); 1.95-1.86 (6H, m); 1.76-1.41 (7H, m); 0.96 and 0.74 (6H, 2xt, J=7.6 Hz)
    395 δ (400 MHz, CDCl3) rotamers present 8.56 and 8.50 (2H, 2xs); 7.71 and 7.64 (1H, 2xs); 5.01 and 4.79 (2H, 2xs); 4.30-4.25 (1H, m); 3.86-3.72 (2H, m); 2.18-2.08 (2H, m); 1.95-1.83 (6H, m); 1.78-1.39 (7H, m); 0.96 and 0.74 (6H, 2xt, J=7.3 Hz)
    396 δ (400 MHz, DMSO-d6) rotamers present 12.26 (1H, brs); 7.75 and 7.60 (1H, 2xs); 7.60 and 7.54 (1H, 2xd, J=5.1 Hz) ; 6.99 and 6.93 (1H, 2xd, J=5.1 Hz) ; 6.31 and 6.08 (1H, 2xs); 5.40-5.36 and 4.82-4.80 (1H, 2xm); 4.30-4.01 (2H, m); 3.39-3.18 (2H, m); 2.07-1.70 (10H, m); 1.53-1.44 (1H, m); 1.28-0.84 (12H, m)
    398 δ (400 MHz, CDCl3) rotamers present 8.55 and 8.46 (1H, 2xd, J=3.2 Hz); 7.84-7.79 (1H, m); 7.66 and 7.50 (1H, 2xs); 7.43-7.40 (1H, m); 4.92 and 4.71 (2H, 2xs); 4.32-4.18 (2H, m); 2.28-1.87 (9H, m); 1.46-1.16 (6H, m); 1.06-0.94 (8H, m)
    401 δ (300 MHz, DMSO-d6) rotamers present 12.27 (1H, brs) ; 8.54-8.52 and 8.41-8.39 (1H, 2xm); 7.83-7.23 (4H, m); 5.75-5.60 (1H, m) ; 5.00-4.96 and 4.64-4.59 (1H, 2xm); 4.30-3.99 (2H, m) ; 3.64-3.31 (2H, m); 2.11-2.02 (2H, m); 1.88-1.74 (8H, m); 1.53-1.37 (1H, m); 1.23-0.82 (12H, m)
    402 δ (400 MHz, CD3OD) rotamers present 8.55 and 8.48 (1H, 2xdd, J=4.6, 1.5 Hz); 7.87 and 7.79 (1H, 2xdd, J=8.1, 1.5 Hz); 7.68 and 7.65 (1H, 2xs); 7.36 and 7.33 (1H, 2xdd, J=8.1, 4.6 Hz) ; 5.64-5.61 and 5.17-5.14 (1H, 2xm); 4.32-4.27 (1H, m) ; 4.07-3.33 (4H, m); 2.30-2.17 (2H, m) ; 1.91-1.89 (6H, m) ; 1.35 and 1.34 (3H, 2xs) ; 1.01 and 0.81 (9H, 2xs)
    404 δ (400 MHz, DMSO-d6) 12.27 (1H, brs) ; 7.66-7.37 (4H, m); 4.76-4.37 (4H, m) ; 2.10-1.74 (10H, m) ; 1.51-1.45 (3H, m) ; 1.34-0.91 (14H, m)
    406 δ (400 MHz, CD3OD) rotamers present 7.77 and 7.60 (1H, 2xs); 7.53-7.21(3H, m); 7.15-6.75 (1H, m); 4.83 and 4.63 (2H, 2xs); 4.31-4.26 (1H, m); 3.41-3.36 (2H, m) ; 2.26-2.14 (2H, m); 1.95-1.84 (6H, m) ; 1.35 and 1.34 (3H, 2xs); 1.01 and 0.85 (9H, 2xs)
    500 δ (500 MHz, DMSO-d6) 12.19 (1H, br. s.), 7.75 (0.3H, s), 7.58 (0.7H, s), 7.34-7.48 (4H, m), 7.13-7.33 (4H, m), 4.78 (1.4H, s), 4.42 (0.6H, s), 4.15-4.28 (1H, m), 3.29-3.60 (2H, m), 2.94-3.00 (0.6H, m), 2.78-2.83 (1.4H, m), 2.25-2.39 (1H, m), 1.89-2.10 (6H, m), 1.46-1.60 (2H, m)
    501 δ (400 MHz, DMSO-d6) 12.18 (1H, br. s.), 7.79 (0.3H, s), 7.74 (0.7H, s), 7.34-7.47 (5H, m), 7.15-7.30 (2H, m), 4.78 (1.6H, s), 4.47 (0.4H, s), 4.14-4.29 (1H, m), 3.24-3.56 (2H, m), 3.15-3.20 (0.4H, m), 2.91-2.99 (1.6H, m), 2.25-2.38 (1H, m), 1.88-2.10 (6H, m), 1.45-1.63 (2H, m)
    502 δ (500 MHz, DMSO-d6) 12.17 (1H, br. s.), 7.68 (0.3H, s), 7.53 (0.7H, s), 7.42-7.45 (1H, m), 7.36-7.40 (2H, m), 7.28-7.32 (1H, m), 7.17-7.26 (3H, m), 7.14 (0.7H, d, J=8.3Hz), 6.93 (1.3H, d, J=7.1Hz), 4.72 (1.3H, s), 4.38 (0.7H, s), 4.13-4.26 (1H, m), 3.55 (0.7H, dd, J=8.6, 6.8), 3.27 (1.3H, t, J=7.6Hz), 2.81-2.86 (0.7H, m), 2.72 (1.3H, t, J=7.7Hz), 2.24-2.37 (1H, m), 1.8,6-2.09 (6H, m), 1.46-1.591 (2H, m)
    503 δ (400 MHz, DMSO-d6) 12.18 (1H, br. s.), 10.97 (1H, br. s.), 7.68 (0.4H, s), 7.57 (0.6H, s), 7.36-7.47 (4.4H, m), 7.25-7.28 (1H, m), 7.21 (0.4H, br. s), 7.11-7.15 (0.6H, m), 6.98 (0.6H, s), 6.85 (0.4H, dd, J=8.0, 1.4Hz), 6.52 (0.6H, dd, J=8.0, 1.4Hz), 6.32-6.38 (1H, m), 4.74 (1.2H, s), 4.36 (0.8H, s), 4.13-4.29 (1H, m), 3.53-3.60 (0.8H, m), 3.23-3.37 (1.2H, m), 2.74-2.93 (2H, m), 2.25-2.38 (1H, m), 1.38-2.10 (6H, m), 1.45-1.61 (2H, m)
    504 δ (500 MHz, DMSO-d6) 12.18 (1H, br. s.), 7.74 (0.3H, s), 7.66 (0.7H, s), 7.56 (0.3H, d, J=1.2Hz), 7.47 (0.7H, d, J=2.2Hz), 7.44 (1.4H, dt, J=2.4, 8.6Hz), 7.33-7.42 (3.6H, m), 7.25 (0.7H, d, J=8.3Hz), 7.14 (0.3H, d, J=8.3Hz), 4.77 (1.3H, s), 4.43 (0.7H, s), 4.13-4.26 (1H, m), 3.57 (0.7H, t, J=7.5Hz), 3.27-3.35 (1.3H, m), 2.95 (0.7H, t, J=7.8Hz), 2.81 (1.3H, t, J=7.8Hz), 2.25-2.38 (1H, m), 1.87-2.09 (6H, m), 1.46-1.59 (2H, m)
    505 δ (500 MHz, DMSO-d6) 12.18 (1H, br. s.), 7.74 (0.3H, s), 7.68 (0.7H, s), 7.37-7.46 (3H, m), 7.17 (0.7H, d, J=8.3Hz), 6.85-7.01 (2.6H, m), 6.77 (0.7H, d, J=8.3Hz), 4.77 (1.4H, s), 4.43 (0.6H, s), 4.14-4.28 (1H, m), 3.40-3.45 (0.6H, m), 3.12-3.19 (1.4H, m), 2.74-2.79 (0.6H, m), 2.58-2.64 (1.4H, m), 2.25-2.37 (1H, m), 2.19-2.22 (1.8H, m), 2.18 (2.1H, s), 1.89-2.09 (6H, m), 1.79 (2.1H, s), 1.47-1.60 (2H, m)
    506 δ (500 MHz, DMSO-d6) 12.18 (1H, s), 11.05 (1H, s), 7.70 (0.3H, s), 7.66 (0.7H, s), 7.19-7.47 (5.4H, m), 7.13 (0.6H, d, J=8.3Hz), 6.98-7.02 (0.3H, m), 6.92-6.96 (0.7H, m), 6.80 (0.3H, d, J=7.1Hz), 6.61 (0.7H, d, J=7.1Hz), 6.48-6.50 (0.3H, m), 5.78-5.80 (0.7H, m), 4.79 (1.4H, s), 4.38 (0.6H, s), 4.15-4.27 (1H, m), 3.58-3.63 (0.6H, m), 3.29-3.63 (1.4H, m), 3.06 (0.6H, dd, J=8.8, 6.8Hz), 2.88-2.94 (1.4H, m), 2.25-2.38 (1H, m), 1.89-2.11 (6H, m), 1.46-1.59 (2H, m)
    507 δ (500 MHz, DMSO-d6) 12.18 (1H, br. s.), 10.82 (1H, br. s.), 7.75 (0.7H, s), 7.70 (0.3H, s), 7.48 (0.3H, d, J=7.8Hz), 7.36-7.40 (3.3H, m), 7.33 (0.3H, d, J=8.1Hz), 7.29 0.7H, d, J=8.1Hz), 7.13-7.17 (1H, m), 6.94-7.08 (2H, m), 6.89 (0.7H, d, J=8.3Hz), 6.84 (0.7H, t, J=7.6), 4.77 (1.4H, s), 4.42 (0.6H, s), 4.16-4.28 (1H, m), 3.59 (0.6H, t, J=8.1Hz), 3.28-3.34 (1.4H, m), 2.95 (0.6H, t, J=7.8Hz), 2.82 (1.4H, t, J=8.1Hz), 2.25-2.37 (1H, m), 1.88-2.10 (6H, m), 1.47-1.59 (2H, m)
    508 δ (500 MHz, DMSO-d6) 12.16 (1H, br. S.), 11.07 (0.4H, s), 10.96 (0.6H, s),7.61 (0.4H, s), 7.28-7.44 (5.4H, m), 7.09 (0.6H, s), 6.86-7.02 (2H, m), 6.59 (0.6H, d, J=7.1Hz), 6.45 (0.4H, dd, J=2.8, 1.8Hz), 6.42 (0.6H, dd, J=2.8, 1.8Hz), 4.73 (1.2H, s), 4.32 (0.8H, s), 4.12-4.21 (1H, m), 3.65 (0.8H, t, J=7.3Hz), 3.30-3.40 (1.2H, m), 3.14 (0.8H, t, J=7.3Hz), 3.05 (1.2H, t, J=7.1Hz), 2.25-2.34 (1H, m), 2.00-2.07 (2H, m), 1.85-1.97 (4H, m), 1.46-1.58 (2H, m)
    509 δ (500 MHz, DMSO-d6) 12.17 (1H, s), 7.74 (0.3H, s), 7.64 (0.7H, s), 7.36-7.47 (3.3H, m), 7.15-7.19 (0.7H, m), 7.03-7.15 (3.3H, m), 6.89-6.92 (0.7H, m), 4.78 (1.4H, s), 4.44 (0.6H, s), 4.15-4.28 (1H, m), 3.43-3.49 (0.6H, m), 3.17-3.23 (1.4H, m), 2.79-2.84 (0.6H, m), 2.62-2.69 (1.4H, m), 2.28-2.37 (1H, m), 2.25 (1H, s), 1.89-2.092 (6H, m), 1.83 (2H, s), 1.48-1.60 (2H, m)
    510 δ (500 MHz, DMSO-d6) 12.21 (1H, br. s.), 7.74 (0.2H, s), 7.70 (0.8H, s), 7.32 (0.4H, s), 7.24 (1.6H, s), 4.17-4.27 (1H, m), 3.52-3.57 (0.4H, m), 3.24-3.41 (3.2H, m), 3.12 (0.4H, d, J=7.1Hz), 3.04 (0.4H, d, J=6.8Hz), 2.91 (1.6H, t, J=8.1Hz), 2.21-2.38 (4H, m), 1.90-2.10 (6H, m), 1.45-1.82 (8H, m), 0.90-1.25 (5H, m)
    511 δ (500 MHz, DMSO-d6) 12.20 (1H, br. s.), 7.79-7.83 (1H, m), 7.24 (2H, s), 4.20-4.28 (1H, m), 3.36-3.47 (2H, m), 2.89 (2H, t, J=7.8Hz), 2.27-2.37 (1H, m), 2.23 (3H, s), 1.89-2.10 (7H, m), 1.21-1.61 (13H, m), 0.93 (3H, s)
    512 δ (500 MHz, DMSO-d6) 12.17 (1H, br. s.), 7.78 (1H, s), 7.24 (2H, s), 4.20-4.28 (1H, m), 3.29-3.42 (4H, m), 2.88 (2H, t, J=8.1Hz), 2.29-2.32 (1H, m), 2.23 (3H, s), 1.90-2.10 (6H, m), 1.55 (2H, qd, J=12.6, 4.2Hz), 0.95 (9H, s)
    513 δ (500 MHz, DMSO-d6) 12.18 (1H, br. s.), 10.69-10.74 (1H, m), 7.79 (0.75H, s), 7.63 (0.25H, s), 7.36-7.47 (4H, m), 7.15-7.23 (1.25H, m), 6.88-6.99 (1.25H, m), 6.77-6.84 (1.5H, m), 4.82 (1.5H, s), 4.44 (0.5H, s), 4.15-4.28 (1H, m), 3.32-3.47 (0.5H, m), 3.13-3.19 (1.5H, m), 2.83-2.88 (0.5H, m), 2.66-2.71 (1.5H, m), 2.30-2.38 (1H, m), 2.28 (0.75, s), 1.89-2.10 (8.25H, m), 1.48-1.61 (2H, m)
    514 δ (500 MHz, DMSO-d6) 12.26 (1H, br. s.), 7.75 (0.2H, s), 7.73 (0.8H, s), 7.32 (0.4H, s), 7.24 (1.6H, s), 4.21-4.28 (1H, m), 3.52-3.57 (0.4H, m), 3.37 (1.6H, d, J=7.3Hz), 3.25-3.33 (1.6H, m), 3.10-3.15 (0.4H, m), 3.04 (0.4H, d, J=6.8Hz), 2.87-2.94 (1.6H, m), 2.28 (0.6H, s), 2.23 (2.4H, s), 2.03-2.13 (2H, m), 1.46-1.90 (12H, m), 0.91-1.27 (8H, m)
    515 δ (500 MHz, DMSO-d6) 12.26 (1H, br. s.), 7.81 (1H, s), 7.24 (2H, s), 4.23-4.30 (1H, m), 3.29-3.40 (2H,m), 2.89 (2H, t, J=8.1Hz), 2.23 (3H, s), 2.04-2.15 (3H, m), 1.74-1.90 (7H, m), 1.25 (3H, s), 0.95 (9H, s)
    516 δ (400 MHz, CDCl3) 7.68 (0.4H, s), 7.55 (0.6H, s), 7.18 (0.8H, s), 7.09 (1.2H, s), 4.70 (1H, br. s.), 4.49-4.64 (1H, m), 4.35-4.49 (1H, m), 4.07-4.35 (1H, m), 3.36-3.58 (1H, m), 2.39-2.53 (1H, m), 2.18-2.39 (4H, m), 1.98-2.18 (4H, m), 1.53-1.75 (6H, m), 1.37-1.53 (3H, m), 1.01-1.15 (1H, m), 0.83-0.97 (6H, m)
    517 δ (400 MHz, CDCl3) 7.57-7.62 (1H, m), 7.09-7.16 (2H, m), 5.48 (0.6H, s) 4.51 (1.4H, s) 4.18-4.24 (1H, m), 4.44-4.58 (1H, m), 2.39-2.54 (1H, m), 2.33 (6H, s), 1.98-2.17 (4H, m), 1.50-1.81 (2H, m), 0.90-1.09 (9H, m)
    518 δ (400 MHz, CDCl3) 7.66 (0.3H, s), 7.57 (0.7H, s), 7.17 (0.7H, s), 7.08 (1.4H, s), 4.81 (0.7H, s), 4.43 (1.4H, s), 4.12-4.33 (1H, m), 3.50-3.53 (1.3H, m), 3.19-3.34 (0.7H, m), 2.42-2.49 (1H, m), 2.31-2.39 (3H, m), 2.19-2.29 (2H, m), 2.04-2.14 (4H, m.), 1.53-1.81 (7H, m), 1.18-1.35 (2H, m), 0.70-1.04 (2H, m), 0.08-0.35 (4H, m)
    519 δ (400 MHz, CDCl3) 7.54-7.64 (1H, m), 7.19-7.08 (2H, m), 4.52 (2H, s), 4.12-4.30 (1H, m), 3.50 (2H, s), 2.46-2.50 (1H, m), 2.20-2.37 (5H, m), 1.97-2.14 (4H, m), 1.12-1.75 (12H, m), 0.85-1.07 (3H, m)
    520 δ (400 MHz, CDCl3) 7.64-7.67 (0.3H, m), 7.55 (0.7H, s), 7.15-7.19 (0.7H, m), 7.10 (1.3H, s), 4.70-4.79 (0.8H, m), 4.39 (1.2H, s), 4.12-4.32 (1H, m), 3.60-3.70 (1.3H, m), 3.37-3.44 (0.7H, m), 2.60 (0.3H, dt, J=16.5, 8.4Hz), 2.40-2.51 (1.7H, m), 2.29-2.39 (3H, m), 2.19-2.29 (2H, m), 1.99-2.17 (4H, m), 1.77-1.93 (2H, m), 1.55-1.74 (4H, m), 1.14-1.11 (6H, m)
    521 δ (400 MHz, CDCl3) 7.66 (0.3H, s), 7.55 (0.7H, s), 7.28-7.39 (3H, m), 4.72-4.82 (0.8H, m), 4.42 (1.2H, s), 4.15-4.32 (1H, m), 3.61-3.74 (1.2H, m), 3.33-3.43 (0.8H, m), 2.54-2.68 (0.6H, m), 2.33-2.54 (1.4H, m), 2.19-2.31 (2H, m), 1.98-2.19 (4H, m), 1.76-1.95 (2H, m), 1.54-1.71 (4H, m), 1.26-1.18 (6H, m)
    522 δ (400 MHz, CDCl3) 7.67 -7.63 (1H, m), 7.16 -7.09 (2H, m), 7.02-6.86 (2H, m), 4.84 (2H, s), 4.35 (2H, s), 4.16-4.30 (1H, m), 2.40-2.52 (1H, m), 2.37-2.23 (5H, m), 2.11-2.05 (4H, m.), 1.53-1.74 (2H, m)
    523 δ (400 MHz, DMSO-d6) 12.16 (br. s., 1H) 7.75 (s, 1H) 7.35-7.44 (m, 2H) 7.21-7.30 (m, 1H) 4.25 (d, J=6.06Hz, 1H) 3.35-3.44 (m, 4H) 2.86-3.00 (m, 2H) 2.24-2.41 (m, 1H) 1.87-2.12 (m, 6H) 1.44-1.65 (m, 2H) 0.95 (s, 9H)
    524 δ (400 MHz, CDCl3) 7.72-7.77 (0.2H, m), 7.58 (0.8H, s), 7.22-7.38 (3H, m), 4.93 (0.4H, br. s.), 4.54 (1.6H, s), 4.25-4.17 (1H, m), 3.30-3.59 (1H, m), 2.37-2.56 (1H, m), 2.25 (2H, d, J=13.5Hz), 1.94-2.16 (3H, m), 1.52-1.76 (4H, m), 1.02 (8H, s), 0.84 (1H, s)
    525 δ (400 MHz, CDCl3) 7.68 (1H, s), 7.54-7.60 (1H, m), 7.28 (3H, s), 4.66-4.81 (1H, m), 4.51-4.64 (1H, m), 4.47 (1H, s), 4.17-4.34 (1H, m), 3.36-3.57 (1H, m), 2.36-2.58 (1H, m), 2.08-2.33 (4H, m), 1.53-1.80 (6H, m), 1.36-1.50 (3H, m), 1.03-1.17 (1H, m), 0.78-0.99 (6H, m)
    526 δ (400 MHz, DMSO-d6) 12.18 (br. s., 1H) 7.56-7.81 (m, 5H) 7.36 (s, 2H) 7.20-7.30 (m, 1H) 4.88 (s, 1.6H) 4.60 (s, 0.4H) 4.08-4.33 (m, 1H) 3.50-3.66 (m, 0.4H) 3.34-3.30 (m, 1.6H) 3.14-3.25 (m, 0.4H) 2.87-3.04 (m, 1.6H) 2.22-2.41 (m, 1H) 1.64-2.13 (m, 4H) 1.40-1.63 (m, 2H) 1.20-1.31 (m, 2H)
    527 δ (400 MHz, CDCl3) 7.55-7.74 (m, 2H) 7.45 (d, J=8.22Hz, 1H) 7.18-7.34 (m, 5H) 4.93 (br. s., 1H) 4.72 (d, J=2.74Hz, 1H) 4.32-4.21 (m, 2H) 2.46 (t, J=12.13Hz, 1H) 2.24 (d, J=13.11Hz, 2H) 2.06-2.13 (m, 5H) 1.53-1.78 (m, 2H)
    528 δ (400 MHz, CDCl3) 7.57-7.72 (3H, m), 7.48-7.55 (0.5H, m), 7.44 (0.9H, d, J=8.1Hz), 7.27-7.32 (1H, m), 7.10-7.17 (0.7H, m), 7.06 (0.9H, s), 4.87-5.08 (1H, m), 4.71 (1H, s), 4.13-4.34 (2H, m), 2.19-2.54 (5H, m), 1.99-2.15 (4H, m), 1.53-1.73 (4H; m)
    529 δ (400 MHz, CDCl3) 7.49 (0.2H, s), 7.44 (0.8H, s), 7.16 (0.4H, s), 7.00-7.11 (1.6H, m), 5.14-5.18 (0.2H, m), 5.04-5.07 (0.8H, m), 4.01-4.29 (1H, m), 3.71-3.76 (1H, m), 3.35-3.55 (1H, m), 3.14 (3H, s), 2.39-2.55 (1H, m), 2.20-2.34 (6H, m), 2.00-2.14 (4H, m), 1.57-1.75 (3H, m), 1.02 (8H, s), 0.81 (1H, s)
    530 δ (400 MHz, CDCl3) 7.39-7.53 (1H, m), 6.97-7.19 (2H, m), 5.42-5.53 (.1H, m), 4.94-5.11 (0.9H, m), 4.16-4.31 (1H, m), 4.03-4.15 (1H, m), 3.64-3.81 (1H, m), 3.18-3.54 (2H, m), 3.13 (3H, s), 2.37-2.52 (1H, m), 2.27 (5H, s), 2.00-2.13 (4H, m), 1.46-1.77 (2H, m), 1.01 (8H, s), 0.80 (1H, s)
    531 δ (400 MHz, CDCl3) 7.48 (0.2H, s), 7.15 (0.8H, s), 7.04 (2H, br. s.), 5.45-5.52 (0.2H, m), 5.04 (0.8H, dd, J=9.6, 4.1Hz), 4.15-4.29 (1H, m), 4.08 (1H, dd, J=14.5, 9.4Hz), 3.74 (1H, d, J=12.1Hz), 3.19-3.48 (2H, m), 3.12 (3H, s), 2.01-2.51 (10H, m), 1.54-1.73 (2H, m), 1.00 (8H, s), 0.79 (1H, s)
    532 δ (400 MHz, CDCl3) 7.66 (s, 0.4H), 7.57 (s, 0.6H), 7.17 (s, 0.8H). 7.10 (s, 1.2H), 4.80 (s, 0.8H), 4.42 (s, 1.2H), 4.14-4.33 (m, 1H), 3.47-3.55 (m, 1.2H), 3.24-3.29 (m, 0.8H), 2.14-2.40 (m, 5H), 1.85-2.00 (m, 5H), 1.05-1.73 (m, 13H), 0.76-1.00 (m, 6H)
    533 δ (400 MHz, DMSO-d6) 7.81 (0.3H, s), 7.70 (0.7H, s), 7.45 (0.6H, s), 7.38 (1.4H, s), 4.77 (0.6H, s), 4.37 (1.4H, s), 4.17-4.32 (1H, m), 2.36 (0.9H,s), 2.30 (2.1H, s), 1.98-2.17 (2H, m), 1.46-1.90 (12H, m)
    534 δ (400 MHz, DMSO-d6) 0.81-1.01 (m, 7H), 1.28-1.42 (m, 2H), 1.43-1.63 (m, 4H), 1.69-1.64 (m, 1H), 1.88-2.11 (m, 6H), 2.27-2.38 (m, 1H), 2.50-2.57 (m , 1H), 2.90-2.98 (m, 1H), 3.18-3.15 (m, 3H), 3.44-3.51 (m, 1H), 4.15-4.29 (m, 2H), 7.24-7.83 (m, 1H), 7.41 (d, J=7.8Hz, 1.3H), 7.49 (d, J=7.8Hz, 0.7H), 7.79 (s, 0.3H), 7.86 (s, 0.7H), 12.19 (br. s, 1H)
    535 δ (400 MHz, DMSO-d6) 7.82 (s, 0.2H), 7.69 (s, 0.8H), 7.47 (s, 0.4H). 7.40 (s, 1.6H), 4.78 (s, 0.4H), 4.59 (s, 1.6H), 4.17-4.29 (m, 1H), 3.14-3.39 (m, 2H), 2.26-2.41 (m, 4H), 1.87-2.11 (m, 6H), 1.33-1.66 (m, 7H), 0.97-1.29 (m, 5H), 0.67-0.95 (m, 6H)
    536 δ (400 MHz, DMSO-d6) 0.67-0.87 (m, 9H), 1.45-1.63 (m, 2H), 1.73-2.14 (m, 8H), 2.15-2.38 (m, 5H), 3.87-3.99 (m, 0.5H), 4.06-4.44 (m, 2.5H), 4.58-4.88 (m, 3H), 7.39 (d, J = 3.9Hz, 1H), 7.47 (d, J = 3.9Hz, 1H), 7.70 (s, 0.5H), 7.78 (s, 0.25H), 7.80 (s, 0.25H), 12.24 (br. S, 1H)
    537 δ (400 MHz, DMSO-d6) 12.17 (1H, s), 7.80 (0.3H, s), 7.68 (0.7H, s), 7.45 (0.6H, s), 7.38 (1.4H, s), 4.77 (0.6H, s), 4.37 (1.4H, s), 4.16-4.32 (1H, m), 3.07-3.37 (1H, m), 2.43-2.69 (1H, m), 2.24-2.38 (4H, m), 1.85-2.11 (6H, m), 1.45-1.76 (7H, m), 0.85-1.27 (5H, m
    538 δ (400 MHz, DMSO-d6) 12.26 (1H, s), 8.88-9.04 (1H, m), 7.10-8.22 (5H, m), 4.81-4.92 (2H, m), 4.29 (1H, d, J=3.5Hz), 3.36 (2H, s), 2.05-2.20 (2H, m), 1.70-1.93 (6H, m), 1.22-1.29 (3H, m), 0.78-1.03 (9H, m)
    539 δ (400 MHz, DMSO-d6) 12.19 (1H, br. s.), 8.81-9.01 (1H, m), 8.12 (1H, dd, J=16.7, 8.3Hz), 6.78-8.02 (8H, m), 4.56-4.87 (4H, m), 4.18-4.33 (1H, m), 2.25-2.41 (1H, m), 1.88-2.14 (6H, m), 1.45-1.66 (2H, m)
    541 δ (400 MHz, CD3OD) 1.62-1.70 (2H, m), 2.04-2.24 (6H, m), 2.39-2.47 (1H, m), 4.29-4.35 (1H, m), 4.57 (2H, s), 4.62-4.69 (2H, m), 7.24 (1H, d, J=8.04Hz), 7.35-7.45 (5H, m), 7.71 (1H, s)
    542 δ (400 MHz, CD3OD) 1.02-1.08 (9H, m), 1.57-1.69 (2H, m), 2.01-2.23 (6H, m), 2.41 (1H, tt, J=12.23, 3.52Hz), 2.50-2.56 (3H, m), 4.26-4.35 (1H, m), 4.72 (2H, s), 7.44 (1H, s), 7.61-7.64 (1H, m)
    543 δ (500 MHz, CDCl3) 7.61 (s, 1H), 7.53 (s, 1), 7.24-7.27 (m, 2H), 7.17-7.20 (m, 2H), 7.11 (s, 1H), 7.01-7.05 (m, 2H), 4.75 (br, s, 2H), 4.60 (s, 1H), 4.54 (s, 1H), 4.12-4.25 (m, 4H), 2.17-2.47 (m, 5H), 1.63-2.02 (m, 3H), 1.56-1.58 (m, 2H)
    544 δ (400 MHz, DMSO-d6) 1.89-2.06 (12H, m), 2.27-2.33 (1H, m), 2.27-2.32 (1H, m), 2.36 (1H, s), 3.29-3.34 (1H, m), 3.57 (1H, t, J=7.04Hz), 3.91-3.95 (1H, m), 4.09-4.14 (1H, m), 4.46 (1H, s), 4.72 (1H, s), 5.89 (1H, s), 5.97 (1H, d, J=5.67Hz), 6.06 (1H, s), 7.10 (1H, d, J=7.49Hz), 7.34-7.44 (4H, m), 7.73 (1H, s)
    739 δ (400 MHz, DMSO-d6) 12.06-12.33 (m, 1H), 8.72 (s, 2H), 7.75 (s, 1H), 4.71 (s, 2H), 4.40 (br. s., 1H), 3.28 (s, 2H), 2.13 (d, J=4.11Hz, 1H), 1.97 (br. s., 1H), 1.91 (br. s., 1H), 1.69-1.86 (m, 3H), 0.88-1.01 (m, 13H), 0.77 (s, 1H)
    • [Example 900] ROR gamma Reporter Gene Assay
  • Luciferase reporter gene assay was used to assess inhibition of RORγ transcriptional activity.
  • ROR gamma expression vector was prepared by inserting the ligand binding domain of human ROR gamma (amino acid 247-497 of Genbank Accession NO. NM_001001523) adjacent to the yeast GAL4 transcription factor DNA binding domain in the expression vector pM (Clontech). The resulting expression vector pM-ROR gamma was used in transfection experiments together with the pGL4 luciferase reporter plasmid (Promega) containing five copies of the UAS GAL4 recognition site and pRL-CMV plasmids (Promega) containing the constitutive CMV promoter and the renilla luciferase.
  • For preparing transfection reagent/DNA mixture, 1 µg pM-ROR gamma, 1 µg pGL4 5xUAS, 625 pg pRL-CMV and 6.25 µL FuGENE™ HD transfection reagent (Promega) were mixed in 0.25 mL OPTI-MEM™ (Life technologies) at room temperature. At the same time, Negative control DNA mixture was prepared by using 1 µg pM empty vector instead of pM-ROR gamma plasmid. After a fifteen minute incubation, 0.25 mL of transfection reagent/DNA mixture was added to 1,000,000 of HEK293T cells (ATCC) in 5 mL of OPTI-MEM™ containing 10% Charcoal Stripped Fetal Bovine Serum.
  • Transfected cells were seeded onto 384 well plate (10 µL/well) and the 7.5 nL of test compounds were added to the wells in 8 concentrations ranging from 3.5 nM to 10.5 µM. The compounds were dissolved in 100% DMSO and the final concentration of DMSO in the assay was 0.075%.
  • After 24 h of incubation at 37°C, 5% CO2 in a cell culture incubator, the Dual-Glo™ Luciferase Assay System was used to detect activity according to the manufacturer's instructions (Promega, Cat. No.: E2920).
    Data was plotted and pIC50 values were calculated using the XLfit program (ID Business Solutions Ltd.). The results are shown in the following tables.
    example result example result example result example result
    1 7.62 41 7.53 81 7.03 121 < 5.00
    2 8.12 42 7.35 82 7.09 122 < 5.00
    3 < 5.00 43 7.47 83 5.78 123 8.31
    4 6.42 44 7.83 84 6.97 124 7.75
    5 6.68 45 7.23 85 5.83 125 6.49
    6 7.06 46 6.40 86 6.79 126 6.04
    7 5.34 47 6.99 87 6.85 127 5.69
    8 < 5.00 48 < 5.00 88 7.06 128 < 5.00
    9 < 5.00 49 7.39 89 5.86 129 5.06
    10 7.59 50 7.15 90 6.30 130 6.76
    11 7.42 51 5.39 91 8.36 131 7.08
    12 5.43 52 6.61 92 6.81 132 7.18
    13 7.03 53 7.79 93 6.24 133 5.46
    14 7.12 54 7.15 94 8.08 134 6.61
    15 7.02 55 8.05 95 6.82 135 5.51
    16 6.93 56 7.81 96 7.54 136 7.08
    17 7.61 57 7.42 97 6.55 137 8.32
    18 7.93 58 6.87 98 < 5.00 138 8.14
    19 < 5.00 59 5.23 99 6.98 139 7.76
    20 7.15 60 < 5.00 100 6.63 140 6.70
    21 < 5.00 61 6.70 101 7.06 141 6.27
    22 < 5.00 62 < 5.00 102 7.13 142 5.18
    23 7.62 63 5.47 103 5.72 143 5.65
    24 6.78 64 < 5.00 104 5.69 144 7.06
    25 6.58 65 < 5.00 105 6.69 145 5.46
    26 6.55 66 7.08 106 6.42 146 6.83
    27 7.25 67 7.25 107 5.55 147 6.46
    28 6.71 68 5.88 108 6.49 148 6.32
    29 7.12 69 < 5.00 109 6.20 149 7.22
    30 7.33 70 < 5.00 110 6.79 150 7.27
    31 7.11 71 5.68 111 6.45 151 5.09
    32 7.09 72 5.88 112 7:21 152 5.55
    33 6.95 73 6.19 113 5.34 153 6.68
    34 5.87 74 6.58 114 5.64 154 < 5.00
    35 6.95 75 6.50 115 6.80 155 5.29
    36 6.93 76 5.77 116 < 5.00 156 5.99
    37 7.73 77 7.47 117 5.45 157 < 5.00
    38 5.81 78 8.00 118 5.76 158 < 5.00
    39 <5.00 79 6.68 119 5.82 159 < 5.00
    40 7.25 80 6.18 120 7.73 160 7.61
    161 5.66 201 < 5.00 241 8.29 281 8.37
    162 5.99 202 8.10 242 7.50 282 8.47
    163 < 5.00 203 6.04 243 7.26 283 8.04
    164 5.93 204 7.22 244 8.16 284 7.95
    165 5.93 205 6.86 245 8.05 285 -
    166 7.81 206 7.00 246 7.94 286 8.04
    167 6.48 207 7.20 247 7.49 287 5.92
    168 6.83 208 6.52 248 7.67 288 7.93
    169 7.39 209 < 5.00 249 > 8.46 289 7.03
    170 6.75 210 5.99 250 > 8.46 290 6.72
    171 6.78 211 7.65 251 8.22 291 5.99
    172 < 5.00 212 7.70 252 8.00 292 7.32
    173 < 5.00 213 6.95 253 7.34 293 7.48
    174 6.18 214 6.49 254 7.73 294 7.31
    175 6.22 215 7.49 255 7.26 295 5.25
    176 5.59 216 < 5.98 256 8.22 296 < 4.98
    177 6.85 217 6.66 257 7.70 297 7.18
    178 5.36 218 6.47 258 8.18 298 7.89
    179 7.28 219 8.31 259 6.93 299 7.68
    180 6.95 220 6.98 260 8.22 300 7.62
    181 < 5.00 221 8.53 261 8.34 301 6.73
    182 7.18 222 8.38 262 7.39 302 7.83
    183 6.76 223 7.30 263 8.23 303 < 5.46
    184 6.79 224 8.57 264 8.09 304 < 4.98
    185 5.74 225 8.53 265 7.74 305 < 4.98
    186 7.57 226 8.47 266 8.27 306 8.08
    187 6.65 227 8.40 267 7.87 307 5.08
    188 6.56 228 6.71 268 6.97 308 7.78
    189 7.52 229 7.89 269 8.09 309 7.95
    190 8.08 230 8.18 270 7.79 310 < 4.98
    191 8.05 231 7.97 271 8.29 311 < 4.98
    192 7.93 232 7.77 272 7.95 312 7.28
    193 8.19 233 7.80 273 7.85 313 5.81
    194 7.85 234 8.00 274 8.08 314 7.38
    195 < 5.00 235 7.88 275 > 8.46 315 7.26
    196 5.46 236 7.98 276 6.91 316 8.04
    197 6.29 237 > 8.46 277 8.14 317 8.00
    198 < 5.00 238 8.36 278 7.93 318 7.70
    199 8.30 239 > 8.46 279 7.42 319 6.85
    200 7.80 240 8.26 280 6.61 320 8.01
    321 7.93 361 5.92 401 5.55
    322 8.09 362 7.24 402 4.98
    323 6.42 363 788 403 5.76
    324 6.42 364 7.34 404 7.65
    325 7.97 365 7.51 405 4.98
    326 6.99 366 7.82 406 7.30
    327 7.01 367 7.52 407 6.32
    328 5.53 368 6.72 408 6.48
    329 7.83 369 5.91 409 6.11
    330 7.62 370 6.27 410 5.67
    331 6.99 371 5.27 411 6.65
    332 6.29 372 6.48 412 5.95
    333 7.77 373 5.47
    334 7.25 374 6.18
    335 7.91 375 6.97
    336 6.84 376 6.51
    337 7.20 377 6.36
    338 6.26 378 7.13
    339 7.08 379 7.10
    340 6.91 380 7.08
    341 6.12 381 7.00
    342 7.34 382 6.59
    343 7.50 383 7.40
    344 5.80 384 6.46
    345 7.58 385 7.73
    346 6.96 386 6.85
    347 6.06 387 7.16
    348 6.81 388 7.14
    349 7.10 389 7.53
    350 5.94 390 6.48
    351 5.14 391 6.85
    352 5.39 392 7.54
    353 6.75 393 5.34
    354 6.29 394 7.69
    355 7.66 395 7.04
    356 6.99 396 6.05
    357 5.00 397 7.21
    358 7.21 398 6.17
    359 7.58 399 7.06
    360 6.75 400 7.54
    • [Example 901] ROR gamma Coactivator Peptide Recruitment Alphascreen™ Assay
  • Alphascreen™ is a bead-based amplified homogenous luminescent proximity assay that can be used for measuring the effect of compounds on protein-protein interactions. When biological interactions bring donor and acceptor beads into close proximity, reactive oxygen; generated upon laser excitation of the donor beads, initiates a luminescence/fluorescence cascade in the acceptor beads that leads to a highly amplified signal that can be measured as light in the 520-620 nm range. When the acceptor and donor beads are not in proximity, the reactive oxygen decays and only a very low background signal is generated.
  • An in vitro assay to assess inhibition of RORγ binding to the coactivator GRIP1 was established using Alphascreen™ technology. The interaction between nuclear receptors (NR) and coactivator proteins is a key step in signal transduction from the receptor to the transcriptional machinery and can be measured in vitro using only the ligand binding domain of the nuclear receptor and a peptide containing a coactivator protein LXXLL nuclear receptor binding motif.
  • For the RORγ construct used in the coactivator recruitment assay, nucleotides corresponding to the ligand binding domain (LBD) of wild type human RORγ (amino acids 262-518 of Genbank Accession No. NM_005060.3) were cloned into the pET24 expression vector (Novagen), downstream of in-frame N-terminal 6xHis and Flag tag sequences. Recombinant 6xHis:Flag-tagged human RORγ-LBD protein was expressed in E.coli (BL-21) and purified by affinity chromatography on a nickel Sepharose column, followed by anion exchange chromatography.
  • A 4x assay mixture of 6xHis:Flag-tagged human RORγ-LBD with the agonist ligand 7-β-hydroxycholesterol was prepared in assay buffer (50 mM HEPES pH 7.4, BSA 0.05%, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 0.01% Tween-20). For control wells a 4x mixture of 6xHis:Flag-tagged human ROR gamma LBD alone was also prepared.
  • A 4x stock of biotinylated coactivator peptide containing the LXXLL motif from GRIP 1 (Biotin-PKKKQNALLRYLLDKDDTKDI) was prepared in assay buffer.
  • A 4x detection mixture of nickel chelate Alphascreen™ acceptor beads (PerkinElmer) and streptavidin Alphascreen™ donor beads (PerkinElmer) was prepared in assay buffer.
  • Compounds to be tested were arranged in a pre-dose 384-well mother plate serially diluted 1 in 2 over 22 columns, in 100% DMSO, at 40x the final test concentration, from a high concentration of 4 mM. DMSO with no compound was placed in control columns. The compounds were robotically dispensed directly into assay plates containing assay buffer to a 4x final test concentration.
  • Following compound addition, the 6xHis:Flag-tagged human RORγ-LBD plus 7-β-hydroxycholesterol assay mixture, biotinylated coactivator peptide and detection mixture were added. Final assay conditions were 5nM 6xHis:Flag-tagged human RORγ-LBD, 30 nM 7-β-hydroxycholesterol, 50nM biotinylated coactivator peptide, 2.5 ug/ml nickel acceptor beads and 10 ug/ml streptavidin donor beads. The final concentration of DMSO in the assay was 2.5%.
  • After overnight incubation at room temperature plates were read on and Envision™ plate reader (PerkinElmer).
    Data was plotted and pIC50 values were calculated using the Genedata Screener™ data analysis suite (Genedata). The results are shown in the following tables.
    example result example result example result example result
    500 7.82 539 7.05 579 8.37 618 7.98
    501 8.42 541 8.50 580 8.30 619 8.11
    502 6.56 542 7.10 581 8.46 620 7.41
    503 6.45 543 8.48 582 7.64 621 6.52
    504 8.16 544 5.44 583 8.62 622 6.64
    505 8.23 545 8.31 584 8.24 623 7.07
    506 7.16 546 7.95 585 7.16 624 6.99
    507 7.49 547 7.71 586 6.48 625 8.13
    508 6.12 548 7.93 587 7.17 626 8.55
    509 7.94 549 8.76 588 8.48 627 7.19
    510 8.75 550 7.67 589 7.37 628 7.57
    511 8.73 552 6.48 590 6.76 629 7.34
    512 8.14 553 8.56 591 8.68 630 8.40
    513 7.48 554 8.15 592 8.17 631 8.00
    514 8.72 555 - 593 7.48 632 8.40
    515 8.33 556 8.62 594 7.13 633 8.09
    516 8.22 557 8.55 595 8.25 634 6.06
    517 7.60 558 8.61 596 6.82 635 6.49
    518 8.58 559 8.15 597 5.62 636 6.88
    519 8.29 560 6.53 598 6.94 637 6.14
    520 8.60 561 - 599 7.86 638 7.81
    521 8.73 562 8.43 600 6.10 639 7.24
    522 8.68 563 6.69 601 7.37 640 6.11
    523 8.06 564 8.38 602 6.76 641 8.67
    524 7.11 565 7.74 603 7.31 642 7.62
    525 8.23 566 8.51 604 5.18 643 8.37
    526 8.23 567 8.62 605 6.82 644 8.40
    527 8.08 568 8.47 606 8.35 645 7.86
    528 8.38 569 5.17 607 6.98 646 6.53
    529 7.20 570 7.73 608 6.91 647 6.44
    530 7.29 571 8.90 609 7.02 648 7.49
    531 5.97 572 8.33 610 7.91 649 8.74
    532 8.13 573 7.10 611 8.22 650 8.10
    533 8.83 574 5.59 612 7.40 651 7.27
    534 8.10 575 7.77 613 6.96 652 8.36
    535 8.88 576 7.46 614 7.27 653 7.15
    536 8.02 577 7.93 615 7.31 654 6.45
    537 8.65 578 7.00 616 7.47 655 7.57
    538 6.95 617 6.93 656 6.73
    657 8.65 696 8.79 735 8.56 774 7.66
    658 8.71 697 7.89 736 6.96 775 8.52
    659 6.48 698 8.68 737 7.85 776 7.66
    660 7.59 699 7.40 738 7.87 777 8.37
    661 7.69 700 7.88 739 8.24 778 8.35
    662 8.15 701 8.03 740 7.84 779 7.74
    663 8.71 702 8.10 741 8.83 780 8.12
    664 8.84 703 7.15 742 8.58 781 8.81
    665 8.86 704 8.61 743 8.65 782 8.40
    666 8.34 705 7.23 744 9.23 783 8.41
    667 6.52 706 7.49 745 9.00 784 7.46
    668 8.46 707 8.21 746 7.49 785 8.40
    669 8.39 708 7.97 747 8.40 786 7.46
    670 7.66 709 9.05 748 8.47 787 8.68
    671 9.06 710 7.56 749 7.22 788 7.76
    672 8.69 711 8.69 750 8.80 789 8.68
    673 7.44 712 7.89 751 8.03 790 7.46
    674 7.75 713 8.39 752 8.32 791 8.28
    675 6.63 714 8.45 753 7.60 792 6.99
    676 7.29 715 7.98 754 8.16 793 7.60
    677 8.25 716 8.57 755 8.63 794 8.53
    678 8.97 717 8.68 756 8.59 795 -
    679 7.92 718 8.76 757 8.10 796 4.74
    680 7.32 719 8.22 758 8.45 797 -
    681 8.02 720 7.13 759 8.43 798 8.50
    682 7.30 721 9.08 760 8.62 799 8.41
    683 8.05 722 8.02 761 8.10 800 8.52
    684 7.86 723 8.00 762 8.27 801 8.07
    685 7.01 724 8.22 763 8.79 802 8.52
    686 7.04 725 8.35 764 8.36 803 7.20
    687 7.83 726 8.56 765 6.61 804 7.27
    688 6.96 727 7.93 766 7.49 805 7.95
    689 8.38 728 8.32 767 6.43 806 6.99
    690 8.17 729 8.62 768 8.40 807 7.34
    691 8.78 730 8.45 769 7.73 808 6.73
    692 8.49 731 9.03 770 7.37 809 7.75
    693 7.36 732 8.04 771 8.20 810 8.51
    694 8.40 733 8.60 772 8.43 811 8.75
    695 8.00 734 8.00 773 7.09 812 8.03
    813 8.22 852 6.05 891 7.81
    814 8.04 853 7.77 892 6.52
    815 7.89 854 8.33 893 8.65
    816 8.35 855 8.24
    817 7.19 856 7.17
    818 8.14 857 7.47
    819 7.30 858 8.70
    820 7.00 859 8.22
    821 8.01 860 7.94
    822 5.23 861 8.32
    823 5.04 862 7.42
    824 7.54 863 8.19
    825 8.86 864 8.53
    826 7.73 865 8.11
    827 - 866 8.65
    828 - 867 7.61
    829 8.02 868 8.34
    830 8.57 869 7.86
    831 8.58 870 6.24
    832 8.41 871 8.30
    833 8.23 872 7.01
    834 8.00 873 8.28
    835 6.60 874 8.11
    836 7.51 875 7.93
    837 8.43 876 8.21
    838 7.86 877 8.21
    839 8.14 878 8.41
    840 6.62 879 8.53
    841 6.71 880 7.79
    842 6.51 881 7.61
    843 8.23 882 6.19
    844 7.52 883 6.15
    845 8.84 884 8.74
    846 8.62 885 6.13
    847 7.66 886 6.33
    848 8.88 887 7.79
    849 8.06 888 8.49
    850 7.89 889 8.69
    851 - 890 9.15

Claims (13)

  1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof:
    Figure imgb1233
     wherein:
    R1 is selected from F, Cl, Br, a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Ra groups and a C3 to C8 cycloalkyl group substituted by 0, 1, 2 or 3 Ra groups;
    Y is selected from a C4 to C6 cycloalkyl group, a C6 to C9 bicycloalkyl group and a C6 to C9 spiroalkyl group, all of which are substituted by a R2 group, 0 or 1 R6 group and 0, 1, 2 or 3 R7 groups;
    R2 is selected from -OH, -CO2H, -SO3H -CONH2, -SO2NH2, a (C1 to C6 alkoxy)carbonyl group substituted by 0, 1, 2 or 3 Rc groups, a (C1 to C6 alkyl)aminocarbonyl group substituted by 0, 1, 2 or 3 Rc groups, a C1 to C6 alkylsulfonyl group substituted by 0, 1, 2 or 3 Rc groups, a C1 to C6 alkylaminosulfonyl group substituted by 0, 1, 2 or 3 Rc groups, a (hydroxycarbonyl)(C1 to C3 alkyl) group substituted by 0, 1, 2 or 3 Rc groups, a (C1 to C6 alkoxy)carbonyl(C1 to C3 alkyl) group substituted by 0, 1, 2 or 3 Rc groups, a (C1 to C6 alkyl)sulfonyl(C1 to C3 alkyl) group substituted by 0, 1, 2 or 3 Rc groups and a (C2 to C6 alkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2 or 3 Rc groups;
    R6 and R7 are independently selected from H, F, -OH, -NH2, -CN, a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Rb groups and a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rb groups;
    R3 is selected from H, F, Cl, -CH3 and -CF3;
    R4 is selected from a C1 to C6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C2 to C6 alkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C2 to C6 alkynyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C1 to C6 alkoxy)(C2 to C4 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C6 to C10 aryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a (5- to 10-membered heteroaryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C3 to C8 cycloalkenyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups and a (3- to 8-membered heterocycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C6 to C9 spiroalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroheteroalkyl group substituted by 0, 1, 2, 3, 4 or Rg groups, a C5 to C9 bicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C5 to C9 bicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 heterobicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, and a (C6 to C9 heterobicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups;
    R5 is selected from a C6 to C10 aryl group substituted by 0, 1, 2, 3, 4 or 5 Ri groups, a 5- to 10-membered heteroaryl group substituted by 0, 1, 2, 3, or 4 Ri groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5Rj groups, a C3 to C8 cycloalkenyl group substituted by 0, 1, 2, 3, 4 or 5Rj groups and a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rj groups;
    R8 and R9 are independently selected from H, F, -OH, -NH2, a C1 to C3 alkyl group substituted by 0, 1, 2 or 3 Rh groups, and a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rh groups; or R8 and R9 together form an oxo group or a thioxo group;
    R12 is H; or R4 and R12 together are -CRmRm-CR13R14-CRmRm- or -CR13R14-CRmRm-CRmRm- to form a pyrrolidine ring;
    R13 is selected from H, a C1 to C6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a C6 to C10 aryl group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a C6 to C10 aryloxy group substituted by 0, 1, 2, 3, 4 or 5 Rf groups,a (C2 to C6 alkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C2 to C6 alkynyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C1 to C6 alkoxy)(C2 to C4 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Re groups, a (C6 to C10 aryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a (5- to 10-membered heteroaryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C3 to C8 cycloalkenyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkenyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups and a (3- to 8-membered heterocycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups; a C6 to C9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C6 to C9 spiroalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroheteroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 bicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C5 to C9 bicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 heterobicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, and a (C6 to C9 heterobicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups;
    R14 is independently selected from H and a C1 to C6 alkyl group substituted by 0, 1, 2, 3, 4 or 5 Re groups; or R13 and R14 together form a C3 to C8 cycloalkane ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups, C3 to C8 cycloalkene ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups, or a 3- to 8-membered heterocycloalkane ring substituted by 0, 1, 2, 3, 4 or 5 Rg groups;
    Rm is independently selected from H, F, Cl, -CH3 and -CF3;
    Rg and Rj are , independently selected from F, Cl, a C1 to C6 alkyl group, -OH, -CN, -NH2, -NO2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3, a C1 to C6 alkylene group substituted by 0, 1, 2 or 3 Rl groups, a C2 to C6 alkenylene group substituted by 0, 1, 2 or 3 Rl groups and an oxo group;
    Rf and Ri are are independently selected from F, Cl, Br, -OH, -CN, -NO2, -CO2H, a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Rk groups, a C2 to C6 alkenyl group substituted by 0, 1, 2 or 3 Rk groups, a C2 to C6 alkynyl group substituted by 0, 1, 2 or 3 Rk groups, a C3 to C8 cycloalkyl group substituted by 0, 1,2 or 3 Rk groups, a C1 to C6 alkoxy group substituted by 0, 1, 2 or 3 Rk groups, a C3 to C8 cycloalkyloxy group substituted by 0, 1,2 or 3 Rk groups, -SH, a C1 to C6 alkylthio group substituted by 0, 1, 2 or 3 Rk groups, a C3 to C8 cycloalkylthio group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkyl)carbonyl group substituted by 0, 1,2 or 3 Rk groups, a (C1 to C6 alkoxy)carbonyl group substituted by 0, 1, 2 or 3 Rk groups, a (C1 to C6 alkyl)aminocarbonyl group substituted by 0, 1, 2 or 3 Rk groups, a 3- to 8-membered heterocycloalkyl group substituted by 0, 1, 2 or 3 Rk groups, a C1 to C6 alkylsulfonyl group substituted by 0, 1, 2 or 3 Rk groups, -NH2, a mono(C1 to C6 alkyl)amino group substituted by 0, 1, 2 or 3 Rk groups and a di(C1 to C6 alkyl)amino group substituted by 0, 1, 2 or 3 Rk groups; and
    Ra, Rb, Rc, Re, Rh, Rk and Rl are independently selected from F, a C1 to C4 alkyl group, -OH, -CN, -NO2, -NH2, -CO2H, a C1 to C6 alkoxy group, a mono(C1 to C6 alkyl)amino group, a di(C1 to C6 alkyl)amino group, -CF3 and an oxo group.
  2. The compound according to claim 1 or pharmaceutically acceptable salt thereof, wherein Y is selected from formula (II-a), formula (II-b), formula (II-c) and formula (II-d):
    Figure imgb1234
     wherein:
    k is 0, 1 or 2;
    and n is 1, 2 for 3.
  3. The compound according to claim 2 or pharmaceutically acceptable salt thereof, wherein Y is a group represented by formula (II-a):
    Figure imgb1235
  4. The compound according to claim 2 or pharmaceutically acceptable salt thereof, wherein Y is a group represented by formula (II-d):
    Figure imgb1236
     and n is 2.
  5. The compound according to any one of claims 1 to 4 or pharmaceutically acceptable salt thereof, wherein R3 is H.
  6. The compound according to any one of claims 1 to 5 or pharmaceutically acceptable salt thereof, wherein R2 is -CO2H or a hydroxycarbonylmethyl group substituted by 0, 1 or 2 Rc groups.
  7. The compound according to any one of claims 1 to 6 or pharmaceutically acceptable salt thereof, wherein R12 is H.
  8. The compound according to any one of claims 1 to 7 or pharmaceutically acceptable salt thereof, wherein R8 and R9 together form an oxo group or both R8 and R9 are H.
  9. The compound according to any one of claims 1 to 8 or pharmaceutically acceptable salt thereof, wherein R1 is -CF3, -CF2H or Cl.
  10. The compound according to any one of claims 1 to 9 or pharmaceutically acceptable salt thereof, wherein R5 is a C6 to C10 aryl group substituted by 0, 1, 2, 3, 4 or 5 Ri groups or a 5- to 10-membered heteroaryl group substituted by 0, 1, 2, 3, or 4 Ri groups.
  11. The compound according to any one of claims 1 to 10 or pharmaceutically acceptable salt thereof, wherein R4 is a C1 to C6 alkyl group substituted by 0, 1, 2 or 3 Re groups, a (C6 to C10 aryl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rf groups, a C3 to C8 cycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C3 to C8 cycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C6 to C9 spiroalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C6 to C9 spiroalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a C5 to C9 bicycloalkyl group substituted by 0, 1, 2, 3, 4 or 5 Rg groups, a (C5 to C9 bicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups or a (C6 to C9 heterobicycloalkyl)(C1 to C3 alkyl) group substituted by 0, 1, 2, 3, 4 or 5 Rg groups.
  12. A compound according to any one of claims 1 to 11 or pharmaceutically acceptable salt thereof for use in a method of treating or preventing a disease, wherein the disease is multiple sclerosis, chronic rheumatoid arthritis, ankylosing spondylitis, systemic erythematodes, psoriasis, psoriatic arthritis, inflammatory bowel disease or asthma.
  13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11 or pharmaceutically acceptable salt thereof.
EP15713244.0A 2014-02-28 2015-02-27 Pyrazole amide derivative Active EP3110810B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SI201530248T SI3110810T1 (en) 2014-02-28 2015-02-27 Pyrazole amide derivative
PL15713244T PL3110810T3 (en) 2014-02-28 2015-02-27 Pyrazole amide derivative
RS20180871A RS57575B1 (en) 2014-02-28 2015-02-27 Pyrazole amide derivative
HRP20180750TT HRP20180750T1 (en) 2014-02-28 2018-05-14 Dérivé de pyrazole amide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014039880 2014-02-28
PCT/JP2015/056584 WO2015129926A1 (en) 2014-02-28 2015-02-27 Pyrazole amide derivative

Publications (2)

Publication Number Publication Date
EP3110810A1 EP3110810A1 (en) 2017-01-04
EP3110810B1 true EP3110810B1 (en) 2018-05-02

Family

ID=52779995

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15713244.0A Active EP3110810B1 (en) 2014-02-28 2015-02-27 Pyrazole amide derivative

Country Status (27)

Country Link
US (1) US9365522B2 (en)
EP (1) EP3110810B1 (en)
JP (1) JP6211207B2 (en)
KR (1) KR102309352B1 (en)
CN (1) CN106459003B (en)
AR (1) AR099602A1 (en)
AU (1) AU2015223742C1 (en)
BR (1) BR112016019592B1 (en)
CA (1) CA2940696C (en)
CY (1) CY1120452T1 (en)
DK (1) DK3110810T3 (en)
ES (1) ES2673279T3 (en)
HR (1) HRP20180750T1 (en)
HU (1) HUE038645T2 (en)
IL (1) IL247426B (en)
LT (1) LT3110810T (en)
MX (1) MX2016011072A (en)
PH (1) PH12016501702A1 (en)
PL (1) PL3110810T3 (en)
PT (1) PT3110810T (en)
RS (1) RS57575B1 (en)
RU (1) RU2658827C2 (en)
SG (1) SG11201607045SA (en)
SI (1) SI3110810T1 (en)
TW (1) TWI659019B (en)
UY (1) UY36014A (en)
WO (1) WO2015129926A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201803869A (en) 2016-04-27 2018-02-01 健生藥品公司 6-aminopyridin-3-yl thiazoles as modulators of ROR[gamma]t
RU2742771C2 (en) 2016-08-31 2021-02-10 Цзянсу Хэнжуй Медицин Ко., Лтд. Oxopicolinamide derivative, a method for production thereof and pharmaceutical use thereof
AU2017376580B2 (en) * 2016-12-15 2020-08-13 F. Hoffmann-La Roche Ag Process for preparing BTK inhibitors
WO2018115984A1 (en) 2016-12-19 2018-06-28 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation
JP2020059651A (en) * 2016-12-26 2020-04-16 科研製薬株式会社 Pyrazole derivative and pharmaceutical containing the same
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN112566901A (en) 2018-06-18 2021-03-26 詹森药业有限公司 Phenyl-substituted pyrazoles as modulators of ROR γ t
CA3103771A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of roryt
JP2021529161A (en) * 2018-06-18 2021-10-28 ヤンセン ファーマシューティカ エヌ．ベー． Pyridinepyrazole as a modulator of RORγt
US11345666B2 (en) 2018-06-18 2022-05-31 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of RORγT
CN108752185A (en) * 2018-07-17 2018-11-06 成都道合尔医药技术有限公司 A kind of synthetic method of the fluoro- cyclopentanecarboxylic acids of 1-
WO2020037109A1 (en) * 2018-08-17 2020-02-20 Dow Agrosciences Llc Processes for fluorination
GB201901559D0 (en) 2019-02-05 2019-03-27 Syngenta Crop Protection Ag Herbicidal compositions
CN112552158B (en) * 2020-12-09 2023-05-19 南京工业大学 Preparation and application of high-absorption chrome tanning auxiliary agent containing ketocarboxylic acid structure
CN115108980B (en) * 2022-06-22 2023-06-16 济南大学 Preparation method of No. 4 acylated derivative of 2-methylquinoline compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
PL2729445T3 (en) 2011-07-04 2016-04-29 Rottapharm Biotech Srl Cyclic amine derivatives as ep4 receptor antagonists
EP2738170B1 (en) * 2011-07-29 2017-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP5918859B2 (en) * 2011-12-02 2016-05-18 フェネックス ファーマシューティカルス アーゲー Pyrrolocarboxamide for the treatment of chronic inflammatory and autoimmune diseases as a modulator of orphan receptor-gamma (RORγ, NR1F3) activity associated with the orphan nuclear receptor RAR
JO3215B1 (en) * 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag Carboxamide or Sulfonamide Substituted Nitrogen-Containing 5-Membered Heterocycles as Modulators for the Orphan Nuclear Receptor RORy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
SI3110810T1 (en) 2018-11-30
UY36014A (en) 2015-09-30
DK3110810T3 (en) 2018-07-23
AR099602A1 (en) 2016-08-03
RS57575B1 (en) 2018-11-30
IL247426A0 (en) 2016-11-30
PL3110810T3 (en) 2018-12-31
CN106459003A (en) 2017-02-22
BR112016019592A2 (en) 2017-08-15
HUE038645T2 (en) 2018-11-28
ES2673279T3 (en) 2018-06-21
JP2017510560A (en) 2017-04-13
AU2015223742A1 (en) 2016-09-01
AU2015223742C1 (en) 2019-02-21
CA2940696A1 (en) 2015-09-03
CA2940696C (en) 2022-04-26
PT3110810T (en) 2018-07-31
WO2015129926A1 (en) 2015-09-03
JP6211207B2 (en) 2017-10-11
MX2016011072A (en) 2016-11-30
NZ723766A (en) 2022-03-25
RU2016138364A (en) 2018-03-30
BR112016019592B1 (en) 2021-03-09
BR112016019592A8 (en) 2018-01-02
RU2016138364A3 (en) 2018-03-30
HRP20180750T1 (en) 2018-06-15
PH12016501702B1 (en) 2016-10-03
AU2015223742B2 (en) 2018-11-15
KR102309352B1 (en) 2021-10-05
CN106459003B (en) 2019-06-21
TW201623236A (en) 2016-07-01
TWI659019B (en) 2019-05-11
SG11201607045SA (en) 2016-09-29
EP3110810A1 (en) 2017-01-04
RU2658827C2 (en) 2018-06-25
US20150266824A1 (en) 2015-09-24
PH12016501702A1 (en) 2016-10-03
US9365522B2 (en) 2016-06-14
IL247426B (en) 2020-01-30
CY1120452T1 (en) 2019-07-10
KR20160141721A (en) 2016-12-09
LT3110810T (en) 2018-07-10

Similar Documents

Publication Publication Date Title
EP3110810B1 (en) Pyrazole amide derivative
EP3740478B1 (en) Fused imidazole derivatives as il-17 modulators
EP3638227B1 (en) Spirocyclic indolines as il-17 modulators
EP3390384B1 (en) Quinoline-3-carboxamides as h-pgds inhibitors
EP2090570B1 (en) Imidazole derivative
EP3068785B1 (en) Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors
EP3889154A1 (en) Heterocyclic compound intermediate, preparation method therefor and application thereof
CN109265400B (en) Arginine methyltransferase inhibitors and uses thereof
EP3166939B1 (en) Therapeutic compounds and methods of use thereof
EP4132650B1 (en) Difluorocyclohexyl derivatives as il-17 modulators
EP3030560B1 (en) Benzimidazolyl-methyl urea derivatives as alx receptor agonists
EP3652178B1 (en) Bicyclic ketone compounds and methods of use thereof
EP3426243B1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP2727920B1 (en) 1,5-naphthyridine derivative or salt thereof
EP3299371B1 (en) Hydroxyl purine compounds and use thereof
EP4169575A1 (en) Condensed ring compounds that inhibit h-pgds
EP3470406A1 (en) Aryl substituted heterocyclyl sulfones
EP2881394B1 (en) Condensed ring heterocyclic compound
NZ723766B2 (en) Pyrazole amide derivative
EP4397309A2 (en) Bicyclic ketone compounds and methods of use thereof
JP2024517906A (en) Sulfonimidoyl-containing ATR inhibitor compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160914

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TEIJIN PHARMA LIMITED

INTG Intention to grant announced

Effective date: 20171123

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20180750

Country of ref document: HR

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 995100

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180515

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015010704

Country of ref document: DE

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015010704

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20180750

Country of ref document: HR

Ref country code: CH

Ref legal event code: NV

Representative=s name: BUGNION S.A., CH

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2673279

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180621

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180716

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3110810

Country of ref document: PT

Date of ref document: 20180731

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20180724

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20180502

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: 015801

Country of ref document: EE

Effective date: 20180727

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E038645

Country of ref document: HU

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 28563

Country of ref document: SK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015010704

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180750

Country of ref document: HR

Payment date: 20190205

Year of fee payment: 5

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180402139

Country of ref document: GR

Effective date: 20190225

26N No opposition filed

Effective date: 20190205

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 995100

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180502

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180750

Country of ref document: HR

Payment date: 20200210

Year of fee payment: 6

REG Reference to a national code

Ref country code: EE

Ref legal event code: GB1A

Ref document number: E015801

Country of ref document: EE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602015010704

Country of ref document: DE

Representative=s name: HOFFMANN - EITLE PATENT- UND RECHTSANWAELTE PA, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602015010704

Country of ref document: DE

Owner name: TEIJIN LIMITED, OSAKA-SHI, JP

Free format text: FORMER OWNER: TEIJIN PHARMA LIMITED, TOKYO, JP

REG Reference to a national code

Ref country code: LU

Ref legal event code: PD

Owner name: TEIJIN LIMITED; JP

Free format text: FORMER OWNER: TEIJIN PHARMA LIMITED

Effective date: 20200702

REG Reference to a national code

Ref country code: HU

Ref legal event code: GB9C

Owner name: TEIJIN LIMITED, JP

Free format text: FORMER OWNER(S): TEIJIN PHARMA LIMITED, JP

Ref country code: HU

Ref legal event code: FH1C

Free format text: FORMER REPRESENTATIVE(S): DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: TEIJIN LIMITED; JP

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION

Effective date: 20200804

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180750

Country of ref document: HR

Payment date: 20210219

Year of fee payment: 7

REG Reference to a national code

Ref country code: NO

Ref legal event code: CHAD

Owner name: TEIJIN LIMITED, JP

REG Reference to a national code

Ref country code: FI

Ref legal event code: PCE

Owner name: TEIJIN LIMITED

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20210617 AND 20210623

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 995100

Country of ref document: AT

Kind code of ref document: T

Owner name: TEIJIN LIMITED, JP

Effective date: 20210728

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: TEIJIN LIMITED; JP

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: TEIJIN PHARMA LIMITED

Effective date: 20200804

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180750

Country of ref document: HR

Payment date: 20220223

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RS

Payment date: 20220218

Year of fee payment: 8

Ref country code: LT

Payment date: 20220120

Year of fee payment: 8

Ref country code: IE

Payment date: 20220216

Year of fee payment: 8

Ref country code: HU

Payment date: 20220213

Year of fee payment: 8

Ref country code: GB

Payment date: 20220223

Year of fee payment: 8

Ref country code: FI

Payment date: 20220217

Year of fee payment: 8

Ref country code: DK

Payment date: 20220218

Year of fee payment: 8

Ref country code: DE

Payment date: 20220217

Year of fee payment: 8

Ref country code: CH

Payment date: 20220216

Year of fee payment: 8

Ref country code: BG

Payment date: 20220217

Year of fee payment: 8

Ref country code: AT

Payment date: 20220217

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20220210

Year of fee payment: 8

Ref country code: TR

Payment date: 20220225

Year of fee payment: 8

Ref country code: SM

Payment date: 20220120

Year of fee payment: 8

Ref country code: SK

Payment date: 20220225

Year of fee payment: 8

Ref country code: SE

Payment date: 20220216

Year of fee payment: 8

Ref country code: RO

Payment date: 20220218

Year of fee payment: 8

Ref country code: PT

Payment date: 20220217

Year of fee payment: 8

Ref country code: PL

Payment date: 20220217

Year of fee payment: 8

Ref country code: NO

Payment date: 20220218

Year of fee payment: 8

Ref country code: NL

Payment date: 20220216

Year of fee payment: 8

Ref country code: MT

Payment date: 20220128

Year of fee payment: 8

Ref country code: MK

Payment date: 20220121

Year of fee payment: 8

Ref country code: MC

Payment date: 20220218

Year of fee payment: 8

Ref country code: LV

Payment date: 20220221

Year of fee payment: 8

Ref country code: LU

Payment date: 20220216

Year of fee payment: 8

Ref country code: IT

Payment date: 20220218

Year of fee payment: 8

Ref country code: HR

Payment date: 20220223

Year of fee payment: 8

Ref country code: GR

Payment date: 20220221

Year of fee payment: 8

Ref country code: FR

Payment date: 20220216

Year of fee payment: 8

Ref country code: EE

Payment date: 20220221

Year of fee payment: 8

Ref country code: CZ

Payment date: 20220225

Year of fee payment: 8

Ref country code: BE

Payment date: 20220216

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20220221

Year of fee payment: 8

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: TEIJIN LIMITED; JP

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: TEIJIN PHARMA LIMITED

Effective date: 20220629

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20220426

Year of fee payment: 8

Ref country code: CY

Payment date: 20220225

Year of fee payment: 8

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: TEIJIN LIMITED

Effective date: 20221019

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20220222

Year of fee payment: 8

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602015010704

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20180750

Country of ref document: HR

Effective date: 20230227

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E015801

Country of ref document: EE

Effective date: 20230228

REG Reference to a national code

Ref country code: NO

Ref legal event code: MMEP

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20230227

Ref country code: DK

Ref legal event code: EBP

Effective date: 20230228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230228

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20230301

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 28563

Country of ref document: SK

Effective date: 20230227

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 995100

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230227

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20230228

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20230227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230905

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230228

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230828

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230228

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230228

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230228

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230228

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230228

Ref country code: RS

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230301

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230228

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230906

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20231024

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230227

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230228

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230228

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230228

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230228